[
    {
        "instruction":"已知信息：\n'Article 17 Where the provincial drug regulatory department decides to grant approval, it shall, within 10 days after the decision of approval is made, serve the approval document for crude drugs importation or for supplementary application for crude drugs importation to the applicant; where the drug regulatory department decides to grant disapproval, it shall, within 10 days after the decision of disapproval is made, serve a Notice of Review Opinions to the applicant with the reasons explained, and inform the applicant of the right to apply for administrative reconsideration or bring an administrative suit according to law.'可被翻译为：第十七条 省级药品监督管理部门决定予以批准的，应当在作出批准决定后10日内，向申请人送达进口药材批件或者进口药材补充申请批件；决定不予批准的，应当在作出不予批准决定后10日内，向申请人送达审查意见通知书，并说明理由，告知申请人享有依法申请行政复议或者提起行政诉讼的权利。\n'(2) If the application items are not within the scope of authority of drug regulatory department in accordance with the law, the relevant department shall make a decision of non-acceptance, issue a notification of non-acceptance, and inform the applicant to resubmit the application to the applicable administrative authority；'可被翻译为：（二）申请事项依法不属于药品监督管理部门职权范围的，应当作出不予受理的决定，出具不予受理通知书，并告知申请人向有关行政机关申请；\n'Article 93 After completion of review and approval of the drug registration application, where the applicant disagrees about the administrative approval decision, an administrative reconsideration or administrative litigation may be raised in accordance with the law.'可被翻译为：第九十三条 药品注册申请审批结束后，申请人对行政许可决定有异议的，可以依法提起行政复议或者行政诉讼。\n'For acceptance or non-acceptance of the application for cosmetics manufacturing license, the drug regulatory department of the province, autonomous region, or municipality directly under the central government shall issue an acceptance or non-acceptance notice. If non-acceptance is determined, the reason for non-acceptance shall be given, and the applicants shall be informed of being entitled to apply for administrative reconsideration or file an administrative litigation according to law.'可被翻译为：省、自治区、直辖市药品监督管理部门受理或者不予受理化妆品生产许可申请的，应当出具受理或者不予受理通知书。决定不予受理的，应当说明不予受理的理由，并告知申请人依法享有申请行政复议或者提起行政诉讼的权利。\n\n根据上述已知信息，请将'Article 155 The written non-acceptance or unapproval decision made by drug regulatory departments by law shall provide the reasons thereof, and inform the applicant of the right to apply for administrative reconsideration or to bring an administrative suit by law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百五十五条 药品监督管理部门依法作出不予受理或者不予批准的书面决定，应当说明理由，并告知申请人享有依法提请行政复议或者提起行政诉讼的权利。"
    },
    {
        "instruction":"已知信息：\n'Where applying for registration of a domestic medical device subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise.'可被翻译为：按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品不得委托其他企业生产。\n'Article 9 The State encourages the research and innovation of in-vitro diagnostic reagents, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of in-vitro diagnostic reagents and promotes the development of medical device industry.'可被翻译为：第九条 国家鼓励体外诊断试剂的研究与创新，对创新体外诊断试剂实行特别审批，促进体外诊断试剂新技术的推广与应用，推动医疗器械产业的发展。\n'At present, the eRPS system business scope covers the NMPA medical device registration affairs, including the registration, change in registration and registration renewal of domestic Class III medical devices, imported Class II and Class III medical devices; the examination and approval of clinical trials for Class III high-risk medical devices; notification for revising medical device instructions; re-review of registration of medical devices and change of licensing items; and special review of innovative medical devices, etc.'可被翻译为：目前，eRPS系统业务范围为国家药品监督管理局医疗器械注册事项，包括境内第三类和进口第二、三类医疗器械注册、注册变更、延续注册，第三类高风险医疗器械临床试验审批，以及医疗器械说明书更改告知、医疗器械注册及许可事项变更复审、创新医疗器械特别审查等。\n'Article 8 The State encourages the research and innovation of medical devices, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of medical devices and promotes the development of medical device industry.'可被翻译为：第八条 国家鼓励医疗器械的研究与创新，对创新医疗器械实行特别审批，促进医疗器械新技术的推广与应用，推动医疗器械产业的发展。\n\n根据上述已知信息，请将'Where applying for registration of a in-vitro diagnostic reagent subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"按照创新医疗器械特别审批程序审批的境内体外诊断试剂申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内体外诊断试剂申请注册时，样品不得委托其他企业生产。"
    },
    {
        "instruction":"已知信息：\n'After receiving the report, the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device distributor or using unit is located shall, in a timely manner, inform the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device manufacturer is located.'可被翻译为：医疗器械经营企业、使用单位所在地省、自治区、直辖市食品药品监督管理部门收到报告后，应当及时通报医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门。\n'Article 18 If a medical device manufacturer establishes the manufacturing premises across the province, autonomous region or municipality directly under the central government, it shall apply to the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the manufacturing premises is located for Medical Device Manufacturing License.'可被翻译为：第十八条  医疗器械生产企业跨省、自治区、直辖市设立生产场地的，应当向新设生产场地所在地省、自治区、直辖市药品监督管理部门申请医疗器械生产许可。\n'Article 19 A medical device manufacturer who makes changes to the submitted recall plan shall, in a timely manner, report to the food and drug regulatory department of the province, autonomous region or municipality directly under the Central Government where it is located for filing.'可被翻译为：第十九条 医疗器械生产企业对上报的召回计划进行变更的，应当及时报所在地省、自治区、直辖市食品药品监督管理部门备案。\n'Article 16 If a medical device manufacturer makes a decision to recall a medical device, it shall immediately submit a medical device recall event report form to the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where it is located and the food and drug regulatory department approving the registration or undertaking the filing of the product; and submit the investigation and assessment report as well as the recall plan to the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where it is located and the food and drug regulatory department approving the registration or undertaking the filing of the product for filing within 5 working days.'可被翻译为：第十六条 医疗器械生产企业作出医疗器械召回决定的，应当立即向所在地省、自治区、直辖市食品药品监督管理部门和批准该产品注册或者办理备案的食品药品监督管理部门提交医疗器械召回事件报告表，并在5个工作日内将调查评估报告和召回计划提交至所在地省、自治区、直辖市食品药品监督管理部门和批准注册或者办理备案的食品药品监督管理部门备案。\n\n根据上述已知信息，请将'Article 7 Upon finding that the medical device it sells and uses may be a detective product, the medical device distributor or using unit shall immediately suspend the sale or use of the medical device, notify the medical device manufacturer or supplier in a timely manner, and report the findings to the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where it is located; if the using unit is a medical institution, it shall also report the findings to the health administration department of the province, autonomous region, or municipality directly under the Central Government where it is located.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七条 医疗器械经营企业、使用单位发现其经营、使用的医疗器械可能为缺陷产品的，应当立即暂停销售或者使用该医疗器械，及时通知医疗器械生产企业或者供货商，并向所在地省、自治区、直辖市食品药品监督管理部门报告；使用单位为医疗机构的，还应当同时向所在地省、自治区、直辖市卫生行政部门报告。"
    },
    {
        "instruction":"已知信息：\n'A retrospective study method in which the cause is explored by the results. It is based on the present diagnosis of a particular disease'可被翻译为：一种由结果探索病因的回顾性研究方法。其基本原理是以现在确诊的患有某特定疾病\n'The different forms of administration of a drug used in the prevention and treatment of a disease are new forms of a drug that have a certain function.'可被翻译为：在防治疾病的过程中所采用的药物的不同给药形式，是具有某种功能的药物新剂型。\n'A method of measuring health status using four dimensions of mobility, physical activity, social ability, and disease symptoms.'可被翻译为：用行动能力、躯体活动能力、社交能力及疾病症状四个维度测量健康状态的一种方法。\n'An evidence-based recommendation of appropriate treatment or care for a patient with a particular disease or condition.'可被翻译为：以证据为基础的，对特定疾病或状况下的病人适宜治疗或护理方案的推荐。\n\n根据上述已知信息，请将'A method of treating a disease, such as by directly combating or removing the cause of the disease itself. Is the theory and treatment method used in Western medicine.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对造成疾病本身的原因直接对抗、移除等治疗疾病的方法。是西医所使用的理论和治疗方法。"
    },
    {
        "instruction":"已知信息：\n'III. In case of inconsistency between the previously issued Guideline for Exemption from Human Bio equivalence Tests and the M9 Guideline, the M9 Guideline shall prevail.'可被翻译为：三、如果先前发布的《人类生物等效性试验豁免指南》与M9指南不一致，应以M9指南为准。\n'I. If M9 requirements are met according to the assessment by the applicant, the applicant can directly propose exemption of human bio equivalence test in the drug registration application. NMPA will not issue a separate catalogue of varieties exempted from human bioequivalence test or subject to simplified human bio equivalence test.'可被翻译为：一、如果经申报人评估符合M9要求，申报人可直接在药品注册申请中提出免除人体生物等效性试验。国家药监局不会单独发布免人生物等效性试验或简化人生物等效性试验的品种目录。\n'Where the CDE considers that there are substantial defects which cannot be addressed by supplement or correction, the applicant shall not be required to supplement the dossier. The application shall be denied based on the existing dossier submitted.'可被翻译为：药品审评中心认为存在实质性缺陷无法补正的，不再要求申请人补充资料。基于已有申报资料做出不予批准的决定。\n'(5) The application shall be accepted if the materials are complete and conforming to the required format examination, or if the applicant has submitted all the supplementary and corrected materials as required.'可被翻译为：（五）申请材料齐全、符合形式审查要求，或者申请人按照要求提交全部补正材料的，予以受理。\n\n根据上述已知信息，请将'II. Applying for exemption from human bio equivalence tests shall be indicated in the application form. If the exemption cannot be made after evaluation, and the substantial defects cannot be corrected, the applicant will not be required to provide supplementary materials, and the registration application shall be disapproved.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"二、申请豁免进行人体生物等效性试验，须在申请表中注明。经评审不能豁免，实质缺陷不能纠正的，不要求申请人提供补充材料，不予批准注册申请。"
    },
    {
        "instruction":"已知信息：\n'Article 17 The following terms are defined as follows:'可被翻译为：第十七条 本规则下列用语的含义：\n'Article 4 The terms in the Provisions are defined as follows:'可被翻译为：第四条  本办法下列用语的含义：\n'Article 3 The terms used in the Rules are defined as follows:'可被翻译为：第三条 本规则有关用语的含义是：\n'Article 63 Terms used in these Provisions are defined as follows:'可被翻译为：第六十三条 本办法下列用语的含义：\n\n根据上述已知信息，请将'Article 178 The terms in this GSP are defined as follows:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百七十八条 本规范下列术语的含义是："
    },
    {
        "instruction":"已知信息：\n'Article 23 CFDI shall organize the implementation of the registration inspection work within the registration inspection time limit, determine the inspection time, and notify the applicant and the inspected institution to accept the registration inspection. If a dynamic manufacturing on-site inspection is required, Manufacturing Site Inspection time shall be determined based on the applicant's dynamic production arrangement.'可被翻译为：第二十三条 核查中心在注册核查时限内，组织实施注册核查工作，确定核查时间，通知申请人和被核查单位接受注册核查。需要进行动态生产现场核查的，结合申请人动态生产安排确定生产现场核查时间。\n'If the problems found in the on-site inspection will affect the determination of the inspection conclusion, CFDI shall request the applicant in writing to provide feedback on the relevant issues within 20 days. If the problem only needs to be explained, the applicant shall be required in writing to submit dossiers within 5 days. After reviewing the feedback and explanations, CFDI shall inspect and review conclusion. If the applicant fails to submit feedback within the time limit, CFDI shall make the inspection and review conclusion based on the existing registration inspection status.'可被翻译为：认为现场核查发现的问题影响核查结论判定的，核查中心应当书面要求申请人于20日内对相关问题进行反馈，如涉及问题仅需进行解释说明的，书面要求申请人于5日内提交材料。核查中心对反馈及解释说明进行审核后，作出核查审核结论。申请人逾期未予反馈提交的，核查中心基于已有注册核查情况作出核查审核结论。\n'Article 52 If it is necessary to extend the time limit due to the variety characteristics or special circumstances of registration inspection, the applicant shall be informed in writing of the extension of the time limit, and CDE shall be notified, or other relevant professional and technical institutions shall be notified when necessary. The extension time limit shall not exceed one half of the original time limit.'可被翻译为：第五十二条 对于因品种特性或者注册核查工作遇到特殊情况，确需延长时限的，书面告知申请人延长时限，并通知药品审评中心，必要时通知其他相关专业技术机构。延长时限不超过原时限的二分之一。\n'(I) The applicant fails to carry out Manufacturing Site Inspection within the prescribed time limit, or fails to accept on-site inspection within the prescribed time limit, except for the legitimate reasons of force majeure such as natural disaster or government acts;'可被翻译为：(一)除自然灾害、政府行为等不可抗力的正当理由外，申请人未在规定时限内进行生产现场核查确认，或者不能在规定时限内接受现场核查的；\n\n根据上述已知信息，请将'Article 51 The necessary feedback or explanation submitted by the applicant after the on-site inspection, the delay of the on-site inspection by the applicant due to force majeure, and the convening of the expert consultation meeting shall not be included in the time limit. Where relevant circumstances affect the time limit for registration inspection, CFDI shall notify CDE.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十一条 申请人现场核查后进行的必要反馈或者提交解释说明、申请人因不可抗力原因延迟现场核查、召开专家咨询会等时间，不计入时限。相关情况影响注册核查时限的，核查中心应当通知药品审评中心。"
    },
    {
        "instruction":"已知信息：\n'The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate.'可被翻译为：以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。\n'The main part of the mass spectrometer is to separate the ions formed in the ion source according to the difference of the mass charge ratio, and receive and amplify the weak ion flow signal and send it to the display unit and computer data processing system to obtain the mass spectrum and data of the analyzed sample.'可被翻译为：质谱仪主体组成部分，将离子源中形成的离子按质荷比的差异进行分离并将这些微弱的离子流信号接收并放大后送至显示单元及计算机数据处理系统，得到被分析样品的质谱图及数据。\n'Also known as the \"drug-time curve\". The change of drug concentration with time migration after administration, with drug concentration (or logarithmic concentration) as the vertical coordinate and time as the horizontal coordinate plot.'可被翻译为：又称“药-时曲线”。给药后药物浓度随时间迁移发生变化,以药物浓度(或对数浓度)为纵坐标,以时间为横坐标绘出的曲线图。\n'mass spectrum'可被翻译为：质谱图\n\n根据上述已知信息，请将'The horizontal coordinate is the mass charge ratio (m\/z), the vertical coordinate is the relative strength of the ion, with the base peak of 100%, after computer processing of mass spectrum rod-like spectrum.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"横坐标是质荷比（m\/z）、纵坐标是离子的相对强度，以基峰为100%、经过计算机处理的质谱棒状谱图。"
    },
    {
        "instruction":"已知信息：\n'(I) Freezer adapted to their business scale and varieties; for vaccines, two or more independent freezers shall be equipped;'可被翻译为：（一）与其经营规模和品种相适应的冷库，储存疫苗的应当配备两个以上独立冷库；\n'8.1. The RU should have appropriate premises with the layout, construction and finishing to suitable for the intended operations. Utilities such as heating, ventilation and air conditioning, as well as gas and water systems, should have sufficient capacity and should be appropriate for the intended process, product or procedure to be transferred.'可被翻译为：RU应具备有恰当的设施，有平面布局图，其建筑和装修适合于既定操作。公用设施如HVAC和水气系统，均应具备足够能力，适合于准备转移的工艺、产品或方法。\n'(II) Be equipped with the organization or personnel adapted to the scale of the business or use to carry out relevant works of medical device adverse event monitoring;'可被翻译为：（二）配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作；\n'1. There should be appropriate instruments and equipment with adequate capacity for carrying out the study;'可被翻译为：1.应具备研究所需的仪器设备且性能满足研究需求；\n\n根据上述已知信息，请将'(1) equipped with appropriate scale and sufficient capacity reserved.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）具备适度规模和足够的产能储备；"
    },
    {
        "instruction":"已知信息：\n'Medical device sold by its registrant and filing applicant at their residence or manufacturing site may not apply for medical device distribution licensing or filing, but shall comply with the specified distribution conditions; for Class II and Class III medical devices stored and sold at other sites, application for medical device distribution licensing or filing shall be made as required.'可被翻译为：医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存、销售第二、三类医疗器械的，应当按照规定办理医疗器械经营许可或者备案。\n'Article 42 If a medical device distributor finds that the medical devices involved in its distribution activities do not conform to mandatory standards, or to registered or filed technical specifications for the products, or have other defects, it shall suspend the distribution immediately, notify the registrant, filing entity and other relevant units of the medical devices, and record the conditions of distribution suspension and notification. If the registrant and filing entity of the medical devices deem that the products need to be recalled, recalls shall be performed immediately.'可被翻译为：第四十二条  医疗器械经营企业发现其经营的医疗器械不符合强制性标准、经注册或者备案的产品技术要求，或者存在其他缺陷的，应当立即停止经营，通知医疗器械注册人、备案人等有关单位，并记录停止经营和通知情况。医疗器械注册人、备案人认为需要召回的，应当立即召回。\n'The registrant or filing entity of medical devices may sell by itself, or entrust medical device distributors to sell the medical devices registered or filed.'可被翻译为：医疗器械注册人、备案人可以自行销售，也可以委托医疗器械经营企业销售其注册、备案的医疗器械。\n'Article 26 An institution engaged in storage, allocation and supply of non-profit contraceptive medical devices shall conform to relevant regulations, without the need to apply for Medical Device Distribution License or filing.'可被翻译为：第二十六条  从事非营利的避孕医疗器械贮存、调拨和供应的机构，应当符合有关规定，无需办理医疗器械经营许可或者备案。\n\n根据上述已知信息，请将'Article 27 If the registrant or filing entity of medical devices sells its registered and filed medical devices at its domicile or manufacturing address, it does not need to apply for Medical Device Distribution License or filing, but shall meet the prescribed distribution conditions; if it stores and sells the medical devices in other places, it shall apply for Medical Device Distribution License or filing as stipulated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条  医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存并销售医疗器械的，应当按照规定办理医疗器械经营许可或者备案。"
    },
    {
        "instruction":"已知信息：\n'The upper-bound excess lifetime cancer risk estimated to result from continuous exposure to an agent at a concentration of 1 µg\/L in water, or 1 µg\/m3 in air. The interpretation of inhalation unit risk would be as follows: if unit risk = 2 x 10-6 per µg\/L, 2 excess cancer cases (upper bound estimate) are expected to develop per 1,000,000 people if exposed daily for a lifetime to 1 µg of the chemical in 1 liter of drinking water. (US EPA)'可被翻译为：连续暴露于 1µg\/L（水中）或 1µg\/m3（空气）某试剂，估计高于终身患癌风险的上限。吸入单位风险可做如下解释：如果单位风险=2×10-6 \/µg\/L，假设终身每天都饮用1升含有1µg 某化学物质的饮用水，预计每 100 万人发现 2 例以上癌症病例（上限估计）。（美国环境保护署）\n'The length of the rotatory tube is 1dm, the concentration of the substance solution to be measured is 1g\/ml, and the rotatory power measured under this condition.'可被翻译为：旋光管的长度为1dm,待测物质溶液的浓度为1g\/ml,在此条件下测得的旋光度。\n'liquid layer theory'可被翻译为：液层理论\n'The number of doses that produce a therapeutic effect after a single dose. Unit weight in kilograms (kg), grams (g), milligrams (mg), micrograms (seat) four weight measurement units; Capacity is expressed in liters (L) or milliliters (mL).'可被翻译为：一次给药后产生药物治疗作用的数量。单位重量以千克(kg)、克(g)、毫克(mg)、微克(座)四级重量计量单位表示；容量以升(L)或毫升(mL)表示。\n\n根据上述已知信息，请将'Absorbance when the solution concentration is l%(g\/ml) and the liquid layer thickness is 1cm.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当溶液浓度为l%(g\/ml),液层厚度为1cm时的吸光度。"
    },
    {
        "instruction":"已知信息：\n'The Provisions for Registration and Filing of Cosmetics adopted at the 14th Executive Meeting of the State Administration for Market Regulation on December 31, 2020 is hereby promulgated and shall go into effect as of May 1, 2021.'可被翻译为：《化妆品注册备案管理办法》已于2020年12月31日经国家市场监督管理总局2020年第14次局务会议审议通过，现予公布，自2021年5月1日起施行。\n'To implement the newly formulated Vaccine Administration Law and the newly revised Drug Administration Law, and reinforce the supervision and administration of the lot release of biological products, NMPA drafted the Provisions for the Lot Release of Biological Products (hereinafter referred to as the Provisions). The Provisions has been adopted upon deliberation at the 11th Executive Meeting of the State Administration for Market Regulation on November 19, 2020, and shall go into effect as of March 1, 2021.'可被翻译为：为贯彻落实新制定的《疫苗管理法》和新修订的《药品管理法》，加强生物制品批签发工作监督管理，药监局起草修订了《生物制品批签发管理办法》（以下称《办法》）。2020年11月19日，国家市场监督管理总局2020年第11次局务会议审议通过《办法》，自2021年3月1日起实施。\n'In order to implement the Regulations for the Supervision and Administration of Cosmetics and the Provisions for Registration and Notification of Cosmetics and further standardize the administration on registration and notification of cosmetics, the issues about implementing the Rules for the Registration and Notification Dossiers of Cosmetics (hereinafter referred to as the Rules) is hereby announced as follows:'可被翻译为：为贯彻落实《化妆品监督管理条例》《化妆品注册备案管理办法》相关规定，进一步规范化妆品注册备案管理工作，现就实施《化妆品注册备案资料管理规定》（以下简称《规定》）有关事项公告如下：\n'In order to implement the Provisions for Registration and Notification of Cosmetics and standardize and guide the registration and notification of cosmetics, the NMPA has developed the Rules for Registration and Notification Dossiers of Cosmetics, which is hereby issued and shall take effect as of May 1, 2021.'可被翻译为：为贯彻落实《化妆品注册备案管理办法》，规范和指导化妆品注册与备案工作，国家药监局制定了《化妆品注册备案资料管理规定》，现予公布，自2021年5月1日起施行。\n\n根据上述已知信息，请将'To implement the newly revised Regulationson the Supervision and Administration of Cosmetics (hereinafter referred to as the Regulations), reinforce the administration of cosmetics registration and notification, protect consumers' health rights, and standardize and promote the healthy development of the cosmetics industry, the NMPA drafted the Provisions for Registration and Notification of Cosmetics (hereinafter referred to as the Provisions).The Provisions has been adopted upon deliberation at the 14th Executive Meeting of the State Administration of Market Regulation on December 31, 2020, and shall go into effect as of May 1, 2021.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为贯彻落实新颁布的《化妆品监督管理条例》（以下简称《条例》），加强化妆品注册和备案管理，保障消费者健康权益，规范和促进化妆品行业健康发展，国家药监局起草了《化妆品注册备案管理办法》（以下简称《办法》）。2020年12月31日，国家市场监督管理总局2020年第14次局务会议审议通过《办法》，自2021年5月1日起实施。"
    },
    {
        "instruction":"已知信息：\n'repeatedly reactive'可被翻译为：多次反应\n'reactive'可被翻译为：DNA反应性\n'An atom or group in a molecule that is reactive, reactive, and reflects the common characteristics of a class of organic compounds.'可被翻译为：有机化合物分子中比较活泼、容易发生反应并反映着某类有机化合物共性的原子或基团。\n'Reactive Oxygen Species'可被翻译为：活性氧自由基\n\n根据上述已知信息，请将'A donation is considered to be repeatedly reactive if it is found reactive in a screening test, is retested in duplicate using the same assay, and at least one of the repeat tests is also reactive.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果在筛选试验中发现具有反应性，使用相同的方法进行两次重新测试，并且至少有一次重复测试也是具有反应性的，则认为捐赠具有重复反应性。"
    },
    {
        "instruction":"已知信息：\n'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government where the registration department is located shall be adopted for domestic class II medical devices.'可被翻译为：境内第二类医疗器械为注册审批部门所在地省、自治区、直辖市简称；\n'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government combines the abbreviation of city divided into districts where filing department is located (if there is no corresponding city divided into districts, only use the abbreviation of province, autonomous region or municipality directly under the central government) shall be adopted for domestic class I in-vitro diagnostic reagent.'可被翻译为：境内第一类体外诊断试剂为备案部门所在地省、自治区、直辖市简称加所在地设区的市级行政区域的简称（无相应设区的市级行政区域时，仅为省、自治区、直辖市的简称）；\n'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government combines the abbreviation of city divided into districts where filing department is located (if there is no corresponding city divided into districts, only use the abbreviation of province, autonomous region or municipality directly under the central government) shall be adopted for domestic class I medical device.'可被翻译为：境内第一类医疗器械为备案部门所在地省、自治区、直辖市简称加所在地设区的市级行政区域的简称（无相应设区的市级行政区域时，仅为省、自治区、直辖市的简称）；\n'Class II in-vitro diagnostic reagents shall be reviewed by the food and drug regulatory department of the provinces, autonomous regions and municipalities directly under the central government, and the medical device registration certificate shall be issued after approval.'可被翻译为：境内第二类体外诊断试剂由省、自治区、直辖市食品药品监督管理部门审查，批准后发给医疗器械注册证。\n\n根据上述已知信息，请将'The abbreviation of the provinces, autonomous regions and municipalities directly under the central government where the registration authority is located shall be adopted for domestic class II in-vitro diagnostic reagents.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"境内第二类体外诊断试剂为注册审批部门所在地省、自治区、直辖市简称；"
    },
    {
        "instruction":"已知信息：\n'The ethics committee refers to the independent institution which is set up by the clinical trial institution to examine the scientific and ethical nature of medical device clinical trial projects.'可被翻译为：伦理委员会，是指临床试验机构设置的对医疗器械临床试验项目的科学性和伦理性进行审查的独立的机构。\n'Article 11 Clinical trials shall be approved by the ethics committee of the medical device clinical trial institution. Clinical trials shall also be approved by China Food and Drug Administration if the corresponding investigational medical device is included in the class III medical device catalogue which requires clinical trial approval.'可被翻译为：第十一条 临床试验应当获得医疗器械临床试验机构伦理委员会的同意。列入需进行临床试验审批的第三类医疗器械目录的，还应当获得国家食品药品监督管理总局的批准。\n'Article 17 Before the clinical trial, the sponsor shall submit the following materials to the ethics committee through the investigator and the medical device clinical trial management department of the clinical trial institution:'可被翻译为：第十七条 临床试验前，申办者应当通过研究者和临床试验机构的医疗器械临床试验管理部门向伦理委员会提交下列文件：\n'Article 62 Before the clinical trial, the medical device clinical trial management department of the clinical trial institution shall coordinate with the sponsor to submit the application to the ethics committee and submit relevant documents according to the regulations.'可被翻译为：第六十二条 临床试验前，临床试验机构的医疗器械临床试验管理部门应当配合申办者向伦理委员会提出申请，并按照规定递交相关文件。\n\n根据上述已知信息，请将'Article 30 The ethics committee of the medical device clinical trial institution shall consist of at least five members, including medical professionals and non-medical professionals, covering different sexes. In the non-medical professionals, at least one is a legal professional and one is independent of the clinical trial institution. The members of the ethics committee shall have the qualification or experience to assess and evaluate the scientific, medical and ethical aspects of the clinical trial. All members shall be familiar with the ethical guidelines and related regulations of medical device clinical trials and follow the articles of the ethics committee.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十条 医疗器械临床试验机构伦理委员会应当至少由5名委员组成，包括医学专业人员、非医学专业人员，其中应当有不同性别的委员。非医学专业委员中至少有1名为法律工作者，1名为该临床试验机构以外的人员。伦理委员会委员应当具有评估和评价该项临床试验的科学、医学和伦理学等方面的资格或者经验。所有委员应当熟悉医疗器械临床试验的伦理准则和相关规定，并遵守伦理委员会的章程。"
    },
    {
        "instruction":"已知信息：\n'Adding an appropriate amount of electrolyte to the suspension to adjust the self-potential can make the repulsive force between the particles slightly lower than the attractive force, forming a loose flocculent aggregate, which is restored to a uniform suspension by shaking.'可被翻译为：混悬剂中加入适量的电解质调节自电位，可使微粒间的排斥力稍低于吸引力，形成疏松的絮状聚集体，经振摇恢复成均匀的混悬剂的现象。\n'If the electrolyte is added to the suspension to increase the potential of the particle surface, the electrostatic repulsion hinders the collision between the particles and the aggregation, the flocculation state disappears, the added electrolyte is called the deflocculant.'可被翻译为：如果在混悬剂中因加入电解质使微粒表面的&电位升高，静电排斥力阻碍了微粒之间的碰撞聚集，絮凝状态消失，所加入的电解质称为反絮凝剂。\n'The addition of electrolyte in the suspension system increases the J potential of the surface of the particles, and the increase of electrostatic repulsion hinders the collision and aggregation of the particles, making the process of reducing the flocculation phenomenon.'可被翻译为：在混悬体系中加入电解质使微粒表面J电位升高，这时静电排斥力的增大阻碍了微粒间的碰撞聚集，使得絮凝现象减少的过程。\n'The force that causes particles to come close and join indirectly. Including the attraction between solid particles, interfacial tension and capillary force generated by free flowing liquids, adhesion and adhesion generated by non-flowing liquids; Solid bridge between particles and mechanical Mosaic between particles, etc.'可被翻译为：导致粒子间接近和结合的力。包括固体粒子间引力，自由可流动液体产生的界面张力和毛细管力，不可流动液体产生的附着力与黏着力；粒子间固体桥和粒子间机械镶嵌等。\n\n根据上述已知信息，请将'If the appropriate amount of electrolyte is added to the suspension, the J potential can be reduced to an appropriate degree, even if the repulsive force between the particles is slightly lower than the attractive force, at this time the particles gather into a loose flocculent aggregate, which can be restored to a uniform suspension by shaking, the added electrolyte is called a flocculant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"混悬剂中如果加入适量的电解质，可使J电位降低到适当的程度，即使微粒间的排斥力稍低于吸引力，此时微粒聚集成疏松的絮状聚集体，经振摇可恢复成均匀的混悬剂，所加电解质称为絮凝剂。"
    },
    {
        "instruction":"已知信息：\n'(1) Class 1 chemical drugs are innovative drugs that contain new compounds with clear structures and pharmacological effects and have clinical values. Class 2.1 drugs in modified new drugs are not included. New compound preparations containing new compounds with clear structures and pharmacological effects shall be applied in accordance with Class 1 chemical drugs.'可被翻译为：（一）化学药品1类为创新药，应含有新的结构明确的、具有药理作用的化合物，且具有临床价值，不包括改良型新药中2.1类的药品。含有新的结构明确的、具有药理作用的化合物的新复方制剂，应按照化学药品1类申报。\n'Class 2: Modified new drugs that have not been marketed in China or overseas. They refer to drugs that have their structure, dosage form, formulation and process, route of administration and indications optimized on the basis of known active ingredients and have significant clinical advantages.'可被翻译为：2类：境内外均未上市的改良型新药。指在已知活性成份的基础上，对其结构、剂型、处方工艺、给药途径、适应症等进行优化，且具有明显临床优势的药品。\n'(2) Class 2 chemical drugs, being modified new drugs, are optimized on the basis of known active ingredients, and shall have obvious clinical advantages over those before modification. Known active ingredients refer to the active ingredients of drugs that have been marketed in China or overseas. If such drugs meet the requirements of multiple conditions at the same time, such conditions shall be described at application.'可被翻译为：（二）化学药品2类为改良型新药，在已知活性成份基础上进行优化，应比改良前具有明显临床优势。已知活性成份指境内或境外已上市药品的活性成份。该类药品同时符合多个情形要求的，须在申报时一并予以说明。\n'Original drugs refer to drugs that have been firstly approved to be marketed in China and overseas and have complete and sufficient safety and effectiveness data as the basis for being marketed.'可被翻译为：原研药品是指境内外首个获准上市，且具有完整和充分的安全性、有效性数据作为上市依据的药品。\n\n根据上述已知信息，请将'Class 1: Innovative drugs that have not been marketed in China or overseas. They refer to drugs that contain new compounds with clear structures and pharmacological effects, and have clinical values.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1类：境内外均未上市的创新药。指含含有新的结构明确的、具有药理作用的化合物，且具有临床价值的药品。"
    },
    {
        "instruction":"已知信息：\n'All handling of materials and products should be carried out according to operation procedures and master manufacturing documents, and recorded accordingly.'可被翻译为：物料和产品的处理应当按照操作规程或工艺规程执行，并有记录。\n'Article 195: Any deviation from master manufacturing documents or operation procedures should be avoided as far as possible. Once a deviation occurs, operation procedures for deviation handling should be followed.'可被翻译为：第一百九十五条 应当尽可能避免出现任何偏离工艺规程或操作规程的偏差。一旦出现偏差，应当按照偏差处理操作规程执行。\n'Article 224: Operation procedures for investigation of testing results out of specification should be established in quality control laboratories. Any out of specification results must be fully investigated following the operation procedures and recorded accordingly.'可被翻译为：第二百二十四条 质量控制实验室应当建立检验结果超标调查的操作规程。任何检验结果超标都必须按照操作规程进行完整的调查，并有相应的记录。\n'Article 101: The pipes for purified water and water for injection should be cleaned and sanitized according to operation procedures and recorded accordingly. If bioburden of water for pharmaceutical use exceeds alert or action limits, actions should be taken according to operation procedures.'可被翻译为：第一百零一条 应当按照操作规程对纯化水、注射用水管道进行清洗消毒，并有相关记录。发现制药用水微生物污染达到警戒限度、纠偏限度时应当按照操作规程处理。\n\n根据上述已知信息，请将'Article 248: The manufacturer should establish operation procedures for deviation handling, define the reporting, recording, investigation, treatment and corrective actions adopted and all should be recorded accordingly.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二百四十八条 企业应当建立偏差处理的操作规程，规定偏差的报告、记录、调查、处理以及所采取的纠正措施，并有相应的记录。"
    },
    {
        "instruction":"已知信息：\n'Clinical Technical Requirements for Drugs Marketed Overseas but Not Marketed in China'可被翻译为：境外已上市境内未上市药品临床技术要求\n'Notice of CDE of China NMPA on Issuing the Technical Requirements for CMC Study and Evaluation of Chemical Drugs Marketed Overseas But Not Marketed in China (Interim)'可被翻译为：国家药监局药品监督管理总局关于印发《境外上市未在境内上市化学药品CMC研究评价技术要求(暂行)》的通知\n'In order to further guide enterprises to carryout drug R&D, accelerate the R&D and marketing process of chemical drugs that have been marketed overseas but not in China, and provide technical standards that can be used as references, the CDE, under the guidance of NMPA, has organized to formulate the Technical Requirements for CMC Study and Evaluation of Chemical Drugs Marketed Overseas But Not Marketed in China (Interim),which was issued and implemented as of March 3.'可被翻译为：为进一步引导企业开展药品研发，加快境外已上市化学药品的研发和上市进程，提供可参考的技术标准，国家药监局组织制定了《境外已上市化学药品CMC研究与评估技术要求(暂行)》，并于3月3日发布实施。\n'For drugs marketed overseas but not marketed in China, technical requirements for clinical trials to support its marketing in China should be established in compliance with the basic logic of clinical evaluation and on the basis of full evaluation of clinical demand of Chinese patients, clinical safety and effectiveness of overseas originator drugs, influences of racial factors as well as the need of benefit\/risk evaluation in Chinese patients.'可被翻译为：境外已上市境内未上市药品的临床技术要求，应遵循临床评价基本逻辑，在充分评价中国患者临床需求、境外原研药品临床安全性和有效性、以及种族因素影响的基础上，基于中国患者获益\/风险评估的需要，确定其在境内上市需开展的临床试验技术要求。\n\n根据上述已知信息，请将'Center for Drug Evaluation, NMPA issued the Clinical Technical Requirements for Drugs Marketed Overseas but Not Marketed in China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局药审中心关于发布《境外已上市境内未上市药品临床技术要求》"
    },
    {
        "instruction":"已知信息：\n'The extent to which a variable (e.g. a rating scale) measures what it is supposed to measure.'可被翻译为：是指一个指标（如量表）测量它所预期测量的内容的程\n度。\n'Determine whether there were any anomalies or deviations from the analytical method. Adherence to method should be verified at the time of analysis, and any major breach of sterility test procedure should also be documented at that time. If any method breaches occurred, determine whether it was likely to cause the contamination. Be aware of any possible weaknesses in the test method (e.g., kit, manifold, etc.) used.'可被翻译为：确定是否有异常或分析方法偏差。核查分析时是否遵守检验方法，严重违反无菌检 测程序的情况亦要即时记录。如果发现违背方法的情况，确定是否有可能导致污染。 了解所用检测方法（例如，检测盒，歧管等）中是否有任何可能弱点。\n'An indicator that affects a patient's final health outcome, but is not in itself the end goal of treatment. It is often used as a proxy variable for final outcome when it is difficult to observe in the short term.'可被翻译为：能影响病人最终健康产出的指标，但该指标本身不是治疗的最终目标。当最终产出难以在短期内观察到，常用来作为最终产出的代理变量。\n'cost-effectiveness analysis(cea)'可被翻译为：成本-效果分析\n\n根据上述已知信息，请将'A method used to determine the reliability of an analytical outcome (e.g., cost-effectiveness analysis, decision analysis). The extent to which an important variable (e.g., cost, outcome, probability of an event, etc.) is affected by examining the possible range of variation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用来测定某种分析结果（如成本-效果分析、决策分析）可靠性的方法。通过检验重要变量（如成本、结果、事件的概率等）可能的变化范围来判断对分析结果产生影响的程度。"
    },
    {
        "instruction":"已知信息：\n'The technique of measuring the relationship between the sound emitted by a substance and its temperature under programmed temperature control.'可被翻译为：在程序控制温度下，测量物质发出的声音与温度关系的技术。\n'A solid with a constant surface area is represented by the amount (mg) of dissolved substance per unit area (cm2) per unit time in the medium (the table is not mg\/time\/cm2).'可被翻译为：具有恒定表面积的固体在介质中单位面积（cm2）单位时间内溶解的物质的量（mg）表示（表不为mg\/time\/cm2）。\n'In a homogeneous reaction, the change in the mass of the components of the reaction system per unit time and per unit volume.'可被翻译为：在均相反应中，单位时间和单位体积内反应体系中组分物质量的改变。\n'The amount of bacteria per unit volume in the medium.'可被翻译为：单位体积培养液中菌体的含量。\n\n根据上述已知信息，请将'The amount of heat absorbed or emitted per unit mass of a substance by lowering its temperature by 1k or increasing it by 1 ° C.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单位质量的某种物质，温度降低1k或升高1℃所吸收或放出的热量。"
    },
    {
        "instruction":"已知信息：\n'Article 26 The legal representative and principal responsible person of the registrant or filing entity of medical devices shall assume full responsibility for quality and safety of the medical devices manufactured.'可被翻译为：第二十六条  医疗器械注册人、备案人的法定代表人、主要负责人对其生产的医疗器械质量安全全面负责。\n'Article 35 The registrant or filing entity of medical devices shall establish and implement the procedures for tracing products, to guarantee the traceability of the products. The contract manufacturer shall assist with the registrant and the filing entity in tracing the products.'可被翻译为：第三十五条  医疗器械注册人、备案人应当建立并实施产品追溯制度，保证产品可追溯。受托生产企业应当协助注册人、备案人实施产品追溯。\n'Article 59 If the registrant, filing entity and distributor of the medical devices fail to take effective removal measures for the existing quality and safety risks of the medical devices, the drug regulatory departments may hold a liability interview with legal representative or person in charge of enterprise of the registrant, filing entity and distributor of the medical devices.'可被翻译为：第五十九条  医疗器械注册人、备案人、经营企业对存在的医疗器械质量安全风险，未采取有效措施消除的，药品监督管理部门可以对医疗器械注册人、备案人、经营企业的法定代表人或者企业负责人进行责任约谈。\n'Article 31 The medical device distributors shall purchase medical devices from medical device registrant, filing entity and distributor with legal qualification.'可被翻译为：第三十一条  医疗器械经营企业应当从具有合法资质的医疗器械注册人、备案人、经营企业购进医疗器械。\n\n根据上述已知信息，请将'Article 61 The registrant or filing entity of imported medical devices shall designate the domestic enterprise legal person as the agent, who shall assist the registrant or filing entity to fulfill the obligations prescribed in the Regulations on Supervision and Administration of Medical Devices and these Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十一条  进口医疗器械注册人、备案人应当指定我国境内企业法人作为代理人，代理人应当协助注册人、备案人履行医疗器械监督管理条例和本办法规定的义务。"
    },
    {
        "instruction":"已知信息：\n'8.2. The SU should provide the RU with information on relevant health, safety and environmental issues, including:'可被翻译为：SU应向RU提供与卫生、安全和环境问题有关的信息，包括：\n'Article 213: In-process control of the product during packaging should include at least the following information:'可被翻译为：第二百一十三条 包装期间，产品的中间控制检查应当至少包括下述内容：\n'A change to any aspect of a pharmaceutical product, including but not limited to, the change of use of a starting material, a change to formulation, method or site of manufacture, specifications for the finished product and ingredients, container and container labelling and product information.'可被翻译为：药品任何方面的变更，包括但不限于:原辅料使用的变更，制剂、生产方法或生产地点的变更，成品和成分规格的变更，容器和容器标签以及产品信息的变更。\n'12.19. The SU should provide to the RU information on current processing and testing, including but not limited to:'可被翻译为：SU应向RU提供当前的工艺和检测信息，包括但不仅限于：\n\n根据上述已知信息，请将'12.16. The SU should provide the product information including its qualitative and quantitative composition, physical description, method of manufacture, in-process controls, control method and specifications, packaging components and configurations, and any safety and handling considerations to the RU.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"SU应向RU提供产品信息，包括其定性和定量配方、物理描述、生产方法、中控、检测方法和质量标准、包装部件和参数，以及所有安全和处置注意事项。"
    },
    {
        "instruction":"已知信息：\n'Article 21 The duration of on-site inspection shall be determined by the inspection team in accordance with the needs of the inspection and principles of making the issues clear and ascertain. The inspection team shall not terminate the inspection without the consent of the food and drug regulatory department organizing the unannounced inspection.'可被翻译为：第二十一条 现场检查时间由检查组根据检查需要确定，以能够查清查实问题为原则。\n'Article 20 Where any of the following circumstances exist, the inspection team shall report promptly to the food and drug regulatory department organizing the unannounced inspection for its timely decisions:'可被翻译为：第二十条 有下列情形之一的，检查组应当立即报组织实施飞行检查的食品药品监督管理部门及时作出决定：\n'Article 13 Where an unannounced inspection is organized by a higher level food and drug regulatory department, the local food and drug regulatory department may be notified at an appropriate time. The local food and drug regulatory department shall assign personnel to assist the inspection, and they shall follow the arrangements of the inspection team.'可被翻译为：第十三条 上级食品药品监督管理部门组织实施飞行检查的，可以适时通知被检查单位所在地食品药品监督管理部门。被检查单位所在地食品药品监督管理部门应当派员协助检查，协助检查的人员应当服从检查组的安排。\n'Article 24 The inspection team shall generally submit the inspection report, records and relevant evidence materials, etc. to the food and drug regulatory department conducting the unannounced inspection within five working days after completing the inspection. When necessary, a copy thereof may be sent to the local food and drug regulatory department.'可被翻译为：第二十四条 检查组一般应当在检查结束后5个工作日内，将检查报告、检查记录、相关证据材料等报组织实施飞行检查的食品药品监督管理部门。必要时，可以抄送被检查单位所在地食品药品监督管理部门。\n\n根据上述已知信息，请将'Article 14 The food and drug regulatory department organizing the conduction of the unannounced inspection shall strengthen the leadership over the inspection team, timely adjust coping strategies according to the feedback of on-site inspection, initiate the coordination mechanisms when necessary, and assign relevant personnel to inspection sites for coordination and leadership.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十四条 组织实施飞行检查的食品药品监督管理部门应当加强对检查组的指挥，根据现场检查反馈的情况及时调整应对策略，必要时启动协调机制，并可以派相关人员赴现场协调和指挥。"
    },
    {
        "instruction":"已知信息：\n'Article 89: Main fixed pipes should be clearly labeled to indicate the contents and the direction of flow.'可被翻译为：第八十九条 主要固定管道应当标明内容物名称和流向。\n'Article 93: Weighing and measuring equipment, gauges, recording and control equipment should be clearly labeled to indicate the calibration validity date.'可被翻译为：第九十三条 衡器、量具、仪表、用于记录和控制的设备以及仪器应当有明显的标识，标明其校准有效期。\n'Article 88: Defective equipment should, if possible, be removed from production and quality control areas, or at least be clearly labeled as defective.'可被翻译为：第八十八条 不合格的设备如有可能应当搬出生产和质量控制区，未搬出前，应当有醒目的状态标识。\n'Article 86: Log books should be established for equipment and instruments used for drug production and testing, to record the use, cleaning, maintenance and repair activities, along with the date, time, and the name, strength ,batch number, etc., of the drug produced and tested.'可被翻译为：第八十六条 用于药品生产或检验的设备和仪器，应当有使用日志，记录内容包括使用、清洁、维护和维修情况以及日期、时间、所生产及检验的药品名称、规格和批号等。\n\n根据上述已知信息，请将'Article 87: Production equipment should be clearly labeled to indicate the equipment reference number and the contents (e.g. product name, strength, batch number, etc.). The equipment without contents should be labeled to indicate its cleaning status.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十七条 生产设备应当有明显的状态标识，标明设备编号和内容物（如名称、规格、批号）；没有内容物的应当标明清洁状态。"
    },
    {
        "instruction":"已知信息：\n'Question 2: Can INTERMEDIATE (IN-PROCESS) sample aliquots be \"pooled\" into a composite and screened for bacterial endotoxin?'可被翻译为：问2：中间体样品等分样是否可以“合并”至组合样中用于细菌内毒素筛选？\n'Question 1: Can FINISHED product units (vials, ampoules, pre-filled syringes, etc.) be \"Pooled\" into a composite and screened for bacterial endotoxin?'可被翻译为：问1：成品单元（西林瓶、安瓿、预充填注射针等）可“混合”至组合中并进行筛 选后执行细菌内毒素检测吗？\n'The standard extracting, rinsing and soaking fluid for medical devices is pyrogen-free water. The analytical approach for testing medical devices is covered in USP. If the extraction fluid shows endotoxin interfering results, modification of testing may be necessary depending on the product configuration. Alternate diluents must be verified to not interfere with the endotoxin assay prior to use.'可被翻译为：医疗器械的标准萃取、淋洗和浸泡流体为无热源水。检测医疗器械的分析方法在USP 中写明。如果萃取流体显示出内毒素干扰结果，可能需要根据产品参数设置对检测进行 修改。替代稀释剂在使用前必须确认其不会干扰内毒素分析。\n'Products including, but not limited to, finished pharmaceutical products, medical devices including in vitro diagnostic medical devices, and vaccines.'可被翻译为：产品包括但不限于成品药品、医疗器械(包括体外诊断医疗器械)和疫苗。\n\n根据上述已知信息，请将'Finished medical devices may also be pooled into a composite sample and assayed for bacterial endotoxins. Testing for medical devices should be conducted using rinsing\/eluting and sampling techniques as described in ISO 10993-1 and ISO 10993-12, as also used for inhibition\/enhancement.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"成品组合器械可能亦会合并成组合样品进行细菌内毒素检测。器械的检测应该使用 ISO 10993-1 和 ISO 10993-12所述淋洗\/洗脱和取样技术，这也用于抑制\/增强。"
    },
    {
        "instruction":"已知信息：\n'combinatorial chemistry'可被翻译为：组合化学\n'A centralized library of combinatorial chemical molecules based on kinase target screening.'可被翻译为：基于激酶靶标筛选的组合化学分子集中库。\n'Combinatorial chemistry refers to a collection of compounds containing a large number and different structures.'可被翻译为：组合化学中表示包含数量较多且为不同结构的化合物集合。\n'combinatorial biosynthesis'可被翻译为：组合生物合成\n\n根据上述已知信息，请将'A new discipline in the fields of combinatorial genomics, proteomics, combinatorial chemistry and cell screening.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"组合基因组学、蛋白质组学、组合化学及细胞筛选等领域的新学科。"
    },
    {
        "instruction":"已知信息：\n'II. From May 1, 2022, electronic registration certificate will be issued to special cosmetics approved of change or renewal of registration.'可被翻译为：二、自2022年5月1日起，特殊化妆品获准注册证变更、延续的，开始发放电子注册证。\n'(1) In the name of the registrants and filing persons, handling the registration and filing of cosmetics and new cosmetic ingredients;'可被翻译为：（一）以注册人、备案人的名义，办理化妆品、化妆品新原料注册、备案；\n'If the procedures and time limit for the registration of special cosmetics are not stipulated, the regulations on registration of new cosmetic ingredients in these Provisions shall be applied.'可被翻译为：特殊化妆品注册程序和时限未作规定的，适用本办法关于化妆品新原料注册的规定。\n'Article 4 The State implements registration administration for special cosmetics and new cosmetic ingredients with high risks, and filing administration for general cosmetics and other new cosmetic ingredients.'可被翻译为：第四条 国家对特殊化妆品和风险程度较高的化妆品新原料实行注册管理，对普通化妆品和其他化妆品新原料实行备案管理。\n\n根据上述已知信息，请将'I. From January 1, 2022, electronic registration certificate will be issued to special cosmetics and new cosmetic ingredients with application submitted and approved for registration according to the Provisions for the Registration and Filing of Cosmetics.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一、自2022年1月1日起，按照《化妆品注册备案管理办法》提出申请并获准注册的特殊化妆品和化妆品新原料，开始发放电子注册证。"
    },
    {
        "instruction":"已知信息：\n'(V) The package, label and package insert of drugs shall comply with relevant provisions;'可被翻译为：（五）药品包装、标签、说明书符合有关规定；\n'Samples taken for acceptance inspection shall be representative.'可被翻译为：验收抽取的样品应当具有代表性。\n'Article 158 Drugs that are qualified in the acceptance inspection shall be warehoused or put on the shelf without delay; those failed the acceptance inspection shall not be warehoused or put on the shelf and shall be instead reported to the quality management personnel for handling.'可被翻译为：第一百五十八条 验收合格的药品应当及时入库或者上架，验收不合格的，不得入库或者上架，并报告质量管理人员处理。\n'Article 77 Enterprises shall carry out sampling inspection for acceptance lot by lot for drugs of each arrival in accordance with the provisions on acceptance inspection, and the samples taken shall be representative:'可被翻译为：第七十七条 企业应当按照验收规定，对每次到货药品进行逐批抽样验收，抽取的样品应当具有代表性：\n\n根据上述已知信息，请将'Article 78 Acceptance inspection personnel shall inspect and check the appearance, package, label, package insert and relevant supporting documents of the sampled drugs one by one; after the acceptance inspection, the intact samples taken shall be put back into the original packaging box, sealed and marked.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十八条 验收人员应当对抽样药品的外观、包装、标签、说明书以及相关的证明文件等逐一进行检查、核对；验收结束后，应当将抽取的完好样品放回原包装箱，加封并标示。"
    },
    {
        "instruction":"已知信息：\n'(13) Free treatment items and other related compensation that the subjects may obtain during the trial.'可被翻译为：（十三）受试者在试验期间可能获得的免费诊疗项目和其他相关补助。\n'3. The Ethics Committee pays close attention to whether injuries of subjects receive timely medical treatment, and monitors whether the sponsor and the investigator timely delivers the compensation to the subjects.'可被翻译为：3.伦理委员会关注受试者的损害是否得到及时的医学处理，监督申办者、研究者及时兑现给与受试者的补偿或赔偿。\n'(6) Whether the treatment and insurance measures to be given to the subjects who suffer from trial-related injuries and death are sufficient.'可被翻译为：（六）受试者若发生与临床试验相关的伤害或者死亡，给予的治疗和保险措施是否充分。\n'Article 48 The sponsor shall bear the treatment costs and corresponding economic compensation for the subjects who suffer injuries or death related to the clinical trial, except for the damage caused by the fault of the medical institutions and its medical personnel in the diagnosis and treatment activities.'可被翻译为：第四十八条 申办者应当为发生与临床试验相关的伤害或者死亡的受试者承担治疗的费用以及相应的经济补偿，但在诊疗活动中由医疗机构及其医务人员过错造成的损害除外。\n\n根据上述已知信息，请将'(11) The subjects may receive treatment and economic compensation for any trial-related injuries.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十一）如发生与试验相关的伤害，受试者可以获得治疗和经济补偿；"
    },
    {
        "instruction":"已知信息：\n'Person responsible for performing the sampling operations.'可被翻译为：负责执行抽样操作的人。\n'sampling inspector'可被翻译为：抽样检查\n'Sampling methods should not pose a risk of contamination to the manufacturing operations.'可被翻译为：釆样方法不应给生产操作带来污染风险。\n'Note 4: Sampling methods should not pose a risk of contamination to the manufacturing operations.'可被翻译为：注 4：釆样方法不应给生产操作带来污染风险。\n\n根据上述已知信息，请将'Person responsible for performing the sampling operations. The sampling inspector need not be a qualified analyst. However, everyone called upon to take samples should be trained in the practical aspects of sampling and should have sufficient knowledge of pharmaceutical substances to execute the work effectively and safely. A conscientious approach, with meticulous attention to detail and cleanliness, is essential. The sampling inspector must remain alert to any signs of contamination, deterioration or tampering. Any suspicious signs should be recorded in detail in the sampling record.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"负责执行抽样操作的人员。抽样检验员不必是合格的分析员。然而，每个被要求取样的人都应该接受取样实践方面的培训，并且应该有足够的药物知识来有效和安全地执行工作。认真负责的方法，对细节和清洁的细致关注是必不可少的。抽样检查员必须对任何污染、变质或篡改的迹象保持警惕。任何可疑迹象都应详细记录在抽样记录中。"
    },
    {
        "instruction":"已知信息：\n'When monosaccharides form a ring structure, the original hydroxyl group is transformed into two different configurations (a or similar isomers).'可被翻译为：单糖形成环状结构时，原来的戮基转变成羟基时形成的两种不同构型（a或似的同分异构体。\n'reference standard'可被翻译为：对照标准品\n'Reference Standard Endotoxin and Control Standard Endotoxins'可被翻译为：参比标准内毒素和受 控标准内毒素\n'The characteristic quantity value of the standard substance shall be measured by accurate and reliable method or by method directly compared with the first class standard substance, and the standard substance whose measurement accuracy meets the needs shall be measured. In the laboratory, it usually refers to the working reference material (standard material) used as a control after comparison with the primary reference material.'可被翻译为：采用准确、可靠的方法或直接与一级标准物质相比较的方法，测量标准物质的特性量值，测量准确度满足需要的标准物质。在实验室中通常是指与一级标准物质比对后作为对照使用的工作对照品（标准品）。\n\n根据上述已知信息，请将'The original type, form, style, or structure, or the typical example, reference, or standard of a class of things.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"泛指原始类型、形式，体例或结构，或代表某类别事物的典型个例、基准物或标准物。"
    },
    {
        "instruction":"已知信息：\n'(7) having any other dereliction of duty in vaccine administration, resulting in serious negative effects or heavy losses.'可被翻译为：（七）其他未履行疫苗监督管理职责的行为，造成严重不良影响或者重大损失。\n'(3) fail to promptly discover systemic risks of drug safety, or fail to promptly eliminate drug safety hazards within their supervision and administration region, resulting in serious effects; or'可被翻译为：（三）未及时发现药品安全系统性风险，或者未及时消除监督管理区域内药品安全隐患，造成严重影响；\n'(3) incompetence in the performance of duties which causes serious adverse effects or serious losses.'可被翻译为：（三）履行职责不力，造成严重不良影响或者重大损失。\n'(4) failing to perform drug supervision and administration duties, resulting in serious adverse impact or serious losses.'可被翻译为：（四）其他不履行药品监督管理职责，造成严重不良影响或者重大损失。\n\n根据上述已知信息，请将'(1) performing responsibility insufficiently, resulting in serious negative effects or heavy losses;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）履行职责不力，造成严重不良影响或者重大损失；"
    },
    {
        "instruction":"已知信息：\n'If the drug meets relevant standards based on verification test, the drug regulatory department at ports of entry shall lift the administrative enforcement measures such as seizure and detention, and report the handling situation to the State Food and Drug Administration and at the same time to the drug regulatory department of each province, autonomous region and municipality directly under the central government and to other drug regulatory departments at ports of entry.'可被翻译为：经复验符合标准规定的，口岸药品监督管理局应当解除查封、扣押的行政强制措施，并将处理情况报告国家食品药品监督管理局，同时通告各省、自治区、直辖市药品监督管理局和其他口岸药品监督管理局。\n'Upon receipt of the Report of Testing for Import Drugs, the local drug regulatory department at ports of entry shall promptly take administrative enforcement measures to seize and detain all such drugs, and make an administrative handling decision within 7 days. In the case of applying for verification test, an administrative handling decision must be made within 15 days since the day of issuing the testing report. Relevant information shall be reported to the State Food and Drug Administration in a timely manner and at the same time to the drug regulatory department of each province, autonomous region and municipality directly under the central government and to other drug regulatory departments at ports of entry.'可被翻译为：所在地口岸药品监督管理局收到《进口药品检验报告书》后，应当及时采取对全部药品予以查封、扣押的行政强制措施,并在7日内作出行政处理决定。对申请复验的，必须自检验报告书发出之日起15日内作出行政处理决定。有关情况应当及时报告国家食品药品监督管理局，同时通告各省、自治区、直辖市药品监督管理局和其他口岸药品监督管理局。\n'The drug control institute of port shall promptly notify the drug regulatory department at ports of entry, and shall, within 10 days after accepting the application for verification test, draw a conclusion on the verification test, notify the drug regulatory department at ports of entry and other drug control institutes of port, and submit it to the State Food and Drug Administration and the National Institute for the Control of Pharmaceutical and Biological Products.'可被翻译为：口岸药品检验所在受理复验申请后，应当及时通知口岸药品监督管理局，并自受理复验之日起10日内，作出复验结论，通知口岸药品监督管理局、其他口岸药品检验所，报国家食品药品监督管理局和中国药品生物制品检定所。\n'Article 33 Other issues found in the record filing of drugs to be imported shall be disposed of by the drug regulatory departments at ports of entry in accordance with the Drug Administration Law and relevant regulations.'可被翻译为：第三十三条 药品进口备案中发现的其他问题，由口岸药品监督管理局按照《药品管理法》以及有关规定予以处理。\n\n根据上述已知信息，请将'Article 32 Where no application for verification testis submitted within the prescribed time or the drug still fails to meet relevant standards based on the verification test, drug regulatory department at ports of entry shall make an administrative handling decision in accordance with the Drug Administration Law and relevant regulations. Relevant information shall be reported to the State Food and Drug Administration in a timely manner and at the same time to the drug regulatory department of each province, autonomous region and municipality directly under the central government and to other drug regulatory departments at ports of entry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十二条 未在规定时间内提出复验或者经复验仍不符合标准规定的，口岸药品监督管理局应当按照《药品管理法》以及有关规定作出行政处理决定。有关情况应当及时报告国家食品药品监督管理局，同时通告各省、自治区、直辖市药品监督管理局和其他口岸药品监督管理局。"
    },
    {
        "instruction":"已知信息：\n'A method of treating a disease, such as by directly combating or removing the cause of the disease itself. Is the theory and treatment method used in Western medicine.'可被翻译为：对造成疾病本身的原因直接对抗、移除等治疗疾病的方法。是西医所使用的理论和治疗方法。\n'A method of administration in which a prescribed daily dose is taken once. To achieve the best results.'可被翻译为：将医嘱每日药物剂量一次服下的给药方法。以期达到最佳治疗效果。\n'The extent to which the results of a particular study or systematic review can be extrapolated to other Settings.'可被翻译为：某种研究或者系统综述的结果能够外推于其他环境的程度。\n'An evidence-based recommendation of appropriate treatment or care for a patient with a particular disease or condition.'可被翻译为：以证据为基础的，对特定疾病或状况下的病人适宜治疗或护理方案的推荐。\n\n根据上述已知信息，请将'A retrospective study method in which the cause is explored by the results. It is based on the present diagnosis of a particular disease'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种由结果探索病因的回顾性研究方法。其基本原理是以现在确诊的患有某特定疾病"
    },
    {
        "instruction":"已知信息：\n'1. The designated name and the internal code reference of the material;'可被翻译为：（一）指定的物料名称和企业内部的物料代码；\n'1. The designated name of the product and the code reference;'可被翻译为：（一）产品名称以及产品代码；\n'1. The name of the product and the internal code reference;'可被翻译为：（一）产品名称和企业内部的产品代码；\n'1. The product name, strength, batch number;'可被翻译为：（一）产品名称、规格、批号。\n\n根据上述已知信息，请将'1. The name of the material on the delivery note and the containers;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）交货单和包装容器上所注物料的名称；"
    },
    {
        "instruction":"已知信息：\n'The supervision refers to the activities performed by special personnel who are selected by the sponsor of carrying out the evaluation and investigation of the clinical trial institutions and the investigators, and verifying, recording and reporting data during the clinical trial, so as to ensure that the clinical trial carried out is in conformity with the clinical trial protocol, standard operating procedures, this GCP and applicable management requirements.'可被翻译为：监查，是指申办者为保证开展的临床试验能够遵循临床试验方案、标准操作规程、本规范和有关适用的管理要求，选派专门人员对临床试验机构、研究者进行评价调查，对临床试验过程中的数据进行验证并记录和报告的活动。\n'Article 92 The basic documents of clinical trial may be used to evaluate the implementation of this GCP and relevant requirements of the food and drug administration departments carried out by the sponsor, the clinical trial institution and the investigator. The food and drug administration departments can check the basic documents of clinical trial.'可被翻译为：第九十二条 临床试验基本文件可以用于评价申办者、临床试验机构和研究者对本规范和食品药品监督管理部门有关要求的执行情况。食品药品监督管理部门可以对临床试验基本文件进行检查。\n'The verification refers to the systematic independent inspection of relevant clinical trial activities and documents organized by the sponsor, so as to determine whether the implementation of such activities, data recording, analysis and reporting conform to the clinical trial protocol, standard operating procedures, the GCP and applicable management requirements.'可被翻译为：核查，是指由申办者组织的对临床试验相关活动和文件进行系统性的独立检查，以确定此类活动的执行、数据的记录、分析和报告是否符合临床试验方案、标准操作规程、本规范和有关适用的管理要求。\n'The source data refers to the original records of clinical findings, observations and other activities in the clinical trial and all information of approved copies, which can be used for clinical trial reconstruction and evaluation.'可被翻译为：源数据，是指临床试验中的临床发现、观察和其他活动的原始记录以及其经核准的副本中的所有信息，可以用于临床试验重建和评价。\n\n根据上述已知信息，请将'The inspection refers to the supervision and administration activities carried out by the regulatory department for inspecting relevant clinical trial documents, facilities, records and other aspects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"检查，是指监管部门对临床试验的有关文件、设施、记录和其他方面进行的监督管理活动。"
    },
    {
        "instruction":"已知信息：\n'(5) an applicant fails to provide supplementary data within the prescribed timeline;'可被翻译为：（五）未能在规定的时限内补充资料的；\n'Article 87 After the drug registration application is accepted, where it is necessary for the applicant to provide new technical dossier on the basis of the original submission dossier, the CDE shall, in principle, make a one-time requirement for supplementary dossier. The CDE shall list all the issues and inform the applicant in a written notice to submit supplementary dossier within 80 days. The applicant shall submit all the supplementary dossier together as required in one submission, and the time needed for the supplement of dossier will not be counted into the drug review timeline. The CDE shall restart review upon receiving all the supplementary dossier from the applicant, and the review timeline shall be extended by 1\/3 of the original review timeline; where the priority review and approval procedure is applicable, the review timeline shall be extended by 1\/4 of the original review timeline.'可被翻译为：第八十七条 药品注册申请受理后，需要申请人在原申报资料基础上补充新的技术资料的，药品审评中心原则上提出一次补充资料要求，列明全部问题后，以书面方式通知申请人在八十日内补充提交资料。申请人应当一次性按要求提交全部补充资料，补充资料时间不计入药品审评时限。药品审评中心收到申请人全部补充资料后启动审评，审评时限延长三分之一；适用优先审评审批程序的，审评时限延长四分之一。\n'(4) Where the dossier is incomplete or not in compliance with the defined format the applicant shall be informed on-site or within 5 days in a one-time notification of what to be supplemented or corrected. Where the dossier needs to be returned when the applicant is informed as per regulations, the dossier shall be returned. The applicant shall complete the supplementation and correction of the dossier within 30 days. Where the applicant fails to make the supplementation or correction within the specified timeline without justifiable reasons, the application shall be deemed to have been abandoned, and there’s no need to make a decision of rejection. Where the applicant is not informed of the need for supplementation and correction within the timeline, the application shall be regarded as- accepted on the date the dossier is received.'可被翻译为：（四）申报资料不齐全或者不符合法定形式的，应当当场或者在五日内一次告知申请人需要补正的全部内容。按照规定需要在告知时一并退回申请材料的，应当予以退回。申请人应当在三十日内完成补正资料。申请人无正当理由逾期不予补正的，视为放弃申请，无需作出不予受理的决定。逾期未告知申请人补正的，自收到申请材料之日起即为受理。\n'Where the applicant fails to submit the supplementary materials within the specified timeline, the technical evaluation institution shall terminate the technical evaluation and come up with a disapproval suggestion, and China Food and Drug Administration shall make a disapproval decision after confirmation.'可被翻译为：申请人逾期未提交补充资料的，由技术审评机构终止技术审评，提出不予批准的建议，国家食品药品监督管理总局核准后作出不予批准的决定。\n\n根据上述已知信息，请将'(4) The applicant fails to submit supplementary dossier within the specified timeline;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）申请人未能在规定时限内补充资料的；"
    },
    {
        "instruction":"已知信息：\n'Guidelines S5 (R3) and S11 shall be applicable to the non-clinical studies starting upon issuance of this Announcement. The designation of the starting date of nonclinical study shall be in accordance with the relevant provisions specified in the Good Laboratory Practice.'可被翻译为：自本公告发布之日起开始的非临床研究适用S5（R3）和S11指导原则。非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。\n'I. Applicants are required to carry out the study in accordance with the ICH Guidelines as early as possible based on current technical requirements. For relevant studies that start 6 months after the issuance date of this Announcement(based on the time point of the trial record), the above ICH Guidelines shall apply.'可被翻译为：1. 申请人需在现行技术要求基础上，尽早按照ICH指导原则的要求开展研究。本公告发布之日起6个月后开始的相关研究（以试验记录时间点为准），适用上述ICH指导原则。\n'Attachment: 13 ICH safety guidelines to be adopted'可被翻译为：附件：适用的13个ICH非临床指导原则\n'Article 22 A pre-clinical drug study shall be in conformity with relevant requirements, among which the Good Laboratory Practice for Non-Clinical Laboratory Studies shall be implemented in the study of safety evaluation.'可被翻译为：第二十二条 药物临床前研究应当执行有关管理规定，其中安全性评价研究必须执行《药物非临床研究质量管理规范》。\n\n根据上述已知信息，请将'I. The sponsors shall conduct research in accordance with the ICH guidelines as soon as possible on the basis of the existing technical requirements. The 13 ICH safety guidelines shall be adopted for non-clinical studies starting from May 1, 2020, and the starting dates of non-clinical studies shall be determined in accordance with the relevant provisions of the Good Laboratory Practice.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一、申请人需在现行技术要求基础上尽早按照ICH指导原则开展研究；自2020年5月1日起开始的非临床研究适用13个ICH非临床指导原则，非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。"
    },
    {
        "instruction":"已知信息：\n'Drugs that inhibit the secretion of gastric juices (or stomach acid). The main ones are H2 blockers such as famotidine, etc.; Proton pump inhibitors such as omeprazole, etc.; And anticholinergics, such as ranunculine and pirenzil.'可被翻译为：抑制胃液（或胃酸）分泌的药物。主要有H2阻滞剂，如法莫替丁等；质子泵抑制剂，如奥美拉唑等;抗胆碱药，如山莨若碱、哌仑西平等。\n'a drug that covalently binds H+-K+ ATPase A subunit to inactivate the enzyme, thereby inhibiting the secretion of gastric acid and pepsin.'可被翻译为：与H+-K+ATP酶a亚单位的筑基以共价键结合而使酶失活，进而抑制胃酸、胃蛋白酶分泌的药物。\n'Drugs that inhibit the contraction of uterine smooth muscle are used to prolong pregnancy and prevent premature birth. Such as Ritodrine.'可被翻译为：抑制子宫平滑肌收缩用于延长妊娠和防止早产的药物。如利托君。\n'Drugs that can directly or indirectly cause a similar sympathetic nervous system excitation. These include: ① alpha-receptor agonists, which can play a role in vasoconstriction and blood pressure increase, such as norepinephrine; ② beta agonists, including beta 1 agonists, which can increase heart rate, and beta 2 agonists, which can cause smooth muscle relaxation.'可被翻译为：可直接或间接引起类似交感神经系统激动的药物。包括：①α受体激动药，可起到血管收缩和血压升高作用,如去甲肾上腺素;②β受体激动药，包括：β1受体激动药，可增加心率，β2受体激动药，可引起平滑肌舒张。\n\n根据上述已知信息，请将'Competitively binds to the h2 receptor, antagonizing histamine compounds that promote gastric acid secretion, increase heart rate, and inhibit smooth muscle contractiles.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"竞争性地与h2受体结合，拮抗组胺促进胃酸分泌，增加心率及抑制平滑肌收缩功能的化合物。"
    },
    {
        "instruction":"已知信息：\n'\"Immunization program vaccines\" are vaccines to be inoculated in citizens as per the government provisions, including vaccines confirmed in the national immunization program, vaccines added by people's governments of provinces, autonomous regions and municipalities directly under the Central Government while implementing the national immunization program, vaccines for emergency immunization or cluster immunization organized by the people's governments or their competent health departments at or above the county level.'可被翻译为：免疫规划疫苗，是指居民应当按照政府的规定接种的疫苗，包括国家免疫规划确定的疫苗，省、自治区、直辖市人民政府在执行国家免疫规划时增加的疫苗，以及县级以上人民政府或者其卫生健康主管部门组织的应急接种或者群体性预防接种所使用的疫苗。\n'People's governments and relevant departments at or above the county level shall ensure that children at proper age are immunized with immunization program vaccines. The guardians shall ensure that children at proper age are immunized with the immunization program vaccines on schedule according to law.'可被翻译为：县级以上人民政府及其有关部门应当保障适龄儿童接种免疫规划疫苗。监护人应当依法保证适龄儿童按时接种免疫规划疫苗。\n'Article 7 People's governments at or above the county level shall incorporate the vaccine safety, immunization work into the national economic and social development plans of the corresponding level, enhance the capacity building of vaccine administration, and establish and improve the work mechanism for vaccine administration.'可被翻译为：第七条 县级以上人民政府应当将疫苗安全工作和预防接种工作纳入本级国民经济和社会发展规划，加强疫苗监督管理能力建设，建立健全疫苗监督管理工作机制。\n'Compensation needed for immunization of immunization program vaccines shall be included in the funding for immunization budgeted by the financial departments of the people's governments of provinces, autonomous regions or municipalities directly under the Central Government; compensation needed for immunization of non-immunization program vaccines shall be paid by the vaccine MAHs involved. The State encourages compensating vaccine recipients with adverse reactions of immunization through commercial insurance and other means.'可被翻译为：接种免疫规划疫苗所需的补偿费用，由省、自治区、直辖市人民政府财政部门在预防接种经费中安排；接种非免疫规划疫苗所需的补偿费用，由相关疫苗上市许可持有人承担。国家鼓励通过商业保险等多种形式对预防接种异常反应受种者予以补偿。\n\n根据上述已知信息，请将'Article 63 To ensure the implementation of national immunization program, the people's government at or above the county level shall incorporate into the budget of the people's governments at the same level the funds needed for vaccine safety, procurement of immunization program vaccines, immunization and information-based construction.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十三条 县级以上人民政府应当将疫苗安全工作、购买免疫规划疫苗和预防接种工作以及信息化建设等所需经费纳入本级政府预算，保证免疫规划制度的实施。"
    },
    {
        "instruction":"已知信息：\n'The diameter of a spherical particle with the same settling velocity and density as the particle being measured when determined by sedimentation method.'可被翻译为：沉降法测定时，与被测粒子沉降速度和密度相同的球形微粒的直径。\n'The diameter of a spherical particle that has the same surface area, volume, or circumscribed circle as the particle under test.'可被翻译为：与被测粒子具有相同的表面积、体积或外接圆的球形粒子的直径。\n'Agar Settling Plates'可被翻译为：琼脂沉降碟\n'Arrange the particles in order of particle size from smallest to largest, with the diameter of the particle located in the middle.'可被翻译为：将粒子按粒径从小到大的顺序排列，位于最中间的粒子的直径。。\n\n根据上述已知信息，请将'The diameter of a spherical particle with the same settling velocity as the particle calculated by the settling formula.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据沉降公式计算出的与粒子具有相同沉降速度的球形粒子的直径。"
    },
    {
        "instruction":"已知信息：\n'Where an MAH stops manufacture of drugs in shortage, it shall report to the drug regulatory department under the State Council or the drug regulatory department of the people's government of the province, autonomous region, or municipality directly under the Central Government.'可被翻译为：药品上市许可持有人停止生产短缺药品的，应当按照规定向国务院药品监督管理部门或者省、自治区、直辖市人民政府药品监督管理部门报告。\n'After receiving the report, the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device distributor or using unit is located shall, in a timely manner, inform the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device manufacturer is located.'可被翻译为：医疗器械经营企业、使用单位所在地省、自治区、直辖市食品药品监督管理部门收到报告后，应当及时通报医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门。\n'Article 17 Where two or more institutions jointly apply for drugs, the application shall be submitted to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, in which the drug manufacturer is located; where the applicants are all drug manufacturers, the application shall be submitted to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, in which the manufacturer of pharmaceutical preparations is located; where none of the applicants is a drug manufacturer, the application shall be submitted to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, in which the site for pilot production of drug samples is located.'可被翻译为：第十七条 两个以上单位共同作为申请人的，应当向其中药品生产企业所在地省、自治区、直辖市药品监督管理部门提出申请；申请人均为药品生产企业的，应当向申请生产制剂的药品生产企业所在地省、自治区、直辖市药品监督管理部门提出申请；申请人均不是药品生产企业的，应当向样品试制现场所在地省、自治区、直辖市药品监督管理部门提出申请。\n'Article 68 Where institutions for drug manufacturing, distribution, use, testing or supervision find any critical quality problem, serious or unexpected adverse reaction of a new drug, they shall report to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government in time. Once receiving the report, the drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall organize prompt investigation, and report to the State Food and Drug Administration.'可被翻译为：第六十八条 药品生产、经营、使用及检验、监督单位发现新药存在严重质量问题、严重或者非预期的不良反应时，应当及时向省、自治区、直辖市药品监督管理部门报告。省、自治区、直辖市药品监督管理部门收到报告后应当立即组织调查，并报告国家食品药品监督管理局。\n\n根据上述已知信息，请将'Article 46 With respect to the drugs included in the list of drugs in shortage, the shutdown of which shall be reported to applicable authorities. If any drug MAH intends to shut down the manufacturing of such drugs, it shall report the shutdown to the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the drug MAH is located 6 months ahead of the shutdown. In the event of unexpected shutdown, the drug MAH shall report it to the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where it is located within 3 days. Where necessary, a report shall be made to the NMPA.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十六条 列入国家实施停产报告的短缺药品清单的药品，药品上市许可持有人停止生产的，应当在计划停产实施六个月前向所在地省、自治区、直辖市药品监督管理部门报告；发生非预期停产的，在三日内报告所在地省、自治区、直辖市药品监督管理部门。必要时，向国家药品监督管理局报告。"
    },
    {
        "instruction":"已知信息：\n'A single or multilayer film-like preparation in which the drug is dissolved or dispersed or encased in a film-forming material.'可被翻译为：药物溶解或分散或包裹于成膜材料中而制成的单层或多层膜状制剂。\n'A uniform semi-solid preparation for external use made by mixing a drug with an oily or water-soluble substrate.'可被翻译为：药物与油脂性或水溶性基质混合制成的均匀的半固体外用制剂。\n'The use of natural or synthetic polymer materials as carrier materials, so that the drug dissolved or\/and dispersed in the polymer material, the formation of a skeleton type of tiny spherical entity.'可被翻译为：利用天然或合成的高分子材料为载体材料，使药物溶解或\/和分散在高分子材料中，形成的骨架型微小球状实体。\n'A device in which two or more materials are dispersed to a uniform state by mechanical means.'可被翻译为：用机械方法使两种或多种物料相互分散而达到均匀状态的设备。\n\n根据上述已知信息，请将'A uniform semisolid preparation for external use in which the drug is dissolved or dispersed in a emulsion type matrix.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物溶解或分散于乳状液型基质中形成的均匀的半固体外用制剂。"
    },
    {
        "instruction":"已知信息：\n'RABS:\nThe design of RABS should ensure grade A conditions with unidirectional airflow and first air protection in thecritical zone. A positive airflow from the critical zone to the supporting background environment should be maintained.'可被翻译为：RABS 的设计应通过具有单向流和关键区域初始气流保护确保 A 级条件。应保持从关键区到支持性背景环境的正向气流。\n'RABS:\nThe background environment for RABS used for aseptic processing should correspond to a minimum of grade B and airflow pattern studies should be performed to demonstrate the absence of air ingress during interventions, including door openings if applicable.'可被翻译为：用于无菌工艺的RABS的环境应至少为 B级，并且应进行气流流型研究以证明在干预过程中没有空气进入，包括开门（如适用）。\n'Preparation and filling of sterile products such as ointments, creams, suspensions and emulsions should be\nperformed in grade A with a grade B background when the product and components are exposed to the\nenvironment and the product is not subsequently filtered (via a sterilising grade filter) or terminally sterilised.\nWhere an isolator or RABS is used, the background should be in accordance with paragraph 4.20.'可被翻译为：如果产品及其组件暴露于环境下，且产品不会进行后续过滤（通过除菌级过滤器）或最终灭菌时，无菌产品（如软膏剂、霜剂、混悬剂和乳剂）的制备和灌装应在 B 级环境下的 A 级内进行。如果采用隔离器或RABS，其环境应符合 4.20 节的规定。\n'Grade A: The critical zone for high-risk operations (e.g. aseptic processing line, filling zone, stopper bowl, open primary packaging or for making aseptic connections under the protection of first air). Normally, such conditions are provided by a localised airflow protection, such as unidirectional airflow workstations within RABS or isolators. The maintenance of unidirectional airflow should be demonstrated and qualified across the whole of the grade A area. Direct intervention (e.g. without the protection of barrier and glove port technology) into the grade\nA area by operators should be minimized by premises, equipment, process and procedural design.'可被翻译为：A 级：进行高风险操作的关键区域（例如，无菌生产线，灌装区，胶塞加料盘，敞口内包装或在初始气流保护下进行无菌连接）。通常情况下，这种条件是通过局部气流保护实现的，例如 RABS 或隔离器内的单向流操作台。应证明并确认整个 A 级区的单向流维护状态。应通过厂房、设备、工艺和程序性设计尽量减少操作人员对 A 级区的直接干预（例如，不使用隔离器和手套箱技术作为保护）。\n\n根据上述已知信息，请将'Air velocity test (Note: For grade B, C and D the air velocity test should be performed according to a risk assessment documented as part of the CCS. However, it is required for filling zones supplied with unidirectional airflow (e.g. when filling terminally sterilised products or background to grade A and RABS). For grades with non-unidirectional airflow, a measurement of recovery testing should replace velocity testing).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"风速测试（注：对于 B 级、C 级和 D 级，风速测试应按照风险评估的结果进行，并将该风险评估包含到CCS 中。但是，使用单向流的灌装区（例如，灌装最终灭菌产品时或 A 级和 RABS 的背景区）需要进行测试。对于非单向流的级别，应以自净测试代替风速测试）。"
    },
    {
        "instruction":"已知信息：\n'Also known as relativemolecularmass (relativemolecularmass). The ratio of the average mass of a molecule or specific unit of a substance to 1\/12 of the mass of a 12C atom. Equal to the sum of the atomic weights of all the atoms in the molecule.'可被翻译为：又称\"相对分子质量（relativemolecularmass）\"。物质分子或特定单元的平均质量与12C原子质量的1\/12之比。等于分子中全部原子的原子量之和。\n'A species of atom characterized by its mass number, atomic number and nuclear energy state, provided that the mean life in that state is long enough to be observable.'可被翻译为：以质量数、原子序数和核能状态为特征的一种原子，只要该状态的平均寿命足够长，可以观察到。\n'A general term for low energy ionization methods such as chemical ionization and field ionization in mass spectrometry.'可被翻译为：质谱分析中化学电离、场致电离等低能量电离方式的总称。\n'The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate.'可被翻译为：以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。\n\n根据上述已知信息，请将'An isotopic peak consisting of the most abundant nuclides in mass spectrometry. For example, the average atomic weight of the hydrogen atom is 1.00794, and the mass of the most abundant isotope,H, is 1.00783.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"质谱分析中由丰度最高的核素组成的同位素峰。如氢原子的平均原子量为1.00794,丰度最高的同位素,H的质量为1.00783。"
    },
    {
        "instruction":"已知信息：\n'In the recording devices of modern analytical instruments, there are signal attenuators, which are used to weaken the detector signal.'可被翻译为：在近代分析仪器的记录装置中都有信号衰减器，用此将检测器信号减弱的过程。\n'A chemical secreted by nerve endings (synapses). Can cause nerve conduction and excite neurons specifically through receptors.'可被翻译为：神经末梢（突触）分泌的化学物质。可引起神经传导并通过受体特异性兴奋神经元。\n'A substance that can be stored in nerve end vesicles in place of neurotransmitters and released by nerve impulses.'可被翻译为：能代替神经递质贮存于神经末梢囊泡中，并为神经冲动所释放的物质。\n'A class of biomacromolecules that bind to hormones, neurotransmitters, drugs, or intracellular signaling molecules and can cause changes in cell function.'可被翻译为：药物靶标中一类能够同激素、神经递质、药物或细胞内的信号分子结合并能引起细胞功能变化的生物大分子。\n\n根据上述已知信息，请将'Usually peptides, which can enhance or weaken the response of neurons to neurotransmitters and play a regulatory role.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一般为肽类，能增强或减弱神经元对神经递质反应，起调节作用。"
    },
    {
        "instruction":"已知信息：\n'Article 73 In any of the following circumstances for MAHs, the drug regulatory departments above county level should order to make correction and give warning, and a fine between 5,000 RMB and 20,000 RMB should be imposed if MAHs refused to make correction:'可被翻译为：第七十三条  持有人有下列情形之一的，由县级以上药品监督管理部门责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款：\n'Article 71 In any of the following circumstances for medical device distributing enterprises and user facility, in accordance with Article 68 of the Regulations for the Supervision and Administration of Medical Devices, the drug regulatory departments and the health administrative departments above the county level according to their respective responsibilities should order to make correction and give warning, and a  fine between 5,000 RMB and  20,000 RMB should be imposed if MAHs refused to make correction; in serious circumstances, the production shall be ordered to stop until the relevant certificates are revoked by the original issuing authority:'可被翻译为：第七十一条  医疗器械经营企业、使用单位有下列情形之一的，依照《医疗器械监督管理条例》第六十八条的规定，由县级以上药品监督管理部门和卫生行政部门依据各自职责责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款；情节严重的，责令停产停业，直至由发证部门吊销相关证明文件：\n'Article 74 In any of the following circumstances for medical device distributing enterprises and user facility, the drug regulatory departments and the health administrative departments above county level according to their respective responsibilities should order to make correction and give warning, and a fine between 5,000 RMB and 20,000 RMB should be imposed if MAHs refused to make correction.'可被翻译为：第七十四条  医疗器械经营企业、使用单位有下列情形之一的，由县级以上药品监督管理部门和卫生行政部门依据各自职责责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款：\n'Article 83 In cases where vaccine MAHs' violation of this Law involves any of the following circumstances, the drug regulatory departments of the people's governments at or above the provincial level shall order to make rectification and give a warning; and those who refuse to make rectification shall be subject to a fine of not less than RMB 200,000 yuan but not more than RMB 500,000 yuan; in serious circumstances, the offender shall be subject to an order to stop production for rectification and a fine of not less than RMB 500,000 yuan but not more than RMB 2,000,000 yuan:'可被翻译为：第八十三条 违反本法规定，疫苗上市许可持有人有下列情形之一的，由省级以上人民政府药品监督管理部门责令改正，给予警告；拒不改正的，处二十万元以上五十万元以下的罚款；情节严重的，责令停产停业整顿，并处五十万元以上二百万元以下的罚款：\n\n根据上述已知信息，请将'Article 70 In any of the following circumstances for MAHs, in accordance with Article 68 of the Regulations for the Supervision and Administration of Medical Devices, the drug regulatory departments above the county level should order to make correction and give warning, and a fine between 5,000 RMB and  20,000 RMB should be imposed if MAHs refused to make correction; in serious circumstances, the production should be instructed to stop until the relevant certificates are revoked by the original issuing authority:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条  持有人有下列情形之一的，依照《医疗器械监督管理条例》第六十八条的规定，由县级以上药品监督管理部门责令改正，给予警告；拒不改正的，处5000元以上2万元以下罚款；情节严重的，责令停产停业，直至由发证部门吊销相关证明文件："
    },
    {
        "instruction":"已知信息：\n'Drugs that inhibit recurrent episodes of brain dysfunction caused by abnormal firing of brain cells. According to its mechanism of action can be divided into: ① sodium channel regulator; ② gamma-aminobutyric acid regulator; ③ excitatory amino acid receptor antagonists and excitatory amino acid release regulators; ④ anti-absence seizure agents related to ethansuxamine (selective calcium channel blockers); ⑤ other drugs whose mechanisms are not well defined.'可被翻译为：抑制由脑细胞异常放电引起的脑功能障碍反复发作的药物。按其作用机制可分为：①钠通道调节剂；②γ-氨基丁酸调节剂；③兴奋性氨基酸受体拮抗剂和兴奋性氨基酸释放调节剂；④与乙琥胺有关的抗失神发作药（选择性钙通道阻滞剂）；⑤其他机制尚不明确的药物。\n'Drugs that can selectively act on the cerebral cortex and have the effect of activating, protecting and restoring the function of nerve cells. Such as piracetam and vincristine.'可被翻译为：能选择性地作用于大脑皮质，对神经细胞具有激活、保护和恢复功能效应的药物。如吡拉西坦和长春胺等。\n'A narcotic and analgesic drug that produces reversible inhibition of the central nervous system. Usually refers to opioids and their synthetic drugs, such as morphine, codeine, and their derivatives, but also includes synthetic drugs that have excitatory, partially excitatory, or agonist-antagonistic mixed effects on opioid receptors. Opioid derivatives such as dihydroetorphine, hydrocodone. In synthetic drugs, agonists such as fentanyl; Agonist-antagonists such as buprenorphine, pentazocin, etc. This class of drugs is mainly used for strong analgesia, easy to cause dependence, and must be used with caution.'可被翻译为：对中枢神经系统能产生可逆性抑制的麻醉又有镇痛作用的药物。通常指阿片类药物及其人工合成药物，如吗啡、可待因及其衍生物，也包括对阿片受体具有激动、部分激动或激动-拮抗混合作用的合成药物。阿片衍生物如二氢埃托啡、氢可酮。合成药物中，激动剂如芬太尼；激动-拮抗剂如丁丙诺啡、喷他唑辛等。本类药物主要用于强效镇痛，易引起依赖性，必须谨慎使用。\n'Brain and medulla spinalis.'可被翻译为：脑和脊髓。\n\n根据上述已知信息，请将'A drug that excites the central nervous system function and improves brain activity function. According to the site of action can be divided into excitatory cerebral cortex drugs, such as xanthine derivatives, such as caffeine, theophylline; Excitatory medullary respiratory center drugs, such as nicoxal rice; Drugs that excite the spinal cord, such as strychnine; And intelligence-boosting drugs that promote brain cell metabolism and improve brain function, such as piracetam.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具有兴奋中枢神经系统功能，提高脑活动功能的药物。按照作用部位可分为兴奋大脑皮质的药物，如黄嘌吟衍生物，如咖啡因、茶碱等；兴奋延髓呼吸中枢的药物，如尼可刹米等；兴奋脊髓的药物，如士的宁；促进脑细胞代谢、改善脑功能的智能促进药物如吡拉西坦等。"
    },
    {
        "instruction":"已知信息：\n'A drug used to treat or prevent infections caused by various pathogens, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, worms, etc. They may be further classified according to their source and properties.'可被翻译为：治疗或预防各种病原体，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫、蠕虫等所致感染用的药物。根据来源和性质的不同可进一步分类。\n'Antimicrobial drugs used to treat infections caused by pathogenic microorganisms such as bacteria, rickettsia, chlamydia, mycoplasma, spirochetes, fungi, etc. Excluded are drugs for treating tuberculosis, parasitic diseases, and various viral infections, as well as traditional Chinese medicine formulations with antibacterial properties.'可被翻译为：治疗细菌、支原体、衣原体、立克次体、螺旋体、真菌等病原微生物所致感染性疾病病原的药物，\n不包括治疗结核病、寄生虫病和各种病毒所致感染性疾病的药物以及具有抗菌作用的中药制剂。\n'A branch of science that refers to microbes of all of types, including bacteria, viruses, rickettsia, protozoa, fungi and prions. Derived words (such as microbiological) have a similar meaning.'可被翻译为：一门科学分支，涉及所有类型的微生物，包括细菌、病毒、立克次体、原生动物、真菌和朊病毒。衍生词(如microbiological)也有类似的意思。\n'Drugs to prevent and treat urinary tract or vaginal infections caused by Trichomonas. It has a direct killing effect on trichomonas vaginalis, and commonly used drugs such as metronidazole.'可被翻译为：防治由毛滴虫引起的尿道或阴道感染的药物。对阴道滴虫具有直接杀灭作用，常用药物如甲硝唑。\n\n根据上述已知信息，请将'Drugs used to treat or prevent infections caused by pathogenic microorganisms, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, etc. Unlike anti-infective drugs, these drugs do not target worms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"治疗或预防致病微生物，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫等所致感染用的药物。与抗感染药的区别是本类药物的作用对象不包括蠕虫类。"
    },
    {
        "instruction":"已知信息：\n'Appropriate alert levels and action limits should be set for the results of viable and total particle monitoring. The maximum total particle action limits are described in Table 5 and the maximum viable particle action limits are described in Table 6. However, more stringent action limits may be applied based on data trending, the nature of the process or as determined within the CCS. Both viable and total particle alert levels should be established based on results of cleanroom qualification tests and periodically reviewed based on ongoing trend data.'可被翻译为：对活性粒子和总微粒监测的结果应设置适当的警戒限和行动限。最大粒子总数行动限见表 5 ，最大活性粒 子行动限见表 6。然而，基于数据趋势分析、工艺性质或按照 CCS 中的规定，可以应用更严格的行动限。应根据洁净室确认测试的结果确定活性粒子和总微粒警戒限，并根据持续趋势数据定期回顾。\n'Examples of operations to be carried out in the various grades are given in Table 3.'可被翻译为：表 3 给出了各级区内操作的示例。\n'Thus, the proportional linearity of release rates across different strengths of the product may be impacted by formulation differences across the strengths that are independent of the proportional responsiveness of the IVRT method. The minimum r2 value ≥ 0.95 for the correlation of the formulation concentration to the average IVRT release rate (slope) takes into account that the IVRT method’s response to differences in release rates may not appear to be perfectly proportional because of formulation differences that are independent of the IVRT method.'可被翻译为：因此，不同规格产品释放率的比例线性可能受到不同规格配方差异的影响，而这些差异与IVRT方法的比例响应性无关。因配方差异与IVRT方法无关，且考虑到IVRT方法对释放速率差异的响应可能不是完全成比例的，因此，要求配方浓度与IVRT平均释放率（斜率）相关性的最小r2值≥0.95。\n'An IVPT study can be sensitive and discriminating to differences in the rate and extent to which compounds applied on the skin from different formulations become available in and through it. Notably, unlike an IVRT study, differences in permeation that are observed in an IVPT study comparing a test versus reference product, if any, may correlate with and\/or be predictive of differences in bioavailability in vivo. The IVPT is routinely carried out to guide semi-solid topical formulation development.'可被翻译为：IVPT研究可以对不同配方的涂抹在皮肤上的化合物在皮肤内和通过皮肤获得的速率和程度的差异进行敏感和区分。值得注意的是，与IVRT研究不同的是，在IVPT研究中观察到的比较测试品与参考产品的渗透差异(如果有的话)可能与体内生物利用度差异相关和\/或预测了差异。IVPT通常用于指导半固体外用制剂的开发。\n\n根据上述已知信息，请将'The selection between IVRT or IVPT should be based on the intended objective(s) of the formulation assessment, as described in Table 2. Intrinsic experimental differences between the two methodologies are further described in Table 3.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"IVRT或IVPT之间的选择应基于制剂评估的预期目标，如表2所示。表3进一步描述了两种方法内在的实验差异。"
    },
    {
        "instruction":"已知信息：\n'Intermediates produced during the manufacture of a drug substance that can be used by downstream manufacturers for further processing into a drug substance.'可被翻译为：生产原料药过程中产生的可以被下游厂家用于进一步加工为原料药的中间产品。\n'Raw material - Any ingredient intended for use in the manufacture of a sterile product, including those that may\nnot appear in the final drug product.'可被翻译为：原材料：拟用于无菌产品生产的任何成分，包括可能不会在成品中出现的成分。\n'A substance other than a starting material, intermediate, or solvent that is used in the manufacture of a new drug substance.'可被翻译为：一种与起始物、中间体或溶剂不同的物质，在新原料药的生产中使用。\n'A version of an xml message designed to provide a reference to how a message should be constructed. A reference instance may not actually be \nvalid since it may contain multiple examples of message components that are actually mutually exclusive. It also may contain data that is explanatory \n(such as ICH IG element numbers) for understanding the structure of the message but not actually valid content per the schema.)'可被翻译为：为如何构建消息提供参考的 XML 消息版本。因为参考实例可能包括实际互斥的消息组件的多个示例，所以参考实例可能实际上是无效的。它还可以包括解释性消息（例如 ICH 实施指南元素编号）用于理解按照模式实际上无效的内容的消息的结构。\n\n根据上述已知信息，请将'An impurity that theoretically can arise during manufacture or storage. It may or may not actually appear in the new drug substance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"按照理论推测在生产或储存过程中可能产生的杂质。其在新原料药中可能存在，也可能不存在。"
    },
    {
        "instruction":"已知信息：\n'The China Food and Drug Administration shall supervise the management of medical device recall nationwide.'可被翻译为：国家食品药品监督管理总局监督全国医疗器械召回的管理工作。\n'Overseas manufacturers of imported drugs who recall drugs abroad shall report the case to the State Food and Drug Administration promptly. In the case of recall inside China, the importer shall be responsible for implementing the recall according to these Provisions.'可被翻译为：进口药品的境外制药厂商在境外实施药品召回的，应当及时报告国家食品药品监督管理局；在境内进行召回的，由进口单位按照本办法的规定负责具体实施。\n'Article 173 The State Food and Drug Administration adopts the coding management for drugs approved for marketing. The provisions for coding management are separately formulated.'可被翻译为：第一百七十三条 国家食品药品监督管理局对批准上市的药品实行编码管理。药品编码管理的规定另行制定。\n'Article 9 The State Food and Drug Administration and the drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall establish the drug recall information disclosure system and publicize information about drugs with safety hazards and recall of drugs to the society in an effective way.'可被翻译为：第九条 国家食品药品监督管理局和省、自治区、直辖市药品监督管理部门应当建立药品召回信息公开制度，采用有效途径向社会公布存在安全隐患的药品信息和药品召回的情况。\n\n根据上述已知信息，请将'The State Food and Drug Administration shall supervise the management of recall of drugs across the country.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家食品药品监督管理局监督全国药品召回的管理工作。"
    },
    {
        "instruction":"已知信息：\n'Non-fat soluble or very little fat soluble substances, with the help of carrier proteins or channel proteins on the cell membrane, along the concentration gradient and\/or along the potential gradient (potential difference) of the transport process through the cell membrane.'可被翻译为：非脂溶性或脂溶性很小的物质，借助于细胞膜上的运载蛋白或通道蛋白的帮助，顺浓度梯度和（或）顺电位梯度（电位差）通过细胞膜的转运过程。\n'A species of atom characterized by its mass number, atomic number and nuclear energy state, provided that the mean life in that state is long enough to be observable.'可被翻译为：以质量数、原子序数和核能状态为特征的一种原子，只要该状态的平均寿命足够长，可以观察到。\n'potential energy'可被翻译为：势能\n'The phenomenon in which molecules at higher vibrational energy levels lose excess vibrational energy by becoming heat energy through collisions with other molecules (sample molecules and solvent molecules).'可被翻译为：处于较高振动能级的分子通过与其他一些分子（样品分子和溶剂分子）间的碰撞变成热能，失去过剩振动能量的现象。\n\n根据上述已知信息，请将'An intermediate state occurring along a given reaction path. It is characterized by a higher potential energy than other states adjacent to it along that pathway.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"沿着一定反应途径所出现的一种中间状态。其特征是比该途径上与之相邻的其他状态有较高的势能。"
    },
    {
        "instruction":"已知信息：\n'The food and drug regulatory department shall issue a dated acceptance or rejection notice affixed with its special seal to indicate its acceptance or rejection of the in-vitro diagnostic reagent registration application.'可被翻译为：食品药品监督管理部门受理或者不予受理体外诊断试剂注册申请，应当出具加盖本部门专用印章并注明日期的受理或者不予受理的通知书。\n'If the provincial drug regulatory department accepts or rejects the application for first importation of crude drugs, it shall issue a Notice of Acceptance or Rejection; if the application is rejected, it shall state the reasons in written form.'可被翻译为：省级药品监督管理部门受理或者不予受理首次进口药材申请，应当出具受理或者不予受理通知书；不予受理的，应当书面说明理由。\n'For acceptance or non-acceptance of the application for Medical Device Manufacturing License, the drug regulatory department of the province, autonomous region, or municipality directly under the central government shall issue an acceptance or non-acceptance notice fixed with special seal of the administrative authority and indicated with date.'可被翻译为：省、自治区、直辖市药品监督管理部门受理或者不予受理医疗器械生产许可申请的，应当出具加盖本行政机关专用印章和注明日期的受理或者不予受理通知书。\n'For acceptance or non-acceptance of the application for Medical Device Distribution License, the department in charge of drug supervision and administration at the level of a city divided into districts shall issue an acceptance or non-acceptance notice fixed with special seal of the administrative authority and indicated with date.'可被翻译为：设区的市级负责药品监督管理的部门受理或者不予受理医疗器械经营许可申请的，应当出具加盖本行政机关专用印章和注明日期的受理或者不予受理通知书。\n\n根据上述已知信息，请将'The food and drug regulatory department shall grant a dated acceptance or rejection notice affixed with its special seal to indicate its acceptance or rejection of the medical device registration application.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"食品药品监督管理部门受理或者不予受理医疗器械注册申请，应当出具加盖本部门专用印章并注明日期的受理或者不予受理的通知书。"
    },
    {
        "instruction":"已知信息：\n'In the process of the lot release of a specific product, the lot release institution may make a comprehensive evaluation according to the process and quality control maturity of the product variety and previous lot release and dynamically adjust the testing items and testing frequency in the registration specification of the product variety. Where there is any nonconforming item of the products subject to lot release, the lot release institution shall add the testing frequency on the corresponding item of the products of subsequent batches.'可被翻译为：批签发机构在对具体品种的批签发过程中，可以根据该品种的工艺及质量控制成熟度和既往批签发等情况进行综合评估，动态调整该品种注册标准中的检验项目和检验频次。批签发产品出现不合格项目的，批签发机构应当对后续批次产品的相应项目增加检验频次。\n'Article 29 For lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. The testing items and testing frequency for lot release of vaccines shall be dynamically adjusted according to the vaccine quality risk evaluation.'可被翻译为：第二十九条 疫苗批签发应当逐批进行资料审核和抽样检验。疫苗批签发检验项目和检验频次应当根据疫苗质量风险评估情况进行动态调整。\n'Article 13 After completion of manufacturing and testing of biological products subject to lot release administration, the lot release applicant shall fill out the Application Form for Lot Release of Biological Products in the IMS, and apply to the lot release institution under jurisdiction for lot release in the place where the MAH applying for lot release is located or the import port is set.'可被翻译为：第十三条    按照批签发管理的生物制品，批签发申请人在生产、检验完成后，应当在生物制品批签发管理系统内填写生物制品批签发申请表，并根据申请批签发产品的药品上市许可持有人所在地或者拟进口口岸所在地批签发机构设置情况，向相应属地的批签发机构申请批签发。\n'Article 29 The lot release institution shall make decision on lot release based on dossier review, sample testing or on-site inspection. If the requirements are met, the institution shall issue a Certificate for Lot Release of Biological Products which is affixed with the special seal for lot release, and send it to the lot release applicant.'可被翻译为：第二十九条    批签发机构根据资料审核、样品检验或者现场检查等结果作出批签发结论。符合要求的，签发生物制品批签发证明，加盖批签发专用章，发给批签发申请人。\n\n根据上述已知信息，请将'In the process of the lot release of specific variety, the lot release institution may make a comprehensive evaluation according to the process and quality control maturity of the variety and previous lot release and dynamically adjust the testing items and testing frequency of the variety. Where there is any nonconforming item of the products subject to lot release, the lot release institution shall increase the testing frequency on the corresponding item of the products in subsequent batches.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批签发机构在对具体品种的批签发过程中，可以根据该品种的工艺及质量控制成熟度和既往批签发等情况进行综合评估，动态调整该品种的检验项目和检验频次。批签发产品出现不合格项目的，批签发机构应当对后续批次产品的相应项目增加检验频次。"
    },
    {
        "instruction":"已知信息：\n'Article 28 If the lot release applicant applies for withdrawal of its lot release application, it shall provide the explanation, and may withdraw the application only upon approval by the lot release institution; the lot release applicant shall report such withdrawal to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government. If the lot release institution has confirmed through review that the dossiers show defects or the testing results do not comply with the requirements, the application shall not be withdrawn by the lot release applicant.'可被翻译为：第二十八条    批签发申请人申请撤回批签发的，应当说明理由，经批签发机构同意后方可撤回；批签发申请人应当向所在地省、自治区、直辖市药品监督管理部门报告批签发申请撤回情况。批签发机构已经确认资料审核提示缺陷、检验结果不符合规定的，批签发申请人不得撤回。\n'Article 29 The lot release institution shall make decision on lot release based on dossier review, sample testing or on-site inspection. If the requirements are met, the institution shall issue a Certificate for Lot Release of Biological Products which is affixed with the special seal for lot release, and send it to the lot release applicant.'可被翻译为：第二十九条    批签发机构根据资料审核、样品检验或者现场检查等结果作出批签发结论。符合要求的，签发生物制品批签发证明，加盖批签发专用章，发给批签发申请人。\n'Article 28 The lot release institution shall make decision on lot release based on dossier review, sample test or on-site inspection and other results. If the requirements are met, the institution shall issue a Certificate for Lot Release of Biological Products which is affixed with the special seal for lot release, and send it to the lot release applicant.'可被翻译为：第二十八条 批签发机构根据资料审核、样品检验或者现场检查等结果作出批签发结论。符合要求的，签发生物制品批签发证明，加盖批签发专用章，发给批签发申请人。\n'Article 18 Lot release may be conducted by means of independent dossier review or by combining dossier review with sample test, and on-site inspection may be conducted as required. For the lot release mode as well as the testing items and testing proportion for different products, the NIFDC shall organize the demonstration and each lot release institution shall conduct test in accordance with the determined mode for lot release and specifications.'可被翻译为：第十八条 批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种所采用的批签发方式及检验项目和检验比例，由中检院负责组织论证，各批签发机构按照确定的批签发方式和检验要求进行检验。\n\n根据上述已知信息，请将'If the lot release institution has confirmed through review that the dossier has defects or the testing results do not comply with the requirements, the application shall not be withdrawn by the lot release applicant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批签发机构已经确认资料审核提示缺陷、检验结果不符合规定的，批签发申请人不得撤回。"
    },
    {
        "instruction":"已知信息：\n'An instrument in chromatographic analysis that accumulates the electrical signals generated by the system over time.'可被翻译为：色谱分析仪器中按时间累积检测系统所产生电信号的仪器。\n'After the test is separated by the chromatographic column, the derivative reagent and auxiliary reaction liquid are added to the chromatographic system, and the chromatographic effluents are directly reacted in the system, and then the operation of the derivative reaction products is determined.'可被翻译为：待测物经色谱柱分离后，在色谱系统中加入衍生试剂及辅助反应液，与色谱流出组分直接在系统中进行反应，然后测定衍生反应产物的操作。\n'Eluting the liquid collected by the chromatographic column.'可被翻译为：洗脱层析柱所收集的液体。\n'Before chromatographic separation, the sample is prepared into appropriate derivatives in advance, and then the operation of separation and detection is carried out.'可被翻译为：在色谱分离前，预先将样品制成适当的衍生物，然后进行分离和检测的操作。\n\n根据上述已知信息，请将'In the chromatographic instrument, after the completion of the separation of the components, according to the qualitative and quantitative requirements of the chromatography, the original chromatographic signals and data are collected and processed, and the computer system is used to control the operation of the chromatographic instrument.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在色谱仪器中，完成了组分的色谱分离后，按照色谱定性、定量要求，对原始色谱信号和数据进行采集、处理，并控制色谱仪器的操作的计算机系统。"
    },
    {
        "instruction":"已知信息：\n'(5) Other circumstances where the cosmetics manufacturing license shall be cancelled as prescribed by laws and regulations.'可被翻译为：（五）法律法规规定应当注销化妆品生产许可的其他情形。\n'(VI) Other circumstances in noncompliance with the laws and regulations.'可被翻译为：（六）其他不符合法律法规要求的。\n'(VIII) Other circumstances in noncompliance with the laws and regulations.'可被翻译为：（八）其他不符合法律法规要求的。\n'(8) other circumstances in which applications shall not be approved according to laws and regulations.'可被翻译为：（八）法律法规规定的不应当批准的其他情形。\n\n根据上述已知信息，请将'9. Other circumstances that should not be passed as prescribed by laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"9.法律法规规定的其他不应当通过的情形。"
    },
    {
        "instruction":"已知信息：\n'preparative thin layer chromatography'可被翻译为：制备薄层色谱法\n'In thin layer chromatography, a certain amount of adhesive is added to the fixed phase in advance, spread on the glass plate, and made of thin layer chromatography plate.'可被翻译为：在薄层色谱法中，预先在固定相中加入一定量的黏合剂，铺展在玻璃板上，烘干制成的薄层色谱板。\n'A titration method in which 0.05mol\/L chloramine T is used as titration agent, and the end point is indicated by potentiometric method (clamp, calomel electrode) in 2mol sulfuric acid solution and at higher temperature. It is generally used for the determination of drugs containing moonwell.'可被翻译为：以0.05mol\/L的氯胺T作为滴定剂，在2mol的硫酸溶液中及较高的温度下，以电位法（钳，甘汞电极）指示终点的一种滴定方法。一般用于含月井基药物的测定。\n'One of the mass spectrometry samplers. It is mainly used for solid samples and high boiling point liquid samples. Place the microgram (Rg) measure sample at the bottom of the capillary tube with closed end and insert it into the top of the injector rod.'可被翻译为：质谱进样器之一。主要用于固体样品及高沸点液体样品的进样。将微克(Rg)量样品置于末端封闭的毛细管底部，插入进样杆顶端。\n\n根据上述已知信息，请将'A tool used in thin layer chromatography to analyze point samples. Micropipette (total capacity 10μl) or microsyringe is generally used to point samples.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"薄层色谱分析中点样用的工具。一般采用微量吸管（总容量10μl）或微量注射器来点样。"
    },
    {
        "instruction":"已知信息：\n'1.The storing of pharmaceutical products and materials up to their point of use.\n2.The storing of pharmaceutical products up to the point of use.\n3.The storing of medical products up to the point of use.'可被翻译为：1.储存:将药品和原料储存到其使用点\n2.将药品储存到使用点。\n3.将医疗产品储存至使用点。\n'When the temperature rises to a certain point, the water solubility of non-ionic surfactant with polyoxyethylene structure drops sharply, and the solution changes from clear to turbidized; When the temperature drops below this point, the solution changes from turbidity to turbidity; This phenomenon from clear to turbidity is called tan, and the transition temperature point is called tan point.'可被翻译为：当温度升高到某一点后具有聚氧乙烯基结构的非离子型表面活性剂的水中溶解度急剧下降，溶液由清变浊；当温度下降低于该点时溶液又由浊变清；这种由清变浊的现象称为起昙，转变温度点称为昙点。\n'up and down method'可被翻译为：上下法\n'A sensitivity analysis method in which the net benefit of an intervention changes from positive to zero when the value of a certain parameter is studied, i.e., the value of the parameter at the break-even point is determined.'可被翻译为：研究某个参数取值多少时，干预的净收益从正值变为零的一种敏感性分析方法，即确定损益平衡点处参数的取值。\n\n根据上述已知信息，请将'The concave point on the curve changes, that is, the point from concave up (down) to concave down (up). If the function representing the curve has a second continuous derivative, the point at which the second derivative changes sign is the inflection point.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"曲线上凹向改变的点，即由凹向上（下）变为凹向下（上）的点。若表示曲线的函数有二阶连续导数，则使二阶导数改变符号的点，就是拐点。"
    },
    {
        "instruction":"已知信息：\n'oral solid dosage form'可被翻译为：口服固体剂型\n'A semi-solid external preparation composed of a large amount of solid powder (generally more than 25%) uniformly dispersed in a suitable substrate.'可被翻译为：大量的固体粉末（一般25%以上）均匀地分散在适宜的基质中所组成的半固体外用制剂。\n'A product consisting of two or more separate pharmaceutical products in their final dosage form that are packaged together for distribution to patients in the co-packaging.'可被翻译为：由最终剂型的两种或两种以上独立药品组成的产品，它们被包装在一起，以便在共包装中分发给患者。\n'A tablet made of a drug with one or more inert solid skeleton materials by press molding. The drug is dispersed in porous or non-porous materials and is slowly released by various mechanisms.'可被翻译为：药物与-种或多种惰性固体骨架材料通过压制成型技术制成的片剂。药物分散在多孔或无孔的材料中，通过各种机制使药物缓慢释放。\n\n根据上述已知信息，请将'A solid dosage form that can be administered to patients in more than one manner, e.g. may be dispersed or taken orally as a whole.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可以一种以上方式给药给病人的固体剂型，例如，可分散或整体口服。"
    },
    {
        "instruction":"已知信息：\n'The hydroxide ion can be ionized in an aqueous solution, which can make the pH value of the solution greater than 7.'可被翻译为：在水溶液中能电离出氢氧根离子，可使溶液的pH值大于7的化合物。\n'The process by which an electrolyte forms freely moving cationic ions in an aqueous solution or molten state.'可被翻译为：电解质在水溶液或熔融状态下生成自由移动阴阳离子的过程。\n'A polymer resin with strong or weak acid groups that can adsorb cations in solution and exchange its own hydrogen ions with them for release into solution.'可被翻译为：带有强酸或弱酸基团的、可吸附溶液中阳离子，并将自身的氢离子与之交换释放到溶液中的高分子树脂。\n'The decrease of the freezing point of the solution belongs to the colligative property of the solution, which is related to the concentration of the solution and can be used to determine the osmotic pressure of the solution.'可被翻译为：溶液凝固点的下降，属于溶液的依数性，与溶液的浓度有关，可用于测定溶液的渗透压。\n\n根据上述已知信息，请将'In an aqueous solution, hydrogen ions can be ionized, which can make the pH value of the solution less than 7 compounds.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在水溶液中能电离出氢离子，可使溶液的pH值小于7的化合物。"
    },
    {
        "instruction":"已知信息：\n'If the operators of cosmetic e-commerce platform know or shall know that the cosmetic marketers in the platform are prohibited from engaging in manufacturing and marketing of cosmetics according to law, they shall not provide e-commerce platform services to such marketers.'可被翻译为：化妆品电子商务平台经营者知道或者应当知道平台内化妆品经营者被依法禁止从事化妆品生产经营活动的，不得向其提供电子商务平台服务。\n'Article 48 In case of discovering the following serious illegal acts, the operator of cosmetic e-commerce platform shall immediately suspend provision of e-commerce platform services for the marketers of cosmetics in the platform:'可被翻译为：第四十八条 化妆品电子商务平台经营者发现有下列严重违法行为的，应当立即停止向平台内化妆品经营者提供电子商务平台服务：\n'The operators of cosmetic e-commerce platform shall assume the responsibility for managing cosmetic marketers within the platform according to law, make daily inspection of the marketing behavior of the cosmetic marketers within the platform, urge the cosmetic marketers within the platform to perform obligations specified in the Regulations on Supervision and Administration of Cosmetics and these Provisions according to law. In case of discovering illegal marketing of cosmetics, the inspectors shall stop timely by necessary means of deleting, shielding and unlinking, etc. in accordance with the laws or with service agreement and trading provisions of the platform, and report to the drug regulatory department of the province, autonomous region or municipality directly under the central government of the place where it is located.'可被翻译为：化妆品电子商务平台经营者应当依法承担平台内化妆品经营者管理责任，对平台内化妆品经营者的经营行为进行日常检查，督促平台内化妆品经营者依法履行化妆品监督管理条例以及本办法规定的义务。发现违法经营化妆品行为的，应当依法或者依据平台服务协议和交易规则采取删除、屏蔽、断开链接等必要措施及时制止，并报告所在地省、自治区、直辖市药品监督管理部门。\n'If the cosmetic marketers within the platform are placed on a file for investigation or are initiated a public prosecution due to being suspected of crime related with quality and safety of cosmetics, and there are evidences proving that this might cause potential harm to human health, then the operators of cosmetic e-commerce platform could suspend provision of e-commerce platform services for the cosmetic marketers within the platform in accordance with the laws or with the service agreement and trading provisions of the platform.'可被翻译为：因涉嫌化妆品质量安全犯罪被立案侦查或者提起公诉，且有证据证明可能危害人体健康的，化妆品电子商务平台经营者可以依法或者依据平台服务协议和交易规则暂停向平台内化妆品经营者提供电子商务平台服务。\n\n根据上述已知信息，请将'If the department in charge of drug supervision and administration requires the operators of cosmetic e-commerce platform to provide relevant information according to law due to the needs for supervision and inspection and case investigation, etc., the operator of cosmetics e-commerce platform shall provide assistance and cooperation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"负责药品监督管理的部门因监督检查、案件调查等工作需要，要求化妆品电子商务平台经营者依法提供相关信息的，化妆品电子商务平台经营者应当予以协助、配合。"
    },
    {
        "instruction":"已知信息：\n'(10) A medical device with measuring function, its class shall not be lower than class II.'可被翻译为：（十）具有计量测试功能的医疗器械，其分类应不低于第二类。\n'(8) A medical device supplied in sterile state, its class shall not be lower than class II.'可被翻译为：（八）以无菌形式提供的医疗器械，其分类应不低于第二类。\n'(9) An orthopedic medical device which is used to actively apply a sustained action force to human body in such action modes as pulling, strutting, twisting, holding and bending and may dynamically adjust the fixed position of limb (not including a medical device with fixation and supporting function only, a medical device used in conjunction for temporary orthopedics in the surgery or a medical device used for limbs orthopedics after surgery or in other treatment), its class shall not be lower than class II.'可被翻译为：（九）通过牵拉、撑开、扭转、压握、弯曲等作用方式，主动施加持续作用力于人体、可动态调整肢体固定位置的矫形器械（不包括仅具有固定、支撑作用的医疗器械，也不包括配合外科手术中进行临时矫形的医疗器械或者外科手术后或其他治疗中进行四肢矫形的医疗器械），其分类应不低于第二类。\n'(2) For a medical device which may be used as an accessory, its classification shall be made with comprehensive consideration of the impact of the accessory to the safety and effectiveness of the major medical device used with. If the accessory has significant impact on the major medical device used with, the class of such an accessory shall not be lower than the major medical device used with.'可被翻译为：（二）可作为附件的医疗器械，其分类应当综合考虑该附件对配套主体医疗器械安全性、有效性的影响；如果附件对配套主体医疗器械有重要影响，附件的分类应不低于配套主体医疗器械的分类。\n\n根据上述已知信息，请将'(11) A medical device intended for the treatment of a certain disease, its class shall not be lower than class II.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十一）如果医疗器械的预期目的是明确用于某种疾病的治疗，其分类应不低于第二类。"
    },
    {
        "instruction":"已知信息：\n'Article 43 The undertaking of drug manufacturing shall comply with the GMP.A quality management system shall be established and improved for drug manufacturing, to ensure that the whole chain of drug manufacturing continuously complies with statutory requirements.'可被翻译为：第四十三条 从事药品生产活动，应当遵守药品生产质量管理规范，建立健全药品生产质量管理体系，保证药品生产全过程持续符合法定要求。\n'Article 26 Undertaking of drug manufacturing shall comply with the GMP. A quality management system shall be established and improved for drug manufacturing, which gives into consideration all factors influencing drug quality, to ensure that the whole process of drug manufacturing continuously complies with statutory requirements.'可被翻译为：第二十六条 从事药品生产活动，应当遵守药品生产质量管理规范，建立健全药品生产质量管理体系，涵盖影响药品质量的所有因素，保证药品生产全过程持续符合法定要求。\n'After the drug is approved for marketing, the MAH shall manufacture the drug in accordance with the manufacturing process and specifications approved by NMPA, and follow the requirements of Good Manufacturing Practice (GMP) for specifics and implementation.'可被翻译为：药品批准上市后，持有人应当按照国家药品监督管理局核准的生产工艺和质量标准生产药品，并按照药品生产质量管理规范要求进行细化和实施。\n'Article 43 Drug MAHs shall, in accordance with the GMP, manage and control any change in manufacturing process, and establish process standard procedures according to the approved manufacturing process. To make changes in manufacturing process, a drug MAH shall conduct studies and obtain the approval according to law, file or report such changes to applicable authorities and accept the supervision and inspection by drug regulatory departments.'可被翻译为：第四十三条 药品上市许可持有人应当按照药品生产质量管理规范的要求对生产工艺变更进行管理和控制，并根据核准的生产工艺制定工艺规程。生产工艺变更应当开展研究，并依法取得批准、备案或者进行报告，接受药品监督管理部门的监督检查。\n\n根据上述已知信息，请将'Article 24 Engaging in drug manufacture activities shall comply with the GMP and the manufacturing process shall be in accordance with the national drug standards, drug registration specifications and the manufacturing process approved by drug regulatory departments. The site management file shall be submitted and continuously updated, the risk assessments and continuous improvements of the quality system operation shall be made to ensure a continuous compliance with statutory requirements throughout the whole process. Manufacturing and test records shall be complete and accurate. No fabrication or falsification is allowed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十四条 从事药品生产活动，应当遵守药品生产质量管理规范，按照国家药品标准、经药品监督管理部门核准的药品注册标准和生产工艺进行生产，按照规定提交并持续更新场地管理文件，对质量体系运行过程进行风险评估和持续改进，保证药品生产全过程持续符合法定要求。生产、检验等记录应当完整准确，不得编造和篡改。"
    },
    {
        "instruction":"已知信息：\n'(III) The records of dismantling sales shall be made, including the starting date of dismantling, adopted name, strength, lot number, manufacturer, and expiry date of drugs, sales quantity, sales date, dismantling and checking personnel, etc.;'可被翻译为：（三）做好拆零销售记录，内容包括拆零起始日期、药品的通用名称、规格、批号、生产厂商、有效期、销售数量、销售日期、分拆及复核人员等；\n'Article 92 Enterprises shall take records of drug sales. Sales records shall include the adopted name, strength, dosage form, lot number, expiry date, manufacturer, purchaser, sales quantity, unit price, amount and sales date of the drug. Special sales records shall be established for the direct transfer of drugs in accordance with Article 69 herein.'可被翻译为：第九十二条 企业应当做好药品销售记录。销售记录应当包括药品的通用名称、规格、剂型、批号、有效期、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。按照本规范第六十九条规定进行药品直调的，应当建立专门的销售记录。\n'If there is no enough space in the package to include all the information mentioned above, the adopted name in China, strength, batch number and expiry date shall be indicated at least.'可被翻译为：包装尺寸过小无法全部标明上述内容的，至少应当标注药品通用名称、规格、产品批号、有效期等内容。\n'The sales records of Chinese crude drugs shall include the name of the product, strength, place of production, purchaser, sales quantity, unit price, amount and sales date; those of Prepared Slices shall include the name of product, strength, lot number, place of production, manufacturer, purchaser, sales quantity, unit price, amount and sales date, etc.'可被翻译为：中药材销售记录应当包括品名、规格、产地、购货单位、销售数量、单价、金额、销售日期等内容；中药饮片销售记录应当包括品名、规格、批号、产地、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。\n\n根据上述已知信息，请将'(IV) For dismantling sales, clean and sanitary package shall be used, on which the name, strength, quantity, usage, dosage, lot number, and expiry date of the drug, and name of the drug store shall be indicated;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）拆零销售应当使用洁净、卫生的包装，包装上注明药品名称、规格、数量、用法、用量、批号、有效期以及药店名称等内容；"
    },
    {
        "instruction":"已知信息：\n'Article 160 Any drug regulatory department or its staff members that violate the provisions of this Provisions and constitute any of the circumstances below shall be instructed by its superior administrative department or supervisory departments to make rectification. If the circumstances are serious, administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible in accordance with law:'可被翻译为：第一百六十条 药品监督管理部门及其工作人员违反本法的规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：\n'Article 40 Any food and drug regulatory department, or lot release institution or its staff members that constitutes any of the following circumstances in the lot release work shall be ordered by its superior administrative authority or supervisory authority to make rectification, and administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第四十条 食品药品监督管理部门、批签发机构及其工作人员在批签发工作中有下列情形之一的，由其上级行政机关或者监察机关责令改正，对直接负责的主管人员和其他直接责任人员依法给予行政处分；构成犯罪的，依法追究刑事责任：\n'Article 162 Any drug regulatory department that constitutes any of the following circumstances in the process of drug registration shall be instructed by its superior administrative department or supervisory departments to make rectification, and administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible by law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第一百六十二条 药品监督管理部门在药品注册过程中有下列情形之一的，由其上级行政机关或者监察机关责令改正，对直接负责的主管人员和其他直接责任人员依法给予行政处分；构成犯罪的，依法追究刑事责任：\n'Article 40 If the drug regulatory departments, lot release institution, CFDI and their staff members constitute any of the following circumstances in the lot release work, sanctions shall be given to the directly responsible persons and  other directly responsible personnel by law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第四十条    药品监督管理部门、批签发机构、核查中心及其工作人员在批签发工作中有下列情形之一的，依法对直接负责的主管人员和其他直接责任人员给予处分；构成犯罪的，依法追究刑事责任：\n\n根据上述已知信息，请将'Article 39 Any food and drug regulatory department, or lot release institution or its staff members that violate the provisions herein and in case of any of the circumstances below shall be ordered by its superior administrative authority or supervisory authority to make rectification. If the circumstances are serious, administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十九条 食品药品监督管理部门、批签发机构及其工作人员违反本办法规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分："
    },
    {
        "instruction":"已知信息：\n'Article 91 The clinical trial institution shall keep clinical trial documents for 10 years after the completion of the clinical trial, and the sponsor shall keep the clinical trial data until the medical device is out of use.'可被翻译为：第九十一条 临床试验机构应当保存临床试验资料至临床试验结束后10年。申办者应当保存临床试验资料至无该医疗器械使用时。\n'Article 90 The clinical trial institution, the investigator and the sponsor shall establish a basic document keeping system. The basic documents of the clinical trial are divided into three parts according to the clinical trial phases: documents in the preparation phase, documents in the implementation phase and documents after the termination or completion.'可被翻译为：第九十条 临床试验机构、研究者、申办者应当建立基本文件保存制度。临床试验基本文件按临床试验阶段分为三部分：准备阶段文件、进行阶段文件和终止或者完成后文件。\n'Article 74 The clinical trial institution and the investigator shall ensure that the data, documents and records formed in the clinical trial are authentic, accurate, clear and secure.'可被翻译为：第七十四条 临床试验机构和研究者应当确保临床试验所形成数据、文件和记录的真实、准确、清晰、安全。\n'The clinical trial institution and investigator shall avoid improperly affecting or misleading the participants or related stakeholders of the clinical trial such as the subjects and sponsor.'可被翻译为：临床试验机构和研究者应当避免对受试者、申办者等临床试验参与者或者相关方产生不当影响或者误导。\n\n根据上述已知信息，请将'Article 60 The clinical trial institutions shall properly keep the clinical trial records and basic documents as per the agreement with the sponsor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十条 临床试验机构应当按照与申办者的约定妥善保存临床试验记录和基本文件。"
    },
    {
        "instruction":"已知信息：\n'Article 3 China Food and Drug Administration shall be responsible for organizing and conducting the unannounced inspection of drugs and medical devices nationwide. Local food and drug regulatory departments at all levels shall be responsible for organizing and conducting the unannounced inspection of drugs and medical devices within their respective administrative areas.'可被翻译为：第三条 国家食品药品监督管理总局负责组织实施全国范围内的药品医疗器械飞行检查。地方各级食品药品监督管理部门负责组织实施本行政区域的药品医疗器械飞行检查。\n'Article 5 The organization being inspected shall provide cooperation, and shall not refuse, delay, deny or limit the unannounced inspection of drugs and medical devices organized by the food and drug regulatory departments.'可被翻译为：第五条 被检查单位对食品药品监督管理部门组织实施的药品医疗器械飞行检查应当予以配合，不得拒绝、逃避或者阻碍。\n'Article 8 Where any of the following circumstances exists, the food and drug regulatory departments can conduct an unannounced inspection for drugs and medical devices:'可被翻译为：第八条 有下列情形之一的，食品药品监督管理部门可以开展药品医疗器械飞行检查：\n'Article 2 The unannounced inspection of drugs and medical devices herein refers to the supervision and inspection conducted in the process of research, development, manufacture, distribution and use of drugs and medical devices by the food and drug regulatory departments without advance notice.'可被翻译为：第二条 本办法所称药品医疗器械飞行检查，是指食品药品监督管理部门针对药品和医疗器械研制、生产、经营、使用等环节开展的不预先告知的监督检查。\n\n根据上述已知信息，请将'Article 34 The food and drug regulatory departments at all levels shall incorporate the costs for unannounced inspection of drugs and medical devices and related sampling and testing fees into annual budget, and shall provide sufficient guarantee as needed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十四条 各级食品药品监督管理部门应当将药品医疗器械飞行检查所需费用及相关抽检费用纳入年度经费预算，并根据工作需要予以足额保障。"
    },
    {
        "instruction":"已知信息：\n'Table 1: Maximum permitted total particle concentration for classification'可被翻译为：表 1：各级别允许的最大总微粒浓度\n'Appropriate alert levels and action limits should be set for the results of viable and total particle monitoring. The maximum total particle action limits are described in Table 5 and the maximum viable particle action limits are described in Table 6. However, more stringent action limits may be applied based on data trending, the nature of the process or as determined within the CCS. Both viable and total particle alert levels should be established based on results of cleanroom qualification tests and periodically reviewed based on ongoing trend data.'可被翻译为：对活性粒子和总微粒监测的结果应设置适当的警戒限和行动限。最大粒子总数行动限见表 5 ，最大活性粒 子行动限见表 6。然而，基于数据趋势分析、工艺性质或按照 CCS 中的规定，可以应用更严格的行动限。应根据洁净室确认测试的结果确定活性粒子和总微粒警戒限，并根据持续趋势数据定期回顾。\n'Table 2: Maximum permitted microbial contamination level during qualification'可被翻译为：表 2：确认过程中允许的最大微生物污染水平\n'Table 6: Maximum action limits for viable particle contamination'可被翻译为：表 6：活性粒子污染的最大行动限\n\n根据上述已知信息，请将'Table 5: Maximum permitted total particle concentration for monitoring.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"表 5：监测最大允许的总粒子浓度。"
    },
    {
        "instruction":"已知信息：\n'Also known as \"liquid agent\". A liquid dispersion system in which the drug is dispersed in a certain form in a liquid medium for internal and external use.'可被翻译为：又称“液体药剂”。药物以一定的形式分散于液体介质中所制成的供内服和外用的液体分散体系。\n'oral liquid preparation'可被翻译为：内服液体制剂\n'Also known as \"heterogeneous liquid pharmaceutical\". A liquid dispersion system in which a drug is dispersed in a liquid medium in the form of particles or droplets.'可被翻译为：又称“非均相液体药剂”。药物以微粒或微滴形式分散于液体介质中所制成的液体分散体系。\n'Also known as \"homogeneous liquid pharmacy\". A liquid dispersion system for internal or external use made by dispersing a drug in a liquid medium in a molecular or ionic state.'可被翻译为：又称“均相液体药剂\"。药物以分子或离子状态分散于液体介质中制成的供内服或外用的液体分散体系。\n\n根据上述已知信息，请将'Also known as \"ingestion of liquid medicine\". A liquid preparation, such as a mixture, syrupy agent, or emulsion, for oral use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"内服液体药剂”。合剂、糖浆剂、乳剂等供口服的液体制剂。"
    },
    {
        "instruction":"已知信息：\n'2. Electronic data collection system passes the system verification, and retains verification record. Set user management, role management and permission management for the computerized system, different personnel or roles have the unique logon rights. With audit track function, it can display the records of modification data and modification reason.'可被翻译为：2.电子数据采集系统经过系统验证， 并保存验证记录。计算机化系统设置用户管理、角色管理和权限管理， 不同人员或角色具有唯一登录权限。具有稽查轨迹功能，能够显示修改数据与修改原因的记录。\n'Once the hydration and temperature of the skin has equilibrated (i.e., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the VDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface. The stirrers can be run during the duration of the equilibration to speed up temperature stabilization.'可被翻译为：一旦皮肤的水合作用和温度达到平衡(即30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。而是直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调节VDC系统的热调节机制，使皮肤表面温度达到32°的目标温度。搅拌器可以在平衡期间运行，以加速温度稳定。\n'Once the hydration and temperature of the skin has equilibrated (e.g., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the FDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface.'可被翻译为：一旦皮肤的水合作用和温度达到平衡(例如，30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。相反，应直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调整FDC系统的温度调节机制，使皮肤表面温度达到32°的目标温度。\n'A preparation that can be retained in gastric juice, prolong the release time of drugs in the digestive tract, improve drug absorption, and contribute to improving drug bioavailability.'可被翻译为：一类能滞留于胃液中，延长药物在消化道的释放时间，改善药物吸收，有利于提高药物生物利用度的制剂。\n\n根据上述已知信息，请将'After proper surface modification, the liposomes can avoid phagocytosis of reticuloendothelial system and prolong the time of circulating system in the body.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"表面经适当修饰后，可避免网状内皮系统吞噬，延长在体内循环系统时间的脂质体。"
    },
    {
        "instruction":"已知信息：\n'Article 127 Personnel at all posts of enterprises shall have received pre-post training and on-the-job training on relevant laws and regulations as well as professional knowledge and skills of drugs to meet the requirements of the GSP.'可被翻译为：第一百二十七条 企业各岗位人员应当接受相关法律法规及药品专业知识与技能的岗前培训和继续培训，以符合本规范要求。\n'Article 129 Enterprises shall provide conditions for the personnel selling drugs under special management, drugs with special management requirements by the State, or refrigerated drugs to receive corresponding training, so that they can master relevant laws, regulations and professional knowledge.'可被翻译为：第一百二十九条 企业应当为销售特殊管理的药品、国家有专门管理要求的药品、冷藏药品的人员接受相应培训提供条件，使其掌握相关法律法规和专业知识。\n'Article 49 Enterprises engaged in storage and transportation of refrigerated and frozen drugs shall be equipped with the following facilities and equipment:'可被翻译为：第四十九条 储存、运输冷藏、冷冻药品的，应当配备以下设施设备：\n'Article 26 The training content shall contain applicable laws and regulations, professional knowledge and skills on drugs, quality management system, responsibilities as well as post operating procedures.'可被翻译为：第二十六条 培训内容应当包括相关法律法规、药品专业知识及技能、质量管理制度、职责及岗位操作规程等。\n\n根据上述已知信息，请将'Article 28 Personnel engaged in the storage and transportation of drugs under special management and refrigerated and frozen drugs shall have received the training on relevant laws and regulations and professional knowledge, and shall not take up their posts until passing the assessment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十八条 从事特殊管理的药品和冷藏冷冻药品的储存、运输等工作的人员，应当接受相关法律法规和专业知识培训并经考核合格后方可上岗。"
    },
    {
        "instruction":"已知信息：\n'A tablet coated with enteric-soluble coating material.'可被翻译为：用肠溶性包衣材料进行包衣的片剂。\n'The operation of coating the surface of the tablet with a suitable material.'可被翻译为：在片剂表面包裹上适宜材料的衣层的操作。\n'One method of coating a tablet. The tablet core is placed in a fluidized bed, the air flow is passed through, and the rapidly rising air flow makes the tablet core suspended in the coating chamber to be in a fluidizing state. The coating liquid is also sprayed into the fluidized chamber to make the surface of the tablet adhere to a layer of coating liquid and dry.'可被翻译为：片剂包衣方法之一。片芯置于流化床中，通入气流，借急速上升的空气流使片芯悬浮于包衣室中处于流化状态，另将包衣液喷入流化室，使片剂表面黏附一层包衣液并干燥。\n'The operation of wrapping suitable material layer on the surface of solid preparation (core, plain sheet, particle).'可被翻译为：在固体制剂（片芯、素片、颗粒）表面包裹上适宜材料层的操作。\n\n根据上述已知信息，请将'The process of coating the surface of the tablet (core, plain) with a layer of enteric-soluble material.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在片剂（片芯、素片）表面包裹肠溶性材料层的过程。"
    },
    {
        "instruction":"已知信息：\n'The ratio of absorbance of the sample solution under different wavelength conditions. Generally used for differential or derivative spectrometry for content determination.'可被翻译为：样品溶液在不同波长条件下的吸光度的比值。一般用于鉴别或导数光谱法进行含量测定。\n'The use of tetrazonium salivary salt in a strong alkaline solution, can be reduced by reducing substances quantitative reduction to the principle of colored substances, through the determination of the absorbance of tetrazonium salivary reducing substance solution, the method of calculating the content of reduced substances.'可被翻译为：利用四氮唾盐在强碱性溶液中，可被还原性物质定量还原为有色物质的原理，通过测定四氮唾还原物溶液的吸光度，计算还原物质含量的方法。\n'The wavelength can be controlled by a user-set program, and an analysis can be measured at different wavelengths to obtain the best sensitivity of the detector.'可被翻译为：波长可以由用户设定程序进行控制，一次分析可在不同的波长进行测定，以获得最佳灵敏度的检测器。\n'The titration operation is combined with the absorbance, and the spectrophotometer is used to measure the ever-changing absorbance of the test liquid in the titration process in order to obtain the titration end point, and the method of calculating the content of the substance to be measured.'可被翻译为：将滴定操作与吸光度相结合，利用分光光度计按次序测量试液在滴定过程中不断变化的吸光度，以获得滴定终点，并由此计算出待测物含量的方法。\n\n根据上述已知信息，请将'The absorbance of test solution and control solution is measured at two different wavelengths, and the difference of absorbance at two wavelengths (A4) is used as a quantitative basis to determine the content of the method.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在两个不同的波长处测定供试品溶液和对照品溶液的吸光度，以两波长处吸光度的差值（A4）作为定量的依据来测定含量的方法。"
    },
    {
        "instruction":"已知信息：\n'(XI) Being responsible for the audit of operation permission of computer system, and the establishment and update of basic data of quality management;'可被翻译为：（十一）负责计算机系统操作权限的审核和质量管理基础数据的建立及更新；\n'(I) The provisions for internal audit of quality management system;'可被翻译为：（一）质量管理体系内审的规定；\n'Section 1 Quality Management System'可被翻译为：第一节 质量管理体系\n'(XV) Organizing the internal audit and risk assessment of the quality management system;'可被翻译为：（十五）组织质量管理体系的内审和风险评估；\n\n根据上述已知信息，请将'1) To participate in quality management activities such as establishment of the quality system, self-inspection, external quality audit, validation, adverse drug reaction reporting and product recalls;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.参与企业质量体系建立、内部自检、外部质量审计、验证以及药品不良反应报告、产品召回等质量管理活动；"
    },
    {
        "instruction":"已知信息：\n'Article 21 The drug regulatory department under the State Council shall examine and approve the production process, quality control standards, package inserts and labels of vaccines during the approval process of the vaccine registration application.'可被翻译为：第二十一条 国务院药品监督管理部门在批准疫苗注册申请时，对疫苗的生产工艺、质量控制标准和说明书、标签予以核准。\n'Article 90 The content of drug advertisements shall be truthful and lawful. The package inserts approved by the drug regulatory department under the State Council shall be taken as the basis, and no false content may be contained in them.'可被翻译为：第九十条 药品广告的内容应当真实、合法，以国务院药品监督管理部门核准的药品说明书为准，不得含有虚假的内容。\n'Article 74 Vaccine MAHs shall establish an information publicity system and in a timely manner publish vaccine information, package inserts, labels, implementation of relevant good manufacturing practice, lot release, product recall, inspection and punishment accepted as well as compulsory vaccine liability insurance on their websites in accordance with relevant regulations.'可被翻译为：第七十四条 疫苗上市许可持有人应当建立信息公开制度，按照规定在其网站上及时公开疫苗产品信息、说明书和标签、药品相关质量管理规范执行情况、批签发情况、召回情况、接受检查和处罚情况以及投保疫苗责任强制保险情况等信息。\n'Article 75 The drug regulatory department under the State Council shall liaise with the health department under the State Council to establish the information sharing mechanism for vaccine quality and immunization.'可被翻译为：第七十五条 国务院药品监督管理部门会同国务院卫生健康主管部门等建立疫苗质量、预防接种等信息共享机制。\n\n根据上述已知信息，请将'The drug regulatory department under the State Council shall publish the content of vaccine package inserts and labels on its websites in a timely manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国务院药品监督管理部门应当在其网站上及时公布疫苗说明书、标签内容。"
    },
    {
        "instruction":"已知信息：\n'Article 30 Cosmetic registrants and filing persons shall select ingredients that meet the requirements of laws, administrative regulations, mandatory national standards and technical specifications for cosmetic production, and shall be responsible for the safety of cosmetic ingredients they use. When applying for registration and filing for filing, the cosmetic registrant and filing person shall clarify the source of ingredients and relevant information on ingredient safety through the information service platform.'可被翻译为：第三十条 化妆品注册人、备案人应当选择符合法律、行政法规、强制性国家标准和技术规范要求的原料用于化妆品生产，对其使用的化妆品原料安全性负责。化妆品注册人、备案人申请注册、进行备案时，应当通过信息服务平台明确原料来源和原料安全相关信息。\n'Article 31 If cosmetic registrants and filing persons entrust cosmetic manufacturing, for domestic cosmetics, the entrustment shall be associated and confirmed by the cosmetic manufacturers through the information service platform when applying for registration or filing; for imported cosmetics, relevant documents demonstrating the entrustment shall be submitted by the cosmetic registrants or filing persons.'可被翻译为：第三十一条 化妆品注册人、备案人委托生产化妆品的，国产化妆品应当在申请注册或者进行备案时，经化妆品生产企业通过信息服务平台关联确认委托生产关系；进口化妆品由化妆品注册人、备案人提交存在委托关系的相关材料。\n'Registrants and filing persons of cosmetics and new cosmetic ingredients shall comply with the requirements of relevant laws, administrative regulations, mandatory national standards and technical specifications when applying for registration or filing for filing, and shall be responsible for the authenticity and scientificalness of the submitted dossiers.'可被翻译为：化妆品、化妆品新原料注册人、备案人申请注册或者进行备案时，应当遵守有关法律、行政法规、强制性国家标准和技术规范的要求，对所提交资料的真实性和科学性负责。\n'Article 33 Cosmetic registrants and filing persons shall entrust a testing agency that has obtained qualification certifications and meets the needs for testing on cosmetic registration and filing to conduct testing according to mandatory national standards, technical specifications and testing requirements of registration and filing.'可被翻译为：第三十三条 化妆品注册申请人、备案人应当委托取得资质认定、满足化妆品注册和备案检验工作需要的检验机构，按照强制性国家标准、技术规范和注册备案检验规定的要求进行检验。\n\n根据上述已知信息，请将'Article 32 Cosmetic registrants and filing persons shall clarify the product standards that are implemented, and submit it to the drug regulatory department when applying for registration or filing for filing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十二条 化妆品注册人、备案人应当明确产品执行的标准，并在申请注册或者进行备案时提交药品监督管理部门。"
    },
    {
        "instruction":"已知信息：\n'Article 40    Any drug manufacturer or distributor in violation of Article 20 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if the drug manufacturer or distributor fails to do so or the circumstances are serious, they shall be fined not more than two times the value of the free drugs offered, but not more than RMB 30,000 yuan.'可被翻译为：第四十条 药品生产、经营企业违反本办法第二十条规定的，限期改正，给予警告；逾期不改正或者情节严重的，处以赠送药品货值金额二倍以下的罚款，但是最高不超过三万元。\n'Article 30    In any of the following circumstances, the drug manufacturer or distributor shall be instructed to rectify within a time limit and given a disciplinary warning; and if the drug manufacturer or distributor fails to do so, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan:'可被翻译为：第三十条 有下列情形之一的，责令限期改正，给予警告；逾期不改正的，处以五千元以上二万元以下的罚款：\n'Article 42    Where a drug manufacturer or distributor in violation of Article 21 of the Provisions or a medical institution in violation of Article 28 of the Provisions sells prescription drugs directly to the public by post, over internet, etc., they shall be instructed to rectify, given a disciplinary warning, and fined not more than two times the value of the drugs sold, but not more than RMB 30,000 yuan.'可被翻译为：第四十二条 药品生产、经营企业违反本办法第二十一条、医疗机构违反本办法第二十八条规定，以邮售、互联网交易等方式直接向公众销售处方药的，责令改正，给予警告，并处销售药品货值金额二倍以下的罚款，但是最高不超过三万元。\n'Article 38    Any drug retailer in violation of the first paragraph of Article 18 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so or the circumstances are serious, it shall be fined not more than RMB 1,000 yuan.'可被翻译为：第三十八条 药品零售企业违反本办法第十八条第一款规定的，责令限期改正，给予警告；逾期不改正或者情节严重的，处以一千元以下的罚款。\n\n根据上述已知信息，请将'Article 35    Where a drug manufacturer or distributor, in violation of Article 13 of the Provisions, knows or should know that any person without certificates produces or distributes drugs, but still provide the person with drugs, they shall be given a disciplinary warning, instructed to rectify and fined not more than RMB 10,000 yuan. If the circumstances are serious, they shall be fined not less than RMB 10,000 yuan but not more than RMB 30,000 yuan.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十五条 违反本办法第十三条规定，药品生产、经营企业知道或者应当知道他人从事无证生产、经营药品行为而为其提供药品的，给予警告，责令改正，并处一万元以下的罚款，情节严重的，处一万元以上三万元以下的罚款。"
    },
    {
        "instruction":"已知信息：\n'(4) Where, according to provisions in Article 83 of the Drug Administration Law, drugs have uncertain efficacy and serious adverse reactions or are otherwise harmful to human health;'可被翻译为：（四）按照《药品管理法》第八十三条的规定，疗效不确切、不良反应大或者因其他原因危害人体健康的；\n'(4) according to provisions in Article 42 of the Drug Administration Law or Article 41 of the Regulations for Implementation of the Drug Administration Law, the drug approval document is withdrawn for any drug with serious adverse reactions or other factors harmful to human health;'可被翻译为：（四）按照《药品管理法》第四十二条和《药品管理法实施条例》第四十一条的规定，对不良反应大或者其他原因危害人体健康的药品，撤销批准证明文件的；\n'Upon evaluation, the drug approval license of drugs with unclear efficacy, serious adverse reactions, or are otherwise harmful to human health shall be revoked.'可被翻译为：经评价，对疗效不确切、不良反应大或者因其他原因危害人体健康的药品，应当注销药品注册证书。\n'(4) Post-marketing evaluation indicates the drug has uncertain efficacy, serious adverse reaction, or harmful to human health due to other reasons;'可被翻译为：（四）经上市后评价，属于疗效不确切、不良反应大或者因其他原因危害人体健康的；\n\n根据上述已知信息，请将'(5) Where, according to the provisions in Article 61 of the Vaccine Administration Law, vaccines have serious adverse events following immunization or are otherwise harmful to human health as indicated by post-marketing evaluation;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）按照《疫苗管理法》第六十一条的规定，经上市后评价，预防接种异常反应严重或者其他原因危害人体健康的；"
    },
    {
        "instruction":"已知信息：\n'NMPA Notice on Issuing the Requirements for Change Items of Marketed Traditional Chinese Medicines and Application Dossiers'可被翻译为：国家药监局关于发布《已上市中药变更事项及申报资料要求》的通告\n'NMPA Announcement on Issuing the Requirements for Change Items and Application Dossiers of Marketed Biological Products'可被翻译为：国家药监局关于发布《已上市生物制品变更事项及申报资料要求》的通告\n'To cooperate with the implementation of the Provisions for Drug Registration, the NMPA has organized to formulate the Requirements for Change Items of Marketed Chemicals and Application Dossier, which has been issued and implemented on February 3, 2021.'可被翻译为：为配合药品注册管理办法实施，国家药品监督管理局组织制定了《已上市化学药品变更事项及申报资料要求》，已于2021年2月3日发布实施。\n'Notice of CDE of China NMPA on Issuing the Technical Requirements for CMC Study and Evaluation of Chemical Drugs Marketed Overseas But Not Marketed in China (Interim)'可被翻译为：国家药监局药品监督管理总局关于印发《境外上市未在境内上市化学药品CMC研究评价技术要求(暂行)》的通知\n\n根据上述已知信息，请将'NMPA Notice on Issuing the Requirements for Change Items of Marketed Chemicals and Application Dossier'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布已上市化学药品变更事项及申报资料要求的通告"
    },
    {
        "instruction":"已知信息：\n'Article 22 The State implements strict access system for vaccine manufacturing.'可被翻译为：第二十二条 国家对疫苗生产实行严格准入制度。\n'Article 26 The State implements lot release system for vaccines.'可被翻译为：第二十六条 国家实行疫苗批签发制度。\n'Article 68 The State implements a compulsory liability insurance system for vaccines.'可被翻译为：第六十八条 国家实行疫苗责任强制保险制度。\n'Article 10 The State implements the whole process electronic traceability system for vaccines.'可被翻译为：第十条 国家实行疫苗全程电子追溯制度。\n\n根据上述已知信息，请将'Article 76 The State implements the uniform release system for vaccine safety information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十六条 国家实行疫苗安全信息统一公布制度。"
    },
    {
        "instruction":"已知信息：\n'Article 63: Quality Control laboratories usually should be separated from production areas. Laboratories for the control of biological, microbiological and radioisotopes should also be separated from each other.'可被翻译为：第六十三条 质量控制实验室通常应当与生产区分开。生物检定、微生物和放射性同位素的实验室还应当彼此分开。\n'Article 68: Rest and refreshment rooms should not bring any hazard to production, storage and quality control areas.'可被翻译为：第六十八条 休息室的设置不应当对生产区、仓储区和质量控制区造成不良影响。\n'Article 197: Measures should be taken to avoid, as far as possible, contamination and cross-contamination during production, for example:'可被翻译为：第一百九十七条 生产过程中应当尽可能采取措施，防止污染和交叉污染，如：\n'Article 85: Production equipment after cleaning should be stored in a clean and dry condition.'可被翻译为：第八十五条 已清洁的生产设备应当在清洁、干燥的条件下存放。\n\n根据上述已知信息，请将'Article 70: Maintenance workshops should as far as possible be separated from production areas. Whenever parts and tools are stored in the clean area, they should be kept in rooms or lockers reserved for that use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条 维修间应当尽可能远离生产区。存放在洁净区内的维修用备件和工具，应当放置在专门的房间或工具柜中。"
    },
    {
        "instruction":"已知信息：\n'(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number.'可被翻译为：（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证编号或者备案编号。\n'(3) Name, residence, manufacturing address, contacts and production license number or filing number of medical device manufacturer. For contract manufacturing, name, address, manufacturing address, production license number or filing number of contracted manufacturer shall be also specified.'可被翻译为：（三）生产企业的名称、住所、生产地址、联系方式及生产许可证编号或者生产备案凭证编号，委托生产的还应当标注受托企业的名称、住所、生产地址、生产许可证编号或者生产备案凭证编号；\n'(4) Name, residence, manufacturing address, contacts and  production license number or filing number of medical device manufacturer. For contract manufacturing, name, address, manufacturing address, production license number or filing number of contracted manufacturer shall be also specified.'可被翻译为：（四）生产企业的名称、住所、生产地址、联系方式及生产许可证编号或者生产备案凭证编号，委托生产的还应当标注受托企业的名称、住所、生产地址、生产许可证编号或者生产备案凭证编号；\n'The contract manufacturer shall promptly inform the medical devices registrant or filing entity of the changes.'可被翻译为：受托生产企业应当及时将变化情况告知医疗器械注册人、备案人。\n\n根据上述已知信息，请将'(3) name of the registrant, filing entity and contract manufacturer of the medical device, manufacturing license number or filing number;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）医疗器械注册人、备案人和受托生产企业名称、生产许可证号或者备案编号；"
    },
    {
        "instruction":"已知信息：\n'(b) The items identified in paragraphs (a)(1), (a)(2), and (a)(3) of this section shall be subject to the same controls as for electronic records and shall be included as part of any human readable form of the electronic record (such as electronic display or printout).'可被翻译为：本节(a)(1), (a)(2), 和(a)(3)中明确的内容应采用电子记录相同的管理方式，且应作为易读电子记录（电子显示或打印输出）的一部分。\n'(e) Use of secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records. Record changes shall not obscure previously recorded information. Such audit trail documentation shall be retained for a period at least as long as that required for the subject electronic records and shall be available for agency review and copying.'可被翻译为：使用计算机生成的可靠、时间戳记的审计跟踪，以独立记录操作者登录和生成、修改、或删除电子记录的日期和时间。记录更改不应覆盖之前记录的信息。审计跟踪文档将至少与目标电子记录保存形同的时限，并便于主管部门审核与复制。\n'medical and pharmaceutical electronic commerce'可被翻译为：医药电子商务\n'Electronic signatures and handwritten signatures executed to electronic records shall be linked to their respective electronic records to ensure that the signatures cannot be excised, copied, or otherwise transferred to falsify an electronic record by ordinary means.'可被翻译为：电子记录上签署的电子签名和手写签名应关联至其相应的电子记录，以确保无法通过普通手段对电子签名进行删除、复制或其他转移方式而实现电子记录的伪造。\n\n根据上述已知信息，请将'(2) Where the electronic medical record has already been adopted in daily diagnosis and treatment, the clinical trials shall use electronic medical records.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(2) 日常诊疗已使用电子病历系统的，临床试验应使用电子病历。"
    },
    {
        "instruction":"已知信息：\n'The use of natural or synthetic polymer materials as carrier materials, so that the drug dissolved or\/and dispersed in the polymer material, the formation of a skeleton type of tiny spherical entity.'可被翻译为：利用天然或合成的高分子材料为载体材料，使药物溶解或\/和分散在高分子材料中，形成的骨架型微小球状实体。\n'A solvent (non-solvent) that is insoluble to the material is added to the solution of the drug and the material, causing phase separation, and the drug is wrapped into a sac or co-precipitation into a ball method.'可被翻译为：药物和材料的溶液中加入一种对材料不溶的溶剂（非溶剂），引起相分离，而将药物包裹成囊或共沉淀成球的方法。\n'The method in which the drug is dispersed in a molten material and then sprayed in a cold air stream to condense into a ball or capsule.'可被翻译为：药物分散于熔融的材料中，再喷于冷气流中凝聚而成球或成囊的方法。\n'The natural or synthetic polymer material that forms the wall of the capsule.'可被翻译为：构成囊壁的天然或合成的高分子材料。\n\n根据上述已知信息，请将'The insoluble drug is dispersed in the aqueous solution of the polymer material, and the coagulant is added to reduce the solubility of the polymer material to condense it into a sac.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"难溶性药物分散在高分子材料的水溶液中，加入凝聚剂以降低高分子材料溶解度使之凝聚成囊的方法。"
    },
    {
        "instruction":"已知信息：\n'Guidance on the requirements for specific training, knowledge and skills. Also gives guidance regarding the qualification of personnel.'可被翻译为：关于具体培训、知识和技能要求，以及关于人员资质确认的指导。\n'1. Design qualification is to verify that the design of the premises, facilities and equipment is suitable for the intended use and in compliance with the Provisions;'可被翻译为：（一）设计确认应当证明厂房、设施、设备的设计符合预定用途和本规范要求；\n'General guidance on the design and operation of equipment.'可被翻译为：关于设备的设计和运行的一般性指导。\n'Guidance on the approaches to be taken regarding aseptic and terminal sterilization processes. Guidance on the approaches to sterilization of products, equipment and packaging components.\nAlso guidance on different technologies such as lyophilization and Form-Fill-Seal where specific requirements apply.'可被翻译为：关于无菌工艺和终端灭菌工艺采用的方法的指导。关于产品、设备和包装组分的灭菌方法的指导。以及针对使用特定要求的各种技术的指导，如冻干和成型-灌装-密封。\n\n根据上述已知信息，请将'General guidance regarding the specific needs for premises design and also guidance on the qualification of premises including the use of Barrier Technology.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"有关具体厂房设计需求的一般性指导，以及关于厂房确认的指导（包括屏障技术的使用）。"
    },
    {
        "instruction":"已知信息：\n'Article 53 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall deliver the review opinions, inspection reports and the application dossiers to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and notice the applicants.'可被翻译为：第五十三条 省、自治区、直辖市药品监督管理部门应当在规定的时限内将审查意见、核查报告以及申报资料送交国家食品药品监督管理局药品审评中心，并通知申请人。\n'Article 64 Drug testing institutes shall conduct sample testing according to the verified specifications, and within the specified timeline, provide testing reports to the Center for Drug Evaluation of the State Food and Drug Administration, and copy to the relevant drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government and the applicants.'可被翻译为：第六十四条 药品检验所应当依据核定的药品标准对抽取的样品进行检验，并在规定的时间内将药品注册检验报告送交国家食品药品监督管理局药品审评中心，同时抄送相关省、自治区、直辖市药品监督管理部门和申请人。\n'Article 79 Drug testing institutes shall conduct sample testing, provide testing reports to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and copy to the drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government that notify them to conduct the verification, and the applicants.'可被翻译为：第七十九条 药品检验所应当对抽取的样品进行检验，并在规定的时间内将药品注册检验报告送交国家食品药品监督管理局药品审评中心，同时抄送通知其检验的省、自治区、直辖市药品监督管理部门和申请人。\n'Article 59 Drug testing institutes shall verify the submitted drug specifications and give the verification opinions to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and at the same time copy to the drug regulatory departments of the provinces, autonomous regions, or municipalities directly under the Central Government that notify them to conduct the verification, and the applicants.'可被翻译为：第五十九条 药品检验所应对申报的药品标准进行复核，并在规定的时间内将复核意见送交国家食品药品监督管理局药品审评中心，同时抄送通知其复核的省、自治区、直辖市药品监督管理部门和申请人。\n\n根据上述已知信息，请将'Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall deliver the review opinions, inspection reports and the application dossiers to the Center for Drug Evaluation of the State Food and Drug Administration within the specified timeline, and notice the applicants.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"省、自治区、直辖市药品监督管理部门应当在规定的时限内将审查意见、核查报告及申报资料送交国家食品药品监督管理局药品审评中心，并通知申请人。"
    },
    {
        "instruction":"已知信息：\n'17.Stability Testing – sample storage conditions, missed sampling dates, etc.'可被翻译为：稳定性试验—样品存贮条件、错过取样日期等\n'The quantity of a medicine given per administration, or per day.'可被翻译为：每次或每天的用药数量。\n'skip lot (periodic) testing'可被翻译为：跳过批次(定期)测试\n'(IX) When it is necessary to appropriately change the sampling method and quantity based on the quality and packing abnormalities of the goods arriving at port, the drug control institute of port shall, communicate with the applicant for testing, and seek agreement on the sampling method so as to take representative samples. Any change in the sampling method shall be recorded in the Record of Sampling for Import Drugs.'可被翻译为：（九）根据到货的质量和包装异常情况，需适当变更抽样方法和数量时，口岸药品检验所应当与报验单位共同议定变更方法，以便抽取代表性样品。变更抽样方法的情况，应当在《进口药品抽样记录单》中予以记录。\n\n根据上述已知信息，请将'9. Product sampling: a representative sample is selected based on lot size as per USP <71> guidelines; quantity per container & units per batch, sample storage (time and temperature), sampling port sanitization or sterilization problems; be aware of skip lot testing on raw material.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"产品取样：按 USP<71>指南中的批量选择具有代表性的样品；每个包装&每批产品件数所取数量，样品存贮（时间和温度）、取样端口灭菌或消毒问题；了解原料的跳批检测"
    },
    {
        "instruction":"已知信息：\n'Medical costs directly related to the delivery of medical services. Such as the cost of diagnosis, treatment, and tests.'可被翻译为：与医疗服务的提供直接相关的医疗成本。如诊断、治疗、检查费。\n'The costs directly related to health care that are incurred specifically to provide a health care service.'可被翻译为：专为提供某医疗服务项目而发生的与医疗服务直接相关的成本。\n'A method of calculating and providing an analysis of the costs and health outcomes of alternative medical interventions.'可被翻译为：计算并给出可供选择的医疗干预措施的成本和健康结果的分析方法。\n'The extra cost incurred by adding one unit of output that is borne by society as a whole. Including private costs and external costs borne by agents.'可被翻译为：增加一个单位产出所产生的额外由全社会承担的成本。包括由行为主体承担的私人成本与外部成本。\n\n根据上述已知信息，请将'Non-medical costs directly related to the provision of medical services. Such as transportation costs for patients to hospitals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与医疗服务的提供直接相关的非医疗成本。比如患者去医院的交通费。"
    },
    {
        "instruction":"已知信息：\n'In accordance with the results of adverse drug reaction assessment, to further guarantee the safety of people in the use of drug, the NMPA decided to revise such items as [Adverse reactions], [Contraindications]and [Precautions] in the package inserts of antiviral syrup, capsules, soft capsules, pills(concentrated pills), dropping pills, tablets, effervescent tablets, chewable tablet, oral liquid, and granules. The relevant issues are hereby announced as follows:'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒说明书【不良反应】、【禁忌】和【注意事项】项进行统一修订。现将有关事项公告如下：\n'I. The marketing authorization holders of the said products shall, in accordance with the Provisions for Drug Registration and the revision requirements for the package insert (see Attachments 1 and 2) of antiviral syrup, capsules, soft capsules, pills (concentrated pills), dropping pills, tablets, effervescent tablets, chewable tablet, oral liquid and granules (both prescription drugs and OTC), file a report as such before December 27, 2021 to provincial medical products regulatory authority.'可被翻译为：一、上述药品的上市许可持有人均应依据《药品注册管理办法》等有关规定，按照抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒的处方药、非处方药说明书修订要求，于2021年12月27日前报省级药品监督管理部门备案。\n'NMPA Announcement on Revising the Package Insert of Misoprostol Tablets for Obstetrical and Gynecological Application'可被翻译为：国家药监局关于修订妇产科用米索前列醇片说明书的公告\n'NMPA Issued the Announcement on Revising the Package Inserts of Prescription and Over-the-counter Oral Preparations such as Huoxuezhitong Capsules'可被翻译为：国家药监局关于修订活血止痛胶囊等口服制剂处方药和非处方药说明书的公告\n\n根据上述已知信息，请将'NMPA Announcement on Revising the Package Insert of Antiviral Syrup, Capsules, Soft Capsules, Pills (Concentrated Pills), Dropping Pills, Tablets, Effervescent Tablets, Chewable Tablet, Oral Liquid, And Granules'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于修订抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒药品说明书的公告"
    },
    {
        "instruction":"已知信息：\n'Article 3 Drugs shall be imported via the ports where drug importation is permitted by the State Council.'可被翻译为：第三条 药品必须经由国务院批准的允许药品进口的口岸进口。\n'Article 3 Crude drugs shall be imported via the ports where drug import is permitted or the border ports where crude drugs importation is permitted by the State Council.'可被翻译为：第三条 药材应当从国务院批准的允许药品进口的口岸或者允许药材进口的边境口岸进口。\n'(VIII) drugs are not imported through the ports where drug importation is permitted by the State Council, or the port of delivery does not fall within the jurisdiction of the local drug regulatory department at ports of entry;'可被翻译为：（八）未在国务院批准的允许药品进口的口岸组织进口的，或者货物到岸地不属于所在地口岸药品监督管理局管辖范围的；\n'Article 2 The Provisions shall apply to the importation record filing, customs declaration, port testing and drug importation.'可被翻译为：第二条 药品的进口备案、报关、口岸检验以及进口，适用本办法。\n\n根据上述已知信息，请将'Article 11 An importer shall choose a port where drug importation is permitted as the port of delivery when signing a purchase contract. Drugs specified in Article 10 of the Provisions shall be imported via a port that is specially permitted by the State for such importation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十一条 进口单位签订购货合同时，货物到岸地应当从允许药品进口的口岸选择。其中本办法第十条规定情形的药品，必须经由国家特别批准的允许药品进口的口岸进口。"
    },
    {
        "instruction":"已知信息：\n'Machinery for the preparation of solid particles.'可被翻译为：可制备固体颗粒的机械。\n'The size of particles.'可被翻译为：颗粒的大小。\n'An apparatus for separating the size of particles.'可被翻译为：用以分离颗粒大小的器具。\n'A dry granular preparation with a certain particle size made of drugs and appropriate excipients.'可被翻译为：药物与适宜的辅料制成的具有一定粒度的干燥颗粒状制剂。\n\n根据上述已知信息，请将'The use of machinery to press the material powder into a certain diameter of the embryo sheet, and then broken into a certain size of particles.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"利用机械将物料粉末压制成一定直径的胚片，再破碎成一定大小颗粒的方法。"
    },
    {
        "instruction":"已知信息：\n'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions] and other Entries on the package inserts of Diclofenac Sodium Suppositories.'可被翻译为：为进一步保障公众用药安全，国家药监局于2020年3月17日发布公告，决定对双氯芬酸钠栓说明书【不良反应】、【注意事项】等项进行修订。\n'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions] and other Entries on the package inserts of hydrocortisone injection and hydrocortisone sodium succinate for injection.'可被翻译为：为进一步保障人民群众用药安全，2020年3月17日，国家药监局发布《公告》，决定修改注射用氢化可的松注射液和琥珀酸氢化可的松钠说明书上的【不良反应】、【注意事项】等内容。\n'To further protect drug safety for the people, on May 7, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions]and other Entries on the package inserts of Polyene Phosphatidylcholine Injection.'可被翻译为：为进一步保障公众用药安全，国家药品监督管理局于2020年5月7日发布对多烯磷脂酰胆碱注射液说明书【不良反应】、【注意事项】等项进行修订的决定。\n'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the Entries of [contraindications], [adverse reactions] and [precautions] on the package inserts of nicotinic acid injections (including nicotinic acid injection and nicotinic acid for injection).'可被翻译为：进一步保障公众用药安全，2020年3月17日，国家药监局发布公告决定对烟酸注射剂（包括烟酸注射液、注射用烟酸）说明书【不良反应】、【禁忌】、【注意事项】项进行修订。\n\n根据上述已知信息，请将'To further protect drug safety for the people, on March 17, 2020, NMPA issued an Announcement with decisions made to revise the [adverse reactions], [precautions] and other Entries on the package inserts of probucol.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为进一步保障公众用药安全，2020年3月17日，国家药品监督管理局发布公告，决定对普罗布考说明书【不良反应】、【注意事项】等项进行修订。"
    },
    {
        "instruction":"已知信息：\n'I. Chongqing Municipal Medical Products Administration is approved to add the filling function for the first import of chemicals. As of the date of printing and issuing this Announcement, the Chongqing Municipal Medical Products Administration can handle the filing of the first importation of chemicals.'可被翻译为：一、同意重庆市药品监督管理局增加化学药品首次药品进口备案职能。自本公告印发之日起，重庆市药品监督管理局可办理化学药品首次药品进口备案手续。\n'According to the Provisions for Drug Importation, the Notice of the China Food and Drug Administration and General Administration of Customs on Printing and Issuing Principles and Standards for the Newly Establishment of Drug Import Ports, the Notice of the China Food and Drug Administration and General Administration of Customs on Printing and Issuing the Evaluation and Assessment Scheme for the Newly Establishment of Drug Import Ports, the Notice of the Comprehensive Department of National Medical Products Administration on Printing and Issuing the Evaluation Criteria for the Ports for the First Drug Importation and other relevant regulations, upon the on-site evaluation and assessment, the NMPA has approved the application of the Chongqing Municipal Medical Products Administration for adding the filing function for the first importation of chemicals, and this Announcement was hereby issued on February 2 as follows:'可被翻译为：根据《药品进口规定》、《中国食品药品监督管理总局、海关总署关于印发新设立药品进口口岸原则和标准的通知》、《中国食品药品监督管理总局、海关总署关于印发新设立药品进口口岸评价考核方案的通知》，《国家药品监督管理局综合司关于印发《药品首次进口口岸评审标准》及其他有关规定的通知》经现场评审评估，国家药品监督管理局批准重庆市药品监督管理局关于增加化学品首次进口备案功能的申请，于2月2日发布本公告如下:\n'II. The Chongqing Institute for Food and Drug Control is responsible for the post inspection for filing the first importation of chemicals.'可被翻译为：二、重庆市食品药品检验检测研究院负责化学药品首次药品进口备案的口岸检验工作。\n'Article 4 The National Medical Products Administration (NMPA) shall be responsible for the supervision and administration of crude drugs importation nationwide. The NMPA shall entrust drug regulatory department of provinces, autonomous regions and municipalities directly under the Central Government (hereinafter referred to as provincial drug regulatory department) to implement the review and approval for first importation of crude drugs, and supervise and guide the acts of review and approval of first importation of crude drugs under entrustment.'可被翻译为：第四条 国家药品监督管理局主管全国进口药材监督管理工作。国家药品监督管理局委托省、自治区、直辖市药品监督管理部门（以下简称省级药品监督管理部门）实施首次进口药材审批，并对委托实施首次进口药材审批的行为进行监督指导。\n\n根据上述已知信息，请将'NMPA Announcement on Approval of Adding the Filing Function for the First Importation of Chemicals to the Chongqing Municipal Medical Products Administration'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于同意重庆市药品监督管理局增加化学药品首次药品进口备案职能的公告"
    },
    {
        "instruction":"已知信息：\n'(2) Changes to the content of drug packaging labels;'可被翻译为：（二）药品包装标签内容的变更；\n'Any materials employed in the packaging of a drug, including immediate packaging materials, container in direct contact with drugs, and printed packaging materials, but excluding any outer packaging materials used for transportation or shipment.'可被翻译为：药品包装所用的材料，包括与药品直接接触的包装材料和容器、印刷包装材料，但不包括发运用的外包装材料。\n'When drugs are produced, packaged or prescribed, labels that meet the regulations should be affixed to the inner and outer packages of drugs; In order to guide patients to use the drug correctly, the pharmacist shall give written notification documents accompanying the drug.'可被翻译为：药品在生产、分装或处方调配时，将符合规定的标签贴在药品的内、外包装上；亦药师为指导患者正确使用药品，随药品所给予的书面告知文书。\n'4) Correct starting materials, packaging materials and labels;'可被翻译为：4.正确的原辅料、包装材料和标签；\n\n根据上述已知信息，请将'Article 16    Drug labels refer to the information printed or pasted on drug packaging, including inner labels and outer labels. Inner labels refer to those that appear on immediate packaging; outer labels are those on the other packaging outside of inner labels.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十六条 药品的标签是指药品包装上印有或者贴有的内容，分为内标签和外标签。药品内标签指直接接触药品的包装的标签，外标签指内标签以外的其他包装的标签。"
    },
    {
        "instruction":"已知信息：\n'The size of monitoring samples taken using automated systems will usually be a function of the sampling rate  of the  system  used.  It  is  not necessary  for the  sample  volume  to  be  the  same  as  that  used  for  formal classification of cleanrooms and clean air equipment. Monitoring sample volumes should be justified.'可被翻译为：使用自动化系统监测时，采样量通常取决于系统的釆样速率。采样量不需要与洁净室和洁净空气设备的正式分级所用的采样量相同。采样量的合理性应经过论证。\n'Where final containers are closed by fusion, e.g. Blow-Fill-Seal (BFS), Form-Fill-Seal (FFS), Small and Large Volume Parenteral (SVP & LVP) bags, glass or plastic ampoules, the critical parameters and variables that affect seal integrity should be evaluated, determined, effectively controlled and monitored during operations. Glass ampoules, BFS units and small volume containers (≤100 ml) closed by fusion should be subject to 100% integrity testing using validated methods. For large volume containers (>100 ml) closed by fusion, reduced sampling may be acceptable where scientifically justified and based on data demonstrating the consistency of the existing process, and a high level of process control. It should be noted that visual inspection is not considered as an acceptable integrity test method.'可被翻译为：当最终容器通过融合密封时，例如吹灌封（BFS）、成型-灌装-密封（FFS）、小容量注射剂和大容量注射剂（SVP&LVP）的袋子、玻璃或塑料安瓶瓶，应评估、确定影响密封完整性的关键参数和变量，并在操作过程中进行有效控制和监测。熔融密封的玻璃安瓿瓶、BFS 单元和小容量容器（≤100 ml）应使用经验证的方法进行 100%完整性测试。对于熔融密封的大容量容器（>100 ml），在经过科学论证并基于证明现有工艺可靠性和高水平工艺控制的数据的情况下，减少取样可能是可以接受的。值得注意的是，目检不被认为是可接受的完整性测试方法。\n'The validity of the sterilizing process should be reviewed and verified at scheduled intervals based on risk.\nHeat sterilization cycles should be revalidated with a minimum frequency of at least annually for load patterns\nthat are considered worst case. Other load patterns should be validated at a frequency justified in the CCS.'可被翻译为：根据风险按照预定的时间间隔审核和确认灭菌工艺的有效性。对于被认为是最差条件的装载模式，应至少每年一次定期开展加热灭菌周期的再验证。其它装载模式应以 CCS 中论证的频率进行验证。\n'6.7. The evaluation of the risk should be based on scientific knowledge and experience including that of the process and product.'可被翻译为：风险评估应基于科学知识与经验，包括对工艺和产品的科学知识与经验。\n\n根据上述已知信息，请将'Samples of products using systems other than fusion should be taken and checked for integrity using\nvalidated methods. The frequency of testing should be based on the knowledge and experience of the container\nand closure systems being used. A scientifically justified sampling plan should be used. The sample size should be\nbased on information such as supplier management, packaging component specifications and process knowledge.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用非融合系统的产品应进行取样并使用经验证的方法检查其完整性。完整性检查的频率应基于所使用容器和密封系统的知识和经验。应使用经科学论证的取样计划。样本量应基于供应商管理、包装组件质量标准和工艺知识等信息。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where adverse events occur shall promptly notify the relevant information to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate.'可被翻译为：不良事件发生地省、自治区、直辖市药品监督管理部门应当及时向持有人所在地省、自治区、直辖市药品监督管理部门通报相关信息。\n'The drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall carry out routine supervision and inspection of suppliers and manufacturers of active drug ingredients, pharmaceutical excipients and primary packaging materials and container in direct contact with drug products and, when necessary, carry out extended inspection.'可被翻译为：省、自治区、直辖市药品监督管理部门应当对原料、辅料、直接接触药品的包装材料和容器等供应商、生产企业开展日常监督检查，必要时开展延伸检查。\n'Article 32 The drug manufacturers shall conduct assessment on the suppliers or manufacturers which supply the materials including active drug ingredients, excipients, primary packaging materials and container in direct contact with drug products involved in manufacturing, to ensure that the sourcing and use of such materials satisfy regulatory requirements.'可被翻译为：第三十二条 从事药品生产活动，应当对使用的原料药、辅料、直接接触药品的包装材料和容器等相关物料供应商或者生产企业进行审核，保证购进、使用符合法规要求。\n'Article 34 After knowing the group adverse events of medical device that occurs within their respective administrative regions, the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall promptly carry out on-site investigation jointly with the health administrative departments at the same level, and the drug regulatory departments of relevant provinces, autonomous regions and municipalities directly under the central government shall cooperate. Investigation, re-evaluation and handling results shall be promptly reported to the NMPA and the Health Administrative Department of the State Council, and copied to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate.'可被翻译为：第三十四条  省、自治区、直辖市药品监督管理部门在获知本行政区域内发生的群体医疗器械不良事件后，应当会同同级卫生行政部门及时开展现场调查，相关省、自治区、直辖市药品监督管理部门应当配合。调查、评价和处理结果应当及时报国家药品监督管理局和国务院卫生行政部门，抄送持有人所在地省、自治区、直辖市药品监督管理部门。\n\n根据上述已知信息，请将'Article 70 Where manufacturers and suppliers of excipients or primary packaging materials and container in direct contact with drug products do not comply with the quality management standards or relevant requirements established by the NMPA and cannot ensure the quality management system persistently complies with regulatory requirements, the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government shall impose punishments in accordance with Article 126 under the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条 辅料、直接接触药品的包装材料和容器的生产企业及供应商未遵守国家药品监督管理局制定的质量管理规范等相关要求，不能确保质量保证体系持续合规的，由所在地省、自治区、直辖市药品监督管理部门按照《药品管理法》第一百二十六条的规定给予处罚。"
    },
    {
        "instruction":"已知信息：\n'Under the guidance of the basic theories of traditional Chinese medicine and the use of modern scientific methods, the study of the interaction and laws between traditional Chinese medicine and the body.'可被翻译为：以中医药基本理论为指导，运用现代科学方法，研究中药和机体相互作用及规律的学科。\n'Article 39 Manufacturers of decoction pieces of Chinese medicine shall fulfill relevant obligations of an MAH, and shall implement whole chain management for the manufacture and distribution of decoction pieces of Chinese medicine and establish a traceability system for decoction pieces of Chinese medicine to ensure the safety, efficacy, and traceability thereof.'可被翻译为：第三十九条 中药饮片生产企业履行药品上市许可持有人的相关义务，对中药饮片生产、销售实行全过程管理，建立中药饮片追溯体系，保证中药饮片安全、有效、可追溯。\n'The discipline of studying the development history and laws of various disciplines of Chinese pharmacy is a branch discipline of history.'可被翻译为：研究中国药学各学科发展历史及规律的学科，是历史学科的分支学科。\n'The branch of Chinese pharmacy in which modern scholars conduct documentary research on ancient materia medica. Materia medica is the special name for medicine in ancient China (now called traditional Chinese medicine).'可被翻译为：现代学者对古代本草进行文献研究的中药学分支学科。本草是中国古代对药物的特称（现称中药）。\n\n根据上述已知信息，请将'The general name of the Chinese medicine discipline. The discipline of studying the basic theory of traditional Chinese medicine and the source, extraction, performance, efficacy and clinical application of various herbal pieces and proprietary Chinese medicines.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"中药学科的统称。研究中药基本理论和各种药材饮片、中成药的来源、采制、性能、功效、临床应用等知识的学科。"
    },
    {
        "instruction":"已知信息：\n'Article 33 The food and drug regulatory department accepting the registration application shall forward the application materials to technical evaluation institution within 3 workdays from the date of acceptance.'可被翻译为：第三十三条 受理注册申请的食品药品监督管理部门应当自受理之日起3个工作日内将申报资料转交技术审评机构。\n'Article 43 The food and drug regulatory department accepting the registration application shall forward the application materials to technical evaluation institution within 3 workdays from the date of acceptance.'可被翻译为：第四十三条 受理注册申请的食品药品监督管理部门应当自受理之日起3个工作日内将申报资料转交技术审评机构。\n'The technical evaluation institution shall complete the technical evaluation within 40 workdays and China Food and Drug Administration shall make decisions within 20 workdays after technical evaluation. If the application of clinical trial is approved, the Approval Letter for Clinical Trial of Medical Device shall be issued. If the application is disapproved, the reasons shall be stated in written form.'可被翻译为：技术审评机构应当在40个工作日内完成技术审评。国家食品药品监督管理总局应当在技术审评结束后20个工作日内作出决定。准予开展临床试验的，发给医疗器械临床试验批件；不予批准的，应当书面说明理由。\n'The service agency shall transfer the application dossiers to the technical assessment agency within 3 working days from the date of accepting the registration application of new cosmetic ingredients.'可被翻译为：受理机构应当自受理注册申请后3个工作日内，将申请资料转交技术审评机构。\n\n根据上述已知信息，请将'Article 27 After accepting the application for approval of clinical trials, China Food and Drug Administration shall forward the application documents to technical evaluation institution within 3 workdays from the date of application acceptance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条 国家食品药品监督管理总局受理医疗器械临床试验审批申请后，应当自受理申请之日起3个工作日内将申报资料转交医疗器械技术审评机构。"
    },
    {
        "instruction":"已知信息：\n'All operations involved in the production of a drug, including processing, compounding, formulating, filling, packaging, and labelling.'可被翻译为：药品生产过程中涉及的所有操作，包括加工、配制、配方、灌装、包装和标签。\n'All operations of receipt of materials, production, packaging, repackaging, labelling, relabelling, quality control, release, storage, and distribution of APIs and related controls.'可被翻译为：包括物料接收，生产，包装，再分装，标识，再标识，质量控制，放行，贮藏和 API 的分发及其他相关控制的所有操作。\n'Table 4: Examples of operations and grades for aseptic preparation and processing operations'可被翻译为：表 4：无菌准备和加工的操作及洁净级别示例\n'Table 3: Examples of operations and grades for terminally sterilised preparation and processing operations'可被翻译为：表 3：最终灭菌产品的制备和加工的操作及洁净级别示例\n\n根据上述已知信息，请将'All operations involved in the preparation of an API from receipt of materials through processing and packaging of the API.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"指从原料到 API 的生产和包装的所有操作。"
    },
    {
        "instruction":"已知信息：\n'Some gases used in medicine and pharmaceuticals. Such as oxygen, carbon dioxide, ammonia, nitrous oxide, etc.'可被翻译为：应用于医疗及制药中的一些气体。如氧、二氧化碳、氨、氧化亚氮等。\n'A barrier between blood and brain tissue formed by tightly connected capillary endothelial cells surrounded by glial cells, and a barrier between blood and cerebrospinal fluid formed by the choroid membrane.'可被翻译为：由紧密连接的毛细血管内皮细胞并由神经胶质细胞包裹其外而形成的血液与脑组织之间的屏障，以及由脉络膜形成的血液与脑脊液之间的屏障。\n'High fat soluble drugs, first distributed to the large blood flow of brain tissue to play a role, and then to the small blood flow of fat tissue transfer phenomenon.'可被翻译为：脂溶性高的药物，首先分布到血流量大的脑组织发挥作用，随后又向血流量少的脂肪组织转移的现象。\n'An instrument used to determine the viscosity of fluids (liquids and gases). There are three main types of capillary viscometers, rotary viscometers and falling ball viscometers.'可被翻译为：用于测定流体（液体和气体）黏度的仪器。主要有毛细管黏度计、旋转黏度计和落球黏度计三类。\n\n根据上述已知信息，请将'Any of a class of volatile liquids or gases inhaled through the airway that diffuse into the blood through the alveolar capillary membranes and reach the brain tissue, blocking synaptic transmission and causing general anesthesia. Commonly used drugs are: halothane, enflurane, isoflurane, nitrous oxide, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一类挥发性液体或气体，经气道吸入后由肺泡毛细血管膜弥散入血而到达脑组织，阻滞其突触传递功能，引起全身麻醉作用的药物。常用药物有：氟烷、恩氟烷、异氟烷、氧化亚氮等。"
    },
    {
        "instruction":"已知信息：\n'Note: Always use LRW as the diluent for the CSE standard serial dilutions.'可被翻译为：注：始终使用LRW作为CSE标准系列稀释液的稀释剂\n'1. The quality control laboratories should at least have the following detailed documents:'可被翻译为：（一）质量控制实验室应当至少有下列详细文件：\n'(1) Employ at least two distinct identification components such as an identification code and password.'可被翻译为：至少采用两种不同的识别方式，例如识别码和密码。\n'least square method'可被翻译为：最小二乘法\n\n根据上述已知信息，请将'The field laboratories are encouraged to mix the reconstituted CSE for at least 5 minutes and for at least 1 minute between dilutions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"鼓励现场实验室将调配的CSE混合至少5分钟，每次稀释之间混合至少1分钟。"
    },
    {
        "instruction":"已知信息：\n'Article 42 If the lot release applicant provides false data or samples, or conceal major changes that will affect product quality and obtain the Certificate for Lot Release of Biological Products by fraud, a penalty shall be imposed in accordance with Article 123 of the Drug Administration Law.'可被翻译为：第四十二条    批签发申请人提供虚假资料或者样品，或者故意瞒报影响产品质量的重大变更情况，骗取生物制品批签发证明的，依照《药品管理法》第一百二十三条的规定予以处罚。\n'If the lot release applicant provides false data, materials, or samples, or engages in deceptive behaviors in the application for lot release of vaccines, a penalty shall be imposed in accordance with the provisions of Article 81 of the Vaccine Administration Law.'可被翻译为：申请疫苗批签发提供虚假数据、资料、样品或者有其他欺骗行为的，依照《疫苗管理法》第八十一条的规定予以处罚。\n'If the Certificate for Lot Release of Biological Products is forged, a penalty shall be imposed in accordance with Article 122 of the Drug Administration Law.'可被翻译为：伪造生物制品批签发证明的，依照《药品管理法》第一百二十二条的规定予以处罚。\n'If the Certificate for Lot Release of Biological Products is forged, a penalty shall be imposed in accordance with Article 81 of the Drug Administration Law.'可被翻译为：伪造生物制品批签发证明的，依照《药品管理法》第八十一条的规定予以处罚。\n\n根据上述已知信息，请将'Article 42 If the lot release applicant provides false data or samples, or conceal major changes that will affect product quality and obtain the Certificate for Lot Release of Biological Products by fraud, a penalty shall be imposed in accordance with Article 82 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十二条 批签发申请人提供虚假资料或者样品，或者故意瞒报影响产品质量的重大变更情况,骗取生物制品批签发证明的，依照《药品管理法》第八十二条的规定予以处罚。"
    },
    {
        "instruction":"已知信息：\n'Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.'可被翻译为：第七十二条 应当建立设备使用、清洁、维护和维修的操作规程，并保存相应的操作记录。\n'Appropriate maintenance procedures should be established based on risk, and include maintenance and inspection plans for items critical to unit sealing, integrity and sterility.'可被翻译为：应根据风险建立适当的维护程序，并包括对单元密封、完整性和无菌性至关重要的物品的维护和检查计划。\n'Appropriate maintenance procedures should be established based on risk, and include maintenance and inspection plans  for tooling  critical to the  effectiveness  of unit  sealing. Any issues  identified that  indicate  a potential product quality concern should be documented and investigated.'可被翻译为：应根据风险建立适当的维护程序，并包括对单元密封有效性至关重要的工具的维护和检查计划。发现的任何表明存在潜在产品质量问题的问题都应记录并进行调查。\n'Article 79: Repair and maintenance operations should not present any hazard to product quality.'可被翻译为：第七十九条 设备的维护和维修不得影响产品质量。\n\n根据上述已知信息，请将'Article 80: Preventive maintenance plans and procedures should be established, and the maintenance and repair activities should be recorded.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十条 应当制定设备的预防性维护计划和操作规程，设备的维护和维修应当有相应的记录。"
    },
    {
        "instruction":"已知信息：\n'Drugs used to treat or prevent infections caused by pathogenic microorganisms, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, etc. Unlike anti-infective drugs, these drugs do not target worms.'可被翻译为：治疗或预防致病微生物，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫等所致感染用的药物。与抗感染药的区别是本类药物的作用对象不包括蠕虫类。\n'Antimicrobial drugs used to treat infections caused by pathogenic microorganisms such as bacteria, rickettsia, chlamydia, mycoplasma, spirochetes, fungi, etc. Excluded are drugs for treating tuberculosis, parasitic diseases, and various viral infections, as well as traditional Chinese medicine formulations with antibacterial properties.'可被翻译为：治疗细菌、支原体、衣原体、立克次体、螺旋体、真菌等病原微生物所致感染性疾病病原的药物，\n不包括治疗结核病、寄生虫病和各种病毒所致感染性疾病的药物以及具有抗菌作用的中药制剂。\n'A branch of science that refers to microbes of all of types, including bacteria, viruses, rickettsia, protozoa, fungi and prions. Derived words (such as microbiological) have a similar meaning.'可被翻译为：一门科学分支，涉及所有类型的微生物，包括细菌、病毒、立克次体、原生动物、真菌和朊病毒。衍生词(如microbiological)也有类似的意思。\n'A drug that kills or inhibits bacteria and is used to treat or prevent infections caused by bacteria. According to the different sources, it is divided into: ① antibiotics, such as cephalosporin; ② synthetic antimicrobials, such as quinolcopper; ③ antibacterial Chinese herbs, such as coptis, tanshinone, etc.; ④ Antifungal drugs, such as fluconazole, etc.'可被翻译为：对细菌有杀灭或抑制作用，用以治疗或预防细菌引起的感染的药物。根据来源的不同分为：①抗生素，如头孢氨卡等；②合成抗菌药，如喹诺铜类；③抗菌中草药，如黄连、丹参酮等；④抗真菌药，如氟康挫等。\n\n根据上述已知信息，请将'A drug used to treat or prevent infections caused by various pathogens, including viruses, chlamydia, mycoplasma, rickettsia, bacteria, spirochaeta, fungi, protozoa, worms, etc. They may be further classified according to their source and properties.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"治疗或预防各种病原体，包括病毒、衣原体、支原体、立克次氏体、细菌、螺旋体、真菌、原虫、蠕虫等所致感染用的药物。根据来源和性质的不同可进一步分类。"
    },
    {
        "instruction":"已知信息：\n'The highest amount of an analyte in a sample that can be quantitatively determined with pre_x0002_defined precision and accuracy'可被翻译为：样品中可通过预先定义的精密度和准确度进行定量测定的待测物最高浓度。\n'The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products.'可被翻译为：某一分析方法的定量限度是指在合适的准确性和精密度下，能够定量测定样品中被分析物的最低量。它是样品中含量下，能够定量测定样品中被分析物的最低量。它是样品中含量低的化合物定量测定的参数，特别适用于杂质和\/或降解产物的测定。\n'Limit of Quantitation: The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and\/or degradation products. (ICH Q2)'可被翻译为：一种独立分析方法的定量限是样品中某待测物能以适当的精密度和准确度被定量检出的最低量。定量限是一种针对样品中低含量物质定量分析的参数，特别用于杂质和\/或降解产物的测定。（ICH Q2）\n'The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value.'可被翻译为：某一分析方法的检测限度是样品中的被分析物能够被检测到的最低量，但不一定要准确定量。\n\n根据上述已知信息，请将'The lowest amount of an analyte in a sample that can be quantitatively determined using a method with predefined precision and accuracy'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用预先定义其精密度和准确度的方法，使样品中的待测物可被定量测定的最低浓度。"
    },
    {
        "instruction":"已知信息：\n'Apply the principles and methods of sociology and behavioral science to study the discipline of human behavior in pharmaceutical practice.'可被翻译为：应用社会学和行为科学的原理和方法，研究药学实践中人的行为学科。\n'Article 9 CFDI and the institutions of drug evaluation, drug testing and others shall establish a joint mechanism for registration inspection, evaluation, and registration test, and strengthen communication, exchanges, and coordination to research and solve problems in the registration inspection work.'可被翻译为：第九条 核查中心与药品审评、药品检验等机构建立注册核查与审评、注册检验的工作衔接机制，并加强沟通和交流，共同协调、研究和解决注册核查工作中出现的问题。\n'Article 20 The conduct of drug clinical trials shall comply with ethical principles, with a clinical trial protocol developed, and be subject to review and approval by the ethics committee.'可被翻译为：第二十条 开展药物临床试验，应当符合伦理原则，制定临床试验方案，经伦理委员会审查同意。\n'The ethics committee shall adhere to the principles of ethics and science to review and supervise the implementation of the clinical trial.'可被翻译为：伦理委员会应当秉承伦理和科学的原则，审查和监督临床试验的实施。\n\n根据上述已知信息，请将'The subject that uses the theories and principles of ethics to explore and solve the problems of right and wrong, good and evil of human behavior in pharmaceutical work.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用伦理学的理论和原则探讨和解决药学工作中人类行为的是非、善恶问题的学科。"
    },
    {
        "instruction":"已知信息：\n'Article 62 Before the clinical trial, the medical device clinical trial management department of the clinical trial institution shall coordinate with the sponsor to submit the application to the ethics committee and submit relevant documents according to the regulations.'可被翻译为：第六十二条 临床试验前，临床试验机构的医疗器械临床试验管理部门应当配合申办者向伦理委员会提出申请，并按照规定递交相关文件。\n'Article 17 Before the clinical trial, the sponsor shall submit the following materials to the ethics committee through the investigator and the medical device clinical trial management department of the clinical trial institution:'可被翻译为：第十七条 临床试验前，申办者应当通过研究者和临床试验机构的医疗器械临床试验管理部门向伦理委员会提交下列文件：\n'Article 26 Before conducting medical device clinical trials, the sponsor shall formulate scientific and reasonable clinical trial protocols in accordance with the type, risk and intended use of the investigational medical devices.'可被翻译为：第二十六条 开展医疗器械临床试验，申办者应当按照试验用医疗器械的类别、风险、预期用途等组织制定科学、合理的临床试验方案。\n'Article 33 The sponsor shall, before carrying out the drug clinical trial, submit the drug clinical trial protocol and other information on the drug clinical trial registry and information disclosure platform. During the drug clinical trial, the sponsor shall continually update the registered information and, after the drug clinical trial ends, submit results of the drug clinical trial and other related information. Information posted on the platform shall be disclosed to the public. The sponsor is responsible for the authenticity of registered information about the drug clinical trial.'可被翻译为：第三十三条 申办者应当在开展药物临床试验前在药物临床试验登记与信息公示平台登记药物临床试验方案等信息。药物临床试验期间，申办者应当持续更新登记信息，并在药物临床试验结束后登记药物临床试验结果等信息。登记信息在平台进行公示，申办者对药物临床试验登记信息的真实性负责。\n\n根据上述已知信息，请将'Article 26 When the drug clinical trial application is approved, the sponsor shall formulate the corresponding drug clinical trial protocols and have them reviewed and approved by the ethics committee before carrying out the subsequent phases of clinical trial, and submit the corresponding protocols and supporting dossiers on the CDE website.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十六条 获准开展药物临床试验的，申办者在开展后续分期药物临床试验前，应当制定相应的药物临床试验方案，经伦理委员会审查同意后开展，并在药品审评中心网站提交相应的药物临床试验方案和支持性资料。"
    },
    {
        "instruction":"已知信息：\n'××××3 shall indicate the year of initial registration.'可被翻译为：××××3为首次注册年份；\n'××××3 shall indicate the serial number of filing.'可被翻译为：××××3为备案流水号。\n'×2 shall indicate the form of registration.'可被翻译为：×2为注册形式：\n'7. The batch number or serial number assigned after receipt;'可被翻译为：（七）接收后企业指定的批号或流水号；\n\n根据上述已知信息，请将'××××6 shall indicate the serial number of initial registration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"××××6为首次注册流水号。"
    },
    {
        "instruction":"已知信息：\n'A cylindrical device with a cannula-like nozzle, with or without a fixed needle and a movable piston, used for the administration, usually parenteral, of an accurately measured quantity of a liquid pharmaceutical form. The syringe may be prefilled, and can be for single-dose or multi- dose use.'可被翻译为：注射器一种圆柱形装置，有类似套管的喷嘴，有或没有固定的针和可移动的活塞，通常用于注射精确测量的液体药物形式该注射器可预先填充，可用于单剂或多剂使用。\n'active pharmaceutical ingredient (API). Any substance or mixture of substances intended to be used in the manufacture of a pharmaceutical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure and function of the body.'可被翻译为：活性药物成分 （API）：准备用于制剂生产成为其中活性成分的物质或其混合物。此类物质用于改变药效活性或其它直接影响诊断、治愈、缓解、治疗或预防疾病影响或影响人体结构和功能。\n'A container, usually cylindrical, suitable for liquid or solid pharmaceutical dosage forms; generally for use in a specially designed apparatus (e.g. a prefilled syringe).'可被翻译为：一种容器，通常为圆柱形，适用于液体或固体药物剂型;一般用于专门设计的器具中(如预充注射器)。\n'pharmaceutical dosage form'可被翻译为：药物齐理\n\n根据上述已知信息，请将'A hollow needle with a locking device intended for the administration of liquid pharmaceutical dosage forms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"带有锁定装置的空心针，用于给药液体药物剂型。"
    },
    {
        "instruction":"已知信息：\n'Article 3  The UDI System of Medical Device mentioned in these Rules consists of the unique device identifier (UDI), UDI data carrier and unique device identification database (UDID).'可被翻译为：第三条 本规则所称医疗器械唯一标识系统，由医疗器械唯一标识、唯一标识数据载体和唯一标识数据库组成。\n'Article 1  The Rules are hereby formulated in accordance with the Regulations on Supervision and Administration of Medical Devices, so as to regulate the establishment of unique device identification system (UDI system) and strengthen the whole-life cycle management of medical devices.'可被翻译为：第一条 为规范医疗器械唯一标识系统建设，加强医疗器械全生命周期管理，根据《医疗器械监督管理条例》，制定本规则。\n'Medical device unique identification database constitutes an important part of the medical device unique identification system. In accordance with the requirements of the Rules for Unique Identification System for Medical Devices and the deployment of the Pilot Work Plan for Medical Device Unique Identification System, the medical device unique identification database was officially launched on December 10, 2019, with functions opened to pilot enterprises to apply for related data of unique identification of pilot varieties. In the next step, NMPA will strengthen guidance and services for the application of unique identification data for medical devices, and open the unique identification database query and sharing services to the pilot units in March 2020 in accordance with the pilot work deployments.'可被翻译为：医疗器械唯一标识数据库是医疗器械唯一标识系统的重要组成部分。按照《医疗器械唯一标识系统规则》的要求和《医疗器械唯一标识系统试点工作方案》的安排，医疗器械唯一标识数据库于2019年12月10日正式上线，面向试点企业开放针对试点品种的唯一标识相关数据申报功能。下一步，国家药监局将加强对医疗器械唯一标识数据申报的指导与服务，按照试点工作安排于2020年3月向试点单位开放唯一标识数据库查询与共享服务。\n'Article 36 The registrant, filing entity or contract manufacturer of medical devices shall, in accordance with relevant requirements of the state for implementing Unique Device Identification (UDI) of medical devices, carry out code assignment, data uploading, maintenance and updating, to guarantee the authenticity, accuracy, integrity and traceability of the information.'可被翻译为：第三十六条  医疗器械注册人、备案人、受托生产企业应当按照国家实施医疗器械唯一标识的有关要求，开展赋码、数据上传和维护更新，保证信息真实、准确、完整和可追溯。\n\n根据上述已知信息，请将'The medical device distributors shall execute Unique Device Identification (UDI) system of medical devices in accordance with relevant regulations of the State.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械经营企业应当按照国家有关规定执行医疗器械唯一标识制度。"
    },
    {
        "instruction":"已知信息：\n'Products applied topically to the skin.'可被翻译为：用于皮肤局部的药物。\n'Male use to reduce the number of sperm until no sperm and achieve contraceptive purposes of the drug. Such as gossypol.'可被翻译为：男性应用后使精子数量减少直至无精子而达到避孕目的的药物。如棉酚。\n'A general term for disinfectants and preservatives. Drugs that can quickly kill pathogenic microorganisms are disinfectants, which are mainly used for the disinfection of skin, mucous membranes, instruments, excreta and the environment; Drugs to prevent corruption by killing or inhibiting biological proliferation are antiseptics, mostly used for living skin or mucous membrane decay. Commonly used drugs, such as alcohols, phenolic disinfectants, heavy metal salt disinfectants and surfactants.'可被翻译为：消毒剂和防腐剂的总称。能迅速杀灭病原微生物的药物为消毒剂，主要用于皮肤、黏膜、器械、排泄物和环境的消毒；通过杀灭或抑制生物增殖而防止腐败的药物为防腐药，多用于活体皮肤或黏膜腐烂等。常用的药物，如醇类、酚类消毒药、重金属盐类消毒药和表面活性剂等。\n'Category 2 – Topically used products made with aqueous bases or vehicles, non-sterile nasal products, and emulsions, including those applied to mucous membranes.'可被翻译为：第二类—用水溶基质或辅料制成的局部使用的产品，非无菌鼻用产品和乳剂，包括用于粘膜的 那些产品。\n\n根据上述已知信息，请将'Male contraceptive, applied topically to kill sperm. Such as commonly used surfactants.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"男用避孕药，局部应用以杀灭精子。如常用的表面活性剂类药。"
    },
    {
        "instruction":"已知信息：\n'(1) Act means the Federal Food, Drug, and Cosmetic Act (secs. 201-903 (21 U.S.C. 321-393)).'可被翻译为：法案是指联邦视频、药品、化妆品法案\n'Submitting Information on IVRT Studies in an ANDA'可被翻译为：ANDA中递交的IVRT研究信息\n'This guidance is intended to assist applicants who are submitting abbreviated new drug applications (ANDAs) for liquid-based and\/or other semisolid products applied to the skin, including integumentary and mucosal (e.g., vaginal) membranes, which are hereinafter called topical products.（注释2）Because of the complex route of delivery associated with these products, which are typically locally acting, and the potential complexity of certain formulations, topical products (other than topical solutions) are classified as complex products.（注释3）This guidance provides recommendations for in vitro release test (IVRT) studies that can be used to compare a proposed generic (test) topical product and its reference standard (RS) for the purpose of supporting a demonstration of bioequivalence (BE) to the reference listed drug (RLD). The reference standard ordinarily is the RLD.（注释4）'可被翻译为：本指南旨在帮助申请人提交用于皮肤的液体和\/或其他半固体产品的仿制药申请（ANDA），包括皮肤和粘膜（如阴道），以下简称“外用制剂”（注释2）。由于这些制剂通常局部起效，具有复杂递送途径和配方，外用制剂（外用溶液除外）通常称为复杂制剂（注释3）。本指南为拟申报的仿制药与其对照制剂（RS）的体外释放试验（IVRT）研究提供建议，以论证与参比制剂（RLD）的生物等效性（BE）。参比制剂通常简称为RLD。（注释4）\n'The drug contains the same active ingredient in the same concentration, dosage form, and route of administration.'可被翻译为：药品含有相同的活性成分并且浓度、剂型及给药途径也相同。\n\n根据上述已知信息，请将'The Federal Food, Drug, and Cosmetic Act (FD&C Act) generally requires an ANDA to contain, among other things, information to show that the proposed generic drug product 1) is the same as the RLD with respect to the active ingredient(s), conditions of use, route of administration, dosage form, strength, and labeling (with certain permissible differences) and 2) is bioequivalent to the RLD.（注释9）Thus, an ANDA will not be approved if the information submitted in the ANDA is insufficient to show that the test product is bioequivalent to the RLD.（注释10）'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"《联邦食品、药品和化妆品法案》（FD&C法案）要求ANDA申请中应包含合适的信息，说明：1）仿制药与RLD相比，具有相同的活性成分、使用条件、给药途径、剂型、规格和说明书（允许存在一些差异）；2）与RLD生物等效（注释9）。因此，如果ANDA中提交的信息不足以证明自制制剂与RLD具有生物等效性，则ANDA将不予批准。（注释10）"
    },
    {
        "instruction":"已知信息：\n'After receiving the report, the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device distributor or using unit is located shall, in a timely manner, inform the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device manufacturer is located.'可被翻译为：医疗器械经营企业、使用单位所在地省、自治区、直辖市食品药品监督管理部门收到报告后，应当及时通报医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门。\n'Article 67 A drug manufacturer shall investigate the manufacturing processes, quality, stability, therapeutic effect and adverse reactions, etc. of a new drug in the observation period, and report annually to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, where it is located. Where a drug manufacturer fails to perform its duties in the observation period, the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government shall order it to make rectifications.'可被翻译为：第六十七条 药品生产企业应当考察处于监测期内的新药的生产工艺、质量、稳定性、疗效及不良反应等情况，并每年向所在地省、自治区、直辖市药品监督管理部门报告。药品生产企业未履行监测期责任的，省、自治区、直辖市药品监督管理部门应当责令其改正。\n'Where an MAH stops manufacture of drugs in shortage, it shall report to the drug regulatory department under the State Council or the drug regulatory department of the people's government of the province, autonomous region, or municipality directly under the Central Government.'可被翻译为：药品上市许可持有人停止生产短缺药品的，应当按照规定向国务院药品监督管理部门或者省、自治区、直辖市人民政府药品监督管理部门报告。\n'Article 17 Where two or more institutions jointly apply for drugs, the application shall be submitted to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, in which the drug manufacturer is located; where the applicants are all drug manufacturers, the application shall be submitted to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, in which the manufacturer of pharmaceutical preparations is located; where none of the applicants is a drug manufacturer, the application shall be submitted to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government, in which the site for pilot production of drug samples is located.'可被翻译为：第十七条 两个以上单位共同作为申请人的，应当向其中药品生产企业所在地省、自治区、直辖市药品监督管理部门提出申请；申请人均为药品生产企业的，应当向申请生产制剂的药品生产企业所在地省、自治区、直辖市药品监督管理部门提出申请；申请人均不是药品生产企业的，应当向样品试制现场所在地省、自治区、直辖市药品监督管理部门提出申请。\n\n根据上述已知信息，请将'Article 68 Where institutions for drug manufacturing, distribution, use, testing or supervision find any critical quality problem, serious or unexpected adverse reaction of a new drug, they shall report to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government in time. Once receiving the report, the drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall organize prompt investigation, and report to the State Food and Drug Administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十八条 药品生产、经营、使用及检验、监督单位发现新药存在严重质量问题、严重或者非预期的不良反应时，应当及时向省、自治区、直辖市药品监督管理部门报告。省、自治区、直辖市药品监督管理部门收到报告后应当立即组织调查，并报告国家食品药品监督管理局。"
    },
    {
        "instruction":"已知信息：\n'2. The storage conditions of the test\/control articles should be in conformity with those specified in the study protocol or other supporting documents (such as instructions for use, certificates of analysis, etc.); records of monitoring storage conditions and handling unexpected events of the test\/control articles and their formulations during the study period should be retained completely;'可被翻译为：2.受试物\/对照品保存条件应符合试验方案或相关证明 性文件(如使用说明书、质检报告等)要求；应完整保留研 究期间受试物\/对照品及其制剂保存条件监测及异常情况处理记录；\n'2. In case of laboratory animals used in a study, there should be proper animal facilities for carrying out the study with the corresponding approval documentation for the use of laboratory animals; records of environmental monitoring of animal facilities and handling of unexpected events in the course of the study should be retained completely;'可被翻译为：2.涉及实验动物研究的，应具备符合研究要求的动物设 施，具有相应的实验动物使用许可证明；应完整保存研究期间动物设施环境控制数据及异常情况处理等记录；\n'5. There should be established standard operating procedures (SOPs) or other operational instructions in place for the study conducted;'可被翻译为：5.建立有与研究相适应的标准操作规程(SOP)或其他试验操作文件；\n'5. Deviations from study protocol, SOPs or other operational instructions should be recorded, and evaluated in a timely manner, and reported truthfully in the final report.'可被翻译为：5.试验方案、SOP  或其他试验操作文件的偏离应及时记录、评估并如实反映在总结报告中。\n\n根据上述已知信息，请将'3. The storage conditions of the test\/control articles and their formulations, biological samples, study files and specimens, etc. should be in conformity with those specified in the study protocol, SOPs or other operational instructions; records of corresponding environmental monitoring and handling of unexpected events in the course of the study should be retained completely.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.受试物\/对照品及其配制制剂、生物样本、研究档案和 标本等储存保管条件应符合试验方案及机构 SOP或其他试验操作文件要求；应完整保存研究开展期间相应环境控制数据以及异常情况处理等记录。"
    },
    {
        "instruction":"已知信息：\n'Center for Food and Drug Inspection of NMPA (hereinafter referred to as CFDI) shall be responsible for overseas on-site inspection during lot release.'可被翻译为：国家药品监督管理局食品药品审核查验中心（以下简称核查中心）承担批签发过程中的境外现场检查等工作。\n'Article 47 During the process of registration technical evaluation, the technical assessment agency may notify the inspection agency to carry out on-site inspection as needed. Domestic on-site inspections should be completed within 45 working days, and overseas on-site inspections should be implemented in accordance with relevant provisions on overseas inspections. The time for on-site inspection is not included in the time limit of technical evaluation.'可被翻译为：第四十七条 技术审评机构在注册技术审评过程中，可以根据需要通知审核查验机构开展现场核查。境内现场核查应当在45个工作日内完成，境外现场核查应当按照境外核查相关规定执行。现场核查所用时间不计算在审评时限之内。\n'Article 56 Regarding the registration inspection of overseas sites, CFDI shall organize the implementation in accordance with the Provisions on the Administration of Overseas Inspection of Drugs and Medical Devices and other relevant requirements.'可被翻译为：第五十六条 对于境外场地进行的注册核查，核查中心结合《药品医疗器械境外核查管理规定》等相关要求组织实施。\n'Section 4 Serious ADRs Occurred Overseas'可被翻译为：第四节 境外发生的严重药品不良反应\n\n根据上述已知信息，请将'(4) Time occupied during overseas inspection where overseas inspection is initiated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）启动境外核查的，境外核查所占用的时间。"
    },
    {
        "instruction":"已知信息：\n'Any of a class of organic substances found in very small amounts in the body that are essential for the maintenance of human life. It is an important active substance for maintaining human health.'可被翻译为：一类在体内含量极微的维持人体生命所必需的有机物质。是保持人体健康的重要活性物质。\n'Natural products or synthetic polymers with high molecular weight above 10000Da or even millions of high molecular weight. Proteins, nucleic acids, polysaccharides, synthetic fibers, etc. are macromolecular compounds. They consist of structural units (equivalent to a covalent small molecule) bound together in covalent bonds. The structure is linear, reticular, or three-dimensional.'可被翻译为：分子量在10000Da以上甚至达数百万的高分子量的天然产物或合成高聚物。蛋白质、核酸、多糖、合成纤维等为大分子化合物。它们由结构单元（相当于一个共价小分子）以共价键结合而成。结构为线形、网状或三维体形。\n'A discipline that uses modern organic synthesis, structural analysis, physical organic chemistry, molecular biology, cell biology, and molecular pharmacology as means to discover small organic molecules with important biological activities and study their interactions with biological macromolecules.'可被翻译为：以现代有机合成、结构分析、物理有机化学、分子生物学、细胞生物学、分子药理学为手段，发现具有重要生物活性的有机小分子并研究其与生物大分子相互作用的学科。\n'molecular weight'可被翻译为：分子量\n\n根据上述已知信息，请将'Any of several organic substances of small molecular weight that are loosely bound to enzyme proteins and are essential for catalytic activity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"某些为催化活性所必需的、与酶蛋白疏松结合的小分子量的有机物质。"
    },
    {
        "instruction":"已知信息：\n'Entities or individuals other than disease prevention and control institutions shall not supply vaccines to immunization entities, and immunization entities shall not accept such vaccines.'可被翻译为：疾病预防控制机构以外的单位和个人不得向接种单位供应疫苗，接种单位不得接收该疫苗。\n'Article 36 Vaccine MAHs shall deliver vaccines to disease prevention and control institutions or immunization entities designated by disease prevention and control institutions in accordance with the procurement contract.'可被翻译为：第三十六条 疫苗上市许可持有人应当按照采购合同约定，向疾病预防控制机构或者疾病预防控制机构指定的接种单位配送疫苗。\n'Disease prevention and control institutions at all levels shall enhance technical guidance for immunization of immunization entities and management of vaccine use.'可被翻译为：各级疾病预防控制机构应当加强对接种单位预防接种工作的技术指导和疫苗使用的管理。\n'Article 37 Disease prevention and control institutions, immunization entities, vaccine MAHs and vaccine distribution entities shall comply with the provision for vaccine storage and transportation to ensure vaccine quality.'可被翻译为：第三十七条 疾病预防控制机构、接种单位、疫苗上市许可持有人、疫苗配送单位应当遵守疫苗储存、运输管理规范，保证疫苗质量。\n\n根据上述已知信息，请将'(3) distributing vaccine to immunization entities by any institution or individual other than disease prevention and control institutions;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）疾病预防控制机构以外的单位或者个人向接种单位供应疫苗；"
    },
    {
        "instruction":"已知信息：\n'Article 75 Where a drug included into the special review and approval procedure is considered to no longer meet the inclusion conditions, the special review and approval procedure for the drug shall be terminated, and the applicant shall be informed.'可被翻译为：第七十五条 对纳入特别审批程序的药品，发现其不再符合纳入条件的，应当终止该药品的特别审批程序，并告知申请人。\n'Article 71 During review, where it is found that a drug registration application included into the priority review and approval procedure does not meet the conditions for priority review and approval, the CDE shall terminate the priority review and approval procedure for the application, evaluate the application as per the normal review procedure and inform the applicant.'可被翻译为：第七十一条 审评过程中，发现纳入优先审评审批程序的药品注册申请不能满足优先审评审批条件的，药品审评中心应当终止该品种优先审评审批程序，按照正常审评程序审评，并告知申请人。\n'Article 65 During review, where it is found that a drug registration application included into the conditional approval procedure does not meet the requirements for conditional approval, the CDE shall terminate the conditional approval procedure and inform the applicant to apply as per the normal review procedure.'可被翻译为：第六十五条 审评过程中，发现纳入附条件批准程序的药品注册申请不能满足附条件批准条件的，药品审评中心应当终止该品种附条件批准程序，并告知申请人按照正常程序研究申报。\n'Article 13 The NMPA shall establish an expedited registration system for drug marketing to support drug innovation guided by clinical value. For a drug registration application that meet relevant conditions, the applicant may apply for the breakthrough therapy drug procedure, the conditional approval procedure, the priority review and approval procedure or the special review and approval procedure and, during the process of drug R&D and registration, drug regulatory departments and their specialized technical institutions shall provide policy and technical support including necessary technical guidance, communication, priority allocation of resources, shortening the review timeline, etc.'可被翻译为：第十三条 国家药品监督管理局建立药品加快上市注册制度，支持以临床价值为导向的药物创新。对符合条件的药品注册申请，申请人可以申请适用突破性治疗药物、附条件批准、优先审评审批及特别审批程序。在药品研制和注册过程中，药品监督管理部门及其专业技术机构给予必要的技术指导、沟通交流、优先配置资源、缩短审评时限等政策和技术支持。\n\n根据上述已知信息，请将'Where an application is recalled by the applicant in the process of drug registration, the review and approval procedure is terminated henceforth.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品注册过程中申请人自行提出撤回申请的，其审批程序自行终止。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the contract manufacturer is located shall be responsible for carrying out supervision and inspection of the contract manufacturer’s manufacturing activities, and if involving relevant conditions of the registrant, the drug regulatory department of the place where the registrant is located shall carry out supervision and inspection on the registrant.'可被翻译为：受托生产企业所在地省、自治区、直辖市药品监督管理部门负责对受托生产企业生产活动开展监督检查，涉及注册人相关情况的，应当由注册人所在地药品监督管理部门对注册人开展监督检查。\n'Article 56 If the medical device registrant and the contract manufacturer are not in the same province, autonomous region or municipality directly under the central government, the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant of medical devices is located shall be responsible for carrying out supervision and inspection of the registrant’s performance of its legal duties such as operation of quality management system, adverse events monitoring and product recall, etc., and if relevant conditions of the contract manufacturer, the drug regulatory department of the place where the contract manufacturer is located shall make cooperation.'可被翻译为：第五十六条  医疗器械注册人和受托生产企业不在同一省、自治区、直辖市的，医疗器械注册人所在地省、自治区、直辖市药品监督管理部门负责对注册人质量管理体系运行、不良事件监测以及产品召回等法定义务履行情况开展监督检查，涉及受托生产企业相关情况的，受托生产企业所在地药品监督管理部门应当配合。\n'Article 57 If the registrant and the contract manufacturer of medical devices are not in the same province, autonomous region or municipality directly under the central government, and the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or the contract manufacturer is located needs to carry out cross-region inspection, it could also make inspection by means of joint inspection and entrusted inspection, etc.'可被翻译为：第五十七条  医疗器械注册人和受托生产企业不在同一省、自治区、直辖市，医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门需要跨区域开展检查的，可以采取联合检查、委托检查等方式进行。\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for supervision and administration of medical device distribution within their administrative areas.'可被翻译为：省、自治区、直辖市药品监督管理部门负责本行政区域的医疗器械经营监督管理工作。\n\n根据上述已知信息，请将'The drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or contract manufacturer of the medical devices is located shall implement local supervision and administration responsibility, establish coordinated supervision and administration mechanism to strengthen communication on regulatory information and realize effective cohesion.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门应当分别落实属地监管责任，建立协同监管机制，加强监管信息沟通，实现监管有效衔接。"
    },
    {
        "instruction":"已知信息：\n'The time it takes for half the drug to be eliminated from the body is also the time it takes for the blood concentration to drop by half.'可被翻译为：药物从体内消除一半所需的时间，也是血药浓度下降一半的时间。\n'The time it takes for the plasma drug concentration to decrease by half after the distribution of the drug in the body reaches equilibrium.'可被翻译为：药物在体内分布达到平衡状态后血浆药物浓度降低一半所需的时间。\n'The amount of time it takes to reach the highest concentration after the drug is administered.'可被翻译为：用药后达到最高浓度所需要的时间。\n'Steady-state plasma drug concentration is a \"zigzag\" plasma drug concentration curve where the highest steady-state plasma drug concentration is the peak steady-state plasma drug concentration.'可被翻译为：稳态血药浓度是一个\"锯齿”状血浆药物浓度曲线，其稳态时的最高血药浓度为稳态血药浓度峰值。\n\n根据上述已知信息，请将'The time it takes for the concentration of the drug in the plasma to drop by half.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"血浆中药物浓度下降一半所需的时间。"
    },
    {
        "instruction":"已知信息：\n'If it is deemed necessary to conduct sample inspection during the on-site inspection, the inspection team shall, with the approval of CFDI, take samples and seal them in accordance with the relevant requirements on drug sampling, and the sampling situation shall be described in the inspection report. The samples shall be sent to the drug testing institution for sample testing as required.'可被翻译为：现场核查过程中认为有必要进行样品检验的，经报核查中心同意后，核查组按照药品抽样的有关要求，抽取样品并封样，抽样情况应当在核查报告中进行描述；样品按要求送交药品检验机构进行样品检验。\n'Article 1 In order to standardize the work process of drug registration inspection (hereinafter referred to as registration inspection), strengthen the connection between registration inspection and evaluation, and ensure the quality and efficiency of registration inspection, the Procedures is formulated in accordance with the Drug Registration Regulation and Drug Manufacture Regulation.'可被翻译为：第一条 为规范药品注册核查(以下简称注册核查)工作行为，加强注册核查与审评工作的衔接，保证注册核查工作质量和效率，根据《药品注册管理办法》《药品生产监督管理办法》,制定本程序。\n'Article 57 During the supervision and inspection, drug MAHs and manufacturers shall provide relevant explanations and the following materials according to the inspection need:'可被翻译为：第五十七条 监督检查时，药品上市许可持有人和药品生产企业应当根据检查需要说明情况、提供有关材料：\n'Registration inspection is divided into the registration on-site inspection of pharmaceutical development (hereinafter referred to as Development Site Inspection) and the drug registration inspection of manufacturing site (hereinafter referred to as Manufacturing Site Inspection).'可被翻译为：注册核查分为药品注册研制现场核查(以下简称研制现场核查)和药品注册生产现场核查(以下简称生产现场核查)。\n\n根据上述已知信息，请将'Article 57 The sampling referred to in the Procedures refers to the sampling, sample sealing and notified inspection conducted by the drug regulatory authority during the registration inspection process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十七条 本程序所指的抽样是指药品监督管理部门在注册核查过程中进行的取样、封样和通知检验。"
    },
    {
        "instruction":"已知信息：\n'In molecular orbitals, the highest occupied orbital and the lowest unoccupied orbital are collectively called.'可被翻译为：分子轨道中，最高占据轨道和最低未占轨道的统称。\n'A series of theoretical indices calculated by quantum chemistry to describe or mark the structure, conformational characteristics and reaction properties of molecules. The commonly used quantum chemical indices are: the highest occupied orbital energy and the lowest empty orbital energy, which are related to the electron transport properties of molecules; The non-electron transfer and non-locality of hypercogranulation, and the total molecular energy, which is often used in conformational analysis or reaction mechanism research.'可被翻译为：经量子化学计算得出的一系列描述或标志分子结构、构象特点和反应性能的理论指数。常用的量子化学指数有：与分子的电子传递特性有关的最高占有轨道能和最低空轨道能；标志分子的无电子转移和超共粒现象的非定域性和常用于构象分析或反应机理研究的分子总能量等。\n'highest occupied orbit'可被翻译为：最高占据轨道\n'When atoms form a molecule, the atomic orbitals are linearly combined into molecular orbitals, and if the energy of the constituent molecular orbitals is higher than the energy of the atomic orbitals, the molecular orbitals are called antibonding orbitals.'可被翻译为：原子组成分子时，原子轨道线性组合成分子轨道，组成的分子轨道的能量若高于原子轨道的能量，则该分子轨道叫做反键轨道。\n\n根据上述已知信息，请将'The highest energy orbital of the electron occupied molecular orbitals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在电子占有的分子轨道中，能量最高的分子轨道。"
    },
    {
        "instruction":"已知信息：\n'Article 17 Drug research and development activities shall comply with the Good Laboratory Practice for Non-Clinical Studies (GLP) and the Good Clinical Practice (GCP), and the entire drug research and development process shall continuously comply with statutory requirements.'可被翻译为：第十七条 从事药品研制活动，应当遵守药物非临床研究质量管理规范、药物临床试验质量管理规范，保证药品研制全过程持续符合法定要求。\n'non-clinical good laboratory practice'可被翻译为：药物非临床研究质量管理规范\n'Article 22 A pre-clinical drug study shall be in conformity with relevant requirements, among which the Good Laboratory Practice for Non-Clinical Laboratory Studies shall be implemented in the study of safety evaluation.'可被翻译为：第二十二条 药物临床前研究应当执行有关管理规定，其中安全性评价研究必须执行《药物非临床研究质量管理规范》。\n'Article 10 Before applying for marketing registration of a drug, the applicant shall complete related research including Chemical, Manufacturing and Control (CMC), pharmacological and toxicological studies and drug clinical trials. Non-clinical safety evaluation studies shall be carried out in institutions meeting Good Laboratory Practice (GLP) requirements and be in compliance with the GLP. Drug clinical trials shall be approved, and bioequivalence studies shall be filed for record. Drug clinical trials shall be carried out in clinical trial institutions that comply with relevant regulations and adhere to the Good Clinical Practice (GCP).'可被翻译为：第十条 申请人在申请药品上市注册前，应当完成药学、药理毒理学和药物临床试验等相关研究工作。药物非临床安全性评价研究应当在经过药物非临床研究质量管理规范认证的机构开展，并遵守药物非临床研究质量管理规范。药物临床试验应当经批准，其中生物等效性试验应当备案；药物临床试验应当在符合相关规定的药物临床试验机构开展，并遵守药物临床试验质量管理规范。\n\n根据上述已知信息，请将'Article 165 Where the Good Laboratory Practice for Non-Clinical Laboratory Studies or the Good Clinical Practice is not executed in the process of drug registration according to regulations, punishments shall be given in accordance with the provisions in Article 79 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百六十五条 在药品注册中未按照规定实施《药物非临床研究质量管理规范》或者《药物临床试验质量管理规范》的，依照《药品管理法》第七十九条的规定处罚。"
    },
    {
        "instruction":"已知信息：\n'The drug is placed in a closed screen with a screen cover and a receiver, and the device for grading the material is shaken and vibrated on the machine for a certain time.'可被翻译为：将药物置于具有筛盖和接受器的密闭筛中，在机器上摇动和振动一定时间以完成物料分级的装置。\n'NMPA Announcement on Revising the Package Insert of Antiviral Syrup, Capsules, Soft Capsules, Pills (Concentrated Pills), Dropping Pills, Tablets, Effervescent Tablets, Chewable Tablet, Oral Liquid, And Granules'可被翻译为：国家药监局关于修订抗病毒糖浆、胶囊、软胶囊、丸（浓缩丸）、滴丸、片、泡腾片、咀嚼片、口服液、颗粒药品说明书的公告\n'Usually refers to solid dosage forms of medicinal products such as tablets, capsules and powders to be taken orally.'可被翻译为：通常是指口服的片剂、胶囊、粉剂等药品的固体剂型。\n'A female drug used to block the normal reproductive process and to prevent or terminate pregnancy. There are different dosage forms, such as short-acting oral tablets, long-acting oral tablets, long-acting injectable drugs, implants, multiphase tablets, vaginal suppositories and gels.'可被翻译为：阻滞正常生殖过程，达到避孕或终止妊娠目的的女用药物。有不同剂型,如短效口服片、长效口服片、长效注射药、埋植剂、多相片剂、阴道栓剂和胶冻剂等。\n\n根据上述已知信息，请将'Under certain conditions, all drug dosage forms (tablets, pills, etc.) were disintegrated and passed the screen with the testing device prescribed by pharmacopeia'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以药典规定的检测装置在一定条件下测得药物剂型（片剂、丸剂等）全部崩解并通过筛"
    },
    {
        "instruction":"已知信息：\n'The Tube Method further states: The percentage coefficient of determinations (%R2) for each \nstandard curve will be NLT 90% (i.e. correlation coefficient of NLT 0.950) and\n2) Absorbance values of the media reference standard [S3] are predetermined per antibiotic. \nRefer USP <81> for testing parameters and acceptable data requirements.'可被翻译为：浊度法还要求，每条标准曲线的测定百分比系数（%R2）应 NLT90%（即相关系数NLT0.950），且中值对照品【S3】的吸光度值要根据不同抗生素分别预先确定。参见USP<81>中检测参数和可接受数据要求。\n'The percentage coefficient of determinations (%R2) for each standard curve will be NLT 95% (i.e. correlation coefficient of NLT 0.9750); and,'可被翻译为：每条标准曲线的测定系数（%R2）应NLT95%（即相关系数NLT0.9750），且\n'1) The calculated potency of the test antibiotic [U3] must be 80% to 125% of the median \nreference standard [S3]'可被翻译为：抗生素样品【U3】的计算效价必须为中值对照品【S3】的 80-125%。\n'1. The percentage coefficient of determinations (%R\n2\n) for each standard curve will be NLT 95% \n(i.e. correlation coefficient of NLT 0.9750); and,'可被翻译为：每条标准曲线测定值的百分系数（%R2）不得低于（NLT）95%（即相关系数\nNMT0.9750），且\n\n根据上述已知信息，请将'USP <81> states the following criteria for both the Plate and Tube Methods: 1) The calculated \npotency of the test antibiotic [U3] must be 80% to 125% of the median reference standard [S3] \n2) Relative standard deviation for all measured and calculated data is NMT 10% and 3) Testing \nis performed in triplicate over a period of three independent test runs. The Plate Method further \nstates: 1) The percentage coefficient of determinations (%R2) for each standard curve will be \nNLT 95% (i.e. correlation coefficient of NLT 0.9750) and 2) ZOIs for all media reference standard (S3 will measure between 14-16 mm). Refer to USP <81> for testing parameters and acceptable data requirements.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"USP<81>要求管碟法和浊度法符合以下标准：（1）测试抗生素【U3】的计算效价必须为中值标准品【S3】的 80-125%，（2）所有测量数据和计算数据的相对标准偏差 NMT 10%，且（3）进行三次独立检测，每次测试一式三份样品。管碟法还要求：（1）每条标准曲线的测试百分比系数（%R2）NLT 95%（即相关系数 NLT 0.9750），且（2）所有中值标准品（S3）的 ZOI 应在 14-16mm。参见 USP<81>中检测参数和可接受数据要求。"
    },
    {
        "instruction":"已知信息：\n'(2) Class 2 chemical drugs, being modified new drugs, are optimized on the basis of known active ingredients, and shall have obvious clinical advantages over those before modification. Known active ingredients refer to the active ingredients of drugs that have been marketed in China or overseas. If such drugs meet the requirements of multiple conditions at the same time, such conditions shall be described at application.'可被翻译为：（二）化学药品2类为改良型新药，在已知活性成份基础上进行优化，应比改良前具有明显临床优势。已知活性成份指境内或境外已上市药品的活性成份。该类药品同时符合多个情形要求的，须在申报时一并予以说明。\n'(3) Class 3 chemical drugs are drugs manufactured by domestic applicants by imitating the original drugs that have been marketed overseas but not yet in China. They have identical active ingredients, dosage forms, specifications, indications, routes of administration, usage and dosage with those of the reference formulations, and have proven consistency of quality and efficacy with those of the reference formulations.'可被翻译为：（三）化学药品3类为境内生产的仿制境外已上市境内未上市原研药品的药品，具有与参比制剂相同的活性成份、剂型、规格、适应症、给药途径和用法用量，并证明质量和疗效与参比制剂一致。\n'(4) Class 4 chemical drugs are drugs manufactured by domestic applicants by imitating the original drugs that have been marketed in China. They have identical active ingredients, dosage forms, specifications, indications, routes of administration, usage and dosage with those of the reference formulations, and have proven consistency of quality and efficacy with those of the reference formulations.'可被翻译为：（四）化学药品4类为境内生产的仿制境内已上市原研药品的药品，具有与参比制剂相同的活性成份、剂型、规格、适应症、给药途径和用法用量，并证明质量和疗效与参比制剂一致。\n'Class 5: Drugs that have been marketed overseas and are under application for being marketed in China.'可被翻译为：5类：境外上市的药品申请在境内上市。\n\n根据上述已知信息，请将'(5) Class 5 chemical drugs are drugs that have been marketed overseas and are under application for being marketed in China. Drugs manufactured in China and overseas are included. Among them, Class5.1 chemical drugs are original drugs and modified drugs, and the latter are optimized on the basis of known active ingredients, and shall have obvious clinical advantages over those before modification. Class 5.2 chemical drugs are generic drugs, whose quality and efficacy shall be proven to be consistent with those of the reference formulations, and whose technical requirements are the same as those of Class 3 and Class 4 chemical drugs. Generic drugs developed simultaneously at home and abroad but produced overseas shall be applied in accordance with Class5.2 chemical drugs. If clinical trials for such drugs are applied, the supporting documents for approval of marketing and sales can be exempted.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）化学药品5类为境外上市的药品申请在境内上市，包括境内外生产的药品。其中化学药品5.1类为原研药品和改良型药品，后者在已知活性成份基础上进行优化，应比改良前具有明显临床优势；化学药品5.2类为仿制药，应证明与参比制剂质量和疗效一致，技术要求与化学药品3类、4类相同。境内外同步研发的境外生产仿制药，应按照化学药品5.2类申报，如申报临床试验，不要求提供允许药品上市销售证明文件。"
    },
    {
        "instruction":"已知信息：\n'Isokinetic  sampling head - A sampling head designed to disturb the air as little as possible  so that the  same particles go into the nozzle as would have passed the area if the nozzle had not been there (i.e. the  sampling condition in which the mean velocity of the air entering the sample probe inlet is nearly the same (±20 percent) as the mean velocity of the airflow at that location).'可被翻译为：等速采样头：一种几乎不会扰乱空气的采样头、使进入管口的粒子与管口不存在时通过该区域的微粒相同，即，采样条件为进入样品探针入口处的空气流速与该位置气流的平均流速几乎相同(±20%）。\n'Air velocity test (Note: For grade B, C and D the air velocity test should be performed according to a risk assessment documented as part of the CCS. However, it is required for filling zones supplied with unidirectional airflow (e.g. when filling terminally sterilised products or background to grade A and RABS). For grades with non-unidirectional airflow, a measurement of recovery testing should replace velocity testing).'可被翻译为：风速测试（注：对于 B 级、C 级和 D 级，风速测试应按照风险评估的结果进行，并将该风险评估包含到CCS 中。但是，使用单向流的灌装区（例如，灌装最终灭菌产品时或 A 级和 RABS 的背景区）需要进行测试。对于非单向流的级别，应以自净测试代替风速测试）。\n'1.Unidirectional airflow is a rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (see also turbulent flow).(Modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow.)\n2.A rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (see also turbulent air flow). (Modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow.)\n3.An airflow moving in a single direction in a robust and uniform manner and at sufficient speed to reproducibly sweep particles away from the critical processing or testing area.'可被翻译为：1.单向气流是在洁净区的整个横截面积上以稳定的速度和近似平行的流线进行整流的气流(另见紊流)。(现代标准不再指层流，而是采用了“单向气流”一词。)\n2.以稳定的速度和近似平行的流线流过洁净区的整个横截面积的整流气流(参见紊流)。(现代标准不再指层流，而采用了单向气流这一术语。)\n3.一种以强劲和均匀的方式沿单一方向移动的气流，并以足够的速度可重复地将颗粒从关键加工或测试区域扫走。\n'A rectified airflow over the entire cross-sectional area of a clean zone with a steady velocity and approximately parallel streamlines (modern standards no longer refer to laminar flow, but have adopted the term unidirectional airflow).'可被翻译为：以稳定的速度和近似平行的流线流过洁净区的整个横截面积的整流气流(现代标准不再指层流，而是采用了术语“单向气流”)。\n\n根据上述已知信息，请将'A sampling head designed to disturb the air as little as possible so that the same particles go into the nozzle as would have passed the area if the nozzle had not been there (that is, the sampling condition in which the mean velocity of the air entering the sample probe inlet is nearly the same (± 20%) as the mean velocity of the airflow at that location).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种采样头，其设计目的是尽可能少地干扰空气，使进入喷嘴的颗粒与没有喷嘴时通过该区域的颗粒相同(即进入样品探头入口的空气的平均速度与该位置气流的平均速度几乎相同(±20%)的采样条件)。"
    },
    {
        "instruction":"已知信息：\n'a detailed risk management plan;'可被翻译为：详细的风险管理计划；\n'Article 77 MAHs shall formulate a drug post-marketing risk management plan and take the initiative to conduct drug post-marketing studies to further confirm the safety, efficacy, and quality management of drugs, and strengthen continuous management of marketed drugs.'可被翻译为：第七十七条 药品上市许可持有人应当制定药品上市后风险管理计划，主动开展药品上市后研究，对药品的安全性、有效性和质量可控性进行进一步确证，加强对已上市药品的持续管理。\n'Article 40 Drug MAHs shall conduct continuous risk-benefit assessment and risk control for drugs, formulate a risk management plan for post-marketing drugs, voluntarily conduct post-marketing studies and further verify the safety, effectiveness and quality controllability of drugs and strengthen ongoing management of post-marketing drugs.'可被翻译为：第四十条 药品上市许可持有人应当持续开展药品风险获益评估和控制，制定上市后药品风险管理计划，主动开展上市后研究，对药品的安全性、有效性和质量可控性进行进一步确证，加强对已上市药品的持续管理。\n'The MAHs shall formulate and implement corresponding risk control measures taking into account risk management opinions received.'可被翻译为：持有人应当根据收到的风险管理意见制定并实施相应的风险控制措施。\n\n根据上述已知信息，请将'(6) fails to formulate a risk management plan after a drug goes to market; or'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）未制定药品上市后风险管理计划；"
    },
    {
        "instruction":"已知信息：\n'Article 18 The third-party platform shall submit the enterprise name, legal representative, unified social credit identifier, website name, domain name and other information to the provincial drug regulatory department where the platform is located for filing. The provincial drug regulatory department shall publicize the filing information of the platform.'可被翻译为：第十八条 第三方平台应当将企业名称、法定代表人、统一社会信用代码、网站名称以及域名等信息向平台所在地省级药品监督管理部门备案。省级药品监督管理部门应当将平台备案信息公示。\n'Article 42 The medical device manufacturer shall report the variety of the manufactured products to the drug regulatory department.'可被翻译为：第四十二条  医疗器械生产企业应当向药品监督管理部门报告所生产的产品品种情况。\n'Article 55 The drug regulatory department shall carry out follow-up inspection of the enterprise’s rectification condition.'可被翻译为：第五十五条  药品监督管理部门对企业的整改情况应当开展跟踪检查。\n'(1) the medical device manufacturer fails to report the variety and related information of the manufactured products to the drug regulatory department in accordance with provisions in Article 42(2) of these Provisions;'可被翻译为：（一）医疗器械生产企业未依照本办法第四十二条第二款的规定向药品监督管理部门报告所生产的产品品种情况及相关信息的；\n\n根据上述已知信息，请将'Article 68 The drug regulatory department shall record the varieties of the products manufactured by the enterprise in the credit file.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十八条  药品监督管理部门应当在信用档案中记录企业生产产品品种情况。"
    },
    {
        "instruction":"已知信息：\n'The phenomenon of enhanced absorption at the short wavelength end of the ultraviolet absorption spectrum. It is produced when the molecules are excited by ultraviolet light, and the electrons in the molecular orbit absorb the photons from the ground state to the excited state, generally located between 180 and 220nm.'可被翻译为：紫外吸收光谱中位于短波末端所出现的吸收增强的现象。是分子在紫外光激发下，分子轨道上的电子吸收了光子后由基态激发到激发态上而产生的，一般位于180~220nm之间。\n'A state description of a molecular vibrational transition process; Sometimes the transition may also occur between excited states, where the lower energy level is not the ground state, and the resulting absorption band is called a thermal band. This peak is weak and is often masked by the fundamental frequency peak.'可被翻译为：分子振动跃迁过程的一种状态描述；有时跃进也可能发生在激发态之间，低能级不是基态，此时产生的吸收谱带称为热谱带。此峰很弱，常被基频峰所掩盖。\n'A reagent used in chemiluminescence analysis. It can be oxidized by a strong oxidizing agent in an alkaline solution to an excited state that emits blue light and returns to the ground state. Aminophenyldihydrazide.'可被翻译为：用于化学发光分析的一种试剂。在碱性溶液中可以被强氧化剂氧化而处于激发态，激态发射蓝光同时回到基态。即氨基苯二酰肼。\n'The process by which a substance changes from its inactive state to an active state. The process by which the electrons of a particle, such as an atom or ion, transition from a lower ground state to a higher energy level after obtaining sufficient energy from the outside world.'可被翻译为：某一物质从其无活性状态转变为具有活性状态的过程。粒子（如原子或离子），从外界获得足够能量后，其电子由较低的基态能级跃迁到较高能级的过程。\n\n根据上述已知信息，请将'After absorbing a certain wavelength of infrared light, molecules transition from the ground state to the second or even the third excited state to produce infrared absorption bands.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"分子吸收一定波长的红外光后，从基态跃迁到第二激发态甚至第三激发态产生的红外吸收带。"
    },
    {
        "instruction":"已知信息：\n'(1) name, model, specification, and quantity of the medical device;'可被翻译为：（一）医疗器械的名称、型号、规格、数量；\n'(1) The information of the investigational medical device, including name, model, specification, date of receipt, lot number or serial number;'可被翻译为：（一）所使用的试验用医疗器械的信息，包括名称、型号、规格、接收日期、批号或者系列号等；\n'The sales records of Chinese crude drugs shall include the name of the product, strength, place of production, purchaser, sales quantity, unit price, amount and sales date; those of Prepared Slices shall include the name of product, strength, lot number, place of production, manufacturer, purchaser, sales quantity, unit price, amount and sales date, etc.'可被翻译为：中药材销售记录应当包括品名、规格、产地、购货单位、销售数量、单价、金额、销售日期等内容；中药饮片销售记录应当包括品名、规格、批号、产地、生产厂商、购货单位、销售数量、单价、金额、销售日期等内容。\n'(2) registration certificate number or filing number of the medical device;'可被翻译为：（二）医疗器械注册证编号或者备案编号；\n\n根据上述已知信息，请将'(1) name, model, specification, registration certificate number or filing number, quantity, unit price and amount of the medical devices;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）医疗器械的名称、型号、规格、注册证编号或者备案编号、数量、单价、金额；"
    },
    {
        "instruction":"已知信息：\n'4. Speciation- Record and copy the method of identification (i.e. API, Vitek, etc.). Determine if there were possible secondary contaminants that were not identified or recorded (check original plates, or isolates); verify accuracy of entry into the LIM system.'可被翻译为：物种形成—记录和复制鉴别方法（即 API，Vitek 等）。确定是否有可能未发现或记录二次污染（检查原始平板或分离物）；核查录入 LIMS 系统的数据准确性。\n'9. Laboratory - Visit the microbiology laboratory and look in the refrigerators, incubators, look at discarded plates from that day’s work or request speciation log book and determine if microbial recovery has occurred, but not recorded on official worksheets or entered into LIMs. Determine where plates or other growth media are stored pending microbial identification. Review available plates or growth media to determine if the findings match those documented in the laboratory records.'可被翻译为：实验室—查看微生物实验室，查看当天工作的冰箱、培养箱、废弃的平板，或要求查看菌种鉴别登记本，确定是否曾发现微生物，却没有记录在正式的工作记录中或录入 LIMS。确定微生物鉴别时平板或其它培养基存放位置。检查现有平板或培养基，确定看到的东西与实验室记录中记录的内容是一致的。\n'11.Integrity and accuracy of the laboratory information management system (LIMS) for microbiology data entry, review and approval'可被翻译为：用于微生物数据输入、审核和批准选择、处理和生物指示剂储存的实验室有信息管理系统（LIMS）的完整性和准确性\n'Record on Analyst's worksheets the day that the primary isolation media, Fluid Thioglycollate Broth (THIO), or Soybean-Casein Digest Broth (SCD) is turbid and inform supervisor. Streak tubes on the day they first appear positive and again at 14 days to determine the presence of other possible slow-growing (i.e., fungi) microorganisms.'可被翻译为：在化验员工作本上记录初始分离培养基、THIO或SCD混浊的情况并通知主管。当首 次发现阳性当天和第14天时在试管上划线，以确定是否有其它可能缓慢生长（例如真 菌）微生物。\n\n根据上述已知信息，请将'7. Worksheets - Review possible falsification or incorrect entry onto worksheets or Laboratory LIM system.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"工作表—审核是否存在伪造或不正确录入记录或实验室 LIMS 系统的可能性"
    },
    {
        "instruction":"已知信息：\n'(1) performing responsibility insufficiently, resulting in serious negative effects or heavy losses;'可被翻译为：（一）履行职责不力，造成严重不良影响或者重大损失；\n'(4) failing to perform drug supervision and administration duties, resulting in serious adverse impact or serious losses.'可被翻译为：（四）其他不履行药品监督管理职责，造成严重不良影响或者重大损失。\n'(3) incompetence in the performance of duties which causes serious adverse effects or serious losses.'可被翻译为：（三）履行职责不力，造成严重不良影响或者重大损失。\n'(3) fail to promptly discover systemic risks of drug safety, or fail to promptly eliminate drug safety hazards within their supervision and administration region, resulting in serious effects; or'可被翻译为：（三）未及时发现药品安全系统性风险，或者未及时消除监督管理区域内药品安全隐患，造成严重影响；\n\n根据上述已知信息，请将'(7) having any other dereliction of duty in vaccine administration, resulting in serious negative effects or heavy losses.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（七）其他未履行疫苗监督管理职责的行为，造成严重不良影响或者重大损失。"
    },
    {
        "instruction":"已知信息：\n'Provisions for Instructions and Labels of Medical Devices'可被翻译为：医疗器械说明书和标签管理规定\n'Article 14 Medical device instructions and labels shall not contain the following contents:'可被翻译为：第十四条 医疗器械说明书和标签不得有下列内容：\n'(VI) Operating areas and equipment for operation and double check of break bulk picking and LCL shipping;'可被翻译为：（六）用于零货拣选、拼箱发货操作及复核的作业区域和设备；\n'Contents in the instructions and labels of medical devices shall be consistent with the relevant information in their registration or filing.'可被翻译为：医疗器械说明书和标签的内容应当与经注册或者备案的相关内容一致。\n\n根据上述已知信息，请将'(VI) Revising the instructions, labels and operating manual, etc.;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）修改说明书、标签、操作手册等；"
    },
    {
        "instruction":"已知信息：\n'Article 38 For the purpose of the Provisions, importer includes distribution enterprises, the consignee and the applicant for testing.'可被翻译为：第三十八条 本办法所称进口单位，包括经营单位、收货单位和报验单位。\n'The consignee refers to the consignee or the owner of the goods as specified in the purchase contract and the shipping invoice.'可被翻译为：收货单位，是指购货合同和货运发票中载明的收货人或者货主。\n'Article 27 The drug regulatory department may request the applicant or the drug research institution responsible for testing to repeat the test based on the items, methods and data specified in the application documents, and may also authorize a drug testing institute or another drug research institution to repeat the test or conduct methodological verification.'可被翻译为：第二十七条 药品监督管理部门可以要求申请人或者承担试验的药物研究机构按照其申报资料的项目、方法和数据进行重复试验，也可以委托药品检验所或者其他药物研究机构进行重复试验或方法学验证。\n'Article 54 Having completed the relevant CMC study supporting drug marketing, the specifications establishment, and commercial-scale manufacturing process validation, the applicant may apply for drug registration testing to the NIFDC or the drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government before the drug registration application is accepted; Where the applicant does not propose drug registration testing before the drug registration application is accepted, the drug registration testing shall be initiated by the CDE within 40 days after accepting the drug registration application. In principle, the applicant can only propose drug registration testing once before the drug registration application is accepted, and may not propose drug registration testing to multiple drug testing institutions at the same time.'可被翻译为：第五十四条 申请人完成支持药品上市的药学相关研究，确定质量标准，并完成商业规模生产工艺验证后，可以在药品注册申请受理前向中检院或者省、自治区、直辖市药品监督管理部门提出药品注册检验；申请人未在药品注册申请受理前提出药品注册检验的，在药品注册申请受理后四十日内由药品审评中心启动药品注册检验。原则上申请人在药品注册申请受理前只能提出一次药品注册检验，不得同时向多个药品检验机构提出药品注册检验。\n\n根据上述已知信息，请将'The consignee and the applicant for testing may be the same.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"收货单位和报验单位可以为同一单位。"
    },
    {
        "instruction":"已知信息：\n'10. Reagents used for microorganism identification and medicine sensitivity experiment.'可被翻译为：10.用于微生物鉴别或者药敏试验的试剂；\n'Inoculate the same microorganism using the same medium without the product as a positive control.'可被翻译为：使用不含产品的相同培养基接种相同的微生物作为阳性对照。\n'Also known as \"increasing bacteria medium\". The use of the isolated object has a specific preference for a certain nutrient in the medium to add the nutrient, so that the microorganism in the number of dominant, in order to achieve the enrichment culture purpose of the medium.'可被翻译为：又称\"增菌培养基”。利用分离对象对某一营养物质有专一偏好的特性，在培养基中加入该营养物，使该微生物在数量上占优势，以达到富集培养目的的培养基。\n'extreme microorganism'可被翻译为：极端微生物\n\n根据上述已知信息，请将'1. Microorganism culture medium (not applicable to microorganism identification and drug sensitivity testing).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.微生物培养基（不用于微生物鉴别和药敏试验）；"
    },
    {
        "instruction":"已知信息：\n'The method of electrophoretic analysis using solid thin layer as support.'可被翻译为：以固体薄层为支持物进行电泳的分析方法。\n'In thin layer chromatography, a certain amount of adhesive is added to the fixed phase in advance, spread on the glass plate, and made of thin layer chromatography plate.'可被翻译为：在薄层色谱法中，预先在固定相中加入一定量的黏合剂，铺展在玻璃板上，烘干制成的薄层色谱板。\n'A material supporting an adsorbent in thin layer chromatography. Usually glass plate or aluminum plate.'可被翻译为：薄层色谱中支持吸附剂的材料。通常为玻璃板或铝板。\n'Using alumina as stationary phase, the chromatographic method of liquid-solid adsorption separation was carried out in the column.'可被翻译为：以氧化铝作为固定相，在柱中进行液-固吸附分离的色谱法。\n\n根据上述已知信息，请将'The stationary phase is spread on the solid in a uniform thin layer for separation and analysis method of chromatography.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将固定相在固体上铺成均匀薄层进行色谱的分离、分析方法。"
    },
    {
        "instruction":"已知信息：\n'Article 11 Health administrative departments of the State Council and health administrative departments at all levels shall be responsible for supervision and administration of user facility of medical device related to medical device adverse event monitoring, urge user facility of medical device to carry out relevant medical device adverse event monitoring work and organize inspection, strengthen  assessment of medical device adverse event monitoring, and take relevant control measures for medical device adverse events within their responsibility according to law.'可被翻译为：第十一条  国务院卫生行政部门和地方各级卫生行政部门负责医疗器械使用单位中与医疗器械不良事件监测相关的监督管理工作，督促医疗器械使用单位开展医疗器械不良事件监测相关工作并组织检查，加强医疗器械不良事件监测工作的考核，在职责范围内依法对医疗器械不良事件采取相关控制措施。\n'Article 63 The drug regulatory departments shall, based on their responsibilities, supervise and inspect the medical device adverse event monitoring and re-evaluation carried out by MAHs and distributing enterprises, and supervise and inspect the medical device adverse event monitoring by user facility of medical device jointly with the health administrative departments at the same level.'可被翻译为：第六十三条  药品监督管理部门应当依据职责对持有人和经营企业开展医疗器械不良事件监测和再评价工作情况进行监督检查，会同同级卫生行政部门对医疗器械使用单位开展医疗器械不良事件监测情况进行监督检查。\n'Article 54 Where suspected medical device adverse events are caused by inferior device quality, the drug regulatory departments shall take proper measures in accordance with relevant regulations of medical devices; where such events are caused by improper use of medical device, the health administrative departments shall take proper measures.'可被翻译为：第五十四条  可疑医疗器械不良事件由医疗器械产品质量原因造成的，由药品监督管理部门按照医疗器械相关法规予以处置；由医疗器械使用行为造成的，由卫生行政部门予以处置。\n'(VII) Cooperating with drug regulatory departments and monitoring agencies in investigation of medical device adverse events.'可被翻译为：（七）配合药品监督管理部门和监测机构组织开展的不良事件调查。\n\n根据上述已知信息，请将'Article 52 The drug regulatory departments and health administrative departments at all levels may entrust medical device inspection agencies with corresponding qualification to inspect the products involved in medical device adverse events when necessary. A medical device testing institution shall perform the test promptly and issue the test report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条  各级药品监督管理部门和卫生行政部门必要时可以将医疗器械不良事件所涉及的产品委托具有相应资质的医疗器械检验机构进行检验。医疗器械检验机构应当及时开展相关检验，并出具检验报告。"
    },
    {
        "instruction":"已知信息：\n'The agent appointed by the overseas manufacturer of imported medical devices within the territory of China shall, in a timely manner, report relevant information of the recall of medical devices implemented only overseas to the China Food and Drug Administration; for any recall within the territory of China, the agent appointed within the territory of China shall organize and implement the recall in accordance with these Provisions.'可被翻译为：进口医疗器械的境外制造厂商在中国境内指定的代理人应当将仅在境外实施医疗器械召回的有关信息及时报告国家食品药品监督管理总局；凡涉及在境内实施召回的，中国境内指定的代理人应当按照本办法的规定组织实施。\n'(I)  MAHs of medical device refer to the holders of medical device registration certificate and filing certificate, namely, medical device registrants and filing persons.'可被翻译为：（一）医疗器械上市许可持有人，是指医疗器械注册证书和医疗器械备案凭证的持有人，即医疗器械注册人和备案人。\n'Article 53 Where imported medical devices are associated with medical device adverse events overseas, or domestically-produced medical devices are associated with medical device adverse events overseas with control measures taken, the designated agents of overseas MAHs or the MAHs of domestic medical devices shall, within 24 hours after being informed, report the information of overseas medical device adverse events, control measures and the control measures to be taken within the territory of China to the NMPA and national monitoring agencies, copy to the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government, and promptly report subsequent disposal.'可被翻译为：第五十三条  进口医疗器械在境外发生医疗器械不良事件，或者国产医疗器械在境外发生医疗器械不良事件，被采取控制措施的，境外持有人指定的代理人或者国产医疗器械持有人应当在获知后24小时内，将境外医疗器械不良事件情况、控制措施情况和在境内拟采取的控制措施报国家药品监督管理局和国家监测机构，抄送所在地省、自治区、直辖市药品监督管理部门，及时报告后续处置情况。\n'This Announcement is applicable to the matters concerning the production of Class II and Class III medical devices with imported medical device registration certificates in China by the imported medical device registrants through their foreign invested enterprises established in China.'可被翻译为：进口医疗器械注册人通过其在境内设立的外商投资企业在境内生产第二类、第三类已获进口医疗器械注册证产品的有关事项，适用本公告。\n\n根据上述已知信息，请将'The medical device manufacturers mentioned in the preceding paragraph refer to the registrants or filing entities of the domestic medical device products, and the agents appointed by the overseas manufacturer of imported medical devices within the territory of China.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"前款所述医疗器械生产企业，是指境内医疗器械产品注册人或者备案人、进口医疗器械的境外制造厂商在中国境内指定的代理人。"
    },
    {
        "instruction":"已知信息：\n'An uninoculated media and rinse fluid control are analyzed to ensure sterility at time of use.'可被翻译为：对未接种培养基和淋洗液控制进行分析，以确保使用时的无菌性。\n'Media and Rinse Fluid Controls'可被翻译为：培养基和淋洗液控制\n'Filter the rinse fluid and aseptically cut the filter membrane into two equal parts, transfer one half into each of two suitable media. If conducting the sterility test using a closed canister system, rinse each canister with the inoculated rinse fluid.'可被翻译为：过滤样品液体，在无菌条件下将滤膜对半剪开，将2半分别转移至一份适 用培养基中。如果是采用封闭式碳罐系统进行无菌测试，则使用接种后的 淋洗液淋洗各碳罐。\n'5. Test on suitability of prepared culture media should be performed and documented. The records for use of culture media should be available.'可被翻译为：（五）配制的培养基应当进行适用性检查，并有相关记录。应当有培养基使用记录。\n\n根据上述已知信息，请将'a. Review QC records for proper\/validated sterilization of all equipment and media used during the sterility test method: manifold\/ Steritest; rinse fluid, culture media, canister kits, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"审核 QC 记录，查看无菌检测中所用的所有设备和培养基是否均有经过恰当\/经验证的灭菌：歧管\/ Steritest 检验系统；冲洗液、培养基、灌装配套工具等"
    },
    {
        "instruction":"已知信息：\n'Where the party concerned has evidences that are sufficient to prove that it has no subjective fault, there shall be no administrative punishment. If there are separate provisions by laws and administrative regulations, such provisions shall prevail.'可被翻译为：当事人有证据足以证明没有主观过错的，不予行政处罚。法律、行政法规另有规定的，从其规定。\n'The department in charge of drug supervision and administration shall, in accordance with the law, promptly publish regulatory information on cosmetics manufacturing license, supervision and inspection, and administrative penalty, etc.'可被翻译为：负责药品监督管理的部门应当依法及时公布化妆品生产许可、监督检查、行政处罚等监督管理信息。\n'Article 3 The formulation and revision, implementation, supervision and administration of medical device standards within the territory of the People’s Republic of China shall conform to laws, administrative regulations and these Provisions.'可被翻译为：第三条 在中华人民共和国境内从事医疗器械标准的制修订、实施及监督管理，应当遵守法律、行政法规及本办法的规定。\n'NMPA Issued the Administrative Measures for Drug Quality Sampling Inspection'可被翻译为：国家药监局关于印发药品质量抽查检验管理办法的通知\n\n根据上述已知信息，请将'The administrative body of drug supervision and administration. Supervision and inspection of the other party's compliance with laws, administrative regulations, administrative orders, decisions and measures in accordance with its statutory functions and powers.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品监督管理的行政主体。依照法定职权，对行政相对方是否遵守法律、行政法规、行政命令、决定和措施所进行的监督检查。"
    },
    {
        "instruction":"已知信息：\n'Article 2 All medical devices sold and used within the territory of the People's Republic of China shall apply for registration or filing according to the Provisions.'可被翻译为：第二条 在中华人民共和国境内销售、使用的医疗器械,应当按照本办法的规定申请注册或者办理备案。\n'Article 2  For medical devices sold and used within the territory of the People's Republic of China, their UDI system shall comply with the requirements of the Rules.'可被翻译为：第二条 在中华人民共和国境内销售、使用的医疗器械，其唯一标识系统应当符合本规则。\n'Article 2 All medical devices that are sold and used within the territory of the People's Republic of China shall use generic names and their naming shall conform to the Rules.'可被翻译为：第二条 凡在中华人民共和国境内销售、使用的医疗器械应当使用通用名称，通用名称的命名应当符合本规则。\n'Article 2 All in-vitro diagnostic reagents sold and used within the territory of the People's Republic of China shall apply for registration or filing according to the Provisions.'可被翻译为：第二条 在中华人民共和国境内销售、使用的体外诊断试剂，应当按照本办法的规定申请注册或者办理备案。\n\n根据上述已知信息，请将'Article 2 All medical devices sold or used within the territory of the People's Republic of China shall be accompanied by the instructions and labels in accordance with the requirements of the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二条 凡在中华人民共和国境内销售、使用的医疗器械，应当按照本规定要求附有说明书和标签。"
    },
    {
        "instruction":"已知信息：\n'The DNA of some cells has been mutated, but the phenotype is still normal, which can enable the expression of various malignant traits of these cells and become the substance of true malignant cells.'可被翻译为：有些细胞DNA已突变，但表型仍正常，能使这些细胞的各种恶性性状得以表达，成为真正的恶性细胞的物质。\n'Does not cause changes in the body's functional form, growth, development and life span, does not cause a reduction in the body's functional capacity, nor does it cause an injury to the body's compensatory ability for additional stress.'可被翻译为：不引起机体机能形态、生长、发育和寿命的改变，不引起机体功能能力的降低，也不引起机体对额外应激状态代偿能力的损伤。\n'Cell cloning in which foreign DNA is introduced into cells and integrated onto the genome with the help of viruses, phages, or other methods.'可被翻译为：借助病毒、噬菌体或其他方法将外源DNA导入细胞并整合到基因组上的细胞克隆。\n'The toxicity of a substance that can damage the hearing organs, affect the central nervous system, or even cause deafness.'可被翻译为：某物质能损害听力器官、影响中枢神经，甚至致耳聋的毒性。\n\n根据上述已知信息，请将'A substance that does not react with DNA and may indirectly affect DNA and alter the genome to cause cells to become cancerous or cause cancer by promoting growth or enhancement.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"不与DNA反应，可能间接影响DNA并改变基因组导致细胞癌变或通过促长，增强作用导致癌产生的物质。"
    },
    {
        "instruction":"已知信息：\n'GMP good manufacturing practices'可被翻译为：优良生产规范\n'good manufacturing practices (gmp)'可被翻译为：良好生产规范(GMP)\n'good regulatory practices (grp)'可被翻译为：良好规管措施(GRP)\n'Good Laboratory Practices'可被翻译为：非临床研究质量管理规范\n\n根据上述已知信息，请将'The evaluation of documentary evidence by a competent regulatory authority recognized by the national regulatory authority, for compliance with the required good practices (good manufacturing practices (GMP), good laboratory practices and good clinical practices) in support of marketing authorization and other regulatory decisions. Desk assessment may be performed in support of a new marketing authorization, or for routine GMP inspection (including in the frame of specified product(s) life-cycle management as required).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由国家监管机构认可的主管监管机构对文件证据的评估，以证明符合所需的良好规范(良好生产规范(GMP)、良好实验室规范和良好临床规范)，以支持上市许可和其他监管决定。案头评估可用于支持新的上市许可，或用于常规GMP检查(包括在所要求的指定产品生命周期管理框架内)。"
    },
    {
        "instruction":"已知信息：\n'CDE accepted 5,979 applications for registration of chemical drugs, of which107 were for NDAs, an increase of 43%compared with 2017; and 982 applications were for ANDAs (generic drugs), an increase of 79% compared with 2017. The details of the acceptance of registration application for various classes of chemical drugs are shown in Figure 2. The 2015-2018 acceptance of registration applications for clinical trial,marketing and consistency evaluation of chemical drugs is detailed in Figure 3.'可被翻译为：药审中心受理化药注册申请共5979件，其中受理化药NDA申请107件，较2017年增长了43%；受理仿制药上市申请（ANDA）982件，较2017年增长了79%。化药各类注册申请受理情况详见图2。2018年化药临床、上市和一致性评价注册申请受理情况与近三年比较详见图3。\n'CDE completed the review of registration applications for 6,624 chemical drugs, including 843 clinical applications (IND and confirmatory trial), 206 NDAs, and 2,353 ANDAs. See Figure 14 for details of the various registration applications for chemical drugs that have been reviewed.'可被翻译为：药审中心完成审评的化药注册申请6624件，其中完成化药临床申请（IND和验证性临床）共843件，完成化药NDA 206件，完成化药ANDA 2353件。完成审评的化药各类注册申请情况详见图14。\n'Of the 7,336 new registration applications accepted by CDE, those for chemical drugs accounted for 82% (5,979) of the total.  For a four-year comparison, see Figure 1 for details.'可被翻译为：2018年，药审中心受理的7336件新注册申请中，化药注册申请受理量为5979件，占2018年全部注册申请受理量的82%，2018年各类药品注册申请受理情况与近三年比较详见图1。\n'CDE accepted 413 TCM registration applications, covering 31 applications for INDs, 8 NDAs, and 8 ANDAs. The details of the acceptance of registration applications for various TCMs are shown in Figure 6. The 2015-2018 acceptance of registration applications for TCM clinical trials and marketing is detailed in Figure 7.'可被翻译为：药审中心受理中药注册申请413件，其中受理中药IND申请31件，受理中药NDA 8件，受理中药ANDA 8件。中药各类注册申请受理情况详见图6。2018年中药临床和上市注册申请受理情况与近三年比较详见图7。\n\n根据上述已知信息，请将'Of the 8,077 drug registration applications accepted by CDE, 80.2% (6,475) of the total are chemical drugs applications in 2019. See Figure 1 for the acceptance of registration applications for various classes of drugs in 2016-2019.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药审中心受理的8077件药品注册申请中，化学药注册申请受理量为6475件，占2019年全部注册申请受理量的80.2%，2016-2019年各类药品注册申请受理情况详见图1。"
    },
    {
        "instruction":"已知信息：\n'The determination of the nucleotide sequence of the DNA molecule, that is, the sequence of the A, T, G, and C components of the DNA molecule. Common methods include Sanger - Courson method and Maxam - Gilbert method.'可被翻译为：对DNA分子的核昔酸排列顺序的测定，也就是测定组成DNA分子的A、T、G、C的排列顺序。常用的方法有桑格-库森法和马克萨姆-吉尔伯特法等。\n'The nucleotide sequence containing specific genetic information is the smallest functional unit of genetic information.'可被翻译为：含特定遗传信息的核昔酸序列，是遗传信息的最小功能单位。\n'The process by which a cell transcribes and translates genetic information stored in the DNA sequence into biologically active protein molecules during its life. Various functional proteins and enzymes in living organisms are encoded by corresponding structural genes.'可被翻译为：细胞在生命过程中，把储存在DNA顺序中的遗传信息经过转录和翻译，转变成具有生物活性蛋白质分子的过程。生物体内的各种功能蛋白质和酶都是同相应的结构基因编码的。\n'An intermediate product formed by viral nucleic acids during cell replication. Double-stranded intermediates, such as those formed by single-stranded DNA or RNA viruses during replication.'可被翻译为：病毒核酸在细胞复制过程中形成的中间产物。如单链DNA或RNA病毒在复制期间形成的双链中间物。\n\n根据上述已知信息，请将'The heritable biological information encoded in the nucleotide sequence of DNA or RNA (some viruses).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"编码于DNA或RNA（一些病毒）核昔酸序列中的可遗传的生物信息。"
    },
    {
        "instruction":"已知信息：\n'4.4. The assessment should further cover resources including personnel, premises, equipment and instruments, utilities, QC, documentation, computerized systems, qualification, validation and further HSE-related considerations including waste management.'可被翻译为：评估应进一步覆盖到资源方面，包括人员、设施、设备和仪器、公用系统、QC、文件、计算机化系统、确认和验证及与HSE有关的更多考量，包括三废管理。\n'6.6. The system for quality risk management should be described in writing and cover appropriate areas such as, but not limited to, premises, equipment, materials, products, production, processes, QC, qualification, validation and the process of technology transfer.'可被翻译为：应以书面形式描述质量风险管理体系，覆盖恰当的领域例如但不仅限于设施、设备、物料、产品、生产、工艺、QC、确认、验证和技术转移流程。\n'5.13. The SU and the RU should jointly verify that the following, satisfactorily completed, validation protocols are available:  Installation qualification (IQ) and operational qualification (OQ) data for manufacturing and packaging equipment at the RU site and analytical equipment; and  Qualification of the rooms for both manufacture and packaging at the RU site.'可被翻译为：SU和RU应一起核查以下内容已圆满完成，并有验证方案： RU工厂生产和包装设备及分析设备的安装确认（IQ）和运行确认（OQ）数据；以及  RU工厂生产和包装间的确认。\n'Article 307: A plan should be available for self inspections, and periodical inspections should be conducted on organization and personnel, premises, facilities, equipment, materials and products, qualification and validation, documentation management, production management, quality control and quality assurance, contract manufacture and analysis, product distribution and recalls, and etc.'可被翻译为：第三百零七条 自检应当有计划，对机构与人员、厂房与设施、设备、物料与产品、确认与验证、文件管理、生产管理、质量控制与质量保证、委托生产与委托检验、产品发运与召回等项目定期进行检查。\n\n根据上述已知信息，请将'5.12. The SU should assess the suitability and degree of preparedness of the RU before transfer, with regard to premises, equipment and support services (e.g. purchasing and inventory control mechanisms and pharmaceutical quality system - QC procedures, documentation, computer validation, site validation, equipment qualification, water for pharmaceutical production and waste management).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"转移前SU应评估RU的在设施、设备和支持服务（例如采购和库存控制机制和药物质量体系—QC程序、文件、计算机验证、场所验证、设备确认、制药生产用水和三废管理）方面的适合度和准备就绪程度。"
    },
    {
        "instruction":"已知信息：\n'The relationship between the instrument response (e.g., peak area, height or signal) and the concentration (amount) of analyte in the calibration standards within a given range. Also referred to as Standard Curve.'可被翻译为：仪器响应（例如峰面积、峰高或信号）与给定范围内校正标样中的待测物浓度（含量）的关系。也称为“标准曲线”。\n'The interval between the upper and lower concentration (amounts) of analyte in the calibration standards (including these concentrations)'可被翻译为：校正标样中待测物的高、低浓度区间（包括两端浓度）。\n'A matrix to which a known amount of analyte has been added or spiked. Calibration standards are used to construct calibration curves.'可被翻译为：加入已知量待测物的基质。校正标样被用于构建校正曲线。\n'An analyte in a solvent or mixture of solvents at a known concentration, which is used to prepare calibration standards or QCs.'可被翻译为：已知浓度的溶剂或溶剂混合物中的待测物，用于制备校正标样或QC样品。\n\n根据上述已知信息，请将'A mathematical expression which adequately describes the relationship between instrument response (e.g., peak area or height ratio or signal) and the concentration (amount) of analyte in the calibration standards. Response function is defined within a given range. See also Calibration Curve.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"充分描述仪器响应（例如，峰面积或高比或信号）与校正标样中待测物浓度（量）之间关系的数学表达式。响应函数是在给定浓度范围内定义的。另见校正曲线。"
    },
    {
        "instruction":"已知信息：\n'Not involving or derived from biology or living organisms.'可被翻译为：不涉及或来源于生物学或活的有机体的。\n'The study of the harmful effects of chemicals on living organisms.'可被翻译为：研究化学物对生物机体有害效应的学科。\n'The degree of interaction between various materials (such as excipients, packaging materials, biological materials, etc.) and living organisms.'可被翻译为：各种材料（如辅料、包材、生物材料等）与生物体间相互作用的程度。\n'Chemically, the insertion of a molecule between two molecules or groups in a reversible process. When DNA is embedded, many molecules can interact with DNA in living organisms. Take ligand as an example, embedding is a way of binding ligand molecules to DNA. When the size of ligand meets the gap between the base pairs, it is possible to insert it, resulting in the distortion of the DNA substructure. Usually ligands embedded in DNA are polycyclic, aromatic, or planar molecules.'可被翻译为：化学上指在两个分子或基团之间加入一个分子，过程可逆。DNA嵌入时有许多分子可与生物体内的DNA发生交互作用，以配体为例，嵌入是配体分子与DNA的一种结合方式，当配体大小符合碱基对之间的空隙 时，就有可能插入其中，从而造成DNA分 子结构的扭曲变形。通常嵌入DNA的配体 是多环类、芳香类，或是平面分子。\n\n根据上述已知信息，请将'Electrophilic compounds and their metabolites form covalent conjugates with DNA in living organisms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"亲电性化合物及其代谢产物和生物体内的DNA形成的共价结合物。"
    },
    {
        "instruction":"已知信息：\n'A reference stringent regulatory authority that agrees to provide outcomes of its regulatory expertise (especially assessment and inspection reports) to applicants\/authorization holders or inspected manufacturers, does not object to sharing of these documents with national medicines regulatory authorities and provides, under specified conditions in line with the principles of the Procedure, support to other parties involved in the Procedure.'可被翻译为：参考严格监管机构同意向申请人\/授权持有人或被检查制造商提供其监管专业知识的结果(特别是评估和检查报告)，不反对与国家药品监管机构共享这些文件，并在符合程序原则的规定条件下向程序涉及的其他各方提供支持。\n'Registration procedure in which assessment and national registration of pharmaceutical products and vaccines approved by stringent regulatory authorities (reference SRAs) is facilitated and accelerated by sharing of detailed assessment and inspection outcomes generated by a reference SRA'可被翻译为：通过分享参考SRA产生的详细评估和检查结果，促进和加速了对经严格监管机构(参考SRA)批准的药品和疫苗进行评估和国家注册的注册程序\n'The regulatory submission package submitted to the national regulatory authority as an application for marketing authorization in line with the applicable country requirements and requirements specified in the respective Procedure guidelines (2, 3).'可被翻译为：作为上市许可申请提交给国家监管机构的监管提交包，符合适用的国家要求和各自程序指南中规定的要求(2,3)。\n'National regulatory authority (NRA) that voluntarily agrees to implement this collaborative procedure and accepts the task of processing applications for registration of medicines approved by reference SRAs in accordance with the terms of the Procedure. A list of participating authorities is posted on the WHO Prequalification Team (WHO PQT) website (http:\/\/www.who.int\/prequal\/).'可被翻译为：自愿同意实施本协作程序的国家监管机构(NRA)，并接受根据本程序条款处理参考sra批准的药品注册申请的任务。WHO资格预审小组(WHO PQT预审小组)网站(http:\/\/www.who.int\/prequal\/)上公布了一份参与当局名单。\n\n根据上述已知信息，请将'A regulatory authority that agrees to provide outcomes of its regulatory expertise (especially assessment and inspection reports) to applicants\/authorization holders or inspected manufacturers; agrees to sharing of these documents with national regulatory authorities; and provides, under specified conditions in line with the principles of the Procedure, support to other parties involved in the Procedure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"同意向申请人\/授权持有人或被检查制造商提供其监管专业知识结果(特别是评估和检查报告)的监管机构;同意与国家监管机构共享这些文件;并在符合程序原则的特定条件下，向参与程序的其他各方提供支持。"
    },
    {
        "instruction":"已知信息：\n'For materials, equipment, components and ancillary items that are not a direct or indirect product contact part\nand are necessary for aseptic processing but cannot be sterilised, an effective and validated disinfection and\ntransfer process should be in place. These items, once disinfected, should be protected to prevent recontamination.\nThese items, and others representing potential routes of contamination, should be included in the environmental\nmonitoring programme.'可被翻译为：对于不直接或间接接触产品，并且是无菌工艺所必需但不能灭菌的物料、设备、组件和辅助用品，应建立有效且经验证的消毒和转移程序。消毒后应采取保护措施，防止物品再污染。这些物品以及代表潜在污染途径的其它因素应包含在环境监测计划中。\n'A \"system control\" is used to demonstrate maintenance of sample integrity during all analytical manipulations. Any piece of equipment that comes in contact with the product under analysis, along with any manipulations by the analysts, must be controlled. Thus, all equipment, fluids, and culture media for the \"system control\" must be handled in a manner which duplicates, as closely as possible, the manipulations of the actual sample being analyzed. All materials used as system controls must be sterilized by the analyzing laboratory. However, the method of sterilization need not be the same as for the product, but they must render the material sterile.'可被翻译为：在所有分析操作过程中，“系统控制”用于证明样品完整性的维护。在分析中与产 品接触的任何设备，以及分析人员的任何操作都必须加以控制。因此，用于“系统 控制”的所有设备、液体和培养基必须与被分析的实际样品尽可能接近的方式进行 处理。用于系统控制的所有物料必须通过分析实验室进行灭菌。物料灭菌的方法不 必与产品相同，但是必须使物料无菌。\n'Contact materials that will ultimately become part of the product.'可被翻译为：最终成为产品一部分的接触物料。\n'Where processes include materials that contact the product contact surfaces but are then discarded (e.g. product flushes), the discarded material should be simulated with nutrient media and be incubated as part of the APS, unless it can be clearly demonstrated that this waste process would not impact the sterility of the product.'可被翻译为：当工艺中包括与产品接触表面接触但随后被丢弃的物料时（例如产品冲洗），在 APS 中，应使用营养培养基模拟被弃物料并进行培养，除非可以清楚地证明不会影响产品的无菌性。\n\n根据上述已知信息，请将'Alternatively, controls for these materials are accomplished as part of the \"system control\" for each manifold. This will also include membrane cutters, and other items that contact the product but cannot be individually controlled.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"或者，完成对这些材料的控制，作为每个歧管的“系统控制”的一部分。这还将 包括薄膜切割器和其他接触产品但无法单独控制的物品。"
    },
    {
        "instruction":"已知信息：\n'The extent to which the results of a particular study or systematic review can be extrapolated to other Settings.'可被翻译为：某种研究或者系统综述的结果能够外推于其他环境的程度。\n'The source data refers to the original records of clinical findings, observations and other activities in the clinical trial and all information of approved copies, which can be used for clinical trial reconstruction and evaluation.'可被翻译为：源数据，是指临床试验中的临床发现、观察和其他活动的原始记录以及其经核准的副本中的所有信息，可以用于临床试验重建和评价。\n'Article 16 The sponsor, clinical trial institution and investigator shall not exaggerate the compensation measures for participation in the clinical trial, which may mislead the subjects into participating in the clinical trial.'可被翻译为：第十六条 申办者、临床试验机构和研究者不得夸大参与临床试验的补偿措施，误导受试者参与临床试验。\n'Article 64 The investigator shall ensure that all clinical trial participants are fully aware of the clinical trial protocol, relevant provisions, characteristics of the investigational medical device and the respective responsibilities in the clinical trial, that sufficient subjects who meet the selection criteria in the clinical trial protocol are involved in the clinical trial and that the time decided in the agreement is sufficient to safely implement and complete the clinical trial in accordance with relevant regulations during the trial period.'可被翻译为：第六十四条 研究者应当保证所有临床试验参与人员充分了解临床试验方案、相关规定、试验用医疗器械特性以及与临床试验相关的职责，并确保有足够数量并符合临床试验方案入选标准的受试者进入临床试验、确保有足够的时间在协议约定的试验期内，按照相关规定安全地实施和完成临床试验。\n\n根据上述已知信息，请将'The extent to which the findings of a clinical trial can be reliably extrapolated from the subjects who participated in the trial to a broader patient population and a broader range of clinical settings.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是指将临床试验的发现从参与试验的受试者可靠地外推到更广泛的患者人群和临床环境的程度。"
    },
    {
        "instruction":"已知信息：\n'Air filter with a filtration efficiency of more than 99.97% for dust particles with a particle size of 0.3nm. Can be used to filter dust smaller than Ijim.'可被翻译为：对粒径0.3nm尘粒的滤过效率在99.97%以上的空气滤过器。可用于滤除小于Ijim的尘埃。\n'Air leaving a space, which could be either return air or exhaust air. Return air refers to air that is returned to the air-handling unit and exhaust air is air that is vented to the atmosphere.'可被翻译为：离开空间的空气，可以是回风，也可以是排风。回风是指返回空气处理机组的空气，排风是指排入大气的空气。\n'Particles with a particle size on the order of micrometers.'可被翻译为：粒径为微米数量级的颗粒。\n'Use an instrument that has a concentration limit (the maximum number of particles per ml) identified by the manufacturer that is greater than the concentration of particles in the test specimen to be counted.'可被翻译为：使用生产商确定的浓度限（每毫升的最大粒子数）大于待测样本中的粒子浓度的 仪器。\n\n根据上述已知信息，请将'It mainly measures the size of dust particles in the air and counts the concentration, which is used to monitor the cleanliness of the air.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"主要测量空气中尘埃粒子的大小以及计数浓度，用于监测空气洁净度。"
    },
    {
        "instruction":"已知信息：\n'A way of numeralizing the molecular structure, obtained by performing some kind of numerical operation on the matrix that characterizes the molecular diagram. It is used to describe the chemical structure and is related to the physical properties, thermodynamic parameters, chemical properties, and biological activities of a compound.'可被翻译为：分子结构数值化的一种方式，通过对表征分子图的矩阵实施某种数字运算而获得。用于描述化学结构，并且与化合物的物理性质、热力学参数、化学性能和生物活性等相关。\n'A series of compounds having the same general molecular formula and the same structural characteristics. Also different substances obtained by the same chemical reaction or procedure.'可被翻译为：具有同一分子通式和相同结构特征的一系列化合物。亦指由同一化学反应或同一步骤所获得的不同物质。\n'A class of endonuclease enzymes that catalyze the hydrolysis of DNA.'可被翻译为：一类催化DNA水解的内切核酸酶。\n'Some enzymes need two or more substrates to participate in the catalytic reaction at the same time. The cofactors involved in such reactions can be regarded as substrates, and the normal substrate of the enzyme is combined with the enzyme molecule at the same time to form a ternary or multicomponent complex. The main structure of two or more substrates is connected into a single molecule, and the configuration of the group can be similar to the transition state structure of the normal catalytic reaction of the enzyme when it is combined with the active site of the enzyme, then the single molecule that \"condenses\" the molecular structure of more than two substrates is called a multi-substrate analogue.'可被翻译为：某些酶进行催化反应需要有两个或两个以上的底物同时参与，参与此类反应的辅因子可认作底物，与酶的正常底物同时结合在酶分子上，形成三元的或多元的复合物。将两个或多个底物的主要结构连接成单个分子，而且基团的配置在与酶活性部位结合时，能够类似于酶正常的催化反应的过渡态结构，则这种\"凝结”了两个以上底物分子结构的单一分子就称为多底物类似物。\n\n根据上述已知信息，请将'A group of enzymes that catalyze the same chemical reaction but differ in molecular structure, physicochemical properties, and even immunological properties.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"催化作用的化学反应相同而分子结构、理化性质乃至免疫学性质不同的-组酶。"
    },
    {
        "instruction":"已知信息：\n'Identification of worst case conditions covering the relevant variables, such as container size and line speed, and\ntheir impact on the process. The outcome of the assessment should justify the variables selected.'可被翻译为：确定最差条件，并涵盖相关变量，例如容器尺寸和生产线速度以及它们对工艺的影响。评估的结果应证明选择的变量是合理的。\n'A statistical test of whether and to what extent variables are correlated.'可被翻译为：对变量之间是否相关以及相关的程度如何所进行的统计检验。\n'A model used in place of physical measurements that estimates variables or attributes (for example, quality attributes of a material) based on measured data (such as process data). Model development, including the selection of these data variables, is driven by a thorough understanding of the product and process.'可被翻译为：用于代替物理测量的模型，其基于测量数据（例如工艺数据）对变量或属性（例如，物料的质量属性）进行估算。模型开发，包括这些数据变量的选择，是由对产品和工艺的全面了解所驱动的。\n'Established criteria indicating that the critical variables of a system are out of acceptable range, and requiring investigation and corrective action.'可被翻译为：系统的关键参数超出可接受标准，需要进行调查并采取纠正措施的限度标准。\n\n根据上述已知信息，请将'For a given set of variables, a new set of variables is generated by mathematical transformation. These new variables are linear functions of the original set of variables, but the two new variables are unrelated.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对给定的一组变量，通过数学变换生成新一组的变量，这些新变量是原来一组变量的线性函数，两个新变量之间却是互不关联的。"
    },
    {
        "instruction":"已知信息：\n'The addition of electrolyte in the suspension system increases the J potential of the surface of the particles, and the increase of electrostatic repulsion hinders the collision and aggregation of the particles, making the process of reducing the flocculation phenomenon.'可被翻译为：在混悬体系中加入电解质使微粒表面J电位升高，这时静电排斥力的增大阻碍了微粒间的碰撞聚集，使得絮凝现象减少的过程。\n'If the appropriate amount of electrolyte is added to the suspension, the J potential can be reduced to an appropriate degree, even if the repulsive force between the particles is slightly lower than the attractive force, at this time the particles gather into a loose flocculent aggregate, which can be restored to a uniform suspension by shaking, the added electrolyte is called a flocculant.'可被翻译为：混悬剂中如果加入适量的电解质，可使J电位降低到适当的程度，即使微粒间的排斥力稍低于吸引力，此时微粒聚集成疏松的絮状聚集体，经振摇可恢复成均匀的混悬剂，所加电解质称为絮凝剂。\n'When a small amount of soluble macromolecular compounds are added to the sol, the sensitivity of the sol to the electrolyte increases and the polysedimentation value decreases significantly.'可被翻译为：溶胶中加入极少量可溶性大分子化合物时溶胶对电解质的敏感性增大，聚沉值显著降低的现象。\n'Adding an appropriate amount of electrolyte to the suspension to adjust the self-potential can make the repulsive force between the particles slightly lower than the attractive force, forming a loose flocculent aggregate, which is restored to a uniform suspension by shaking.'可被翻译为：混悬剂中加入适量的电解质调节自电位，可使微粒间的排斥力稍低于吸引力，形成疏松的絮状聚集体，经振摇恢复成均匀的混悬剂的现象。\n\n根据上述已知信息，请将'If the electrolyte is added to the suspension to increase the potential of the particle surface, the electrostatic repulsion hinders the collision between the particles and the aggregation, the flocculation state disappears, the added electrolyte is called the deflocculant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果在混悬剂中因加入电解质使微粒表面的&电位升高，静电排斥力阻碍了微粒之间的碰撞聚集，絮凝状态消失，所加入的电解质称为反絮凝剂。"
    },
    {
        "instruction":"已知信息：\n'The semi-solid ophthalmic preparation is made of a sterile solution or a suspended paste, which is evenly mixed with a suitable substrate.'可被翻译为：由药物与适宜基质均匀混合，制成无菌溶液型或混悬型膏状的眼用半固体制剂。\n'A uniform semi-solid preparation for external use made by mixing a drug with an oily or water-soluble substrate.'可被翻译为：药物与油脂性或水溶性基质混合制成的均匀的半固体外用制剂。\n'A sterilizing preparation made of medicine for injection into the body.'可被翻译为：药物制成的供注入人体内的灭菌制剂。\n'ophthalmic preparation'可被翻译为：眼用制剂\n\n根据上述已知信息，请将'A pasteurized preparation for ophthalmic use made of medicine and a suitable substrate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物与适宜基质制成的供眼用的膏状灭菌制剂。"
    },
    {
        "instruction":"已知信息：\n'1.This is a system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to GEP only.\n2.A system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to good engineering practice only.'可被翻译为：1.这是一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据GEP进行设计和调试。\n2.一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据良好的工程实践进行设计和调试。\n'A system that is expected to have a direct impact on product quality. These systems are designed and commissioned in line with good engineering practice (GEP) and, in addition, are subject to qualification practices.'可被翻译为：预期对产品质量有直接影响的系统。这些系统的设计和调试符合良好工程实践(GEP)，此外，还受资格认证实践的约束。\n'Persons responsible for the certification\/release of sterile products have appropriate access to manufacturing and quality information and possess adequate knowledge and experience in the manufacture of sterile products and the associated critical quality attributes. This is in order to allow such persons to determine if the sterile\nproducts have been manufactured in accordance with the registered specifications and approved process and are of the required quality.'可被翻译为：负责无菌产品认证\/放行的人员应能适当获取生产和质量信息，并具备无菌产品生产及其相关关键质量属性方面的足够知识和经验，从而确保这些人员能够辨别无菌产品是否按照注册的质量标准和批准的工艺生产并符合质量要求。\n'9.6. The impact of the potential product to be transferred, on existing products manufactured on site, should be assessed.'可被翻译为：应评估准备转移的产品对工厂已生产的现有产品产影响。\n\n根据上述已知信息，请将'The manufacturer has sufficient knowledge and expertise in relation to the products manufactured and the equipment, engineering and manufacturing methods employed that have an impact on product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生产商对所生产的产品以及对产品质量有影响的设备、工程和制造方法具备充分的知识和专业技能。"
    },
    {
        "instruction":"已知信息：\n'A certified, homogeneous substance used for specific chemical and physical tests. One or more properties of the chemical reference required in the test to be compared with the sample to be tested, and the chemical reference should be of an appropriate purity for its purpose.'可被翻译为：用于特定化学和物理检测的经过检定、性质均匀的物质。在检测中需要化学对照品的一个或多个性质与待测样品进行比较，化学对照品应具有满足其用途的适当纯度。\n'The documented process by which an analytical procedure (or method) is demonstrated to be suitable for its intended use.'可被翻译为：证明分析程序(或方法)适合其预期用途的形成文件的过程。\n'1.The combination of physical, chemical, biological, and microbiological tests and acceptance criteria that determine the suitability of an API or FPP at the time of its release.\n2.The combination of physical, chemical, biological, and microbiological tests and acceptance criteria that determine the suitability of an active pharmaceutical ingredient or finished pharmaceutical product at the time of its release.'可被翻译为：1.在API或FPP发布时确定其适用性的物理、化学、生物和微生物测试和验收标准的组合。\n2.物理、化学、生物和微生物试验和验收标准的组合，确定药物活性成分或药品成品在放行时的适宜性。\n'One or more materials whose specified properties are sufficiently uniform and stable. Has been determined to be suitable for the intended use of the measurement process.'可被翻译为：一种或多种规定特性足够均匀和稳定的材料。已被确定其符合测量过程的预期用途。\n\n根据上述已知信息，请将'1.The term chemical reference substances, as used in this text, refers to an authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use.\n2.An authenticated, uniform material that is intended for use in specified chemical and physical tests, in which its properties are compared with those of the product under examination, and which possesses a degree of purity adequate for its intended use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.本文所用的“化学对照物质”一词是指一种经过认证的、统一的材料，用于特定的化学和物理测试，其性能与被检查产品的性能进行比较，并具有足以满足其预期用途的纯度。\n2.一种经过认证的、统一的材料，用于特定的化学和物理测试，其性能与被检查产品的性能进行比较，并具有适合其预期用途的纯度。"
    },
    {
        "instruction":"已知信息：\n'(5) a drug manufacturer that conducts repackaging shall hold the Drug Manufacturing Certificate. To apply for repackaging of import unpackaged tablets and capsules, the manufacturer shall also hold the GMP certificate covering the dosage forms for repackaging; and'可被翻译为：（五）接受分包装的药品生产企业，应当持有《药品生产许可证》。进口裸片、胶囊申请在国内分包装的，接受分包装的药品生产企业还应当持有与分包装的剂型相一致的《药品生产质量管理规范》认证证书；\n'When a drug manufacturer applies for importation record filing for drug substances and intermediate preparations used for its own manufacture, photocopies of the Drug Manufacturing Certificate and the Business License for Legal Person shall be submitted corresponding to the materials specified in subparagraph (II) of this Article.'可被翻译为：药品生产企业自行进口本企业生产所需原料药和制剂中间体的进口备案，第（二）项资料应当提交其《药品生产许可证》和《企业法人营业执照》复印件。\n'(V) the importer has not obtained the Drug Supply License (in the case of a drug manufacturer, Drug Manufacturing Certificate shall be obtained) and the Business License for Legal Person;'可被翻译为：（五）进口单位未取得《药品经营许可证》（生产企业应当取得《药品生产许可证》）和《企业法人营业执照》的；\n'Article 22 No entity or individual shall forge, alter, rent, lend, or buy and sell the Drug Manufacturing Certificate.'可被翻译为：第二十二条 任何单位或者个人不得伪造、变造、出租、出借、买卖药品生产许可证。\n\n根据上述已知信息，请将'Article 9 An entity which applies for port testing shall be an independent legal entity and hold the Drug Supply Certificate. A drug manufacturer shall hold the Drug Manufacturing Certificate to import the active pharmaceutical ingredients and intermediate (including pharmaceutical preparations for re-packaging within China) used for its own manufacture.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九条 报验单位应当是持有《药品经营许可证》的独立法人。药品生产企业进口本企业所需原料药和制剂中间体（包括境内分包装用制剂），应当持有《药品生产许可证》。"
    },
    {
        "instruction":"已知信息：\n'A diet formulated according to the nutrient requirements of the human body and with reference to the amino acid patterns of high-quality proteins such as human milk and eggs and nutrients such as sugars, fats, vitamins and inorganic salts.'可被翻译为：以人体营养素需要量为标准，并参照优质蛋白如人乳、鸡蛋等氨基酸模式和糖、脂肪、维生素、无机盐等营养素配制而成的膳食。\n'A protein containing a complete range of essential amino acids in sufficient amounts and proportions to sustain life and promote growth and development.'可被翻译为：含有的必需氨基酸种类齐全、含量充足、比例适当因而能够维持生命和促进生长发育的一类蛋白质。\n'A method of administration in which a drug injection (liquid) with water as the solvent is injected directly into a vein.'可被翻译为：将以水为溶媒的药物注射液(药液)直接注射入静脉的给药方法。\n'Polysaccharides containing uronic acids and amino sugar residues.'可被翻译为：含糖醛酸和氨基糖残基的多糖。\n\n根据上述已知信息，请将'A type of intravenous infusion. Clinical according to the needs of special conditions, the injection containing essential nutrients - amino acids, fats, carbohydrates, vitamins, trace elements, etc., is directly injected into the vein administration method.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"静脉输液的一种。临床针对特殊病情需要，将含有人体必需的营养素--氨基酸、脂肪、碳水化合物、维生素、微量元素等的注射液直接注射入静脉的给药方法。"
    },
    {
        "instruction":"已知信息：\n'(IX) Break-bulk drugs whose outer packages have been removed shall be stored in a centralized manner;'可被翻译为：（九）拆除外包装的零货药品应当集中存放；\n'(VII) Storage of refrigerated drugs in business premises;'可被翻译为：（七）营业场所冷藏药品的存放；\n'(VIII) LCL shipping: the method of packing break-bulk drugs into the same packaging box for shipping;'可被翻译为：（八）拼箱发货：将零货药品集中拼装至同一包装箱内发货的方式。\n'Chapter VII  Application of Non-Prescription Drugs'可被翻译为：第七章 非处方药的申报\n\n根据上述已知信息，请将'(VII) Break-bulk drugs: drugs with their packaging for transportation and storage removed;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（七）零货：拆除了用于运输、储藏包装的药品。"
    },
    {
        "instruction":"已知信息：\n'The cross discipline of chemical engineering and industrial manufacturing engineering. Based on pharmacy, biology, chemical engineering and technology, the research scope covers chemical drug synthesis and process, biological separation engineering, pharmaceutical engineering and equipment, preparation process design, quality control, etc.'可被翻译为：化学工程和工业制造工程学的交叉学科。以药学、生物学、化学工程与技术为基础，研究范围涉及化学药物合成和工艺、生物分离工程、制药工程与设备、制剂工艺设计、质量控制等。\n'biochemical engineering'可被翻译为：生化工程\n'fermentation engineering'可被翻译为：发酵工程\n'Using traditional methods such as biochemistry and biophysics and modern biotechnology such as gene engineering, cell engineering, protein separation and purification technology and bioreactor, the preparation of biological materials such as animals, plants and microorganisms, from which bioactive substances are separated and extracted.'可被翻译为：采用生物化学、生物物理学等传统方法及基因工程、细胞工程、蛋白质分离纯化技术和生物反应器等现代生物技术，将动物、植物和微生物等生物材料加以制备，从中分离提取出具有生物活性物质的一门学科。\n\n根据上述已知信息，请将'An important part of bioengineering, including substrate or nutrient solution preparation, pretreatment, transformation and product separation, refining and other engineering and technology. Generally, fermentation engineering, large-scale culture of plant and animal cells, enzyme engineering, biochemical reaction engineering, biological separation engineering (downstream engineering), biological functional components (such as enzyme electrodes, etc.) and the control and optimization of biological processes are included in biochemical engineering.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生物工程的重要组成部分，包括底物或营养液的准备、预处理、转化以及产品的分离、精制等工程和工艺。一般把发酵工程、动植物细胞的大规模培养、酶工程、生化反应工程、生物分离工程（下游工程）、生物功能元件（如酶电极等）以及生物过程中的控制和优化都包括在生化工程之内。"
    },
    {
        "instruction":"已知信息：\n'1.Steps taken to eliminate the cause of existing nonconformities in order to prevent recurrence. The corrective action process tries to make sure that existing nonconformities and potentially undesirable situations do not happen again.\n2.Steps that are taken to eliminate the causes of existing nonconformities in order to prevent recurrence. The corrective action process tries to ensure that existing nonconformities and potentially undesirable situations do not happen again.'可被翻译为：1.为消除现有不合格的原因而采取的步骤，以防止不合格的再次发生。纠正措施过程试图确保已存在的不符合和潜在的不良情况不再发生。\n2.为消除现有不符合的原因，防止不符合再次发生而采取的步骤。纠正措施过程试图确保已存在的不符合和潜在的不期望情况不再发生。\n'Action to eliminate the cause of a detected non-conformity or other undesirable situation. NOTE: Corrective action is taken to prevent recurrence whereas preventive action is taken to prevent occurrence. (ISO 9000:2005)'可被翻译为：为消除已发现的违规或其他非期望状况的原因(所采取)的措施。注:采取纠正措施是为了防止(事情)再次发生，而采取预防措施是为了防止(事情)发生。 (ISO 9000:2005)\n'Action to eliminate the cause of a potential non-conformity or other undesirable potential situation. NOTE: Preventive action is taken to prevent occurrence whereas corrective action is taken to prevent recurrence. (ISO 9000:2005)'可被翻译为：为消除潜在的违规或其他潜在的非期望状况的原因(所采取)的措施。注:采取预防措施是为了防止(事情)发生，而采取纠正措施是为了防止(事情)再次发生。(ISO 9000:2005)\n'Any action taken and the outcome should be appropriately recorded.'可被翻译为：退货处理的过程和结果应当有相应记录。\n\n根据上述已知信息，请将'Any action that is taken to eliminate a nonconformity. However, corrections do not address causes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为消除不符合而采取的任何措施。然而，纠正不解决原因。"
    },
    {
        "instruction":"已知信息：\n'Article 39 After completion of a clinical trial, the applicant shall submit a clinical trial final report, a statistical analysis report and its database to the State Food and Drug Administration.'可被翻译为：第三十九条 申请人完成临床试验后，应当向国家食品药品监督管理局提交临床试验总结报告、统计分析报告以及数据库。\n'Article 36 The clinical trial institution shall respectively provide the clinical trial report after completing the clinical trial. The applicant or leading unit of clinical trial shall summarize the results of clinical trials and complete the final report according to the relevant technical guidelines.'可被翻译为：第三十六条 临床试验机构完成临床试验后，应当分别出具临床试验报告。申请人或者临床试验牵头单位根据相关技术指导原则，对临床试验结果进行汇总，完成临床试验总结报告。\n'Article 42 In any of the following circumstances during a clinical trial, the State Food and Drug Administration may order the applicant to modify the protocol, suspend or terminate the clinical trial,:'可被翻译为：第四十二条 临床试验有下列情形之一的，国家食品药品监督管理局可以责令申请人修改试验方案、暂停或者终止临床试验：\n'Article 82 After completing drug clinical trials, applicants shall submit clinical trial data to the Center for Drug Evaluation of the State Food and Drug Administration. The State Food and Drug Administration shall issue a drug approval number or a Disapproval Notice based on the technical review opinions.'可被翻译为：第八十二条 申请人完成临床试验后，应当向国家食品药品监督管理局药品审评中心报送临床试验资料。国家食品药品监督管理局依据技术意见，发给药品批准文号或者《审批意见通知件》。\n\n根据上述已知信息，请将'(4) the applicant shall submit a complete clinical trial report to the State Food and Drug Administration after the completion of a clinical trial; and'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）临床试验结束后，申请人应当将完整的临床试验报告报送国家食品药品监督管理局；"
    },
    {
        "instruction":"已知信息：\n'Article 41 For an accepted registration application, where there are evidences indicating that the registration application materials may be spurious, the food and drug regulatory department shall suspend the evaluation and approval process. After investigation, the food and drug regulatory department shall determine to continue the process or to reject the registration application in accordance with the investigation conclusion.'可被翻译为：第四十一条 对于已受理的注册申请，有证据表明注册申报资料可能虚假的，食品药品监督管理部门可以中止审批。经核实后，根据核实结论继续审查或者作出不予注册的决定。\n'Article 39 For accepted registration applications, where one of the following circumstances exists, the food and drug regulatory department shall decide to reject the application and notify the applicant:'可被翻译为：第三十九条 对于已受理的注册申请，有下列情形之一的，食品药品监督管理部门作出不予注册的决定，并告知申请人：\n'Article 49 For accepted registration applications, where one of the following circumstances exists, the food and drug regulatory department shall decide to reject the application and notify the applicant:'可被翻译为：第四十九条 对于已受理的注册申请，有下列情形之一的，食品药品监督管理部门作出不予注册的决定，并告知申请人：\n'Article 40 For an accepted registration application, the applicant may, prior to the administrative permission decision is made, withdraw the registration application and relevant materials, and give reasons to the food and drug regulatory department which accepted the application.'可被翻译为：第四十条 对于已受理的注册申请，申请人可以在行政许可决定作出前，向受理该申请的食品药品监督管理部门申请撤回注册申请及相关资料，并说明理由。\n\n根据上述已知信息，请将'Article 51 For an accepted registration application, where there are evidences indicating that the registration application materials may be spurious, the food and drug regulatory department shall suspend the evaluation and approval process. After investigation, the food and drug regulatory department shall determine to continue the process or to reject the registration application in accordance with the investigation conclusion.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十一条 对于已受理的注册申请，有证据表明注册申报资料可能虚假的，食品药品监督管理部门可以中止审批。经核实后，根据核实结论继续审查或者作出不予注册的决定。"
    },
    {
        "instruction":"已知信息：\n'interventional clinical trial'可被翻译为：干预性临床试 验\n'The date of the first marketing authorisation for any product containing the active substance granted to any company in any country in the world.'可被翻译为：任何公司的任何含有活性物质的药品在世界上任何国家\/区域被首次批准上市销售的日期。\n'An organisation, usually a biopharmaceutical firm, that holds a valid marketing authorisation for a medicinal product delivered by the Health Authority of a country.'可被翻译为：持有由国家卫生部门颁发的有效的药品上市许可证的一个机构，通常是一家生物制药公司。\n'(v) The finished products contain active ingredients complying with the qualitative and quantitative composition of the Marketing Authorisation or Clinical Trial Authorisation, are of the purity required, and are enclosed within their proper containers and correctly labelled;'可被翻译为：(v)含有的活性成分符合注册或临床试验的定性和定量要求的成品，应符合纯度要求，用适当的容器包装，并正确标识；\n\n根据上述已知信息，请将'Date of first approval (or authorisation) for conducting an interventional clinical trial in any country.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"干预性临床试验在任何国家首次获准（或许可的）的日期。"
    },
    {
        "instruction":"已知信息：\n'Article 70 The investigator is responsible for making medical decisions related to the clinical trial. When any adverse event related to the clinical trial occurs, the clinical trial institution and the investigator shall ensure that the subjects are in a timely manner provided with adequate treatment and solution. When the subjects develop complications which require treatment, the investigator shall promptly inform the subjects of the situation.'可被翻译为：第七十条 研究者负责作出与临床试验相关的医疗决定，在发生与临床试验相关的不良事件时，临床试验机构和研究者应当保证为受试者提供足够、及时的治疗和处理。当受试者出现并发疾病需要治疗和处理时，研究者应当及时告知受试者。\n'Article 65 The investigator shall ensure that the investigational medical device is used only for the subjects of the clinical trial and shall not charge any fees.'可被翻译为：第六十五条 研究者应当保证将试验用医疗器械只用于该临床试验的受试者，并不得收取任何费用。\n'The informed consent form shall use the language and words that the subjects or the guardians can understand. The informed consent form shall not contain such content that may cause the subjects to abandon the lawful rights or exempt the clinical trial institution, investigator, and sponsor or its agent from their responsibilities.'可被翻译为：知情同意书应当采用受试者或者监护人能够理解的语言和文字。知情同意书不应当含有会引起受试者放弃合法权益以及免除临床试验机构和研究者、申办者或者其代理人应当负责任的内容。\n'When receiving a notice from the sponsor or the ethics committee to suspend or terminate the clinical trial, the investigator shall inform the subjects promptly and ensure that the subjects are properly treated and followed up.'可被翻译为：研究者接到申办者或者伦理委员会需要暂停或者终止临床试验的通知时，应当及时通知受试者，并保证受试者得到适当治疗和随访。\n\n根据上述已知信息，请将'Article 67 The investigator is responsible for recruiting subjects and talking with them or the guardians. The investigator shall explain to the subjects the details of the investigational medical device and details about the clinical trial, inform the subjects of possible benefits and known and foreseeable risks, and obtain signed and dated informed consent forms from the subjects or the guardians.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十七条 研究者负责招募受试者、与受试者或者其监护人谈话。研究者有责任向受试者说明试验用医疗器械以及临床试验有关的详细情况，告知受试者可能的受益和已知的、可以预见的风险，并取得受试者或者其监护人签字和注明日期的知情同意书。"
    },
    {
        "instruction":"已知信息：\n'Article 20 Clinical evaluation of medical devices refers to the process that the applicant or filing entity validates whether the products under registration can meet their intended use and indications based on the information of clinical literature, clinical experience data and clinical trials.'可被翻译为：第二十条 医疗器械临床评价是指申请人或者备案人通过临床文献资料、临床经验数据、临床试验等信息对产品是否满足使用要求或者适用范围进行确认的过程。\n'Article 28 Clinical evaluation of in-vitro diagnostic reagents refers to the process that the applicant or filing entity validates whether the products under registration can meet their intended use and indications based on the information of clinical literature, clinical experience data and clinical trials.'可被翻译为：第二十八条 体外诊断试剂临床评价是指申请人或者备案人通过临床文献资料、临床经验数据、临床试验等信息对产品是否满足使用要求或者预期用途进行确认的过程。\n'As of June 1, 2021, medical device registrants and filing applicants shall carryout clinical evaluation in accordance with the new Regulations. Clinical evaluation may be exempted for those complying with the provisions for exemption from clinical evaluation in the new Regulations; for the purpose of performing clinical evaluation, it is feasible to prove the safety and effectiveness of the medical device by carrying out clinical trials according to the product characteristics, clinical risks and the existing clinical data or by performing analysis and evaluation on the clinical literature and clinical data of predicate medical devices; clinical trials shall be carried out for medical devices whose safety and effectiveness cannot be proved by the existing clinical literatures and clinical data. Prior to the issuance and implementation of relevant documents on exemption from clinical evaluation, the current Catalogue of Medical Devices Exempted from ClinicalTrials shall be referenced for the Catalogue of Medical Devices Exempted from Clinical Evaluation.'可被翻译为：自2021年6月1日起，医疗器械注册申请人、备案人根据新《条例》规定开展临床评价。符合新《条例》规定的免于临床评价情形的，可以免于临床评价；进行临床评价，可以根据产品特征、临床风险、已有临床数据等情形，通过开展临床试验，或者通过对同品种医疗器械临床文献资料、临床数据进行分析评价，证明医疗器械安全、有效；已有临床文献资料、临床数据不足以确认产品安全、有效的医疗器械，应当开展临床试验。在免于临床评价的相关文件发布实施前，免于进行临床评价医疗器械目录参照现行免于进行临床试验医疗器械目录执行。\n'The assessment and analysis of clinical data pertaining to a medical device to verify the clinical safety and performance of the device when used as intended by the manufacturer (7).'可被翻译为：评估和分析与医疗器械有关的临床数据，以验证器械在按制造商预期使用时的临床安全性和性能(7)。\n\n根据上述已知信息，请将'The clinical data refers to the safety and performance information which is obtained from relevant literature or in the clinical use of medical device.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"临床数据，是指在有关文献或者医疗器械的临床使用中获得的安全性、性能的信息。"
    },
    {
        "instruction":"已知信息：\n'(VIII) Other circumstances in noncompliance with the laws and regulations.'可被翻译为：（八）其他不符合法律法规要求的。\n'9. Other circumstances that should not be passed as prescribed by laws and regulations.'可被翻译为：9.法律法规规定的其他不应当通过的情形。\n'(8) other circumstances in which applications shall not be approved according to laws and regulations.'可被翻译为：（八）法律法规规定的不应当批准的其他情形。\n'(5) other circumstances where administrative licensing shall be canceled as stipulated by laws and regulations.'可被翻译为：（五）法律、法规规定应当注销行政许可的其他情形。\n\n根据上述已知信息，请将'(VI) Other circumstances in noncompliance with the laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）其他不符合法律法规要求的。"
    },
    {
        "instruction":"已知信息：\n'In order to strengthen the supervision over medical device production, guarantee the safety and effectiveness of medical devices, and guide registrants, filing entities and contract manufacturers of medical devices to jointly manage the quality of contract manufacturing of medical devices, according to Paragraph 2 of Article 34 in the Regulations on Supervision and Administration of Medical Devices, the National Medical Products Administration organized to revise the Guidance for Preparation of Contract Manufacturing Quality Agreement of Medical Devices, which was issued on March 22, 2022.'可被翻译为：为加强医疗器械生产监管，保障医疗器械安全有效，指导医疗器械注册人、备案人与受托生产企业共同做好医疗器械委托生产质量管理工作，根据《医疗器械监督管理条例》第三十四条第二款规定，国家药品监督管理局组织制定了《医疗器械委托生产质量协议编制指南》，于2022年3月22日发布。\n'Article 1 The Provisions is formulated in accordance with the Regulations on Supervision and Administration of Medical Devices, with a view to standardizing the administration of medical device registration and filing and guaranteeing the safety and effectiveness of medical devices.'可被翻译为：第一条 为规范医疗器械的注册与备案管理，保证医疗器械的安全、有效，根据《医疗器械监督管理条例》，制定本办法。\n'Article 1 The Provisions is formulated in accordance with the Regulations on Supervision and Administration of Medical Devices, with a view to standardizing the administration on registration and filing of in-vitro diagnostic reagents and ensuring the safety and effectiveness of in-vitro diagnostic reagents.'可被翻译为：第一条 为规范体外诊断试剂的注册与备案管理，保证体外诊断试剂的安全、有效，根据《医疗器械监督管理条例》，制定本办法。\n'In order to strengthen the management of medical device registration, standardize the self-test for registration carried out by registration applicants and ensure the orderly implementation of test for medical device registration, the NMPA organized to formulate the Provisions for Self-Test for Medical Device Registration according to the Regulations for the Supervision and Administration of Medical Devices (State Council Decree No.739), Provisions for Medical Device Registration and Filing (SAMR Decree No.47) and Provisions for In-vitro Diagnostic Reagent Registration and Filing (SAMR Decree No.48). The Provisions for Self-Test for Medical Device Registration was issued and implemented on October 22, 2021.'可被翻译为：为加强医疗器械注册管理，规范注册申请人注册自检工作，确保医疗器械注册检验工作有序开展，根据《医疗器械监督管理条例》（国务院令第739号）及《医疗器械注册与备案管理办法》（市场监管总局令第47号）、《体外诊断试剂注册与备案管理办法》（市场监管总局令第48号），国家药品监督管理局组织制定了《医疗器械注册自检管理规定》，于2021年10月22日予以发布，自发布之日起施行。\n\n根据上述已知信息，请将'In order to improve the normalization and scientificity of technical evaluation of medical devices and guide medical device registrants\/filing entities to prepare product technical requirements,in accordance with the Regulations on Supervision and Administration of Medical Devices, Provisions for Medical Device Registration and Filing and Provisions for Registration and Filing of In-vitro Diagnostic Reagents, the National Medical Products Administration has organized the revision of the Guidance for Compiling the Product Technical Requirements for Medical Devices, which was issued on February 8,2022.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为提高医疗器械技术审评的规范性和科学性，指导医疗器械注册人\/备案人编写产品技术要求，根据《医疗器械监督管理条例》及《医疗器械注册与备案管理办法》《体外诊断试剂注册与备案管理办法》的规定，国家药品监督管理局组织修订了《医疗器械产品技术要求编写指导原则》，并于2022年2月8日发布。"
    },
    {
        "instruction":"已知信息：\n'd. Whirl-pak® bag Sterility Control: Include one unopened Whirl- pak® bag as a closed control.'可被翻译为：Whirl- pak®袋的无菌控制：放入一个未开封的 Whirl- pak®袋作为密封控制。\n'bag'可被翻译为：袋\n'e. Glove Sterility Control: If the sampler uses ORS sterile gloves then have an intact unit containing gloves placed into a sterile plastic bag and sent as a control.'可被翻译为：手套无菌性控制：如果取样器使用 ORS 无菌手套，则将带有手套的完整装置放入无菌塑料袋中，并作为对照。\n'e. Sterile Whirl-pak® bags'可被翻译为：无菌 Whirl-pak®袋\n\n根据上述已知信息，请将'5. Place the EM sample into a sterile Whirl-pak® bag and identify the bag immediately after.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将 EM 样品放入 Whirl-pak®无菌袋，然后立即对袋子进行标示。"
    },
    {
        "instruction":"已知信息：\n'For shuttle type equipment used for aseptic filling, the parison is open to the environment and therefore the areas where parison  extrusion, blow-moulding and  sealing take place  should meet grade A  conditions  at the critical zones. The filling environment should be designed and maintained to meet grade A conditions for viable and total particle limits both at rest and when in operation.'可被翻译为：对于用于无菌灌装的往复式设备，模具在环境中是开放的，因此进行模具挤出、吹塑和密封的关键区域应 符合 A 级条件。灌装环境应进行设计和维护，从而在静态和动态下均符合活性粒子和总微粒限度的 A 级条件。\n'Due to the generation of particles from polymer extrusion and cutting during operation, and the restrictive size of critical filling zones of BFS equipment, in operation monitoring of total particle for BFS equipment is not expected. However, data should be available to demonstrate that the design of the equipment ensures that critical zones of the filling process environment would meet grade A conditions in operation.'可被翻译为：由于操作过程中聚合物挤出和切割产生的微粒， 以及 BFS 设备关键灌装区的尺寸限制，预计不会对 BFS 设备的总微粒进行动态监测。但是，应有数据证明设备的设计可确保灌装工艺环境的关键区域在动态下满足 A 级条件。\n'A technology in which containers are formed from a thermoplastic granulate, filled with product, and then sealed in a continuous, integrated, automatic operation. The two most common types of BFS machines are the shuttle type (with parison cut) and the rotary type (closed parison).'可被翻译为：一种由热塑性颗粒形成容器，填充产品，然后在连续的、集成的、自动的操作中密封的技术。BFS机最常见的两种类型是梭式(有parison切割)和旋转式(封闭parison)。\n'Blow-Fill-Seal (BFS) - A technology in which containers are formed from a thermoplastic granulate, filled with product, and then sealed in a continuous, integrated, automatic operation. The two most common types of BFS machines are the Shuttle type (with Parison cut) and the Rotary type (Closed Parison).'可被翻译为：吹灌封（BFS）：一种由热塑性颗粒形成容器、灌装产品、然后密封的连续、集成化、自动化操作技术。两种最常见的 BFS 机器类型是往复式（带有型坯切割）和旋转式（密封型坯）。\n\n根据上述已知信息，请将'For rotary-type equipment used for aseptic filling, the parison is generally closed to the environment once formed, the filling environment within the parison should be designed and maintained to meet grade A conditions for viable and total particle limits both at rest and when in operation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于用于无菌灌装的旋转式设备，包材通常在成型后密闭于环境，包材内灌装环境的设计和维护应在静态和动态下均符合活性粒子和总微粒限度的 A 级条件。"
    },
    {
        "instruction":"已知信息：\n'bracketing. An experimental design to test the extremes of, for example, dosage strength. The design assumes that the extremes will be representative of all the samples between the extremes.'可被翻译为：分组：对例如剂量的极端进行检测的实验设计。该设计假定极端情况代表了极端中间的所有样本。\n'orthogonal design'可被翻译为：正交设计\n'Experimental Design'可被翻译为：试验设计\n'orthogonal function method'可被翻译为：正交函数法\n\n根据上述已知信息，请将'A design method to study multi-factors and multi-levels. It is to select some representative points from the comprehensive test according to the orthogonality, these representative points have the characteristics of \"uniform dispersion, uniform comparison\", orthogonal experimental design is the main method of fractional factorial design.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究多因素多水平的一种设计方法。它是根据正交性从全面试验中挑选出部分有代表性的点进行试验，这些有代表性的点具备了\"均匀分散，齐整可比”的特点，正交试验 设计是分式析因设计的主要方法。"
    },
    {
        "instruction":"已知信息：\n'Article 45 Drug registration inspection refers to the inspection of drug R&D and manufacturing site in order to verify the authenticity and consistency of the application dossiers and the conditions for commercial manufacturing of the drug to be marketed, and to check the compliance and data integrity of drug R&D; when necessary, inspection may be extended to the manufacturers, suppliers or other contracted organizations for chemical active drug ingredients, excipient and primary packaging materials and containers involved in the drug application dossiers.'可被翻译为：第四十五条 药品注册核查，是指为核实申报资料的真实性、一致性以及药品上市商业化生产条件，检查药品研制的合规性、数据可靠性等，对研制现场和生产现场开展的核查活动，以及必要时对药品注册申请所涉及的化学原料药、辅料及直接接触药品的包装材料和容器生产企业、供应商或者其他受托机构开展的延伸检查活动。\n'Article 27 The applicant shall coordinate with the relevant institutions of drug development, manufacturing, and registration applications and the involved manufacturers and suppliers of chemical raw materials, TCM materials, TCM decoction pieces and extracts, excipients, and packaging materials and container that directly contact drugs, or other entrusted institutions to accept on-site inspections as required, and when necessary, coordinate and organize part of the inspection-related personnel and materials to be inspected at designated locations.'可被翻译为：第二十七条 申请人应当协调与药品研制、生产、注册申请相关单位及所涉及的化学原料药、中药材、中药饮片和提取物、辅料及直接接触药品的包装材料和容器生产企业、供应商或者其他受托机构按要求接受现场核查，必要时协调组织部分核查相关人员和材料到指定地点接受核查。\n'Article 4 Development Site Inspection is to check the compliance and data integrity of drug development, verify the development of drug registration application, and review the original records and data to confirm the authenticity and consistency of application dossiers. Development Site Inspection includes on-site inspection of Chemical Manufacturing and Control (hereinafter referred to as CMC) development, on-site inspection of Pharmacological and Toxicological study, and on-site inspection of drug clinical trials.'可被翻译为：第四条 研制现场核查是通过对药品研制合规性、数据可靠性进行检查，对药品注册申请的研制情况进行核实，对原始记录和数据进行审查，确认申报资料真实性、一致性的过程。研制现场核查包括药学研制现场核查、药理毒理学研究现场核查和药物临床试验现场核查等。\n'Registration inspection is divided into the registration on-site inspection of pharmaceutical development (hereinafter referred to as Development Site Inspection) and the drug registration inspection of manufacturing site (hereinafter referred to as Manufacturing Site Inspection).'可被翻译为：注册核查分为药品注册研制现场核查(以下简称研制现场核查)和药品注册生产现场核查(以下简称生产现场核查)。\n\n根据上述已知信息，请将'Article 3 Registration inspection is the inspection activity initiated by the Center for Drug Evaluation of NMPA (hereinafter referred to as CDE) to verify the authenticity and consistency of the drug registration application dossiers, and the commercial production conditions of the drug ,check the compliance, data  integrity, etc. on the development site and manufacturing site focusing on the development and manufacturing involved in the application dossiers of relevant registration applications; and, if necessary, extended inspection activities may be carried out to the manufacturers, suppliers or other contracted institutions of chemical active pharmaceutical ingredient, traditional Chinese medicine (TCM) materials, TCM decoction pieces and extracts, excipients, and packaging materials and containers that directly contact the drugs involved in drug registration applications.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三条 注册核查是由国家药品监督管理局药品审评中心(以下简称药品审评中心)启动，为核实药品注册申报资料的真实性、一致性以及药品上市商业化生产条件，检查药品研制的合规性、数据可靠性等，围绕相关注册申请事项申报资料中涉及的研制和生产情况，对研制现场和生产现场开展的核查活动，以及必要时对药品注册申请所涉及的化学原料药、中药材、中药饮片和提取物、辅料及直接接触药品的包装材料和容器生产企业、供应商或者其他受托机构开展的延伸检查活动。"
    },
    {
        "instruction":"已知信息：\n'4. Qualification of Stirring\/Agitation\/Flow Rate: The stirring rate should be verified with a suitable device, such as a photo tachometer. For VDC, stirring rates in the range of 400–600 rpm are common. The stirring rate measured is typically applicable to the specific location where the stirring impeller is (e.g., a specific position in a rack that holds multiple VDC, or a specific stir plate). Stirring rate can be measured using a surrogate stir bar if the stir bar used in the diffusion cell is too small to obtain an accurate measurement. The paddle stirring rate for immersion cells of 50 or 100 rpm is common and should be verified and maintained during the test.'可被翻译为：4.（桨法）搅拌\/（搅拌子）搅拌\/流速的确认:搅拌速率应使用合适的设备进行验证，例如光转速计。对于VDC，搅拌速率范围在400-600 rpm是常见的。测量的搅拌速率通常适用于搅拌叶轮所在的特定位置(例如，在容纳多个VDC的机架中的特定位置，或特定的搅拌板)。如果扩散池中使用的搅拌子太小而无法获得准确的测量，则可以使用替代搅拌子来测量搅拌速率。浸没池的桨叶搅拌速率通常为50或100转\/分，在试验期间应加以验证和保持。\n'Mixing rate variation (e.g., slight change in stirring speed, as applicable)'可被翻译为：混合速率变化（如，轻微改变搅拌速率，如适用）\n'flow rate'可被翻译为：流速\n'Sample Flow Rate'可被翻译为：样品流速\n\n根据上述已知信息，请将'4. Rate of stirring or agitation for VDCs or immersion cells, or the flow rate for FDCs, as applicable'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"VDCs或浸没池的搅拌或搅拌速率，或FDCs的流量，视情况而定"
    },
    {
        "instruction":"已知信息：\n'Where WFI storage tanks are equipped with hydrophobic bacteria retentive vent filters, the filters should not be a source of contamination and the integrity of the filter tested before installation and after use. Controls should\nbe in place to prevent condensation formation on the filter (e.g. by heating).'可被翻译为：如果 WFI 储罐配有疏水性除菌过滤器，过滤器不应成为污染的来源，并应在安装前和使用后进行过滤器的完整性测试。应采取控制措施，防止在过滤器上形成冷凝水（例如加热）。\n'Article 101: The pipes for purified water and water for injection should be cleaned and sanitized according to operation procedures and recorded accordingly. If bioburden of water for pharmaceutical use exceeds alert or action limits, actions should be taken according to operation procedures.'可被翻译为：第一百零一条 应当按照操作规程对纯化水、注射用水管道进行清洗消毒，并有相关记录。发现制药用水微生物污染达到警戒限度、纠偏限度时应当按照操作规程处理。\n'Article 99: Purified water and water for injection should be produced, stored and distributed in a manner that prevents microbial growth. Purified water can be circulated, and water for injection can be circulated at a temperature above 70℃.'可被翻译为：第九十九条 纯化水、注射用水的制备、贮存和分配应当能够防止微生物的滋生。纯化水可采用循环，注射用水可采用70℃以上保温循环。\n'Water treatment plant and distribution systems should be designed, constructed, installed, commissioned, qualified, monitored and maintained to prevent microbiological contamination and to ensure a reliable source of\nwater of an appropriate quality. Measures should be taken to minimize the risk of presence of particulates, microbial contamination\/proliferation and endotoxin\/pyrogen (e.g. sloping of piping to provide complete drainage and the avoidance of dead legs). Where filters are included in the system, special attention should be given to their\nmonitoring and maintenance. Water produced should comply with the current monograph of the relevant\nPharmacopeia.'可被翻译为：水处理设施及其分配系统地设计、建造、安装、调试、确认、监测和维护应防止微生物污染，并确保高质量的可靠水源。应釆取措施，最大程度降低微粒、微生物污染\/增殖和内毒素\/热原的风险（例如倾斜管道以完全排水以及避免死角）。当系统中包含过滤器时，应特别注意对其进行监测和维护。产出的水应符合相关药典的现行各论。\n\n根据上述已知信息，请将'Article 98: The materials of storage tanks and pipes for transport of purified water and water for injection should be non-toxical and corrosion resistant. The vent of storage tanks should be installed with non-fiber releasing hydrophobic microorganism retention filter. Dead legs should be avoided in the design and installation of pipelines.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九十八条 纯化水、注射用水储罐和输送管道所用材料应当无毒、耐腐蚀；储罐的通气口应当安装不脱落纤维的疏水性除菌滤器；管道的设计和安装应当避免死角、盲管。"
    },
    {
        "instruction":"已知信息：\n'closed system'可被翻译为：封闭的系统\n'isothermal method'可被翻译为：等温法\n'The period of time within which the quality of drugs can be guaranteed under certain storage conditions.'可被翻译为：药品在一定的贮存条件下，能够保证质量的期限。\n'Closed system - A system in which the product is not exposed to the surrounding environment. For example, this can be achieved by the use of bulk product holders (such as tanks or bags) that are connected to each other by pipes or tubes as a system, and where used for sterile products, the full system is sterilised after the connections are made. Examples of these can be (but are not limited to) large scale reusable systems, such as those seen in active substance manufacturing, or disposable bag and manifold systems, such as those seen in the manufacture of biological products. Closed systems are not opened until the conclusion of an operation. The use of the term “closed systems” in this Annex does not refer to systems such as RABS or isolator systems.'可被翻译为：密闭系统：产品未暴露于周围环境的系统。例如，对于散装产品的容器（例如罐或袋），可以使用彼此连 接的管道或管子作为一个系统，并且如果用于无菌产品，则在连接完成后对整个系统进行灭菌。密闭系统可以是（但不限于）大规模可重复使用系的统，例如原料药生产中所见到的系统，或一次性软袋和歧管系统，例如生物制品生产中所见到的系统。密闭系统在操作结束前不应被打开。本附录中使用的术语“密闭系统 ”并非指 RABS 或隔离器等系统。\n\n根据上述已知信息，请将'The maximum useful work that a closed system can perform under isothermal and isobaric conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"封闭系统在等温等压条件下可能做出的最大有用功。"
    },
    {
        "instruction":"已知信息：\n'(VI) Other circumstances in noncompliance with the laws and regulations.'可被翻译为：（六）其他不符合法律法规要求的。\n'9. Other circumstances that should not be passed as prescribed by laws and regulations.'可被翻译为：9.法律法规规定的其他不应当通过的情形。\n'(8) other circumstances in which applications shall not be approved according to laws and regulations.'可被翻译为：（八）法律法规规定的不应当批准的其他情形。\n'(5) other circumstances where administrative licensing shall be canceled as stipulated by laws and regulations.'可被翻译为：（五）法律、法规规定应当注销行政许可的其他情形。\n\n根据上述已知信息，请将'(VIII) Other circumstances in noncompliance with the laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（八）其他不符合法律法规要求的。"
    },
    {
        "instruction":"已知信息：\n'Article 41 If the lot release institution issues a false testing report when undertaking the lot release work, a penalty shall be imposed in accordance with Article 138 of the Drug Administration Law.'可被翻译为：第四十一条    批签发机构在承担批签发相关工作时，出具虚假检验报告的，依照《药品管理法》第一百三十八条的规定予以处罚。\n'Article 163 When undertaking testing for drug review and approval, a drug testing institute that issues a false certificate of analysis shall be punished in accordance with the provisions in Article 87 of the Drug Administration Law.'可被翻译为：第一百六十三条 药品检验所在承担药品审批所需要的检验工作时，出具虚假检验报告的，依照《药品管理法》第八十七条的规定处罚。\n'Article 41 If the lot release institution issues a false testing report when undertaking the lot release work, a penalty shall be imposed in accordance with Article 86 of the Drug Administration Law.'可被翻译为：第四十一条 批签发机构在承担批签发相关工作时，出具虚假检验报告的，依照《药品管理法》第八十六条的规定予以处罚。\n'Article 111 Where an applicant obtains the clinical trial permit or Drug Approval License by providing false certificates, data, documents or samples or by other fraudulent means during the drug registration process, the case shall be handled according to Article 123 of the Drug Administration Law.'可被翻译为：第一百一十一条 在药品注册过程中，提供虚假的证明、数据、资料、样品或者采取其他手段骗取临床试验许可或者药品注册等许可的，按照《药品管理法》第一百二十三条处理。\n\n根据上述已知信息，请将'Article 117 Where a drug testing institution undertaking testing for drug registration issues false testing reports, the case shall be handled according to Article 138 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百一十七条 药品检验机构在承担药品注册所需要的检验工作时，出具虚假检验报告的，按照《药品管理法》第一百三十八条处理。"
    },
    {
        "instruction":"已知信息：\n'The medium density of plasma lipoprotein is 0.95 ~ 1.006g\/cn? Is a lipoprotein. Is a very low density of plasma lipoproteins - lipoproteins, which can be determined by class separation of plasma lipoproteins by ultracentrifugation or electrophoresis.'可被翻译为：血浆脂蛋白中密度为0.95〜1.006g\/cn?的脂蛋白。是血浆脂蛋白中密度极低的-类脂蛋白，可用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。\n'Plasma lipoproteins have a density of 1.063-1.21g\/cm3. Is the higher density of the plasma lipoprotein - lipoprotein, light by ultracentrifugation or electrophoresis of plasma lipoprotein category separation to determine.'可被翻译为：血浆脂蛋白中密度为1.063-1.21g\/cm3的脂蛋白。是血浆脂蛋白中密度较高的-类脂蛋白，灯用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。\n'high density lipoprotein'可被翻译为：高密度脂蛋白\n'low density lipoprotein'可被翻译为：低密度脂蛋白\n\n根据上述已知信息，请将'The medium density of plasma lipoprotein is 1.006-1.063g\/cn? Is a lipoprotein. Is a lower density of plasma lipoprotein - lipoprotein, can be determined by ultra-fast centrifugation or electrophoresis of plasma lipoprotein class separation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"血浆脂蛋白中密度为1.006-1.063g\/cn?的脂蛋白。是血浆脂蛋白中密度较低的-类脂蛋白，可用超速离心或电泳法对血浆脂蛋白进行类别分离而确定。"
    },
    {
        "instruction":"已知信息：\n'Article 17 Drug manufacturers, distributors and medical institutions shall cooperate with drug regulatory departments, health administrative departments and ADR monitoring institutions in investigating ADRs or ADE clusters and provide materials necessary for the investigation.'可被翻译为：第十七条 药品生产、经营企业和医疗机构应当配合药品监督管理部门、卫生行政部门和药品不良反应监测机构对药品不良反应或者群体不良事件的调查，并提供调查所需的资料。\n'Article 19 Drug manufacturers, distributors and medical institutions shall spontaneously collect ADRs. When an ADR is known or discovered, it shall be recorded, analyzed and handled in detail, and a Form for ADR\/ADE Report (see Attached Table 1) shall be filled out and submitted.'可被翻译为：第十九条 药品生产、经营企业和医疗机构应当主动收集药品不良反应，获知或者发现药品不良反应后应当详细记录、分析和处理，填写《药品不良反应\/事件报告表》（见附表1）并报告。\n'Article 28 Drug regulatory departments of municipalities with districts and counties shall, upon knowing of ADE clusters, immediately conduct on-site investigation jointly with the health administrative departments at the same level, and promptly report the investigation results level by level to the provincial drug regulatory departments and health administrative departments.'可被翻译为：第二十八条 设区的市级、县级药品监督管理部门获知药品群体不良事件后，应当立即与同级卫生行政部门联合组织开展现场调查，并及时将调查结果逐级报至省级药品监督管理部门和卫生行政部门。\n'In 2019, the National ADR Monitoring Network received 1.514 million copies of ADR\/ADE Report Form. From 1999 to 2019, the National ADR Monitoring Network received an accumulative total of 15.19 million copies of the ADR\/ADE Report Form (See Figure 1).'可被翻译为：2019年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》151.4万份。1999年至2019年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1,519万份（图1）。\n\n根据上述已知信息，请将'Article 27 Drug manufacturers, distributors and medical institutions shall, upon knowing or discovering ADE clusters, immediately report to the county-level drug regulatory departments, health administrative departments and ADR monitoring institutions where they are located by telephone or by fax; when necessary, they may report directly to authorities at a higher level; at the same time, a Form for Basic Information of ADE Clusters (see Attached Table 2) and a Form for ADR\/ADE Report for each case shall be filled out promptly and submitted via the national ADR monitoring information network.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条 药品生产、经营企业和医疗机构获知或者发现药品群体不良事件后，应当立即通过电话或者传真等方式报所在地的县级药品监督管理部门、卫生行政部门和药品不良反应监测机构，必要时可以越级报告；同时填写《药品群体不良事件基本信息表》（见附表2），对每一病例还应当及时填写《药品不良反应\/事件报告表》，通过国家药品不良反应监测信息网络报告。"
    },
    {
        "instruction":"已知信息：\n'Article 12 China Food and Drug Administration shall, based on the demands of medical device standardization, establish technical committees on medical device standardization upon approval in accordance with laws.'可被翻译为：第十二条 国家食品药品监督管理总局根据医疗器械标准化工作的需要，经批准依法组建医疗器械标准化技术委员会。\n'Where the initiation proposal for the standards plan project involves two or more technical committees on medical device standardization, the Center for Medical Device Standardization Administration shall be responsible for coordinating and determining the leading technical committee which shall put forward the project initiation application for the standards plan project.'可被翻译为：涉及两个或者两个以上医疗器械标准化技术委员会的标准计划项目立项提案，应当由医疗器械标准管理中心负责协调，确定牵头医疗器械标准化技术委员会，并由其提出标准计划项目立项申请。\n'Article 21 The technical committee on medical device standardization that undertakes the medical device standards plan project shall be responsible for organizing the technical review of the proposed draft of the medical device standard. After the proposed draft passes the technical review, the draft for approval, implementation suggestions and relevant materials for medical device standards shall be submitted to the Center for Medical Device Standardization Administration for examination.'可被翻译为：第二十一条 承担医疗器械标准计划项目的医疗器械标准化技术委员会负责组织对医疗器械标准送审稿进行技术审查。审查通过后，将医疗器械标准报批稿、实施建议及相关资料报送医疗器械标准管理中心进行审核。\n'Article 17 The Center for Medical Device Standardization Administration shall solicit project initiation proposals for the formulation and revision of medical device standards openly in accordance with the medical device standards plan.'可被翻译为：第十七条 医疗器械标准管理中心应当根据医疗器械标准规划，向社会公开征集医疗器械标准制定、修订立项提案。\n\n根据上述已知信息，请将'Article 32 The technical committees on medical device standardization shall conduct follow-up assessment on standards implementation. The Center for Medical Device Standardization Administration shall make statistical analysis on the implementation of mandatory standards based on the follow-up assessment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十二条 医疗器械标准化技术委员会对标准的实施情况进行跟踪评价。医疗器械标准管理中心根据跟踪评价情况对强制性标准实施情况进行统计分析。"
    },
    {
        "instruction":"已知信息：\n'A defined list of values and terms to be used for transmitting information on a topic in a specific field or element in a message. A code list will usually \nconsist of a value (the code) and a label (the term being coded).'可被翻译为：值或术语的定义列表，用于某一特定领域的一个主题或一则消息中元素的信息传输。编码列表通常由值（编码）和标签（被编码的术语）组成。\n'A list of coded values that are used to structure the xml coding within a message. These values do not carry source data that is being transmitted by \nthe message, i.e. they do not represent data contained in the content of a message, but instead are used to identify components of an xml file for \nparsing by an IT system receiving transmitted message. Usually they are not entered by an end user (for instance through a drop-down pick list such as \nused for coded elements), but are instead used by an implementing IT system to construct an xml message for export and transmission.'可被翻译为：在消息中构建XML编码的编码值列表。这些值不携带消息发送的源数据，即不表示包含在消息内容中的数据，而旨在标识 XML 文件的组件，以供接收传输消息的 IT 系统进行解析。通常，它们不是由最终用户输入的（例如，借助用于编码元素的下拉选择列表等），而是被实施应用的IT系统构建的用于导出和传输的XML消息。\n'code list,technical'可被翻译为：编码列表，技术上\n'code list (general definition)'可被翻译为：编码列表（一般定义）\n\n根据上述已知信息，请将'A technical identifier that allows the transmission of coded values for which there is no ICH accessible master list of values. Namespaces identify the \nsource or domain of a coded value without providing the list of values to allow the code to be interpreted, i.e. namespaces identify the domain of an \nidentifier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种技术识别符，允许在无 ICH 可访问的主编码值列表时，传输编码值。命名空间对编码值的源或域进行标识，但不提供解读编码值的列表，即命名空间确认 \n标识符的域。"
    },
    {
        "instruction":"已知信息：\n'Article 59 Where drug regulatory departments at provincial level or above order to carry out re-evaluation, MAHs shall submit the re-evaluation plan and re-evaluation report to the corresponding drug regulatory departments and monitoring agencies before implementation of re-evaluation and within 30 days upon the completion of re-evaluation.'可被翻译为：第五十九条  省级以上药品监督管理部门责令开展再评价的，持有人应当在再评价实施前和再评价结束后30日内向相应药品监督管理部门及监测机构提交再评价方案和再评价报告。\n'Article 60 Monitoring agencies shall review the re-evaluation reports by MAHs and submit the review opinions to the corresponding drug regulatory departments.'可被翻译为：第六十条  监测机构对收到的持有人再评价报告进行审核，并将审核意见报相应的药品监督管理部门。\n'Article 55 In case of any of following situations, MAHs shall voluntarily carry out re-evaluation and take corresponding measures based on re-evaluation conclusions:'可被翻译为：第五十五条  有下列情形之一的，持有人应当主动开展再评价，并依据再评价结论，采取相应措施：\n'Article 61 Where drug regulatory departments organize to carry out medical device re-evaluation, the designated monitoring agencies shall formulate the re-evaluation plan, organize the implementation after the plan has been approved by the drug regulatory departments organizing re-evaluation, complete re-evaluation reports, and submit to corresponding drug regulatory departments.'可被翻译为：第六十一条  药品监督管理部门组织开展医疗器械再评价的，由指定的监测机构制定再评价方案，经组织开展再评价的药品监督管理部门批准后组织实施，形成再评价报告后向相应药品监督管理部门报告。\n\n根据上述已知信息，请将'Article 58 In case of voluntarily carrying out medical device re-evaluation, MAHs shall develop re-evaluation plan. Where control measures are required through re-evaluation, MAHs shall submit the re-evaluation report within 15 days upon the formation of re-evaluation conclusion. For medical devices approved by the NMPA to be registered or filed shall submit the report to national monitoring agencies; MAHs of other medical devices shall submit the report to the provincial monitoring agencies where MAHs locate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十八条  持有人主动开展医疗器械再评价的，应当制定再评价工作方案。通过再评价确定需要采取控制措施的，应当在再评价结论形成后15日内，提交再评价报告。其中，国家药品监督管理局批准注册或者备案的医疗器械，持有人应当向国家监测机构提交；其他医疗器械的持有人应当向所在地省级监测机构提交。"
    },
    {
        "instruction":"已知信息：\n'In order to strengthen the supervision and administration of recombinant collagen products and promote the high-quality development of the industry, NMPA has organized to formulate the Principles for the Classification Defining of Recombinant Collagen Products, which was issued on April 13,2021.'可被翻译为：为进一步加强重组胶原蛋白类医疗产品监督管理，推动产业高质量发展，国家药监局组织制定了《重组胶原蛋白类医疗产品分类界定原则》，于2021年4月13日予公布。\n'NMPA Announcement on Guidance for the Classification Defining of AI-Based Medical Software Products'可被翻译为：国家药监局关于发布人工智能医用软件产品分类界定指导原则的通告\n'In order to regulate the academic promotion of medical representatives and promote the healthy and orderly development of the pharmaceutical industry, NMPA has organized to formulate the Provisions for the Filing of Medical Representatives (Interim), which was issued on September 22, 2020.'可被翻译为：为规范医药代表学术推广行为，促进医药产业健康有序发展，国家药监局组织制定了《医药代表备案管理办法（试行）》，于2020年9月22日发布。\n'In order to strengthen the classification management of medical devices and standardize the dynamic adjustment of the Classification Catalogue for Medical Devices, according to the Regulations for the Supervision and Administration of Medical Devices and the Classification Rules for Medical Devices, NMPA has organized to formulate the Working Procedures for Dynamic Adjustment of Classification Catalogue for Medical Devices, which was issued on April 27.'可被翻译为：为加强医疗器械分类管理，规范《医疗器械分类目录》动态调整工作，根据《医疗器械监督管理条例》《医疗器械分类规则》，国家药监局组织制定了《医疗器械分类目录动态调整工作程序》，并于4月27日发布。\n\n根据上述已知信息，请将'In order to strengthen the supervision and administration of AI-based medical software products and promote the high-quality development of the industry, the NMPA has organized to formulate the Principles for the Classification Defining of AI-Based Medical Software Products, which was issued on July 1.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为进一步加强人工智能医用软件类产品监督管理，推动产业高质量发展，国家药监局组织制定了《人工智能医用软件产品分类界定指导原则》，并于7月1日发布。"
    },
    {
        "instruction":"已知信息：\n'Drugs that can lower blood ammonia. Mainly used to treat liver coma, drugs are glutamic acid, arginine, lactulose, etc.'可被翻译为：可以降低血氨的药物。主要用于治疗肝昏迷，药物有谷氨酸、精氨酸、乳果糖等。\n'A class of drugs used to treat hypothyroidism. Such as thyroid powder, iodoseronine, levothyroxine, etc.'可被翻译为：用于甲状腺功能低下症治疗的一类药物。如甲状腺粉、碘塞罗宁、左甲状腺素等。\n'A drug that corrects various low blood cells, resulting in different types of anemia. It can be divided into: ① to correct low red blood cells, such as iron, folic acid, vitamins or epotin; ② promote leukocyte proliferation, such as recombinant human granulocyte macrophage colony factors.'可被翻译为：纠正各种血细胞低下，所致不同类型贫血的药物。分为：①纠正红细胞低下，如铁剂、叶酸、维生素或依泊汀类；②促进白细胞增生，如重组人粒细胞巨噬细胞集落因子等。\n'A class of drugs that inhibit the release and action of pancreatic lipase. Such as aprotinin, octreotide, gabetate, etc., used in the treatment of acute pancreatitis.'可被翻译为：抑制胰脂酶释放和作用的一类药物。如抑肽酶、奥曲肽、加贝酯等，用于治疗急性胰腺炎。\n\n根据上述已知信息，请将'A class of drugs used to treat agranulocytosis. Includes drugs that promote leukocyte proliferation and metabolism, such as inosine, madder bisester, anisene, berberine, etc.; Some cytokines, such as mixostim, sargasstim, etc., can stimulate bone marrow to produce white blood cells for the adjuvant treatment of tumors.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于治疗粒细胞缺乏症的一类药物。包括促进白细胞增生和代谢的药物，如肌苷、茜草双酯、茴香烯、小檗胺等；一些细胞因子，如米格司亭、沙格司亭等可刺激骨髓生成白细胞，用于肿瘤的辅助治疗。"
    },
    {
        "instruction":"已知信息：\n'Mixing of two or more substances will result in a decrease in the melting point.'可被翻译为：两种或两种以上物质混合会导致熔点降低。\n'The property of interaction between two or more substances combined to form a compound.'可被翻译为：两种以上物质结合成化合物时互相作用的性质。\n'When two atoms are near each other, the repulsive force of the electrons outside the nucleus and the attraction to the nucleus are in equilibrium at half the distance between the nuclei.'可被翻译为：两个原子靠近时，核外电子的相互排斥力和与核的吸引力达到平衡时原子核间距离的一半。\n'When two cells or two mycelia with different traits are connected and anastomosed, two or more nuclei of different genetic types coexist in one cell or one mycelia.'可被翻译为：具有不同性状的两个细胞或两条菌丝相互联结吻合时，导致在一个细胞或一条菌丝中并存两种或两种以上不同遗传型的核。\n\n根据上述已知信息，请将'When two or more substances are mixed, there is no repulsive separation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"两种或两种以上物质混合时，不产生相斥分离的现象。"
    },
    {
        "instruction":"已知信息：\n'Article 121: Packaging materials should be issued for use only by designated personnel according to operation procedures. Measures should be taken to prevent mixups and errors to ensure the correct use of packaging materials for drug production.'可被翻译为：第一百二十一条 包装材料应当由专人按照操作规程发放，并采取措施避免混淆和差错，确保用于药品生产的包装材料正确无误。\n'Article 127: Outdated or obsolete printed packaging materials should be destroyed and its disposal recorded.'可被翻译为：第一百二十七条 过期或废弃的印刷包装材料应当予以销毁并记录。\n'Note: In case of any difference in interpretation between the English version and the Chinese version, the Chinese version shall prevail.'可被翻译为：注：如中英版本间出现任何歧义，则以中文版本为准\n'Article 122: Procedures for the design, review and approval of printed packaging materials should be established to ensure the contents printed are in line with what is approved by drug regulatory department. . Specific documents should be established, to store the original specimen of printed packaging materials approved with signature.'可被翻译为：第一百二十二条 应当建立印刷包装材料设计、审核、批准的操作规程，确保印刷包装材料印制的内容与药品监督管理部门核准的一致，并建立专门的文档，保存经签名批准的印刷包装材料原版实样。\n\n根据上述已知信息，请将'Article 123: When the version of a printed packaging material is changed, actions should be taken to ensure that the correct version is used for production. It is recommended that the obsolete stencil plates be withdrawn and destroyed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百二十三条 印刷包装材料的版本变更时，应当采取措施，确保产品所用印刷包装材料的版本正确无误。宜收回作废的旧版印刷模版并予以销毁。"
    },
    {
        "instruction":"已知信息：\n'Article 38 For a medical device which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the food and drug regulatory department may require its applicant to further complete relevant work after the product is put on market, and specify the requirements on the medical device registration certificate.'可被翻译为：第三十八条 对用于治疗罕见疾病以及应对突发公共卫生事件急需的医疗器械，食品药品监督管理部门可以在批准该医疗器械注册时要求申请人在产品上市后进一步完成相关工作，并将要求载明于医疗器械注册证中。\n'(3) For an in-vitro diagnostic reagent which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the registrant fails to complete items stated in medical device registration certificate within specified time as required by registration department upon approving such registration.'可被翻译为：（三）对用于罕见疾病以及应对突发公共卫生事件急需的体外诊断试剂，批准注册部门在批准上市时提出要求，注册人未在规定期限内完成医疗器械注册证载明事项的。\n'(III) For a medical device which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the registrant fails to complete items stated in medical device registration certificate within specified time as required by registration department upon approving such registration.'可被翻译为：（三）对用于治疗罕见疾病以及应对突发公共卫生事件急需的医疗器械，批准注册部门在批准上市时提出要求，注册人未在规定期限内完成医疗器械注册证载明事项的。\n'For an in-vitro diagnostic reagent which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, which requires cases number reduction or clinical trial exempt, the applicant shall apply for trial exempt and provide detailed reasons while submitting the application materials. The technical evaluation institution of food and drug regulatory departments shall perform comprehensive technical evaluation to the registration application materials, and inform the applicant by notice for supplements or corrections in the case that clinical trial is required.'可被翻译为：用于罕见疾病以及应对突发公共卫生事件急需的体外诊断试剂，要求减少临床试验病例数或者免做临床试验的，申请人应当在提交注册申报资料的同时，提出减免临床试验的申请，并详细说明理由。食品药品监督管理部门技术审评机构对注册申报资料进行全面的技术审评后予以确定，需要补充临床试验的，以补正资料的方式通知申请人。\n\n根据上述已知信息，请将'Article 48 For a in-vitro diagnostic reagent which is used to treat a rare disease or is urgently needed in dealing with emergent public health incidents, the food and drug regulatory department may require its applicant to further complete relevant work after the product is put on market, and specify the requirements on the medical device registration certificate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十八条 对用于罕见疾病以及应对突发公共卫生事件急需的体外诊断试剂，食品药品监督管理部门可以在批准该体外诊断试剂注册时要求申请人在产品上市后进一步完成相关工作，并将要求载明于医疗器械注册证中。"
    },
    {
        "instruction":"已知信息：\n'Routine process  controls  should be  implemented to  ensure  adherence to validated  filtration parameters. Results of critical process parameters should be included in the batch record, including but not limited to the minimum time taken to filter a known volume of bulk  solution and pressure difference across the filter. Any significant difference from critical parameters during manufacturing should be documented and investigated.'可被翻译为：应实施常规工艺控制以确保符合经验证的过滤参数。关键工艺参数的结果应包含在批记录中，包括但不限 于过滤已知体积的待包装溶液所需的最短时间和过滤器两端的压差。生产过程中与关键参数的任何显着差异都应记录并调查。\n'Bioburden samples should be taken from the bulk product and immediately prior to the final sterile filtration. In case where a redundant filtration set-up is used, it should be taken prior to the first filter. Systems for taking samples should be designed so as not to introduce contamination.'可被翻译为：生物负载样品应取自待包装产品，并在最终除菌过滤前即时取样。如果配备了冗余过滤装置，应在第一个过滤器之前进行取样。取样系统的设计不得引入污染。\n'The difference in pressure between two points, such as the pressure difference between an \nenclosed space and an independent reference point, or the pressure difference between two \nenclosed spaces.'可被翻译为：两点之间的压差，如安之间的压差\n封闭空间与独立参考点之间的压力差，或两者之间的压力差\n封闭的空间。\n'A filter made of hard neutral glass fired. Suitable for pre-filtration before a fine filter or membrane filter.'可被翻译为：用硬质中性玻璃烧制而成的过滤器。适用于精滤或膜滤器前的预滤。\n\n根据上述已知信息，请将'The time taken to filter a known volume of bulk solution and the pressure difference to be used across the filter.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"过滤已知体积的待包装溶液所需时间以及过滤器两端的压差。"
    },
    {
        "instruction":"已知信息：\n'If the quantity is below 20,000 vials (including), take 1 product for sampling; if the quantity is below 50,000 vials (including), take 2 products for sampling; if the quantity is below 100,000 vials (including), take 3 products for sampling; if the quantity is more than 100,000 vials, take additional 1 product for sampling for every additional 100,000 vials, and the odd less than 100,000 shall be counted as 100,000.'可被翻译为：2万支（瓶）以下（含2万支），抽样1件；5万支（瓶）以下（含5万支），抽样2件；10万支（瓶）以下（含10万支），抽样3件；10万支（瓶）以上，每增加10万支（瓶）加抽1件，不足10万支（瓶）以10万支（瓶）计。\n'If the injection is 100 ml to 1000 ml (including), take 1 product for sampling for every 10,000 vials, and the odd less than 10,000 vials shall be counted as 10,000. If the injection (including dialysate) is more than 1000 ml, take 1 product for sampling for every 5,000 vials (bags), and the odd less than 5,000 vials (bags)shall be counted as 5,000.'可被翻译为：100－1000毫升（含1000毫升）的注射液，每1万瓶抽样1件，不足1万瓶的按1万瓶计。1000毫升以上的注射液（含透析液），每5000瓶（袋）抽样1件，不足5000瓶（袋）的按5000瓶计。\n'If the quantity is less than 10, take 1 product for sampling; if the quantity is 11 to 50, take additional 1 product for sampling for every additional 10, and the odd less than 10 shall be counted as 10; if the quantity is 51 to 100, take additional 1 product for sampling for every additional 20, and the odd less than 20 shall be counted as 20; if the quantity is more than 101, take additional 1 product for sampling for every additional 50, and the odd less than 50 shall be counted as 50; if the quantity is more than 1001, take additional 1 product for sampling for every additional 100, and the odd less than 100 shall be counted as 100;'可被翻译为：10件以内，抽样1件；11件－50件，每增加10件加抽1件，不足10件者以10件计；51件－100件，每增加20件加抽1件，不足20件者以20件计；101件以上，每增加50件加抽1件，不足50件者以50件计；1001件以上，每增加100件加抽1件，不足100件者以100件计；\n'3. If the products within one package are 1 (including) to 5 kg, take 1 product for sampling for every 50 kg, and the odd less than 50 kg shall be counted as 50 kg;'可被翻译为：3．药品包装为1－5公斤的（含1公斤），每50公斤抽样1件，不足50公斤者以50公斤计；\n\n根据上述已知信息，请将'Take 1 product for sampling for every 20,000 boxes (vials), and the odd less than 20,000 boxes (vials) shall be counted as 20,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"每2万盒（瓶），抽样一件，不足2万盒（瓶）的按2万盒（瓶）计。"
    },
    {
        "instruction":"已知信息：\n'(1) failing to appoint a dedicated person in charge of quality to independently undertake drug quality management and supervise GMP implementation;'可被翻译为：（一）未配备专门质量负责人独立负责药品质量管理、监督质量管理规范执行；\n'(1) appoint a dedicated quality responsible person to independently undertake responsibilities for drug quality management;'可被翻译为：（一）配备专门质量负责人独立负责药品质量管理；\n'(2) appoint a dedicated qualified person to independently fulfill responsibilities for drug marketing release;'可被翻译为：（二）配备专门质量受权人独立履行药品上市放行责任；\n'(3) supervise the daily operation of the quality management system and guarantee the in-process control and quality control, and authenticity of records and data;'可被翻译为：（三）监督质量管理体系正常运行，保证药品生产过程控制、质量控制以及记录和数据真实性；\n\n根据上述已知信息，请将'(1) appoint a qualified dedicated person who is independently in charge of drug quality management, to supervise the implementation of the GMP, ensure suitable in-process control and quality control and guarantee the compliance of drugs with national drug standards and drug registration specifications;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）配备专门质量负责人独立负责药品质量管理，监督质量管理规范执行，确保适当的生产过程控制和质量控制，保证药品符合国家药品标准和药品注册标准；"
    },
    {
        "instruction":"已知信息：\n'Article 8 The drug regulatory department under the State Council shall be responsible for drug administration nationwide. The relevant departments under the State Council shall be responsible for the related administrative work within the scope of their duties. The drug regulatory department under the State Council shall cooperate with relevant departments under the State Council in implementing national drug development programs and policies.'可被翻译为：第八条 国务院药品监督管理部门主管全国药品监督管理工作。国务院有关部门在各自职责范围内负责与药品有关的监督管理工作。国务院药品监督管理部门配合国务院有关部门，执行国家药品行业发展规划和产业政策。\n'Article 41 The competent health department under the State Council shall formulate the national immunization program; vaccine varieties in the national immunization program shall be proposed by the competent health department under the State Council jointly with the financial department under the State Council, and released upon approval by the State Council.'可被翻译为：第四十一条 国务院卫生健康主管部门制定国家免疫规划；国家免疫规划疫苗种类由国务院卫生健康主管部门会同国务院财政部门拟订，报国务院批准后公布。\n'The drug regulatory department under the State Council, in conjunction with the health department under the State Council, shall organize a Pharmacopoeia Commission, which is responsible for the formulation and revision of national drug standards.'可被翻译为：国务院药品监督管理部门会同国务院卫生健康主管部门组织药典委员会，负责国家药品标准的制定和修订。\n'The drug regulatory department under the State Council jointly with relevant departments under the State Council shall formulate the GLP and GCP.'可被翻译为：药物非临床研究质量管理规范、药物临床试验质量管理规范由国务院药品监督管理部门会同国务院有关部门制定。\n\n根据上述已知信息，请将'Article 8 The drug regulatory department under the State Council shall be responsible for the administration of vaccines nationwide. The competent health department under the State Council shall be responsible for the administration of immunization nationwide. Other relevant departments under the State Council shall be responsible for the administration of vaccines within the scope of their respective responsibilities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八条 国务院药品监督管理部门负责全国疫苗监督管理工作。国务院卫生健康主管部门负责全国预防接种监督管理工作。国务院其他有关部门在各自职责范围内负责与疫苗有关的监督管理工作。"
    },
    {
        "instruction":"已知信息：\n'12.37. The number of analysts involved in the transfer, from both SU and RU, should be defined and justified.'可被翻译为：从SU转移至RU过程中所涉及的化验员的数量应予以规定并说明理由。\n'5.6. The technology transfer should be managed by responsible persons from each site (the SU and RU) and any other units with the appropriate technical and quality oversight. A technology transfer team may be appointed with identified and documented responsibilities.'可被翻译为：技术转移应由来自双方（SU和RU）的负责人，和其它技术和质量监管部门的人进行管理。可指定一个技术转移小组，并书面说明其职责。\n'4.3. The assessment should be done by a team of appropriately qualified persons with knowledge and experience in the field of GxP and the activity to be transferred. It is recommended that the quality units of the SU and RU participate in this activity.'可被翻译为：应由在GXP领域和准备转移的活动方面具备恰当资质和知识经验的人员组成小组进行评估。建议SU和RU质量部分参与该活动。\n'5.3. All the necessary activities to be executed during the technology transfer project should be identified, organized and documented at the start of the project. Responsibilities across the SU, RU, sponsor and Marketing Authorization Holder (MAH) should be defined in writing.'可被翻译为：在技术转移项目期间要执行的所有必要活动均应在项目之初即进行识别、组织和记录。应书面规定SU、RU、申办人和上市许可持有人（MAH）的相关职责。\n\n根据上述已知信息，请将'6.1. The SU and RU should each have an appropriately designed, clearly defined and documented quality system.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"SU与RU应分别具备经过恰当设计、清楚规定和文件化的质量体系。"
    },
    {
        "instruction":"已知信息：\n'A mark affixed to the package of a drug to indicate the name, dosage form, dosage, usage, and other information.'可被翻译为：贴于药品包装上用于指示药物名称、剂型、装量、用法用量等信息的标志。\n'Article 49 The drug package shall include a label together with a package insert as required by regulations.'可被翻译为：第四十九条 药品包装应当按照规定印有或者贴有标签并附有说明书。\n'The online drug retailers shall not directly display the package and label of prescription drugs on the main page and the home page of prescription drug sales. Before the prescription examination is passed, the enterprises shall not display the package inserts and other relevant information, or provide services related to the purchase of prescription drugs.'可被翻译为：药品网络零售企业在处方药销售主页面、首页面不得直接公开展示处方药包装、标签等信息。通过处方审核前，不得展示说明书等信息，不得提供处方药购买的相关服务。\n'Article 35 A label shall be attached to the minimum sales unit of cosmetics in Chinese. The label contents shall be consistent with the sample manuscript of the product label in registration or filing documents of the cosmetics.'可被翻译为：第三十五条 化妆品的最小销售单元应当有中文标签。标签内容应当与化妆品注册或者备案资料中产品标签样稿一致。\n\n根据上述已知信息，请将'Article 4    A drug label shall be printed on or affixed to the drug package, and no other written words, audio and\/or visual materials or other information are attached to introduce or publicize the product or the enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四条 药品包装必须按照规定印有或者贴有标签，不得夹带其他任何介绍或者宣传产品、企业的文字、音像及其他资料。"
    },
    {
        "instruction":"已知信息：\n'(IV) Post-marketing change approval documents;'可被翻译为：（四）上市后变更的批准证明性文件；\n'Drug approval numbers shall not change in the event of a post-marketing change of registration items.'可被翻译为：药品批准文号，不因上市后的注册事项的变更而改变。\n'(IV) the packaging and labeling of drugs to be imported is inconsistent with the documents; and'可被翻译为：（四）进口药品包装及标签与单证不符的；\n'(II) Drug approval documents;'可被翻译为：（二）药品批准证明文件；\n\n根据上述已知信息，请将'(IV)  Post-marketing change approval documents\/filing documents;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）上市后变更的批准或者备案文件；"
    },
    {
        "instruction":"已知信息：\n'(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the in-vitro diagnostic reagent to be sold on the market.'可被翻译为：（一）申请人对拟上市销售体外诊断试剂的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；\n'(I) Cognitional changes of the safety and effectiveness of the medical device according to the development of scientific research;'可被翻译为：（一）根据科学研究的发展，对医疗器械的安全、有效有认识上改变的；\n'Article 3 Medical device registration refers to the prescribed procedures conducted by the food and drug regulatory department upon an application submitted by the registration applicant to decide whether the medical device to be marketed can be sold based on a comprehensive evaluation of the research and results of its safety and effectiveness.'可被翻译为：第三条 医疗器械注册是食品药品监督管理部门根据医疗器械注册申请人的申请，依照法定程序，对其拟上市医疗器械的安全性、有效性研究及其结果进行系统评价，以决定是否同意其申请的过程。\n'Article 4 In-vitro diagnostic reagent registration refers to the prescribed procedures conducted by the food and drug regulatory department upon an application submitted by the registration applicant to decide whether the medical device to be marketed can be sold based on a comprehensive evaluation of the research and results of its safety and effectiveness.'可被翻译为：第四条 体外诊断试剂注册是食品药品监督管理部门根据注册申请人的申请，依照法定程序，对其拟上市体外诊断试剂的安全性、有效性研究及其结果进行系统评价，以决定是否同意其申请的过程。\n\n根据上述已知信息，请将'(I) The research conducted by the applicant and its result cannot prove the safety and effectiveness of the medical device to be sold on the market.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）申请人对拟上市销售医疗器械的安全性、有效性进行的研究及其结果无法证明产品安全、有效的；"
    },
    {
        "instruction":"已知信息：\n'Prior to product testing, the exterior of the unit container should be disinfected before transfer to the work station or HEPA filtered laminar flow hood. If the product container is not hermetically sealed do not soak the product container in a disinfection solution which may allow the ingress of bactericidal solution into the product.'可被翻译为：产品测试前，单元容器的外部应在转移到工作站或HEPA过滤层流罩之前进行消毒。 如果产品容器未密封，请勿将产品容器浸泡在消毒溶液中，否则灭菌溶液可能会渗 入产品中。\n'2. Swab corner crevices inside the HEPA Filtered work station.'可被翻译为：擦拭取样有 HEPA 过滤的工作站内的角落缝隙\n'The work area for opening the unit container should be either a HEPA filtered laminar flow hood or an alternate controlled environment to safeguard the exposure of open media and product to either environmental or personnel contamination.'可被翻译为：打开单元容器的工作区应该是一个 HEPA 过滤层流罩或一个替代的受控环境，以保 护打开的介质和产品暴露在环境或人员污染中。\n'Within a HEPA filtered biosafety cabinet or equivalent outside the clean room, streak turbid tubes onto Modified Soybean-Casein Digest Medium [SCD broth + 1.5% agar] (Modified SCDA) or other non-selective agar plate.'可被翻译为：在有HEPA过滤的生物案例柜内或等同的洁净室外，将混浊试管划线接种至改良大豆 酪蛋白消化培养基【SCD 肉汤+1.5%琼脂】（改良 SCDA）或其它非选择性琼脂平板。\n\n根据上述已知信息，请将'5. Swab tables or benches within the controlled room where product container(s) or post sterilized product may be held outside of the HEPA filtered workstation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"擦拭取样控制室内但不在 HEPA 过滤工作台内，可能会放置产品容器或消毒后的产品的桌子或长凳"
    },
    {
        "instruction":"已知信息：\n'A room (or an area) with defined environmental control of particulate and microbial contamination, constructed, outfitted and used in such a way as to reduce the introduction, generation and retention of contaminants within the room or area.'可被翻译为：需要对环境中尘粒及微生物数量进行控制的房间（区域），其建筑结构、装备及其使用应当能够减少该区域内污染物的引入、产生和滞留。\n'Cleanroom - A room designed, maintained, and controlled to prevent particle and microbial contamination of drug\nproducts. Such a room is assigned and reproducibly meets an appropriate air cleanliness level.'可被翻译为：洁净室：一种经设计、维护和控制以防止微粒和微生物污染药品的房间。这样的房间是指定的，可持续性地符合适当的空气洁净水平。\n'Airlock  -  An  enclosed  space  with  interlocked  doors,  constructed  to  maintain  air  pressure  control  between adjoining rooms (generally with different air cleanliness standards). The intent of an airlock is to preclude ingress\nof particle matter and microorganism contamination from a lesser controlled area.'可被翻译为：气锁：带互锁门的封闭空间，其构建目的是维持相邻房间（通常具有不同的空气洁净标准）之间的气压控制。气锁的目的是预防从较低级别控制区域引入微粒和微生物污染。\n'1.An area within the facility in which specific environmental facility conditions and procedures are defined, controlled, and monitored to prevent degradation or cross-contamination of the product.\n2.An area within the facility in which specific procedures and environmental parameters, including viable and nonviable particles, are defined, controlled and monitored to prevent degradation, contamination or cross-contamination of the product.'可被翻译为：1.设施内的一个区域，在该区域内，特定的环境设施条件和程序被定义、控制和监测，以防止产品的降解或交叉污染。\n2.设施内特定程序和环境参数(包括活的和非活的颗粒)被定义、控制和监测以防止产品降解、污染或交叉污染的区域。\n\n根据上述已知信息，请将'1.A room or area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area.\n2.A room designed, maintained and controlled to prevent particle and microbial contamination of drug products. Such a room is assigned and reproducibly meets an appropriate air cleanliness level.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.对微粒和微生物污染有明确环境控制的房间或区域，其建造和使用方式可减少该区域内污染物的引入、产生和滞留。\n2.为防止药品被颗粒和微生物污染而设计、维护和控制的房间。这样的房间是指定的，并且可重复地满足适当的空气洁净度水平。"
    },
    {
        "instruction":"已知信息：\n'3. Dedicated facilities (e.g. a dedicated air handling system) and equipment must be used in production of β-lactam products and sex hormonal contraceptives, and their production areas must be strictly segregated from those of other products.'可被翻译为：（三）生产β－内酰胺结构类药品、性激素类避孕药品必须使用专用设施（如独立的空气净化系统）和设备，并与其他药品生产区严格分开。\n'2. Dedicated and self-contained premises, facilities and equipment must be used for the production of products with particular properties such as highly sensitizing products (e.g. penicillins) or biological preparations (e.g. Bacillus Calmette Guerin vaccine or any other products derived from live microorganisms). Dust generating operation areas in penicillin production should maintain relatively negative pressure, the exhaust air should be decontaminated as required, and the air outlet should be far away from the air inlet of other air-handling systems.'可被翻译为：（二）生产特殊性质的药品，如高致敏性药品（如青霉素类）或生物制品（如卡介苗或其他用活性微生物制备而成的药品），必须采用专用和独立的厂房、生产设施和设备。青霉素类药品产尘量大的操作区域应当保持相对负压，排至室外的废气应当经过净化处理并符合要求，排风口应当远离其他空气净化系统的进风口。\n'Article 67: Experimental animal houses should be well isolated from other areas, and their design and construction should comply with relevant regulatory requirements. There should be dedicated air handling facilities and separate entrance for animal access.'可被翻译为：第六十七条 实验动物房应当与其他区域严格分开，其设计、建造应当符合国家有关规定，并设有独立的空气处理设施以及动物的专用通道。\n'2. Facilities and Equipment System'可被翻译为：设施和设备系统\n\n根据上述已知信息，请将'4. Dedicated facilities (e.g. a dedicated air handling system) and equipment should be used for some hormonal, cytotoxic and highly potent chemical products. In exceptional cases, the principle of campaign working in the same facilities and equipment can be accepted provided that specific precautions are taken and the necessary validations are made.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）生产某些激素类、细胞毒性类、高活性化学药品应当使用专用设施（如独立的空气净化系统）和设备；特殊情况下，如采取特别防护措施并经过必要的验证，上述药品制剂则可通过阶段性生产方式共用同一生产设施和设备。"
    },
    {
        "instruction":"已知信息：\n'A class of pharmaceutical preparations that use certain physical or chemical methods to kill all living microbial propagules and buds.'可被翻译为：采用某种物理或化学方法杀灭所有活的微生物繁殖体和芽抱的一类药物制剂。\n'aseptic sampling techniques'可被翻译为：无菌取样技术\n'Personnel are critical to the maintenance of asepsis in the controlled environment. Thorough training in aseptic techniques is required.'可被翻译为：人员对于在受控环境中保持无菌至关重要。需要进行彻底的无菌技术培训。\n'For non-filterable formulations, any additional aseptic steps should be assessed.'可被翻译为：对于不可过滤的剂型，所有额外的无菌步骤应经过评估。\n\n根据上述已知信息，请将'A class of pharmaceutical preparations prepared by aseptic manipulation or aseptic techniques that do not contain any living microbial propagules or buds.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"采用无菌操作法或无菌技术制备的不含任何活的微生物繁殖体和芽抱的一类药物制剂。"
    },
    {
        "instruction":"已知信息：\n'Article 75 Where, for a registered in-vitro diagnostic reagent, there exists a revocation situation in accordance with laws and regulations, or a registrant applies for revocation before the expiration of a registration certificate, the food and drug regulatory department shall revoke the registration certificate according to law and disclose to the society.'可被翻译为：第七十五条 已注册的体外诊断试剂有法律、法规规定应当注销的情形，或者注册证有效期未满但注册人主动提出注销的，食品药品监督管理部门应当依法注销，并向社会公布。\n'Article 54 Where it is required to extend the period of validity of the medical device registration certificate, the registrant shall submit application for registration renewal to the food and drug regulatory department six months before the expiration of period of validity and submit application documents according to corresponding requirements.'可被翻译为：第五十四条 医疗器械注册证有效期届满需要延续注册的，注册人应当在医疗器械注册证有效期届满6个月前，向食品药品监督管理部门申请延续注册，并按照相关要求提交申报资料。\n'Article 64 Where it is required to extend the period of validity of the medical device registration certificate, the registrant shall submit application for registration renewal to the food and drug regulatory department six months before the expiration of period of validity and submit application documents according to corresponding requirements.'可被翻译为：第六十四条 医疗器械注册证有效期届满需要延续注册的，注册人应当在医疗器械注册证有效期届满6个月前，向食品药品监督管理部门申请延续注册，并按照相关要求提交申报资料。\n'Article 72 Where, in violation of the Provisions, a registration alteration of permission items for a medical device is not performed according to law, punishments shall be imposed according to the situation concerning not obtaining a medical device registration certificate in the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第七十二条 违反本办法规定，未依法办理医疗器械注册许可事项变更的，按照《医疗器械监督管理条例》有关未取得医疗器械注册证的情形予以处罚。\n\n根据上述已知信息，请将'Article 65 Where, for a registered medical device, there exists a revocation situation in accordance with laws and regulations, or a registrant applies for revocation before the expiration of a registration certificate, the food and drug regulatory department shall revoke the registration certificate according to law and disclose to the society.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十五条 已注册的医疗器械有法律、法规规定应当注销的情形，或者注册证有效期未满但注册人主动提出注销的，食品药品监督管理部门应当依法注销，并向社会公布。"
    },
    {
        "instruction":"已知信息：\n'A multidimensional measure of health status. These include physical changes, functional changes, social activity, cognition, emotion, sleep and rest, energy and vitality, health awareness, and overall life satisfaction.'可被翻译为：健康状态的一种多维测量指标。包括生理变化、功能变化、社会活动、认知、情感、睡眠与休息、精力与活力、健康意识以及总的生活满意度等。\n'A method of measuring health status using four dimensions of mobility, physical activity, social ability, and disease symptoms.'可被翻译为：用行动能力、躯体活动能力、社交能力及疾病症状四个维度测量健康状态的一种方法。\n'A standardized tool for measuring health status using multiple dimensions such as sensory and communication skills, well-being, self-care ability, pain and discomfort, learning ability, and physical activity ability.'可被翻译为：用感官和沟通能力、幸福感、自我照顾能力、疼痛与不适、学习能力、身体活动能力等多个维度测量健康状态的一种标准化工具。\n'The degree to which an individual prefers a particular state of health or health outcome.'可被翻译为：个人对某一健康状态或健康产出的偏好程度。\n\n根据上述已知信息，请将'A measure of a patient's health outcome. The measurement extends beyond traditional mortality and morbidity to include measures of multiple dimensions such as physiology, functioning, social activity, cognition, emotion, sleep and rest, energy and activity, perceived health, and overall survival satisfaction.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种测量患者健康结果的指标。其测量范围超越了传统的死亡率和患病率，还包括生理、功能、社会活动、认知、情感、睡眠和休息、精力和活动、健康感知和总体生存满意度等多个维度的测量。"
    },
    {
        "instruction":"已知信息：\n'Article 36    Drug manufacturers and distributors in violation of Article 14 of the Provisions shall be punished pursuant to the provisions in Article 82 of the Drug Administration Law.'可被翻译为：第三十六条 药品生产、经营企业违反本办法第十四条规定的，按照《药品管理法》第八十二条的规定予以处罚。\n'Article 33    Any drug manufacturer or distributor, in violation of Article 8 of the Provisions, storing drugs on the premises not approved by the drug regulatory departments，shall be punished pursuant to the provisions in Article 74 of the Regulations for Implementation of the Drug Administration Law.'可被翻译为：第三十三条 药品生产、经营企业违反本办法第八条规定，在经药品监督管理部门核准的地址以外的场所储存药品的，按照《药品管理法实施条例》第七十四条的规定予以处罚。\n'Article 37    Where a drug distributor, in violation of Article 16 of the Provisions, purchases or sells pharmaceutical preparations dispensed by medical institutions, it shall be punished pursuant to the provisions in Article 80 of the Drug Administration Law.'可被翻译为：第三十七条 违反本办法第十六条规定，药品经营企业购进或者销售医疗机构配制的制剂的，按照《药品管理法》第八十条规定予以处罚。\n'Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to store drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be punished pursuant to the provisions in Article 79 of the Drug Administration Law. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.'可被翻译为：药品生产、批发企业违反本办法第十九条规定，未在药品说明书规定的低温、冷藏条件下储存药品的，按照《药品管理法》第七十九条的规定予以处罚；有关药品经依法确认属于假劣药品的，按照《药品管理法》有关规定予以处罚。\n\n根据上述已知信息，请将'Article 43    Any illegal purchase of drugs, in violation of Article 22 of the Provisions, shall be punished pursuant to the provisions in Article 73 of the Drug Administration Law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十三条 违反本办法第二十二条规定非法收购药品的，按照《药品管理法》第七十三条的规定予以处罚。"
    },
    {
        "instruction":"已知信息：\n'The DNA sequence corresponding to mature mRNA, rRNA, or tRNA molecules in eukaryotic genes. Is the coding sequence.'可被翻译为：真核生物基因中与成熟mRNA、rRNA或tRNA分子相对应的DNA序列。为编码序列。\n'The expression vector which contains the coding sequence of the recombinant protein and the elements necessary for its expression.'可被翻译为：是含有重组蛋白的编码序列和它表达所需元件的表达载体。\n'(1) A specific nucleotide sequence in the operon that binds to the repressor. Controls the transcriptional activity of adjacent structural genes. (2) Genes in operons that are adjacent to one or a group of structural genes and control their transcription.'可被翻译为：(1)操纵子中与阻遏物结合的一段特定核昔酸序列。对相邻的结构基因的转录活动有控制作用。(2)操纵子中与一个或一组结构基因相邻并控制它们转录的基因。\n'The finished formulated product; it may be freeze-dried and contain excipients, which should have been shown not to affect stability adversely.'可被翻译为：制剂成品;它可能是冷冻干燥的，含有辅料，这些辅料应该被证明不会对稳定性产生不利影响。\n\n根据上述已知信息，请将'Non-coding nucleotide sequences that are adjacent to the 5' and 3' end of the coding sequence of the product which contain important elements that affect the transcription, translation, or stability of the coding sequence. These regions include, e.g., promoter, enhancer, and splicing sequences and do not include origins of replication and antibiotic resistance genes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是与产品编码序列的5'和3'末端相邻的非编码核苷酸序列,含有影响编码序列转录、翻译和稳定性的重要元件,包括启动子、增强子和剪接序列等区域,但不包括复制起点和抗生素耐药基因区域。"
    },
    {
        "instruction":"已知信息：\n'If the results do not meet this criterion, 4 additional tests (2 reference and 2 test) of 6 cells each should be performed, resulting in 12 additional slope determinations for each product tested. The T\/R slope ratios for all 18 slopes for each product tested are determined. All 324 individual T\/R slope ratios are ordered from the lowest to the highest. To pass this second stage testing, the 110th and 215th slope ratios, representing the 90% confidence interval, must be within the range of 75%–133.33%.'可被翻译为：如果结果不符合此标准，则应执行4个额外的测试(2个参考和2个测试)，每个测试6个单元，从而为每个测试产品进行12个额外的斜率测定。确认了每个测试样品的所有18个T\/R斜率比率。所有324个单独的T\/R斜率比从低到高排序。为了通过第二阶段的测试，代表90%置信区间的第110和215斜率比率必须在75%-133.33%的范围内。\n'The T\/R slope ratios are calculated for each test-to-reference combination of all pairs of T\/R slopes. This procedure is facilitated with a table where the values for the slopes for T are listed down the left side of the table and the slopes for R are listed across the top of the table. The T\/R slope ratios are then determined. See Table 1.'可被翻译为：计算每次试验相对于参考坡度的T\/R斜率比。该程序通过一个表格来实现，其中测试批次和参考批次的斜率值分别列在表格的左侧和顶部。然后确定T\/R斜率。见表1。\n'IVRT is commonly used to assess the sameness of a drug product after postapproval changes. Because common testing artifacts, such as air bubbles and membrane defects, yield measurements that are not normally distributed, a nonparametric statistical technique is used to evaluate the test results. The Mann-Whitney U test is used to calculate the 90% confidence interval for the ratio of the slopes between the test and the reference batches. This is illustrated by the following example in which the initial drug product batch is referred to as the reference batch (R) and the changed or subsequent batch is referred to as the test batch (T). The individual amounts of drug released from R are plotted versus the square root of time, and the resulting slopes are determined. Those are the reference slopes. The process is repeated for the test batch (T).'可被翻译为：IVRT通常用于评估药品批准后变更后的一致性。由于常见的测试工件，如气泡和膜缺陷，产生的测量结果不是正态分布的，因此使用非参数统计技术来评估测试结果。Mann-Whitney U检验用于计算试验批次与参考批次之间斜率之比的90%置信区间。下面的例子说明了这一点，其中初始药品批次被称为参考批次(R)，改变或后续批次被称为测试批次(T)。从R中释放的单个药物量与时间的平方根相对应，并确定了结果斜率。这些是参考斜率。对测试批次(T)重复此过程。\n'Absorbance =-lgr,r is the ratio of transmitted light intensity to incident light intensity.'可被翻译为：吸光度=-lgr,r为透射光强与入射光强的比值。\n\n根据上述已知信息，请将'After the T\/R ratios have been calculated, they are ordered from the lowest to the highest. The 8th and 29th T\/R ratios are identified and converted to percent (multiplied by 100). These values represent the 90% confidence interval for the ratio of test to reference release rates. To pass first stage testing, those ratios must be within the range of 75%–133.33%.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在计算出T\/R比后，它们按从低到高的顺序排列。识别第8和第29个T\/R比率并将其转换为百分比（乘以100）。这些值代表试验与参考释放率之比的90%置信区间。要通过第一阶段测试，这些比率必须在75%-133.33%的范围内。"
    },
    {
        "instruction":"已知信息：\n'(V) Any drug identified with suspicious issues shall be locked and recorded in the computer system in time and notified to the quality management department for disposal;'可被翻译为：（五）发现有问题的药品应当及时在计算机系统中锁定和记录，并通知质量管理部门处理。\n'Article 162 Enterprises shall regularly inspect the drugs on display or in storage, with the focus on dismantled drugs, perishable drugs, drugs approaching the expiry date, drugs that have been displayed for a long time and Prepared Slices. Any drugs identified with suspected quality issues shall be promptly withdrawn, the sales shall be discontinued, and quality management personnel shall confirm and take corresponding measures, and also keep the relevant records.'可被翻译为：第一百六十二条 企业应当定期对陈列、存放的药品进行检查，重点检查拆零药品和易变质、近效期、摆放时间较长的药品以及中药饮片。发现有质量疑问的药品应当及时撤柜，停止销售，由质量管理人员确认和处理，并保留相关记录。\n'Article 94 For the ex-warehousing, the drugs shall be checked against the sales records. In case of the following situations identified, ex-warehousing shall not be allowed and such situations shall be reported to the quality management department for handling:'可被翻译为：第九十四条 出库时应当对照销售记录进行复核。发现以下情况不得出库，并报告质量管理部门处理：\n'Article 101 For the transportation of drugs, appropriate means of transport shall be selected in light of the packaging and quality characteristics of the drugs and according to such factors as vehicle conditions, roads and weather, and corresponding measures shall be taken to prevent damage and contamination.'可被翻译为：第一百零一条 运输药品，应当根据药品的包装、质量特性并针对车况、道路、天气等因素，选用适宜的运输工具，采取相应措施防止出现破损、污染等问题。\n\n根据上述已知信息，请将'Article 87 For drugs likely to have quality issues, measures of suspending the sales shall be taken immediately, and the drugs shall be locked in the computer system and reported to the quality management department for confirmation. With respect to drugs with quality issues, the following measures shall be taken:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十七条 对质量可疑的药品应当立即采取停售措施，并在计算机系统中锁定，同时报告质量管理部门确认。对存在质量问题的药品应当采取以下措施："
    },
    {
        "instruction":"已知信息：\n'An enclosure capable of being subject to reproducible interior biodecontamination, with an internal work zone meeting grade A conditions that provide uncompromised continuous isolation of its interior from the external environment (for example, surrounding cleanroom air and personnel). There are two major types of isolators:\n•□Closed isolator systems exclude external contamination of the isolator’s interior by accomplishing material transfer via aseptic connection to auxiliary equipment rather than use of openings to the surrounding environment. Closed systems remain sealed throughout operations.\n•□Open isolator systems are designed to allow for the continuous or semicontinuous ingress or egress of materials during operations through one or more openings. Openings are engineered (for example, using continuous overpressure) to exclude the entry of external contaminant into the isolator.'可被翻译为：能够进行可重复的内部生物净化的外壳，其内部工作区域满足A级条件，可将其内部与外部环境(例如，周围洁净室空气和人员)不受损害地连续隔离。隔离器主要有两种类型:\n•□闭式隔离器系统通过与辅助设备的无菌连接来完成物料转移，而不是使用对周围环境的开口，从而排除隔离器内部的外部污染。封闭系统在整个操作过程中保持密封。\n•□开放式隔离系统的设计允许物料在操作期间通过一个或多个开口连续或半连续地进入或流出。开口设计(例如，使用连续超压)以排除外部污染物进入隔离器。\n'Closed isolator  systems  exclude external  contamination of the  isolator's  interior by accomplishing material  transfer via aseptic connection to auxiliary equipment, rather than use of openings to the surrounding environment.Closed systems remain sealed throughout operations.'可被翻译为：密闭隔离器系统通过与辅助设备的无菌连接而不是对周围环境开放来完成物料转移，从而阻断外部污染物进入隔离器内部。密闭系统在整个操作中保持密封。\n'(ii) When an individual executes one or more signings not performed during a single, continuous period of controlled system access, each signing shall be executed using all of the electronic signature components.'可被翻译为：当一个体不是对单个受控系统兼续访问时签署一个或多个签名，则每个签名应包含电子签名的所有组成部分。\n'Isolator - An enclosure capable of being subject to reproducible interior bio -decontamination, with an internal work zone meeting grade A conditions that provides uncompromised, continuous isolation of its interior from the external environment (e.g. surrounding cleanroom air and personnel). There are two major types of isolators:'可被翻译为：隔离器：能够进行可重复的内部生物净化的外壳，内部工作区符合 A 级条件，提供其内部环境与外部环境（例如周围洁净室空气和人员）的无间断的持续隔离。隔离器主要有两种类型：\n\n根据上述已知信息，请将'Open isolator systems are designed to allow for the continuous or semi-continuous ingress and\/or egress of materials  during  operations  through  one  or  more  openings.  Openings  are  engineered  (e.g.  using  continuous overpressure) to exclude the entry of external contaminant into the isolator.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"开放隔离器系统的设计允许操作过程中物料通过一个或多个开口连续或半连续进出。开口的设计（如使用连续过压）可以阻断外部污染进入隔离器。"
    },
    {
        "instruction":"已知信息：\n'An establishment or institution that is subcontracting particular work or services to a different institution and sets up a contract defining the duties and responsibilities of each side.'可被翻译为：将特定的工作或服务分包给另一个机构，并订立合同规定双方的义务和责任的机构或机构。\n'The use of contract laboratories, not applicable under normal circumstances, in conformity with the principles of contract analysis detailed in Chapter 11, can be accepted for particular reasons, but this should be stated in the certificate of analysis.'可被翻译为：企业通常不得进行委托检验，确需委托检验的，应当按照第十一章中委托检验部分的规定，委托外部实验室进行检验，但应当在检验报告中予以说明。\n'III. The drugs imported under the same contract may be sampled as the same batch only if the drug name, country of manufacture, manufacturer, package, batch number, dosage form, strength, shipping mark and contract number are identical. If drugs are imported under the same contract but shipped in different batches, they shall be sampled in different batches.'可被翻译为：三、同一合同，药品名称、生产国家、厂商、包装、批号、剂型、规格、唛头标记以及合同编号均相同者，方可作为同批药品进行抽样；同一合同进口的药品分次到货者，分次抽样。\n'If the application is not accepted by the lot release institution, the applicant shall not re-apply for lot release to some other lot release institution.'可被翻译为：未获批签发机构受理的，不得更换其他批签发机构再次申请。\n\n根据上述已知信息，请将'An establishment or institution that performs particular work or services under a contract for a different institution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据合同为另一机构提供特定工作或服务的机构或机构。"
    },
    {
        "instruction":"已知信息：\n'Article 185: Operation procedures should be established to differentiate production batches, and the differentiations of production batches should achieve homogenous quality and property of the product within the same batch.'可被翻译为：第一百八十五条 应当建立划分产品生产批次的操作规程，生产批次的划分应当能够确保同一批次产品质量和特性的均一性。\n'1.Validation carried out during routine production of products intended for sale.\n2.Validation carried out during routine production of products intended for sale in exceptional circumstances when data from replicate production runs are unavailable because only a limited number of batches have been produced, batches are produced infrequently or batches are produced by a validated process that has been modified. Individual batches may be evaluated and released before completion of the validation exercise, based on thorough monitoring and testing of the batches.'可被翻译为：1.在拟销售产品的常规生产过程中进行的验证。\n2.在特殊情况下，在用于销售的产品的常规生产期间进行验证，当由于只生产了有限数量的批次、不经常生产批次或由已修改的经过验证的工艺生产批次而无法获得复制生产运行的数据时。在对批次进行全面监控和测试的基础上，可以在验证工作完成之前对单个批次进行评估和放行。\n'approximate timing of key activities\/deliverables including the timing of trial production batches and validation batches;'可被翻译为：关键活动\/可交付物的适当时间点，例如试生产批次和验证批次的时间；\n'Where the workshops or production lines involved in the entrusted production have not passed the compliance inspection of the Good Manufacturing Practice for Drugs drug production quality management standards (hereinafter referred to as GMP compliance inspection), the local provincial drug administration department should conduct a GMP compliance inspection.'可被翻译为：委托生产涉及的车间或者生产线没有经过药品生产质量管理规范符合性检查（以下简称“GMP符合性检查”），所在地省级药品监管部门应当进行GMP符合性检查。\n\n根据上述已知信息，请将'Commercial-scale production process verification batches and on-site inspection dynamic production batches if needs should be organized on the planned commercial production line in accordance with the requirements of Good Manufacturing Practice of Medical Products (GMP); in principle, the batches should be consistent with the planned commercial production batches.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"商业规模生产工艺验证批次和必要的现场核查动态生产批次，应当在拟定的商业化生产线上按照药品生产质量管理规范的要求组织生产；其批量原则上应当与拟定的商业化生产批量一致。"
    },
    {
        "instruction":"已知信息：\n'A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality.'可被翻译为：一种物理、化学、生物或微生物性质或特性，应在适当的限制、范围或分布范围内，以确保所需的产品质量。\n'Critical Quality Attribute – a physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to assure the desired product quality. (Q8(R2))'可被翻译为：关键质量属性——一种物理、化学、生物学或微生物学属性或特征，其应在一个合适的限度、范围或分布内，以确保 符合预期 的产品质量。（Q8 R2）\n'The combination of physical, chemical, biological, and microbiological tests and acceptance criteria that determine the suitability of a drug product at the time of its release.'可被翻译为：包括物理、化学、生物学、微生物学试验和认可的限度要求。在放行时，用于判断制剂是否合格。\n'1.The combination of physical, chemical, biological, and microbiological tests and acceptance criteria that determine the suitability of an API or FPP at the time of its release.\n2.The combination of physical, chemical, biological, and microbiological tests and acceptance criteria that determine the suitability of an active pharmaceutical ingredient or finished pharmaceutical product at the time of its release.'可被翻译为：1.在API或FPP发布时确定其适用性的物理、化学、生物和微生物测试和验收标准的组合。\n2.物理、化学、生物和微生物试验和验收标准的组合，确定药物活性成分或药品成品在放行时的适宜性。\n\n根据上述已知信息，请将'A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"指产品的物理、化学、生物或微生物性质或特征，应在适当的限度、范围或分布之内，以确保预期的产品质量。"
    },
    {
        "instruction":"已知信息：\n'Article 150 Where drug supervision and administration officers abuse their powers, engage in malpractice for personal gains, or neglect their duties, they shall be punished in accordance with the law.'可被翻译为：第一百五十条 药品监督管理人员滥用职权、徇私舞弊、玩忽职守的，依法给予处分。\n'Article 70 Personnel of the drug regulatory departments that abuse their powers, neglect their duties, engage in malpractice for personal gains in violation of these Provisions shall receive disciplinary punishment according to law.'可被翻译为：第七十条  药品监督管理部门工作人员违反本办法规定，滥用职权、玩忽职守、徇私舞弊的，依法给予处分。\n'Article 41 If the drug regulatory department and its personnel fail to perform their duties or abuse their powers, neglect their duties, commit malpractices for personal gains, they shall be investigated for legal responsibility according to law; if such act constitutes a crime, corresponding criminal liabilities shall be pursued according to law.'可被翻译为：第四十一条 药品监督管理部门及其工作人员不履行职责或者滥用职权、玩忽职守、徇私舞弊，依法追究法律责任；构成犯罪的，依法追究刑事责任。\n'Article 160 Any drug regulatory department or its staff members that violate the provisions of this Provisions and constitute any of the circumstances below shall be instructed by its superior administrative department or supervisory departments to make rectification. If the circumstances are serious, administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible in accordance with law:'可被翻译为：第一百六十条 药品监督管理部门及其工作人员违反本法的规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：\n\n根据上述已知信息，请将'Article 80 Officers from the drug regulatory department who abuse their powers, neglect their duties, or engage in malpractice for personal gains violating provisions of these Provisions, shall be given sanctions in accordance with the law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十条  药品监督管理部门工作人员违反本办法规定，滥用职权、玩忽职守、徇私舞弊的，依法给予处分。"
    },
    {
        "instruction":"已知信息：\n'Article 17 CFDI shall establish an expert consultation system if needs and seek for expert opinions on major and difficult issues during the registration inspection process.'可被翻译为：第十七条 核查中心根据工作需要建立专家咨询制度，在注册核查过程中就重大疑难问题听取专家意见。\n'Expert Working Group'可被翻译为：专家工作组\n'The test is often conducted with a group of 6 or 12 cells per test run. The results from 6 diffusion cells dosed with a specific product are routinely sufficient to characterize the performance (release rate) of that product using that specific IVRT method. In instances when two products are compared, the results from 6 cells of a test product are often compared with the results from 6 cells of a reference product during the first stage of data analysis. See Data Reporting for more details on the use of additional replicates in instances when a second stage of testing is performed in a comparative IVRT study.'可被翻译为：每次测试运行通常使用6或12个单元进行测试。用特定产品给药的6个扩散池的结果通常足以用特定的IVRT方法表征该产品的性能(释放率)。在比较两种产品的情况下，在数据分析的第一阶段，通常将测试产品的6个单元的结果与参考产品的6个单元的结果进行比较。有关在比较IVRT研究中进行第二阶段测试时使用额外重复的更多详细信息，请参见数据报告。\n'An indicator that affects a patient's final health outcome, but is not in itself the end goal of treatment. It is often used as a proxy variable for final outcome when it is difficult to observe in the short term.'可被翻译为：能影响病人最终健康产出的指标，但该指标本身不是治疗的最终目标。当最终产出难以在短期内观察到，常用来作为最终产出的代理变量。\n\n根据上述已知信息，请将'A method of soliciting opinions from people with specific expertise. Often in a group setting, the aim is to use expert experience to make a quick assessment when certain variables are difficult to obtain.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"向具有特定专业知识的人征求意见的方法。通常采用小组座谈的方式,其目的在于当某些变量难以获得时,利用专家经验做出快速评估。"
    },
    {
        "instruction":"已知信息：\n'A layer of material coated during the coating process in order to smooth out the edges of the tablet and facilitate the coating operation.'可被翻译为：包衣过程中，为了消除片剂棱角并有利于包衣操作而包上的一层物质。\n'The surface color of the tablet is lightened.'可被翻译为：片剂的表面颜色发生变浅的现象。\n'The operation of coating the surface of the tablet with a suitable material.'可被翻译为：在片剂表面包裹上适宜材料的衣层的操作。\n'Excipients that increase the weight and volume of the tablet, facilitate molding and dosing.'可被翻译为：增加片剂的重量和体积、有利于成型和分剂量的辅料。\n\n根据上述已知信息，请将'Also known as \"scratch tablet\". A tablet in which dividing lines are marked on the surface of the tablet during production. In order to facilitate the patient to cut into half or even 1\/4 pieces.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"划痕片”。生产过程中在片剂表面划出分割线的片剂。以方便患者切割成半片乃至1\/4片。"
    },
    {
        "instruction":"已知信息：\n'(II) Failing to be equipped with the organization and personnel corresponding to the scale of business or use to carry out relevant works of medical device adverse event monitoring as required;'可被翻译为：（二）未按照要求配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作的；\n'(II) Equipped with the organization and personnel corresponding to the products to carry out relevant works of medical device adverse event monitoring;'可被翻译为：（二）配备与其产品相适应的机构和人员从事医疗器械不良事件监测相关工作；\n'(II) Failing to be equipped with the organization and personnel corresponding to the products to carry out the relevant medical device adverse event monitoring work as required;'可被翻译为：（二）未按照要求配备与其产品相适应的机构和人员从事医疗器械不良事件监测相关工作的；\n'Article 6 Drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall establish and improve medical device adverse event monitoring system, be equipped with corresponding monitoring agencies and personnel and carry out medical device adverse event monitoring.'可被翻译为：第六条  省、自治区、直辖市药品监督管理部门应当建立医疗器械不良事件监测体系，完善相关制度，配备相应监测机构和人员，开展医疗器械不良事件监测工作。\n\n根据上述已知信息，请将'(II) Be equipped with the organization or personnel adapted to the scale of the business or use to carry out relevant works of medical device adverse event monitoring;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作；"
    },
    {
        "instruction":"已知信息：\n'Article 20 Where the change management category of circumstances of change has been specified in laws, regulations or technical guidelines, MAHs shall generally determine the change management category in accordance with relevant provisions.'可被翻译为：第二十条 变更情形在法律、法规或技术指导原则中已明确变更管理类别的，持有人一般应当根据有关规定确定变更管理类别。\n'Article 27 The reporting category shall be managed by the MAHs in accordance with the relevant requirements for change management, which shall be indicated in the annual report.'可被翻译为：第二十七条 报告类变更应当由持有人按照变更管理的有关要求进行管理，在年度报告中载明。\n'Where the change management category of circumstances of change has not been specified in laws, regulations or technical guidelines, MAHs shall determine the change management category on the basis of sufficient study, evaluation and necessary verification according to the internal change classification principle, working procedures and risk management criteria, by referring to relevant technical guidelines in combination with product characteristics.'可被翻译为：变更情形在法律、法规或技术指导原则中未明确变更管理类别的，持有人应当根据内部变更分类原则、工作程序和风险管理标准，结合产品特点，参考有关技术指导原则，在充分研究、评估和必要验证的基础上确定变更管理类别。\n'Where the change management category specified in the technical guidelines is to be lowered, or the change management category in the list of MAHs changes is to be lowered, the domestic MAH shall, on the basis of sufficient study, evaluation and necessary verification, communicate with the provincial drug regulatory department which shall give a written reply within 20 days, and implement it as required for those reached agreement, and the change management category shall not be lowered if agreements are not reached. The specific communication procedure shall be developed by each provincial drug regulatory department.'可被翻译为：其中，降低技术指导原则中明确的变更管理类别，或降低持有人变更清单中的变更管理类别，境内持有人应当在充分研究、评估和必要验证的基础上与省级药品监管部门沟通，省级药品监管部门应当在20日内书面答复，意见一致的按规定执行，意见不一致的不得降低变更管理类别。具体沟通程序由各省级药品监管部门自行制定。\n\n根据上述已知信息，请将'Article 22 MAHs may adjust the change management category according to the management and production technology changes, and implement the change as per the adjusted change management category upon approval or filing, or report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十二条 持有人可以根据管理和生产技术变化对变更管理类别进行调整，并按照调整后的变更管理类别经批准、备案后实施或报告。"
    },
    {
        "instruction":"已知信息：\n'Test materials beyond those used in the current Chinese Pharmacopoeia, including excipients i n preparations, special chromatographic columns, special reagents, and laboratory supplies, etc.'可被翻译为：超出现行版《中国药典》标准中使用的实验材料，包括制剂中的辅料、特殊色谱柱、特殊试剂、实验用品等\n'(II)  Whether the raw materials and auxiliaries, bacterial strains\/seeds, viral strains\/seeds and cells used for production are consistent with those approved by the NMPA;'可被翻译为：（二）生产用原辅材料、菌种、毒种、细胞等是否与国家药品监督管理局批准的一致；\n'(II)  Whether the raw materials and subsidiary, bacterial strains\/seeds, viral strains\/seeds and cells used for production are consistent with those approved by the CFDA;'可被翻译为：（二）生产用原辅材料、菌种、毒种、细胞等是否与食品药品监管总局批准的一致；\n'Bacterial and viral strains and cell strains used in the development, manufacturing and testing of vaccines shall have their track record, biological features and passage numbers specified, detailed archives established, to ensure legal, clear and traceable source; and those with unidentified source shall not be used.'可被翻译为：疫苗研制、生产、检验等使用的菌毒株和细胞株，应当明确历史、生物学特征、代次，建立详细档案，保证来源合法、清晰、可追溯；来源不明的，不得使用。\n\n根据上述已知信息，请将'Test materials beyond those used in the current Chinese Pharmacopoeia, including excipients i n preparations, special chromatographic columns, special reagents, cell strains for assay, bacterial strains, and laboratory supplies, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"超出现行版《中国药典》标准中使用的实验材料，包括制剂中的辅料、特殊色谱柱、特殊试剂、检定用细胞株和菌毒种、实验用品等。"
    },
    {
        "instruction":"已知信息：\n'(2) the License is not renewed upon expiration of the valid term;'可被翻译为：（二）有效期届满未延续的；\n'(3) upon expiration of valid term of the Medical Device Manufacturing License, the manufacturer continues to engage in manufacturing of Class II and Class III medical devices without handling renewal formalities according to law;'可被翻译为：（三）医疗器械生产许可证有效期届满后，未依法办理延续手续，仍继续从事第二类、第三类医疗器械生产；\n'Article 17 If the Medical Device Manufacturing License needs to be renewed upon expiration of the valid term, the applicant shall apply for renewal within 30 to 90 working days before expiration of the valid term. If an application for renewal fails to be made within prescribed time limit, such application shall no longer be accepted.'可被翻译为：第十七条  医疗器械生产许可证有效期届满延续的，应当在有效期届满前90个工作日至30个工作日期间提出延续申请。逾期未提出延续申请的，不再受理其延续申请。\n'If the cosmetics manufactured by the cosmetic manufacturer do not belong to the classification units of the licensed items stated on the License for manufacturing of cosmetics, but the manufacturer relocates the premises without licensing, or fails to obtain renewal of the license for manufacturing of cosmetics at the expiration of the validity period, it shall be deemed that the manufacturer engages in manufacturing of cosmetics without licensing.'可被翻译为：化妆品生产企业生产的化妆品不属于化妆品生产许可证上载明的许可项目划分单元，未经许可擅自迁址，或者化妆品生产许可有效期届满且未获得延续许可的，视为未经许可从事化妆品生产活动。\n\n根据上述已知信息，请将'(3) Cosmetics Manufacturing License is not renewed upon expiration;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）化妆品生产许可证有效期届满未申请延续的；"
    },
    {
        "instruction":"已知信息：\n'Persons who use closed systems to create, modify, maintain, or transmit electronic records shall employ procedures and controls designed to ensure the authenticity, integrity, and, when appropriate, the confidentiality of electronic records, and to ensure that the signer cannot readily repudiate the signed record as not genuine. Such procedures and controls shall include the following:'可被翻译为：使用封闭系统来生成、修改、维护或传送电子记录的人员应采用能够保证真实性、完整性、以及必要时的机密性的规程和管理方式，以确保签名者不能轻易否认签名的非真实记录。规程和管理的内容应包括：\n'Persons who use electronic signatures based upon use of identification codes in combination with passwords shall employ controls to ensure their security and integrity. Such controls shall include:'可被翻译为：同时使用识别码和密码的电子签名应给予管理以确保其安全性和完整性，管理内容应包括：\n'(i) Determination that persons who develop, maintain, or use electronic record\/electronic signature systems have the education, training, and experience to perform their assigned tasks.'可被翻译为：确定从事电子记录\/电子签名系统开发、维护或使用的人员应接受相应的教育、培训，并具备实践经验，方可从事分配的各项工作。\n'(k) Use of appropriate controls over systems documentation including:'可被翻译为：对系统文件方面采取相应的控制，内容包括：\n\n根据上述已知信息，请将'Persons who use open systems to create, modify, maintain, or transmit electronic records shall employ procedures and controls designed to ensure the authenticity, integrity, and, as appropriate, the confidentiality of electronic records from the point of their creation to the point of their receipt. Such procedures and controls shall include those identified in 11.10, as appropriate, and additional measures such as document encryption and use of appropriate digital signature standards to ensure, as necessary under the circumstances, record authenticity, integrity, and confidentiality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用开放式系统来生成、修改、维护或传送电子记录的人员应采用能够保证记录从创建点至接收点的真实性、完整性以及必要时的机密性的规程和个人管理方式，必要时应包括11.10中明确的内容，以及额外的措施，例如文档加密和运用相应的数字签名标准以确保记录必要的真实性、完整性和保密性。"
    },
    {
        "instruction":"已知信息：\n'Article 54 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-issue the medical device registration certificate within 20 workdays.'可被翻译为：第五十四条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。\n'Article 21 In the event that a drug MAH or manufacturer has lost the Drug Manufacturing Certificate, they may apply to the original issuing authority for a replacement of the Certificate. The original issuing authority shall issue the replacing Drug Manufacturing Certificate with the same previously authorized contents within 10 days. The information such as Certificate number and valid term specified on the replacing Certificate shall be the same as that specified on the original Certificate.'可被翻译为：第二十一条 药品生产许可证遗失的，药品上市许可持有人、药品生产企业应当向原发证机关申请补发，原发证机关按照原核准事项在十日内补发药品生产许可证。许可证编号、有效期等与原许可证一致。\n'Article 52 The medical device registration alteration document shall be used in conjunction with the original medical device registration certificate and its period of validity shall be the same with that of the original registration certificate. After obtaining the registration alteration document, the registrant shall alter the product technical requirements, instructions and labels by himself.'可被翻译为：第五十二条 医疗器械注册变更文件与原医疗器械注册证合并使用，其有效期与该注册证相同。取得注册变更文件后，注册人应当根据变更内容自行修改产品技术要求、说明书和标签。\n'Article 62 The medical device registration alteration document shall be used in conjunction with the original medical device registration certificate and its period of validity shall be the same with that of the original registration certificate. After obtaining the registration alteration document, the registrant shall alter the product technical requirements, instructions and labels by himself.'可被翻译为：第六十二条 医疗器械注册变更文件与原医疗器械注册证合并使用，其有效期与该注册证相同。取得注册变更文件后，注册人应当根据变更内容自行修改产品技术要求、说明书和标签。\n\n根据上述已知信息，请将'Article 45 Where a medical device registration certificate is lost, the registrant shall publish a loss declaration immediately at the media specified by the original certificate-issuing authority, and apply after 1 month of declaration to the original certificate-issuing authority for re-issuing the certificate. The original certificate-issuing authority shall re-grant the medical device registration certificate within 20 workdays.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十五条 医疗器械注册证遗失的，注册人应当立即在原发证机关指定的媒体上登载遗失声明。自登载遗失声明之日起满1个月后，向原发证机关申请补发，原发证机关在20个工作日内予以补发。"
    },
    {
        "instruction":"已知信息：\n'NMPA Issues the Announcement on 6 Technical Review Guidances for Registration Including the Technical Review Guidance for the Registration of Disposable Breast localization Wire'可被翻译为：国家药监局关于发布一次性使用乳腺定位丝注册技术审查等6项注册技术审查指导原则的通告\n'NMPA Issues 5 Technical Review Guidances for the Registration of Tendon and Ligament Fixation Systems and Others'可被翻译为：国家药监局关于发布肌腱韧带固定系统等5项注册技术审查指导原则的通告\n'NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems'可被翻译为：国家药监局关于发布视力筛查仪和乳腺X射线系统2项注册技术审查指导原则的通告\n'NMPA Issued 7 Guidances for Technical Review Including the Guidance for Technical Review of the Registration of Vertebroplasty Balloon Dilation Catheters'可被翻译为：国家药监局关于发布椎体成形球囊扩张导管等7项注册技术审查指导原则的通告\n\n根据上述已知信息，请将'NMPA Announcement on Issuing 5 Technical Review Guidances for Registration'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布5项注册技术审查指导原则的通告"
    },
    {
        "instruction":"已知信息：\n'e. Validation and security of computerized or automated processes'可被翻译为：计算机化或自动化流程的验证和安全保护\n'computerized system validation'可被翻译为：计算机化系统验证\n'Validation of sterilisation processes'可被翻译为：灭菌工艺的验证\n'Process validation'可被翻译为：工艺验证\n\n根据上述已知信息，请将'h. Process validation, including validation and security of computerized or automated processes (i.e. simulation studies)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"工艺验证，包括计算机化或自动化工艺的验证和安全保护（即模拟研究）"
    },
    {
        "instruction":"已知信息：\n'The CCS should consider all aspects of contamination control with ongoing and periodic review resulting in updates within the pharmaceutical quality system as appropriate. Changes to the systems in place should be\nassessed for any impact on the CCS before and after implementation.'可被翻译为：CCS 应考虑污染控制的所有方面，并进行持续、定期的回顾，酌情更新药品质量体系。现行体系如有变更，应在实施前后评估对 CCS 的任何影响。\n'The aseptic process should be clearly defined. The risks associated with the aseptic process, and any\nassociated requirements, should be identified, assessed and appropriately controlled. The site's CCS should clearly\ndefine the acceptance criteria for these controls, requirements for monitoring and the review of their effectiveness.\nMethods and procedures to control these risks should be described and implemented. Accepted residual risks\nshould be formally documented.'可被翻译为：无菌工艺应被明确定义。无菌工艺相关风险以及任何相关要求应被识别、评估并适当控制。工厂的 CCS应明确规定这些控制的可接受标准、监测要求及其有效性审核。应描述并执行控制这些风险的方法和程序。可接受的残留风险应形成正式记录。\n'Risk management is applied in the development and maintenance of the CCS, to identify, assess,\nreduce\/eliminate (where applicable) and control contamination risks. Risk management should be documented and should include the rationale for decisions taken in relation to risk reduction and acceptance of residual risk.'可被翻译为：在 CCS 的制定和维护中进行风险管理，来识别、评估、减少\/消除（如适用）和控制污染风险。风险管理应书面化，并应包括降低风险和接受剩余风险有关决策的理由。\n'Where campaign manufacture of a product has been appropriately justified in the  CCS and validated, the filter user should:'可被翻译为：如果产品的阶段式生产在 CCS 中经过适当论证并经过验证，过滤器使用人员应：\n\n根据上述已知信息，请将'A Contamination Control Strategy (CCS) should be implemented across the facility in order to define all critical control points and assess the effectiveness of all the controls (design, procedural, technical and organisational) and monitoring measures employed to manage risks to medicinal product quality and safety. The\ncombined strategy of the CCS should establish robust assurance of contamination prevention. The CCS should be actively reviewed and, where appropriate, updated and should drive continual improvement of the manufacturing and control methods. Its effectiveness should form part of the periodic management review. Where existing control systems are in place and are appropriately managed, these may not require replacement but should be referenced in the CCS and the associated interactions between systems should be understood.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"污染控制策略（CCS）应在整个设施内实施，从而明确所有关键控制点，并评估所有用于管理药品质量和安全风险的控制措施（设计，程序性、技术性和组织性措施）和监测措施的有效性。CCS 的综合策略应建立起强有力的污染预防保障。应积极回顾并适当更新 CCS，并应推动生产和控制方法的持续改进。CCS 的有效性应成为定期管理回顾的一部分。如果控制系统已经建立并得到了妥善管理，则这些系统可能不需要更换，但应在 CCS 中提及，并应了解系统之间在相关方面的相互作用。"
    },
    {
        "instruction":"已知信息：\n'Article 108 For the registration application of a non-prescription drug, the insert sheet and package label shall comply with the relevant regulations on non-prescription drugs.'可被翻译为：第一百零八条 非处方药的注册申请，其药品说明书和包装标签应当符合非处方药的有关规定。\n'Section 3  Drug Name, Insert Sheet and Label'可被翻译为：第三节 药品名称、说明书和标签\n'Article 116 Supplementary applications of import drugs shall be reviewed and approved by the State Food and Drug Administration. Those supplementary applications to change the place of production of the drug substance used for any import drug preparation, change the appearance of an import drug not resulting in specification changes, amend the insert sheet of an import drug according to the national specifications or the requirements of the State Food and Drug Administration, update the safety information in the insert sheet of an import drug, alter drug packaging label in accordance with regulations, or change the registration agent shall be filed to the State Food and Drug Administration for record.'可被翻译为：第一百一十六条 进口药品的补充申请，由国家食品药品监督管理局审批。其中改变进口药品制剂所用原料药的产地、变更进口药品外观但不改变药品标准、根据国家药品标准或国家食品药品监督管理局的要求修改进口药说明书、补充完善进口药说明书的安全性内容、按规定变更进口药品包装标签、改变注册代理机构的补充申请，由国家食品药品监督管理局备案。\n'Article 3    Drug insert sheets and labels shall be reviewed and approved by the State Food and Drug Administration.'可被翻译为：第三条 药品说明书和标签由国家食品药品监督管理局予以核准。\n\n根据上述已知信息，请将'Article 142 The name, insert sheet and label of any drug for which the registration is applied, shall comply with the provisions of the State Food and Drug Administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百四十二条 申请注册药品的名称、说明书和标签应当符合国家食品药品监督管理局的规定。"
    },
    {
        "instruction":"已知信息：\n'The receptor compartment of the Model A VDC should be filled with receptor solution that is equilibrated to the target temperature (typically 32° or 37°) during the preparation and dosing of the membrane in the cell top assembly. The stirrers can be run during this period to speed up temperature stabilization. The receptor solution temperature should be measured and ensured to be within ±1° of the target temperature prior to mounting the cell top assembly. The stirrers can be run to help speed up temperature stabilization.'可被翻译为：A型VDC的受体室应充满受体溶液，在池体顶部组装膜的制备和给药过程中，受体溶液应平衡到目标温度(通常为32°或37°)。在此期间可以运行搅拌子以加速温度稳定。在安装池体顶部组件之前，应测量并确保受体溶液温度在目标温度的±1°范围内。搅拌子可以运行，以帮助加快温度稳定。\n'Once the hydration and temperature of the skin has equilibrated (i.e., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the VDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface. The stirrers can be run during the duration of the equilibration to speed up temperature stabilization.'可被翻译为：一旦皮肤的水合作用和温度达到平衡(即30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。而是直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调节VDC系统的热调节机制，使皮肤表面温度达到32°的目标温度。搅拌器可以在平衡期间运行，以加速温度稳定。\n'Once the hydration and temperature of the skin has equilibrated (e.g., after 30 min) the skin surface temperature should be measured. The skin surface temperature should be within ±1° of the target temperature (32°) prior to applying the dosage form. The temperature of the receptor solution, or the circulating water bath, or the set point of a dry heat system, or any other component of the system should not be assumed to be the same as the skin surface temperature. Instead, the skin surface temperature should be directly measured (with an infrared thermometer or a thermocouple), and the thermoregulatory mechanism of the FDC system should be adjusted as needed to produce the target temperature of 32° at the skin surface.'可被翻译为：一旦皮肤的水合作用和温度达到平衡(例如，30分钟后)，应测量皮肤表面温度。在施用剂型之前，皮肤表面温度应在目标温度(32°)的±1°内。受体溶液的温度，或循环水浴的温度，或干热系统的设定点，或系统的任何其他组成部分的温度不应假定与皮肤表面温度相同。相反，应直接测量皮肤表面温度(使用红外温度计或热电偶)，并根据需要调整FDC系统的温度调节机制，使皮肤表面温度达到32°的目标温度。\n'3. Qualification of Temperature Control: The temperature of each cell should be equilibrated to provide the target temperature at the membrane, and the initial qualification of the equipment should verify that the temperature can be maintained for the duration of the test when using the relevant equipment and method parameters. Depending on the VDC or FDC equipment design, a measurement of the membrane temperature can often be made conveniently using an infrared thermometer, or using a thermocouple mounted with the membrane; for immersion cells, the temperature at the membrane may be assumed to be the same as the bulk volume of the receptor solution in the dissolution vessel, once equilibrated and stabilized. The temperature of each cell should typically remain within ±1° of the target temperature (typically 32° or 37°) during the test.'可被翻译为：温度控制的确认:应平衡每个池体的温度使膜达到目标温度，并且设备的初始确认应验证在使用相关设备和方法参数时，该温度可在测试期间保持。根据VDC或FDC设备的设计，膜温度的测量通常可以方便地使用红外温度计，或使用安装在膜上的热电偶;对于浸没池，可以假设膜上的温度与溶解容器中受体溶液的体积相同，一旦达到平衡和稳定。在测试过程中，每个池体的温度通常应保持在目标温度(通常为32°或37°)的±1°内。\n\n根据上述已知信息，请将'The system should be equilibrated, and the temperature should be measured at the membrane. The membrane should be within ±1° of the target temperature (typically 32° or 37°) prior to applying the dosage form. The stirrers should be turned on during the equilibration period.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"系统应平衡，并在膜处测量温度。在上样之前，膜应在目标温度(通常为32°或37°)的±1°范围内。在平衡期间应打开搅拌子搅拌。"
    },
    {
        "instruction":"已知信息：\n'The legal representative and the principal responsible person of a drug manufacturer shall be fully responsible for the drug manufacturing activities.'可被翻译为：药品生产企业的法定代表人、主要负责人对本企业的药品生产活动全面负责。\n'Article 28 The legal representative and the principal of a drug MAH shall be fully responsible for drug quality and fulfill the following responsibilities:'可被翻译为：第二十八条 药品上市许可持有人的法定代表人、主要负责人应当对药品质量全面负责，履行以下职责：\n'The legal representative and the principal responsible person of a drug distributor shall be fully responsible for the drug distribution activities.'可被翻译为：药品经营企业的法定代表人、主要负责人对本企业的药品经营活动全面负责。\n'The legal representative and the principal responsible person of an MAH shall take full responsibility for drug quality.'可被翻译为：药品上市许可持有人的法定代表人、主要负责人对药品质量全面负责。\n\n根据上述已知信息，请将'Article 29 The legal representative and principal of a drug manufacturer shall be responsible for drug manufacturing of the company in all aspects and perform the following duties:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十九条 药品生产企业的法定代表人、主要负责人应当对本企业的药品生产活动全面负责，履行以下职责："
    },
    {
        "instruction":"已知信息：\n'functional group'可被翻译为：官能团\n'The addition of refractive index of each atom, chemical bond and functional group in the molecule.'可被翻译为：分子中各原子、各化学键及官能团的折射率加和。\n'The receptor, target molecule, and target organ or system on which the drug acts.'可被翻译为：药物作用的受体、靶分子和靶器官或靶系统。\n'The phenomenon in which the structure of some organic compounds is in dynamic equilibrium by the rapid transformation of two functional group isomers into each other.'可被翻译为：某些有机化合物的结构以两种官能团异构体互相迅速变换而处于动态平衡的现象。\n\n根据上述已知信息，请将'In designing the synthetic route of the target molecule, a logical reasoning analysis method conforming to the principle of organic synthesis is adopted. The target molecule is converted reasonably (including functional group tautometry, functional group addition, functional group removal, connection, etc.) or divided to produce molecular fragments and new target molecules. The latter is then repeatedly converted or segmented until readily available reagents are obtained.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在设计目标分子的合成路线时，采用的一种符合有机合成原理的逻辑推理分析法。将目标分子经过合理的转换（包括官能团互变，官能团加成，官能团脱去、连接等）或分割，产生分子碎片和新的目标分子。后者再重复进行转换或分割，直至得到易得的试剂为止。"
    },
    {
        "instruction":"已知信息：\n'Article 7    Drug insert sheets and labels shall be written in standardized Chinese characters published by the National Language Commission. The versions in other languages shall comply with the Chinese version.'可被翻译为：第七条 药品说明书和标签应当使用国家语言文字工作委员会公布的规范化汉字，增加其他文字对照的，应当以汉字表述为准。\n'Provisions for Instructions and Labels of Medical Devices'可被翻译为：医疗器械说明书和标签管理规定\n'Contents in the instructions and labels of medical devices shall be consistent with the relevant information in their registration or filing.'可被翻译为：医疗器械说明书和标签的内容应当与经注册或者备案的相关内容一致。\n'Article 6 Symbols or identification colors used in the instructions and labels of medical devices shall meet corresponding national standards. Where no such standards exist, the symbols and identification colors shall be described in the instructions.'可被翻译为：第六条 医疗器械说明书和标签中使用的符号或者识别颜色应当符合国家相关标准的规定；无相关标准规定的，该符号及识别颜色应当在说明书中描述。\n\n根据上述已知信息，请将'Article 9 Text in the instructions and labels of medical devices shall be in Chinese, and the use of Chinese shall meet the national general rules for language and words. Other languages are optional in the instructions and labels of medical devices, but the Chinese version shall prevail.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九条 医疗器械说明书和标签文字内容应当使用中文，中文的使用应当符合国家通用的语言文字规范。医疗器械说明书和标签可以附加其他文种，但应当以中文表述为准。"
    },
    {
        "instruction":"已知信息：\n'These are drugs supplied only in licensed pharmacies on the presentation of signed prescriptions issued by a licensed and registered medical practitioner, licensed and\/or registered dentist (for dental treatment only), and\/or licensed and\/or registered veterinarian (for animal treatment only), and the supply and dispensing of these drugs must be carried out by a pharmacist or under the supervision of a pharmacist. Prescription drugs are further subdivided into controlled drugs (narcotic drugs and psychotropic substances) and non- controlled drugs.'可被翻译为：这些药物仅在持牌药房供应，需出示由持牌和注册医生、持牌和\/或注册牙医(仅用于牙科治疗)和\/或持牌和\/或注册兽医(仅用于动物治疗)签发的签名处方，并且这些药物的供应和配药必须由药剂师或在药剂师的监督下进行。处方药又进一步细分为管制药物(麻醉药品和精神药物)和非管制药物。\n'These are drugs that can be sold from licensed dealers without professional supervision and without prescriptions. These drugs are suitable for self-medication for minor diseases and symptoms.'可被翻译为：这些药物可以在没有专业监督和处方的情况下从有执照的经销商那里出售。这些药物适合小病小症的自我药疗。\n'(I) Prescription can be dispensed only after being audited by licensed pharmacists. The drugs listed in the prescription shall not be altered or substituted without authorization. The dispensing of prescriptions with incompatibility or overdose shall be refused; however, those may be dispensed after being corrected or re-signed by the prescriber. After the dispensing of prescription, the drugs can be sold only after being checked;'可被翻译为：（一）处方经执业药师审核后方可调配；对处方所列药品不得擅自更改或者代用，对有配伍禁忌或者超剂量的处方，应当拒绝调配，但经处方医师更正或者重新签字确认的，可以调配；调配处方后经过核对方可销售。\n'The imported crude drugs can be sold and used only after passing the port testing.'可被翻译为：经口岸检验合格的进口药材方可销售使用。\n\n根据上述已知信息，请将'These are drugs authorized to be sold only in licensed pharmacies under the supervision of licensed or registered pharmacists; they may be sold without a prescription.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这是指在持牌或注册药剂师的监督下，只能在持牌药房销售的药物;可以在没有处方的情况下销售。"
    },
    {
        "instruction":"已知信息：\n'Article 11 Provincial drug control institutions shall, within 30 days upon the receipt of test samples and related materials, complete the sample testing, issue the testing report of imported drugs to the applicants, and submit it to the provincial drug regulatory department. Where it is necessary to extend the testing time due to characteristics of varieties or testing items, the duration and reasons of the extension shall be reported to provincial drug regulatory department in written form and notified to the applicants.'可被翻译为：第十一条 省级药品检验机构收到检验样品和相关资料后，应当在30日内完成样品检验，向申请人出具进口药材检验报告书，并报送省级药品监督管理部门。因品种特性或者检验项目等原因确需延长检验时间的，应当将延期的时限、理由书面报告省级药品监督管理部门并告知申请人。\n'Article 22 When necessary, within 3 months upon completion of filing, the department in charge of drug supervision and administration at the level of a city divided into districts shall carry out on-site inspection of the submitted materials and the implementation of the Good Supply Practice for medical devices.'可被翻译为：第二十二条  必要时，设区的市级负责药品监督管理的部门在完成备案之日起3个月内，对提交的资料以及执行医疗器械经营质量管理规范情况开展现场检查。\n'Article 59 Where drug regulatory departments at provincial level or above order to carry out re-evaluation, MAHs shall submit the re-evaluation plan and re-evaluation report to the corresponding drug regulatory departments and monitoring agencies before implementation of re-evaluation and within 30 days upon the completion of re-evaluation.'可被翻译为：第五十九条  省级以上药品监督管理部门责令开展再评价的，持有人应当在再评价实施前和再评价结束后30日内向相应药品监督管理部门及监测机构提交再评价方案和再评价报告。\n'Provincial drug regulatory departments shall be responsible for the permit and registration of the post-approval change of supervision items for production, and the filing and reporting of the post-approval change of administrative items for registration for the drugs of MAHs within their respective administrative regions in accordance with their responsibilities; and organize the supervision and administration of post-approval changes of drugs in accordance with law.'可被翻译为：省级药品监管部门依职责负责辖区内持有人药品上市后生产监管事项变更的许可、登记和注册管理事项变更的备案、报告等管理工作；依法组织实施对药品上市后变更的监督管理。\n\n根据上述已知信息，请将'Provincial drug regulatory departments shall strengthen the supervision and administration, complete the review on the notified materials within 30 days upon the completion of filing according to the risk characteristics and safety credit of the filing change items, and may carry out inspection and testing when necessary.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"省级药品监管部门应当加强监管，根据备案变更事项的风险特点和安全信用情况，自备案完成之日起30日内完成对备案资料的审查，必要时可实施检查与检验。"
    },
    {
        "instruction":"已知信息：\n'reference substance'可被翻译为：对照品\n'chemical reference substance'可被翻译为：化学参比物质\n'drug reference substance'可被翻译为：药品标准物质\n'primary reference substance'可被翻译为：主要参比物质\n\n根据上述已知信息，请将'A high-purity non-standard substance provided by a pharmaceutical reference substance development institution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由药品标准物质研制机构提供的高纯度非标准物质。"
    },
    {
        "instruction":"已知信息：\n'Method for electrophoretic analysis using paper as a support.'可被翻译为：以纸为支持物进行电泳的分析方法。\n'The method of electrophoretic analysis using solid thin layer as support.'可被翻译为：以固体薄层为支持物进行电泳的分析方法。\n'The electrophoretic mode, in which solutes migrate at different speeds in the background electrolyte solution in the capillary tube to form independent solute bands, is the most basic and widely used separation mode in capillary electrophoresis.'可被翻译为：溶质在毛细管内的背景电解质溶液中，以不同速度迁移而形成独立溶质带的电泳模式，是毛细管电泳中最基本、应用最广泛的一种分离模式。\n'The electrophoretic separation analysis method is based on the difference of mobility and distribution behavior of each component in the sample by using elastic quartz capillary as the separation channel and high voltage direct current electric field as the driving force.'可被翻译为：以弹性石英毛细管为分离通道，以高压直流电场为驱动力，依据样品中各组分之间淌度和分配行为上的差异而实现分离的电泳分离分析方法。\n\n根据上述已知信息，请将'Recording of zoned electrophoretic patterns. The form or the electrophoretic carrier itself or a scan of it.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"区带电泳图形的记录。其形式或电泳载体本身或为对它的扫描图。"
    },
    {
        "instruction":"已知信息：\n'5. The name, batch number and actually used quantities of each kind of packaging materials;'可被翻译为：（五）每一包装材料的名称、批号和实际使用的数量。\n'NMPA Announcement on Issuing the Catalogue of Used Cosmetic Raw Materials (Edition 2021)'可被翻译为：国家药监局关于发布《已使用化妆品原料目录（2021年版）》的公告\n'Raw materials, excipients, packaging materials, and equipment used specifically for producing counterfeit or inferior drugs shall be confiscated.'可被翻译为：对生产者专门用于生产假药、劣药的原料、辅料、包装材料、生产设备予以没收。\n'In order to further standardize the management of cosmetic raw materials, according to the Regulations for the Supervision and Administration of Cosmetics, NMPA has organized the revisions to the Directory of Used Cosmetic Raw Materials(Edition 2015) and formed the Catalogue of Used Cosmetic Raw Materials (Edition 2021), which was issued on April 27, and takes effect as of May 1, 2021.'可被翻译为：为进一步规范化妆品原料管理，依据《化妆品监督管理条例》相关规定，国家药监局组织对《已使用化妆品原料目录名称（2015版）》进行修订，形成了《已使用化妆品原料目录（2021年版）》，于2021年4月27日予以公布，自2021年5月1日起施行。\n\n根据上述已知信息，请将'An additive used to reduce the adhesion of raw materials to the die. It is a kind of lubricant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于减轻原料对冲模的黏附作用的添加剂。为润滑剂的一种。"
    },
    {
        "instruction":"已知信息：\n'Article 147 Where an enterprise establishes a warehouse, it shall ensure that the inner walls and ceiling of the warehouse are smooth and clean, the floor is flat and the doors and windows have a tight structure; and there are reliable safety protection, anti-theft and other measures.'可被翻译为：第一百四十七条 企业设置库房的，应当做到库房内墙、顶光洁，地面平整，门窗结构严密；有可靠的安全防护、防盗等措施。\n'Article 49: Interior surfaces (walls, floors and ceilings) of a clean area should be smooth, free from cracks, open joints and dust retention, and should not shed particulate matter, and should permit easy and effective cleaning and, if necessary, disinfection.'可被翻译为：第四十九条 洁净区的内表面（墙壁、地面、天棚）应当平整光滑、无裂缝、接口严密、无颗粒物脱落，避免积尘，便于有效清洁，必要时应当进行消毒。\n'(VI) Drugs shall be stacked according to lot numbers. Drugs with different lot numbers shall not be stacked together. The distance between the stacks shall be no less than 5 cm, and that from the stacks to the inner walls, ceiling, temperature control equipment and pipelines of the warehouse shall be no less than 30 cm, and that from the stacks to the ground shall be no less than 10 cm;'可被翻译为：（六）药品按批号堆码，不同批号的药品不得混垛，垛间距不小于5厘米，与库房内墙、顶、温度调控设备及管道等设施间距不小于30厘米，与地面间距不小于10厘米；\n'Article 164 Where an enterprise establishes a warehouse, the drug storage and maintenance management in the warehouse shall comply with Section 10 of Chapter II herein.'可被翻译为：第一百六十四条 企业设置库房的，库房的药品储存与养护管理应当符合本规范第二章第十节的相关规定。\n\n根据上述已知信息，请将'(II) The warehouse has smooth interior walls and ceiling as well as flat floor with tight structure of door and window;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）库房内墙、顶光洁，地面平整，门窗结构严密；"
    },
    {
        "instruction":"已知信息：\n'A person who routinely donates blood, blood components or plasma in the same blood establishment in accordance with the minimum time intervals.'可被翻译为：在同一血库按最低时间间隔定期捐献血液、血液成分或血浆的人。\n'A unit or site used for the collection of blood and\/or blood components, operating temporarily or at movable locations off-site from a permanent collection site, under the responsibility of a blood establishment.'可被翻译为：用于采集血液和\/或血液成分的单位或场所，在血液机构的负责下，临时或在永久采集点以外的可移动位置操作。\n'A biological material including, but not limited to, blood, serum, plasma and urine.'可被翻译为：一种生物材料，包括但不限于全血、血清、血浆和尿液。\n'The process by which one or more blood components are selectively obtained from a donor by withdrawing whole blood, separating it by centrifugation and\/or filtration into its components, and returning those not required to the donor.'可被翻译为：从献血者身上选择性地提取一种或多种血液成分的过程，通过离心和\/或过滤将其分离到其成分中，并将不需要的成分返回给献血者。\n\n根据上述已知信息，请将'A donor whose blood or plasma is tested for the first time for infectious disease markers in a blood establishment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"首次在血液机构进行血液或血浆传染病标志物检测的献血者。"
    },
    {
        "instruction":"已知信息：\n'(3) For varieties having passed GMP compliance inspection for manufacturing conditions of the products, the drug regulatory departments of related provinces, autonomous regions and municipalities directly under the Central Government shall decide whether or not to carry out pre-marketing GMP inspection according to risk management principles.'可被翻译为：（三）已通过与生产该药品的生产条件相适应的药品生产质量管理规范符合性检查的品种，相关省、自治区、直辖市药品监督管理部门根据风险管理原则决定是否开展上市前的药品生产质量管理规范符合性检查。\n'Where pre-marketing GMP inspection is necessary, the CFDI shall coordinate the relevant drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government to implement the inspection concurrently with the drug registration inspection of the manufacturing site. The administrative requirements for pre-marketing GMP inspection shall be stipulated by the Provisions for Drug Manufacturing Supervision and Administration.'可被翻译为：需要上市前药品生产质量管理规范检查的，由药品核查中心协调相关省、自治区、直辖市药品监督管理部门与药品注册生产现场核查同步实施。上市前药品生产质量管理规范检查的管理要求，按照药品生产监督管理办法的有关规定执行。\n'The drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government may adjust the inspection frequency depending on the practical situation of drug manufacturing supervision within respective administrative regions.'可被翻译为：省、自治区、直辖市药品监督管理部门可以结合本行政区域内药品生产监管工作实际情况，调整检查频次。\n'(2) Where drug registration on-site inspection is not needed for the drug to be manufactured, the NMPA Center for Drug Evaluation shall inform the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the manufacturing site is located and the applicant; and the drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall carry out pre-marketing GMP compliance inspection of its own accord.'可被翻译为：（二）拟生产药品不需要进行药品注册现场核查的，国家药品监督管理局药品审评中心告知生产场地所在地省、自治区、直辖市药品监督管理部门和申请人，相关省、自治区、直辖市药品监督管理部门自行开展上市前的药品生产质量管理规范符合性检查；\n\n根据上述已知信息，请将'Article 52 The drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government may, as needed for supervision and administration, carry out pre-marketing GMP compliance inspection on drug marketing authorization applicants holding Drug Manufacturing Certificate and its contract manufacturer as required below:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条 省、自治区、直辖市药品监督管理部门根据监管需要，对持有药品生产许可证的药品上市许可申请人及其受托生产企业，按以下要求进行上市前的药品生产质量管理规范符合性检查："
    },
    {
        "instruction":"已知信息：\n'The sales records shall be kept till 2 years after expiration of valid term of the medical devices; if there is no valid term for such medical devices, the records shall be kept for no less than 5 years. The sales records of implantable medical devices shall be kept permanently.'可被翻译为：销售记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械销售记录应当永久保存。\n'The inspection records of incoming goods shall be kept till 2 years after expiration of valid term of the medical device; if there is no valid term for such medical device, the records shall be kept for no less than 5 years. The inspection records of incoming implantable medical devices shall be kept permanently.'可被翻译为：进货查验记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械进货查验记录应当永久保存。\n'Article 3 Medical device marketing authorization holders (hereinafter referred to as MAHs) shall possess the capacities of quality management and corresponding responsibilities to ensure that the medical devices are safe and effective, establish medical device adverse event monitoring system and directly report medical device adverse events to medical device adverse event monitoring agencies (hereinafter referred to as monitoring agencies). Distributing enterprises and user facility of medical device authorized by MAHs shall report medical device adverse events to MAHs and monitoring agencies.'可被翻译为：第三条  医疗器械上市许可持有人（以下简称持有人），应当具有保证医疗器械安全有效的质量管理能力和相应责任能力，建立医疗器械不良事件监测体系，向医疗器械不良事件监测技术机构（以下简称监测机构）直接报告医疗器械不良事件。由持有人授权销售的经营企业、医疗器械使用单位应当向持有人和监测机构报告医疗器械不良事件。\n'Article 26 In case of identifying any medical device adverse event causing or possibly causing severe injuries or death, other units and individuals other than MAHs, distributing enterprises and user facility shall  report to either monitoring agencies or MAHs, distributing enterprises or the medical institutions providing treatment, and provide relevant medical records if necessary.'可被翻译为：第二十六条  除持有人、经营企业、使用单位以外的其他单位和个人发现导致或者可能导致严重伤害或者死亡的医疗器械不良事件的，可以向监测机构报告，也可以向持有人、经营企业或者经治的医疗机构报告，必要时提供相关的病历资料。\n\n根据上述已知信息，请将'Article 22 MAHs, medical device distributing enterprises as well as user facility shall establish and keep medical device adverse event monitoring records. The records shall be kept until 2 years upon shelf life expiration of medical devices; for those without shelf life label, the record-keeping period shall not be less than 5 years. The monitoring records of implantable medical devices shall be kept permanently, and medical institutions shall keep them in accordance with the relevant provisions for medical records.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十二条  持有人、经营企业、使用单位应当建立并保存医疗器械不良事件监测记录。记录应当保存至医疗器械有效期后2年；无有效期的，保存期限不得少于5年。植入性医疗器械的监测记录应当永久保存，医疗机构应当按照病例相关规定保存。"
    },
    {
        "instruction":"已知信息：\n'The test Apparatus is described in USP<788> with additional information found in USP<1788> .'可被翻译为：USP<788>中描述了检测仪器，更多信息参见USP<1788>。\n'Test Environment and Environmental Blank:'可被翻译为：检测环境和环境空白\n'Both prepared and purchased media must meet the requirements of the USP growth promotion test of aerobes, anaerobes and fungi.'可被翻译为：无论是制备的还是购买的培养基均应满足USP的需氧菌、厌氧菌和真菌促生长测试 要求。\n'Prior to beginning a test procedure an environment blank must be prepared and tested according to ORA-LAB.019. After passing results have been obtained the instrument can now be used to perform the test procedure.'可被翻译为：在开始检测程序之前，必须根据ORA-LAB.019制备和检测一份环境空白。在得 到合格结果之后，可使用该仪器执行检测程序。\n\n根据上述已知信息，请将'Prior to initiating the test sequence with a specimen, a blank determination is required and must be carried out according to USP<788> . The environmental blank must meet the requirements set forth in USP <788>in order to initiate testing of the specimen.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在开始样本检测序列之前，应根据USP<788>进行空白检测。环境空白必须符合USP<788>中所设定的要求方可开始样本检测。"
    },
    {
        "instruction":"已知信息：\n'1.An area within the facility in which specific environmental facility conditions and procedures are defined, controlled, and monitored to prevent degradation or cross-contamination of the product.\n2.An area within the facility in which specific procedures and environmental parameters, including viable and nonviable particles, are defined, controlled and monitored to prevent degradation, contamination or cross-contamination of the product.'可被翻译为：1.设施内的一个区域，在该区域内，特定的环境设施条件和程序被定义、控制和监测，以防止产品的降解或交叉污染。\n2.设施内特定程序和环境参数(包括活的和非活的颗粒)被定义、控制和监测以防止产品降解、污染或交叉污染的区域。\n'(1) having manufacturing premises, environmental conditions, manufacturing equipment, and professional technicians required for the medical devices manufactured;'可被翻译为：（一）有与生产的医疗器械相适应的生产场地、环境条件、生产设备以及专业技术人员；\n'Article 105: Materials and products should be transported in a manner to protect their quality. Where special requirements are needed, the transportation conditions should be verified.'可被翻译为：第一百零五条 物料和产品的运输应当能够满足其保证质量的要求，对运输有特殊要求的，其运输条件应当予以确认。\n'Any pharmaceutical good or product which, when not stored or transported within predefined environmental conditions and\/or within predefined time limits, is degraded to the extent that it no longer performs as originally intended.'可被翻译为：任何未在预定的环境条件和\/或预定的时间限制内储存或运输的药品或产品，其降解程度不再像最初预期的那样。\n\n根据上述已知信息，请将'environmental conditions or any special requirement needed for the facility or equipment depending on the nature of the product to be transferred.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"准备转移的产品特性所决定的设施或设备所需的环境条件和所有特殊要求。"
    },
    {
        "instruction":"已知信息：\n'Exposure during gestation to physical and chemical factors that can cause offspring malformations.'可被翻译为：在妊娠期接触能引起子代畸形的物理化学因素。\n'Exogenous physical and chemical factors cause all toxicity before and after implantation until the end of the organ-forming period.'可被翻译为：外源性物理化学因素造成孕体着床前后一直到器官形成期结束的所有毒性。\n'The discipline that studies the pathogenesis and consequences of developing organisms during the development of the fertilized egg, during pregnancy, after birth, and until sexual maturity, as a result of pre-birth exposure to physical and chemical factors or environmental conditions that cause abnormal development.'可被翻译为：研究发育生物体在受精卵、妊娠期、出生后、直到性成熟的发育过程中，由于出生前接触导致异常发育的理化因素或环境条件后的发病机制和后果的学科。\n'Structural and functional damage to various parts of the nervous system caused by exogenous physical, chemical, or biological factors.'可被翻译为：外源性物理、化学物或生物因素对神经系统各部位所引起的结构和功能损害作用。\n\n根据上述已知信息，请将'Exposure to exogenous physical and chemical factors during gestation (before birth) causes structural deformities in offspring.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在妊娠期（出生前）接触外源性物理化学因素，引起后代结构畸形的作用。"
    },
    {
        "instruction":"已知信息：\n'In chromatographic analysis, a quantitative method is performed by comparing the chromatographic peak area or peak height of the reference and the test.'可被翻译为：在色谱分析中，一种通过对照品和供试品色谱峰面积或峰高的比较进行定量的方法。\n'To measure the normal chromatographic peak and abnormal chromatographic peak index.'可被翻译为：为衡量正常色谱峰与不正常色谱峰的指标。\n'Change of the original integration of a chromatographic peak'可被翻译为：重新分析色谱峰。\n'The small peak on the trailing peak of the chromatogram. The packing bed in the general column produces cracks and voids, which will make the chromatographic peak appear \"hump\" or \"opposite peak\".'可被翻译为：色谱分析图的拖尾峰上的小峰。一般色谱柱柱内填料床层产生裂缝和空隙，会使色谱峰出现\"驼峰”或“对峰\"。\n\n根据上述已知信息，请将'The method uses the percentage of the chromatographic peak area of each component in the total peak area of a multi-component sample for chromatographic quantification. Usually used only for the examination of the substance in question.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种利用多组分样品中各组分的色谱峰面积占总峰面积的百分比进行色谱定量的方法。通常仅用于有关物质检查。"
    },
    {
        "instruction":"已知信息：\n'Article 9 The State encourages the research and innovation of in-vitro diagnostic reagents, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of in-vitro diagnostic reagents and promotes the development of medical device industry.'可被翻译为：第九条 国家鼓励体外诊断试剂的研究与创新，对创新体外诊断试剂实行特别审批，促进体外诊断试剂新技术的推广与应用，推动医疗器械产业的发展。\n'Article 4 The State encourages the research and development of new drugs and adopts the special review and approval with respect to innovative drugs, new drugs for serious and life-threatening diseases and to address unmet medical needs and drugs.'可被翻译为：第四条 国家鼓励研究创制新药，对创制的新药、治疗疑难危重疾病的新药实行特殊审批。\n'Where applying for registration of a domestic medical device subject to the special review procedures for innovative medical devices and its sample production is entrusted to another enterprise, the applicant shall entrust a medical device manufacturer having corresponding production range. Where the domestic medical device applied for registration is not subject to the special review procedures for innovative medical devices, the sample production shall not be entrusted to another enterprise.'可被翻译为：按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品委托其他企业生产的，应当委托具有相应生产范围的医疗器械生产企业；不属于按照创新医疗器械特别审批程序审批的境内医疗器械申请注册时，样品不得委托其他企业生产。\n'At present, the eRPS system business scope covers the NMPA medical device registration affairs, including the registration, change in registration and registration renewal of domestic Class III medical devices, imported Class II and Class III medical devices; the examination and approval of clinical trials for Class III high-risk medical devices; notification for revising medical device instructions; re-review of registration of medical devices and change of licensing items; and special review of innovative medical devices, etc.'可被翻译为：目前，eRPS系统业务范围为国家药品监督管理局医疗器械注册事项，包括境内第三类和进口第二、三类医疗器械注册、注册变更、延续注册，第三类高风险医疗器械临床试验审批，以及医疗器械说明书更改告知、医疗器械注册及许可事项变更复审、创新医疗器械特别审查等。\n\n根据上述已知信息，请将'Article 8 The State encourages the research and innovation of medical devices, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of medical devices and promotes the development of medical device industry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八条 国家鼓励医疗器械的研究与创新，对创新医疗器械实行特别审批，促进医疗器械新技术的推广与应用，推动医疗器械产业的发展。"
    },
    {
        "instruction":"已知信息：\n'(1) The test sample analysis is conducted according to the analysis plan, the preprocessing and testing method of the samples in the analysis batch are consist with the method validation, and the plasma concentration data is consistent with that in the application dossier.'可被翻译为：(1) 试验样品分析按照分析计划执行， 分析批中样品预处理的过程和检测方法与方法学验证一致， 血药浓度数据与申报资料一致。\n'(4) Samples introduced into all the instruments are recorded in the original records, and investigation and analysis are conducted for abnormal circumstances occurred during the process of sample analysis, consist with the application dossier.'可被翻译为：(4) 所有在仪器中进样的样品均记录在原始记录中， 并对样品分析过程中出现的异常情况进行调查和分析， 与申报资料一致。\n'(3) Extract part of the electronic chromatograms of the test sample, accompanying standard curves and QC samples as well as method validation sample, which are consist with the application dossier.'可被翻译为：(3) 抽取工作站中的试验样品、随行标准曲线和 QC 样品以及方法学验证样品的部分电子图谱， 与申报资料一致。\n'(5) All samples introduced into the instruments are recorded in the original records, and investigation and analysis is conducted for abnormal circumstances occurred during the process of method validation, which are consist with those in the application dossier.'可被翻译为：(5) 所有在仪器中进样的样品均记录在原始记录中， 并对方法学验证过程中出现的异常情况进行调查和分析， 与申报资料一致。\n\n根据上述已知信息，请将'(5) If there is residual during the process of test sample analysis, evaluate the impact on the concentration of the test sample and carry out specific measures, consist with the application dossier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(5) 试验样品分析过程中如有残留， 对试验样品浓度的影响进行评估并采取具体措施， 与申报资料一致。"
    },
    {
        "instruction":"已知信息：\n'1. All changes of starting materials used for the product, especially those materials from new suppliers;'可被翻译为：（一）产品所用原辅料的所有变更，尤其是来自新供应商的原辅料；\n'1.A general term used to denote starting materials (active pharmaceutical ingredients and excipients), reagents, solvents, process aids, intermediates, packaging materials and labelling materials.\n2.A general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials.\n3.A term used to denote starting materials, process aids, intermediates, active pharmaceutical ingredients, packaging and labelling materials.'可被翻译为：1.用于表示起始原料(活性药物成分和赋形剂)、试剂、溶剂、工艺助剂、中间体、包装材料和标签材料的总称。\n2.用于表示原材料(起始原料、试剂、溶剂)、工艺助剂、中间体、原料药以及包装和标签材料的通用术语。\n3.用于表示起始原料、工艺助剂、中间体、活性药物成分、包装和标签材料的术语。\n'A general term for a report on the testing of starting materials, intermediates, active substances, excipients, reference substances and their finished products used in the manufacture of pharmaceutical products.'可被翻译为：对用于药品生产的起始物料、中间体、活性物质、辅料、标准物质及其成品的检测报告的通称。\n'4) Correct starting materials, packaging materials and labels;'可被翻译为：4.正确的原辅料、包装材料和标签；\n\n根据上述已知信息，请将'(i) A review of starting materials including packaging materials used in the product, especially those from new sources and in particular the review of supply chain traceability of active substances;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(i) 对产品中使用的原材料包括包装材料进行回顾，特别是新供应商的包装材料，以及贵活性物质的供应链追溯性的回顾；"
    },
    {
        "instruction":"已知信息：\n'(I) Undertake the collection, evaluation, feedback and reporting of ADR reporting and monitoring data nationwide, and set up and maintain the national information network for ADR monitoring;'可被翻译为：（一）承担国家药品不良反应报告和监测资料的收集、评价、反馈和上报，以及全国药品不良反应监测信息网络的建设和维护；\n'Article 10 The National Center for ADR Monitoring is responsible for the technical work of ADR reporting and monitoring nationwide, and fulfills the following main responsibilities:'可被翻译为：第十条 国家药品不良反应监测中心负责全国药品不良反应报告和监测的技术工作，并履行以下主要职责：\n'Article 26 The National Center for ADR Monitoring shall analyze and evaluate the death cases and report the evaluation results to the SFDA and the Ministry of Health in a timely manner.'可被翻译为：第二十六条 国家药品不良反应监测中心应当及时对死亡病例进行分析、评价，并将评价结果报国家食品药品监督管理局和卫生部。\n'(I) Undertake the collection, evaluation, feedback and reporting of ADR reporting and monitoring data, and maintain and manage the information network for ADR monitoring within their respective administrative regions;'可被翻译为：（一）承担本行政区域内药品不良反应报告和监测资料的收集、评价、反馈和上报，以及药品不良反应监测信息网络的维护和管理；\n\n根据上述已知信息，请将'Article 52 The National Center for ADR Monitoring shall release ADR warning information in a timely manner based on results of comprehensive analysis and evaluation on ADR reporting and monitoring data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条 国家药品不良反应监测中心应当根据对药品不良反应报告和监测资料的综合分析和评价结果，及时发布药品不良反应警示信息。"
    },
    {
        "instruction":"已知信息：\n'(2) having the institutions, full-time testing personnel and equipment capable of meeting the quality testing requirements for the medical devices manufactured;'可被翻译为：（二）有能对生产的医疗器械进行质量检验的机构或者专职检验人员以及检验设备；\n'Article 18 Medical device testing institutions shall have the relevant qualification of medical device testing, and perform testing within their specified testing scope. It shall carry out pre-evaluation of the product technical requirements. The pre-evaluation opinions together with the medical device registration testing report shall be submitted to the applicant.'可被翻译为：第十八条 医疗器械检验机构应当具有医疗器械检验资质、在其承检范围内进行检验，并对申请人提交的产品技术要求进行预评价。预评价意见随注册检验报告一同出具给申请人。\n'Article 26 Medical device testing institutions shall have the relevant qualification of medical device testing, and perform testing within their specified testing scope. It shall carry out pre-evaluation of the product technical requirements. The pre-evaluation opinions together with the medical device registration testing report shall be submitted to the applicant.'可被翻译为：第二十六条 医疗器械检验机构应当具有医疗器械检验资质、在其承检范围内进行检验，并对申请人提交的产品技术要求进行预评价。预评价意见随注册检验报告一同出具给申请人。\n'Article 16 When applying for class II and class III medical device registration, registration testing shall be conducted. The medical device testing institutions shall carry out relevant registration testing on the products in accordance with the product technical requirements.'可被翻译为：第十六条 申请第二类、第三类医疗器械注册，应当进行注册检验。医疗器械检验机构应当依据产品技术要求对相关产品进行注册检验。\n\n根据上述已知信息，请将'For the medical devices having not included in the testing scope of any medical device testing institutions, the corresponding registration department shall designate a testing institution which has the capability to conduct the testing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"尚未列入医疗器械检验机构承检范围的医疗器械，由相应的注册审批部门指定有能力的检验机构进行检验。"
    },
    {
        "instruction":"已知信息：\n'Records of the test\/control articles on stability, batch number, purity, specification, quantity, physical and chemical characteristics, storage conditions, expiration date, etc. should be retained completely;'可被翻译为：受试物与对照品的稳定性、批号、纯度含量、规格、数量、理化特征、保存条件、有效期等记录完整；\n'A test to study the law of the change of raw materials or pharmaceutical preparations over time under the influence of temperature, humidity, and light. The test provides a scientific basis for the production, packaging, storage and transportation conditions of the drug, and establishes the validity period of the drug.'可被翻译为：研究原料药或药物制剂在温度、湿度、光线的影响下随时间变化规律的试验。通过该试验为药品的生产、包装、贮存、运输条件提供科学依据，并建立药品的有效期。\n'Under the correct storage conditions, it is expected that the drug product will meet the quality standards established through multiple batch product stability studies.'可被翻译为：在正确的贮存条件下，预期药品将符合经多批产品稳定性研究制定的质量标准的时间。\n'4. Reagents and media- proper storage, expiration date, and growth promotion'可被翻译为：试剂和培养基适当存贮、有效期和促生长试验\n\n根据上述已知信息，请将'A stability test performed under conditions close to the actual storage of the drug to provide a basis for establishing the expiration date of the drug.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在接近药品实际贮存条件下进行的，为制定药物的有效期提供依据的稳定性试验。"
    },
    {
        "instruction":"已知信息：\n'(4) The status of use or the effects generated of medical devices, according to their different structural characteristics, whether are in contact with human body and patterns of use, include:'可被翻译为：（四）根据不同的结构特征、是否接触人体以及使用形式，医疗器械的使用状态或者其产生的影响包括以下情形：\n'(3) Patterns of use of medical devices, according to their different structural characteristics and whether are in contact with human body, include:'可被翻译为：（三）根据不同的结构特征和是否接触人体，医疗器械的使用形式包括：\n'Instructions for use. Information provided by the manufacturer to inform the device user of the medical device’s intended purpose and proper use and of any precautions to be taken (17).Inform the device user of the medical device’s intended purpose and proper use and of any precautions to be taken (17).'可被翻译为：使用说明。制造商提供的信息，告知设备用户医疗器械的预期用途和正确使用以及需要采取的任何预防措施(17)。告知医疗器械使用者医疗器械的预期用途和正确使用以及需要采取的任何预防措施(17)。\n'National medical device varieties under intensive surveillance shall be determined according to the medical device registration, adverse event monitoring, supervisory inspection and testing and based on risk degree and product use.'可被翻译为：国家医疗器械重点监测品种应当根据医疗器械注册、不良事件监测、监督检查、检验等情况，结合产品风险程度和使用情况确定。\n\n根据上述已知信息，请将'The risk degree of a medical device shall be determined comprehensively according to the intended purpose, structural characteristics, pattern of use, status of use as well as whether the device is body contacting.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械风险程度，应当根据医疗器械的预期目的，通过结构特征、使用形式、使用状态、是否接触人体等因素综合判定。"
    },
    {
        "instruction":"已知信息：\n'Article 60 Where the management classification of a filed medical device is adjusted, the filing entity shall apply to the food and drug regulatory department for cancellation of the original filing. Where the management classification is adjusted to a class II or class III medical device, the filing entity shall apply for registration in accordance with the Provisions.'可被翻译为：第六十条 已备案的医疗器械管理类别调整的，备案人应当主动向食品药品监督管理部门提出取消原备案；管理类别调整为第二类或者第三类医疗器械的，按照本办法规定申请注册。\n'For a newly developed in-vitro diagnostic reagent not yet listed in the classification catalogue, the applicant may directly apply for a class III in-vitro diagnostic reagent registration, or, after determining the class of the product in accordance with the classification rules and applying for class confirmation to the China Food and Drug Administration, apply for registration or for filing.'可被翻译为：对新研制的尚未列入体外诊断试剂分类目录的体外诊断试剂，申请人可以直接申请第三类体外诊断试剂产品注册，也可以依据分类规则判断产品类别向国家食品药品监督管理总局申请类别确认后，申请产品注册或者办理产品备案。\n'To apply for filing of class I in-vitro diagnostic reagent, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .'可被翻译为：境内第一类体外诊断试剂备案，备案人向设区的市级食品药品监督管理部门提交备案资料。\n'Article 69 For a filed in-vitro diagnostic reagent, where the contents set forth in the filing information form for in-vitro diagnostic reagent changed, the filing entity shall submit a description of the change and related supporting documents to the original filing department and apply for change of filing. Where the filing materials meet the formal requirements, the food and drug regulatory department shall put the changes in the information of changes, and file a record.'可被翻译为：第六十九条 已备案的体外诊断试剂，备案信息表中登载内容及备案的产品技术要求发生变化的，备案人应当提交变化情况的说明及相关证明文件，向原备案部门提出变更备案信息。备案资料符合形式要求的，食品药品监督管理部门应当将变更情况登载于变更信息中，将备案资料存档。\n\n根据上述已知信息，请将'Article 70 Where the management classification of a filed in-vitro diagnostic reagent is adjusted, the filing entity shall apply to the food and drug regulatory department for cancellation of the original filing. Where the management classification is adjusted to a class II or class III in-vitro diagnostic reagent, the filing entity shall apply for registration in accordance with the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十条 已备案的体外诊断试剂管理类别调整的，备案人应当主动向食品药品监督管理部门提出取消原备案；管理类别调整为第二类或者第三类体外诊断试剂的，按照本办法规定申请注册。"
    },
    {
        "instruction":"已知信息：\n'For all product types, follow current USP methodology in , with the following additional instructions.'可被翻译为：所有产品类型应遵循中现行USP方法和以下附加说明。\n'Follow the current edition of the USP for the amount of sample to be tested.'可被翻译为：样本量执行USP现行版本要求。\n'Antimicrobial Effectiveness testing is described in USP<51> . Previously this chapter was known as “Preservative Effectiveness Testing”. Detailed procedure for the performance of the test can be found in USP <51>.'可被翻译为：在USP<51>中描述了抑菌效力试验，以前这一章被称为“防腐效力试验”。执行测试的详细程序 可以在USP<51>中找到。\n'Follow the current edition of the USP to determine the correct number of units to be tested and the amount of product to be analyzed from each unit. It is preferable to test the entire contents of each unit if possible. Follow laboratory policy if it requires testing more units than the USP requires.'可被翻译为：按照现行版本的USP确定要测试的正确件数以及每件要分析的产品数量。如 果可能，最好测试每件的全部内容。如果实验室政策要求测试的单元数超过 USP要求，则遵循实验室政策。\n\n根据上述已知信息，请将'For all product types, follow current USP<51> methodology in chapter , with the following additional instructions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有的产品类型均需遵守现行USP<51>的方法，和以下附加说明。"
    },
    {
        "instruction":"已知信息：\n'Article 244: When changes involve key quality factors such as starting materials, immediate packaging materials, manufacturing process, major equipment, etc., the quality of at least the first three batches produced after the change should be evaluated. If the change has potential impact on the shelf life, stability studies should also be conducted.'可被翻译为：第二百四十四条 改变原辅料、与药品直接接触的包装材料、生产工艺、主要生产设备以及其他影响药品质量的主要因素时，还应当对变更实施后最初至少三个批次的药品质量进行评估。如果变更可能影响药品的有效期，则质量评估还应当包括对变更实施后生产的药品进行稳定性考察。\n'(VIII)  Other materials relating to product quality.'可被翻译为：（八）与产品质量相关的其他资料。\n'Ability of a process to tolerate variability of materials and changes of the process and equipment without negative impact on quality.'可被翻译为：工艺承受物料的波动及工艺与设备改变，而不造成负面质量影响的能力。\n'The selection of the monitoring system should take into account any risk presented by the materials used in the manufacturing operation (e.g. those involving live organisms, powdery products or radiopharmaceuticals) that may give rise to biological, chemical or radiation hazards.'可被翻译为：监测系统的选择应考虑生产操作中使用的可能导致生物、化学或放射性危害的物料所带来的任何风险（例如涉及活微生物的物料，粉末物料或放射性物料）。\n\n根据上述已知信息，请将'The determination of key materials should comprehensively take into account of the quality risk of the drugs produced by the manufacturer, the materials consumption and the impact on product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"主要物料的确定应当综合考虑企业所生产的药品质量风险、物料用量以及物料对药品质量的影响程度等因素。"
    },
    {
        "instruction":"已知信息：\n'Chemical products with simple chemical structure as the starting material, through a series of chemical reactions and physical processing process to produce drugs.'可被翻译为：以化学结构简单的化工产品为起始原料，经过一系列化学反应和物理处理过程制得药物的过程。\n'The use of mechanical, electronic and computer technology in vitro to simulate the process of drugs in vivo, and obtain the pharmacokinetic parameters of technology.'可被翻译为：利用机械、电子学以及电子计算机技术在体外模拟药物的体内过程，并求得药动学参数的技术。\n'The purpose of on-site inspection of Pharmacological and Toxicological study is to check the compliance of Pharmacological and Toxicological study and verify the authenticity and consistency of relevant application dossiers through the inspection and \/ or on-site confirmation of the data integrity of the original data of Pharmacological and Toxicological study.'可被翻译为：药理毒理学研究现场核查的目的主要是通过对药理毒  理学研究的原始资料进行数据可靠性的核实和\/或实地确证，  检查药理毒理学研究的合规性，核实相关申报资料的真实性、一致性。\n'(Pharmacological and Toxicological Study)'可被翻译为：(药理毒理学研究)\n\n根据上述已知信息，请将'Through chemical structure modification and in vitro and in vivo pharmacological and toxicological evaluation, the process of further discovering the derivative of the lead compound series with excellent efficacy, safety and pharmacokinetic properties.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过化学结构改造，并经体外和体内药理毒理方法评价，进一步发现先导化合物系列中，其药效、安全性、药动学特性优良的衍生物的过程。"
    },
    {
        "instruction":"已知信息：\n'x-ray diffraction of single crystal'可被翻译为：X 射线单晶衍射\n'x-ray diffraction of powder'可被翻译为：X 射线粉末衍射\n'When a crystal is illuminated with X-rays, the scattered X-rays of the atoms in the crystal add up. When the X-ray is monochromatic, the scattered X-ray of each atom interferes, producing strong X-ray diffraction lines in a specific direction. The structure of the crystal can be determined by the diffraction effect of the X-ray of a single crystal.'可被翻译为：当晶体被X射线照射时，晶体中各原子的散射X射线会叠加起来。当X射线为单色时，各原子的散射X射线发生干涉，在特定的方向上产生强的X射线衍射线，利用单晶体的X射线的衍射效应可测定晶体的结构。\n'A resource database of protein structure information collected from methods such as X-ray crystal diffraction and nuclear magnetic resonance analysis.'可被翻译为：收集来源于X射线晶体衍射和核磁共振解析等方法测定的蛋白质结构信息资源数据库。\n\n根据上述已知信息，请将'The X-ray diffraction method using powder crystal or polycrystal as the sample.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"采用粉末状晶体或多晶体为试样的X射线衍射法。"
    },
    {
        "instruction":"已知信息：\n'Article 66 For drug MAHs and manufacturers with bad credit records, drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government shall increase the supervision and inspection frequency and may impose joint punishment according to national regulations.'可被翻译为：第六十六条 省、自治区、直辖市药品监督管理部门对有不良信用记录的药品上市许可持有人、药品生产企业，应当增加监督检查频次，并可以按照国家规定实施联合惩戒。\n'Article 108 The NMPA establishes the drug safety credit management system, and the CFDI is responsible for establishing the drug safety credit record for drug non-clinical safety evaluation and research institutes and drug clinical trial organizations, recording license issuance, routine supervision and inspection results, and investigation and handling of illegal acts, disclosing the records to the public in accordance with the law and updating records in a timely manner. For entities with poor credit records, the drug regulatory departments shall increase the supervision and inspection frequency and may impose joint punishment according to national regulations. Relevant provisions for the drug safety credit record of drug non-clinical safety evaluation and research institutes and drug clinical trial organizations shall be formulated and issued by the CFDI.'可被翻译为：第一百零八条 国家药品监督管理局建立药品安全信用管理制度，药品核查中心负责建立药物非临床安全性评价研究机构、药物临床试验机构药品安全信用档案，记录许可颁发、日常监督检查结果、违法行为查处等情况，依法向社会公布并及时更新。药品监督管理部门对有不良信用记录的，增加监督检查频次，并可以按照国家规定实施联合惩戒。药物非临床安全性评价研究机构、药物临床试验机构药品安全信用档案的相关制度，由药品核查中心制定公布。\n'The Information Center of NMPA is responsible for the construction and management of the drug traceability coordination service platform and drug safety credit archives, and is in charge of the unified coding of drug manufacture sites.'可被翻译为：国家药品监督管理局信息中心负责药品追溯协同服务平台、药品安全信用档案建设和管理，对药品生产场地进行统一编码。\n'For the registrant, filing entity and distributor of medical devices with bad credit records, the drug regulatory departments shall increase the supervision and inspection frequency, and impose heavier punishment on dishonest behaviors according to law.'可被翻译为：对有不良信用记录的医疗器械注册人、备案人和经营企业，药品监督管理部门应当增加监督检查频次，依法加强失信惩戒。\n\n根据上述已知信息，请将'Drug regulatory departments shall establish a credit record system for the vaccine MAHs and their responsible persons and include them into the national credit information sharing platform, release information of their serious loss of honesty according to regulations and impose joint punishment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品监督管理部门应当建立疫苗上市许可持有人及其相关人员信用记录制度，纳入全国信用信息共享平台，按照规定公示其严重失信信息，实施联合惩戒。"
    },
    {
        "instruction":"已知信息：\n'In the DNA double strand, the strand that is not used to transcribe mRNA.'可被翻译为：DNA双链中，不用于转录mRNA的那条链。\n'A replication model of double-stranded deoxyribonucleic acid (DNA) in which each single strand is used as a template for the synthesis of a new strand after the separation of the parental double strand. Thus, when replication is complete, there will be two daughter DNA molecules, each with the same nucleotide sequence as the parent molecule.'可被翻译为：一种双链脱氧核糖核酸（DNA）的复制模型，其中亲代双链分离后，每条单链均作为新链合成的模板。因此，复制完成时将有两个子代DNA分子，每个分子的核昔酸序列均与亲代分子相同。\n'Single or double strand scissions in the DNA.'可被翻译为：DNA的单链或双链被切断。\n'dna strand breaks'可被翻译为：DNA链断裂\n\n根据上述已知信息，请将'The strand of a DNA double that is used to transcribe mRNA.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"DNA双链中，用于转录mRNA的那条链。"
    },
    {
        "instruction":"已知信息：\n'1.Subjecting an in-process or bulk process intermediate (final biological bulk intermediate) or final product of a single batch to an alternate manufacturing process due to a failure to meet predetermined specifications. Reworking is an unexpected occurrence and is not pre- approved as part of the marketing authorization.\n2.Subjecting an intermediate or API that does not conform to standards or specifications to one or more processing steps that are different from the established manufacturing process to obtain acceptable quality intermediate or API (e.g. recrystallizing with a different solvent).'可被翻译为：1.由于未能达到预定的规格，使制程或散装工艺中间体(最终生物散装中间体)或单个批次的最终产品采用替代生产工艺。返工是一种意外事件，不作为上市许可的一部分预先批准。\n2.对不符合标准或规范的中间体或API进行一个或多个不同于既定生产工艺的加工步骤，以获得质量可接受的中间体或API(例如，用不同的溶剂重结晶)。\n'Measurement where the sample is diverted from the manufacturing process, and may be returned to the process stream.'可被翻译为：测量样品从制造过程中转移，并可能返回到工艺流。\n'Subjecting an intermediate or API that does not conform to standards or specifications to one or more processing steps that are different from the established manufacturing process to obtain acceptable quality intermediate or API (e.g., recrystallizing with a different solvent).'可被翻译为：为得到合格的物料，将不符合要求的中间体或 API 进行与已确定工艺不同的一步或多步操作(例如:用不同的溶剂进行重结晶)。\n'Sample resulting from the pooling of all or parts of two or more samples of the material.'可被翻译为：将材料的两个或两个以上样品的全部或部分汇集而成的样品。\n\n根据上述已知信息，请将'FDA does not recommend pooling in-process samples from different in- process stages of the manufacturing process because it may be difficult to ensure the homogeneity of these materials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"FDA不建议对生产工艺中不同中控步骤的中控样品进行合并，因为可能难以确保这 些物料的均一性。"
    },
    {
        "instruction":"已知信息：\n'Raw materials and excipients packaging materials, and etc.'可被翻译为：指原料、辅料和包装材料等。\n'2. Requirements for registration of medical packaging materials (Interim) (omitted)'可被翻译为：2.药包材登记资料要求（试行）（略）\n'Raw materials, excipients, packaging materials, and equipment used specifically for producing counterfeit or inferior drugs shall be confiscated.'可被翻译为：对生产者专门用于生产假药、劣药的原料、辅料、包装材料、生产设备予以没收。\n'3. Pharmaceutical excipients and pharmaceutical packaging materials whose applications have been accepted and completed for review;'可被翻译为：3.已受理并完成审评的药用辅料和药包材；\n\n根据上述已知信息，请将'4. Basic requirements for the annual report of medicinal raw materials, excipients and pharmaceutical packaging materials (omitted)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"4.药用原辅料、药包材年度报告基本要求（略）"
    },
    {
        "instruction":"已知信息：\n'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers and samples.'可被翻译为：申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料和样品之日起即为受理。\n'Article 24 If the lot release institution believes that relevant data in the application dossiers needs to be verified or supplemented, it shall notify the lot release applicant of supplementing data in writing and specify the time limit for reply.'可被翻译为：第二十四条 批签发机构认为申请资料中的有关数据需要核对或者补充的，应当书面通知批签发申请人补正资料，并明确回复时限。\n'(IV) Not informing the lot release applicant at once of all the content needed to be supplemented or corrected, where the application dossiers and samples submitted are incomplete or not conforming with the prescribed format;'可被翻译为：（四）批签发申请人提交的申请资料、样品不齐全、不符合法定形式，不一次告知批签发申请人必须补正的全部内容的；\n'(3) Where the application dossiers are incomplete or do not conform to the prescribed form, a notice of supplement shall be issued to notify the applicant of all the contents that need to be supplemented and corrected at one time. If no notice is made within the time limit, the application shall be deemed as accepted since the date of receipt; and'可被翻译为：（三）申请资料不齐全或者不符合规定形式的，出具补正通知书，一次告知申请人需要补正的全部内容，逾期未告知的，自收到申请资料之日起即为受理；\n\n根据上述已知信息，请将'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料之日起即为受理。"
    },
    {
        "instruction":"已知信息：\n'Management system to direct and control a pharmaceutical company with regard to quality. (ICH Q10 based upon ISO 9000:2005)'可被翻译为：为在质量方面指导和控制制药公司而建立的管理体系。(ICH Q10 依据 ISO 9000:2005)\n'Person(s) who direct and control an organization at the highest levels and who have the authority and responsibility to mobilize resources within the organization. In NRAs, the terms “senior management” or “top management” can be used interchangeably.'可被翻译为：在组织最高层指导和控制组织的人，他们有权力和责任在组织内调动资源。在国家注册机构中，术语“高级管理人员”或“最高管理人员”可以互换使用。\n'Part of quality management focused on setting quality objectives and specifying necessary operational processes and related resources to fulfil the quality objectives. (ISO 9000:2005)'可被翻译为：质量管理的一部分，着重于设定质量目标，并详细规定必要的操作程序和相关资源以实 现质量目标。(ISO 9000:2005)\n'Management system to direct and control a pharmaceutical company with regard to quality.'可被翻译为：指导和控制制药公司质量的管理体系。\n\n根据上述已知信息，请将'Person(s) who direct and control a company or site at the highest levels with the authority and responsibility to mobilise resources within the company or site. (ICH Q10 based in part on ISO 9000:2005)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在最高级别上指导和控制一个公司或工厂、具有权力和责任在公司或工厂内部调动资源 的人员。 (ICH Q10 部分依据 ISO 9000:2005)"
    },
    {
        "instruction":"已知信息：\n'A collaborated method prepared by an ORS laboratory is available for extraction of endotoxin from devices and may be used if necessary. Analytical verification of the final version should be conducted by the responsible laboratory. The ORS laboratory protocol is summarized below for convenience.'可被翻译为：ORS实验室起草了一份协作方法，用于从医疗器械中萃取内毒素，必要时可使用之。 应由责任实验室对最终版本的分析方法进行确认。方便起见，将ORS实验室方案总结 如下：\n'The percentage of the total volume available for storing temperature-sensitive pharmaceutical products (TTSPPS) that can reliably be achieved in practice, taking account of the types of stock-keeping unit (SKU), the types of load support system and the stock management systems used in the store.'可被翻译为：考虑到库存单位(SKU)的类型、负载支持系统的类型和仓库中使用的库存管理系统，在实践中可以可靠地实现的可用于存储温度敏感药品(TTSPPS)的总体容量的百分比。\n'NOTE: The rinse or extract volume may be adjusted for the size and configuration of the device. The device or components may be cut into smaller pieces using sterile, nonpyrogenic equipment such as forceps, scissors, wire cutters, etc. prior to the extraction.'可被翻译为：注：淋洗或萃取容积可根据医疗器械的尺寸和参数设置进行调整。医疗器械或组份可在 萃取前使用无菌无热源设备如镊子、剪刀、剪线钳等切为更小块。\n'The total volume available for storing TTSPPs, taking account of the type of load support system employed (floor-standing pallets, adjustable pallet racking or shelving units), as modified by the utilization factor that can be achieved in the store.'可被翻译为：可用于存储ttspp的总容量，考虑到所采用的负载支撑系统的类型(地板支撑托盘，可调节托盘货架或货架单元)，根据可以在商店中实现的利用率进行修改。\n\n根据上述已知信息，请将'NOTE: Adjust the final endotoxin value taking into account the volume of the rinse solution used in the extraction procedure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"注：调整最终内毒素值时要考虑提取程序所用淋洗溶液的体积。"
    },
    {
        "instruction":"已知信息：\n'The liquid in which the microorganisms are inoculated into the liquid medium for a period of time and then metabolized to synthesize the bacteria and secrete the products.'可被翻译为：微生物接种到液体培养基培养一段时间后，经微生物代谢合成菌体及分泌产物的液体。\n'The period in which the bacteria are inoculated into the fermentation medium and begin to grow and reproduce under suitable culture conditions.'可被翻译为：产生菌接种至发酵培养基后，在合适的培养条件下，开始生长和繁殖的时期。\n'Also known as \"increasing bacteria medium\". The use of the isolated object has a specific preference for a certain nutrient in the medium to add the nutrient, so that the microorganism in the number of dominant, in order to achieve the enrichment culture purpose of the medium.'可被翻译为：又称\"增菌培养基”。利用分离对象对某一营养物质有专一偏好的特性，在培养基中加入该营养物，使该微生物在数量上占优势，以达到富集培养目的的培养基。\n'The drug molecules are removed after dissolving from the surface of the solid preparation, or the dissolving medium is so large that there is a large concentration difference between the drug on the solid surface and the drug in the medium.'可被翻译为：药物分子自固体制剂表面溶出后即被移除，或溶出介质体积很大而导致固体表面药物与介质中药物之间呈现较大的浓度差。\n\n根据上述已知信息，请将'The period in which the seeds or bacteria grown on the solid medium are transferred to the liquid medium for culture, so that they can multiply into a large number of mycelia or bacteria.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将在固体培养基上培养出的抱子或菌体转入到液体培养基中培养，使其繁殖成大量菌丝或菌体的时期。"
    },
    {
        "instruction":"已知信息：\n'Article 28 The food and drug regulatory departments shall supervise and inspect the implementation of medical device mandatory standards and the registered or filed product technical requirements by medical device enterprises.'可被翻译为：第二十八条 食品药品监督管理部门对医疗器械企业实施医疗器械强制性标准以及经注册或者备案的产品技术要求的情况进行监督检查。\n'Article 25 Medical device manufacturers shall organize the manufacturing in strict accordance with the registered or filed product technical requirements and ensure that the delivered medical devices meet the mandatory standards as well as the registered and filed product technical requirements.'可被翻译为：第二十五条 医疗器械企业应当严格按照经注册或者备案的产品技术要求组织生产，保证出厂的医疗器械符合强制性标准以及经注册或者备案的产品技术要求。\n'Article 54 Where suspected medical device adverse events are caused by inferior device quality, the drug regulatory departments shall take proper measures in accordance with relevant regulations of medical devices; where such events are caused by improper use of medical device, the health administrative departments shall take proper measures.'可被翻译为：第五十四条  可疑医疗器械不良事件由医疗器械产品质量原因造成的，由药品监督管理部门按照医疗器械相关法规予以处置；由医疗器械使用行为造成的，由卫生行政部门予以处置。\n'Article 61 The drug regulatory departments shall publish the contact information receiving complaints and reports. Upon receipt of reports, the drug regulatory departments shall make verification, handling and reply in a timely manner. If authentic upon verification, the drug regulatory departments shall reward the reporters in accordance with relevant regulations.'可被翻译为：第六十一条  药品监督管理部门应当公布接受投诉、举报的联系方式。接到举报的药品监督管理部门应当及时核实、处理、答复。经查证属实的，应当按照有关规定对举报人给予奖励。\n\n根据上述已知信息，请将'Article 29 Any unit or individual have the right to report to the food and drug regulatory departments misbehaviors that violate the medical device mandatory standards and registered or filed product technical requirements. Departments receiving such reports shall take proper actions in accordance with regulations in a timely manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十九条 任何单位和个人有权向食品药品监督管理部门举报或者反映违反医疗器械强制性标准以及经注册或者备案的产品技术要求的行为。收到举报或者反映的部门，应当及时按规定作出处理。"
    },
    {
        "instruction":"已知信息：\n'(2) not publicizing at the acceptance place the information that shall be publicized by la]w;'可被翻译为：（二）不在受理场所公示依法应当公示的材料的；\n'(2) The enterprise's eligibility as an entity is terminated according to law;'可被翻译为：（二）企业主体资格被依法终止的；\n'Article 38 The lot release institution shall publicize lot release application procedures, the list of materials for lot release to be submitted, sample texts of application form, requirements for time limit and other information on its website or in the place where the application is accepted.'可被翻译为：第三十八条   批签发机构应当在本机构网站或者申请受理场所公开批签发申请程序、需要提交的批签发材料目录和申请书示范文本、时限要求等信息。\n'Article 37 The lot release institution shall publicize lot release application procedures, list of materials for lot release to be submitted, sample text of application form, charging standards and basis, requirements for time limit and other information on its website or in the place where the application is accepted.'可被翻译为：第三十七条 批签发机构应当在本机构网站或者申请受理场所公开批签发申请程序、需要提交的批签发材料目录和申请书示范文本、收费标准和依据、时限要求等信息。\n\n根据上述已知信息，请将'(II) Not publicizing on the institution's website or at the acceptance place the information that should be publicized according to law;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）不在本机构网站或者申请受理场所公示依法应当公示的材料的；"
    },
    {
        "instruction":"已知信息：\n'Article 87 Where any disease prevention and control institution or immunization entity is under any of the following circumstances in violation of this Law, the competent health department of the people's government at or above the county level shall order to make rectification, give a warning, and confiscate the illegal income; and in serious circumstances, impose sanctions of a warning and up to  dismissal on the main responsible person, directly responsible persons and other directly responsible personnel according to law, and order the responsible medical personnel to suspend practice activities for more than one year and less than eighteen months; and for serious consequence, give an expulsion to the main responsible person and executive in charge and other directly responsible personnel according to law, and responsible medical and health personnel shall be revoked of business certificate by original issuing department:'可被翻译为：第八十七条 违反本法规定，疾病预防控制机构、接种单位有下列情形之一的，由县级以上人民政府卫生健康主管部门责令改正，给予警告，没收违法所得；情节严重的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至撤职处分，责令负有责任的医疗卫生人员暂停一年以上十八个月以下执业活动；造成严重后果的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予开除处分，由原发证部门吊销负有责任的医疗卫生人员的执业证书：\n'Article 95 For any of the following behaviors of drug regulatory departments or competent health departments in vaccine administration, the executive in charge and other directly responsible personnel shall be given a downgrade or dismissal; and in serious circumstances, the executive in charge and other directly responsible personnel shall be given an expulsion; if it causes serious consequence, the principal shall resign to assume responsibility:'可被翻译为：第九十五条 药品监督管理部门、卫生健康主管部门等部门在疫苗监督管理工作中有下列情形之一的，对直接负责的主管人员和其他直接责任人员依法给予降级或者撤职处分；情节严重的，依法给予开除处分；造成严重后果的，其主要负责人应当引咎辞职：\n'Where any disease prevention and control institution or immunization entity commits illegal acts as prescribed in the preceding paragraph, the competent health department of the people's government at or above the county level may impose sanctions of  warning and up to the dismissal on the main responsible person, the executive in charge and other directly responsible personnel according to law, and order the responsible medical and health personnel to suspend practice activities for more than six months and less than one year; and for serious consequences, give a dismissal to the principal, the executive in charge and other directly responsible personnel according to law, and responsible medical and health personnel shall be revoked of business certificate by original issuing department.'可被翻译为：疾病预防控制机构、接种单位有前款规定违法行为的，县级以上人民政府卫生健康主管部门可以对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至撤职处分，责令负有责任的医疗卫生人员暂停六个月以上一年以下执业活动；造成严重后果的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予开除处分，由原发证部门吊销负有责任的医疗卫生人员的执业证书。\n'Article 88 In cases where violation of this Law by disease prevention and control institution or immunization entity involves any of the following circumstances, the competent health department of the people's government at or above the county level shall order to make rectification, give a warning, and confiscate the illegal income; and in serious circumstances, impose sanctions of a warning and up to dismissal on the main responsible person, directly responsible persons and other directly responsible personnel according to law, and order the responsible medical personnel to suspend practice activities for more than six months and less than one year; for serious consequences, give an expulsion to the principal and executive in charge and other directly responsible personnel according to law, and responsible medical and health personnel shall be revoked of business certificate by original issuing department:'可被翻译为：第八十八条 违反本法规定，疾病预防控制机构、接种单位有下列情形之一的，由县级以上人民政府卫生健康主管部门责令改正，给予警告；情节严重的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至撤职处分，责令负有责任的医疗卫生人员暂停六个月以上一年以下执业活动；造成严重后果的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予开除处分，由原发证部门吊销负有责任的医疗卫生人员的执业证书：\n\n根据上述已知信息，请将'Relevant competent departments shall impose sanctions according to law on a newspaper, journal, radio, television, internet website or any other media where they fabricate or disseminate any false information about vaccine safety, and on the main responsible person, executive in charge and other directly responsible personnel.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"报纸、期刊、广播、电视、互联网站等传播媒介编造、散布虚假疫苗安全信息的，由有关部门依法给予处罚，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予处分。"
    },
    {
        "instruction":"已知信息：\n'Article 84 The registration shall not be renewed in any of the following circumstances:'可被翻译为：第八十四条 有下列情形之一的，不予再注册：\n'(2) the re-registration is not allowed according to provisions in Article 126 of the Provisions;'可被翻译为：（二）按照本办法第一百二十六条的规定不予再注册的；\n'(2) the License is not renewed upon expiration of the valid term;'可被翻译为：（二）有效期届满未延续的；\n'Article 72 Where, in violation of the Provisions, a registration alteration of permission items for a medical device is not performed according to law, punishments shall be imposed according to the situation concerning not obtaining a medical device registration certificate in the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第七十二条 违反本办法规定，未依法办理医疗器械注册许可事项变更的，按照《医疗器械监督管理条例》有关未取得医疗器械注册证的情形予以处罚。\n\n根据上述已知信息，请将'(2) Where registration shall not be renewed according to these Provisions;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）按照本办法规定不予再注册的；"
    },
    {
        "instruction":"已知信息：\n'In the sequence of peptide or protein, the amino group and the carboxyl group between amino acids are dehydrated to form a bond, so the amino acid in the peptide or protein molecule is not a complete amino acid and is called residue.'可被翻译为：在肽或蛋白质的序列中，氨基酸之间的氨基和竣基脱水成键，因此肽或蛋白质分子中的氨基酸已不是完整的氨基酸，被称为残基。\n'Also called \"p-aminobenzenesulfonic acid\". A compound prepared by the reaction of aniline with concentrated sulfuric acid at 180 7.'可被翻译为：又称\"对氨基苯磺酸\"。由苯胺和浓硫酸在180七反应制得的化合物。\n'If the base sequence of one nucleic acid chain is paired against the base sequence of another nucleic acid chain, the two are called complementary chains.'可被翻译为：若一条核酸链的碱基序列与另-条核酸链的碱基序列反平行配对，则二者互称互补链。\n'Also called a \"silentmutation.\" The mutation replaces the bases, but the amino acid sequence remains the same, maintaining the function of the wild type.'可被翻译为：又称\"沉默突变（silentmutation）\"。突变虽然替换了碱基，但氨基酸顺序未变，保持野生型的功能。\n\n根据上述已知信息，请将'A protein compound consisting of a non-protein group of cogroups bound to an amino acid sequence. The non-protein portion of which is nucleic acid is called riboprotein, lipid compound is called lipoprotein, polysaccharide is called glycoprotein, and flavin riboxylic acid is called flavin protein.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由非蛋白质基团的辅基结合于氨基酸序列上组成的蛋白质类化合物。其非蛋白质部分是核酸的称为核蛋白，是类脂化合物的称为脂蛋白，是多糖的称为糖蛋白，是黄素核昔酸的称为黄素蛋白。"
    },
    {
        "instruction":"已知信息：\n'The online drug sales enterprises shall keep complete records of qualification documents and electronic transactions of the suppliers. The online drug retailers selling prescription drugs shall also keep records of prescriptions, online pharmaceutical services, etc. The relevant records shall be kept for not less than 5 years, and not less than 1 year after the expiration of the drug.'可被翻译为：药品网络销售企业应当完整保存供货企业资质文件、电子交易等记录。销售处方药的药品网络零售企业还应当保存处方、在线药学服务等记录。相关记录保存期限不少于5年，且不少于药品有效期满后1年。\n'The third-party platform shall strengthen the examination, manage the drug information display, prescription examination, drug sales and delivery, and other behaviors of the online drug sales enterprises settled on the platform, and urge them to strictly perform their legal obligations.'可被翻译为：第三方平台应当加强检查，对入驻平台的药品网络销售企业的药品信息展示、处方审核、药品销售和配送等行为进行管理，督促其严格履行法定义务。\n'Article 5 Those engaged in online drug sales and providing online drug transaction platform services shall take effective measures to ensure the authenticity, accuracy, integrity and traceability of information throughout the transaction process, and shall observe relevant national provisions on the protection of personal information.'可被翻译为：第五条 从事药品网络销售、提供药品网络交易平台服务，应当采取有效措施保证交易全过程信息真实、准确、完整和可追溯，并遵守国家个人信息保护的有关规定。\n'Article 20 The third-party platform shall audit the qualifications, and the quality and safety assurance capabilities of the online drug sales enterprises that apply for settlement, establish registration record for online drug sales enterprises, and check and update such information at least every six months to ensure that the settled online drug sales enterprises meet the legal requirements.'可被翻译为：第二十条 第三方平台应当对申请入驻的药品网络销售企业资质、质量安全保证能力等进行审核，对药品网络销售企业建立登记档案，至少每六个月核验更新一次，确保入驻的药品网络销售企业符合法定要求。\n\n根据上述已知信息，请将'Article 21 The third-party platform shall keep the information on drug display, transaction records, complaints and reports, and other relevant information. The storage period shall not be less than 5 years, and not less than 1 year after the expiration of the drug. The third-party platform shall ensure the authenticity and integrity of relevant materials, information, and data, and provide convenience for the settled online drug sales enterprises to save their own data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十一条 第三方平台应当保存药品展示、交易记录与投诉举报等信息。保存期限不少于5年，且不少于药品有效期满后1年。第三方平台应当确保有关资料、信息和数据的真实、完整，并为入驻的药品网络销售企业自行保存数据提供便利。"
    },
    {
        "instruction":"已知信息：\n'Article 48 The National Center for ADR Monitoring shall conduct comprehensive analysis on serious ADR reports received quarterly, extract and evaluate safety information that needs attention, propose risk management measures, and promptly report to the SFDA and the Ministry of Health.'可被翻译为：第四十八条 国家药品不良反应监测中心应当每季度对收到的严重药品不良反应报告进行综合分析，提取需要关注的安全性信息，并进行评价，提出风险管理建议，及时报国家食品药品监督管理局和卫生部。\n'For death cases, the provincial ADR monitoring institutions where the event occurs and where the drug manufacturer is located shall analyze and evaluate the event based on the investigation report in a timely manner, conduct on-site investigation when necessary, and report the evaluation results to the provincial drug regulatory departments and health administrative departments and the National Center for ADR Monitoring.'可被翻译为：对死亡病例，事件发生地和药品生产企业所在地的省级药品不良反应监测机构均应当及时根据调查报告进行分析、评价，必要时进行现场调查，并将评价结果报省级药品监督管理部门和卫生行政部门，以及国家药品不良反应监测中心。\n'Article 39 Provincial ADR monitoring institutions shall summarize, analyze and evaluate PSURs received and report the statistics and the analysis and evaluation results of previous year's PSURs to the provincial drug regulatory departments and the National Center for ADR Monitoring before April 1 each year.'可被翻译为：第三十九条 省级药品不良反应监测机构应当对收到的定期安全性更新报告进行汇总、分析和评价，于每年4月1日前将上一年度定期安全性更新报告统计情况和分析评价结果报省级药品监督管理部门和国家药品不良反应监测中心。\n'Article 53 Drug regulatory departments at or above the provincial level shall regularly release information on ADR reporting and monitoring.'可被翻译为：第五十三条 省级以上药品监督管理部门应当定期发布药品不良反应报告和监测情况。\n\n根据上述已知信息，请将'Article 47 Provincial ADR monitoring institutions shall conduct comprehensive analysis on ADR reports received quarterly, extract and evaluate safety information that needs attention, propose risk management measures, and promptly report to drug regulatory departments and health administrative departments at the provincial level and the National Center for ADR Monitoring.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十七条 省级药品不良反应监测机构应当每季度对收到的药品不良反应报告进行综合分析，提取需要关注的安全性信息，并进行评价，提出风险管理建议，及时报省级药品监督管理部门、卫生行政部门和国家药品不良反应监测中心。"
    },
    {
        "instruction":"已知信息：\n'Article 46 Where major interest relationship between the applicant and others is directly involved in the application for medical device registration, the food and drug regulatory department shall inform the applicant and the interested party of their right to apply for a hearing in accordance with laws, regulations and other provisions of China Food and Drug Administration. During the process of reviewing the application for medical device registration, if the food and drug regulatory department believes there are major licensing issues concerning public interests, it shall make a public announcement and hold a hearing.'可被翻译为：第四十六条 医疗器械注册申请直接涉及申请人与他人之间重大利益关系的，食品药品监督管理部门应当告知申请人、利害关系人可以依照法律、法规以及国家食品药品监督管理总局的其他规定享有申请听证的权利；对医疗器械注册申请进行审查时，食品药品监督管理部门认为属于涉及公共利益的重大许可事项，应当向社会公告，并举行听证。\n'Article 41 To apply for in-vitro diagnostic reagent registration, the applicant shall submit application materials to the food and drug regulatory department in accordance with relevant requirements.'可被翻译为：第四十一条 申请体外诊断试剂注册，申请人应当按照相关要求向食品药品监督管理部门报送申报资料。\n'Article 12 For matters of which a public hearing shall be held for implementation of administrative licensing as stipulated by laws, regulations and provisions, or for other important administrative licensing matters involving public interests for which a public hearing needs to be held as deemed by the drug regulatory department, the drug regulatory department shall make an announcement to the public and hold a public hearing. If the application for Medical Device Manufacturing License involves vital interests between the applicant and others directly, then before making a decision on administrative licensing, the drug regulatory department shall notify the applicant and the stakeholders that they are entitled to request for a public hearing.'可被翻译为：第十二条  法律、法规、规章规定实施行政许可应当听证的事项，或者药品监督管理部门认为需要听证的其他涉及公共利益的重大行政许可事项，药品监督管理部门应当向社会公告，并举行听证。医疗器械生产许可申请直接涉及申请人与他人之间重大利益关系的，药品监督管理部门在作出行政许可决定前，应当告知申请人、利害关系人享有要求听证的权利。\n'Article 12 For matters of which a public hearing shall be held for implementation of administrative licensing as stipulated by laws, regulations, and provisions, or for other important administrative licensing matters involving public interests for which a public hearing needs to be held as deemed by the drug regulatory department, the drug regulatory department shall make an announcement to the public and hold a public hearing. If the application for Medical Device Distribution License involves vital interests between the applicant and others directly, then before making a decision on administrative licensing, the drug regulatory departments shall notify the applicant and the stakeholders that they are entitled to request for a public hearing.'可被翻译为：第十二条  法律、法规、规章规定实施行政许可应当听证的事项，或者药品监督管理部门认为需要听证的其他涉及公共利益的重大行政许可事项，药品监督管理部门应当向社会公告，并举行听证。医疗器械经营许可申请直接涉及申请人与他人之间重大利益关系的，药品监督管理部门在作出行政许可决定前，应当告知申请人、利害关系人享有要求听证的权利。\n\n根据上述已知信息，请将'Article 56 Where major interest relationship between the applicant and others is directly involved in the application for in-vitro diagnostic reagent registration, the food and drug regulatory department shall inform the applicant and the interested party of their right to apply for a hearing in accordance with laws, regulations and other provisions of China Food and Drug Administration. During the process of reviewing the application for in-vitro diagnostic reagent registration, if the food and drug regulatory department believes there are major licensing issues concerning public interests, it shall make a public announcement and hold a hearing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十六条 体外诊断试剂注册申请直接涉及申请人与他人之间重大利益关系的，食品药品监督管理部门应当告知申请人、利害关系人依照法律、法规以及国家食品药品监督管理总局的有关规定享有申请听证的权利；对体外诊断试剂注册申请进行审查时，食品药品监督管理部门认为属于涉及公共利益的重大许可事项，应当向社会公告，并举行听证。"
    },
    {
        "instruction":"已知信息：\n'macrolide antibiotics'可被翻译为：大环内酯类抗生素\n'A nitrogen-containing macrolide formed from the rearrangement of 14-membered macrolide -9. Fatty Beckmann.'可被翻译为：十四元环大环内酯-9.肪经贝克曼(Beckmann)重排形成的含氮大环内酯。\n'Any of a class of enzymes produced by bacteria that hydrolyze and inactivate the β-lactam ring of an antibiotic.'可被翻译为：由细菌产生的，能将抗生素的β-内酰胺环水解，使抗生素失活的一类酶。\n'Also known as \"polyene macrolide antibiotic: an antibiotic whose molecule contains multiple covalent double bonds. These antibiotics are often called macrolides.'可被翻译为：又称\"多烯大环内酯类抗生素:分子中含有多个共甄双键的抗生素。此类抗生素常为大环内酯。\n\n根据上述已知信息，请将'The 3-position of the tetradecyclic macrolide is converted into a keto-based antibiotic.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"十四元环大环内酯的3-位转变为酮基的抗生素。"
    },
    {
        "instruction":"已知信息：\n'Methods and parameters for integrity testing of 100% of all filled containers (see paragraph 8.22).'可被翻译为：所有已灌装容器 100%完整性测试的方法和参数（参见第 8.22 节）。\n'The performance of the pre- and post-use integrity testing for sterilising grade filters (see paragraph 8.87).'可被翻译为：除菌级过滤器的使用前后完整性测试的性能（参见第 8.87 节）。\n'Open primary packaging containers should be maintained under grade A conditions with the appropriate\nbackground for the technology as described in paragraph 4.20. For partially stoppered vials or prefilled syringes\n(see paragraph 8.126).'可被翻译为：敞口的内包装容器应置于 A 级环境中，并具有适用于技术的适当背景，如 4.20 节所述。对于半压塞的西\n林瓶或预填充注射器，请参见 8.126节。\n'Permit in-place integrity testing, of the 0.22 μm final sterilising grade filter, preferably as a closed system, both prior to, and following filtration as necessary. In-place integrity testing methods should be selected to avoid any adverse impact on the quality of the product.'可被翻译为：允许在必要时在过滤之前和之后对 0.22μm 最终除菌级过滤器进行在线完整性测试，最好作为密闭系统，应选择在线完整性测试方法， 以避免对产品质量产生任何不良影响。\n\n根据上述已知信息，请将'Methods and parameters for integrity testing of filled containers (see paragraph 8.22).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"已灌装容器完整性测试的方法和参数（参见第 8.22 节）。"
    },
    {
        "instruction":"已知信息：\n'Article 6 The drug regulatory departments of the provinces, autonomous regions, and municipalities directly under the Central Government are responsible for the following administrative tasks pertaining to drug registration within their respective administrative regions:'可被翻译为：第六条 省、自治区、直辖市药品监督管理部门负责本行政区域内以下药品注册相关管理工作：\n'Article 65 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall strengthen the training and assessment of staff engaging in medical device adverse event monitoring and re-evaluation within their respective administrative regions.'可被翻译为：第六十五条  省、自治区、直辖市药品监督管理部门应当加强对本行政区域内从事医疗器械不良事件监测和再评价工作人员的培训和考核。\n'Article 7 Drug regulatory departments of the provinces, autonomous regions and municipalities directly under the Central Government are responsible for management of ADR reporting and monitoring within their respective administrative regions, and fulfill the following main responsibilities:'可被翻译为：第七条 省、自治区、直辖市药品监督管理部门负责本行政区域内药品不良反应报告和监测的管理工作，并履行以下主要职责：\n'Article 34 After knowing the group adverse events of medical device that occurs within their respective administrative regions, the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall promptly carry out on-site investigation jointly with the health administrative departments at the same level, and the drug regulatory departments of relevant provinces, autonomous regions and municipalities directly under the central government shall cooperate. Investigation, re-evaluation and handling results shall be promptly reported to the NMPA and the Health Administrative Department of the State Council, and copied to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate.'可被翻译为：第三十四条  省、自治区、直辖市药品监督管理部门在获知本行政区域内发生的群体医疗器械不良事件后，应当会同同级卫生行政部门及时开展现场调查，相关省、自治区、直辖市药品监督管理部门应当配合。调查、评价和处理结果应当及时报国家药品监督管理局和国务院卫生行政部门，抄送持有人所在地省、自治区、直辖市药品监督管理部门。\n\n根据上述已知信息，请将'The drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government may adjust the inspection frequency depending on the practical situation of drug manufacturing supervision within respective administrative regions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"省、自治区、直辖市药品监督管理部门可以结合本行政区域内药品生产监管工作实际情况，调整检查频次。"
    },
    {
        "instruction":"已知信息：\n'II. Drug marketing authorization holders and drug registration applicants shall actively prepare for the implementation of the Good Pharmacovigilance Practice, establish and continuously improve the pharmacovigilance system and conduct pharmacovigilance activities in a standardized manner.'可被翻译为：二、药品上市许可持有人和药品注册申请人应当积极做好执行《药物警戒质量管理规范》的准备工作，按要求建立并持续完善药物警戒体系，规范开展药物警戒活动。\n'In order to implement the principal responsibilities of drug marketing authorization holders and pharmacovigilance main body responsibility and guide drug marketing authorization holders to create and maintain master files of pharmacovigilance system, the National Center for ADR Monitoring has formulated the Guidance for the Preparation of Master Files of Pharmacovigilance System in accordance with the requirements of the National Medical Products Administration, which was issued on February 25, 2022.'可被翻译为：为落实药品上市许可持有人药物警戒主体责任，指导药品上市许可持有人创建和维护药物警戒体系主文件，按照国家药品监督管理局要求，国家药品不良反应监测中心组织制定了《药物警戒体系主文件撰写指南》，并于2022年2月25日发布。\n'V. Provincial medical products regulatory authorities shall urge the drug marketing authorization holders of the product within their respective jurisdiction to revise the package inserts and replacement of the labels and package inserts as required and impose severe punishment in accordance with the law for violations of laws and regulations.'可被翻译为：五、省级药品监督管理部门应当及时督促行政区域内上述药品的药品上市许可持有人按要求做好相应说明书修订和标签、说明书更换工作，对违法违规行为依法严厉查处。\n'According to the Drug Administration Law of the People's Republic of China and the Vaccine Administration Law of the People's Republic of China, NMPA has organized to formulate the Good Pharmacovigilance Practice to standardize and guide drug marketing authorization holders and drug registration applicants to conduct pharmacovigilance activities, which was issued on May 7,2021. The issues related to the implementation of the Good Pharmacovigilance Practice are hereby announced as follows:'可被翻译为：根据《中华人民共和国药品管理法》《中华人民共和国疫苗管理法》，为规范和指导药品上市许可持有人和药品注册申请人的药物警戒活动，国家药监局组织制定了《药物警戒质量管理规范》，于2021年5月7日予以公布，并就实施《药物警戒质量管理规范》有关事宜公告如下：\n\n根据上述已知信息，请将'IV. All the provincial medical products administration shall supervise and urge the drug marketing authorization holders within their respective administrative areas to actively make preparations, cooperate with relevant publicity and interpretation, supervise and guide drug marketing authorization holders to implement the Good Pharmacovigilance Practice as required by strengthening routine inspection and other activities, and in a timely manner collect and feedback relevant questions and comments.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"四、各省级药品监督管理部门应当督促本行政区域内的药品上市许可持有人积极做好相关准备工作，配合做好有关宣贯和解读，通过加强日常检查等工作监督和指导药品上市许可持有人按要求执行《药物警戒质量管理规范》，及时收集和反馈相关问题和意见。"
    },
    {
        "instruction":"已知信息：\n'Except for special regulations and requirements, the quantity of drug samples required for sampling generally shall be three times of the quantity required for testing. The remaining samples after testing, except for the retained samples for future reference, shall be returned to the applicant for testing.'可被翻译为：除特殊规定与要求外，一般为检验用量的三倍。检验后剩余样品除留样备查外，应当退回报验单位。\n'Article 24 For the application of registration testing, the applicant shall submit relevant technical documents and samples for registration testing, product technical requirements and standard products or reference materials as required according to the registration testing to the testing institutions.'可被翻译为：第二十四条 申请注册检验，申请人应当向检验机构提供注册检验所需要的有关技术资料、注册检验用样品、产品技术要求及标准品或者参考品。\n'Registrants shall cooperate with the on-site inspection, and provide samples as required when sampling and testing is required.'可被翻译为：注册申请人应当配合现场核查工作，需要抽样检验的，应当按照要求提供样品。\n'Article 17 For the application of registration testing, the applicant shall submit relevant technical documents and samples for registration testing, and product technical requirements as required according to the registration testing to the testing institutions.'可被翻译为：第十七条 申请注册检验，申请人应当向检验机构提供注册检验所需要的有关技术资料、注册检验用样品及产品技术要求。\n\n根据上述已知信息，请将'Article 133 An applicant shall provide the relevant data, samples and reference standards, or assist in sampling, which are required for the testing for drug registration. The amount of samples shall be three times the amount used for testing and, for biological products, manufacturing record for the relevant batches of products shall also be provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百三十三条 申请人应当提供药品注册检验所需要的有关资料、报送样品或者配合抽取检验用样品、提供检验用标准物质。报送或者抽取的样品量应当为检验用量的3倍；生物制品的注册检验还应当提供相应批次的制造检定记录。"
    },
    {
        "instruction":"已知信息：\n'b. Gently but firmly touch the RODAC agar surface against the area being sampled, exert moderate, even, vertical pressure and then carefully replace lid. Avoid using rubbing motions of the plate at the sample site as this may break the agar.'可被翻译为：将 RODAC 碟用于取样的琼脂表面轻轻但牢固地接触被取样的表面，垂直均匀按压，取下，小心地重新盖上盖子。避免碟表面与取样面摩擦，因为可能会使琼脂裂开。\n'a. Carefully remove the lid of RODAC plate or loosen the cap on the Hycheck slide tube. \nTake care not to touch the agar surface.\nNote: Examine agar for contamination and or dehydration'可被翻译为：小心取下 RODAC 碟的盖子或松开 Hycheck 滑管的盖子。小心不要接触琼脂培养基表面\n注：检查琼脂是否被污染或脱水\n'c. *Hycheck or equivalent surface samplers'可被翻译为：Hycheck 或等同的表面取样器\n'b. Apply swab (or sponge with handle) to surface (or equipment) being monitored with firm application pressure.'可被翻译为：将棉签（或带有手柄的海绵）用固定压力擦拭被监测表面（或设备）\n\n根据上述已知信息，请将'c. When using Hycheck press down on the spike to bend the paddle at the hinge line gently lowering the slide and press the agar to the surface with firm and even pressure. Repeat this step using the 2nd agar surface on an area adjacent to the initial test site. \nReplace slide in container and close tightly.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"使用 Hycheck 取样条时，以尖头为着力点，手持盖按压，让取样条在折线处向下弯曲，垂直均匀地将培养基表面压在被取样表面。翻转，将反面培养基同样操作，从第一个取样点的邻近表面取样。将培养基条放回瓶中，盖紧。"
    },
    {
        "instruction":"已知信息：\n'Article 43 When evaluating a drug registration application, the CDE conducts bundling review of the chemical active drug ingredients, excipients and primary packaging materials and containers of the drug product. Where supplementary dossiers are needed, the drug product applicant or the enterprise that registers chemical active drug ingredients, excipients and primary packaging materials and containers shall be required to provide supplementary dossiers in compliance with relevant procedures. When necessary, extended inspection on enterprises of chemical active drug ingredients, excipients and primary packaging materials and containers may be proposed based on risks.'可被翻译为：第四十三条 药品审评中心在审评药品制剂注册申请时，对药品制剂选用的化学原料药、辅料及直接接触药品的包装材料和容器进行关联审评，需补充资料的，按照补充资料程序要求药品制剂申请人或者化学原料药、辅料及直接接触药品的包装材料和容器登记企业补充资料，可以基于风险提出对化学原料药、辅料及直接接触药品的包装材料和容器企业进行延伸检查。\n'Article 14 The NMPA shall establish a bundling review and approval system for chemical active drug ingredients, excipients and primary packaging materials and containers. When reviewing and approving drug products, the review and approval for the chemical active drug ingredients and review for the relevant excipients and primary packaging materials and containers shall be carried out together. The CDE shall establish a platform for registries of chemical active drug ingredients, excipients and primary packaging materials and containers, release relevant registry information to applicants or MAHs for their selection, and conduct the bundling review when reviewing registration applications of relevant drug products.'可被翻译为：第十四条 国家药品监督管理局建立化学原料药、辅料及直接接触药品的包装材料和容器关联审评审批制度。在审批药品制剂时，对化学原料药一并审评审批，对相关辅料、直接接触药品的包装材料和容器一并审评。药品审评中心建立化学原料药、辅料及直接接触药品的包装材料和容器信息登记平台，对相关登记信息进行公示，供相关申请人或者持有人选择，并在相关药品制剂注册申请审评时关联审评。\n'Article 41 When evaluating a drug registration application, the CDE shall conduct bundling review of the chemical active drug ingredients, excipients and primary packaging materials and containers used for the drug products.'可被翻译为：第四十一条 药品审评中心在审评药品制剂注册申请时，对药品制剂选用的化学原料药、辅料及直接接触药品的包装材料和容器进行关联审评。\n'Article 42 When submitting a drug registration application, the drug product applicant may directly select chemical active drug ingredients, excipients and primary packaging materials and containers that have been registered; where chemical active drug ingredients, excipients and primary packaging materials and containers that have not been registered are selected, relevant study data shall be submitted together with the drug registration application.'可被翻译为：第四十二条 药品制剂申请人提出药品注册申请，可以直接选用已登记的化学原料药、辅料及直接接触药品的包装材料和容器；选用未登记的化学原料药、辅料及直接接触药品的包装材料和容器的，相关研究资料应当随药品制剂注册申请一并申报。\n\n根据上述已知信息，请将'When preparing drug preparations, medical institutions shall perform their duties in accordance with the approved process, and the required active drug ingredients, excipients, and packaging materials shall comply with medicinal requirements.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗机构配制制剂，应当按照经核准的工艺进行，所需的原料、辅料和包装材料等应当符合药用要求。"
    },
    {
        "instruction":"已知信息：\n'Article 287: A contract should be drawn up between the contract giver and the contract acceptor which specifies their respective responsibilities relating to the manufacture and control of the product. Technical aspects of the contract should be drawn up by competent persons with suitable knowledge in the pharmaceutical technology, analysis and the provisions. All arrangements for manufacture and analysis must be in accordance with the drug registration requirements and agreed by both parties.'可被翻译为：第二百八十七条 委托方与受托方之间签订的合同应当详细规定各自的产品生产和控制职责，其中的技术性条款应当由具有制药技术、检验专业知识和熟悉本规范的主管人员拟订。委托生产及检验的各项工作必须符合药品生产许可和药品注册的有关要求并经双方同意。\n'Article 278: To ensure the product quality of contract manufacture, and the accuracy and reliability of contract analysis, there must be a written contract between the contract giver and the contract acceptor, which clearly establishes the duties of each party, and covers the manufacture and\/or analysis arranged under contract and any technical arrangements made in connection with it.'可被翻译为：第二百七十八条 为确保委托生产产品的质量和委托检验的准确性和可靠性，委托方和受托方必须签订书面合同，明确规定各方责任、委托生产或委托检验的内容及相关的技术事项。\n'Article281: The contract giver should provide the contract acceptor with all the information necessary to carry out the contracted operations correctly in accordance with the drug registration and any other legitimate requirements.'可被翻译为：第二百八十一条 委托方应当向受托方提供所有必要的资料，以使受托方能够按照药品注册和其他法定要求正确实施所委托的操作。\n'Article 14 Where the MAH or drug manufacturer within the territory of China makes internal change on the manufacturing sites, or the MAH within the territory of China makes change on their manufacturers (including change of contract manufacturers, addition of contract manufacturers, change of self-production by MAH to contract manufacturer, and change of contract manufacturing to self-manufacturing), MAH (drug manufacturers) shall conduct study, evaluation and necessary verification in accordance with the requirements in the Provisions for the Supervision and Administration of Drug Manufacture and relevant technical guidelines for changes, and file an application for changing the Drug Manufacturing Certificate with the local provincial drug regulatory department and submit relevant dossiers.'可被翻译为：第十四条 境内持有人或药品生产企业内部变更生产场地、境内持有人变更生产企业（包括变更受托生产企业、增加受托生产企业、持有人自行生产变更为委托生产、委托生产变更为自行生产）的，持有人（药品生产企业）应当按照《药品生产监督管理办法》及相关变更技术指导原则要求进行研究、评估和必要的验证，向所在地省级药品监管部门提出变更《药品生产许可证》申请并提交相关资料。\n\n根据上述已知信息，请将'Article 279: All arrangements for contract manufacture and analysis including any proposed changes in technical or other arrangements should be in accordance with the drug manufacturing licensing and registration requirements for the product concerned.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二百七十九条 委托生产或委托检验的所有活动，包括在技术或其他方面拟采取的任何变更，均应当符合药品生产许可和注册的有关要求。"
    },
    {
        "instruction":"已知信息：\n'In metrology absorptiometry, a data processing method used for multi-component analysis.'可被翻译为：在计量学吸光光度法中，对多组分分析时采用的一种数据处理方法。\n'The application of multivariate statistical techniques to analyse complex process data with potentially correlated variables. (Ph. Eur.)'可被翻译为：应用多变量统计技术分析具有潜在相关变量的复杂工艺数据。\n'A discipline developed in the middle of the 20th century, all equations and functions in the linear programming model are linear, and it is a method to solve the multi-variable optimal decision. It is a problem to solve or plan the linear objective function optimization of an object under various interrelated multi-variable constraints. In the metrology absorptiometry, it is a data processing method used for multi-component analysis.'可被翻译为：20世纪中期发展起来的学科,线性规划模式中的所有方程式及函数都是线性的，是解决多变量最优决策的方法，是在各种相互关联的多变量约束条件下，解决或规划一个对象的线性目标函数最优的问题。在计量学吸光光度法中，是用于多组分分析的一种数据处理方法。\n'A stoichiometric data processing method used in the analysis and detection of multi-component systems by metrological absorbance spectrophotometry.'可被翻译为：在计量学吸光光度法分析检测多组分体系时，采用的一种化学计量学数据处理方法。\n\n根据上述已知信息，请将'A new method of multivariate statistical data analysis, first proposed by the Swedish econometrician H. Wolde in 1966, is the regression modeling method of multivariate variables to multi-independent variables. In metrology absorptiometry, it is a data processing method for multi-component analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由瑞典经济计量学家沃尔德（H.Wold）于1966年首次提出的一种新型多元统计数据分析方法，是多因变量对多自变量的回归建模方法。在计量学吸光光度法中，是一种用于多组分分析的数据处理方法。"
    },
    {
        "instruction":"已知信息：\n'An auxiliary solvent that increases the solubility of the drug in the main solvent.'可被翻译为：能提高药物在主溶剂中溶解度的辅助溶剂。\n'In a mixture of two enantiomers (El and E2), where the amount of E1 is assumed to be greater than E2, the percentage of enantiomer E1 excess is called the enantiomer excess of E1.'可被翻译为：在两个对映体（El和E2）的混合物中，假定E1的量大于E2,则对映体E1过量的百分数称为E1的对映体过量。\n'Any of various solvents other than water.'可被翻译为：除水以外的溶剂的统称。\n'An absorption cell with a small volume and an optical path\/volume ratio much greater than 0.2.'可被翻译为：容积小、光程\/体积比远大于0.2的吸收池。\n\n根据上述已知信息，请将'The phenomenon in which the solubility of a drug in a mixture of two solvents in a certain ratio is greater than that in any single solvent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在混合溶剂中两溶剂在某一比例时，药物的溶解度比在任一单纯溶剂中的溶解度均大的现象。"
    },
    {
        "instruction":"已知信息：\n'A substance that is present in the matrix that may affect the quantification of an analyte.'可被翻译为：在基质中存在的可能影响待测物定量的物质。\n'(5) the severity of injury to human health;'可被翻译为：（五）对人体健康造成的伤害程度；\n'Any leaks from these systems that would present a risk to the product should be detectable (e.g. an indication system for leakage).'可被翻译为：对产品造成风险的系统泄漏应是可检岀的（例如泄漏指示系统）。\n'A physical injury or damage to the health of people or damage to property or the environment (15).'可被翻译为：人身伤害或对人的健康的损害或对财产或环境的损害(15)。\n\n根据上述已知信息，请将'A product or substance that may present a substantial risk of injury, to health or to the environment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"可能对健康或环境造成重大伤害风险的产品或物质。"
    },
    {
        "instruction":"已知信息：\n'I. On June 24, 2020, the government website of NMPA has released a new version of drug registration application software for applicants.'可被翻译为：一、2020年6月24日，国家药监局政府网站将发布供申请人使用的新版药品注册申报软件。\n'NMPA Issued the Notice on Enabling the New Version of the Drug Production License and other Certificates'可被翻译为：国家药监局综合司关于启用新版《药品生产许可证》等许可证书的通知\n'For the smooth and steady transition of drug registration, relevant drug registration applicants can continue to use the original drug registration application software to fill in the application after the Online Application Module is launched. As of April 1, 2021, application offers generated by the original drug registration application software shall no longer be handled.'可被翻译为：为确保药品注册申报工作平稳过渡，网上申报功能上线后相关药品注册申请人仍可继续使用原药品注册申报软件填报申请表，自2021年4月1日起停止接收原药品注册申报软件生成的报盘文件。\n'NMPA Issued the Announcement on Enabling the New Version of Management System for Import Filing of Drugs and Medicinal Materials'可被翻译为：国家药监局关于启用新版药品和药材进口备案管理系统的公告\n\n根据上述已知信息，请将'III. From July 1, 2020, NMPA will enable a new version of related system for drug registration. Drug registrants are advised to download the latest version of the application software, and submit registration application as required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"三、2020年7月1日起，国家药监局将启用新版药品注册相关系统，请药品注册申请人注意下载最新版申报软件，按要求提交注册申请。"
    },
    {
        "instruction":"已知信息：\n'NMPA Notice on Launching the Cosmetic Ingredient Safety Information Registration Platform'可被翻译为：国家药监局关于化妆品原料安全信息登记平台上线通知\n'After the launch of the Cosmetic Ingredient Safety Information Registration Platform, cosmetics registrants, filing applicants and persons in charge within the territory of China can still fill out and submit the safety information document of ingredients issued by raw material manufacturers through the Information Service Platform for Registration and Filing of Cosmetics, or fill in the safety information document of ingredients associated with the ingredients submission code generated by the platform.'可被翻译为：化妆品原料安全信息登记平台上线后，化妆品注册人、备案人、境内责任人仍可以通过化妆品注册备案信息服务平台填报原料生产商出具的原料安全信息文件，也可以填写化妆品原料安全信息登记平台生成的原料报送码关联原料安全信息文件。\n'In order to facilitate enterprises to makegood preparation for the registration and notification of cosmetics in advance, as of April 1, 2021, domestic cosmetic registration persons, notification persons, domestic responsible persons and cosmetic manufacturers may submit relevant documents and apply for the user account for registration and notification at the Information Service Platform of Cosmetics Registration and Notification(hereinafter referred to as the new platform) according to the requirements in the Rules through the NMPA Online Service Hall (https:\/\/zwfw.nmpa.gov.cn), a national integrated online government service platform. As of May 1, 2021, cosmetic registration persons, notification persons and domestic responsible persons shall apply for the registration of special cosmetics or file notification of the general cosmetics through the new platform.'可被翻译为：为方便企业提前做好化妆品注册备案准备工作，自2021年4月1日起，境内的化妆品注册人、备案人、境内责任人和化妆品生产企业，可以通过全国一体化在线政务服务平台国家药监局网上办事大厅（https:\/\/zwfw.nmpa.gov.cn），按照《规定》的要求在化妆品注册备案信息服务平台（以下简称新注册备案平台）提交相关资料，办理注册备案用户账号；自2021年5月1日起，化妆品注册人、备案人、境内责任人，应当通过新注册备案平台申请特殊化妆品注册或者进行普通化妆品备案。\n'Registrants and filing persons of cosmetics and new cosmetic ingredients shall apply for registration and filing through the information service platform of registration and filing for cosmetics and new cosmetic ingredients (hereinafter referred to as the information service platform) in accordance with regulations.'可被翻译为：化妆品、化妆品新原料注册人、备案人按照规定通过化妆品、化妆品新原料注册备案信息服务平台（以下简称信息服务平台）申请注册、进行备案。\n\n根据上述已知信息，请将'In order to implement the Provisions for the Registration and Filing of Cosmetics, Provisions for the Registration or Filing Dossier of Cosmetics and other regulatory documents, NMPA organized to establish the Cosmetic Ingredient Safety Information Registration Platform. Since 9 A.M. on December 31, 2021, cosmetic ingredient manufacturers or their authorized enterprises can log in to this platform to report information related to the safety of ingredients. Domestic users may log in to the platform directly through the \"Cosmetic Ingredient Safety Information Registration Platform\" module at NMPA Online Service Hall (https:\/\/zwfw.nmpa.gov.cn); and overseas users need to set up an account at the \"Cosmetic Ingredient Safety Information Registration Platform” (http:\/\/ciip.nifdc.org.cn) before login.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为贯彻落实《化妆品注册备案管理办法》《化妆品注册备案资料管理规定》等法规文件，国家药监局组织建立了化妆品原料安全信息登记平台，自2021年12月31日上午9时起，化妆品原料生产商或其授权企业可以登陆该平台报送原料安全相关信息。境内用户直接通过国家药监局网上办事大厅（https:\/\/zwfw.nmpa.gov.cn）的“化妆品原料安全信息登记平台”模块进行登陆；境外用户需在“化妆品原料安全信息登记平台”（http:\/\/ciip.nifdc.org.cn）开通账号后登陆。"
    },
    {
        "instruction":"已知信息：\n'median lethal dose(ld50)'可被翻译为：半数致死剂量\n'median lethal concentration(lc50)'可被翻译为：半数致死浓度\n'median lethal time(lt50)'可被翻译为：半数致死时间\n'median intoxic dose(td50)'可被翻译为：半数中毒剂量\n\n根据上述已知信息，请将'The ratio of median lethal dose to median effective dose. A large therapeutic index indicates high curative effect and relatively safe drug use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"半数致死量与半数有效量的比值。治疗指数大表示疗效高、用药比较安全。"
    },
    {
        "instruction":"已知信息：\n'In 2019, the National ADR Monitoring Network received 1.514 million copies of ADR\/ADE Report Form. From 1999 to 2019, the National ADR Monitoring Network received an accumulative total of 15.19 million copies of the ADR\/ADE Report Form (See Figure 1).'可被翻译为：2019年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》151.4万份。1999年至2019年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1,519万份（图1）。\n'In 2018, the National ADR Monitoring Network received 1.499 million copies of the Report on Adverse Drug Reactions\/Events. From 1999 to 2018, the National ADR Monitoring Network received a total of 13.68 million copies of the ADRs \/ ADEs Report Forms (Figure 1).'可被翻译为：2018年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》149.9万份。1999年至2018年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1368万份（图1）。\n'In 2019, the National ADR Monitoring Network received 477,000 new and serious ADR\/ADE reports, accounting for 31.5 percent of the total number reported in the same period.'可被翻译为：2019年全国药品不良反应监测网络收到新的和严重药品不良反应\/事件报告47.7万份；新的和严重药品不良反应\/事件报告占同期报告总数的31.5%。\n'In 2018, the National ADR Monitoring Network received 495,000 new and serious ADR\/ADE reports, accounting for 33.1% of the total number reported in the same period.The steady growth of the proportion of new and serious ADR\/ADE reports indicates a constant upclimbing of the availability of ADR reports in China.'可被翻译为：2018年全国药品不良反应监测网络收到新的和严重药品不良反应\/事件报告49.5万份；新的和严重药品不良反应\/事件报告占同期报告总数的33.1%。新的和严重药品不良反应\/事件报告比例持续增加，显示我国药品不良反应报告可利用性持续增加。\n\n根据上述已知信息，请将'In 2020, the China National ADR Monitoring Network received 1.676 million copies of ADR\/ADE Reports. From 1999 to 2020, the National ADR Monitoring Network received a total of 16.87 million copies of ADR\/ADE Reports.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2020年全国药品不良反应监测网络收到《药品不良反应\/事件报告表》167.6万份。1999年至2020年，全国药品不良反应监测网络累计收到《药品不良反应\/事件报告表》1,687万份。"
    },
    {
        "instruction":"已知信息：\n'Article 48 Where a patent dispute arises during the registration review or after approval, it shall be dealt with according to relevant laws and regulations.'可被翻译为：第四十八条 注册申请审查过程中及批准后发生专利权纠纷的，应当按照有关法律、法规的规定处理。\n'Article 57 Where a patent dispute arises during the registration review or after approval, it shall be dealt with according to relevant laws and regulations.'可被翻译为：第五十七条 注册申请审查过程中及批准后发生专利权纠纷的，应当按照有关法律、法规的规定处理。\n'Article 94 The drug registration timeline mentioned in these Provisions is the longest time needed for drug registration acceptance, review, inspection, testing, approval, etc. The timeline for priority review and approval procedures shall be implemented in accordance with relevant provisions on priority review and approval.'可被翻译为：第九十四条 本办法所规定的时限是药品注册的受理、审评、核查、检验、审批等工作的最长时间。优先审评审批程序相关工作时限，按优先审评审批相关规定执行。\n'1. The review and approval of master manufacturing documents, procedures, etc;'可被翻译为：（一）审核和批准产品的工艺规程、操作规程等文件；\n\n根据上述已知信息，请将'(3) Time occupied during suspension of the review and approval procedures where the review and approval procedures are suspended in accordance with laws and regulations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）根据法律法规的规定中止审评审批程序的，中止审评审批程序期间所占用的时间；"
    },
    {
        "instruction":"已知信息：\n'In 2020, the total number of registered grassroots users increased by 10.03% compared with the previous year. Among them, the registered grassroots users of registrants, distributors and using units have increased by 38.31%, 11.52% and 3.24% compared with the previous year, respectively.'可被翻译为：2020年，注册基层用户总数比上年增长10.03%。其中，注册人注册基层用户比上年增长38.31%，经营企业和使用单位的注册基层用户分别比上年增长11.52%和3.24%。\n'In 2018, the total number of registered grassroots users increased by 8.87% over2017. It shows that the scope of monitoring of adverse events of medical devices in China has been expanding. Among them, the registered grassroots users of manufacturers,distributors and user units have increased by 16.44%, 11.59% and 4.97% over 2017,respectively (Figure 5) .'可被翻译为：2018年，注册基层用户总数比2017年增长8.87%。显示我国医疗器械不良事件监测范围不断扩大。其中，生产企业、经营企业和使用单位的注册基层用户分别比2017年增长16.44%、11.59%和4.97%(图5)。\n'(II) Number of registered grassroots users nationwide'可被翻译为：（二）全国注册基层用户数量\n'As of Dec 31, 2019, there were a total of 318,986 grassroots user units (incl.registrants, distributors and user units)registered in the National Medical Device Adverse Event Monitoring Information System, covering 19,662 registrants(6.16%); 178,295 distributors (55.89%); and 121,029 user units (37.94%).'可被翻译为：截至2019年12月31日，在国家医疗器械不良事件监测信息系统中注册的基层用户（包括注册人、经营企业和使用单位）共318986家，其中注册人19662家，占用户总数的6.16%；经营企业178295家，占用户总数的55.89%；使用单位121029家，占用户总数的37.94%。\n\n根据上述已知信息，请将'In 2019, the total number of registered grassroots users increased by 15.69 percent over the previous year. Among them, the registered grassroots users of registrants, distributors and user units have increased by 41.92 percent, 24.22 percent and 2.28 percent over 2017, respectively.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2019年，注册基层用户总数比上年增长15.69%。其中，注册人注册基层用户比上年增长41.92%，经营企业和使用单位的注册基层用户分别比上年增长24.22%和2.28%。"
    },
    {
        "instruction":"已知信息：\n'Evaluation studies that evaluate, analyze, and interpret the proportions, costs, and reasonableness of drug use in order to evaluate the irrational use of drugs, prevent adverse drug interactions, and optimize the rational use of drugs.'可被翻译为：评价、分析和解释药物使用的比例、成本和合理性，以评估药物的不合理使用，防止药物不良相互作用及优化药品的合理使用的评价研究。\n'To strengthen the supervision and guidance over medical device product registration and further improve the quality of registration review, NMPA has organized the formulation of the Guidance for Technical Review of the Registration of Vertebroplasty Balloon Dilation Catheters, Guidance for Technical Review of the Registration of Acrylic Bone Cement for Artificial Joint Replacement, Guidance for Technical Review of the Registration of Metal Intramedullary Nail System, Guidance for Technical Review of the Registration of Vaseline Gauze, Guidance for Technical Review of the Registration of Hydrocolloid Dressings, Guidance for Technical Review of the Registration of Ovum Aspiration Needles for Assisted Reproduction, and Guidance for Technical Review of the Registration of Spinal Implant Quality Control and Clinical Evaluation, which have been released on May 9, 2020.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《椎体成形球囊扩张导管注册技术审查指导原则》《人工关节置换术用丙烯酸树脂骨水泥注册技术审查指导原则》《金属髓内钉系统产品注册技术审查指导原则》《凡士林纱布产品注册技术审查指导原则》《水胶体敷料产品注册技术审查指导原则》《辅助生殖用穿刺取卵针注册技术审查指导原则》《脊柱植入物临床评价质量控制注册技术审查指导原则》，并于2020年5月9日发布。\n'NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products'可被翻译为：国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA organized the formulation of and published the Guidelines for Technical Review of the Registration of Synthetic Resin Teeth, the Guidelines for Technical Review of the Registration of IUD, and  the Guidelines for  Technical Review of the Registration of Implantable Drug Delivery System on May 22, 2019.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2019年5月22日组织制定并发布了《合成树脂牙注册技术审查指导原则》《宫内节育器注册技术审查指导原则》《植入式给药装置注册技术审查指导原则》，\n\n根据上述已知信息，请将'A technical evaluation of the reasonableness and controllability of drug registration criteria. Such as the review of imported drugs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对药品注册标准的合理性和可控性进行的技术评价。比如进口药品复核。"
    },
    {
        "instruction":"已知信息：\n'Article 21 When conducting a drug clinical trial, details such as the clinical trial objective and risks shall be truthfully stated and explained to the trial subjects or their guardians, an informed consent letter signed voluntarily by the trial subject or their guardian shall be obtained, and effective measures shall be taken to protect the lawful rights and interests of the trial subjects.'可被翻译为：第二十一条 实施药物临床试验，应当向受试者或者其监护人如实说明和解释临床试验的目的和风险等详细情况，取得受试者或者其监护人自愿签署的知情同意书，并采取有效措施保护受试者合法权益。\n'Standards for the whole process of clinical trials to protect the rights and interests of subjects and ensure their safety.'可被翻译为：临床试验全过程的标准规定，保护受试者的权益并保障其安全。\n'Article 30 Where safety issues or other risks are observed during drug clinical trials, the sponsor shall promptly modify the clinical trial protocol, suspend or terminate the clinical trial, and report the case to the CDE.'可被翻译为：第三十条 药物临床试验期间，发现存在安全性问题或者其他风险的，申办者应当及时调整临床试验方案、暂停或者终止临床试验，并向药品审评中心报告。\n'The ethics committee shall establish an ethics review system to ensure that the ethics review process is independent, objective, and fair, supervise the standard conduct of drug clinical trials, protect the legitimate rights and interests of trial subjects, and safeguard the public interest.'可被翻译为：伦理委员会应当建立伦理审查工作制度，保证伦理审查过程独立、客观、公正，监督规范开展药物临床试验，保障受试者合法权益，维护社会公共利益。\n\n根据上述已知信息，请将'Article 17 The sponsor of vaccine clinical trials shall design the clinical trial protocol, establish the safety monitoring and evaluation system for clinical trials, prudently select subjects, appropriately set up subject population and age groups, and take effective measures based on risk levels to protect legal interests of subjects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十七条 疫苗临床试验申办者应当制定临床试验方案，建立临床试验安全监测与评价制度，审慎选择受试者，合理设置受试者群体和年龄组，并根据风险程度采取有效措施，保护受试者合法权益。"
    },
    {
        "instruction":"已知信息：\n'On November 29, 2019, NMPA issued the Announcement on Issues Pertaining to the Implementation of the Drug Administration Law of the People's Republic of China (2019 No. 103), which reads as follows:'可被翻译为：2019年11月29日，国家药监局发布了关于贯彻实施《中华人民共和国药品管理法》有关事项的公告（2019No.103），其内容如下：\n'NMPA Issued the Announcement on Issues Pertaining to the Implementation of the Newly Revised Provisions for the Supervision and Administration of Drug Production'可被翻译为：国家药监局关于实施新修订《药品生产监督管理办法》有关事项的公告\n'NMPA Issued the Announcement on Issues Pertaining to the Current Administration on Drug Distribution'可被翻译为：国家药监局关于当前药品经营监督管理有关事宜的通告\n'Article 1 To regulate drug registration and ensure the safety, efficacy and quality controlbility of drugs, these Provisions are formulated in accordance with the Drug Administration Law of the People's Republic of China (hereinafter referred to as \"Drug Administration Law\"), the Law of the People's Republic of China on Traditional Chinese Medicine, the Vaccine Administration Law of the People's Republic of China (hereinafter referred to as \"Vaccine Administration Law\"), the Administrative Licensing Law of the People's Republic of China, the Regulations for the Implementation of the Drug Administration Law of the People's Republic of China and other laws and administrative regulations.'可被翻译为：第一条 为规范药品注册行为，保证药品的安全、有效和质量可控，根据《中华人民共和国药品管理法》（以下简称《药品管理法》）、《中华人民共和国中医药法》、《中华人民共和国疫苗管理法》（以下简称《疫苗管理法》）、《中华人民共和国行政许可法》、《中华人民共和国药品管理法实施条例》等法律、行政法规，制定本办法。\n\n根据上述已知信息，请将'NMPA Issued the Announcement on Issues Pertaining to the Implementation of the Drug Administration Law of the People's Republic of China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于贯彻实施《中华人民共和国药品管理法》有关事项的公告"
    },
    {
        "instruction":"已知信息：\n'Article 74 Site master file refers to a summary document of drug production activities prepared by a drug manufacturer, which is a part of the files in the manufacturer's quality management system. The requirements for site master files will be defined separately.'可被翻译为：第七十四条 场地管理文件，是指由药品生产企业编写的药品生产活动概述性文件，是药品生产企业质量管理文件体系的一部分。场地管理文件有关要求另行制定。\n'drug master file. Detailed information concerning a specific facility, process or product submitted to the medicines regulatory authority, intended for incorporation into the application for marketing authorization.'可被翻译为：药物主文件 向药监机构提交的关于某个场所、工艺或产品的详细信息，意在将其结合至上市许可申报资料中。\n'SMF: Site Master File'可被翻译为：工厂主述文件\n'(1) site master files and the materials in connection with any change;'可被翻译为：（一）药品生产场地管理文件以及变更材料；\n\n根据上述已知信息，请将'New document format introduced to replace the product dossier and site master file.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"引入新的文档格式，以取代产品档案和站点主文件。"
    },
    {
        "instruction":"已知信息：\n'A method of searching for specific biosynthetic genes by means of genetic engineering such as mutation complementation, resistance gene probe and homologous gene probe.'可被翻译为：利用突变互补、抗性基因探针以及同源基因探针等基因工程手段寻找特异的生物合成基因的方法。\n'gene recombination'可被翻译为：基因重组\n'A new cell or individual produced by deoxyribonucleic acid (DNA) recombination technology (genetic engineering).'可被翻译为：经脱氧核糖核酸(DNA)重组技术(基因工程技术)产生的新细胞或新个体。\n'The technique of manipulating genes at the molecular level to alter the genetic characteristics of a species. For example, the operation of introducing the foreign gene into the recipient cell after recombination in vitro, so that the gene can be copied, transcribed, translated and expressed in the recipient cell.'可被翻译为：在分子水平上对基因进行操作，以达到改变物种遗传特征的技术总称。如将外源基因通过体外重组后导入受体细胞内，使这个基因能在受体细胞内复制、转录、翻译表达的操作。\n\n根据上述已知信息，请将'An experimental technique in which a specific gene in the genome is altered by site-specific homologous recombination of DNA in order to study the function of the gene in vivo. It builds on the achievements of embryonic stem cell technology and homologous recombination technology, and promotes the further development of related technologies. It is widely used in the research of gene function, the development of animal models of human diseases and the improvement of genetic material of economic animals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过DNA定点同源重组，改变基因组中的某一特定基因，从而在生物活体内研究此基因功能的实验技术。它建立在胚胎干细胞技术和同源重组技术成就的基础上，并促进了相关技术的进一步发展。广泛应用于基因功能研究、人类疾病动物模型的研制以及经济动物遗传物质的改良等方面。"
    },
    {
        "instruction":"已知信息：\n'Article 98 At the time of ex-warehousing of drugs, the accompanying sheet (bill) stamped with the original special seal for drug ex-warehousing of enterprises shall be attached.'可被翻译为：第九十八条 药品出库时，应当附加盖企业药品出库专用章原印章的随货同行单（票）。\n'The accompanying sheet (bill) shall include the supplier, the manufacturer, the adopted name, dosage form, strength, lot number and quantity of drugs, the consignee, receiving address, shipping date and other contents, and stamped with the original special seal for drug ex-warehousing of the supplier.'可被翻译为：随货同行单（票）应当包括供货单位、生产厂商、药品的通用名称、剂型、规格、批号、数量、收货单位、收货地址、发货日期等内容，并加盖供货单位药品出库专用章原印章。\n'Where an enterprise directly transfers drugs in accordance with Article 69 herein, the supplier shall issue two copies of the same accompanying sheet (bill) at the time of ex-warehousing of the directly transferred drugs which shall be respectively sent to the directly transferring enterprise and the purchaser. The contents of the accompanying sheet (bill) shall comply with the requirements of Paragraph 2 of Article 73 herein and also indicate the name of the directly transferring enterprise.'可被翻译为：企业按照本规范第六十九条规定直调药品的，直调药品出库时，由供货单位开具两份随货同行单（票），分别发往直调企业和购货单位。随货同行单（票）的内容应当符合本规范第七十三条第二款的要求，还应当标明直调企业名称。\n'Article 153 Upon arrival of drugs, the receiving personnel shall, in accordance with the purchase records, check the material objects according to the accompanying sheet (bill) provided by suppliers and ensure that the bills, account and goods are consistent.'可被翻译为：第一百五十三条 药品到货时，收货人员应当按采购记录，对照供货单位的随货同行单（票）核实药品实物，做到票、账、货相符。\n\n根据上述已知信息，请将'(IV) Model of relevant seal and the accompanying sheet (bill);'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）相关印章、随货同行单（票）样式；"
    },
    {
        "instruction":"已知信息：\n'The loading pattern within the lyophilizer should be specified and documented.'可被翻译为：应规定并记录冻干机的装载方式。\n'Quantitative aspects of worst-case situations, e.g. loading the largest number of trays, replicating the longest duration of loading where the chamber is open to the environment.'可被翻译为：量化最差条件，例如：装载托盘的最大载量，重现装载（冻干室与环境连通）的最长时间。\n'The  sterilisation  of the  lyophilizer  and  associated  equipment  (e.g.  trays, vial  support rings)  should  be validated and the holding time between the sterilisation cycle and use appropriately challenged during APS (see paragraph 9.33). The lyophilizer should be sterilised regularly, based on system design. Re-sterilisation should be performed  following  maintenance  or  cleaning.   Sterilised   lyophilizers  and  associated  equipment  should  be protected from contamination after sterilisation.'可被翻译为：冻干机和相关设备（例如托盘、西林瓶支撑环）的灭菌应经过验证，应在 APS 期间适当挑战灭菌循环和使 用之间的保持时间（参见第 9.33 节）。冻干机应根据系统设计定期灭菌。在维护或清洁后应进行再灭菌。应保护灭菌后的冻干机和相关设备，防止污染。\n'(IV) Protective measures against the impact of abnormal weather during outdoor loading and unloading, handling, receiving, shipment, and other operations shall be in place.'可被翻译为：（四）有防止室外装卸、搬运、接收、发运等作业受异常天气影响的措施。\n\n根据上述已知信息，请将'Utensils used during loading and unloading of the lyophilizer (e.g. trays, bags, placing devices, tweezers) should be sterile.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"冻干机装载和卸载过程中使用的器具（例如托盘、袋子、定位装置、镶子）应为无菌状态。"
    },
    {
        "instruction":"已知信息：\n'5.5. The SU should provide criteria and information on inherent risks, hazards and critical steps associated with the process, product or procedure to be transferred. This may serve as a basis for the risk assessment exercise.'可被翻译为：SU应提供准备转移的工艺、产品或方法相关的固有风险、危害和关键步骤的标准和信息。这可作为风险评估活动的基础。\n'All personnel including those performing cleaning, maintenance, monitoring and those that access cleanrooms\nshould receive regular training, gowning qualification and assessment in disciplines relevant to the correct manufacture of sterile products. This training should include the basic elements of microbiology and hygiene, with a specific focus on cleanroom practices, contamination control, aseptic techniques and the protection of sterile products (for those operators entering the grade B cleanrooms and\/or intervening into grade A) and the potential safety implications to the patient if the product is not sterile. The level of training should be based on the criticality of the function and area in which the personnel are working.'可被翻译为：所有人员，包括执行清洁、维护、监控以及进入洁净室的人员，均应定期接受无菌产品正确生产相关纪律的培训、更衣确认和评估。该培训应包括微生物学和卫生学的基本要素，特别关注洁净室实践、污染控制、无菌技术和无菌产品的保护（对于进入 B 级洁净室和\/或干预 A 级的操作人员）以及产品非无菌对患者的潜在安全性影响。培训水平应基于人员职能以及工作区域的关键程度。\n'8.1. The RU should have appropriate premises with the layout, construction and finishing to suitable for the intended operations. Utilities such as heating, ventilation and air conditioning, as well as gas and water systems, should have sufficient capacity and should be appropriate for the intended process, product or procedure to be transferred.'可被翻译为：RU应具备有恰当的设施，有平面布局图，其建筑和装修适合于既定操作。公用设施如HVAC和水气系统，均应具备足够能力，适合于准备转移的工艺、产品或方法。\n'The involved disciplines at an organization where a designated product, process or method is expected to be transferred.'可被翻译为：组织中涉及的学科，其中指定的产品、过程或方法预计将被转移。\n\n根据上述已知信息，请将'5.14. A training programme should be implemented covering various topics, including those specific to the process, product or procedure to be transferred.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应针对准备转移的工艺、产品和程序执行专门的不同主题培训。"
    },
    {
        "instruction":"已知信息：\n'To strengthen the supervision and guidance over medical device registration, and further improve the quality of registration review, NMPA has organized to formulate the Technical Review Guidance for the Registration of Disposable Breast localization Wire, Technical Review Guidance for the Registration of Dural(Spinal) Patches, Technical Review Guidance for the Registration of Customized and Personalized Equivalent Models of Bone Implants, Technical Review Guidance for the Registration of Finite Element Analysis Data of Orthopedic Metal Implants, Guidance for Clinical Trials of Hernia Repair Meshes, and Guidance for Animal Study of Bioabsorbable Coronary Artery Drug-Eluting Stents, and they were issued on July 7, 2020.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《一次性使用乳腺定位丝注册技术审查指导原则》《硬脑（脊）膜补片注册技术审查指导原则》《定制式个性化骨植入物等效性模型注册技术审查指导原则》《骨科金属植入物有限元分析资料注册技术审查指导原则》《疝修补补片临床试验指导原则》《生物可吸收冠状动脉药物洗脱支架动物实验研究指导原则》，现予发布。\n'NMPA Issued 7 Guidances for Technical Review Including the Guidance for Technical Review of the Registration of Vertebroplasty Balloon Dilation Catheters'可被翻译为：国家药监局关于发布椎体成形球囊扩张导管等7项注册技术审查指导原则的通告\n'NMPA Announcement on Issuing 5 Technical Review Guidances for Registration'可被翻译为：国家药监局关于发布5项注册技术审查指导原则的通告\n'NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems'可被翻译为：国家药监局关于发布视力筛查仪和乳腺X射线系统2项注册技术审查指导原则的通告\n\n根据上述已知信息，请将'NMPA Issues the Announcement on 6 Technical Review Guidances for Registration Including the Technical Review Guidance for the Registration of Disposable Breast localization Wire'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布一次性使用乳腺定位丝注册技术审查等6项注册技术审查指导原则的通告"
    },
    {
        "instruction":"已知信息：\n'Article 107 Drug regulatory departments of provinces, autonomous regions and municipalities directly under the Central Government shall perform routine GLP and GCP inspections of drug non-clinical safety evaluation and research institutes, drug clinical trial organizations and other research institutions to ensure their continuous compliance with statutory requirements. The NMPA may initiate supervision and inspection of drug non-clinical safety evaluation and research institutes, drug clinical trial organizations and other research institutions as needed.'可被翻译为：第一百零七条 省、自治区、直辖市药品监督管理部门应当组织对辖区内药物非临床安全性评价研究机构、药物临床试验机构等遵守药物非临床研究质量管理规范、药物临床试验质量管理规范等情况进行日常监督检查，监督其持续符合法定要求。国家药品监督管理局根据需要进行药物非临床安全性评价研究机构、药物临床试验机构等研究机构的监督检查。\n'Article 42 Drug regulatory departments at or above the provincial level may request drug manufacturers to conduct intensive surveillance on specific drugs based on information of clinical drug use and ADR monitoring; when necessary, they may directly organize ADR monitoring institutions, medical institutions and scientific research institutions to conduct intensified drug monitoring.'可被翻译为：第四十二条 省级以上药品监督管理部门根据药品临床使用和不良反应监测情况，可以要求药品生产企业对特定药品进行重点监测；必要时，也可以直接组织药品不良反应监测机构、医疗机构和科研单位开展药品重点监测。\n'The National Institute for the Control of Pharmaceutical and Biological Products may organize relevant drug testing institute of provinces, autonomous regions, and municipalities directly under the Central Government, drug research institutions or drug manufacturers to undertake collaborative assays of such standards.'可被翻译为：中国药品生物制品检定所可以组织有关的省、自治区、直辖市药品检验所、药品研究机构或者药品生产企业协作标定国家药品标准物质。\n'Article 105 Drug regulatory departments establish drug safety credit record for MAHs, drug manufacturers, drug distributors, drug non-clinical safety evaluation research institutions, drug clinical trial organizations, and medical institutions to record issuance of permits, regular supervision and inspection findings, and investigations and handling of illegal acts, and shall make the records available to the public in accordance with the law and promptly update them. They may increase the frequency of supervision and inspection for entities with poor credit records and may implement joint punishment in accordance with the provisions of the State.'可被翻译为：第一百零五条 药品监督管理部门建立药品上市许可持有人、药品生产企业、药品经营企业、药物非临床安全性评价研究机构、药物临床试验机构和医疗机构药品安全信用档案，记录许可颁发、日常监督检查结果、违法行为查处等情况，依法向社会公布并及时更新；对有不良信用记录的，增加监督检查频次，并可以按照国家规定实施联合惩戒。\n\n根据上述已知信息，请将'No unscientific, categorical assertion, or guarantee of described function or safety may be included in drug advertisements. No names or images of government departments, research institutions, and academic institutions, or of experts, scholars, physicians, pharmacists and patients may be used as evidence for drug advertising.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品广告不得含有表示功效、安全性的断言或者保证；不得利用国家机关、科研单位、学术机构、行业协会或者专家、学者、医师、药师、患者等的名义或者形象作推荐、证明。"
    },
    {
        "instruction":"已知信息：\n'The term applied to third party attestation related to a conformity assessment body conveying formal demonstration of its competence to carry out specific conformity assessment tasks (2).'可被翻译为：该术语适用于与合格评定机构有关的第三方认证，该机构正式证明了其执行特定合格评定任务的能力(2)。\n'1.The term biowaiver is applied to a regulatory drug approval process when the dossier (application) is approved based on evidence of equivalence other than through in vivo equivalence testing.\n2.The term biowaiver is applied to a regulatory pharmaceutical product approval process when the dossier (application) is approved based on evidence of equivalence other than through in vivo equivalence testing.'可被翻译为：1.当档案(申请)基于等效性证据而不是通过体内等效性试验获得批准时，术语生物豁免适用于监管药物批准过程。\n2.当档案(申请)基于等效性证据而不是通过体内等效性试验获得批准时，术语生物豁免适用于监管药品批准过程。\n'1.The storing of pharmaceutical products and materials up to their point of use.\n2.The storing of pharmaceutical products up to the point of use.\n3.The storing of medical products up to the point of use.'可被翻译为：1.储存:将药品和原料储存到其使用点\n2.将药品储存到使用点。\n3.将医疗产品储存至使用点。\n'(3) in the process of acceptance, review and approval, not fulfilling the regulatory informing obligation to the applicant or interest party;'可被翻译为：（三）在受理、审评、审批过程中，未向申请人、利害关系人履行法定告知义务的；\n\n根据上述已知信息，请将'1.The final review and formal approval of a validation or revalidation, followed by approval of a process for routine use.\n2.The term applied to third party attestation related to products, processes, systems or persons (2).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.确认或再确认的最终审查和正式批准，随后批准常规使用的过程\n2.该术语适用于与产品、过程、体系或人员相关的第三方认证(2)。"
    },
    {
        "instruction":"已知信息：\n'b. Validation of Growth-Based Rapid Microbiological Methods for Sterility Testing of Cellular and Gene Therapy Products (draft guidance, 2\/2008)'可被翻译为：基于生长快速微生物方法用于细胞和基因治疗产品无菌检测的验证（2008 年 2月，草案）\n's. Stability testing program, including demonstration of stability indicating capability of the test methods (i.e. container\/closure, AET)'可被翻译为：稳定性测试计划，包括检测方法的稳定性指示性能力的证明（即容器\/密闭器，AET）\n'c. Rejection of any component, container, closure not meeting acceptance requirements. Investigate the firm's procedures for verification of the source of components.'可被翻译为：拒收所有不符合可接受标准的组份、容器和密闭器。检查公司用于核查组份来源的程序\n'container closure system'可被翻译为：包装系统\n\n根据上述已知信息，请将'c. Guidance for Industry- Container and Closure system Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products (2\/2008)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"行业指南—容器和密闭器系统完整性测试替代无菌检测，作为无菌药品的稳定性试验方案的一部分（2008 年 2 月）"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing of Two Registration Technical Review Guidelines Including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products'可被翻译为：国家药监局关于发布影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则的通告\n'To strengthen the supervision and guidance of medical device registration and further improve the quality of registration review, the NMPA organized to formulate the Guidance (Revision 2020) for Technical Review of Clinical Evaluation of Equivalent Devices of Medical Magnetic Resonance Imaging Systems which was issued on January 27, 2021.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了《医用磁共振成像系统同品种临床评价技术审查指导原则（2020年修订版）》，并于2021年1月27日发布。\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA organized the formulation of and published the Guidelines for Technical Review of the Registration of Synthetic Resin Teeth, the Guidelines for Technical Review of the Registration of IUD, and  the Guidelines for  Technical Review of the Registration of Implantable Drug Delivery System on May 22, 2019.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2019年5月22日组织制定并发布了《合成树脂牙注册技术审查指导原则》《宫内节育器注册技术审查指导原则》《植入式给药装置注册技术审查指导原则》，\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA organized the formulation of and published the Guidelines for Technical Review of the Registration of Synthetic Resin Teeth, the Guidelines for Technical Review of the Registration of IUD, and the Guidelines for Technical Review of the Registration of Implantable Drug Delivery System on May 22, 2019.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织于2019年5月22日组织制定并发布了《合成树脂牙注册技术审查指导原则》《宫内节育器注册技术审查指导原则》《植入式给药装置注册技术审查指导原则》。\n\n根据上述已知信息，请将'In order to strengthen the supervision and guidance over medical device registration and further improve the quality of registration review, the NMPA has organized to formulate 2 technical review guidelines for registration including the Guidelines for Technical Review of Clinical Evaluation of Ultrasound Diagnostic Imaging Equipment Based on Predicate Products, which are hereby promulgated on January 15, 2021.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药监局组织制定了影像型超声诊断设备同品种临床评价技术审查指导原则等2项注册技术审查指导原则，于2021年1月15日予以发布。"
    },
    {
        "instruction":"已知信息：\n'The binding between the drug and the protein is in homeostasis, a phenomenon in which the drug molecule with strong binding force to the protein replaces the drug molecule that is already bound to albumin but has weak binding force.'可被翻译为：药物与蛋白质之间的结合处于动态平衡，与蛋白结合力强的药物分子将已经与白蛋白结合、但结合力弱的药物分子置换出来的现象。\n'colloidal particle'可被翻译为：胶粒\n'In thin layer chromatography, a certain amount of adhesive is added to the fixed phase in advance, spread on the glass plate, and made of thin layer chromatography plate.'可被翻译为：在薄层色谱法中，预先在固定相中加入一定量的黏合剂，铺展在玻璃板上，烘干制成的薄层色谱板。\n'A gel formed by dispersing small pharmaceutical colloidal particles (such as aluminum hydroxide) in a gel matrix. A two-phase dispersion system.'可被翻译为：药物胶体小粒子（如氢氧化铝）分散在凝胶基质中形成的凝胶剂。属于两相分散系统。\n\n根据上述已知信息，请将'The solvation layer of the colloidal particles is heated or other soluble compounds are added! 1 (it and the original loss of solvent has a strong binding force) under the conditions, the solvation layer is weakened, resulting in the phenomenon of colloidal condensation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"溶胶胶粒的溶剂化层在受热或加入其他溶齐!1（它和原失溶剂有较强的结合力）的条件下，溶剂化层被削弱，导致胶体聚沉的现象。"
    },
    {
        "instruction":"已知信息：\n'Article 24 When carrying out on-site sampling, the drug control institute of port shall impose close inspection on the actual condition of the imported drugs upon arrival, make sampling records, and fill in the Record of Sampling for Import Drugs.'可被翻译为：第二十四条 口岸药品检验所现场抽样时，应当注意核查进口品种的实际到货情况，做好抽样记录并填写《进口药品抽样记录单》。\n'(Ⅱ) Refuse to assist the drug regulatory department in carrying out investigation;'可被翻译为：（二）拒绝协助药品监督管理部门开展调查的；\n'(2) refuse to cooperate with the food and drug regulatory department in carrying out an investigation;'可被翻译为：（二）拒绝配合食品药品监督管理部门开展调查的；\n'(V)  carrying out a verification test when the testing result is objected; and'可被翻译为：（五）对有异议的检验结果进行复验；\n\n根据上述已知信息，请将'Article 63 When carrying out on-site inspection, the drug regulatory department can make sample testing as needed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十三条  药品监督管理部门开展现场检查时，可以根据需要进行抽查检验。"
    },
    {
        "instruction":"已知信息：\n'Article 126 Personnel engaged in quality management, acceptance inspection and purchase shall have academic qualifications in pharmacy or medicine, biology, chemistry or other related disciplines or have professional and technical titles in pharmacy. Personnel engaged in the quality management, acceptance inspection and purchase of Prepared Slices shall have a degree of technical school or above, or a primary professional and technical title or above in traditional Chinese medicine.'可被翻译为：第一百二十六条 质量管理、验收、采购人员应当具有药学或者医学、生物、化学等相关专业学历或者具有药学专业技术职称。从事中药饮片质量管理、验收、采购人员应当具有中药学中专以上学历或者具有中药学专业初级以上专业技术职称。\n'(II) Personnel engaged in acceptance inspection and maintenance shall have a degree of technical school or above in pharmacy or medicine, biology, chemistry or other related disciplines, or a primary professional and technical title or above in pharmacy;'可被翻译为：（二）从事验收、养护工作的，应当具有药学或者医学、生物、化学等相关专业中专以上学历或者具有药学初级以上专业技术职称；\n'(I) Personnel engaged in quality management shall have a degree of technical school in pharmacy, or college degree or above in medicine, biology and chemistry, or primary professional and technical title or above in pharmacy;'可被翻译为：（一）从事质量管理工作的，应当具有药学中专或者医学、生物、化学等相关专业大学专科以上学历或者具有药学初级以上专业技术职称；\n'Pharmaceutical professional and technical personnel who have passed the national unified examination, obtained the Qualification Certificate of Licensed Pharmacists and have been registered to practice in the units that produce, distribute and use drugs.'可被翻译为：经全国统一考试合格，取得《执业药师资格证书》并经注册登记，在药品生产、经营、使用单位中执业的药学专业技术人员。\n\n根据上述已知信息，请将'Pharmaceutical professional and technical personnel who have received academic education in pharmacy and are engaged in drug dispensing, preparation, testing, production and other work, and have been recognized as qualified according to law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"受过药学专业学历教育，从事药物调剂、制备、检定、生产等工作，并依法经资格认定的药学专业技术人员。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where adverse events occur shall promptly notify the relevant information to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate.'可被翻译为：不良事件发生地省、自治区、直辖市药品监督管理部门应当及时向持有人所在地省、自治区、直辖市药品监督管理部门通报相关信息。\n'Article 38 Where the applicant finds a clinical trial institution violating relevant regulations or failing to implement the clinical trial protocol, it shall urge the institution to make corrections; if the circumstances are serious, the applicant may demand suspension or termination of the clinical trial, and shall report the matter to the State Food and Drug Administration and the drug regulatory departments of the relevant provinces, autonomous regions or municipalities directly under the Central Government.'可被翻译为：第三十八条 申请人发现药物临床试验机构违反有关规定或者未按照临床试验方案执行的，应当督促其改正；情节严重的，可以要求暂停或者终止临床试验，并将情况报告国家食品药品监督管理局和有关省、自治区、直辖市药品监督管理部门。\n'Article 62 The food and drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall be responsible for the supervision and administration of medical device registration and filing within their administrative areas, and organize supervision and inspection and report relevant situations to China Food and Drug Administration.'可被翻译为：第六十二条 省、自治区、直辖市食品药品监督管理部门负责本行政区域的医疗器械注册与备案的监督管理工作，组织开展监督检查，并将有关情况及时报送国家食品药品监督管理总局。\n'Article 34 After knowing the group adverse events of medical device that occurs within their respective administrative regions, the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall promptly carry out on-site investigation jointly with the health administrative departments at the same level, and the drug regulatory departments of relevant provinces, autonomous regions and municipalities directly under the central government shall cooperate. Investigation, re-evaluation and handling results shall be promptly reported to the NMPA and the Health Administrative Department of the State Council, and copied to local drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government where MAHs locate.'可被翻译为：第三十四条  省、自治区、直辖市药品监督管理部门在获知本行政区域内发生的群体医疗器械不良事件后，应当会同同级卫生行政部门及时开展现场调查，相关省、自治区、直辖市药品监督管理部门应当配合。调查、评价和处理结果应当及时报国家药品监督管理局和国务院卫生行政部门，抄送持有人所在地省、自治区、直辖市药品监督管理部门。\n\n根据上述已知信息，请将'Article 41 If any serious adverse event occurs during the clinical trial, the investigators shall report to the drug regulatory departments of the relevant provinces, autonomous regions or municipalities directly under the Central Government and the State Food and Drug Administration and notify the applicant within 24 hours, and report to the ethic committee in time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十一条 临床试验过程中发生严重不良事件的，研究者应当在24小时内报告有关省、自治区、直辖市药品监督管理部门和国家食品药品监督管理局，通知申请人，并及时向伦理委员会报告。"
    },
    {
        "instruction":"已知信息：\n'Tablets coated with sucrose as the main coating material.'可被翻译为：以蔗糖为主要包衣材料进行包衣的片剂。\n'A tablet coated with enteric-soluble coating material.'可被翻译为：用肠溶性包衣材料进行包衣的片剂。\n'The process of coating the surface of the tablet (core, plain) with a layer of enteric-soluble material.'可被翻译为：在片剂（片芯、素片）表面包裹肠溶性材料层的过程。\n'medicated feed'可被翻译为：药用物料\n\n根据上述已知信息，请将'The core material of medicated tablets is coated with sucrose as the main material. To protect the drug or cover up the bad odor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以蔗糖为主要材料对含药片剂芯材进行包覆的操作。以保护药物或掩盖不良嗅味。"
    },
    {
        "instruction":"已知信息：\n'Article 134 Enterprises shall take measures to ensure that the personnel at all the posts can correctly understand the quality management documents to ensure their effective implementation.'可被翻译为：第一百三十四条 企业应当采取措施确保各岗位人员正确理解质量管理文件的内容，保证质量管理文件有效执行。\n'Article 13 Enterprises shall set up an organization or posts corresponding to their distribution activities and quality management and clearly define their duties, authorities and relations with each other.'可被翻译为：第十三条 企业应当设立与其经营活动和质量管理相适应的组织机构或者岗位，明确规定其职责、权限及相互关系。\n'Article 35 Enterprises shall ensure that all posts have access to necessary documents corresponding to their work contents, and carry out their work in strict accordance with the provisions.'可被翻译为：第三十五条 企业应当保证各岗位获得与其工作内容相对应的必要文件，并严格按照规定开展工作。\n'Article 127 Personnel at all posts of enterprises shall have received pre-post training and on-the-job training on relevant laws and regulations as well as professional knowledge and skills of drugs to meet the requirements of the GSP.'可被翻译为：第一百二十七条 企业各岗位人员应当接受相关法律法规及药品专业知识与技能的岗前培训和继续培训，以符合本规范要求。\n\n根据上述已知信息，请将'Article 12 Enterprises shall have all their employees involved in quality management. Personnel of all departments and posts shall correctly understand and perform their duties and assume corresponding quality responsibilities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十二条 企业应当全员参与质量管理。各部门、岗位人员应当正确理解并履行职责，承担相应质量责任。"
    },
    {
        "instruction":"已知信息：\n'1. All processing of swabs must be aseptically performed within a HEPA Filtered II Biological Safety Cabinet (BSC) or HEPA Filtered Laminar Flow Hood (LFH) with an air classification at the same rating or better than that from which the swab was collected'可被翻译为：拭子处理必须在 HEPA 过滤 II 级生物安全柜（BSC）或 HEPA 过滤层流罩（LFH）内无菌操作，其中的空气级别应该等于或优于擦拭取样点。\n'b. Laminar Flow Hood (LFH) with HEPA filtration'可被翻译为：带 HEPA 过滤的层流罩（LFH）\n'Repeat disinfection procedure using appropriate disinfectant\/sporicidal immediately prior to placing product primary containers in a working certified laminar flow hood. Allow all disinfected containers to completely air dry in the laminar flow hood prior to opening for analysis. Alternatively, if conducting the testing in an isolator, place the disinfected items into the isolator and proceed with the local procedures for the proper decontamination of the interior of the isolator.'可被翻译为：使用适当的消毒剂\/杀孢子重复消毒程序，然后立即在将产品内包容器放入经过认证的工作层流罩中。在打开进行分析之前，让所有已消毒的容器在层流罩中完全晾干。或者，如果在隔离器中进行测试，则将已消毒的物品放入隔离器中，并按照当地程序对隔离器内部进行适当的净化。\n'Cleanse outer surfaces of sample containers with sterile wipes using a validated effective antimicrobial agent. Place on a disinfected tray or surface in a properly disinfected laminar flow hood or biosafety cabinet. Allow containers to dry.'可被翻译为：采用经过验证的有效抑菌剂，用无菌抹布清洁样品容器外表。放在经过消毒的托盘 或放在经过适当消毒的层流罩或生物安全柜表面上，让容器干燥。\n\n根据上述已知信息，请将'Aseptically open containers and perform weighing procedures in a laminar flow hood or biological safety cabinet if possible.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如可能的话，在无菌条件下打开容器，在层流罩中或生物安全柜中称重。"
    },
    {
        "instruction":"已知信息：\n'The number of units processed (filled) for APS should be sufficient to effectively simulate all activities that are representative of the aseptic manufacturing process. Justification for the number of units to be filled should be clearly captured in the CCS. Typically, a minimum of 5000 to 10000 units are filled. For small batches (e.g. those under 5000 units), the number of containers for APS should at least equal the size of the production batch.'可被翻译为：APS 的加工（灌装）单元的数量应足以有效模拟代表无菌生产工艺的所有活动。应在 CCS 中明确记录待 灌装数量的合理性。通常，至少灌装 5000 至 10000 个单元。对于小批量（例如 5000 单元以下），APS 的容器数量应至少等于生产批次的数量。\n'Filled APS units should be incubated without unnecessary delay to achieve the best possible recovery of potential contamination. The selection of the incubation conditions and duration should be scientifically justified and validated to provide an appropriate level of sensitivity of detection of microbial contamination.'可被翻译为：培养已灌装 APS 单元应避免延迟，以尽确保达到潜在微生物的最高回收率。培养条件和培养时长的选择应经过科学论证，并进行验证以提供适当水平的微生物污染检测灵敏度。\n'Interventions and stoppages should be recorded in the batch record. Each line stoppage or intervention should\nbe sufficiently documented in batch records with the associated time, duration of the event, and operators involved\n(ref to paragraph 9.34).'可被翻译为：干预和停工应记录在批记录中。每次生产线的停工或干预都应在批记录中充分记录，包括相关的时间、持\n续时间和操作人员（参见 9.34 节）\n'Filled APS units should be inspected by personnel who have been appropriately trained and qualified for the detection of microbiological contamination. Inspection should be conducted under conditions that facilitate the identification of any microbial contamination.'可被翻译为：已灌装的 APS 单元应由接受过适当的微生物污染检测培训和资质确认的人员进行检查。检查应在便于识别任何微生物污染的条件下进行。\n\n根据上述已知信息，请将'All APS runs should be fully documented and include a reconciliation of units processed (e.g. units filled, incubated  and  not   incubated).  Justification   for  filled  and  non-incubated  units   should  be   included  in  the documentation. All interventions performed during the APS should be recorded, including the start and end time of each intervention and the involved person. All microbial monitoring data as well as other testing data should be recorded in the APS batch record.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有 APS 运行应完整记录，并包括已处理单元的物料平衡（例如已灌装、已培养和未培养的单元）。已灌 装和未培养的单元的说明应包含在文件中。在 APS 过程中进行的所有干预操作都应进行记录，包括每次干预的开始和结束时间以及涉及的人员。所有微生物监测数据以及其它检测数据应记录在 APS 批记录中。"
    },
    {
        "instruction":"已知信息：\n'(7) condition of carrying out adverse events monitoring and reevaluation, and collection and evaluation of information on product safety risks;'可被翻译为：（七）开展不良事件监测、再评价以及产品安全风险信息收集与评估等情况；\n'Article 56 In case of carrying out medical device re-evaluation, MAHs shall, based on the product safety and effectiveness information learned after products are marketed, clinical data and use experiences, re-evaluate the summary information, study data, clinical evaluation materials, product risk analysis materials, product technical requirements, instructions, labels and other technical data and content in original registration materials of medical devices.'可被翻译为：第五十六条  持有人开展医疗器械再评价，应当根据产品上市后获知和掌握的产品安全有效信息、临床数据和使用经验等，对原医疗器械注册资料中的综述资料、研究资料、临床评价资料、产品风险分析资料、产品技术要求、说明书、标签等技术数据和内容进行重新评价。\n'No clinical evaluation data shall be submitted for the filing of Class I medical devices.'可被翻译为：第一类医疗器械备案不需提交临床评价资料。\n'(II) Effectiveness and safety evaluation'可被翻译为：（二）有效性和安全性评价\n\n根据上述已知信息，请将'(II) The analysis and evaluation of monitoring data are reinforced for product risks mining and promoting the safety of medical devices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(二）夯实监测数据分析评价，挖掘产品风险促进用械安全"
    },
    {
        "instruction":"已知信息：\n'For short, \"metabolism\". A general term for all ordered chemical changes in an organism, including both material metabolism and energy metabolism.'可被翻译为：简称\"代谢”。生物体内全部有序化学变化的总称，包括物质代谢和能量代谢两个方面。\n'(e) Computer systems (including hardware and software), controls, and attendant documentation maintained under this part shall be readily available for, and subject to, FDA inspection.'可被翻译为：按本法规条例要求维护的计算机系统（包括硬件和软件）、控制方式、和随附的文件应在FDA现场检查时备查。\n'General guidance regarding the specific needs for premises design and also guidance on the qualification of premises including the use of Barrier Technology.'可被翻译为：有关具体厂房设计需求的一般性指导，以及关于厂房确认的指导（包括屏障技术的使用）。\n'The activities, including study design, conduct of studies, and evaluation of data, that are designed to investigate whether the products are comparable.'可被翻译为：包括试验设计、研究实施和数据评估在内的活动，用于调查产品是否具有可比性。\n\n根据上述已知信息，请将'A general term for the design and construction of computer systems, including technical infrastructure, information (data), and applications.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"计算机系统设计和构建的一般术语，包括技术基础设备、信息（数据）和应用程序。"
    },
    {
        "instruction":"已知信息：\n'4. Records of formulating, storage, use, return and disposal of narcotic drugs and modeling reagents (drugs) used in the study should be retained completely.'可被翻译为：4.应完整保留研究所需毒麻药品、造模试剂(药品)等的配制、保存、使用、返还或废弃等记录。\n'1. The receipt, storage, distribution, use, reserve samples, return or disposal of the test\/control articles should be recorded completely and their accountability should be maintained;'可被翻译为：1.受试物\/对照品的接收、保存、分发、使用、留样、返还或废弃等应有完整记录且数量吻合；\n'4. There are complete records for the process of receipt, processing, inspection and testing, storage, return (if applicable) and destruction of samples to be tested.'可被翻译为：4.待测样本接收、处理、检验检测、储存、归还( 如适用)、销毁等过程具有完整的记录。\n'5. The quantity of investigational medicinal products used, the remaining quantity and other circumstances (such as loss and authorized destruction) is consistent with the quantity provided by the sponsor.'可被翻译为：5.试验用药品的使用数量、剩余数量和其他情况(如丢失、授权销毁等) 与申办者提供的数量一致。\n\n根据上述已知信息，请将'3. There are records retained for the receipt, storage, distribution, use, recovery, return and unused disposal of investigational medicinal products (such as authorized destruction).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"3.试验用药品的接收、贮存、分发、使用、回收、退还及未使用药品的处置(如授权销毁) 等环节留有记录。"
    },
    {
        "instruction":"已知信息：\n'A polysaccharide chiral stationary phase using cellulose and amylose derived from different functional groups as stationary phases.'可被翻译为：一种利用不同官能团衍生化的纤维素和直链淀粉作为固定相的多聚糖手性固定相。\n'Different types of chromatographic analysis techniques are combined to form a combined system to achieve the separation and analysis of multi-component methods in complex samples.'可被翻译为：将不同类型的色谱分析技术组合构成联用系统，以实现复杂样品中多组分的分离和分析的方法。\n'A method of separation that utilizes the difference in the ability of ion exchange to occur between the separated component and the stationary phase. The fixed phase of ion exchange chromatography is generally an ion exchange resin. There are many ionizing groups in the molecular structure of the resin. The ions in the components to be separated will exchange ions with these groups to form an ion exchange balance, thus forming a distribution between the mobile phase and the fixed phase. The inherent ions of the fixed phase and the ions in the components to be separated compete with each other for the ion exchange groups in the fixed phase, and move with the movement of the mobile phase, and finally achieve separation.'可被翻译为：利用被分离组分与固定相之间发生离子交换能力的差异来实现分离的方法。离子交换色谱的固定相一般为离子交换树脂，树脂分子结构中存在许多可以电离的基团，待分离组分中的离子会与这些基团发生离子交换，形成离子交换平衡，从而在流动相与固定相之间形成分配。固定相的固有离子与待分离组分中的离子之间相互争夺固定相中的离子交换基团，并随着流动相的运动而运动，最终实现分离。\n'A technique for separating mixed components based on the different distribution coefficients of different substances between the mobile phase and the fixed phase. When a mobile phase (liquid or gas) flows through a stationary phase (a porous solid or a liquid covering a solid support), the components move along the stationary phase at different speeds and separate. It can be used for the analysis of trace samples and the purification preparation of large samples.'可被翻译为：基于不同物质在流动相和固定相之间的分配系数不同而将混合组分分离的技术。当流动相（液体或气体）流经固定相（多孔的固体或覆盖在固体支持物上的液体）时，各组分沿固定相移动的速度不同而分离。能用于微量样品的分析和大量样品的纯化制备。\n\n根据上述已知信息，请将'In the analysis of complex component samples containing different functional groups by column chromatography, often a single component of the stationary phase can not achieve the purpose of complete separation, and must use a multi-component stationary phase.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在用柱色谱分析含有不同功能团的复杂组分样品时，往往单一组分的固定相不能达到全分离的目的，而必须采用多组分的固定相。"
    },
    {
        "instruction":"已知信息：\n'Article 61 The investigator who is responsible for the clinical trial shall meet the following conditions:'可被翻译为：第六十一条 负责临床试验的研究者应当具备下列条件：\n'The auditor refers to the person who is entrusted by the sponsor to carry out the verification of the medical device clinical trial project.'可被翻译为：核查员，是指受申办者委托对医疗器械临床试验项目进行核查的人员。\n'Article 86 The clinical trial report shall be signed and dated by the investigator, and submitted to the sponsor after being issued with opinions, dated and affixed with the seal of the clinical trial institution by the medical device clinical trial management department of the clinical trial institution.'可被翻译为：第八十六条 临床试验报告应当由研究者签名、注明日期，经临床试验机构医疗器械临床试验管理部门审核出具意见、注明日期并加盖临床试验机构印章后交申办者。\n'(2) The coordinating investigator is responsible for the work coordination between the clinical trial institutions in the clinical trial, organization of the investigator meeting in the early, middle and late phases of the clinical trial, and implementation of the whole trial together with the sponsor;'可被翻译为：（二）协调研究者负责临床试验过程中各临床试验机构间的工作协调，在临床试验前期、中期和后期组织研究者会议，并与申办者共同对整个试验的实施负责；\n\n根据上述已知信息，请将'The investigator refers to the person who is responsible for implementing the clinical trial in a clinical trial institution. Where the trial is carried out by a group of personnel in a clinical trial institution, the investigator shall be the person who is in charge of the group, also known as the principal investigator.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究者，是指在临床试验机构中负责实施临床试验的人。如果在临床试验机构中是由一组人员实施试验的，则研究者是指该组的负责人，也称主要研究者。"
    },
    {
        "instruction":"已知信息：\n'Article 2 All in-vitro diagnostic reagents sold and used within the territory of the People's Republic of China shall apply for registration or filing according to the Provisions.'可被翻译为：第二条 在中华人民共和国境内销售、使用的体外诊断试剂，应当按照本办法的规定申请注册或者办理备案。\n'Article 2 All medical devices sold or used within the territory of the People's Republic of China shall be accompanied by the instructions and labels in accordance with the requirements of the Provisions.'可被翻译为：第二条 凡在中华人民共和国境内销售、使用的医疗器械，应当按照本规定要求附有说明书和标签。\n'Article 2 All medical devices that are sold and used within the territory of the People's Republic of China shall use generic names and their naming shall conform to the Rules.'可被翻译为：第二条 凡在中华人民共和国境内销售、使用的医疗器械应当使用通用名称，通用名称的命名应当符合本规则。\n'Article 2  For medical devices sold and used within the territory of the People's Republic of China, their UDI system shall comply with the requirements of the Rules.'可被翻译为：第二条 在中华人民共和国境内销售、使用的医疗器械，其唯一标识系统应当符合本规则。\n\n根据上述已知信息，请将'Article 2 All medical devices sold and used within the territory of the People's Republic of China shall apply for registration or filing according to the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二条 在中华人民共和国境内销售、使用的医疗器械,应当按照本办法的规定申请注册或者办理备案。"
    },
    {
        "instruction":"已知信息：\n'The technique of introducing artificially isolated and modified genes into the genome of an organism and causing heritable modification of the traits of the organism due to the expression of the imported genes.'可被翻译为：将人工分离和修饰过的基因导入到生物体基因组中，由于导入基因的表达，引起生物体性状的可遗传性修饰的技术。\n'The alteration of an organism's chromosomes or genes by physical or chemical mutagens.'可被翻译为：通过物理或化学诱变剂造成生物染色体或基因的改变而产生遗传性状的变异。\n'A non-primary metabolic pathway formed by an organism during metabolism.'可被翻译为：由生物体代谢过程中形成的非主要的代谢途径。\n'The process of synthesizing a new progeny molecule from one parent's DNA or one parent's RNA, using the parent molecule as a template for synthesis.'可被翻译为：用亲代分子作为合成的模板，由一个亲代DNA或一个亲代RNA合成一个新的子代分子的过程。\n\n根据上述已知信息，请将'The technique or method of synthesizing new compounds by replacing, adding, or deleting genes involved in the synthase of an organism's metabolic product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过对参与生物体某种代谢产物合成酶的基因进行替换、添加以及删除等操作，使其合成新的化合物的技术或方法。"
    },
    {
        "instruction":"已知信息：\n'A fluid whose shear stress (t) is proportional to the shear velocity (Q). Its flow properties can be expressed by the formula: t=ηD, where the proportional coefficient η is called the viscosity coefficient. For Newton fluids, the viscosity is constant at a certain temperature and does not change with the shear rate.'可被翻译为：切应力（t）与切变速度（Q）成正比的流体。其流动性质可用公式表示：t=ηD,式中的比例系数η称为黏滞系数。对于牛顿流体，黏度在一定温度下是常数，不随切变速度而变。\n'The viscosity of a liquid varies at different shear rates.'可被翻译为：不同的剪切速率下有不同的黏度。\n'apparent viscosity'可被翻译为：表观黏度\n'shear mixing'可被翻译为：剪切混合\n\n根据上述已知信息，请将'The fluids that do not conform to Newton's formula mainly include polymer solutions and colloidal solutions. The ratio of shear stress and shear velocity of non-Newtonian fluid G\/D) is called the apparent viscosity, which is commonly expressed by %. Apparent viscosity is not only a function of temperature, but is also related to shear velocity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"不符合牛顿公式的流体，主要有高分子溶液及胶体溶液等。非牛顿流体的切应力与切变速度的比值G\/D）称为表观黏度，常用%表示。表观黏度不仅是温度的函数，而且与切变速度有关。"
    },
    {
        "instruction":"已知信息：\n'The opening and closing of an ion channel is regulated by the potential difference between the two sides of the membrane.'可被翻译为：通道的开闭受膜两侧电位差调控的离子通道。\n'The difference in pressure between two points, such as the pressure difference between an \nenclosed space and an independent reference point, or the pressure difference between two \nenclosed spaces.'可被翻译为：两点之间的压差，如安之间的压差\n封闭空间与独立参考点之间的压力差，或两者之间的压力差\n封闭的空间。\n'The motion state of two types of molecules, membrane lipids and membrane proteins. Is one of the basic characteristics of biofilm.'可被翻译为：膜脂和膜蛋白两类分子的运动状态。是生物膜的基本特征之一。\n'The diffusion of a solvent (or a solvent in a dilute solution) through a semi-permeable membrane into a solution (or a concentrated solution) when the solution is separated from the pure solvent (or two solutions of different concentrations) by a semi-permeable membrane.'可被翻译为：当溶液与纯溶剂（或两种浓度不同的溶液）在半透膜隔开的情况下，溶剂（或较稀溶液中的溶剂）通过半透膜向溶液（或较浓溶液）扩散的现象。\n\n根据上述已知信息，请将'The potential difference between the two sides of the membrane due to the different types (or concentrations) of electrolytes leads to ion migration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"膜两侧因电解质种类（或浓度）不同而导致离子迁移时所产生的电位差。"
    },
    {
        "instruction":"已知信息：\n'Article 8: Quality Assurance is a part of the quality management system. The manufacturer should establish the Quality Assurance system with the support of a complete documentation system to ensure its effective operation.'可被翻译为：第八条 质量保证是质量管理体系的一部分。企业必须建立质量保证系统，同时建立完整的文件体系，以保证系统有效运行。\n'Article 9: The system of Quality Assurance should ensure that:'可被翻译为：第九条 质量保证系统应当确保：\n'(Ⅰ) Fail to establish the drug recall system, drug quality assurance system and adverse drug reaction monitoring system according to these Provisions;'可被翻译为：（一）未按本办法规定建立药品召回制度、药品质量保证体系与药品不良反应监测系统的；\n'10. Self-inspection is regularly carried out to appraise the effectiveness and applicability of the Quality Assurance system, according to the procedures.'可被翻译为：（十）按照自检操作规程，定期检查评估质量保证系统的有效性和适用性。\n\n根据上述已知信息，请将'2. To investigate causes related to the product, process and quality assurance system;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）调查与产品、工艺和质量保证系统有关的原因。"
    },
    {
        "instruction":"已知信息：\n'gowning qualification'可被翻译为：净化服资格\n'Note 3: For the qualification of personnel gowning, the limits given for contact plates and glove prints in Table 6 should apply.'可被翻译为：注 3：对于人员更衣的确认，应采用表 6 中的表面微生物和五指手套的限度要求。\n'Personnel monitoring must be performed after analysts conclude sterility testing and prior to exiting the aseptic clean room. The analyst shall use general media touch plates to monitor the sterile condition of their clean room attire and to ensure aseptic techniques were followed.'可被翻译为：化验员在结束无菌性检测之后，退出无菌洁净室之前，必须对人员进行监测。化 验员应使用通用培养基接触碟，对其洁净室服装的无菌条件进行监测，确保遵守 了无菌技术。\n'Care should be taken to choose gowning that does not expose any skin to the aseptic clean room environment.'可被翻译为：应注意要选择不会将皮肤暴露于无菌洁净室环境的洁净服。\n\n根据上述已知信息，请将'Personnel gowning qualification should be performed by any analyst that enters the aseptic clean room. Personnel gowning qualification must consist of:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"进入无菌洁净室的任何分析员都应进行人员更衣资格确认。人员更衣资格必须包 括："
    },
    {
        "instruction":"已知信息：\n'1.A systematic process for the assessment, control, communication and review of risks to the quality of the product across the product’s life cycle.\n2.Quality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product throughout the product life- cycle.'可被翻译为：1.在整个产品生命周期内对产品质量风险进行评估、控制、沟通和审查的系统过程。\n2.质量风险管理是对药品在整个生命周期内的质量风险进行评估、控制、沟通和评审的系统过程。\n'quality risk management (QRM). A systematic process for the assessment, control, communication and review of risks to the quality of the pharmaceutical product throughout the product’s life cycle.'可被翻译为：质量风险管理 （QRM）：贯穿药品整个生命周期的质量风险评估、控制、沟通和回顾系统化流程\n'6.5. Quality risk management should be implemented as a systematic process for the assessment, control, communication and review of risks.'可被翻译为：质量风险管理应作为系统性流程执行，用于评估、控制、沟通和回顾风险。\n'Article 13: Quality risk management is a systematic process for the assessment, control, communication and review of the risk to quality throughout the entire product life cycle. It can be applied both proactively and retrospectively.'可被翻译为：第十三条 质量风险管理是在整个产品生命周期中采用前瞻或回顾的方式，对质量风险进行评估、控制、沟通、审核的系统过程。\n\n根据上述已知信息，请将'A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是一套系统的、基于充分的科学知识和质量风险管理的研发方法，从预先确定的目标出发，强调对产品和工艺的理解以及工艺控制。"
    },
    {
        "instruction":"已知信息：\n'8. The application dossier is inconsistent with the original record, and has an impact on the result evaluation;'可被翻译为：8.申报资料与原始记录不一致且影响结果评价；\n'2. All original records should be recorded truthfully, promptly, accurately, completely and traceably, and the results should be consistent with those in the application dossiers; the changes made in the records should not obscure the original entry, and the person who made the change should sign and date with the reason for change;'可被翻译为：2.各项原始记录应真实、及时、准确、完整、可追溯，且 结果与申报资料一致；记录修改不得覆盖原有数据痕迹，并标注修改人、修改日期和修改理由；\n'6. Records of checks according to master manufacturing documents, including the results of in-process controls;'可被翻译为：（六）根据工艺规程所进行的检查记录，包括中间控制结果。\n'Article 13 The inspection report and inspection results are only for the scope and content of the inspection of the registration application, and do not cover all the registration application dossiers of the registration application and the evaluation of related development activities.'可被翻译为：第十三条 核查报告、核查结果仅针对该注册申请该次核查范围和内容，不覆盖该注册申请全部注册申报资料和相关研制行为的评价。\n\n根据上述已知信息，请将'6. The application dossiers are inconsistent with the original records and affect the evaluation results;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"6.申报资料与原始记录不一致且影响结果评价；"
    },
    {
        "instruction":"已知信息：\n'Convert the actual number of years of survival in one or a series of identified conditions of less than full health to the number of years of survival in full health.'可被翻译为：将一个或一系列已确定的非完全健康状态下的实际生存年数折算成完全健康状态下的生存年数。\n'A membrane or intracellular receptor capable of binding to toxin molecules to activate a series of biochemical reactions within cells with corresponding effects.'可被翻译为：能与毒素分子结合进而激活细胞内一系列生物化学反应并产生相应效应的胞膜或胞内受体。\n'In a series of enzymatic reactions, some intermediates or end products regulate the activity and synthesis of enzymes that catalyze the initial step of the reaction.'可被翻译为：酶促系列反应中，某些中间产物或终产物对催化起始步骤反应的酶活性和酶合成进行调节的作用。\n'Chemical products with simple chemical structure as the starting material, through a series of chemical reactions and physical processing process to produce drugs.'可被翻译为：以化学结构简单的化工产品为起始原料，经过一系列化学反应和物理处理过程制得药物的过程。\n\n根据上述已知信息，请将'A series of reactions in which microorganisms, under the action of a series of biosynthetases, convert nutrients into final products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"微生物在其体内一系列生物合成酶作用下，将营养成分转变为终产物所经历的一系列反应过程。"
    },
    {
        "instruction":"已知信息：\n'A compound capable of forming a complex ion with a metal ion.'可被翻译为：能与金属离子形成络合离子的化合物。\n'Common methods for identifying metal ions (e.g., iron salts), inorganic anions (e.g., chlorides), or organic acid salts (e.g., salicylate) under the Pharmacopoeia Quality Standard for variety identification in the Pharmacopoeia Appendix.'可被翻译为：药典附录中对药典品种质量标准鉴别项下对金属离子(比如铁盐)、无机阴离子(比如氯化物)或水杨酸盐等有机酸盐进行鉴别试验的通用方法。\n'Astringent drugs with zinc 2,4, 6-trinitroresorcinol as the main active ingredient. This drug is synthesized by 2,4, 6-trinitroresorcinol and zinc metal ion (Zn2+).'可被翻译为：以2,4,6-三硝基间苯二酚锌为主要有效成分的收敛药物。此药物由2,4,6-三硝基间苯二酚与金属锌离子（Zn2+）合成而得。\n'heavy metal'可被翻译为：重金属\n\n根据上述已知信息，请将'The interdisciplinary study of metal-containing biomolecules (e.g., metalloenzymes) and metal-biomolecular interactions (e.g., metal ion channels, metal drugs).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"无机化学与生物化学的交叉学科，主要研究含金属的生物分子（如金属酶）、金属与生物分子的相互作用（如金属离子通道、金属药物）等。"
    },
    {
        "instruction":"已知信息：\n'Where a class III medical device registration is directly applied for, China Food and Drug Administration shall determine the class according to its risk degree. Where a domestic medical device is determined as class II, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the province, autonomous region or municipality directly under the central government where the applicant is located, for evaluation and approval. Where a medical device is determined as class I, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the city consists of its districts where the applicant is located, for filing.'可被翻译为：直接申请第三类医疗器械注册的，国家食品药品监督管理总局按照风险程度确定类别。境内医疗器械确定为第二类的，国家食品药品监督管理总局将申报资料转申请人所在地省、自治区、直辖市食品药品监督管理部门审评审批；境内医疗器械确定为第一类的，国家食品药品监督管理总局将申报资料转申请人所在地设区的市级食品药品监督管理部门备案。\n'Article 77 Where a food and drug regulatory department of a province, autonomous region or municipality directly under the central government conducts an in-vitro diagnostic reagent registration by violating the Provisions, China Food and Drug Administration shall order it to correct within a deadline. Where it fails to correct before the deadline, China Food and Drug Administration may directly announce a revocation of the medical device registration certificate.'可被翻译为：第七十七条 省、自治区、直辖市食品药品监督管理部门违反本办法规定实施体外诊断试剂注册的，由国家食品药品监督管理总局责令限期改正；逾期不改正的，国家食品药品监督管理总局可以直接公告撤销该医疗器械注册证。\n'To apply for filing of class I in-vitro diagnostic reagent, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .'可被翻译为：境内第一类体外诊断试剂备案，备案人向设区的市级食品药品监督管理部门提交备案资料。\n'For a newly developed in-vitro diagnostic reagent not yet listed in the classification catalogue, the applicant may directly apply for a class III in-vitro diagnostic reagent registration, or, after determining the class of the product in accordance with the classification rules and applying for class confirmation to the China Food and Drug Administration, apply for registration or for filing.'可被翻译为：对新研制的尚未列入体外诊断试剂分类目录的体外诊断试剂，申请人可以直接申请第三类体外诊断试剂产品注册，也可以依据分类规则判断产品类别向国家食品药品监督管理总局申请类别确认后，申请产品注册或者办理产品备案。\n\n根据上述已知信息，请将'Where a class III in-vitro diagnostic reagent registration is directly applied for, China Food and Drug Administration shall determine the class based on its risk degree. Where a domestic in-vitro diagnostic reagent is determined as class II, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the province, autonomous region, or municipality directly under the central government where the applicant is located for evaluation and approval. Where a domestic in-vitro diagnostic reagent is determined as class I, China Food and Drug Administration shall forward the application materials to the food and drug regulatory department of the city consisting of districts where the applicant is located.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"直接申请第三类体外诊断试剂注册的，国家食品药品监督管理总局按照风险程度确定类别。境内体外诊断试剂确定为第二类的，国家食品药品监督管理总局将申报资料转申请人所在地省、自治区、直辖市食品药品监督管理部门审评审批；境内体外诊断试剂确定为第一类的，国家食品药品监督管理总局将申报资料转申请人所在地设区的市级食品药品监督管理部门备案。"
    },
    {
        "instruction":"已知信息：\n'The State formulates development planning and industry policies for the vaccine industry to support development and structural optimization of the vaccine industry, and encourages scale and intensive production and constant improvement on the production process and quality of vaccines.'可被翻译为：国家制定疫苗行业发展规划和产业政策，支持疫苗产业发展和结构优化，鼓励疫苗生产规模化、集约化，不断提升疫苗生产工艺和质量水平。\n'An alternative approach to process validation in which manufacturing process performance is continuously monitored and evaluated.'可被翻译为：工艺验证的另一种方法，持续监控和评价生产工艺性能。\n'(5) meeting the requirements specified in the documents on product development and manufacturing process.'可被翻译为：（五）符合产品研制、生产工艺文件规定的要求。\n'In the process of transportation, drugs shall not be in direct contact with the ice bags, ice raft and other coolants to prevent their impacts on the quality of drugs.'可被翻译为：运输过程中，药品不得直接接触冰袋、冰排等蓄冷剂，防止对药品质量造成影响。\n\n根据上述已知信息，请将'Process of examining the probable impacts of a proposed regulation and of alternative policies to assist the policy development process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"审查拟议法规和替代政策可能产生的影响，以协助政策制定过程的过程。"
    },
    {
        "instruction":"已知信息：\n'Secondly, scientific evaluation is reinforced to timely deal with risk warning signals. We established and improved the working mechanism of daily monitoring, weekly summarization and quarterly analysis. At the same time, we paid close attention to the domestic and foreign regulatory dynamics in close integration with our actual clinical medication practice, and continuously strengthened the analysis and evaluation of the ADR report data. According to the evaluation outputs, we timely released pharmacovigilance information. In 2019, we issued the Announcement on the Cessation of Production, Sale and Use of Furazolidone containing Compound Preparations, as well as 27 Announcements on the revision of drug package inserts, and 12 volumes of Pharmacovigilance Express. The functions of the early warning management platform were further optimized to realize early detection, response, investigation, and disposal of early warning signals to ensure effective protection of drug safety for the public.'可被翻译为：二是加强科学评价，及时处置风险预警信号。建立健全日监测、周汇总、季度分析工作机制，同时密切关注国内外监管动态，紧密结合临床用药实际，不断强化对药品不良反应报告数据的分析评价。根据评价结果，及时发布药品安全警示信息。2019年发布停止含呋喃唑酮复方制剂生产销售使用公告，发布药品说明书修订公告27期，发布《药物警戒快讯》12期。继续优化预警管理平台功能，对预警信号做到早发现、早应对、早调查、早处置，切实保障公众用药安全。\n'In 2018, the evaluation and disposal of risk signals for the monitoring of adverse events in medical devices were carried out in depth.We've strengthened the daily monitoring,early warning analysis and quarterly summary of national medical device adverse event reports. Based on the risk conditions,3 issues of Medical Device Adverse Event Information Notification and 6 Medical Device Pharmacovigilance Expresses were issued throughout the year. The intensive monitoring of adverse events in medical devices 13th Five-Year Plan continued to advance. The National Center for ADR Monitoring has organized inspections on key surveillance work. The relevant undertaking units proactively collected monitoring data to dig deeper into the risks of medical devices, and the relevant work saw steady progress.'可被翻译为：2018年，医疗器械不良事件监测风险信号评价处置工作深入开展。强化对全国医疗器械不良事件报告的日常监测、预警分析及季度汇总，根据发现的风险情况，全年共发布《医疗器械不良事件信息通报》3期、《医疗器械警戒快讯》6期。“十三五”医疗器械不良事件重点监测工作持续推进。国家药品不良反应监测中心组织对重点监测工作进行督查，相关承担单位主动收集监测数据，深入挖掘医疗器械风险，工作进展顺利。\n'In 2019, the risk signal evaluation &disposal of medical device adverse events has been carried out in depth. We’ve strengthened the daily monitoring, early warning analysis and quarterly summary of national medical device adverse event reports. Based on spotted risk conditions, 3 issues of Medical Device Adverse Event Information Notification and 12 volumes of Medical Device Pharmacovigilance expresses were released in 2019. The intensive monitoring of medical device adverse events continued to advance in the 13th Five-Year Plan period, and each undertaking unit actively reviewed the previous work, sorted out product risks, and ensured the orderliness of key monitoring.'可被翻译为：2019年，医疗器械不良事件风险信号评价处置工作深入开展。强化对全国医疗器械不良事件报告的日常监测、预警分析及季度汇总，根据发现的风险情况，全年共发布《医疗器械不良事件信息通报》3期、《医疗器械警戒快讯》12期。“十三五”医疗器械不良事件重点监测工作持续推进，各承担单位积极回顾前期工作，梳理产品风险，确保重点监测工作有序开展。\n'Established criteria giving early warning of drift of the critical variables of a system from normal conditions, while not reaching the action limit, which are not necessarily grounds for definitive corrective action.'可被翻译为：系统的关键参数超出正常范围，但未达到纠偏限度，需要引起警觉，可能需要采取纠正措施的限度标准。\n\n根据上述已知信息，请将'Second, conduct in-depth safety evaluation and timely address risk warning signals.Based on monitoring data analysis and evaluation results, in 2018, we've released a total of 33 announcements on the revision of drug package inserts; mandated the cessation of production, sales and use of Pyrithioxine Injections, Composite Terfenadine Tablets, Sulfisomidiae Tablets and Terfenadine, Ibuprofen and Pseudoephedrine Capsules, and issued 12volumes of Pharmacovigilance Express.We continued to optimize the early warning system and timely handled more than 150highly concerned ADR-events clustering signals, focusing on early detection, early response, early investigation and early disposal to ensure safety of public drug use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"二是深入开展安全性评价，及时处置风险预警信号。根据监测数据分析评价结果，2018年共发布药品说明书修订公告33期、停止吡硫醇注射剂、特酚伪麻片、磺胺索嘧啶片和特洛伪麻胶囊生产销售使用、发布《药物警戒快讯》12期。继续优化预警系统，对重点关注的150余个药品不良反应事件聚集性信号及时进行处置，做到早发现、早应对、早调查、早处置，保障公众用药安全。"
    },
    {
        "instruction":"已知信息：\n'Validated loading patterns should be established for all sterilisation processes and load patterns should be subject to periodic revalidation. Maximum and minimum loads should also be considered as part of the overall load validation strategy.'可被翻译为：所有灭菌工艺都应建立经验证的装载模式，并且装载模式应定期进行再验证。最大装载和最小装载也应视为装载验证策略的一部分。\n'Samples of products using systems other than fusion should be taken and checked for integrity using\nvalidated methods. The frequency of testing should be based on the knowledge and experience of the container\nand closure systems being used. A scientifically justified sampling plan should be used. The sample size should be\nbased on information such as supplier management, packaging component specifications and process knowledge.'可被翻译为：使用非融合系统的产品应进行取样并使用经验证的方法检查其完整性。完整性检查的频率应基于所使用容器和密封系统的知识和经验。应使用经科学论证的取样计划。样本量应基于供应商管理、包装组件质量标准和工艺知识等信息。\n'Validation of the sterilisation of fluids loads in a superheated water autoclave should include temperature mapping of the entire load and heat penetration and reproducibility studies. All parts of the load should heat up uniformly and achieve the desired temperature for the specified time. Routine temperature monitoring probes should be correlated to the worst case positions identified during the qualification process.'可被翻译为：过热水高压灭菌柜中液体负载的灭菌验证应包括整个负载的温度分布以及热穿透和重现性研究。负载的所有部分应均匀加热并在指定的时间内达到要求的温度。常规温度监测探头应与确认过程中确定的最差条件相关联。\n'For products which have been heat sterilised in their final containers, samples taken should be representative of the worst case locations (e.g. the potentially coolest or slowest to heat part of each load).'可被翻译为：对于在最终容器内进行加热灭菌的产品，取样应代表最差条件下的位置（例如每批负载中潜在的最冷点或加热最慢的部分）。\n\n根据上述已知信息，请将'The validity of the sterilizing process should be reviewed and verified at scheduled intervals based on risk.\nHeat sterilization cycles should be revalidated with a minimum frequency of at least annually for load patterns\nthat are considered worst case. Other load patterns should be validated at a frequency justified in the CCS.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据风险按照预定的时间间隔审核和确认灭菌工艺的有效性。对于被认为是最差条件的装载模式，应至少每年一次定期开展加热灭菌周期的再验证。其它装载模式应以 CCS 中论证的频率进行验证。"
    },
    {
        "instruction":"已知信息：\n'The products subject to lot release shall be manufactured as per the process approved by the CFDA. Enterprises shall be responsible for the authenticity of the materials, records and data generated during the production and testing processes of the products subject to lot release. The materials for lot release shall be reviewed, signed and issued by the Qualified Person of the enterprise.'可被翻译为：批签发产品应当按照食品药品监管总局核准的工艺生产。企业对批签发产品生产、检验等过程中形成的资料、记录和数据的真实性负责。批签发资料应当经企业质量受权人审核并签发。\n'Article 12 For each variety subject to the application for lot release, the lot release applicant shall establish an independent template for the summary of the production and testing records of lot release, which shall be submitted to the NIFDC for verification and then be distributed after approval to the lot release institution and the applicant by the NIFDC. In case of a revision of the verified template for the summary of the production and testing records of lot release required, the lot release applicant shall submit an application to the NIFDC. The template shall not be changed until verified by the NIFDC.'可被翻译为：第十二条    对拟申请批签发的每个品种，批签发申请人应当建立独立的批签发生产及检验记录摘要模板，报中检院核定后，由中检院分发给批签发机构和申请人。批签发申请人需要修订已核定的批签发生产及检验记录摘要模板的，应当向中检院提出申请，经中检院核定后方可变更。\n'Article 12 For each product subject to the application for lot release, the lot release applicant shall establish an independent template for the summary of the production and control test records of lot release, which shall be submitted to the NIFDC for verification and then distributed after approval to the lot release institution and the applicant by the NIFDC. In case of a revision of the verified template for the summary of the production and testing records of lot release required, the lot release applicant shall submit an application to the NIFDC. The template shall not be changed until verified by the NIFDC.'可被翻译为：第十二条 对拟申请批签发的每个品种，批签发申请人应当建立独立的批签发生产及检定记录摘要模板，报中检院核定后，由中检院分发给批签发机构和申请人。批签发申请人需要修订已核定的批签发生产及检定记录摘要模板的，应当向中检院提出申请，经中检院核定后方可变更。\n'Article 33 MAHs shall establish a marketing release procedure to audit drug products released by drug manufacturers. Drug products shall not be released until signed off by a qualified person and those that do not conform to national drug standards shall not be released.'可被翻译为：第三十三条 药品上市许可持有人应当建立药品上市放行规程，对药品生产企业出厂放行的药品进行审核，经质量受权人签字后方可放行。不符合国家药品标准的，不得放行。\n\n根据上述已知信息，请将'Lot release products shall be manufactured in accordance with the approved process and shall conform to the national drug standards and drug registration standards. The entire production process shall comply with the Good Manufacture Practice for Pharmaceutical Products. MAHs shall establish a complete production quality management system and continuously strengthen the management of deviation. MAHs shall be responsible for the authenticity of the materials, records and data generated during the production, testing and relevant processes of the lot release products. Lot release materials shall be reviewed, signed and issued by the qualified person of the MAHs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批签发产品应当按照经核准的工艺生产，并应当符合国家药品标准和药品注册标准。生产全过程应当符合药品生产质量管理规范的要求。药品上市许可持有人应当建立完整的生产质量管理体系，持续加强偏差管理。药品上市许可持有人对批签发产品生产、检验等过程中形成的资料、记录和数据的真实性负责。批签发资料应当经药品上市许可持有人的质量受权人审核并签发。"
    },
    {
        "instruction":"已知信息：\n'The original strain used for breeding.'可被翻译为：用于育种的原始菌株。\n'Endpoint and kinetic assays are photometric quantitative assays used for the detection of bacterial endotoxins. Endpoint and kinetic assays may utilize turbidimetric or chromogenic formats. Endpoint assays measure endotoxin the increase in turbidity (turbidimetric) or color (chromogenic) at the end of the incubation time.'可被翻译为：终点和动力学法是细菌内毒素检测用光度定量分析。终点和动力学分析可使用浊度或色 度形式。终点测定法测量内毒素在培养时间结束时浊度（浊度）或颜色（显色）的增加。\n'Applied to quantitative microbiological tests. The lowest number of microorganisms within a defined variability that may be counted under the experimental conditions of the method under evaluation.'可被翻译为：适用于定量微生物检测。在评估方法的实验条件下，在规定的可变性内可计数的最低微生物数量。\n'f. <1116> Microbiological evaluation of clean rooms and other controlled environments'可被翻译为：<1116>洁净室和其它受控环境的微生物评估\n\n根据上述已知信息，请将'A standard strain used for microbiological assays and other tests.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于微生物测定和其他检查用的标准菌株。"
    },
    {
        "instruction":"已知信息：\n'1.Overall intentions and direction of an organization related to quality as formally expressed by senior management.\n2.A brief statement that describes the organization’s purpose, overall intentions and strategic direction; provides a framework for quality objectives; and includes a commitment to meet applicable requirements.\n3.A brief statement that describes the organization’s purpose, overall intentions and strategic direction; provides a framework for quality objectives; and includes a commitment to meet applicable requirements.'可被翻译为：1.由高级管理层正式表达的与质量有关的组织的总体意图和方向。\n2.一份描述组织宗旨、总体意图和战略方向的简短声明;提供质量目标的框架;并包括满足适用要求的承诺。\n3.一份描述组织宗旨、总体意图和战略方向的简短声明;提供质量目标的框架;并包括满足适用要求的承诺。\n'quality policy. A brief statement that describes the organization’s purpose, overall intentions and strategic direction; provides a framework for quality objectives; and includes a commitment to meet applicable requirements.'可被翻译为：质量方针：说明公司的目的、全面目标和策略方向，表达质量目标框架，包括承诺满足适用要求的简要声明\n'3. A laboratory quality management system is established for the central laboratory.'可被翻译为：3.中心实验室建立有实验室质量管理体系。\n'The sum of all aspects of a system that implements quality policy and ensures that quality objectives are met. (ICH Q10)'可被翻译为：实现质量方针和确保质量目标系统的全方面的总和。（ICH Q10）\n\n根据上述已知信息，请将'1.A handbook that describes the various elements of the system for assuring the quality of the test results generated by a laboratory.\n2.A handbook that describes the various elements of the quality management system for assuring the quality of the test results generated by a laboratory (see Part one, sections 2.1–2.2).\n3.A document that includes the quality policy and objectives and describes the various elements of the QMS.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.描述保证实验室产生的检测结果质量的系统的各种要素的手册。\n2.描述质量管理体系各种要素的手册，以保证实验室产生的检测结果的质量(见第一部分2.1-2.2节)。\n3.包括质量方针和目标并描述质量管理体系各要素的文件。"
    },
    {
        "instruction":"已知信息：\n'(V) The sales of drugs under special management and drugs with special management requirements by the State;'可被翻译为：（五）特殊管理的药品和国家有专门管理要求的药品的销售；\n'Article 170 The sales of drugs under special management and those with special management requirements of the State shall be carried out in strict accordance with the relevant national provisions.'可被翻译为：第一百七十条 销售特殊管理的药品和国家有专门管理要求的药品，应当严格执行国家有关规定。\n'Article 93 The sales of drugs under special management and those with special management requirements of the State shall be carried out in strict accordance with the relevant national provisions.'可被翻译为：第九十三条 销售特殊管理的药品以及国家有专门管理要求的药品，应当严格按照国家有关规定执行。\n'(VII) Provisions for drugs under special management;'可被翻译为：（七）特殊管理的药品的规定；\n\n根据上述已知信息，请将'(V) Management of drugs under special management and drugs with special management requirements by the State;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）特殊管理的药品和国家有专门管理要求的药品的管理；"
    },
    {
        "instruction":"已知信息：\n'Article 155 This Law shall go into effect as of December 1, 2019.'可被翻译为：第一百五十五条 本法自2019年12月1日起施行。\n'Note: The statistics period of this report is from January 1, 2019 to December 31, 2019.'可被翻译为：注：本报告的数据统计自2019年1月1日至2019年12月31日。\n'The Drug Administration Law of the People's Republic of China adopted at the 12th Meeting of the Standing Committee of the Thirteenth National People's Congress on August 26, 2019 is hereby promulgated and shall go into effect as of December 1, 2019.'可被翻译为：《中华人民共和国药品管理法》已由中华人民共和国第十三届全国人民代表大会常务委员会第十二次会议于2019年8月26日修订通过，现予公布，自2019年12月1日起施行。\n'The Vaccine Administration Law of the People's Republic of China, adopted at the 11th Meeting of the Standing Committee of the Thirteenth National People's Congress on June 29, 2019, is hereby promulgated and shall go into effect as of December 1, 2019.'可被翻译为：《中华人民共和国疫苗管理法》已由中华人民共和国第十三届全国人民代表大会常务委员会第十一次会议于2019年6月29日通过，现予公布，自2019年12月1日起施行。\n\n根据上述已知信息，请将'Article 100 This Law shall be effective as of December 1, 2019.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百条 本法自2019年12月1日起施行。"
    },
    {
        "instruction":"已知信息：\n'(2) have the premises, facilities, and hygienic environment required for drug manufacturing;'可被翻译为：（二）有与药品生产相适应的厂房、设施和卫生环境；\n'(2) having the premises, facilities, equipment and hygienic environment required for drug manufacturing;'可被翻译为：（二）有与药品生产相适应的厂房、设施、设备和卫生环境；\n'Article 43 Enterprises shall have business premises and warehouses adapted to their drug distribution scale and scope.'可被翻译为：第四十三条 企业应当具有与其药品经营范围、经营规模相适应的经营场所和库房。\n'Article 23    The pharmacy established by a medical institution shall have the premise, equipment, storage facilities, hygienic environment, and pharmaceutical professionals required for drug dispensing. It shall also have the drug quality control units or personnel, and establish a system for drug storage.'可被翻译为：第二十三条 医疗机构设置的药房，应当具有与所使用药品相适应的场所、设备、仓储设施和卫生环境，配备相应的药学技术人员，并设立药品质量管理机构或者配备质量管理人员，建立药品保管制度。\n\n根据上述已知信息，请将'(2) have the premises, equipment, warehouses, and hygienic environment required for drug distribution;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）有与所经营药品相适应的营业场所、设备、仓储设施和卫生环境；"
    },
    {
        "instruction":"已知信息：\n'An emulsion made by further dispersing colostrum of oil in water (o\/w) or water in oil (W\/O) in an oil phase (O\/W\/O) or water phase (W\/O\/W) for emulsification.'可被翻译为：将水包油(o\/w)或油包水(W\/O)的初乳进一步分散在油相(O\/W\/O)或水相(W\/O\/W)中进行乳化所制成的乳剂。\n'The liquid drug or drug solution with the projectile (liquid that is insoluble in water) forms an oil-in-water (O\/W) or oil-in-water (W\/O) emulsion! L Oil-in-water emulsions are ejected in foam form as the inner phase ejector vaporizes during ejection. The oil-in-water emulsion forms a flow as the outer phase ejector vaporizes during ejection.'可被翻译为：液体药物或药物溶液与抛射剂（不溶于水的液体）形成水包油（O\/W）或油包水（W\/O）乳齐!L水包油乳剂在喷射时随着内相抛射剂的气化而以泡沫形式喷出。油包水乳剂在喷射时随着外相抛射剂的气化而形成流液。\n'oil-in-water emulsion'可被翻译为：水包油乳剂\n'A matrix consisting of natural or synthetic water-soluble polymers.'可被翻译为：由天然或合成的水溶性高分子物质所组成的基质。\n\n根据上述已知信息，请将'Ointments made from oil-in-water (O\/W) emulsion matrix and water-soluble matrix.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由水包油（O\/W）乳剂基质及水溶性基质制备而成的软膏。"
    },
    {
        "instruction":"已知信息：\n'Article 292: The contract should define that the contract acceptor has the obligation to accept the inspection conducted by drug regulatory department.'可被翻译为：第二百九十二条 委托检验合同应当明确受托方有义务接受药品监督管理部门检查。\n'Article 31 The food and drug regulatory department at higher level shall timely notify the results of an unannounced inspection organized by itself, to the local food and drug regulatory department.'可被翻译为：第三十一条 上级食品药品监督管理部门应当及时将其组织实施的飞行检查结果通报被检查单位所在地食品药品监督管理部门。\n'Drug regulatory departments shall implement intensive supervision and inspection for high-risk drugs.'可被翻译为：药品监督管理部门应当对高风险的药品实施重点监督检查。\n'(VII) Cooperating with drug regulatory departments and monitoring agencies in investigation of medical device adverse events.'可被翻译为：（七）配合药品监督管理部门和监测机构组织开展的不良事件调查。\n\n根据上述已知信息，请将'(5) Cooperating with the supervision and inspection of the drug regulatory department.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）配合药品监督管理部门的监督检查工作。"
    },
    {
        "instruction":"已知信息：\n'The inspection records of incoming goods shall be kept till 2 years after expiration of valid term of the medical device; if there is no valid term for such medical device, the records shall be kept for no less than 5 years. The inspection records of incoming implantable medical devices shall be kept permanently.'可被翻译为：进货查验记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械进货查验记录应当永久保存。\n'Article 22 MAHs, medical device distributing enterprises as well as user facility shall establish and keep medical device adverse event monitoring records. The records shall be kept until 2 years upon shelf life expiration of medical devices; for those without shelf life label, the record-keeping period shall not be less than 5 years. The monitoring records of implantable medical devices shall be kept permanently, and medical institutions shall keep them in accordance with the relevant provisions for medical records.'可被翻译为：第二十二条  持有人、经营企业、使用单位应当建立并保存医疗器械不良事件监测记录。记录应当保存至医疗器械有效期后2年；无有效期的，保存期限不得少于5年。植入性医疗器械的监测记录应当永久保存，医疗机构应当按照病例相关规定保存。\n'Drug purchase records shall be kept till one year after the date of expiry, but not less than three years.'可被翻译为：药品购进记录必须保存至超过药品有效期1年，但不得少于3年。\n'The online drug sales enterprises shall keep complete records of qualification documents and electronic transactions of the suppliers. The online drug retailers selling prescription drugs shall also keep records of prescriptions, online pharmaceutical services, etc. The relevant records shall be kept for not less than 5 years, and not less than 1 year after the expiration of the drug.'可被翻译为：药品网络销售企业应当完整保存供货企业资质文件、电子交易等记录。销售处方药的药品网络零售企业还应当保存处方、在线药学服务等记录。相关记录保存期限不少于5年，且不少于药品有效期满后1年。\n\n根据上述已知信息，请将'The sales records shall be kept till 2 years after expiration of valid term of the medical devices; if there is no valid term for such medical devices, the records shall be kept for no less than 5 years. The sales records of implantable medical devices shall be kept permanently.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"销售记录应当保存至医疗器械有效期满后2年；没有有效期的，不得少于5年。植入类医疗器械销售记录应当永久保存。"
    },
    {
        "instruction":"已知信息：\n'(1) In the name of the registrants and filing persons, handling the registration and filing of cosmetics and new cosmetic ingredients;'可被翻译为：（一）以注册人、备案人的名义，办理化妆品、化妆品新原料注册、备案；\n'(2) Assisting the registrants and filing persons in carrying out cosmetic adverse reaction monitoring, safety monitoring and reporting of new cosmetic ingredients;'可被翻译为：（二）协助注册人、备案人开展化妆品不良反应监测、化妆品新原料安全监测与报告工作；\n'Registrants and filing persons of cosmetics and new cosmetic ingredients shall apply for registration and filing through the information service platform of registration and filing for cosmetics and new cosmetic ingredients (hereinafter referred to as the information service platform) in accordance with regulations.'可被翻译为：化妆品、化妆品新原料注册人、备案人按照规定通过化妆品、化妆品新原料注册备案信息服务平台（以下简称信息服务平台）申请注册、进行备案。\n'If cosmetic registrants and filing persons use new cosmetic ingredients to produce cosmetics, the relevant cosmetic registration application and filing shall be associated and confirmed by the registrant or filing person of the new cosmetic ingredient through the information service platform.'可被翻译为：化妆品注册人、备案人使用化妆品新原料生产化妆品的，相关化妆品申请注册、办理备案时应当通过信息服务平台经化妆品新原料注册人、备案人关联确认。\n\n根据上述已知信息，请将'(3) Assisting the registrants and filing persons in implementing the recall of cosmetics and new cosmetic ingredients;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）协助注册人、备案人实施化妆品、化妆品新原料召回工作；"
    },
    {
        "instruction":"已知信息：\n'Assess and document the risks associated with the duration of filter use for the sterile filtration process for a given fluid.'可被翻译为：评估并记录与给定液体除菌过滤工艺中过滤器的使用时间相关的风险。\n'Suitable bioburden reduction prefilters and\/or sterilising grade filters may be used at multiple points during the manufacturing process to ensure a low and controlled bioburden of the liquid prior to the final sterilising filter. Due to the potential additional risks of a sterile filtration process, as compared with other sterilisation processes, an additional filtration through a sterile sterilising grade filter, as close to the point of fill as possible, should be considered as part of an overall CCS.'可被翻译为：在生产工艺过程中，可在多个点使用预过滤器和\/或除菌过滤器，以确保液体在经过最终除菌过滤器之前生 物负载处于较低且受控的水平。由于除菌过滤工艺相比于其它灭菌工艺具有潜在的额外风险，因此应考虑尽可能靠近灌装点通过除菌过滤器进行额外过滤，作为整体 CCS 的一部分。\n'Minimize the number of aseptic connections required between the final sterilising grade filter and the final filling of the product.'可被翻译为：最大程度地减少最终除菌级过滤器和最终灌装之间所需的无菌连接次数。\n'If the product cannot be sterilised in its final container, solutions or liquids should be sterilised by filtration through  a  sterile  sterilising  grade  filter  (with  a  nominal  pore  size  of a maximum  of 0.22  μm  that has been appropriately validated to obtain a sterile filtrate) and subsequently aseptically filled into a previously sterilised container. The selection of the filter used should ensure that it is compatible with the product and as described in the marketing authorization (see paragraph 8.135).'可被翻译为：如果产品不能在最终容器中灭菌，溶液或液体应通过除菌过滤器（经过适当验证的标称孔径最大 0.22um， 以获得无菌滤液）进行灭菌，然后无菌灌装到预先灭菌的容器中。所用过滤器应确保与产品相容并与其销售许可的描述相符（参见第 8.135 节）。\n\n根据上述已知信息，请将'Conduct and document effective validation and qualification studies to demonstrate that the duration of filter use for a given  sterile  filtration process and for a given  fluid does not compromise performance of the final sterilising grade filter or filtrate quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"执行有效的验证和确认研究并进行记录，以证明给定液体和给定除菌过滤工艺中过滤器的使用时间不会影响最终除菌级过滤器的性能或滤液质量。"
    },
    {
        "instruction":"已知信息：\n'Article 37 The NMPA shall establish a unified IMS, where it can publish information on the lot release institutions and relevant adjustments, decision on handling major issues, provide the lot release applicants with the searchable progress and conclusions of lot release, and disclose the products approved for lot release for public inquiries.'可被翻译为：第三十七条   国家药品监督管理局建立统一的生物制品批签发信息平台，公布批签发机构及调整情况、重大问题处理决定等信息，向批签发申请人提供可查询的批签发进度、批签发结论，及时公布已通过批签发的产品信息，供公众查询。\n'Article 38 The lot release institution shall disclose the lot release conclusion and other information within 7 days after the decision on lot release for each batch of products made by the institution.'可被翻译为：第三十八条 批签发机构应当在本机构每一批产品批签发决定作出后7日内公开批签发结论等信息。\n'Before the lot release institution makes any conclusion in lot release, the lot release applicant shall supplement the lot release application dossiers and submit them to the lot release institution.'可被翻译为：在批签发机构作出批签发合格结论前，批签发申请人应当将批签发申请资料补充完整并提交批签发机构。\n'Article 4 The CFDA shall be in charge of lot release of biological products nationwide, specifies the scope of product varieties subject to lot release, designates lot release institutions, and guides the implementation of lot release.'可被翻译为：第四条 食品药品监管总局主管全国生物制品批签发工作，负责规定批签发品种范围，指定批签发机构，指导批签发工作的实施。\n\n根据上述已知信息，请将'Article 36 The CFDA shall establish a unified Information Management System for Lot Release, release the determination and adjustment by the lot release institutions and provide the lot release applicants with the searchable progress and conclusions of lot release, and summarize and disclose the lot release conclusion of the products with the lot release completed and handling decision of major issues and other information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十六条 食品药品监管总局建立统一的批签发信息管理系统，公布批签发机构确定及调整情况，向批签发申请人提供可查询的批签发进度、批签发结论，汇总公开已完成批签发的产品批签发结论以及重大问题处理决定等信息。"
    },
    {
        "instruction":"已知信息：\n'The difference in pressure between two points, such as the pressure difference between an \nenclosed space and an independent reference point, or the pressure difference between two \nenclosed spaces.'可被翻译为：两点之间的压差，如安之间的压差\n封闭空间与独立参考点之间的压力差，或两者之间的压力差\n封闭的空间。\n'The absorbance of test solution and control solution is measured at two different wavelengths, and the difference of absorbance at two wavelengths (A4) is used as a quantitative basis to determine the content of the method.'可被翻译为：在两个不同的波长处测定供试品溶液和对照品溶液的吸光度，以两波长处吸光度的差值（A4）作为定量的依据来测定含量的方法。\n'A statistical test of whether and to what extent variables are correlated.'可被翻译为：对变量之间是否相关以及相关的程度如何所进行的统计检验。\n'Assessment of potential bias between two bioanalytical methods or the same bioanalytical method used in different laboratories in order to determine whether reported data are comparable.'可被翻译为：对两个生物分析方法之间或同一生物分析方法用于不同实验室的潜在偏差的评估，以确定报告的数据是否有可比性。\n\n根据上述已知信息，请将'A statistical test to determine whether the difference between two means is significant by applying T-distribution theory to infer the probability of the difference.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应用t分布理论推断差异发生的概率，从而判定两个平均数的差异是否显著的一种统计学检验方法。"
    },
    {
        "instruction":"已知信息：\n'In a redundant filtration system (where a second redundant sterilising grade filter is present as a backup but the sterilising process is validated as only requiring one filter), post-use integrity test of the primary sterilising grade filter should be performed and if demonstrated to be integral, then a post-use integrity test of the redundant (backup) filter is not necessary. However, in the event of a failure of the post-use integrity test on the primary filter, post-use integrity test  on the  secondary (redundant) filter  should be performed, in conjunction with an investigation and risk assessment to determine the reason for the primary filter test failure.'可被翻译为：对于冗余过滤系统（存在第二个冗余除菌级过滤器作为备用过滤器，但灭菌工艺验证时仅用一个过滤器）， 应进行主除菌级过滤器的使用后完整性测试，如果证明该过滤器是完整的，则不需要对冗余（备用）过滤 器进行使用后完整性测试。但如果主过滤器的使用后完整性测试失败，应对二级（冗余）过滤器进行使用后完整性测试，同时进行调查和风险评估，确定主过滤器测试失败的原因。\n'Methods and parameters for integrity testing of filled containers (see paragraph 8.22).'可被翻译为：已灌装容器完整性测试的方法和参数（参见第 8.22 节）。\n'Methods and parameters for integrity testing of 100% of all filled containers (see paragraph 8.22).'可被翻译为：所有已灌装容器 100%完整性测试的方法和参数（参见第 8.22 节）。\n'If the sterilising filtration process has been validated as a system consisting of multiple filters to achieve the sterility for a given fluid, the filtration system is considered to be a single sterilising unit and all filters within the system should satisfactorily pass integrity testing after use.'可被翻译为：如果除菌过滤工艺已作为多个过滤器组成的单个系统经过验证，能保证给定液体的无菌性，则该过滤系统被认为是单个灭菌单元，系统内的所有过滤器应在使用后通过完整性测试。\n\n根据上述已知信息，请将'The performance of the pre- and post-use integrity testing for sterilising grade filters (see paragraph 8.87).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除菌级过滤器的使用前后完整性测试的性能（参见第 8.87 节）。"
    },
    {
        "instruction":"已知信息：\n'Stereoisomers that are mirror images of each other.'可被翻译为：互为镜像关系的立体异构体。\n'The phenomenon of being physical objects and mirror images of each other but not overlapping.'可被翻译为：互为实物与镜像而不可重叠的现象。\n'An asymmetric molecule that cannot overlap with its own mirror image and has the property of rotating the vibrational plane of polarized light.'可被翻译为：不能与自身的镜像相重叠，并具有使偏振光振动面旋转性质的不对称分子。\n'A synthetic reaction in which the product is two or more stereoisomers, one of which predominates.'可被翻译为：产物为两个或两个以上的立体异构体，其中一个占优势的合成反应。\n\n根据上述已知信息，请将'For stereoisomers that have two or more asymmetric centers in a molecule and whose molecules are not mirror images of each other.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于分子中具有两个或多个不对称中心，并且其分子不互为镜像关系的立体异构体。"
    },
    {
        "instruction":"已知信息：\n'(I) Personnel engaged in quality management shall have a degree of technical school in pharmacy, or college degree or above in medicine, biology and chemistry, or primary professional and technical title or above in pharmacy;'可被翻译为：（一）从事质量管理工作的，应当具有药学中专或者医学、生物、化学等相关专业大学专科以上学历或者具有药学初级以上专业技术职称；\n'(II) Personnel engaged in acceptance inspection and maintenance shall have a degree of technical school or above in pharmacy or medicine, biology, chemistry or other related disciplines, or a primary professional and technical title or above in pharmacy;'可被翻译为：（二）从事验收、养护工作的，应当具有药学或者医学、生物、化学等相关专业中专以上学历或者具有药学初级以上专业技术职称；\n'(III) Personnel engaged in the acceptance inspection of Chinese crude drugs and Prepared Slices shall have a degree of technical school or above or an intermediate professional and technical title or above in traditional Chinese medicine; those engaged in the maintenance of Chinese crude drugs and Prepared Slices shall have a degree of technical school or above or a primary professional and technical title or above in traditional Chinese medicine; for the direct purchase of Chinese crude drugs at the place of production, the acceptance inspection personnel shall have the intermediate professional title or above in traditional Chinese medicine.'可被翻译为：（三）从事中药材、中药饮片验收工作的，应当具有中药学专业中专以上学历或者具有中药学中级以上专业技术职称；从事中药材、中药饮片养护工作的，应当具有中药学专业中专以上学历或者具有中药学初级以上专业技术职称；直接收购地产中药材的，验收人员应当具有中药学中级以上专业技术职称。\n'Article 126 Personnel engaged in quality management, acceptance inspection and purchase shall have academic qualifications in pharmacy or medicine, biology, chemistry or other related disciplines or have professional and technical titles in pharmacy. Personnel engaged in the quality management, acceptance inspection and purchase of Prepared Slices shall have a degree of technical school or above, or a primary professional and technical title or above in traditional Chinese medicine.'可被翻译为：第一百二十六条 质量管理、验收、采购人员应当具有药学或者医学、生物、化学等相关专业学历或者具有药学专业技术职称。从事中药饮片质量管理、验收、采购人员应当具有中药学中专以上学历或者具有中药学专业初级以上专业技术职称。\n\n根据上述已知信息，请将'For the dispatch of vaccines, there shall be at least two professionals especially responsible for the quality management and acceptance inspection of vaccines. Professionals shall have a bachelor's degree or above and intermediate professional and technical title or above in preventive medicine, pharmacy, microbiology or medicine, and have working experiences in vaccine management or techniques for more than 3 years.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"从事疫苗配送的，还应当配备2名以上专业技术人员专门负责疫苗质量管理和验收工作。专业技术人员应当具有预防医学、药学、微生物学或者医学等专业本科以上学历及中级以上专业技术职称，并有3年以上从事疫苗管理或者技术工作经历。"
    },
    {
        "instruction":"已知信息：\n'Place all pieces into the 20 x 150 mm tube containing 15 mL of preheated (37°C ±1°C) 0.01% SLS rinse solution.'可被翻译为：将所有小片放入装有15ml预热（37°C ±1°C）0.01%SLS淋洗液的20 x 150 mm 试管。\n'The storage and mixing of samples prior to analysis may affect recovery of endotoxin contamination. Sample (product) bottles should be vigorously shaken prior to analysis, preferably on a vortex (see reference for supporting evidence for this step). A minimum of 30 seconds to 1 min on the vortex is recommended for each product unit.'可被翻译为：样品在分析之前的存贮和混合可能影响内毒素污染的回收。样品（产品）瓶在分析 之前应剧烈震摇，最好在涡旋器上震摇（参见参考文献中本步骤支持性证据）。建 议每个产品单位在涡旋器上震摇至少30秒至1分钟。\n'Vortex the tubes for 2 minutes. Remove a portion of the eluate (5 – 10 mL) for LAL testing. If the eluates are not tested immediately for endotoxin, they should be refrigerated. All eluates must be tested within 24 hours of extraction. Prior to analysis vortex at least one minute.'可被翻译为：涡旋震摇试管2分钟。取出一部分用于LAL检测洗脱（5-10ml）。如果不能立 即检测洗脱液的内毒素，则应冷藏。所有洗脱液必须在24小时内进行萃取检测。 分析前至少涡旋震摇1分钟。\n'Aseptically remove the device from its packaging and cut it diagonally into pieces less than 5mm in length. Small metal and plastic pieces such as needles and luer-locks should be tested whole. Pyrogen-free fluid pathways should be flushed with extract solution.'可被翻译为：在无菌操作下从包装中取出器械，将其斜切成小于5mm的小片。金属和塑料小 片如针头和鲁尔锁应整个检测。无热源液体通道应使用萃取液淋洗。\n\n根据上述已知信息，请将'Vortex the tubes for 30 – 60 seconds or until all pieces of the device are immersed in the rinse solution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"涡旋震摇试管30-60秒钟或直到器械的所有小块均浸入淋洗液。"
    },
    {
        "instruction":"已知信息：\n'In a prescribed release medium, the drug is released slowly and at a non-constant rate as required, and the frequency of administration is reduced by half or somewhat than that of the ordinary preparation compared with the corresponding ordinary preparation, and the patient's compliance is significantly increased.'可被翻译为：在规定释放介质中，按要求缓慢地非恒速释放药物，与相应的普通制剂比较，给药频率比普通制剂减少一半或给药频率比普通制剂有所减少，且能显著增加患者的顺应性的制剂。\n'In the prescribed release medium, the drug is slowly released at or near a constant rate as required, and compared with the corresponding ordinary preparation, the frequency of administration is reduced by half or the frequency of administration is reduced compared with the ordinary preparation, the blood concentration is more stable than the sustained release preparation, and can significantly increase the patient's compliance.'可被翻译为：在规定释放介质中，按要求缓慢地恒速或接近恒速释放药物，与相应的普通制剂比较，给药频率比普通制剂减少一半或给药频率比普通制剂有所减少，血药浓度比缓释制剂更加平稳，且能显著增加患者的顺应性的制剂。\n'release rate'可被翻译为：释放度\n'rate constant'可被翻译为：速度常数\n\n根据上述已知信息，请将'Capsules that slowly release the drug at a non-constant rate or near constant rate in water or a prescribed release medium.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在水中或规定的释放介质中缓慢地以非恒速或接近恒速释放药物的胶囊剂。"
    },
    {
        "instruction":"已知信息：\n'(2) Persons using electronic signatures shall, upon agency request, provide additional certification or testimony that a specific electronic signature is the legally binding equivalent of the signer's handwritten signature.'可被翻译为：应FDA要求人们在使用电子签名时，应提供一份明确电子签名与签字者手写签名具有同等的法律效力的附加的证明书或证据。\n'1.Record of the individual who performed a particular action or review. The record can be initials, full handwritten signature, personal seal or authenticated and secure electronic signature.\n2.The record of the individual who performed a particular action or review. This record can be in the form of initials, full handwritten signature, personal seal or an authenticated and secure electronic signature.'可被翻译为：1.执行特定行动或审查的个人记录。记录可以是首字母缩写、完整的手写签名、个人印章或经过认证和安全的电子签名。\n2.记录:执行某一特定行动或审查的个人的记录记录的形式可以是首字母缩写、完整的手写签名、个人印章或经过认证的安全电子签名。\n'The record of the individual who performed a particular action or review. This record can be initials, full handwritten signature, personal seal, or authenticated and secure electronic signature.'可被翻译为：执行某一具体工作或审核的人员记录。这种记录可以是姓名缩写，完整签名，个人印章或真实安全的电子签名。\n'(8) Handwritten signature means the scripted name or legal mark of an individual handwritten by that individual and executed or adopted with the present intention to authenticate a writing in a permanent form. The act of signing with a writing or marking instrument such as a pen or stylus is preserved. The scripted name or legal mark, while conventionally applied to paper, may also be applied to other devices that capture the name or mark.'可被翻译为：手写签名系指个体的，且在永久验证书写真实性的前提下签署或采纳的手写签名或合法印记。保留采用书写及标记工具（例如笔或者光笔）的签名方式。通常纸上的手写签名或合法标记也可使用与读取名字及标记的其他设备。\n\n根据上述已知信息，请将'(7) Electronic signature means a computer data compilation of any symbol or series of symbols executed, adopted, or authorized by an individual to be the legally binding equivalent of the individual's handwritten signature.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"电子签名系指与手写签名具有相同法律效力，且由一个个体签署、采纳或授权的符号或一系列符号的计算机数据编制。"
    },
    {
        "instruction":"已知信息：\n'If it is included in the priority evaluation and approval procedures, the time limit for registration inspection is 80 days.'可被翻译为：纳入优先审评审批程序的，注册核查工作时限为80日。\n'(3) Where inspection, testing and approval of the adopted name are needed, priority will be given;'可被翻译为：（三）需要核查、检验和核准药品通用名称的，予以优先安排；\n'Article 94 The drug registration timeline mentioned in these Provisions is the longest time needed for drug registration acceptance, review, inspection, testing, approval, etc. The timeline for priority review and approval procedures shall be implemented in accordance with relevant provisions on priority review and approval.'可被翻译为：第九十四条 本办法所规定的时限是药品注册的受理、审评、核查、检验、审批等工作的最长时间。优先审评审批程序相关工作时限，按优先审评审批相关规定执行。\n'Article 71 During review, where it is found that a drug registration application included into the priority review and approval procedure does not meet the conditions for priority review and approval, the CDE shall terminate the priority review and approval procedure for the application, evaluate the application as per the normal review procedure and inform the applicant.'可被翻译为：第七十一条 审评过程中，发现纳入优先审评审批程序的药品注册申请不能满足优先审评审批条件的，药品审评中心应当终止该品种优先审评审批程序，按照正常审评程序审评，并告知申请人。\n\n根据上述已知信息，请将'Article 14 Priority shall be given to registration inspection of the drugs in special approval procedures and priority evaluation and approval procedures.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十四条 特别审批程序、优先审评审批程序的品种，予以优先安排注册核查。"
    },
    {
        "instruction":"已知信息：\n'(II) Packaging and sealing of refrigerated or frozen drugs shall be completed in refrigerated environment;'可被翻译为：（二）应当在冷藏环境下完成冷藏、冷冻药品的装箱、封箱工作；\n'Article 49 Enterprises engaged in storage and transportation of refrigerated and frozen drugs shall be equipped with the following facilities and equipment:'可被翻译为：第四十九条 储存、运输冷藏、冷冻药品的，应当配备以下设施设备：\n'Article 75 For drugs conforming to receipt requirements, the receiving personnel shall place them in the corresponding area for quarantine according to the characteristics and requirements of the varieties, or set status identification, and notify relevant personnel for acceptance inspection. The refrigerated and frozen drugs shall be placed in the freezer for quarantine.'可被翻译为：第七十五条 收货人员对符合收货要求的药品，应当按品种特性要求放于相应待验区域，或者设置状态标志，通知验收。冷藏、冷冻药品应当在冷库内待验。\n'Article 105 During the transportation of refrigerated or frozen drugs, real-time monitoring and recording of temperature data in refrigerated vehicles, refrigerated container or thermal insulation container shall be conducted.'可被翻译为：第一百零五条 在冷藏、冷冻药品运输途中，应当实时监测并记录冷藏车、冷藏箱或者保温箱内的温度数据。\n\n根据上述已知信息，请将'Article 99 Specially-assigned personnel shall be responsible for the operations such as packaging and loading of refrigerated or frozen drugs, which shall conform to the following requirements:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九十九条 冷藏、冷冻药品的装箱、装车等项作业，应当由专人负责并符合以下要求："
    },
    {
        "instruction":"已知信息：\n'The process by which a drug is transported from one side of a biofilm to the other side of a biofilm with a higher concentration.'可被翻译为：药物从浓度低的一侧生物膜向浓度高的一侧的转运过程。\n'The transmembrane transport of a drug from one side with a high concentration to the other side with a low concentration.'可被翻译为：药物从浓度高的一侧向浓度低的一侧的跨膜转运。\n'The motion state of two types of molecules, membrane lipids and membrane proteins. Is one of the basic characteristics of biofilm.'可被翻译为：膜脂和膜蛋白两类分子的运动状态。是生物膜的基本特征之一。\n'A small peak that is not completely separated on one side of the larger chromatographic peak.'可被翻译为：较大色谱峰一侧未完全分离的小峰。\n\n根据上述已知信息，请将'The process by which a non-fat-soluble small molecule is transported from one side of the biofilm to the other with the help of special membrane proteins.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"非脂溶性小分子物质，在特殊膜蛋白质帮助下，由高浓度向低浓度一侧转运的过程。"
    },
    {
        "instruction":"已知信息：\n'In order to strengthen the supervision and administration of cosmetics labels, standardize the use of cosmetics labels and protect the legitimate rights and interests of consumers, according to the Regulations for the Supervision and Administration of Cosmetics, NMPA has drafted the Measures for the Administration of Cosmetics Labels (hereinafter referred to as the Measures),which are hereby promulgated. On May 31, matters related to implementation of the Measures are hereby announced as follows:'可被翻译为：为加强化妆品标签监督管理，规范化妆品标签使用，保障消费者合法权益，依据《化妆品监督管理条例》，国家药监局组织起草了《化妆品标签管理办法》（以下简称《办法》），现予公布。现就《办法》实施有关事宜公告如下：\n'Announcement of National Medical Products Administration and National Intellectual Property Administration on the Issuance of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (Interim)'可被翻译为：国家药监局 国家知识产权局关于发布《药品专利纠纷早期解决机制实施办法（试行）》的公告\n'NMPA Announcement on the Issues Related to the Implementation of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (interim)'可被翻译为：国家药监局关于实施《药品专利纠纷早期解决机制实施办法（试行）》相关事宜的通告\n'NMPA Announcement on Issuing the Provisions for the Administration of Adverse Reaction Monitoring of Cosmetics'可被翻译为：国家药监局关于发布《化妆品不良反应监测管理办法》的公告\n\n根据上述已知信息，请将'NMPA Announcement on Issuance and Implementation of the Measures for the Administration of Cosmetics Labels'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布实施《化妆品标签管理办法》的公告"
    },
    {
        "instruction":"已知信息：\n'Where a drug distributor fails to report suspected adverse drug reactions as required, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to production suspension for rectification and be fined not less than RMB 50,000 but not more than RMB 500,000.'可被翻译为：药品经营企业未按照规定报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，责令停产停业整顿，并处五万元以上五十万元以下的罚款。\n'Where a medical institution fails to report suspected adverse drug reactions, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to a fine of not less than RMB 50,000 but not more than RMB 500,000.'可被翻译为：医疗机构未按照规定报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，处五万元以上五十万元以下的罚款。\n'Article 127 In any of the following circumstances in violation of this Law, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to a fine of not less than RMB 100,000 but not more than RMB 500,000.'可被翻译为：第一百二十七条 违反本法规定，有下列行为之一的，责令限期改正，给予警告；逾期不改正的，处十万元以上五十万元以下的罚款：\n'Article 39 In case of violation of the provisions of Article 18 of these Provisions, it shall be ordered to make correction within the time limit; where correction is not made within the prescribed period, a fine of not less than RMB 50,000 and not more than RMB 100,000 shall be imposed; for hazardous consequences, a fine of not less than RMB 100,000 and not more than RMB 200,000 shall be imposed.'可被翻译为：第三十九条 违反本办法第十八条的规定，责令限期改正；逾期不改正的，处5万元以上10万元以下罚款；造成危害后果的，处10万元以上20万元以下罚款。\n\n根据上述已知信息，请将'Article 134 Where a drug MAH fails to monitor adverse drug reactions or report suspected adverse drug reactions as required, the offender shall be ordered to make correction within the time limit and be given a disciplinary warning. Where correction is not made within the prescribed period, it shall be subject to production suspension and be fined not less than RMB 100,000 but not more than RMB 1,000,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百三十四条 药品上市许可持有人未按照规定开展药品不良反应监测或者报告疑似药品不良反应的，责令限期改正，给予警告；逾期不改正的，责令停产停业整顿，并处十万元以上一百万元以下的罚款。"
    },
    {
        "instruction":"已知信息：\n'On November 29, 2019, approved by the State Council, the Leading Group for Deepening the Reform of the Medical and Health System Issued the Notice on Several Policies and Measures to Further Deepen the Reform of the Medical and Health System with Centralized Procurement &Use of Drugs as a Breakthrough in order to implement the decisions and plans of the CPC central Committee and the State Council on deepening the reform of the medical and health care systems and promote the interlocked reform of healthcare, health insurance, and pharmaceuticals. The Notice pointed out that it is necessary to promote the interlocked reform of healthcare, health insurance, and pharmaceuticals, magnify the effects of reform, and better address the problems complicating medical services to the people, the following policies and measures shall be implemented, covering 15 aspects:'可被翻译为：为贯彻落实党中央、国务院关于深化医药卫生体制改革的决策部署，推动各地加大力度持续深化医疗、医保、医药联动改革，2019年11月29日，经国务院同意，国务院深化医药卫生体制改革领导小组发布《关于以药品集中采购和使用为突破口 进一步深化医药卫生体制改革的若干政策措施》。通知指出要促进医疗、医保、医药联动，放大改革效应，更好推动解决群众看病就医问题。\n'1. Deepening the reform of state-led centralized procurement and use of drugs'可被翻译为：一、全面深化国家组织药品集中采购和使用改革\n'In order to further implement the Opinions on the Reform of Review and Approval System for Drugs and Medical Devices issued by the State Council and the Opinions on Deepening the Reform of Review and Approval System to Encourage Innovation of Drugs and Medical Devices issued by the General Office of the CPC Central Committee and the General Office of the State Council as well as there form of \"Streamline Administration,Delegate Power, Strengthen Regulation and Improve Services\", and optimize business environment requirements, comprehensively deepen reform of the review and approval system for medical devices, promote high quality development of the medical device industry, and better meet public health needs, on September 18, 2020, NMPA announced the following matters concerning the production of products with imported medical device registration certificates in domestic enterprises in China:'可被翻译为：为进一步贯彻落实国务院《关于改革药品医疗器械审评审批制度的意见》和中共中央办公厅、国务院办公厅印发的《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》，落实“放管服”改革和优化营商环境要求，全面深化医疗器械审评审批制度改革，推动医疗器械产业高质量发展，更好地满足公众健康需求，现就已获进口医疗器械注册证产品在中国境内企业生产的有关事项公告如下：\n'General Office of the State Council Issued the Key Tasks for Deepening the Reform of the Pharmaceutical and Healthcare System in 2019'可被翻译为：国务院办公厅印发《深化医药卫生体制改革2019年重点工作任务》\n\n根据上述已知信息，请将'The State Council's Leading Group for Deepening the Reform of the Medical and Health System Issued the Notice on Policies and Measures to Further Deepen the Reform of the Medical and Health System with Centralized Procurement & Use of Drugs as a Breakthrough'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国务院深化医药卫生体制改革领导小组印发关于以药品集中采购和使用为突破口进一步深化医药卫生体制改革若干政策措施的通知"
    },
    {
        "instruction":"已知信息：\n'Article 82 Where an enterprise directly transfers the drugs in accordance with Article 69 herein, it may entrust the purchaser to conduct drug acceptance inspection. The purchaser shall conduct acceptance inspection on the drugs in strict accordance with the GSP and establish special acceptance inspection records for the directly transferred drugs. On the day of acceptance inspection, relevant information of acceptance inspection records shall be transmitted to the directly transferring enterprise.'可被翻译为：第八十二条 企业按本规范第六十九条规定进行药品直调的，可委托购货单位进行药品验收。购货单位应当严格按照本规范的要求验收药品，并建立专门的直调药品验收记录。验收当日应当将验收记录相关信息传递给直调企业。\n'Article 98 At the time of ex-warehousing of drugs, the accompanying sheet (bill) stamped with the original special seal for drug ex-warehousing of enterprises shall be attached.'可被翻译为：第九十八条 药品出库时，应当附加盖企业药品出库专用章原印章的随货同行单（票）。\n'The accompanying sheet (bill) shall include the supplier, the manufacturer, the adopted name, dosage form, strength, lot number and quantity of drugs, the consignee, receiving address, shipping date and other contents, and stamped with the original special seal for drug ex-warehousing of the supplier.'可被翻译为：随货同行单（票）应当包括供货单位、生产厂商、药品的通用名称、剂型、规格、批号、数量、收货单位、收货地址、发货日期等内容，并加盖供货单位药品出库专用章原印章。\n'(IV) Model of relevant seal and the accompanying sheet (bill);'可被翻译为：（四）相关印章、随货同行单（票）样式；\n\n根据上述已知信息，请将'Where an enterprise directly transfers drugs in accordance with Article 69 herein, the supplier shall issue two copies of the same accompanying sheet (bill) at the time of ex-warehousing of the directly transferred drugs which shall be respectively sent to the directly transferring enterprise and the purchaser. The contents of the accompanying sheet (bill) shall comply with the requirements of Paragraph 2 of Article 73 herein and also indicate the name of the directly transferring enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"企业按照本规范第六十九条规定直调药品的，直调药品出库时，由供货单位开具两份随货同行单（票），分别发往直调企业和购货单位。随货同行单（票）的内容应当符合本规范第七十三条第二款的要求，还应当标明直调企业名称。"
    },
    {
        "instruction":"已知信息：\n'A substance that changes the genetic information of a strain by physical action.'可被翻译为：通过物理作用使菌种发生遗传信息改变的物质。\n'A type of physical mutagen. The genetic information of the strain is altered by exposure to ultraviolet light.'可被翻译为：物理诱变剂的一种。用紫外线进行照射使菌种发生遗传信息改变。\n'The metabolic pathways of cells are altered by genetic engineering.'可被翻译为：通过基因工程方法改变细胞的代谢途径。\n'Bacteria that have received foreign genetic material (such as plasmid DNA) that has altered their genetic characteristics. It can be identified by selecting culture medium, etc.'可被翻译为：接受了外源遗传物质（如质粒DNA等）使遗传特性发生了改变的细菌。可以通过选择培养液等方法鉴定获得。\n\n根据上述已知信息，请将'A substance that causes the genetic information of a strain to be altered by chemical action.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过化学作用使菌种发生遗传信息改变的物质。"
    },
    {
        "instruction":"已知信息：\n'Article 67 For a conditionally approved drug, where the MAH fails to complete the studies as required within the specified timeline or fails to prove that the benefits outweigh risks, the NMPA shall handle the matter in accordance with the law until the Drug Approval License is revoked.'可被翻译为：第六十七条 对附条件批准的药品，持有人逾期未按照要求完成研究或者不能证明其获益大于风险的，国家药品监督管理局应当依法处理，直至注销药品注册证书。\n'Where further studies are required when approval is given to a vaccine registration application, the vaccine MAH shall complete the studies within the specified period.'可被翻译为：对批准疫苗注册申请时提出进一步研究要求的，疫苗持有人应当在规定期限内完成研究。\n'Article 78 For drugs given conditional approval, MAHs shall adopt corresponding risk management measures and complete relevant studies within the stipulated period in accordance with regulations. Where MAHs are unable to complete the study within the stipulated period as required or are unable to prove that the benefits outweigh the risks, the drug regulatory department under the State Council shall handle the matter in accordance with the law, until the drug approval license is revoked.'可被翻译为：第七十八条 对附条件批准的药品，药品上市许可持有人应当采取相应风险管理措施，并在规定期限内按照要求完成相关研究；逾期未按照要求完成研究或者不能证明其获益大于风险的，国务院药品监督管理部门应当依法处理，直至注销药品注册证书。\n'The vaccine MAHs shall organize production and ensure the vaccine supply according to law; Vaccine MAHs stopping the manufacture of the vaccine shall promptly report to the drug regulatory department under the State Council or the drug regulatory departments of the people's government of the province, autonomous region or municipality directly under the Central Government.'可被翻译为：疫苗上市许可持有人应当依法组织生产，保障疫苗供应；疫苗上市许可持有人停止疫苗生产的，应当及时向国务院药品监督管理部门或者省、自治区、直辖市人民政府药品监督管理部门报告。\n\n根据上述已知信息，请将'Where further study is required when a vaccine's registration application is approved, the vaccine MAH shall complete the study within the prescribed time limit; where the study fails to be completed on time or fails to prove that the benefits outweigh the risks, the drug regulatory department under the State Council shall take actions in accordance with law up to revoke the vaccine's registration certificate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对批准疫苗注册申请时提出进一步研究要求的疫苗，疫苗上市许可持有人应当在规定期限内完成研究；逾期未完成研究或者不能证明其获益大于风险的，国务院药品监督管理部门应当依法处理，直至注销该疫苗的药品注册证书。"
    },
    {
        "instruction":"已知信息：\n'2. Relative standard deviation for all measured (i.e. millimeters or absorbance) and calculated \ndata (e.g. averages) is NMT 10%; and,'可被翻译为：所有测量所得（即毫米或吸光度）和计算所得数据（例如平均值）的相对标准偏差\n不得过 10%，且\n'2) Relative standard deviation for all measured and calculated data is NMT 10% and'可被翻译为：所有测量和计算所得数据的相对标准偏差应 NMT 10%，且\n'USP <81> states the following criteria for both the Plate and Tube Methods: 1) The calculated \npotency of the test antibiotic [U3] must be 80% to 125% of the median reference standard [S3] \n2) Relative standard deviation for all measured and calculated data is NMT 10% and 3) Testing \nis performed in triplicate over a period of three independent test runs. The Plate Method further \nstates: 1) The percentage coefficient of determinations (%R2) for each standard curve will be \nNLT 95% (i.e. correlation coefficient of NLT 0.9750) and 2) ZOIs for all media reference standard (S3 will measure between 14-16 mm). Refer to USP <81> for testing parameters and acceptable data requirements.'可被翻译为：USP<81>要求管碟法和浊度法符合以下标准：（1）测试抗生素【U3】的计算效价必须为中值标准品【S3】的 80-125%，（2）所有测量数据和计算数据的相对标准偏差 NMT 10%，且（3）进行三次独立检测，每次测试一式三份样品。管碟法还要求：（1）每条标准曲线的测试百分比系数（%R2）NLT 95%（即相关系数 NLT 0.9750），且（2）所有中值标准品（S3）的 ZOI 应在 14-16mm。参见 USP<81>中检测参数和可接受数据要求。\n'standard deviation'可被翻译为：标准差\n\n根据上述已知信息，请将'Relative standard deviation for all measured (i.e. millimeters or absorbance) and calculated data (e.g. averages) is NMT 10%; and,'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有测量值（即，mm或吸光度）的相对标准偏差和计算所得数据（例如平均值） NMT10%；且"
    },
    {
        "instruction":"已知信息：\n'Article 23 The legal representative and principal responsible person of vaccine MAHs shall have good credit records, and personnel in key positions such as the responsible person for manufacturing management, the responsible person for quality management and the quality authorized person shall have relevant professional background and work experience.'可被翻译为：第二十三条 疫苗上市许可持有人的法定代表人、主要负责人应当具有良好的信用记录，生产管理负责人、质量管理负责人、质量受权人等关键岗位人员应当具有相关专业背景和从业经历。\n'3) Prior to the release of each batch, the Qualified Person must issue a review record for product release according to the requirements in the above paragraph 2, and archive it to the batch record.'可被翻译为：3.在产品放行前，质量受权人必须按照上述第2项的要求出具产品放行审核记录，并纳入批记录。\n'(2) persons in key positions such as legal representative, the principal, responsible person for manufacturing management, the responsible person for quality management and the quality authorized person, etc. failing to meet the prescribed conditions or failing to train and appraise these persons as required;'可被翻译为：（二）法定代表人、主要负责人和生产管理负责人、质量管理负责人、质量受权人等关键岗位人员不符合规定条件或者未按照规定对其进行培训、考核；\n'Article 288: The contract should specify the way in which the qualified person approving to release the batch for sale ensures that each batch has been manufactured and checked for compliance with the requirements of the Marketing Authorization.'可被翻译为：第二百八十八条 合同应当详细规定质量受权人批准放行每批药品的程序，确保每批产品都已按照药品注册的要求完成生产和检验。\n\n根据上述已知信息，请将'1.A person responsible for the release of batches of finished product for sale. In certain countries the batch documentation of a batch of finished product must be signed by an authorized person from the production department and the batch test results by an authorized person from the quality control department for batch release.\n2.A person (among key personnel of a manufacturing establishment) responsible for the release of batches of finished products for sale.\n3.The person recognized by the national regulatory authority as having the responsibility for ensuring that each batch of finished product has been manufactured, tested and approved for release in compliance with the laws and regulations in force in that country.\n4.A person (among key personnel of a manufacturing establishment) responsible for the release of batches of finished products for sale. In some good manufacturing practice (GMP) guides and legal texts, the term qualified person is used to describe analogous functions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.负责放行成批销售的成品的人。在某些国家，一批成品的批文件必须由生产部门的授权人员签字，批检测结果必须由质量控制部门的授权人员签字才能批放行。\n2.负责放行成批成品供销售的人员(在制造企业的关键人员中)。\n3.经国家监管机构认可的负责确保每批成品的生产、检测和放行符合该国现行法律法规的人员。\n4.负责放行成批成品供销售的人员(在制造企业的关键人员中)。在一些良好生产规范(GMP)指南和法律文本中，“合格人员”一词用于描述类似的功能。"
    },
    {
        "instruction":"已知信息：\n'Article 12 If the drug regulatory authorities of a province, autonomous region, or municipality directly under the Central Government determine that it is necessary to conduct Pre-market inspection of Good Manufacturing Practice of Medical Products (GMP) during the Manufacturing Site Inspection period, CFDI shall coordinate the drug regulatory authorities of the relevant province, autonomous region, or municipality directly under the Central Government to implement the inspection simultaneously with Manufacturing Site Inspection.'可被翻译为：第十二条 对于省、自治区、直辖市药品监督管理部门确定需要在生产现场核查期间开展上市前药品生产质量管理规范符合性检查的，核查中心协调相关省、自治区、直辖市药品监督管理部门与生产现场核查同步实施。\n'(2) Where drug registration on-site inspection is not needed for the drug to be manufactured, the NMPA Center for Drug Evaluation shall inform the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the manufacturing site is located and the applicant; and the drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall carry out pre-marketing GMP compliance inspection of its own accord.'可被翻译为：（二）拟生产药品不需要进行药品注册现场核查的，国家药品监督管理局药品审评中心告知生产场地所在地省、自治区、直辖市药品监督管理部门和申请人，相关省、自治区、直辖市药品监督管理部门自行开展上市前的药品生产质量管理规范符合性检查；\n'Article 41 The undertaking of drug manufacturing shall be subject to approval by the local drug regulatory department of the people's government of the province, autonomous region, or municipality directly under the central government, and shall obtain a Drug Manufacturing Certificate. No one may manufacture drugs without the certificate.'可被翻译为：第四十一条 从事药品生产活动，应当经所在地省、自治区、直辖市人民政府药品监督管理部门批准，取得药品生产许可证。无药品生产许可证的，不得生产药品。\n'Article 68 Where institutions for drug manufacturing, distribution, use, testing or supervision find any critical quality problem, serious or unexpected adverse reaction of a new drug, they shall report to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government in time. Once receiving the report, the drug regulatory department of a province, autonomous region, or municipality directly under the Central Government shall organize prompt investigation, and report to the State Food and Drug Administration.'可被翻译为：第六十八条 药品生产、经营、使用及检验、监督单位发现新药存在严重质量问题、严重或者非预期的不良反应时，应当及时向省、自治区、直辖市药品监督管理部门报告。省、自治区、直辖市药品监督管理部门收到报告后应当立即组织调查，并报告国家食品药品监督管理局。\n\n根据上述已知信息，请将'Article 117 For supplementary applications of drug manufacturing technology transfer, altering formula or manufacturing process that may affect product quality, etc., the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government shall organize production site inspection, according to the attachment of the Letter of Approval for Drug Registration or the verified manufacturing process. Drug testing institutes shall conduct testing on samples of three batches of product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百一十七条 对药品生产技术转让、变更处方和生产工艺可能影响产品质量等的补充申请，省、自治区、直辖市药品监督管理部门应当根据其《药品注册批件》附件或者核定的生产工艺，组织进行生产现场检查，药品检验所应当对抽取的3批样品进行检验。"
    },
    {
        "instruction":"已知信息：\n'(ix) A review of adequacy of any other previous product process or equipment corrective actions;'可被翻译为：(ix)对任何以前产品工艺或设备纠正措施的充分性进行回顾；\n'(VIII)  Other materials relating to product quality.'可被翻译为：（八）与产品质量相关的其他资料。\n'1.This is a system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to GEP only.\n2.A system that will not have any impact, either directly or indirectly, on product quality. These systems are designed and commissioned according to good engineering practice only.'可被翻译为：1.这是一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据GEP进行设计和调试。\n2.一个不会对产品质量产生任何直接或间接影响的系统。这些系统仅根据良好的工程实践进行设计和调试。\n'Aseptically remove the device from its packaging and cut it diagonally into pieces less than 5mm in length. Small metal and plastic pieces such as needles and luer-locks should be tested whole. Pyrogen-free fluid pathways should be flushed with extract solution.'可被翻译为：在无菌操作下从包装中取出器械，将其斜切成小于5mm的小片。金属和塑料小 片如针头和鲁尔锁应整个检测。无热源液体通道应使用萃取液淋洗。\n\n根据上述已知信息，请将'If the system is flushed or integrity tested in-situ with a fluid other than the product, appropriate actions are taken to avoid any deleterious effect on product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果使用产品之外的其他液体冲洗系统或进行在线完整性测试，应釆取适当措施避以免对产品质量的任何有害影响。"
    },
    {
        "instruction":"已知信息：\n'laser desorption mass spectrometry'可被翻译为：激光解吸质谱法\n'plasma desorption mass spectrometry'可被翻译为：等离子体解吸质谱法\n'secondary ion mass spectrometry'可被翻译为：次级离子质谱法\n'The maximum peak is 100% in the range of the specified mass nucleus ratio in the mass spectrum, and the intensity obtained by the normalization of other ion peaks. Now the standard mass spectrometry is the relative abundance value of ions as the ordinate.'可被翻译为：以质谱图中指定质核比范围内最强峰为100%,其他离子峰对其归一化所得的强度。现在标准质谱图均以离子相对丰度值为纵坐标。\n\n根据上述已知信息，请将'One of the mass spectrometry sampler. It consists of a valve, a storage tank and a pinhole leak.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"质谱进样器之一。由阀、贮槽和针孔漏组成。"
    },
    {
        "instruction":"已知信息：\n'Article 19 For a drug patented in China, applicants other than the patentee may submit the application for registration two years prior to the expiry date of the patent. The State Food and Drug Administration shall review the drug application in accordance with the Provisions, and after the expiry date of the patent, check and issue the drug approval number, Import Drug License or a Pharmaceutical Product License if the application conforms with the provisions.'可被翻译为：第十九条 对他人已获得中国专利权的药品，申请人可以在该药品专利期届满前2年内提出注册申请。国家食品药品监督管理局按照本办法予以审查，符合规定的，在专利期满后核发药品批准文号、《进口药品注册证》或者《医药产品注册证》。\n'expiry date'可被翻译为：截止日期\n'(III) For the sales of drugs approaching expiry date, customers shall be informed of its expiry date;'可被翻译为：（三）销售近效期药品应当向顾客告知有效期。\n'Where the expiry date is labeled to the day, it shall be marked as one day earlier than the actual expiry date; where the expiry date is labeled to the month, it shall be marked as one month earlier than the actual expiry month.'可被翻译为：有效期若标注到日，应当为起算日期对应年月日的前一天，若标注到月，应当为起算月份对应年月的前一月。\n\n根据上述已知信息，请将'(1) the application for re-registration is not made prior to the expiry date;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）有效期届满前未提出再注册申请的；"
    },
    {
        "instruction":"已知信息：\n'Any untoward medical occurrence that at any dose: \n- results in death, \n- is life-threatening, \n- requires inpatient hospitalization or prolongation of existing hospitalization, \n- results in persistent or significant disability\/incapacity, or \n- is a congenital anomaly\/birth defect (see the ICH Guideline for Clinical Safety Data Management: \nDefinitions and Standards for Expedited Reporting).[ICH E6(R1)]'可被翻译为：在任何剂量下发生的任何不良医疗事件：\n- 导致死亡\n- 危及生命\n- 需要住院治疗或延长现有住院治疗\n- 导致永久的或严重的残疾或功能损失，或\n- 治疗现有住院治疗永久的或严重的残疾或功能损失先天性异常\/出生缺陷\n（见 ICH 指导原则临床安全数据管理：加速报告的定义和标准）。[ICH E6 (R1) ]\n'Medical events that may not be immediately life -threatening or result in death or  hospitalisation, but may jeopardise the patient or may require intervention to prevent serious  outcomes; these events require medical and scientific judgement and fall under the expedited  reporting rules (see ICH E2A).'可被翻译为：可能不会立即危及生命、死亡或住院，但可能危害患者或可能需要干预以预防严重后果的医学事件；这些事件需要医学判断，符 合快速报告规则的类别（参见ICH E2A）。\n'5. Requiring inpatient hospitalization or resulting in prolongation of existing hospitalization;'可被翻译为：5.导致住院或者住院时间延长；\n'3. Causing cancer, malformation or congenital anomaly;'可被翻译为：3.致癌、致畸、致出生缺陷；\n\n根据上述已知信息，请将'Any untoward medical occurrence that at any dose: - results in death,   - is life -threatening,   - requires inpatient hospitali sation or prolongation of existing hospitali sation,   - results in persistent or significant disability\/incapacity,   or  - is a congenital anomaly\/birth defect   (see ICH E2A and ICH E6 ).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在任何剂量下发生的以下任何不良医学事件：\n- 导致死亡，\n- 危及生命，\n- 需要住院或者延长住院时间，\n- 导致永久性或显著的残疾\/功能丧失，\n或- 先天性异常\/出生缺陷\n（参见ICH E2A和ICH E6）。"
    },
    {
        "instruction":"已知信息：\n'Where any violation by a medical institution defined in the preceding paragraph is identified by the drug regulatory department, the case shall be transferred to the health administrative department at the same level for handling.'可被翻译为：药品监督管理部门发现医疗机构有前款规定行为之一的，应当移交同级卫生行政部门处理。\n'In the case of failures to stop manufacture, sales, distribution, use and recall of vaccines as the preceding paragraph, the drug regulatory departments and the health departments at or above the county level shallr to stop manufacture, sales, distribution, use and recall of such vaccines according to their respective responsibilities.'可被翻译为：未依照前款规定停止生产、销售、配送、使用或者召回疫苗的，县级以上人民政府药品监督管理部门、卫生健康主管部门应当按照各自职责责令停止生产、销售、配送、使用或者召回疫苗。\n'The drug regulatory departments at provincial level or above shall notify the annual reports to the health administrative departments at the same level.'可被翻译为：省级以上药品监督管理部门应当将年度报告情况通报同级卫生行政部门。\n'Information defined in the preceding paragraph that needs unified release may also be released by provincial drug regulatory departments and health administrative departments under the authorization of the SFDA and the Ministry of Health.'可被翻译为：前款规定统一发布的信息，国家食品药品监督管理局和卫生部也可以授权省级药品监督管理部门和卫生行政部门发布。\n\n根据上述已知信息，请将'In case of identifying any using unit having violations specified in preceding paragraph, the drug regulatory departments shall transfer the case to the health administrative departments at the same level for disposition.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品监督管理部门发现使用单位有前款规定行为的，应当移交同级卫生行政部门处理。"
    },
    {
        "instruction":"已知信息：\n'A liquid preparation for use by anal injection into the rectum.'可被翻译为：经肛门灌入直肠使用的液体制剂。\n'(1) substitute narcotics, psychotropic substances, toxic drugs for medical use, radioactive drugs or pharmaceutical precursor chemicals for other drugs, or vice versa;'可被翻译为：（一）以麻醉药品、精神药品、医疗用毒性药品、放射性药品、药品类易制毒化学品冒充其他药品，或者以其他药品冒充上述药品；\n'A liquid preparation intended for use by drops into the nasal cavity.'可被翻译为：专供滴入鼻腔内使用的液体制剂。\n'substitute'可被翻译为：替代药\n\n根据上述已知信息，请将'2. Use the reference preparation substitute for the test preparation, use the test preparation substitute for the reference preparation or use product purchased in the market substitute for self-developed investigational drug, or otherwise use false investigational drugs;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.以参比制剂替代试验制剂、以试验制剂替代参比制剂或者以市场购买药品替代自行研制的试验用药品， 以及以其他方式使用虚假试验用药品；"
    },
    {
        "instruction":"已知信息：\n'Most IVPT experiments report skin flux and the total cumulative amount of drug that has permeated into the receptor solution (or as a percentage of drug from the total applied dose). Depending on the purpose of the study, an evaluation of drug tissue distribution (amounts in the stratum corneum, viable epidermis, and dermis) and total mass balance may provide additional insights.'可被翻译为：大多数IVPT实验报告皮肤通量和渗透到受体溶液中的药物总累积量(或药物占总应用剂量的百分比)。根据研究的目的，对药物组织分布(角质层、活表皮和真皮层中的药物量)和总质量平衡的评估可能会提供额外的见解。\n'Full mass balance requires more intensive bioanalytical method development to ensure that the drug(s) of interest are efficiently extracted from each sample matrix type, such as cotton swabs used to remove the excess of formulation present on the skin surface at the end of the experiment, tape strips used to remove stratum corneum, and homogenized viable epidermis and dermis.'可被翻译为：完全的质量守衡需要更深入的生物分析方法开发，以确保从每种样品基质类型中有效地提取感兴趣的药物，例如在实验结束时用于去除皮肤表面过量配方的棉签，用于去除角质层的胶带，以及均质活表皮和真皮层。\n'The flux (rate of drug permeation) should be calculated for each time point in units of mass\/area\/time (e.g., ng\/cm2\/h) on the y-axis versus time in the x-axis. The extent of drug permeation should also be reported in units of mass\/area (e.g., ng\/cm2) in the y-axis versus time in the x-axis—the slope of this curve can help determine the overall drug flux through the skin at different points in time. Drug levels in the viable epidermis and dermis can be reported as absolute mass amount (e.g., nanograms or micrograms) or concentration (e.g., nanograms or micrograms of drug per milligram of tissue [ng\/mg or µg\/ mg]).'可被翻译为：每个时间点的通量(药物渗透率)应以质量\/面积\/时间(例如，ng\/cm2\/h)为单位在y轴上与时间在x轴上进行计算。药物的渗透程度也应在y轴上以质量\/面积(例如，ng\/cm2)为单位报告，在x轴上以时间为单位报告——该曲线的斜率可以帮助确定在不同时间点通过皮肤的总体药物通量。活的表皮和真皮层中的药物水平可以用绝对质量(例如，纳克或微克)或浓度(例如，每毫克组织中药物的纳克或微克[ng\/mg或µg\/ mg])来报告。\n'Depending on the purpose of the study (bioequivalence, formulation development, prototype screening, etc.), data may be reported and assessed using different parameters (endpoints). For example: a bioequivalence study will focus on the cutaneous pharmacokinetic endpoints of maximum flux (Jmax), and total cumulative amount (AMT) of drug permeated. Studies conducted in early stages of drug development, such as those intended to select a new chemical entity (NCE), or to rank different formulation prototypes, may report tissue (epidermis and dermis) concentrations in addition to the parameters (endpoints) above, and may include full mass balance data.'可被翻译为：根据研究目的(生物等效性、制剂开发、原型筛选等)，可以使用不同的参数(终点)报告和评估数据。例如:生物等效性研究将关注皮肤药代动力学的最大通量终点(Jmax)和药物渗透的总累积量(AMT)。在药物开发的早期阶段进行的研究，例如那些旨在选择新化学实体(NCE)或对不同配方原型进行排序的研究，除了上述参数(终点)外，还可能报告组织(表皮和真皮)浓度，并可能包括完整的质量平衡数据。\n\n根据上述已知信息，请将'Full mass balance results are generally reported as percentage of drug(s) in each compartment (e.g., stratum corneum, viable epidermis, dermis and receptor solution) relative to the total amount applied at the beginning of the experiment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"全质量守衡结果通常报告为每个部分(例如角质层、活表皮、真皮层和受体溶液)中药物相对于实验开始时施用的总量的百分比。"
    },
    {
        "instruction":"已知信息：\n'To reflect the physiological and biochemical metabolism changes in the process of fermentation of organisms.'可被翻译为：反映生物体发酵过程中生理生化代谢变化的检测数据。\n'A general term for low energy ionization methods such as chemical ionization and field ionization in mass spectrometry.'可被翻译为：质谱分析中化学电离、场致电离等低能量电离方式的总称。\n'metabolism'可被翻译为：新陈代谢\n'enantioselective metabolism'可被翻译为：对映体选择代谢\n\n根据上述已知信息，请将'For short, \"metabolism\". A general term for all ordered chemical changes in an organism, including both material metabolism and energy metabolism.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"简称\"代谢”。生物体内全部有序化学变化的总称，包括物质代谢和能量代谢两个方面。"
    },
    {
        "instruction":"已知信息：\n'(1) Employ at least two distinct identification components such as an identification code and password.'可被翻译为：至少采用两种不同的识别方式，例如识别码和密码。\n'(b) Ensuring that identification code and password issuances are periodically checked, recalled, or revised (e.g., to cover such events as password aging).'可被翻译为：保证定期检查、收回或修订识别码和密码（例如，解决密码老化）。\n'(e) Initial and periodic testing of devices, such as tokens or cards, that bear or generate identification code or password information to ensure that they function properly and have not been altered in an unauthorized manner.'可被翻译为：初始和定期的设备检测，例如含有或生成识别码或密码信息的记号或卡，以确保其运行正常，且未遭受未经授权的修改。\n'The State encourages code issuing agencies to establish unique identification operation system as per relevant international standards.'可被翻译为：国家鼓励发码机构采用相关国际标准建立唯一标识运行体系。\n\n根据上述已知信息，请将'(a) Maintaining the uniqueness of each combined identification code and password, such that no two individuals have the same combination of identification code and password.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"保持每一组的识别码和密码的唯一性，即不存在两个个体拥有同组识别码和密码的现象。"
    },
    {
        "instruction":"已知信息：\n'A drug distributor shall operate within the approved distribution scope in the Drug Supply Certificate.'可被翻译为：药品经营企业应当按照《药品经营许可证》许可的经营范围经营药品。\n'Article 50 When applying for drug marketing authorization, both the applicant and the manufacturer should have obtained the corresponding Drug Manufacturing Certificate.'可被翻译为：第五十条 申请药品上市许可时，申请人和生产企业应当已取得相应的药品生产许可证。\n'Article 105 Where the applied generic drug is regulated as a non-prescription drug, the applicant shall indicate the item of non-prescription drug in the \"additional application items\" of the Application Form for Drug Registration.'可被翻译为：第一百零五条 申请仿制的药品属于按非处方药管理的，申请人应当在《药品注册申请表》的“附加申请事项”中标注非处方药项。\n'The valid term and the scope of manufacturing shall be indicated in the Drug Manufacturing Certificate. For renewal of the certificate on expiration, reexamination is required.'可被翻译为：药品生产许可证应当标明有效期和生产范围，到期重新审查发证。\n\n根据上述已知信息，请将'Article 73 The applicant applying for registration of a generic drug shall be a drug manufacturer. The applied drug shall be within the production scope specified in the Drug Manufacturing Certificate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十三条 仿制药申请人应当是药品生产企业，其申请的药品应当与《药品生产许可证》载明的生产范围一致。"
    },
    {
        "instruction":"已知信息：\n'filling machine'可被翻译为：灌装机\n'10. Processing steps such as preparation, filtration, filling\/sealing and sterilization of liquid products should be completed within the defined time limits;'可被翻译为：（十）液体制剂的配制、过滤、灌封、灭菌等工序应当在规定时间内完成。\n'For shuttle type equipment used for aseptic filling, the parison is open to the environment and therefore the areas where parison  extrusion, blow-moulding and  sealing take place  should meet grade A  conditions  at the critical zones. The filling environment should be designed and maintained to meet grade A conditions for viable and total particle limits both at rest and when in operation.'可被翻译为：对于用于无菌灌装的往复式设备，模具在环境中是开放的，因此进行模具挤出、吹塑和密封的关键区域应 符合 A 级条件。灌装环境应进行设计和维护，从而在静态和动态下均符合活性粒子和总微粒限度的 A 级条件。\n'Environmental control, cleaning, sterilisation and monitoring of the critical extrusion, transfer and filling areas as relevant.'可被翻译为：关键挤压出区、转移区和灌装区的环境控制、清洁、灭菌和监测（如相关）。\n\n根据上述已知信息，请将'Interventions requiring cessation of filling and\/or extrusion, moulding and sealing and, where required, re-sterilisation of the filling machine should be clearly defined and described in the filling procedure, and included in the APS as relevant (see paragraphs 9.34, 9.35 and 9.36).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"要求停止灌装和\/或挤出、模塑和密封，以及必要时灌装机再灭菌的干预措施，应在灌装程序中明确规定和描述，并包括在 APS 中（如相关）（参见第 9.34 、9.35 和 9.36 节）。"
    },
    {
        "instruction":"已知信息：\n'Drugs that constrict blood vessels and raise blood pressure. Divided into two categories according to their effects: (1) adrenergic receptor agonists, such as epinephrine, norepinephrine, dopamine, ephedrine, mehydroxyamine, etc., can raise blood pressure and can be used in the early stage of shock; (2) Angiotensin amines, that is, pressors and their derivatives, such as phrenopressin.'可被翻译为：使血管收缩而升高血压的药物。按其作用分为两类：①肾上腺素受体激动药，如肾上腺素、去甲肾上腺素、多巴胺、麻黄素、间羟胺等，可以升高血压，可用于休克早期；②血管紧张素胺，即增压素及其衍生物，如苯赖加压素。\n'A class of peptides that have strong effects such as constricting blood vessels and stimulating the secretion of aldosterone by the adrenal cortex. Angiotensinogen is changed to angiotensin I by renin and then to angiotensin n by angiotensin-converting enzyme, which plays an important role in blood pressure regulation and the cause of hypertension.'可被翻译为：一类具有极强的收缩血管和刺激肾上腺皮质分泌醛固酮等作用的肽类物质。血管紧张素原在肾素作用下变为血管紧张素I,然后在血管紧张素转化酶作用下又变为血管紧张素n,在血压调节和高血压病因中起重要作用。\n'A drug that corrects various low blood cells, resulting in different types of anemia. It can be divided into: ① to correct low red blood cells, such as iron, folic acid, vitamins or epotin; ② promote leukocyte proliferation, such as recombinant human granulocyte macrophage colony factors.'可被翻译为：纠正各种血细胞低下，所致不同类型贫血的药物。分为：①纠正红细胞低下，如铁剂、叶酸、维生素或依泊汀类；②促进白细胞增生，如重组人粒细胞巨噬细胞集落因子等。\n'The process by which fluid and cellular components in blood vessels enter the interstitial tissue, body cavity, and mucosal surface through the wall of blood vessels. Exudation is the most characteristic change of inflammation.'可被翻译为：炎症局部组织血管内的液体和细胞成分，通过血管壁进入组织间质、体腔、黏膜表面的过程。渗出是炎症最具特征性变化。\n\n根据上述已知信息，请将'Medications used to correct low blood pressure, such as shock. These include alpha-agonist epinephrines and angiotensin amines that directly contraindicate blood vessels.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用以纠正血压过低(如休克)的治疗药物。包括具有α激动作用的肾上腺素类和直接收缩血管的血管紧张素胺。"
    },
    {
        "instruction":"已知信息：\n'Information to the user provided on the package label or in the patient information leaflet.'可被翻译为：在包装标签或患者信息单张上提供给用户的信息。\n'drug information for consumer'可被翻译为：消费者用药信息\n'Consumer is defined as a person who is not a healthcare professional such as a patient, lawyer, friend, or relative of a patient.'可被翻译为：消费者定义为非卫生保健专业人员的个人，如病人、律师、友人，或病人的亲戚。\n'(iv) Instructions and procedures are written in an instructional form in clear and unambiguous language, specifically applicable to the facilities provided;'可被翻译为：(iv) 应当使用准确、易懂的语言制定程序和操作指令，特别是设施设备的操作；\n\n根据上述已知信息，请将'Drug information provided to the patient (consumer) in plain language and manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以通俗的语言和方式，向患者（消费者）提供的药物信息。"
    },
    {
        "instruction":"已知信息：\n'Article 60 Where the application materials for change of registry items conform to the requirements, the food and drug regulatory department shall issue the medical device registration alteration document within 10 workdays. Where the application materials are not complete or do not meet the requirements for preliminary review, the food and drug regulatory department shall inform the applicant one-off of all the supplements to be completed.'可被翻译为：第六十条 登记事项变更资料符合要求的，食品药品监督管理部门应当在10个工作日内发给医疗器械注册变更文件。登记事项变更资料不齐全或者不符合形式审查要求的，食品药品监督管理部门应当一次告知需要补正的全部内容。\n'Article 9 Provincial drug regulatory department shall conduct preliminary review on the normalization and completeness of application dossiers upon the receipt of application dossiers for first importation of crude drugs. Where application dossiers have errors which can be corrected on site, the applicant shall be allowed for error correction on site; where application dossiers are incomplete or does not comply with the defined format, the applicant shall be informed on-site or within 5 days of what to be supplemented or corrected all at once; if the applicant is not informed within the regulatory timeline, the application is regarded as accepted on the date the dossiers are received.'可被翻译为：第九条 省级药品监督管理部门收到首次进口药材申报资料后，应当对申报资料的规范性、完整性进行形式审查。申报资料存在可以当场更正的错误的，应当允许申请人当场更正；申报资料不齐全或者不符合法定形式的，应当当场或者5日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申报资料之日起即为受理。\n'(4) If the application materials are incomplete or do not meet the requirements for format examination, the notification on correcting and supplementing materials of amendments shall be sent to the applicant on the spot or within five days, with all the content needs to be corrected or supplemented at one time. The application materials shall be deemed as accepted since the date of submission if there is no notification after the timeline.'可被翻译为：（四）申请材料不齐全或者不符合形式审查要求的，应当当场或者在五日内发给申请人补正材料通知书，一次性告知申请人需要补正的全部内容，逾期不告知的，自收到申请材料之日起即为受理；\n'(I) Where the application is within functions and duties of department, and the application materials are complete and meet the preliminary review requirements.'可被翻译为：（一）申请事项属于本部门职权范围，申报资料齐全、符合形式审查要求的，予以受理；\n\n根据上述已知信息，请将'(III) Where the application materials are incomplete or do not meet the preliminary review requirements, the applicants shall be informed one-off of all the supplements or corrections required within 5 workdays. Where the application is not informed, the application shall be deemed as accepted from the date the application materials are received.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）申报资料不齐全或者不符合形式审查要求的，应当在5个工作日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申报资料之日起即为受理；"
    },
    {
        "instruction":"已知信息：\n'The total number of healthy years lost from onset to death. Years of life lost due to premature death and years of life lost due to disability due to disease are often used to measure the burden of disease.'可被翻译为：从发病到死亡所损失的全部健康年。包括因早亡所致的寿命损失年和疾病所致伤残引起的寿命损失年两部分，经常用于测量疾病负担。\n'body burden'可被翻译为：机体负荷\n'burden of disease'可被翻译为：疾病负担\n'A glycosaminoglycan used in the prevention, treatment, and diagnosis of disease.'可被翻译为：用于预防、治疗和诊断疾病的糖胺聚糖。\n\n根据上述已知信息，请将'The socio-economic and population health effects of disease. It includes two aspects: epidemiological burden and economic burden of disease.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"疾病对社会经济及人群健康的影响。包括疾病的流行病学负担和经济负担两个方面。"
    },
    {
        "instruction":"已知信息：\n'Excipients in this Law refer to the vehicles and additives used for drug manufacturing and prescription dispensing.'可被翻译为：本法所称辅料，是指生产药品和调配处方时所用的赋形剂和附加剂。\n'Article 14 The NMPA shall establish a bundling review and approval system for chemical active drug ingredients, excipients and primary packaging materials and containers. When reviewing and approving drug products, the review and approval for the chemical active drug ingredients and review for the relevant excipients and primary packaging materials and containers shall be carried out together. The CDE shall establish a platform for registries of chemical active drug ingredients, excipients and primary packaging materials and containers, release relevant registry information to applicants or MAHs for their selection, and conduct the bundling review when reviewing registration applications of relevant drug products.'可被翻译为：第十四条 国家药品监督管理局建立化学原料药、辅料及直接接触药品的包装材料和容器关联审评审批制度。在审批药品制剂时，对化学原料药一并审评审批，对相关辅料、直接接触药品的包装材料和容器一并审评。药品审评中心建立化学原料药、辅料及直接接触药品的包装材料和容器信息登记平台，对相关登记信息进行公示，供相关申请人或者持有人选择，并在相关药品制剂注册申请审评时关联审评。\n'Article 44 Where chemical active drug ingredients, excipients and primary packaging materials and containers have passed a bundling review or a separated review and approval, the CDE shall update the registry status flag on the registry platform and disclose relevant information to the public. For the chemical active drug ingredients, a chemical active drug ingredients approval notice shall be issued together with the approved manufacturing process, specifications and labels. The chemical active drug ingredients approval notice shall bear the registry number. In case of disapproval, a chemical active drug ingredients disapproval notice shall be issued.'可被翻译为：第四十四条 化学原料药、辅料及直接接触药品的包装材料和容器关联审评通过的或者单独审评审批通过的，药品审评中心在化学原料药、辅料及直接接触药品的包装材料和容器登记平台更新登记状态标识，向社会公示相关信息。其中，化学原料药同时发给化学原料药批准通知书及核准后的生产工艺、质量标准和标签，化学原料药批准通知书中载明登记号；不予批准的，发给化学原料药不予批准通知书。\n'Manufacturers of chemical active drug ingredients, excipients and primary packaging materials and containers shall register product information and research data on the registry platform for chemical active drug ingredients, excipients and primary packaging materials and containers in accordance with requirements of the bundling review and approval system. The CDE shall disclose general information including registry number, product name, enterprise name, and manufacturing address etc. to the public for selection by drug product registration applicants.'可被翻译为：化学原料药、辅料及直接接触药品的包装材料和容器生产企业应当按照关联审评审批制度要求，在化学原料药、辅料及直接接触药品的包装材料和容器登记平台登记产品信息和研究资料。药品审评中心向社会公示登记号、产品名称、企业名称、生产地址等基本信息，供药品制剂注册申请人选择。\n\n根据上述已知信息，请将'information on solubility of active ingredients, excipients and vehicles;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"活性成分、辅料和载体的溶解度信息；"
    },
    {
        "instruction":"已知信息：\n'Article 56 The State implements a compensation system for adverse reactions of immunization. Where, during or after the immunization process, a vaccine recipient suffers from harm including death, severe disability, organ and tissue damage, etc., compensation shall be given thereto if these conditions are adverse reactions of immunization or the possibility cannot be ruled out. The scope of compensation is subject to catalogue management, and shall be adjusted based on the actual situations.'可被翻译为：第五十六条 国家实行预防接种异常反应补偿制度。实施接种过程中或者实施接种后出现受种者死亡、严重残疾、器官组织损伤等损害，属于预防接种异常反应或者不能排除的，应当给予补偿。补偿范围实行目录管理，并根据实际情况进行动态调整。\n'Before administering vaccines, medical and healthcare professionals shall, in accordance with the prescribed guidance for immunization, examine the vaccine recipient's health status, immunization contraindication, check the immunization certificate, examine the appearance, lot number and expiration date of the vaccine and syringe, and verify the recipient's name and age and the vaccine's name, specifications, dose, injection site and route of administration. Vaccine administration shall only take place after confirmation of information on the recipient, the immunization certificate and the vaccine to be administered.'可被翻译为：医疗卫生人员在实施接种前，应当按照预防接种工作规范的要求，检查受种者健康状况、核查接种禁忌，查对预防接种证，检查疫苗、注射器的外观、批号、有效期，核对受种者的姓名、年龄和疫苗的品名、规格、剂量、接种部位、接种途径，做到受种者、预防接种证和疫苗信息相一致，确认无误后方可实施接种。\n'(3) injury to the vaccine recipient due to the immunization entity's incompliance with the guidance for immunization, immunization procedure, vaccine use guidelines and immunization plans;'可被翻译为：（三）因接种单位违反预防接种工作规范、免疫程序、疫苗使用指导原则、接种方案给受种者造成的损害；\n'serious adverse reaction or serious adverse drug reaction'可被翻译为：严重不良反应或严重药物不良反应\n\n根据上述已知信息，请将'Article 52 An adverse reaction of immunization is an adverse drug reaction that causes damage to the vaccine recipient's body tissue, organ and functions during or following the standard process of administering a qualified vaccine, for which no party involved is at fault.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十二条 预防接种异常反应，是指合格的疫苗在实施规范接种过程中或者实施规范接种后造成受种者机体组织器官、功能损害，相关各方均无过错的药品不良反应。"
    },
    {
        "instruction":"已知信息：\n'These are drugs authorized to be sold only in licensed pharmacies under the supervision of licensed or registered pharmacists; they may be sold without a prescription.'可被翻译为：这是指在持牌或注册药剂师的监督下，只能在持牌药房销售的药物;可以在没有处方的情况下销售。\n'The importation of a small number of drugs that are already legally marketed overseas without approval, if the circumstances are relatively minor, may be given lighter punishment or exempted from punishment in accordance with the law.'可被翻译为：未经批准进口少量境外已合法上市的药品，情节较轻的，可以依法减轻或者免予处罚。\n'(I) Prescription can be dispensed only after being audited by licensed pharmacists. The drugs listed in the prescription shall not be altered or substituted without authorization. The dispensing of prescriptions with incompatibility or overdose shall be refused; however, those may be dispensed after being corrected or re-signed by the prescriber. After the dispensing of prescription, the drugs can be sold only after being checked;'可被翻译为：（一）处方经执业药师审核后方可调配；对处方所列药品不得擅自更改或者代用，对有配伍禁忌或者超剂量的处方，应当拒绝调配，但经处方医师更正或者重新签字确认的，可以调配；调配处方后经过核对方可销售。\n'(1) manufacture of import drugs without drug approval documents;'可被翻译为：（一）未取得药品批准证明文件生产、进口药品；\n\n根据上述已知信息，请将'These are drugs that can be sold from licensed dealers without professional supervision and without prescriptions. These drugs are suitable for self-medication for minor diseases and symptoms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"这些药物可以在没有专业监督和处方的情况下从有执照的经销商那里出售。这些药物适合小病小症的自我药疗。"
    },
    {
        "instruction":"已知信息：\n'Human readable information (HRI) means direct recognition of code by human eyes matching with the medium of machine readable information.'可被翻译为：人工识读，是指与机器识读媒介相对应的，可由人眼直接识别的编码信息。\n'Electronic Data Interchange. A technology for exchanging structured information for the purpose of conducting business transactions.'可被翻译为：电子数据交换。为开展业务而交换结构化信息的技术。\n'Information related to the drug. Including the collection, processing and use of information.'可被翻译为：与药物有关的信息。包括对信息的采集、加工和利用等。\n'American Pharmaceutical Review (www.americanpharmaceuticalreview.com)'可被翻译为：美国药物评论\n\n根据上述已知信息，请将'American Standard Code for Information Interchange. A specification for representing text as computer-readable information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"美国信息交换标准代码。将文本表示为计算机可读的信息规范。"
    },
    {
        "instruction":"已知信息：\n'An intervention that is an integral part of the aseptic process and is required for set-up, routine operation or monitoring (for example, aseptic assembly, container replenishment or environmental sampling). Inherent interventions are required by procedure or work instruction for the execution of the aseptic process.'可被翻译为：是无菌工艺的一个组成部分，是设置、常规操作或监控所必需的干预(例如，无菌装配、容器补充或环境取样)。固有干预措施是无菌工艺执行的程序或作业指导书所要求的。\n'Inherent and corrective interventions representative of the routine process should be performed in a manner and\nfrequency similar to that during the routine aseptic process.'可被翻译为：代表常规工艺的固有性和纠正性干预措施应以与常规无菌工艺类似的方式和频率进行。\n'Continuous viable air monitoring in grade A (e.g. air sampling or settle plates) should be undertaken for the full  duration  of critical processing,  including  equipment  (aseptic  set-up)  assembly  and  critical processing.  A similar  approach  should  be  considered  for  grade  B  cleanrooms  based  on  the  risk  of  impact  on  the  aseptic processing. The monitoring should be performed in such a way that all interventions, transient events and any system deterioration would be captured and any risk caused by interventions of the monitoring operations is\navoided.'可被翻译为：在关键操作的全过程中，包括设备组装（无菌安装）和关键操作，应当对 A 级进行连续的空气活性粒子监 测（例如空气采样或沉降碟）。对于 B 级洁净室，应基于对无菌工艺的影响风险，考虑类似的方式。监测方式应能捕获所有干扰、瞬态事件和任何系统损坏，并且避免由监测操作的干预引起的任何风险。\n'Aseptic Process Simulation (APS) - A simulation of the entire aseptic manufacturing process in order to verify the capability  of the  process  to  assure  product  sterility.  Includes  all  aseptic  operations  associated  with  routine manufacturing, e.g. equipment assembly, formulation, filling, lyophilization and sealing processes as necessary.'可被翻译为：无菌工艺模拟（APS）：对整个无菌生产工艺的模拟， 以确认工艺确保产品无菌性的能力。包括与日常生产相关的所有无菌操作，例如必要的设备装配、配料、灌装、冻干以及必要时的密封工艺。\n\n根据上述已知信息，请将'Inherent interventions - An intervention that is an integral part of the aseptic process and is required for either set-up,  routine  operation  and\/or  monitoring  (e.g.  aseptic  assembly,  container  replenishment,  environmental sampling). Inherent interventions are required by procedure or work instruction for the execution of the aseptic process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"固有性干预：无菌工艺不可或缺的、在组装、常规操作和\/或监测（例如无菌装配、容器补充、环境采样）中必须要进行的干预措施。关于无菌工艺执行的程序或工作指令要求固有干预。"
    },
    {
        "instruction":"已知信息：\n'A complex formed when the molecules of one compound are wholly or partially enclosed in a molecular cavity of another compound.'可被翻译为：由-种化合物分子全部或部分包入另一种化合物分子腔中形成的络合物。\n'One element replaces the other elements in a compound.'可被翻译为：一种元素把某种化合物中的其他元素替换出来。\n'A thing or things produced by labour or effort for a specific use and marketed to satisfy a need or want. [HL7 Patient Safety]'可被翻译为：针对特殊用途、通过劳动或努力生产且上市以满足需求或愿望的一个或多个产品。[HL7 患者安全]\n'A process or device to contain product, dust or contaminants in one zone, preventing it from escaping to another zone.'可被翻译为：在一个区域内容纳产品、灰尘或污染物，防止其泄漏到另一个区域的过程或设备。\n\n根据上述已知信息，请将'Something else, such as another compound, that is produced in the process of making one thing, such as a compound.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在制作生产某种物品（如某化合物）时附带产生的另外物品（如另一化合物）."
    },
    {
        "instruction":"已知信息：\n'Article 67 For violation of relevant requirements in the Good Supply Practice for medical devices, the drug regulatory departments shall order rectification within prescribed time limit; if safety and effectiveness of medical device products are influenced, punishment shall be imposed as stipulated in Article 86 of the Regulations on Supervision and Administration of Medical Devices.'可被翻译为：第六十七条  违反医疗器械经营质量管理规范有关要求的，由药品监督管理部门责令限期改正；影响医疗器械产品安全、有效的，依照医疗器械监督管理条例第八十六条的规定处罚。\n'Article 1 The Provisions is formulated according to the Regulations on Supervision and Administration of Medical Devices for the purpose of regulating instructions and labels of medical devices and ensuring safe use of medical devices.'可被翻译为：第一条 为规范医疗器械说明书和标签，保证医疗器械使用的安全，根据《医疗器械监督管理条例》，制定本规定。\n'Article 76  Where the drug regulatory departments, health administrative departments and monitoring agencies at all levels and their staff fail to fulfill   responsibilities in accordance with regulations, they shall be penalized in accordance with Article 72 and Article 74 of the Regulations for the Supervision and Administration of Medical Devices.'可被翻译为：第七十六条  各级药品监督管理部门、卫生行政部门、监测机构及其工作人员，不按规定履行职责的，依照《医疗器械监督管理条例》第七十二条和第七十四条的规定予以处理。\n'Article 74 In one of the following circumstances, punishment shall be imposed in accordance with provisions in Article 81 of the Regulations on Supervision and Administration of Medical Devices:'可被翻译为：第七十四条  有下列情形之一的，依照医疗器械监督管理条例第八十一条的规定处罚：\n\n根据上述已知信息，请将'Article 18 Where the instructions and labels fail to comply with the Provisions, punishment shall be imposed by the food and drug regulatory departments at or above the county level according to stipulations of Article 67 of Regulations on Supervision and Administration of Medical Devices.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十八条 说明书和标签不符合本规定要求的，由县级以上食品药品监督管理部门按照《医疗器械监督管理条例》第六十七条的规定予以处罚。"
    },
    {
        "instruction":"已知信息：\n'A distribution procedure to ensure that the oldest stock is distributed and\/or used before a newer and identical stock item is distributed and\/or used.'可被翻译为：一种分配程序，以确保在分发和\/或使用较新的和相同的库存项目之前分发和\/或使用最旧的库存。\n'A distribution procedure to ensure that the stock with the earliest expiry date is distributed and\/or utilized before an identical stock item with a later expiry date is distributed and\/or utilized.'可被翻译为：一种分配程序，以确保具有最早到期日的库存在具有较晚到期日的相同库存被分配和\/或使用之前被分配和\/或使用。\n'1.A distribution procedure that ensures the stock with the earliest expiry date is distributed and\/or used before an identical stock item with a later expiry date is distributed and\/or used; earliest expiry\/first out (EEFO) has a similar meaning.\n2.A distribution procedure that ensures that the stock with the earliest expiry date is distributed and\/or used before an identical stock item with a later expiry date is distributed and\/or used.'可被翻译为：1.一种分配程序，确保具有最早到期日的库存在具有较晚到期日的相同库存被分发和\/或使用之前被分发和\/或使用;最早到期\/先出(EEFO)也有类似的含义。\n2.一种分配程序，确保在分配和\/或使用截止日期最早的存货之前，先分配和\/或使用截止日期较晚的相同存货。\n'regulatory stock'可被翻译为：监管证券\n\n根据上述已知信息，请将'A distribution procedure to ensure that the oldest stock is distributed and\/or utilized before a newer and identical stock item is distributed and\/or utilized.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种分配程序，以确保较旧的库存在较新的和相同的库存项目分发和\/或使用之前被分发和\/或使用。"
    },
    {
        "instruction":"已知信息：\n'area under the concentration-time curve'可被翻译为：浓度-时间曲线下面积\n'When steady-state plasma concentration is reached, the area under the plasma concentration curve is divided by the quotient of the dosing interval during one dose interval.'可被翻译为：血药浓度达稳态时，在一个剂量间隔时间内，血药浓度一时间曲线下面积除以给药间隔时间的商值。\n'A measure of the rate and degree of absorption of a drug preparation by the body. It is the ratio of the area under the concentration-time curve after non-intravenous administration to the area under the concentration-time curve after intravenous administration.'可被翻译为：药物制剂被机体吸收的速率和吸收程度的种量度。为非静脉注射给药后的浓度-时间曲线下面积与静脉给药后的浓度-时间曲线下面积的比值。\n'Also known as the \"drug-time curve\". The change of drug concentration with time migration after administration, with drug concentration (or logarithmic concentration) as the vertical coordinate and time as the horizontal coordinate plot.'可被翻译为：又称“药-时曲线”。给药后药物浓度随时间迁移发生变化,以药物浓度(或对数浓度)为纵坐标,以时间为横坐标绘出的曲线图。\n\n根据上述已知信息，请将'1.Area Under the Curve\n2.Area under the concentration versus time curve'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"曲线下面积；血药浓度-时间曲线下面积"
    },
    {
        "instruction":"已知信息：\n'It is also called \"anticholinesterase drug\". A drug that inhibits the activity of cholinesterase, preventing the hydrolysis of acetylcholine (Ach) released by cholinergic nerve endings and enhancing its M - and N-like effects. According to the rate of hydrolysis after binding to cholinesterase (AchE), it can be divided into two classes: ① reversible cholinesterase inhibitors, such as neostigmine and physostigmine; ② Refractory cholinesterase inhibitors, such as organophosphate esters. Acetylcholinesterase inhibitors that can enter the center, such as galantamine, rivanstigmine, Donepezil, etc., can be used for Alzheimer's disease as symptomatic treatment.'可被翻译为：又称\"抗胆碱酯酶药\"。能抑制胆碱酯酶的活性，使胆碱能神经末梢释放的乙酰胆碱(Ach)免遭水解而加强其M和N样作用的药物。根据与胆碱酯酶(AchE)结合后水解速度的快慢，可分为两类：①易逆性胆碱酯酶抑制药，如新斯的明和毒扁豆碱；②难逆性胆碱酯酶抑制药，如有机磷酸酯类。可进入中枢的乙酰胆碱酯酶抑制药，如加兰他敏、利凡斯的明，多奈哌齐等，可用于阿尔茨海默痴呆症，作为症状性治疗。\n'Drugs that mimic parasympathetic nervous system excitation. Drugs that cause cholinergic receptor excitation, including cholinomimetic drugs and cholinesterase inhibitors, the latter being neostigmine.'可被翻译为：类似副交感神经系统激动的药物。引起胆碱受体激动，包括拟胆碱药和胆碱酯酶药抑制药，后者如新斯的明。\n'cholinesterase inhibitors'可被翻译为：胆碱酯酶抑制药\n'eye drop'可被翻译为：滴眼剂\n\n根据上述已知信息，请将'The drugs that can make the pupil shrink and the intraocular pressure drop after the application of local eye drops are mostly paracoleceptive agents. Including M receptor agonists and cholinesterase inhibitors, such as pilocarpine, physostigmine, etc., for glaucoma.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"局部滴眼应用后能使瞳孔缩小、眼压下降的药，多为拟副交感受神经药。包括M受体激动药及胆碱酯酶抑制药，如毛果芸香碱、毒扁豆碱等，用于青光眼。"
    },
    {
        "instruction":"已知信息：\n'The legal representative and principal responsible person of the registrant, the filing entity and the contract manufacturer shall assume full responsibility for quality and safety of cosmetics.'可被翻译为：化妆品注册人、备案人、受托生产企业的法定代表人、主要负责人对化妆品质量安全工作全面负责。\n'Article 26 The legal representative and principal responsible person of the registrant or filing entity of medical devices shall assume full responsibility for quality and safety of the medical devices manufactured.'可被翻译为：第二十六条  医疗器械注册人、备案人的法定代表人、主要负责人对其生产的医疗器械质量安全全面负责。\n'Article 28 The person in charge of quality and safety shall, in accordance with the requirements of the responsibility system for quality and safety of cosmetics, assist the legal representative and principal responsible person of the registrant, the filing entity and contract manufacturer of cosmetics to undertake the corresponding responsibilities for product quality and safety management and product release as follows:'可被翻译为：第二十八条 质量安全负责人按照化妆品质量安全责任制的要求协助化妆品注册人、备案人、受托生产企业法定代表人、主要负责人承担下列相应的产品质量安全管理和产品放行职责：\n'Article 66 If the registrant, filing entity or contract manufacturer of medical devices fails to take effective measures for removing existing quality and safety risks of the medical devices, the drug regulatory department may make responsibility interview with the legal representative or the person in charge of the enterprise of the registrant, filing entity or contract manufacturer of medical devices. If cross-region entrusted manufacturing is involved, the interview condition shall be informed to related drug regulatory departments.'可被翻译为：第六十六条  医疗器械注册人、备案人、受托生产企业对存在的医疗器械质量安全风险，未采取有效措施消除的，药品监督管理部门可以对医疗器械注册人、备案人、受托生产企业的法定代表人或者企业负责人进行责任约谈。涉及跨区域委托生产的，约谈情况应当通报相关药品监督管理部门。\n\n根据上述已知信息，请将'Article 27 The registrant, filing entity or contract manufacturer of medical devices shall designate a management representative. The management representative is entrusted by the legal representative or principal responsible person with establishing, implementing and maintaining effective operation of the quality management system, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条  医疗器械注册人、备案人、受托生产企业应当配备管理者代表。管理者代表受法定代表人或者主要负责人委派，履行建立、实施并保持质量管理体系有效运行等责任。"
    },
    {
        "instruction":"已知信息：\n'Manual aseptic processing— An aseptic process where the operator manually compounds, fills, places and \/or seals an open container with sterile product.'可被翻译为：手动无菌工艺：操作人员手动配制、灌装、放置和\/或密封无菌产品敞口容器的无菌工艺。\n'Sterile Product - For purpose of this guidance, sterile product refers to one or more of the  sterilised elements exposed to aseptic conditions and ultimately making up the sterile active substance or finished sterile product. These elements include the containers, closures, and components of the finished drug product. Or, a product that is rendered sterile by a terminal sterilisation process.'可被翻译为：无菌产品：在本指南中，无菌产品指的一种或多种经灭菌、暴露于无菌条件下并最终制成无菌原料药或无 菌成品制剂的要素。这些要素包括容器、密封件和成品制剂的成分。或者，是指通过最终灭菌工艺灭菌的产品。\n'For the purpose of this guidance, sterile product refers to one or more of the sterilized elements exposed to aseptic conditions and, ultimately, making up the sterile active substance or finished sterile product. These elements include the containers, closures and components  of the finished drug product. Or, a product that is rendered sterile by a terminal sterilization process.'可被翻译为：就本指南而言，无菌产品是指暴露于无菌条件下的一种或多种灭菌元件，并最终构成无菌原料药或无菌成品。这些要素包括成品药品的容器、瓶盖和组分。或者，通过终端灭菌过程实现无菌的产品。\n'a. Open a sterile swab (or sponge). Dampen with wetting agent (sterile water, saline, or D\/E neutralizing broth) and squeeze off excess by pressing against the inside of the container holding the wetting agent.'可被翻译为：打开一个无菌棉签（或海棉），用润湿剂（无菌水、盐水或 D\/E 中和肉汤）浸湿，按压装有湿润剂的容器挤出多余水分\n\n根据上述已知信息，请将'An aseptic process whereby the operator manually compounds, fills, places or seals an open container with sterile product.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"操作人员用无菌产品手动配制、填充、放置或密封一个开放容器的无菌过程。"
    },
    {
        "instruction":"已知信息：\n'In 2019, the total number of registered grassroots users increased by 15.69 percent over the previous year. Among them, the registered grassroots users of registrants, distributors and user units have increased by 41.92 percent, 24.22 percent and 2.28 percent over 2017, respectively.'可被翻译为：2019年，注册基层用户总数比上年增长15.69%。其中，注册人注册基层用户比上年增长41.92%，经营企业和使用单位的注册基层用户分别比上年增长24.22%和2.28%。\n'In 2018, the total number of registered grassroots users increased by 8.87% over2017. It shows that the scope of monitoring of adverse events of medical devices in China has been expanding. Among them, the registered grassroots users of manufacturers,distributors and user units have increased by 16.44%, 11.59% and 4.97% over 2017,respectively (Figure 5) .'可被翻译为：2018年，注册基层用户总数比2017年增长8.87%。显示我国医疗器械不良事件监测范围不断扩大。其中，生产企业、经营企业和使用单位的注册基层用户分别比2017年增长16.44%、11.59%和4.97%(图5)。\n'As of December 31, 2020, there were a total of 350,973 grassroots users (incl. registrants, distributors and using units) registered in the National Medical Device Adverse Event Monitoring Information System, covering 27,195 registrants (7.75%); 198,833 distributors (56.65%); and 124,945 using units (35.60%).'可被翻译为：截至2020年12月31日，在国家医疗器械不良事件监测信息系统中注册的基层用户（包括注册人、经营企业和使用单位）共350,973家，其中注册人27,195家，占用户总数的7.75%；经营企业198,833家，占用户总数的56.65%；使用单位124,945家，占用户总数的35.60%。\n'(II) Number of registered grassroots users nationwide'可被翻译为：（二）全国注册基层用户数量\n\n根据上述已知信息，请将'In 2020, the total number of registered grassroots users increased by 10.03% compared with the previous year. Among them, the registered grassroots users of registrants, distributors and using units have increased by 38.31%, 11.52% and 3.24% compared with the previous year, respectively.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2020年，注册基层用户总数比上年增长10.03%。其中，注册人注册基层用户比上年增长38.31%，经营企业和使用单位的注册基层用户分别比上年增长11.52%和3.24%。"
    },
    {
        "instruction":"已知信息：\n'An aerosol made by dispersing solid particles of a drug in a projectile. Its content is a suspended liquid, and the solid particles of the drug are ejected in a haze as the ejector evaporates.'可被翻译为：将药物的固体微粒分散在抛射剂中制成的气雾剂。其内容物属于混悬型液体，喷射时随着抛射剂的挥发药物的固体微粒以烟雾状喷出。\n'A liquid sol with a solid as a dispersing phase, that is, a dispersing system formed by an insoluble solid dispersed in a liquid. The linear size of solid particles is above 0.1pm.'可被翻译为：以固体为分散相的液溶胶，即由不溶性的固体分散在液体中所形成的分散物系。固体粒子的线性大小在0.1pm以上。\n'The process by which solid or liquid particles suspended in a gas or liquid collide with each other to form larger particles due to Brownian motion, eddy currents, thermal effects, or sound waves.'可被翻译为：悬浮在气体或液体中的固体或液体微粒，由于布朗运动、涡流、热效应或声波等的作用，相互碰撞而团聚成较大颗粒的过程。\n'The ease with which a solid surface can be wetted by a liquid.'可被翻译为：固体表面被液体润湿的难易程度。\n\n根据上述已知信息，请将'The act of continuous settling of solid particles suspended in a liquid.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"悬浮在液体中的固体颗粒的连续沉降的行为。"
    },
    {
        "instruction":"已知信息：\n'Incubation period for THIO and SCD:'可被翻译为：THIO 和 SCD的培养时间\n'b. All other culture media should be incubated at 30ºto 35ºfor 2 to 3 days.'可被翻译为：所有其它培养基应该在 30º -35ºC 培养 2-3 天。\n'g. Check the original plates used for isolation for possible pre- existing contamination (i.e. growth in non-streaked locations on the agar surface, subsurface growth)'可被翻译为：检查分离时所用的原始碟，查看是否可能在使用前就被污染（即，在琼脂表面未接种位置生长，表面下生长）\n'Daily observations of primary test media (THIO and SCD) containing product should be performed without unnecessary disturbance. All handling of positive tubes, streaked plates, or subsequent inoculations of additional media will be done outside the clean room. These culture transfers are to be performed within a HEPA filtered biosafety cabinet or equivalent outside the ISO5 area which has been cleansed with an effective sporicidal\/disinfectant anti-microbial agent. The analyst should be gowned with at least sterile gloves, sterile sleeves and a mask to minimize any possible cross contamination.'可被翻译为：含有产品的原始测试培养基（THIO和SCD）的日常观察应该没有不必要的干扰。所有 阳性试管、划线平板或其他培养基后续接种的处理将在洁净室外进行。这些培养物转移 应在HEPA过滤生物安全柜内进行，或者在使用有效的杀孢子剂\/抑菌消毒剂进行了清 洁的等同ISO5区域外执行。分析人员应该至少穿戴无菌手套、无菌护袖和面罩，减少 任何可能的交叉污染。\n\n根据上述已知信息，请将'All streaked plates are incubated for a period at least as long as required for growth in original isolation media (THIO or SCD) not to exceed seven days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有划线平板均培养原始分离培养基（THIO或SCD）生长所要求的相同时长，但不 得超过7天。"
    },
    {
        "instruction":"已知信息：\n'Key Points and Determination Principles for Drug Registration Inspection(Drug Clinical Trials)(Trial)'可被翻译为：药品注册核查要点与判定原则(药物临床试验)(试行)\n'In order to ensure the quality of drug registration inspection and to unify the scope of inspection and determination standards, in accordance with the Drug Administration Law of the People's Republic of China, Measures for Administration of Drug Registration and other laws and regulations and related guidelines, the Key Points and Determination Principles of Drug Registration Inspection (Pharmacological and Toxicological study) (Trial) is hereby formulated.'可被翻译为：为保证药品注册核查质量，统一核查范围和判定标准， 根据《中华人民共和国药品管理法》《药品注册管理办法》等 法律法规及相关指导原则，特制定《药品注册核查要点与判定原则(药理毒理学研究)(试行)》。\n'Key Points and Determination Principles of Drug Registration Inspection'可被翻译为：药品注册核查要点与判定原则\n'3.《Key Points and Determination Principles for Drug Registration Inspection(Drug Clinical Trials)(Trial)》'可被翻译为：3. 药品注册核查要点与判定原则（药物临床试验）（试行）\n\n根据上述已知信息，请将'2.《Key Points and Determination Principles of Drug Registration Inspection(Pharmacological and Toxicological Study)(Trial)》'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2. 药品注册核查要点与判定原则（药理毒理学研究）（试行）"
    },
    {
        "instruction":"已知信息：\n'pepsin chiral stationary phase'可被翻译为：胃蛋白酶手性固定相\n'A protein chiral stationary phase covalently bonded by human serum albumin to a diol activated silica gel support using silica gel as a carrier. Used in protein analysis.'可被翻译为：以硅胶为载体，由人血清白蛋白与双醇激活硅胶担体共价键合的一种蛋白质手性固定相。用于蛋白质分析。\n'cellulose-based chiral stationary phase'可被翻译为：纤维素型手性固定相\n'ligand chiral stationary phase'可被翻译为：配体交换型手性固定相\n\n根据上述已知信息，请将'A chiral stationary phase of protein prepared by N, v-dissuccinimide binding pepsin to aminopropyl silica gel.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"由N,V-二琥珀酰亚胺酯将胃蛋白酶结合在胺丙基硅胶上制备的一种蛋白质手性固定相。"
    },
    {
        "instruction":"已知信息：\n'IV. Under the leadership of the provincial Party Committee and the provincial government, the relevant administrative departments of each province should cooperate with and assist the people's government of the place of origin of Chinese crude drugs to achieve regulated development of Chinese crude drugs, such as improving the working mechanism for high-quality development of Chinese crude drugs industry; formulating the development plan for Chinese medicine materials industry; refining the incentive policies to promote the regulated development of Chinese crude drugs; establishing a standing book and credit archives for TCM manufacturers and their manufacturing bases to implement dynamic supervision; and establishing an information platform for regulated manufacturing and traceability for Chinese crude drugs. Provinces with a better basis for regulated and intensive manufacturing of Chinese crude drugs are encouraged to study and formulate implementation rules based on the actual development of Chinese crude drugs in the areas under their jurisdiction, and make active exploration and promotion, so as to accumulate experiences for further promotion of the GAP.'可被翻译为：四、各省相关管理部门在省委省政府领导下，配合和协助中药材产地人民政府做好中药材规范化发展工作，如完善中药材产业高质量发展工作机制；制定中药材产业发展规划；细化推进中药材规范化发展的激励政策；建立中药材生产企业及其生产基地台账和信用档案，实施动态监管；建立中药材规范化生产追溯信息化平台等。鼓励中药材规范化、集约化生产基础较好的省份，结合本辖区中药材发展实际，研究制定实施细则，积极探索推进，为本规范的深入推广积累经验。\n'Article 6 The drug regulatory departments shall strengthen cooperation with relevant departments, give full play to the role of industry organizations and other institutions, promote the construction of credit system, and promote social co-governance.'可被翻译为：第六条 药品监督管理部门应当与相关部门加强协作，充分发挥行业组织等机构的作用，推进信用体系建设，促进社会共治。\n'V. The relevant administrative departments of each province should conduct inspection and provide technical guidance on the implementation and promotion of the GAP according to their responsibilities. Relevant authorities of Ministry of Agriculture and Rural Affairs should take the lead in providing guidance on the supply of seeds, seedlings and provenances of Chinese crude drugs, field management, use of pesticides and fertilizers, and pest control. Relevant authorities of the National Forestry and Grassland Administration should take the lead in providing guidance on ecological planting, wild cultivation and imitated wild cultivation of Chinese crude drugs, as well as planting and breeding of Chinese crude drugs under the management category of endangered plants. TCM regulatory authorities should work together to provide guidance on seeds and seeding, standardized planting, harvesting and processing, and ecological planting of Chinese crude drugs. The drug regulatory departments should carry out extended inspections on the corresponding manufacturers of Chinese crude drugs, and provide guidance on the requirements for medicinal use, processing in the place of origin and quality inspection.'可被翻译为：五、各省相关管理部门依职责对本规范的实施和推进进行检查和技术指导。农业农村部门牵头做好中药材种子种苗及种源提供、田间管理、农药和肥料使用、病虫害防治等指导。林业和草原部门牵头做好中药材生态种植、野生抚育、仿野生栽培，以及属于濒危管理范畴的中药材种植、养殖等指导。中医药管理部门协同做好中药材种子种苗、规范种植、采收加工以及生态种植等指导。药品监督管理部门对相应的中药材生产企业开展延伸检查，做好药用要求、产地加工、质量检验等指导。\n'5. Should any problems and suggestions arise therein, please contact the NMPA Department of Drug Supervision in time.'可被翻译为：五、在换证工作中如有问题和建议，请及时与国家药监局药品监管司联系。\n\n根据上述已知信息，请将'VI. The relevant administrative departments of each province should strengthen cooperation to form a joint force, jointly promote the regulated, standardized and intensive development of Chinese crude drugs, enhance publicity and training according to their responsibilities, and promote the implementation of the GAP. The relevant administrative departments of each province should strengthen the routine supervision during the implementation. In case identifying any major problems or suggestions on the improvement of major policies, please report to the corresponding management department of the State intime.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"六、各省相关管理部门应加强协作，形成合力，共同推进中药材规范化、标准化、集约化发展，按职责强化宣传培训，推动本规范落地实施。加强实施中日常监管，如发现存在重大问题或者有重大政策完善建议的，请及时报告国家相应的管理部门。"
    },
    {
        "instruction":"已知信息：\n'Article 61 Cosmetics of which the last process touching the contents completes in China are domestic products, and those that completes overseas are imported products. Those that completes in Taiwan, Hong Kong SAR and Macau SAR shall be regulated by the reference of imported products.'可被翻译为：第六十一条 化妆品最后一道接触内容物的工序在境内完成的为国产产品，在境外完成的为进口产品，在中国台湾、香港和澳门地区完成的参照进口产品管理。\n'For imported medical devices, overseas registration applicants (filing applicants)shall apply for registration (handle the filling). For medical devices manufactured in China by overseas enterprises, domestic manufacturing enterprises shall apply for registration (handle the filing) as the registration applicants (filing applicants).'可被翻译为：进口医疗器械，应当由境外注册申请人（备案人）申请注册（办理备案）；境外企业在境内生产的医疗器械，应当由境内生产的企业作为注册申请人（备案人）申请注册（办理备案）。\n'Article 42 If the registered product is no longer produced or imported, the registrant shall take the initiative to apply for cancellation of the registration license.'可被翻译为：第四十二条 已经注册的产品不再生产或者进口的，注册人应当主动申请注销注册证。\n'If the products that have been filed are no longer produced or imported, the filing person shall promptly report to the drug regulatory department responsible for the filing administration for cancelling the filing.'可被翻译为：已经备案的产品不再生产或者进口的，备案人应当及时报告承担备案管理工作的药品监督管理部门取消备案。\n\n根据上述已知信息，请将'For products used in conjunction or combination products that apply for registration or file for filing under one product name, if any of the last process touching the contents are produced overseas, the set shall be regulated as imported products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以一个产品名称申请注册或者进行备案的配合使用产品或者组合包装产品，任何一剂的最后一道接触内容物的工序在境外完成的，按照进口产品管理。"
    },
    {
        "instruction":"已知信息：\n'The lot release institution, under the premise of guaranteeing independence of dossier review, sample test and other technical review work, may communicate with the lot release applicant about specific problems requiring explanation in the lot release process.'可被翻译为：批签发机构在保证资料审核和样品检验等技术审查工作独立性的前提下，可就批签发过程中需要解释的具体问题与批签发申请人进行沟通。\n'Article 22 The lot release institution shall complete lot release within the work time limit stipulated herein. The time for the lot release applicant to supplement and correct the materials and the time for on-site verification, on-site inspection and technical evaluation shall not be included in the time limit for lot release.'可被翻译为：第二十二条 批签发机构应当在本办法规定的工作时限内完成批签发工作。批签发申请人补正资料的时间、现场核实、现场检查和技术评估时间不计入批签发工作时限。\n'Article 23 If the lot release institution is unable to complete lot release within the stipulated time limit due to force majeure, handling of public health emergencies or other reasons, it shall inform the lot release applicant in writing of the extended time limit for lot release, reasons and expected time of recovery. If the lot release institution indeed can hardly complete lot release, the NIFDC may coordinate with other lot release institutions for undertaking the work.'可被翻译为：第二十三条 批签发机构因不可抗力或者突发公共卫生事件应急处置等原因，在规定的时限内不能完成批签发工作的，应当将批签发延期的时限、理由及预期恢复的时间书面通知批签发申请人。确实难以完成的，由中检院协调其他批签发机构承担。\n'Article 19  For the lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. For other biological products, lot release may be conducted by means of independent dossier review or by combining dossier review with sample testing, and on-site verification may be conducted as required. For the testing items and testing proportion for different varieties, the NIFDC shall organize the demonstration and submit a copy to the NMPA. Each lot release institution shall conduct test in accordance with the determined specifications.'可被翻译为：第十九条    疫苗批签发应当逐批进行资料审核和抽样检验，其他生物制品批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种检验项目和检验比例，由中检院负责组织论证，并抄报国家药品监督管理局。批签发机构按照确定的检验要求进行检验。\n\n根据上述已知信息，请将'Article 24 The lot release institution, under the premise of guaranteeing independence of dossier review, sample testing and other technical review work, may communicate with the lot release applicant about specific issues requiring explanation in the lot release process. Verification can be carried out through telephone communication, written notice and other forms, and on-site verification can be carried out if necessary. If it is necessary for the lot release applicant to provide explanations or supplement materials, a written notice shall be given and the time limit for reply shall be specified.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十四条    批签发机构在保证资料审核和样品检验等技术审查工作独立性的前提下，可就批签发过程中需要解释的具体问题与批签发申请人进行沟通核实。核实工作可通过电话沟通、书面通知等形式进行，必要时可开展现场核实。需要批签发申请人提供说明或者补充资料的，应当书面通知，并明确回复时限。"
    },
    {
        "instruction":"已知信息：\n'finished pharmaceutical product (FPP). A product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more active pharmaceutical ingredients (APIs). In some cases, it may be in combination with a medical device.'可被翻译为：制剂成品（FPP） 经过了所有生产步骤包括包装在最终容器中并贴上标签的产品。一种FPP可包括一种或多种API。有时可能会与医疗器械的组合。\n'A product which has undergone all stages of production, including packaging in its final container.'可被翻译为：已完成所有生产操作步骤和最终包装的产品。\n'1.The product following purification, but before final formulation. It is obtained from a bulk harvest, and is kept in a single container and used in the preparation of the final dosage form.\n2.Any product that has completed all processing stages up to, but not including, final packaging.\n3.A product that has completed all processing stages up to, but not including, final packaging. (Reference to (should conform with) \"Good manufacturing practices for pharmaceutical products\")\n4.Any pharmaceutical product that has completed all processing stages up to, but not including, final packaging.\n5.Any product that has completed all processing stages, usually not including final packaging and labelling.'可被翻译为：1.净化后的产品，但在最终配方之前。它从批量收获中获得，并保存在单个容器中，用于制备最终剂型。\n2.任何已完成所有加工阶段直至但不包括最终包装的产品。\n3.成品:已完成直至但不包括最终包装的所有加工阶段的产品(参考(应符合)《药品生产质量管理规范》)\n4.任何已完成直至但不包括最终包装的所有加工阶段的药品。\n5.任何已完成所有加工阶段的产品，通常不包括最终包装和标签。\n'1.An FPP that contains two or more APIs.\n2.A finished pharmaceutical product that contains two or more actives.'可被翻译为：1.包含两个或多个原料药的FPP。\n2.含有两种或两种以上活性物质的制成品\n\n根据上述已知信息，请将'A product that has undergone all stages of production, including packaging in its ﬁnal container and labelling. A finished pharmaceutical product may contain one or more APIs. In some cases, it may be in combination with a medical device.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"经过所有生产阶段的产品，包括最终容器的包装和标签。药品成品可能含有一种或多种原料药。在某些情况下，它可能与医疗器械结合使用。"
    },
    {
        "instruction":"已知信息：\n'For a filed medical device, the food and drug regulatory department shall make filing certificates according to the format in relevant requirements and publish the information from the filing information form for medical device on their website.'可被翻译为：对备案的医疗器械，食品药品监督管理部门应当按照相关要求的格式制作备案凭证，并将备案信息表中登载的信息在其网站上予以公布。\n'Article 69 For a filed in-vitro diagnostic reagent, where the contents set forth in the filing information form for in-vitro diagnostic reagent changed, the filing entity shall submit a description of the change and related supporting documents to the original filing department and apply for change of filing. Where the filing materials meet the formal requirements, the food and drug regulatory department shall put the changes in the information of changes, and file a record.'可被翻译为：第六十九条 已备案的体外诊断试剂，备案信息表中登载内容及备案的产品技术要求发生变化的，备案人应当提交变化情况的说明及相关证明文件，向原备案部门提出变更备案信息。备案资料符合形式要求的，食品药品监督管理部门应当将变更情况登载于变更信息中，将备案资料存档。\n'Article 59 For a filed medical device, where the contents set forth in the filing information form for medical device changed, the filing entity shall submit a description of the change and related supporting documents to the original filing department and apply for change of filing. Where the filing documents meet the format requirements, the food and drug regulatory department shall put the changes in the information of changes, and file a record.'可被翻译为：第五十九条 已备案的医疗器械，备案信息表中登载内容及备案的产品技术要求发生变化的，备案人应当提交变化情况的说明及相关证明文件，向原备案部门提出变更备案信息。备案资料符合形式要求的，食品药品监督管理部门应当将变更情况登载于变更信息中，将备案资料存档。\n'In-vitro diagnostic reagent filing is a process that the filing entity submits the filing documents to the food and drug regulatory department and the food and drug regulatory department files the filing documents submitted by the filing entity.'可被翻译为：体外诊断试剂备案是备案人向食品药品监督管理部门提交备案资料，食品药品监督管理部门对提交的备案资料存档备查。\n\n根据上述已知信息，请将'For a filed in-vitro diagnostic reagent, the food and drug regulatory department shall make filing certificates according to the format in relevant requirements and publish the information from the filing information form for medical device on their website.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对备案的体外诊断试剂，食品药品监督管理部门应当按照相关要求的格式制作备案凭证，并将备案信息表中登载的信息在其网站上予以公布。"
    },
    {
        "instruction":"已知信息：\n'For the filing of class I in-vitro diagnostic reagent, the filing entity may submit the product self-testing report.'可被翻译为：办理第一类体外诊断试剂备案的，备案人可以提交产品自检报告。\n'To apply for filing of import class I medical devices, the filing entity shall submit the filing documents to China Food and Drug Administration.'可被翻译为：进口第一类医疗器械备案，备案人向国家食品药品监督管理总局提交备案资料。\n'To apply for filing of class I domestic medical devices, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .'可被翻译为：境内第一类医疗器械备案，备案人向设区的市级食品药品监督管理部门提交备案资料。\n'To apply for filing of import class I in-vitro diagnostic reagents, the filing entity shall submit the filing documents to China Food and Drug Administration.'可被翻译为：进口第一类体外诊断试剂备案，备案人向国家食品药品监督管理总局提交备案资料。\n\n根据上述已知信息，请将'For the filing of class I medical device, the filing entity may submit the product self-testing report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"办理第一类医疗器械备案的，备案人可以提交产品自检报告。"
    },
    {
        "instruction":"已知信息：\n'Due to the conformation of the molecule leads to the influence on the physical properties, chemical reaction characteristics and biological activity.'可被翻译为：由于分子的构象导致对物理特性、化学反应特征和生物活性的影响。\n'ground state'可被翻译为：基态\n'After absorbing a certain wavelength of infrared light, molecules transition from the ground state to the second or even the third excited state to produce infrared absorption bands.'可被翻译为：分子吸收一定波长的红外光后，从基态跃迁到第二激发态甚至第三激发态产生的红外吸收带。\n'transition state'可被翻译为：过渡态\n\n根据上述已知信息，请将'According to the conformation distribution of the ground state and transition state of a compound, the influence on the physical and chemical behavior and biological activity of the compound is studied.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据一个化合物的基态、过渡态的构象分布，研究对该化合物物理、化学行为和生物活性的影响。"
    },
    {
        "instruction":"已知信息：\n'Article 21 Pre-clinical drug study for drug registration application includes drug synthetic processes, extraction methods, physical and chemical properties, purity, selection of dosage form, screening of formula, preparing processes, testing methods, quality specifications, stability, pharmacology, toxicology and animal pharmacokinetics, etc. For traditional Chinese medicine preparations, in addition to the above-mentioned items, pre-clinical drug study also includes the study in the source of the crude drugs, and of their pre-treatment and processing, etc. For biological products, it also includes study on the source, quality specifications, storage conditions, biological characteristics and genetic stability of the starting materials such as bacterial and viral seeds\/strains, cell lines, bio-tissues, and immunological study, etc.'可被翻译为：第二十一条 为申请药品注册而进行的药物临床前研究，包括药物的合成工艺、提取方法、理化性质及纯度、剂型选择、处方筛选、制备工艺、检验方法、质量指标、稳定性、药理、毒理、动物药代动力学研究等。中药制剂还包括原药材的来源、加工及炮制等的研究；生物制品还包括菌毒种、细胞株、生物组织等起始原材料的来源、质量标准、保存条件、生物学特征、遗传稳定性及免疫学的研究等。\n'The entire process of a new drug from laboratory research to marketing and expansion of clinical application. It involves many disciplines such as pharmacy, pharmacology, toxicology, drug analysis, pharmacodynamics and clinical medicine.'可被翻译为：新药从实验室研究到上市、扩大临床应用的整个过程。涉及药剂学、药理学、毒理学、药物分析、药物动力及临床医学等诸多学科。\n'The study of the toxic effects of drugs on living organisms. It mainly includes preclinical toxicology studies or preclinical safety evaluation and clinical toxicology studies of new drugs.'可被翻译为：研究药物对生物体产生的毒性作用的学科。主要包括新药临床前毒理学研究或临床前安全性评价和临床毒理学研究。\n'Phase I Clinical Trial: initial clinical pharmacology and safety evaluation studies in humans. These studies are designed to observe tolerability of humans to and pharmacokinetics of a new drug, in order to provide basis for establishing the administration regimen.'可被翻译为：I期临床试验：初步的临床药理学及人体安全性评价试验。观察人体对于新药的耐受程度和药代动力学，为制定给药方案提供依据。\n\n根据上述已知信息，请将'A series of laboratory studies carried out to prepare a proposed new drug for clinical trials. It includes synthetic process, extraction method, physicochemical properties and purity, prescription screening, preparation process, test method, quality index, stability, pharmacology and toxicology, animal pharmacokinetics, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为拟开发的新药用于临床试验而开展的一系列实验室研究工作的总称。包括合成工艺、提取方法、理化性质及纯度、处方筛选、制备工艺、检验方法、质量指标、稳定性、药理毒理、动物药动学等。"
    },
    {
        "instruction":"已知信息：\n'Article 60 If in violation of Paragraph 3 of Article 42 of these Provisions, the organizer of a trade fair fails to report the basis information on the trade fair to the department in charge of drug supervision and administration where it is located as required, the department in charge of drug supervision and administration shall order it to make rectification and give warning to it; if refusing to making rectification, the department shall impose a fine of not less than RMB 5,000 and not more than RMB 30,000.'可被翻译为：第六十条 违反本办法第四十二条第三款，展销会举办者未按要求向所在地负责药品监督管理的部门报告展销会基本信息的，由负责药品监督管理的部门责令改正，给予警告；拒不改正的，处5000元以上3万元以下罚款。\n'Article 58 If in violation of Paragraph 1 of Article 17, Article 18 and Paragraph 1 of Article 19 of these Provisions, the cosmetic manufacturer changes its licensing conditions, or needs to change the items stated on the License, but fails to apply for changes as the drug regulatory department issued former license shall order it to make rectification, give warning to it, and impose a fine of not less than RMB 10,000 and not more than RMB 30,000.'可被翻译为：第五十八条 违反本办法第十七条、第十八条第一款、第十九条第一款，化妆品生产企业许可条件发生变化，或者需要变更许可证载明的事项，未按规定申请变更的，由原发证的药品监督管理部门责令改正，给予警告，并处1万元以上3万元以下罚款。\n'Article 83 In cases where vaccine MAHs' violation of this Law involves any of the following circumstances, the drug regulatory departments of the people's governments at or above the provincial level shall order to make rectification and give a warning; and those who refuse to make rectification shall be subject to a fine of not less than RMB 200,000 yuan but not more than RMB 500,000 yuan; in serious circumstances, the offender shall be subject to an order to stop production for rectification and a fine of not less than RMB 500,000 yuan but not more than RMB 2,000,000 yuan:'可被翻译为：第八十三条 违反本法规定，疫苗上市许可持有人有下列情形之一的，由省级以上人民政府药品监督管理部门责令改正，给予警告；拒不改正的，处二十万元以上五十万元以下的罚款；情节严重的，责令停产停业整顿，并处五十万元以上二百万元以下的罚款：\n'Article 56 If the registrant of cosmetics and new cosmetic ingredients fails to apply for the change of registration for special cosmetics and new cosmetic ingredients in accordance with the requirements of these Provisions, the drug regulatory department that originally issued the license shall give an order for rectification, give a disciplinary warning, and impose a fine of not less than 10,000 yuan but no more than 30,000 yuan.'可被翻译为：第五十六条 化妆品、化妆品新原料注册人未按照本办法规定申请特殊化妆品、化妆品新原料变更注册的，由原发证的药品监督管理部门责令改正，给予警告，处1万元以上3万元以下罚款。\n\n根据上述已知信息，请将'If in violation of Paragraph 2 of Article 19 of these Provisions, the person in charge of quality and safety and the reserved contact information are changed, without reporting to related department as required, the drug regulatory department issued former license shall order the applicant to make rectification; if refusing to make rectification, the department shall give warning, and impose a fine of not more than RMB 5,000.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"违反本办法第十九条第二款，质量安全负责人、预留的联系方式发生变化，未按规定报告的，由原发证的药品监督管理部门责令改正；拒不改正的，给予警告，并处5000元以下罚款。"
    },
    {
        "instruction":"已知信息：\n'I. The GAP is applicable to the whole process management of regulated manufacturing of Chinese crude drugs by Chinese crude drugs manufacturers, and is the basic requirement of regulated manufacturing and management of Chinese crude drugs. The Chinese crude drugs in the GAP refer to the medicinal raw materials derived from medicinal plants, medicinal animals and other resources and used for the manufacturing of prepared slices of Chinese crude drugs and preparations after standardized planting (including ecological planting, wild cultivation and imitated wild cultivation), breeding, harvesting and processing in the manufacturing place.'可被翻译为：一、本规范适用于中药材生产企业规范生产中药材的全过程管理，是中药材规范化生产和管理的基本要求。本规范涉及的中药材是指来源于药用植物、药用动物等资源，经规范化的种植（含生态种植、野生抚育和仿野生栽培）、养殖、采收和产地加工后，用于生产中药饮片、中药制剂的药用原料。\n'(V) Information on the crude drugs' ecological environment, resource reserves, wild or planting and breeding conditions, harvest and primary processing at the place of production;'可被翻译为：（五）药材产地生态环境、资源储量、野生或者种植养殖情况、采收及产地初加工等信息；\n'V. The relevant administrative departments of each province should conduct inspection and provide technical guidance on the implementation and promotion of the GAP according to their responsibilities. Relevant authorities of Ministry of Agriculture and Rural Affairs should take the lead in providing guidance on the supply of seeds, seedlings and provenances of Chinese crude drugs, field management, use of pesticides and fertilizers, and pest control. Relevant authorities of the National Forestry and Grassland Administration should take the lead in providing guidance on ecological planting, wild cultivation and imitated wild cultivation of Chinese crude drugs, as well as planting and breeding of Chinese crude drugs under the management category of endangered plants. TCM regulatory authorities should work together to provide guidance on seeds and seeding, standardized planting, harvesting and processing, and ecological planting of Chinese crude drugs. The drug regulatory departments should carry out extended inspections on the corresponding manufacturers of Chinese crude drugs, and provide guidance on the requirements for medicinal use, processing in the place of origin and quality inspection.'可被翻译为：五、各省相关管理部门依职责对本规范的实施和推进进行检查和技术指导。农业农村部门牵头做好中药材种子种苗及种源提供、田间管理、农药和肥料使用、病虫害防治等指导。林业和草原部门牵头做好中药材生态种植、野生抚育、仿野生栽培，以及属于濒危管理范畴的中药材种植、养殖等指导。中医药管理部门协同做好中药材种子种苗、规范种植、采收加工以及生态种植等指导。药品监督管理部门对相应的中药材生产企业开展延伸检查，做好药用要求、产地加工、质量检验等指导。\n'II. Manufacturers of prepared slices of Chinese crude drugs, marketing authorization holders of Chinese patent medicine are encouraged to build or jointly build manufacturers and manufacturing bases of Chinese crude drugs at the place of origin of Chinese crude drugs in accordance with the GAP, and extend the drug quality management system to the place of origin of Chinese crude drugs.'可被翻译为：二、鼓励中药饮片生产企业、中成药上市许可持有人等中药生产企业在中药材产地自建、共建符合本规范的中药材生产企业及生产基地，将药品质量管理体系延伸到中药材产地。\n\n根据上述已知信息，请将'Chinese crude drugs manufacturers in this announcement include planting and breeding specialized cooperatives or cooperatives with the nature of an enterprise.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本公告所指中药材生产企业包括具有企业性质的种植、养殖专业合作社或联合社。"
    },
    {
        "instruction":"已知信息：\n'The quantitative relationship between the structure of a series of compounds and their biological activity is investigated using theoretical calculations and statistical analysis methods.'可被翻译为：利用理论计算和统计分析方法研究系列化合物结构与生物活性之间所存在的定量关系。\n'The qualitative and quantitative analysis of a chemical substance is carried out by using some corresponding quantitative relationship between a physical or chemical signal and a substance to be measured in the analysis system.'可被翻译为：利用某一物理或化学信号与分析体系中某一待测物质存在的某种对应数量关系，对该化学物质进行定性、定量分析。\n'A new method of multivariate statistical data analysis, first proposed by the Swedish econometrician H. Wolde in 1966, is the regression modeling method of multivariate variables to multi-independent variables. In metrology absorptiometry, it is a data processing method for multi-component analysis.'可被翻译为：由瑞典经济计量学家沃尔德（H.Wold）于1966年首次提出的一种新型多元统计数据分析方法，是多因变量对多自变量的回归建模方法。在计量学吸光光度法中，是一种用于多组分分析的数据处理方法。\n'In the analysis of the multi-factor quantitative treatment experiment, the relationship between the analysis test index (dependent variable) and several test factors (independent variable) is drawn as a three-dimensional surface.'可被翻译为：在多因素数量处理试验的分析中，将分析试验指标（因变量）与多个试验因素（自变量）间的关系绘图，绘制成的三维曲面。\n\n根据上述已知信息，请将'A method of statistical analysis that determines a quantitative relationship of interdependence between two or more variables.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"确定两种或两种以上变数间相互依赖的定量关系的一种统计分析方法。"
    },
    {
        "instruction":"已知信息：\n'Article 58 Drug distributors shall retail drugs properly and include an accurate description of dosage and administration and precautions. Prescriptions for dispensing shall be checked, and no drugs listed in the prescription may be changed or substituted without authorization. Requests to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.'可被翻译为：第五十八条 药品经营企业零售药品应当准确无误，并正确说明用法、用量和注意事项；调配处方应当经过核对，对处方所列药品不得擅自更改或者代用。对有配伍禁忌或者超剂量的处方，应当拒绝调配；必要时，经处方医师更正或者重新签字，方可调配。\n'Article 73 Prescriptions dispensed by pharmacists or other drug professionals who are qualified in accordance with the law shall be checked, and no drugs listed in the prescriptions may be changed or substituted without authorization. The pharmacists shall refuse to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.'可被翻译为：第七十三条 依法经过资格认定的药师或者其他药学技术人员调配处方，应当进行核对，对处方所列药品不得擅自更改或者代用。对有配伍禁忌或者超剂量的处方，应当拒绝调配；必要时，经处方医师更正或者重新签字，方可调配。\n'Drugs that can be purchased, dispensed and used only on the prescription of a medical practitioner or assistant medical practitioner.'可被翻译为：凭执业医师和执业助理医师处方方可购买、调配和使用的药品。\n'Article 115: Dispensing should only be carried out by designated personnel according to operation procedures. After being checked, materials should be accurately weighed or measured, and well labeled.'可被翻译为：第一百一十五条 应当由指定人员按照操作规程进行配料，核对物料后，精确称量或计量，并作好标识。\n\n根据上述已知信息，请将'(I) Prescription can be dispensed only after being audited by licensed pharmacists. The drugs listed in the prescription shall not be altered or substituted without authorization. The dispensing of prescriptions with incompatibility or overdose shall be refused; however, those may be dispensed after being corrected or re-signed by the prescriber. After the dispensing of prescription, the drugs can be sold only after being checked;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）处方经执业药师审核后方可调配；对处方所列药品不得擅自更改或者代用，对有配伍禁忌或者超剂量的处方，应当拒绝调配，但经处方医师更正或者重新签字确认的，可以调配；调配处方后经过核对方可销售。"
    },
    {
        "instruction":"已知信息：\n'Article 39 Any food and drug regulatory department, or lot release institution or its staff members that violate the provisions herein and in case of any of the circumstances below shall be ordered by its superior administrative authority or supervisory authority to make rectification. If the circumstances are serious, administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law:'可被翻译为：第三十九条 食品药品监督管理部门、批签发机构及其工作人员违反本办法规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：\n'Article 162 Any drug regulatory department that constitutes any of the following circumstances in the process of drug registration shall be instructed by its superior administrative department or supervisory departments to make rectification, and administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible by law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第一百六十二条 药品监督管理部门在药品注册过程中有下列情形之一的，由其上级行政机关或者监察机关责令改正，对直接负责的主管人员和其他直接责任人员依法给予行政处分；构成犯罪的，依法追究刑事责任：\n'Article 40 If the drug regulatory departments, lot release institution, CFDI and their staff members constitute any of the following circumstances in the lot release work, sanctions shall be given to the directly responsible persons and  other directly responsible personnel by law; if a crime is committed, criminal liabilities shall be investigated by law:'可被翻译为：第四十条    药品监督管理部门、批签发机构、核查中心及其工作人员在批签发工作中有下列情形之一的，依法对直接负责的主管人员和其他直接责任人员给予处分；构成犯罪的，依法追究刑事责任：\n'Article 160 Any drug regulatory department or its staff members that violate the provisions of this Provisions and constitute any of the circumstances below shall be instructed by its superior administrative department or supervisory departments to make rectification. If the circumstances are serious, administrative sanctions shall be given to the persons directly in charge and the other persons directly responsible in accordance with law:'可被翻译为：第一百六十条 药品监督管理部门及其工作人员违反本法的规定，有下列情形之一的，由其上级行政机关或者监察机关责令改正；情节严重的，对直接负责的主管人员和其他直接责任人员依法给予行政处分：\n\n根据上述已知信息，请将'Article 40 Any food and drug regulatory department, or lot release institution or its staff members that constitutes any of the following circumstances in the lot release work shall be ordered by its superior administrative authority or supervisory authority to make rectification, and administrative sanctions shall be given to persons directly in charge and other directly responsible persons in accordance with law; if a crime is committed, criminal liabilities shall be investigated by law:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十条 食品药品监督管理部门、批签发机构及其工作人员在批签发工作中有下列情形之一的，由其上级行政机关或者监察机关责令改正，对直接负责的主管人员和其他直接责任人员依法给予行政处分；构成犯罪的，依法追究刑事责任："
    },
    {
        "instruction":"已知信息：\n'Article 49 During the drug review process, where on-site inspection is needed due to the circumstances such as the authenticity of the application dossiers is in doubt or reports with confirmed evidence are received, the CDE shall initiate for-cause inspection and, when necessary, sampling and testing shall be performed.'可被翻译为：第四十九条 药品审评中心在审评过程中，发现申报资料真实性存疑或者有明确线索举报等，需要现场检查核实的，应当启动有因检查，必要时进行抽样检验。\n'(2) when the application dossier is found false in the process of registration, and the applicant cannot prove the authenticity thereof;'可被翻译为：（二）在注册过程中发现申报资料不真实，申请人不能证明其申报资料真实的；\n'(6) During the drug registration process, the application dossier is considered untruthful, and the applicant cannot prove the authenticity thereof;'可被翻译为：（六）药品注册过程中认为申报资料不真实，申请人不能证明其真实性的；\n'If there is any doubt about the authenticity of the application dossier or samples for lot release of vaccines or any other situation which requires further verification, lot release institutions shall make the verification, and may organize on-site verifications such as sampling on-site for testing if necessary.'可被翻译为：对疫苗批签发申请资料或者样品的真实性有疑问，或者存在其他需要进一步核实的情况的，批签发机构应当予以核实，必要时应当采用现场抽样检验等方式组织开展现场核实。\n\n根据上述已知信息，请将'Article 58 During the drug review and inspection process, where it is found that the authenticity of the application dossier is in doubt or reports with confirmed evidence are received, when necessary, sampling and testing shall be performed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十八条 在药品审评、核查过程中，发现申报资料真实性存疑或者有明确线索举报，或者认为有必要进行样品检验的，可抽取样品进行样品检验。"
    },
    {
        "instruction":"已知信息：\n'Since humans are more sensitive to the toxic reactions of most chemical poisons than animals, there are many uncertainties in the process of extrapolating the results of animal experiments to humans, which will cause errors. Especially in mg\/kg body weight to indicate the dose is even more so, so in the calculation, the experimental animal should not observe the harmful effect dose or observed harmful effect of the lowest dose to reduce a certain multiple to correct the error, to ensure safety.'可被翻译为：由于人对于大多数化学毒物的毒性反应要比动物敏感，在把动物实验结果向人外推的过程中，存在许多不确定因素，会造成误差。尤其是以mg\/kg体重表示剂量时更是如此，故在计算时，应该把实验动物的未观察到的有害作用剂量或观察到的有害作用的最低剂量缩小一定倍数来校正误差，确保安全。\n'Where there have been PK, and\/or PD, effectiveness and safety data of Chinese population in global data, and the analysis shows that the benefits of the drug used for Chinese patients outweigh the risks, data from relevant domestic and overseas clinical trials can be directly used to support the marketing application.'可被翻译为：对于全球数据中已有中国人群PK、和\/或PD、有效性和安全性数据，经分析认为其用于中国患者的获益大于风险的，相关境内外临床试验数据可直接用于支持上市申请。\n'Any chemical that causes an increase in morbidity or mortality from malignant neoplasms in animals and humans'可被翻译为：凡能引起动物和人类恶性肿瘤增加发病率或死亡率的化学物质\n'Selected information from the Complete Clinical Data Package that is relevant to the population of the new region, including pharmacokinetic data, and any preliminary pharmacodynamic and dose-response data and, if needed, supplemental data obtained from a bridging study in the new region that will allow extrapolation of the foreign safety and efficacy data to the population of the new region.'可被翻译为：从完整临床数据集中选出的与新地区人群相关的信息，包括药动学数据和任何原始的药效学数据、以及量-效关系数据。如有必要，从新地区桥接研究中获得的额外数据，可促进国外的有效性和安全性数据外推到新地区人群。\n\n根据上述已知信息，请将'A factor set to eliminate the uncertainties involved in determining the adverse effects of an evaluated chemical on a large population by extrapolating data from animal trials to humans, or from small-population surveys. It is used to establish standards for the control of chemicals to ensure the safety of exposed populations.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在以动物试验数据外推到人，或以小范围人群调查结果判断所评价的化学品对大范围人群的有害作用时，为排除所涉及的不确定因素而设定的系数。用于制定化学品控制标准，以保证接触人群的安全。"
    },
    {
        "instruction":"已知信息：\n'NMPA Issued the Administrative Measures for Drug Quality Sampling Inspection'可被翻译为：国家药监局关于印发药品质量抽查检验管理办法的通知\n'To strengthen medical device administration and standardize the sampling inspection of medical device quality, NMPA has organized the revision of and released on March 13, 2020 the Administrative Measures for Sampling Inspection of Medical Device Quality. The Administrative Regulations on Quality Supervision and Sampling Inspection of Medical Devices (CFDA Department of Medical Device Supervision [2013] No. 212) and the Work Procedures for National Medical Device Sampling Inspection (CFDA General Office [2014] No. 213) issued by the former China Food and Drug Administration shall be repealed simultaneously.'可被翻译为：为加强医疗器械监督管理，规范医疗器械质量抽查检验工作，国家药监局于2020年3月13日组织修订并发布了《医疗器械质量抽查检验管理办法》。原国家食品药品监督管理总局发布的《医疗器械质量监督抽查检验管理规定》（食药监械监〔2013〕212号）和《国家医疗器械抽查检验工作程序》（食药监办〔2014〕213号）同时废止。\n'On August 19, 2019, NMPA issued the Administrative Measures for Drug Quality Sampling Inspection (hereinafter referred to as the Measures), effective as of the date of promulgation. The SFDA Notice on the Issuance of Regulations for Drug Quality Sampling Inspection (SFDA Department of Market Supervision [2006] No. 379) shall be repealed simultaneously.'可被翻译为：2019年8月19日，国家药监局发布了《药品质量抽查检验管理办法》（以下简称本办法），自发布之日起施行。原国家食品药品监督管理局发布的《药品质量抽查检验管理规定》（国食药监市〔2006〕379号）同时废止。\n'NMPA Issued the Administrative Measures for Key Laboratories of NMPA'可被翻译为：国家药监局关于印发国家药品监督管理局重点实验室管理办法的通知\n\n根据上述已知信息，请将'NMPA Issued the Administrative Measures for Sampling Inspection of Medical Device Quality'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于印发医疗器械质量抽查检验管理办法的通知"
    },
    {
        "instruction":"已知信息：\n'Class III medical device distribution shall be subject to licensing management; Class II medical device distribution shall be subject to filing management, while Class I medical device distribution could be carried out without licensing or filing.'可被翻译为：经营第三类医疗器械实行许可管理，经营第二类医疗器械实行备案管理，经营第一类医疗器械不需要许可和备案。\n'Article 27 If the registrant or filing entity of medical devices sells its registered and filed medical devices at its domicile or manufacturing address, it does not need to apply for Medical Device Distribution License or filing, but shall meet the prescribed distribution conditions; if it stores and sells the medical devices in other places, it shall apply for Medical Device Distribution License or filing as stipulated.'可被翻译为：第二十七条  医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存并销售医疗器械的，应当按照规定办理医疗器械经营许可或者备案。\n'Article 23 If an entity applies for Class III Medical Device Distribution License and files for Class II medical device distribution concurrently, or has obtained Class III Medical Device Distribution License when filing for Class II medical device distribution, then it may be exempted from submitting corresponding materials.'可被翻译为：第二十三条  同时申请第三类医疗器械经营许可和进行第二类医疗器械经营备案的，或者已经取得第三类医疗器械经营许可进行第二类医疗器械备案的，可以免予提交相应资料。\n'In case of significant changes in distribution conditions of the registrant, filing entity and distributor of the medical devices, thus not conforming to requirements of the quality management system for medical device distribution, rectification measures shall be taken immediately; if safety and effectiveness of the medical devices might be influenced, distribution activities shall be suspended immediately, and report shall be made to the former licensing department or filing department.'可被翻译为：医疗器械注册人、备案人、经营企业经营条件发生重大变化，不再符合医疗器械经营质量管理体系要求的，应当立即采取整改措施；可能影响医疗器械安全、有效的，应当立即停止经营活动，并向原经营许可或者备案部门报告。\n\n根据上述已知信息，请将'Medical device sold by its registrant and filing applicant at their residence or manufacturing site may not apply for medical device distribution licensing or filing, but shall comply with the specified distribution conditions; for Class II and Class III medical devices stored and sold at other sites, application for medical device distribution licensing or filing shall be made as required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械注册人、备案人在其住所或者生产地址销售其注册、备案的医疗器械，无需办理医疗器械经营许可或者备案，但应当符合规定的经营条件；在其他场所贮存、销售第二、三类医疗器械的，应当按照规定办理医疗器械经营许可或者备案。"
    },
    {
        "instruction":"已知信息：\n'The liquid part of human blood remaining after separation of the cellular elements from blood collected in a container containing an anticoagulant, or separated by continuous filtration and\/or centrifugation of anticoagulated blood in an apheresis procedure, intended for further manufacturing.'可被翻译为：从含有抗凝剂的容器中收集的血液中分离细胞成分后，或在单采过程中通过抗凝血的连续过滤和\/或离心分离，用于进一步生产的人体血液的液体部分。\n'blood coagulation'可被翻译为：血液凝固\n'blood coagulation factor'可被翻译为：凝血因子\n'Cleanroom gowning and hand washing should follow a written procedure designed to minimize contamination of cleanroom clothing and\/or the transfer of contaminants to the clean areas.'可被翻译为：洁净室更衣和洗手应遵循相应书面程序，该程序应旨在最大限度减少洁净服污染和\/或减少污染物转移至洁浄区。\n\n根据上述已知信息，请将'The procedure whereby a single donation of blood is collected in an anticoagulant and\/or stabilizing solution, under conditions designed to minimize microbial contamination, cellular damage and\/or coagulation activation of the resulting blood donation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单次献血的血液在抗凝和\/或稳定溶液中收集的过程，在设计的条件下尽量减少微生物污染、细胞损伤和\/或由此产生的献血的凝血激活。"
    },
    {
        "instruction":"已知信息：\n'Article 2 The registration and filing activities of cosmetics and new cosmetic ingredients and their supervision and administration within the territory of the People's Republic of China shall comply with these Provisions.'可被翻译为：第二条 在中华人民共和国境内从事化妆品和化妆品新原料注册、备案及其监督管理活动，适用本办法。\n'Article 1 These Provisions are formulated in accordance with the Standardization Law of the People's Republic of China, the Regulations for the Implementation of the Standardization Law of the People's Republic of China and the Regulations for the Supervision and Administration of Medical Devices as well as other laws and regulations to promote progress in science and technology, ensure the safety and effectiveness of medical devices, improve health care and enhance medical device standards administration.'可被翻译为：第一条 为促进科学技术进步，保障医疗器械安全有效，提高健康保障水平，加强医疗器械标准管理，根据《中华人民共和国标准化法》《中华人民共和国标准化法实施条例》和《医疗器械监督管理条例》等法律法规，制定本办法。\n'Article 2 These Provisions shall apply to medical device distribution activities and their supervision and administration within the territory of the People's Republic of China.'可被翻译为：第二条  在中华人民共和国境内从事医疗器械经营活动及其监督管理，应当遵守本办法。\n'Article 2 These Provisions shall apply to medical device manufacturing activities and its supervision and administration within the territory of the People’s Republic of China.'可被翻译为：第二条  在中华人民共和国境内从事医疗器械生产活动及其监督管理，应当遵守本办法。\n\n根据上述已知信息，请将'Article 3 The formulation and revision, implementation, supervision and administration of medical device standards within the territory of the People’s Republic of China shall conform to laws, administrative regulations and these Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三条 在中华人民共和国境内从事医疗器械标准的制修订、实施及监督管理，应当遵守法律、行政法规及本办法的规定。"
    },
    {
        "instruction":"已知信息：\n'(I) Class I products'可被翻译为：（一）第一类产品\n'(II) Class II products'可被翻译为：（二）第二类产品\n'(III) Class III products'可被翻译为：（三）第三类产品\n'Notes: 1. “I”,“II”and“III”herein respectively refer to class I, II and III medical devices.'可被翻译为：注：1．本表中“Ⅰ”、“Ⅱ”、“Ⅲ”分别代表第一类、第二类、第三类医疗器械；\n\n根据上述已知信息，请将'Products not clearly defined as class I and class III products are class II products, mainly including:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除已明确为第一类、第三类的产品，其他为第二类产品，主要包括："
    },
    {
        "instruction":"已知信息：\n'cellulose-based chiral stationary phase'可被翻译为：纤维素型手性固定相\n'ligand chiral stationary phase'可被翻译为：配体交换型手性固定相\n'pepsin chiral stationary phase'可被翻译为：胃蛋白酶手性固定相\n'Also known as \"AGP stationary phase\". 6 Acidic glycoprotein is a natural protein that has some special binding sites in the molecule and is highly stereoselective to drug enantiomers. A single chain polypeptide consisting of 181 amino acids and 5 heteropolysaccharides, a chiral stationary phase of a protein containing 14 sialic acid residues.'可被翻译为：又称“AGP固定相”。6酸性糖蛋白是一种天然蛋白质，分子中具有一些特殊的结合位点，对药物对映体具有高度的立体选择性。由181个氨基酸和5个杂多糖组成的单链多肽，包含14个唾液酸残基的一种蛋白质手性固定相。\n\n根据上述已知信息，请将'A chiral stationary phase of polymers prepared by coating phase and bonding phase of photoactive amino acids or pipercoic acid as chiral selective factors, which is mainly used for the analysis of amino acids and their derivatives.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以光活性氨基酸或哌可酸作为手性选择因子的涂渍相和键合相制备的，主要用于氨基酸及其衍生物分析的一种高聚物手性固定相。"
    },
    {
        "instruction":"已知信息：\n'Apply the principles and methods of sociology and behavioral science to study the discipline of human behavior in pharmaceutical practice.'可被翻译为：应用社会学和行为科学的原理和方法，研究药学实践中人的行为学科。\n'A basic discipline that applies the basic principles and methods of quantum mechanics to the study of the structure of matter molecules and the microscopic processes involved in chemical reactions.'可被翻译为：应用量子力学的基本原理和方法，研究物质分子的结构和化学反应中微观过程的一门基础学科。\n'1.The total set of characteristics of an entity that affect its ability to satisfy stated and implied needs, and the consistent and reliable performance of services or products in conformity with specified requirements. Implied needs include safety and quality attributes of products intended both for therapeutic use and as starting materials for further manufacturing.\n2.The suitability of either an active pharmaceutical ingredient or a pharmaceutical product for its intended use. This term includes such attributes as the identity, strength and purity.\n3.The total set of characteristics of an entity that affect its ability to satisfy stated and implied needs and to ensure the consistent and reliable performance of services or products in conformity with specified requirements.'可被翻译为：1.一个实体影响其满足明示的和隐含的需要的能力，以及符合规定要求的服务或产品的一致和可靠性能的全部特征。隐含需求包括用于治疗用途和作为进一步生产的起始材料的产品的安全和质量属性。\n2.活性药物成分或药品对其预期用途的适宜性。该术语包括特性、强度和纯度等属性。\n3.一个实体影响其满足明示和暗示的需要，并确保服务或产品符合规定要求的一致和可靠性能的能力的全部特征。\n'In pattern recognition, according to certain principles, select methods or processes that reflect those characteristics of the nature of pattern recognition.'可被翻译为：在模式识别中根据一定的原则，选取反映识别模式本质的那些特征的方法或过程。\n\n根据上述已知信息，请将'An applied discipline that applies marketing principles, methods, and strategies to the study of the characteristics and needs of the pharmaceutical market, and how to provide pharmaceutical products and services to meet those needs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应用市场营销学原理、方法和策略，研究医药市场特征、需求，以及如何提供医药产品和服务满足需求的一门应用性学科。"
    },
    {
        "instruction":"已知信息：\n'In the analysis of variance, if a measurement result is affected by multiple factors at the same time, the sum of the squares of the total deviation is equal to the sum of the squares of the experimental error and the deviation formed by various factors, the total degree of freedom is equal to the sum of the degrees of freedom, the total variance is equal to the sum of the variance of each part, which is called addivity.'可被翻译为：在方差分析中，如果-个测定结果同时受到多个因素的影响，总偏差平方和等于实验误差与各因素所形成的偏差平方和之总和，总自由度等于各项自由度之和，总方差等于各部分方差之和，此称为加和性。\n'The property of interaction between two or more substances combined to form a compound.'可被翻译为：两种以上物质结合成化合物时互相作用的性质。\n'A covalent bond in which three pairs of electrons are shared between two atoms in a chemical compound.'可被翻译为：在化合物分子中两个原子间以三对共用电子构成的共价键。\n'The combination of two drugs shows an effect significantly greater than the sum of the two.'可被翻译为：两药联合应用所显示的效应明显超过两者之和。\n\n根据上述已知信息，请将'The action of two or more drugs is equal to the sum of the separate actions of each chemical compound.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"两种以上药物作用等于每一种化合物质单独作用的总和。"
    },
    {
        "instruction":"已知信息：\n'A WHO-type certificate of the form described in Guidelines for implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. Geneva,World Health Organization, 1998.'可被翻译为：在国际贸易中流通的药品质量WHO认证计划实施指南中所述形式的世卫组织类型证书。日内瓦，世界卫生组织，1998年。\n'2. WHO guidelines on good manufacturing practices for pharmaceutical products: main principle. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: forty-eighth report. Geneva: World Health Organization; 2014: Annex 2 (WHO Technical Report Series, No. 986; https:\/\/www.who.int\/medicines\/areas\/quality_safety\/quality_assurance\/TRS986annex2.p df? ua=1, accessed 30 November 2020).'可被翻译为：WHO 药品GMP指南：总则，WHO TRS986附录2，2014\n'11. WHO guidelines on quality risk management. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: forty-seventh report. Geneva: World Health Organization; 2013: Annex 2 (WHO Technical Report Series, No. 981;http:\/\/digicollection.org\/whoqapharm\/documents\/s20093en\/s20093en.pdf, accessed 30 November 2020).'可被翻译为：WHO质量风险管理指南，WHO TRS981附录2，2013\n'1. WHO guidelines on the transfer of technology in pharmaceutical manufacturing. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: forty-fifth report. Geneva: World Health Organization; 2011: Annex 7 (WHO Technical Report Series, No. 961; https:\/\/www.who.int\/docs\/default-source\/medicines\/norms-and- standards\/guidelines\/production\/trs961-annex7-transfer-technology-pharmaceutical- manufacturing.pdf?sfvrsn=2e302838_0, accessed 30 November 2020).'可被翻译为：WHO 药品生产技术转移指南，WHO TRS961附录7，2011\n\n根据上述已知信息，请将'A certificate of pharmaceutical product of the type defined in the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce* .\n\n*World Health Organization. WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. Geneva, World Health Organization, 2000 WHO\/EDM\/QSM\/2000.2.\n(http:\/\/www.who.int\/medicines\/organization\/qsm\/activities\/drugregul\/certification\/certifschemes. html).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在国际贸易中流通的药品质量世界卫生组织认证计划中定义的药品类型的证书*。\n\n*世界卫生组织。在国际贸易中流通的药品质量世界卫生组织认证计划。日内瓦，世界卫生组织，2000年，世界卫生组织\/EDM\/QSM\/2000.2。\n(http:\/\/www.who.int\/medicines\/organization\/qsm\/activities\/drugregul\/certification\/certifschemes。html)。"
    },
    {
        "instruction":"已知信息：\n'A location within the aseptic processing area in which product and critical surfaces are exposed to the environment.'可被翻译为：无菌加工区内产品和关键表面暴露在环境中的位置。\n'The design of the technology and processes used should ensure appropriate conditions are maintained in the critical zone to protect the exposed product during operations.'可被翻译为：所用技术和工艺的设计应确保在关键区域维持适当的条件，从而保护操作期间暴露的产品。\n'critical zone'可被翻译为：临界区域\n'Personnel are critical to the maintenance of asepsis in the controlled environment. Thorough training in aseptic techniques is required.'可被翻译为：人员对于在受控环境中保持无菌至关重要。需要进行彻底的无菌技术培训。\n\n根据上述已知信息，请将'Critical zone - A location within the aseptic processing area in which product and critical surfaces are exposed to the environment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"关键区：位于无菌工艺区内的、产品和关键表面暴露于其中的位置。"
    },
    {
        "instruction":"已知信息：\n'A drug that excites the central nervous system function and improves brain activity function. According to the site of action can be divided into excitatory cerebral cortex drugs, such as xanthine derivatives, such as caffeine, theophylline; Excitatory medullary respiratory center drugs, such as nicoxal rice; Drugs that excite the spinal cord, such as strychnine; And intelligence-boosting drugs that promote brain cell metabolism and improve brain function, such as piracetam.'可被翻译为：具有兴奋中枢神经系统功能，提高脑活动功能的药物。按照作用部位可分为兴奋大脑皮质的药物，如黄嘌吟衍生物，如咖啡因、茶碱等；兴奋延髓呼吸中枢的药物，如尼可刹米等；兴奋脊髓的药物，如士的宁；促进脑细胞代谢、改善脑功能的智能促进药物如吡拉西坦等。\n'The antagonistic action is mainly, and there is a certain intrinsic activity, that is, the effect of activating the receptor.'可被翻译为：以拮抗作用为主，还有一定内在活性，即激动受体的效应的药物。\n'Drugs that inhibit proliferative cells. Often used as anticancer drugs. This class of drugs can be divided into two categories according to the different cell cycle of drug action: (1) Cycle non-specific drugs: including alkylation agents and most anticancer antibiotics; ② cell cycle specific drugs, which can also be divided into drugs that mainly act on the S phase, such as anti-metabolic drugs; Mainly in the M phase of the drug, such as colchicine, colchicine and so on.'可被翻译为：能抑制增殖期细胞的药物。多为抗癌药。本类药物依药物作用细胞周期不同时相，又可分为两类：①周期非特异性药物：包括烃化剂和大部分抗癌抗生素类；②细胞周期特异性药,又可分为主要作用于S期的药物,如抗代谢药;主要作用于M期的药物,如长春新碱、秋水仙碱等。\n'A substance that can be stored in nerve end vesicles in place of neurotransmitters and released by nerve impulses.'可被翻译为：能代替神经递质贮存于神经末梢囊泡中，并为神经冲动所释放的物质。\n\n根据上述已知信息，请将'Drugs that can selectively act on the cerebral cortex and have the effect of activating, protecting and restoring the function of nerve cells. Such as piracetam and vincristine.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"能选择性地作用于大脑皮质，对神经细胞具有激活、保护和恢复功能效应的药物。如吡拉西坦和长春胺等。"
    },
    {
        "instruction":"已知信息：\n'Article 48 In accordance with degree of risks of the products and enterprise, the drug regulatory department shall make graded management of the registrant, filing entity or contract manufacturer of medical devices as well as dynamic adjustment.'可被翻译为：第四十八条  药品监督管理部门依据产品和企业的风险程度，对医疗器械注册人、备案人、受托生产企业实行分级管理并动态调整。\n'Article 4 Medical device distribution is subject to classified management in accordance with their degree of risks.'可被翻译为：第四条  按照医疗器械风险程度，医疗器械经营实施分类管理。\n'Article 4 Medical device manufacturing is subject to classified management in accordance with their degree of risks.'可被翻译为：第四条  根据医疗器械风险程度，医疗器械生产实施分类管理。\n'Article 30 The medical device distributors shall establish and implement product traceability system, to guarantee traceability of the products.'可被翻译为：第三十条  医疗器械经营企业应当建立并实施产品追溯制度，保证产品可追溯。\n\n根据上述已知信息，请将'Article 47 The drug regulatory departments shall implement classified and graded management and make dynamic adjustment in accordance with quality management of the medical device distributors and degree of risk of the distributed medical device products.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十七条  药品监督管理部门根据医疗器械经营企业质量管理和所经营医疗器械产品的风险程度，实施分类分级管理并动态调整。"
    },
    {
        "instruction":"已知信息：\n'Glossary'可被翻译为：术语表\n'3. Glossary'可被翻译为：术语\n'15. Glossary\/Definitions'可被翻译为：术语\/定义\n'Also known as \"dibenzo-y-voman\". Colorless flake crystal, melting point 99.5 ~ 100.5K, boiling point 310 ~ 312 7. Insoluble in water, soluble in ethyl wine, chloroform, benzene and petroleum wine, soluble in concentrated sulfuric acid, yellow solution, and display yellow-green fluorescence. Many of its derivatives are strong fluorescent agents.'可被翻译为：又称\"二苯并-Y-吐喃\"。无色片状晶体，熔点99.5〜100.5K,沸点310〜312七。不溶于水，溶于乙醴、氯仿、苯和石油醴，溶于浓硫酸为黄色溶液，并显示黄绿色荧光。其许多衍生物为强荧光剂。\n\n根据上述已知信息，请将'Article 312: Glossary:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三百一十二条 本规范下列术语（按汉语拼音排序）的含义是："
    },
    {
        "instruction":"已知信息：\n'Where the drug regulatory departments have objection to the re-evaluation conclusions by MAHs, which shall, in accordance with the requirements by drug regulatory departments, re-confirm the re-evaluation conclusions and carry out re-evaluation.'可被翻译为：药品监督管理部门对持有人开展的再评价结论有异议的，持有人应当按照药品监督管理部门的要求重新确认再评价结果或者重新开展再评价。\n'Article 58 In case of voluntarily carrying out medical device re-evaluation, MAHs shall develop re-evaluation plan. Where control measures are required through re-evaluation, MAHs shall submit the re-evaluation report within 15 days upon the formation of re-evaluation conclusion. For medical devices approved by the NMPA to be registered or filed shall submit the report to national monitoring agencies; MAHs of other medical devices shall submit the report to the provincial monitoring agencies where MAHs locate.'可被翻译为：第五十八条  持有人主动开展医疗器械再评价的，应当制定再评价工作方案。通过再评价确定需要采取控制措施的，应当在再评价结论形成后15日内，提交再评价报告。其中，国家药品监督管理局批准注册或者备案的医疗器械，持有人应当向国家监测机构提交；其他医疗器械的持有人应当向所在地省级监测机构提交。\n'Review and re-check results shall be fed back to MAHs. In case of any objection to the evaluation results of MAHs, MAHs may be required to carry out re-evaluation again.'可被翻译为：审核和复核结果应当反馈持有人。对持有人的评价结果存在异议的，可以要求持有人重新开展评价。\n'Article 59 Where drug regulatory departments at provincial level or above order to carry out re-evaluation, MAHs shall submit the re-evaluation plan and re-evaluation report to the corresponding drug regulatory departments and monitoring agencies before implementation of re-evaluation and within 30 days upon the completion of re-evaluation.'可被翻译为：第五十九条  省级以上药品监督管理部门责令开展再评价的，持有人应当在再评价实施前和再评价结束后30日内向相应药品监督管理部门及监测机构提交再评价方案和再评价报告。\n\n根据上述已知信息，请将'Article 55 In case of any of following situations, MAHs shall voluntarily carry out re-evaluation and take corresponding measures based on re-evaluation conclusions:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十五条  有下列情形之一的，持有人应当主动开展再评价，并依据再评价结论，采取相应措施："
    },
    {
        "instruction":"已知信息：\n'Article 5    The wording in drug insert sheets and labels shall be scientific, standardized and accurate. The insert sheet of a non-prescription drug shall be written intelligibly and convenient for patients to judge, choose and use the drug on their own.'可被翻译为：第五条 药品说明书和标签的文字表述应当科学、规范、准确。非处方药说明书还应当使用容易理解的文字表述，以便患者自行判断、选择和使用。\n'Section 3  Drug Name, Insert Sheet and Label'可被翻译为：第三节 药品名称、说明书和标签\n'Article 13    After the modification to the insert sheet is approved, the drug manufacturer shall inform relevant drug distributors, drug users and other departments of the modified content immediately, and use the modified insert sheet and label timely as required.'可被翻译为：第十三条 药品说明书获准修改后，药品生产企业应当将修改的内容立即通知相关药品经营企业、使用单位及其他部门，并按要求及时使用修改后的说明书和标签。\n'Article 108 For the registration application of a non-prescription drug, the insert sheet and package label shall comply with the relevant regulations on non-prescription drugs.'可被翻译为：第一百零八条 非处方药的注册申请，其药品说明书和包装标签应当符合非处方药的有关规定。\n\n根据上述已知信息，请将'The applicant shall be responsible for making the drug insert sheet and label scientific, standard and accurate.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"申请人应当对药品说明书和标签的科学性、规范性与准确性负责。"
    },
    {
        "instruction":"已知信息：\n'Article 28 If a medical device manufacturer violates laws, regulations and rules and causes defects in the marketed medical devices, administrative penalties shall be imposed according to law. For the manufacturer who has taken recall measures to initiatively eliminate or reduce the harmful consequences, the food and drug regulatory department shall impose a lighter or mitigated penalty according to the Law of the People's Republic of China on Administrative Penalty; for the manufacturer who has committed minor violations and made prompt corrections but has not caused any serious consequences, the punishment shall be exempted.'可被翻译为：第二十八条 医疗器械生产企业因违反法律、法规、规章规定造成上市医疗器械存在缺陷，依法应当给予行政处罚，但该企业已经采取召回措施主动消除或者减轻危害后果的，食品药品监督管理部门依照《中华人民共和国行政处罚法》的规定给予从轻或者减轻处罚；违法行为轻微并及时纠正，没有造成危害后果的，不予处罚。\n'Severe and well-placed punishment for serious violations of the law'可被翻译为：严惩重处违法 落实处罚到人\n'Article 29 According to law, the drug regulatory department shall impose administrative punishment\/sanctions on drug manufacturers that are confirmed to have caused safety hazards in drugs on the market by violating relevant laws, rules and regulations. The manufacturers who have taken active recall measures to eliminate or mitigate harmful consequences shall receive lenient or mitigated punishment; the manufacturers who have committed minor violations and made prompt corrections but have not caused any serious consequences shall be exempted from punishment.'可被翻译为：第二十九条 药品监督管理部门确认药品生产企业因违反法律、法规、规章规定造成上市药品存在安全隐患，依法应当给予行政处罚，但该企业已经采取召回措施主动消除或者减轻危害后果的，依照《行政处罚法》的规定从轻或者减轻处罚；违法行为轻微并及时纠正，没有造成危害后果的，不予处罚。\n'Article 26 In case of identifying any medical device adverse event causing or possibly causing severe injuries or death, other units and individuals other than MAHs, distributing enterprises and user facility shall  report to either monitoring agencies or MAHs, distributing enterprises or the medical institutions providing treatment, and provide relevant medical records if necessary.'可被翻译为：第二十六条  除持有人、经营企业、使用单位以外的其他单位和个人发现导致或者可能导致严重伤害或者死亡的医疗器械不良事件的，可以向监测机构报告，也可以向持有人、经营企业或者经治的医疗机构报告，必要时提供相关的病历资料。\n\n根据上述已知信息，请将'Article 75 MAHs, distributing enterprises and user facility report, investigate, evaluate and dispose medical device adverse events in accordance with the requirements of the Provisions to proactively eliminate or reduce serious consequence, they shall impose a lighter or mitigated punishment for the relevant violations in accordance with Law of the People's Republic of China on Administrative Penalties, and impose no punishment for those having mild violations and making timely correction without causing serious consequences but are not exempt from other legal liabilities according to laws.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十五条  持有人、经营企业、使用单位按照本办法要求报告、调查、评价、处置医疗器械不良事件，主动消除或者减轻危害后果的，对其相关违法行为，依照《中华人民共和国行政处罚法》的规定从轻或者减轻处罚。违法行为轻微并及时纠正，没有造成危害后果的，不予处罚，但不免除其依法应当承担的其他法律责任。"
    },
    {
        "instruction":"已知信息：\n'penicillin'可被翻译为：青霉素\n'elimination'可被翻译为：消除\n'A drug with anti-treponema pallidum action. Commonly used drugs are: antibiotics such as penicillin, procaine penicillin, etc. For those allergic to penicillin and procaine, erythromycin, azithromycin, minocycline, etc., can be used.'可被翻译为：具有抗梅毒螺旋体作用的药物。常用的药物有：抗生素类药物，如青霉素、普鲁卡因青霉素等。对青霉素过敏和对普鲁卡因过敏者，可用红霉素、阿奇霉素、米诺环素等。\n'elimination rate constant'可被翻译为：消除速率常数\n\n根据上述已知信息，请将'Penicillin with the elimination of the 6-amide-superacyl group.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"消去6-位酰胺基上酰基的青霉素。"
    },
    {
        "instruction":"已知信息：\n'The unwrapping, assembly and preparation of sterilised equipment, components and ancillary items with\ndirect or indirect product contact should be treated as an aseptic process and performed in grade A with a grade B background. The filling line set-up and filling of the sterile product should be treated as an aseptic process and\nperformed in grade A with a grade B background. Where an isolator is used, the background should be in\naccordance with paragraph 4.20'可被翻译为：与产品直接或间接接触的已灭菌设备、组件和辅助用品的拆包、装配和准备应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。无菌产品的灌装线组装和灌装应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。当使用隔离器时，背景应符合 4.20 节的规定\n'Table 4: Examples of operations and grades for aseptic preparation and processing operations'可被翻译为：表 4：无菌准备和加工的操作及洁净级别示例\n'Note 1: All methods indicated for a specific grade in the table should be used for qualifying the area of that specific grade. If one of the methods tabulated is not used, or alternative methods are used, the approach taken should be appropriately justified.'可被翻译为：注 1：指示表中具体级别的所有方法应用于该级别区域的确认。如果不釆用表格中的某种方法，或使用替代方法，应进行适当论证。\n'Grade A: The critical zone for high-risk operations (e.g. aseptic processing line, filling zone, stopper bowl, open primary packaging or for making aseptic connections under the protection of first air). Normally, such conditions are provided by a localised airflow protection, such as unidirectional airflow workstations within RABS or isolators. The maintenance of unidirectional airflow should be demonstrated and qualified across the whole of the grade A area. Direct intervention (e.g. without the protection of barrier and glove port technology) into the grade\nA area by operators should be minimized by premises, equipment, process and procedural design.'可被翻译为：A 级：进行高风险操作的关键区域（例如，无菌生产线，灌装区，胶塞加料盘，敞口内包装或在初始气流保护下进行无菌连接）。通常情况下，这种条件是通过局部气流保护实现的，例如 RABS 或隔离器内的单向流操作台。应证明并确认整个 A 级区的单向流维护状态。应通过厂房、设备、工艺和程序性设计尽量减少操作人员对 A 级区的直接干预（例如，不使用隔离器和手套箱技术作为保护）。\n\n根据上述已知信息，请将'Note 1: It should be noted that the types of monitoring methods listed in the table above are examples and other methods can be used provided they meet the intent of providing information across the whole of the critical process where product may be contaminated (e.g. aseptic line set-up, aseptic processing, filling and lyophilizer\nloading).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"注 1：应注意，上表中列出的监测方法类型是示例，可以使用其它方法，只要这些方法满足相同目的，即在产品可能被污染是提供整个关键工艺过程的信息（例如无菌生产线组装、无菌工艺、灌装和冻干机上料）。"
    },
    {
        "instruction":"已知信息：\n'The sum total of the complete set of genes contained in an individual or cell.'可被翻译为：个体或细胞所含的全套基因的总和。\n'The sum of all aspects of a system that implements quality policy and ensures that quality objectives are met. (ICH Q10)'可被翻译为：实现质量方针和确保质量目标系统的全方面的总和。（ICH Q10）\n'3) To ensure that all necessary testing is carried out;'可被翻译为：3.确保完成所有必要的检验；\n'Genes that are essential for a cell to function at a minimum level. Such as genes encoding histone proteins, genes encoding ribosomal proteins, mitochondrial protein genes, glycolytic enzymes, etc. Such genes are expressed in all types of cells because the products of these genes are essential for maintaining the basic structure and metabolic function of the cell.'可被翻译为：维持细胞最低限度功能所不可少的基因。如编码组蛋白基因、编码核糖体蛋白基因、线粒体蛋白基因、糖酵解酶的基因等。这类基因在所有类型的细胞中都进行表达，因为这些基因的产物对于维持细胞的基本结构和代谢功能是必不可少的。\n\n根据上述已知信息，请将'The sum of all the genes carried by all the individuals of a population.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一个种群全部个体所带有的全部基因的总和。"
    },
    {
        "instruction":"已知信息：\n'Article 46 Immediate packaging materials and containers shall meet the requirements for medicinal use and the standards for ensuring human health and safety.'可被翻译为：第四十六条 直接接触药品的包装材料和容器，应当符合药用要求，符合保障人体健康、安全的标准。\n'Any materials employed in the packaging of a drug, including immediate packaging materials, container in direct contact with drugs, and printed packaging materials, but excluding any outer packaging materials used for transportation or shipment.'可被翻译为：药品包装所用的材料，包括与药品直接接触的包装材料和容器、印刷包装材料，但不包括发运用的外包装材料。\n'During the review and approval of a drug application, the drug regulatory department under the State Council shall combine the review and approval of relevant chemical drug substances, the review of relevant excipients and immediate packaging materials and containers and the verification of its specification, manufacturing process, labeling and package insert.'可被翻译为：国务院药品监督管理部门在审批药品时，对化学原料药一并审评审批，对相关辅料、直接接触药品的包装材料和容器一并审评，对药品的质量标准、生产工艺、标签和说明书一并核准。\n'1) The samples should be retained for every batch of starting materials and immediate packaging materials used for preparation. It is not necessary to retain some immediate packaging materials (such as infusion bottles) if the finished product has already been retained.'可被翻译为：1.制剂生产用每批原辅料和与药品直接接触的包装材料均应当有留样。与药品直接接触的包装材料（如输液瓶），如成品已有留样，可不必单独留样。\n\n根据上述已知信息，请将'Where the immediate packaging materials and containers are not up to standard, the drug regulatory department shall order a stop to the use of the materials and containers.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对不合格的直接接触药品的包装材料和容器，由药品监督管理部门责令停止使用。"
    },
    {
        "instruction":"已知信息：\n'When the drugs are compatible, chemical reactions occur, and the drugs have different degrees of deterioration or failure, reducing the efficacy or increasing side effects.'可被翻译为：药物配伍时，发生化学反应，而使药物产生不同程度的变质或失效，降低疗效或增加副作用。\n'The internal process of a drug (absorption, distribution, metabolism, elimination) is changed due to the combined application of other drugs or food, resulting in changes in the effective amount of the drug in the body and corresponding changes in the effect, affecting the efficacy or causing toxic side effects.'可被翻译为：药物的体内过程（吸收、分布、代谢、消除）因其他药物或食物联合应用而发生改变，致使体内有效药量发生变化而效应相应变化，影响疗效或引发毒副作用。\n'Validated analytical procedures that can detect the changes with time in the chemical, physical or microbiological properties of the API or FPP, and that are specific so that the content of the API, degradation products, and other components of interest can be accurately measured without interference.'可被翻译为：经过验证的分析程序，可以检测API或FPP的化学、物理或微生物特性随时间的变化，并且是特定的，以便API、降解产物和其他感兴趣的成分的含量可以在不受干扰的情况下准确测量。\n'In the course of medical treatment, according to the efficacy and condition, according to a certain law to increase or reduce the drug dose to achieve effective and safe medical behavior.'可被翻译为：在医疗过程中，根据疗效和病情，按照一定规律增加或减少药物剂量使达到有效和安全的医疗行为。\n\n根据上述已知信息，请将'Physical properties change when drugs are compatible, so that they can not meet the requirements of the preparation, reduce the efficacy or increase side effects.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物配伍时发生的物理性质改变，因而得不到符合要求的制剂、降低疗效或增加副作用。"
    },
    {
        "instruction":"已知信息：\n'(n) This part does not apply to records required to be established or maintained by subpart O of part 1 of this chapter. Records that satisfy the requirements of subpart O of part 1 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第1部分的O部分要求建立或维护的记录。符合本章第1部分的O部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n'(k) This part does not apply to records required to be established or maintained by part 112 of this chapter. Records that satisfy the requirements of part 112 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第112部分要求建立或维护的记录。符合本章第112部分要求的同时 也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n'(i) This part does not apply to records required to be established or maintained by part 117 of this chapter. Records that satisfy the requirements of part 117 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第117部分要求建立或维护的记录。符合本章第117部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n'(j) This part does not apply to records required to be established or maintained by part 507 of this chapter. Records that satisfy the requirements of part 507 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'可被翻译为：本部分不适用于根据本章第507部分要求建立或维护的记录。符合本章第507部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。\n\n根据上述已知信息，请将'(o) This part does not apply to records required to be established or maintained by part 121 of this chapter. Records that satisfy the requirements of part 121 of this chapter, but that also are required under other applicable statutory provisions or regulations, remain subject to this part.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"本部分不适用于根据本章第121部分要求建立或维护的记录。符合本章第121部分要求的同时也是其他适用的法规和条例所要求的记录，仍受本部分的约束。"
    },
    {
        "instruction":"已知信息：\n'In accordance with the \"Regulations on the Trial Implementation of Professional Titles for Health Technical Personnel,\" individuals who have obtained qualifications for pharmaceutical technical positions include Chief Pharmacist, Deputy Chief Pharmacist, Supervising Pharmacist, Pharmacist, and Pharmacy Technician.'可被翻译为：按照《卫生技术人员职务试行条例》规定，取得药学专业技术职务任职资格人员，包括主任药师、\n副主任药师、主管药师、药师和药士。\n'Chapter VII Responsibilities of Clinical Trial Institution and Investigator'可被翻译为：第七章 临床试验机构和研究者职责\n'(1) The trial protocol shall be organized and developed by the sponsor and finalized through discussion among all clinical trial institutions and investigators involved, and the investigator from the clinical trial institution of the leading unit shall be the coordinating investigator;'可被翻译为：（一）试验方案由申办者组织制定并经各临床试验机构以及研究者共同讨论认定，且明确牵头单位临床试验机构的研究者为协调研究者；\n'(1) having quality management agencies or quality management personnel compatible with the distribution scope and scale, and the quality management personnel shall have relevant professional degrees or titles;'可被翻译为：（一）与经营范围和经营规模相适应的质量管理机构或者质量管理人员，质量管理人员应当具有相关专业学历或者职称；\n\n根据上述已知信息，请将'(1) Having the professional technical titles and qualifications of deputy chief physician, associate professor and associate investigator in the clinical trial institution;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）在该临床试验机构中具有副主任医师、副教授、副研究员等副高级以上相关专业技术职称和资质；"
    },
    {
        "instruction":"已知信息：\n'(2) Undertake the drafting, public consultation, technical review of medical device standards and other organizational work in each specialized field and be responsible for the technical contents and quality of the standards;'可被翻译为：（二）承担本专业领域医疗器械标准起草、征求意见、技术审查等组织工作，并对标准的技术内容和质量负责；\n'(4) Be responsible for collecting and sorting documents for medical device standards in each specialized field and establish technical archives;'可被翻译为：（四）负责收集、整理本专业领域的医疗器械标准资料，并建立技术档案；\n'(5) Be responsible for the follow-up assessment of the implementation of medical device standards in each specialized field;'可被翻译为：（五）负责本专业领域医疗器械标准实施情况的跟踪评价;\n'(3) Undertake technical guidance of medical device standards in each specialized field and assist in solving technical problems during the implementation of standards;'可被翻译为：（三）承担本专业领域医疗器械标准的技术指导工作，协助解决标准实施中的技术问题；\n\n根据上述已知信息，请将'(6) Be responsible for the consultation and explanation on technical contents of the medical device standards in each specialized field;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（六）负责本专业领域医疗器械标准技术内容的咨询和解释;"
    },
    {
        "instruction":"已知信息：\n'Under certain conditions, the lowest electrolyte concentration that causes a certain sol to appear polysedimentation.'可被翻译为：在一定条件下引起某种溶胶出现聚沉的最低电解质浓度。\n'A series of symptoms that occur when the body suddenly stops taking a dependent drug after receiving it continuously to a certain extent. Such as painful or even life threatening.'可被翻译为：当机体连续接受外界给予有依赖性药物达到一定程度而突然停药后出现的一系列症状。诸如痛苦，甚至威胁生命。\n'The drug is an ophthalmic preparation with a certain shape and slow release in the conjunctiva capsule with a polymer film-forming material as the carrier.'可被翻译为：药物以高分子成膜材料为载体，制成一定形状，在结膜囊内缓慢释药的眼用制剂。\n'The phenomenon of the formation of new phase precipitation between the drug and the material under certain conditions.'可被翻译为：药物与材料在一定条件下形成新相析出的现象。\n\n根据上述已知信息，请将'A preparation that does not release the drug immediately, but releases the drug suddenly one or more times under certain conditions (such as after a certain time or under a certain pH or certain enzymes in body fluids).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"不立即释放药物，而在某种条件下（如在体液中经过一定时间或一定pH或某些酶作用下）一次或多次突然释放药物的制剂。"
    },
    {
        "instruction":"已知信息：\n'The validation of the receptor sample analytical method should include relevant qualifications of dilution integrity, if applicable, as well as stability assessments with the highest relevant temperature in the receptor solution for the longest relevant duration; the highest relevant temperature may be warmer than the IVRT membrane surface temperature because the temperature of the receptor solution is often higher than the temperature at the surface of the membrane (e.g., the temperature of the receptor solution may be 34°C when the temperature of membrane surface is 32°C, so stability assessments with the IVRT receptor solution may be performed at 34°C for 6 hours; the temperature would be higher for an IVRT with a vaginal gel, for example).'可被翻译为：如适用，接收液中样品分析方法的验证应包括相关的稀释完整性确认，以及样品在最高相关温度的接收液中放置最长相关时间的稳定性评估；最高相关温度可以略高于IVRT膜表面温度，因为接收液的温度通常高于膜表面温度（例如，当膜表面温度为32℃时，接收液温度可能是34℃，因此，IVRT接收液的稳定性评估可以设定为34℃维持6小时；而在阴道凝胶制剂的IVRT研究中，温度会更高）。\n'The operating principles and specific test procedures differ among the various equipment; relevant procedures from the manufacturer may be used for installation, operation, and performance qualifications. The laboratory qualification of each diffusion cell should, at minimum, include: (1) measurements of the diffusional area of the orifices of the donor and receptor compartments between which the membrane is mounte; (2) the empirically measured volume of the receptor solution compartment\/vessel for each diffusion cell; (3) the stability of the temperature measured at the membrane surface (e.g., at 32°C ± 1°C), or just below the membrane, across a relevant duration (e.g., 6 hours); and (4) the rate of stirring or agitation, as applicable.'可被翻译为：每种设备的操作原理和特定测试方法均不相同；可根据生产商提供的相关规程进行安装、操作和性能确认。每个扩散池的实验室确认内容，至少应包括：1）测定供给室和接收室之间膜安装位置的孔口扩散面积；2）测量每个接收室的容积；3）在相关研究期间（如，6小时），测定膜表面或膜下温度（如，32℃±1℃）的稳定性；和4）如适用，测定搅拌速率。\n'Skin surface temperature should be measured using an IR thermometer. The temperature of the heating block must be set higher than the desired membrane temperature (e.g., 33° for a 32° skin surface temperature).'可被翻译为：皮肤表面温度应使用红外温度计测量。加热块的温度必须设置高于所需的膜温度(例如，对于32°的皮肤表面温度设为33°)。\n'The test is conducted at 32 ± 1° for products applied to the skin (measured at the surface of the membrane, when possible, or inferred based upon the temperature of the receptor solution for immersion cells or VDC Model A). The test is conducted at 37 ± 1° for products intended for internal application (e.g., rectal and vaginal products).'可被翻译为：应用于皮肤的产品在32±1°温度下进行测试(如果可能，在膜表面测量，或根据浸没池或VDC模型A的受体溶液的温度推断)。用于内部应用的产品(例如，直肠和阴道产品)在37±1°温度下进行测试。\n\n根据上述已知信息，请将'3. Stability of the temperature measured at the membrane surface (e.g., 32 ± 1°) across a relevant duration (e.g., 6 h for IVRT or 48 h for IVPT)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在相关持续时间内(例如，IVRT为6小时或IVPT为48小时)膜表面测量温度的稳定性(例如，32±1°)"
    },
    {
        "instruction":"已知信息：\n'Article 9 The inspection team shall write registration inspection and Pre-market GMP inspection reports and draw conclusions on registration inspection and Pre-market GMP inspection respectively based on the on-site inspection.'可被翻译为：第九条 检查组依据现场检查情况，分别撰写注册核查、上市前 GMP 检查报告，分别作出注册核查、上市前GMP 检查结论。\n'Article 10 CFDI shall establish a quality management system related to registration inspection, formulate standard operating procedures for registration inspection and the corresponding Key Points and Determination Principles of Drug Registration Inspection, strengthen the construction of the inspector team, establish a registration inspection inspector database, and regulate the related work of registration inspection.'可被翻译为：第十条 核查中心建立注册核查相关质量管理体系，制定注册核查的标准操作程序及相应的《药品注册核查要点与判定原则》,加强检查员队伍建设，建立注册核查检查员库，规范注册核查有关工作。\n'Article 26 Before CFDI implements registration inspection, it shall formulate an inspection protocol in accordance with the Key Points and Determination Principles of Drug Registration Inspection, based on the risk principle, and in combination with the inspection objects and inspection concerns (if any) proposed by CDE. The content of the inspection protocol includes: the basic information of the inspected institution, the type of inspection, the purpose of the inspection, the basis of the inspection, the time of the on-site inspection, the content of the inspection, the members of the inspection team, etc.'可被翻译为：第二十六条 核查中心实施注册核查前，根据《药品注册核查要点与判定原则》,基于风险原则，并结合药品审评中心提出的核查对象和核查关注点(如有),制定核查方案。核查方案内容包括：被核查单位基本情况、核查品种、核查目的、核查依据、现场核查时间、核查内容、核查组成员等。\n'Article 37 CFDI shall review the on-site inspection report based on the principle of determining the inspection result.'可被翻译为：第三十七条 核查中心应当根据核查结果判定原则，对现场核查报告进行审核。\n\n根据上述已知信息，请将'Article 18 CFDI explores the establishment of a caused-related registration inspection model based on information such as the drug product archives and institutional files of the NMPA; explores the application of off-site inspection methods based on the development of information management methods; continues to improve the system of technical guidelines for inspection.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十八条 核查中心基于国家药品监督管理局药品品种档案和机构档案等信息，探索建立基于风险的注册核查模式；基于信息化管理手段的发展，探索应用非现场的核查方式；持续完善核查相关技术指导原则体系。"
    },
    {
        "instruction":"已知信息：\n'A gas that, when packaged for transport, is partially liquid (or solid) at a temperature above –50 °C.'可被翻译为：一种气体，在包装运输时，在-50°C以上的温度下部分为液体(或固体)。\n'Any substance that is completely gaseous at 1.013 bar and +20 °C or has a vapour pressure exceeding 3 bar at +500 °C.'可被翻译为：在1.013 bar和+20°C时完全气态或在+500°C时蒸气压超过3bar的任何物质。\n'3. If the products within one package are 1 (including) to 5 kg, take 1 product for sampling for every 50 kg, and the odd less than 50 kg shall be counted as 50 kg;'可被翻译为：3．药品包装为1－5公斤的（含1公斤），每50公斤抽样1件，不足50公斤者以50公斤计；\n'If the quantity is less than 10, take 1 product for sampling; if the quantity is 11 to 50, take additional 1 product for sampling for every additional 10, and the odd less than 10 shall be counted as 10; if the quantity is 51 to 100, take additional 1 product for sampling for every additional 20, and the odd less than 20 shall be counted as 20; if the quantity is more than 101, take additional 1 product for sampling for every additional 50, and the odd less than 50 shall be counted as 50; if the quantity is more than 1001, take additional 1 product for sampling for every additional 100, and the odd less than 100 shall be counted as 100;'可被翻译为：10件以内，抽样1件；11件－50件，每增加10件加抽1件，不足10件者以10件计；51件－100件，每增加20件加抽1件，不足20件者以20件计；101件以上，每增加50件加抽1件，不足50件者以50件计；1001件以上，每增加100件加抽1件，不足100件者以100件计；\n\n根据上述已知信息，请将'A gas that, when packaged under pressure for transport, is entirely gaseous at –50 °C; this category includes all gases with a critical temperature less than or equal to –50 °C.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种在压力下包装运输时，在-50℃时完全为气态的气体;这一类气体包括临界温度小于或等于-50℃的所有气体。"
    },
    {
        "instruction":"已知信息：\n'Gauze, Purified Cotton, Sutures and Surgical Dressings'可被翻译为：纱布、净化棉布、缝合线和外 科绷带\n'The USP method for analysis of surgical dressing\/cotton\/gauze (in packages) calls for a minimum quantity of 100 mg, to be tested in each medium. It is recommended that an entire unit shall be tested in each medium for individually packaged single-use articles.'可被翻译为：USP 分析手术敷料\/棉花\/纱布（包装内）的方法要求最少 100 mg，在每种培养基中进行 测试。对于单独包装的一次性用品，建议在每种培养基中对整个单元进行测试。\n'Non-active body-contacting devices: liquid transportation devices, blood and other body fluids alternation devices, medical dressing, invasive devices, reusable surgical devices, implantable devices, contraceptive and family planning devices and other non-active body-contacting devices.'可被翻译为：无源接触人体器械：液体输送器械、改变血液体液器械、医用敷料、侵入器械、重复使用手术器械、植入器械、避孕和计划生育器械、其他无源接触人体器械。\n'(III) Statistical analysis according to the management categories of medical devices'可被翻译为：（三）按医疗器械管理类别统计分析\n\n根据上述已知信息，请将'Analysis of Medical Devices (ex. Purified Cotton, Gauze, Sutures and Surgical Dressings)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械的分析（除净化棉、纱布、缝合线和手术敷料外）"
    },
    {
        "instruction":"已知信息：\n'The following topics should be reviewed and evaluated by a microbiologist although some aspects will also be covered by the Consumer Safety Officer during the inspection.'可被翻译为：虽然消费品安全官员亦要检查有些问题，但在检查期间，微生物专家应查看并评价以下问题\n'Pharmaceutical Microbiology Manual'可被翻译为：药物微生物手册\n'Equipment monitoring requirements should be defined in “user requirements specifications” during early stages of development, and confirmed during qualification. Process and equipment alarm events should be acknowledged and evaluated for trends. The frequency at which alarms are assessed should be based on their criticality (with critical alarms reviewed immediately).'可被翻译为：设备监测要求应在开发的早期阶段在“用户需求标准”中进行定义，并在确认过程中予以确认。应确认工艺和设备报警事件，并评估其趋势。评估报警的频率应基于报警的关键程度（关键报警立即审核）。\n'Article 57 During the supervision and inspection, drug MAHs and manufacturers shall provide relevant explanations and the following materials according to the inspection need:'可被翻译为：第五十七条 监督检查时，药品上市许可持有人和药品生产企业应当根据检查需要说明情况、提供有关材料：\n\n根据上述已知信息，请将'The following topics should be reviewed and evaluated during an inspection of a pharmaceutical microbiology laboratory.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在对药物微生物实验室进行检查期间应查看和评估以下方面："
    },
    {
        "instruction":"已知信息：\n'The personnel participating in the unannounced inspection shall sign a statement of having no conflict of interest and a letter of integrity commitments. Where the inspection activities contradict or conflict with the personal interests of the personnel, a withdrawal shall be raised.'可被翻译为：参加检查的人员应当签署无利益冲突声明和廉政承诺书；所从事的检查活动与其个人利益之间可能发生矛盾或者冲突的，应当主动提出回避。\n'The personnel participating in the registration inspection shall sign the declaration of no conflict of interest and the inspector's undertaking; if the registration inspection activities they are engaged in may cause conflicts of interest, they shall take the initiative to withdraw.'可被翻译为：参加注册核查的人员应当签署无利益冲突声明、检查员承诺书；所从事的注册核查活动与其可能发生利益冲突的，应当主动提出回避。\n'human capital approach'可被翻译为：人力资本法\n'audit trail'可被翻译为：审计跟踪\n\n根据上述已知信息，请将'(5) Capital source and possible conflict of interest of the trail;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）试验的资金来源、可能的利益冲突；"
    },
    {
        "instruction":"已知信息：\n'In the conformation, the Angle of torsion (or dihedral Angle) between each of the more connected groups (or atoms) on two adjacent atoms is +90. To +150. The range may be between -150. To -90. Conformation between ranges.'可被翻译为：在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在+90。至+150。范围间或在-150。至-90。范围间的构象。\n'Also known as \"eclipsedconformation\". In the conformation, the Angle of torsion (or dihedral Angle) between the superior groups (or atoms) connected on each of the two adjacent atoms is -30. To +30. Conformation between ranges.'可被翻译为：又称\"重叠构象（eclipsedconformation）\"。在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在-30。至+30。范围间的构象。\n'Also known as the \"gaucheconformation\", in which the torsion Angle (or dihedral Angle) between the superior groups (or atoms) connected on each of the two adjacent atoms is +30. To +90. Between ranges, or at -90. To -30. Conformation between ranges.'可被翻译为：又称\"邻位交叉构象（gaucheconformation）\"在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在+30。至+90。范围间，或在-90。至-30。范围间的构象。\n'In the Newman projection conformation, the Angle between non-bonded groups resulting from rotation of a single bond.'可被翻译为：在纽曼投影构象式中，由于单键旋转而产生的非键合基团之间的夹角。\n\n根据上述已知信息，请将'Also known as \"staggeredconformation\" \\ In the conformation, the torsion Angle (or dihedral Angle) between the two adjacent atoms on each of the better connected groups (or atoms) is +150. To -150. Conformation between ranges.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"对位交叉构象（staggeredconformation）\\在构象式中，两个相邻原子上各连接的较优基团（或原子）之间，扭转角（或二面角）在+150。至-150。范围间的构象。"
    },
    {
        "instruction":"已知信息：\n'Pentose is one of the most important in nature. Found primarily in type D form, it is the carbohydrate component of ribonucleic acid and occurs in many nucleotides and nucleotides and their derivatives.'可被翻译为：自然界中最重要的一种戊糖。主要以D型形式存在，是核糖核酸的糖类组分，并出现在许多核昔和核昔酸以及其衍生物中。\n'The process by which denatured proteins or nucleic acids are reassembled to regain their original spatial structure and properties.'可被翻译为：变性后的蛋白质或核酸重新组装恢复其原来的空间结构和性质的现象。\n'A chiral stationary phase of polymers prepared by coating phase and bonding phase of photoactive amino acids or pipercoic acid as chiral selective factors, which is mainly used for the analysis of amino acids and their derivatives.'可被翻译为：以光活性氨基酸或哌可酸作为手性选择因子的涂渍相和键合相制备的，主要用于氨基酸及其衍生物分析的一种高聚物手性固定相。\n'Drugs to prevent and treat viral infections. Various types of antiviral drugs have different mechanisms of action and applications. The main drugs against herpes virus infection are acyclovir and its analogues; The anti-influenza virus infection mainly includes oselivir and its analogues; Antiretrovirals are mainly used to treat HIV\/AIDS infection.'可被翻译为：预防和治疗病毒感染的药物。各类抗病毒药具有不同的作用机制和应用。抗疱疹病毒感染的药主要有阿昔洛韦及其类似物；抗流感病毒感染的主要有奥司米韦及类似物；抗逆转录病毒药则主要用于治疗人免疫缺陷病毒\/艾滋病感染。\n\n根据上述已知信息，请将'Nucleic acids, nucleotides, nucleotides, or bases having medicinal properties. Including its analogues, derivatives, or polymers of such analogues or derivatives.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具有药用价值的核酸、核昔酸、核昔或者碱基的统称。包括其类似物、衍生物或这些类似物、衍生物的聚合物。"
    },
    {
        "instruction":"已知信息：\n'(III) Medical device adverse event monitoring information requiring regularly release;'可被翻译为：（三）需要定期发布的医疗器械不良事件监测信息；\n'III. Statistical analysis of national medical device adverse event reports (omitted)'可被翻译为：三、全国医疗器械不良事件报告统计分析（省略）\n'(I)  Information on group adverse event of medical device;'可被翻译为：（一）群体医疗器械不良事件相关信息；\n'In 2020, medical device adverse event reports received by the National Medical Device Adverse Event Monitoring Information System involved all categories in the Medical Device ClassificationCatalogue.'可被翻译为：2020年，国家医疗器械不良事件监测信息系统收到的医疗器械不良事件报告涉及了医疗器械分类目录中的所有类别。\n\n根据上述已知信息，请将'IV. Release of medical device adverse event information notification (omitted)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"四、医疗器械不良事件信息通报发布情况（省略）"
    },
    {
        "instruction":"已知信息：\n'This Announcement is applicable to the matters concerning the production of Class II and Class III medical devices with imported medical device registration certificates in China by the imported medical device registrants through their foreign invested enterprises established in China.'可被翻译为：进口医疗器械注册人通过其在境内设立的外商投资企业在境内生产第二类、第三类已获进口医疗器械注册证产品的有关事项，适用本公告。\n'The production of Class II and Class III medical devices with imported medical device registration certificates in China by overseas registrants invested by domestic enterprises in China can be implemented with reference to this Announcement. The domestic enterprises in China that invest the overseas registrants should apply for product registration as the registration applicants.'可被翻译为：中国境内企业投资的境外注册人在境内生产已获进口医疗器械注册证的第二类、第三类医疗器械产品的，参照本公告执行，由投资境外注册人的中国境内企业作为注册申请人申请该产品注册。\n'NMPA issued the Announcement on Adjusting the Relevant Matters Concerning the Definition of the Attributes of Drug\/Device Combination Products'可被翻译为：关于调整药械组合产品属性界定有关事项的通告【废止】\n'NMPA Announcement on Implementing Relevant Matters of the Regulations for the Supervision and Administration of Medical Devices'可被翻译为：国家药监局关于贯彻实施《医疗器械监督管理条例》有关事项的公告\n\n根据上述已知信息，请将'NMPA issued the Announcement on Matters Concerning the Production of Imported Medical Devices in Domestic Enterprises in China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于进口医疗器械产品在中国境内企业生产有关事项的公告"
    },
    {
        "instruction":"已知信息：\n'For generic drugs or other products, drug registration inspection of the manufacturing site and\/or  pre-marketing GMP inspection shall be carried out based on risks, taking into consideration the circumstances such as whether Drug Manufacturing Certificate covering the corresponding manufacturing scope has been obtained and product of the same dosage form has been marketed,.'可被翻译为：对于仿制药等，根据是否已获得相应生产范围药品生产许可证且已有同剂型品种上市等情况，基于风险进行药品注册生产现场核查、上市前药品生产质量管理规范检查。\n'(1) For varieties having not passing GMP compliance inspection for manufacturing conditions of the products, pre-marketing GMP compliance inspection shall be carried out. Where drug registration on-site inspection is needed for the drug to be manufactured, the NMPA Center for Drug Evaluation shall notify the CFDI and inform the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the manufacturing site is located and the applicant; and the CFDI shall coordinate the drug regulatory department of the province, autonomous region or municipality directly under the Central Government to concurrently carry out drug registration on-site inspection and pre-marketing GMP compliance inspection.'可被翻译为：（一）未通过与生产该药品的生产条件相适应的药品生产质量管理规范符合性检查的品种，应当进行上市前的药品生产质量管理规范符合性检查。其中，拟生产药品需要进行药品注册现场核查的，国家药品监督管理局药品审评中心通知核查中心，告知相关省、自治区、直辖市药品监督管理部门和申请人。核查中心协调相关省、自治区、直辖市药品监督管理部门，同步开展药品注册现场核查和上市前的药品生产质量管理规范符合性检查；\n'Registration of chemical drugs is classified into such categories as innovative chemical drugs, modified new chemical drugs, generic drugs, etc.'可被翻译为：化学药注册按照化学药创新药、化学药改良型新药、仿制药等进行分类。\n'Registration of biological products is classified into categories such as innovative biological products, modified new biological products, biological products already marketed (including biosimilar products), etc.'可被翻译为：生物制品注册按照生物制品创新药、生物制品改良型新药、已上市生物制品（含生物类似药）等进行分类。\n\n根据上述已知信息，请将'Drug registration inspection of the manufacturing site and pre-marketing GMP inspection shall be carried out for innovative drugs, modified new drugs and biological products, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于创新药、改良型新药以及生物制品等，应当进行药品注册生产现场核查和上市前药品生产质量管理规范检查。"
    },
    {
        "instruction":"已知信息：\n'(3) If the application dossiers are not complete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application dossiers;'可被翻译为：（三）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容，逾期不告知的，自收到申请资料之日起即为受理；\n'(3) If the application dossiers are not complete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected one-off on site or within 5 working days. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application dossiers;'可被翻译为：（三）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容。逾期不告知的，自收到申请资料之日起即为受理；\n'(3) Where the application dossiers are incomplete or do not conform to the prescribed form, a notice of supplement shall be issued to notify the applicant of all the contents that need to be supplemented and corrected at one time. If no notice is made within the time limit, the application shall be deemed as accepted since the date of receipt; and'可被翻译为：（三）申请资料不齐全或者不符合规定形式的，出具补正通知书，一次告知申请人需要补正的全部内容，逾期未告知的，自收到申请资料之日起即为受理；\n'If the application dossiers are incomplete or nonconforming to the prescribed form, the lot release institution shall inform the lot release applicant of all contents to be supplemented and corrected and the time limit for supplementation in writing all at once within 5 days. Where the lot release institution fails to notify the applicant within the time limit, it shall be regarded as acceptance as of the date of receipt of application dossiers and samples.'可被翻译为：申请资料不齐全或者不符合规定形式的，批签发机构应当在5日内一次性书面告知批签发申请人需要补正的全部内容及资料补正时限。逾期不告知的，自收到申请资料和样品之日起即为受理。\n\n根据上述已知信息，请将'(4) If the application documents are incomplete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application documents;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容以及提交补正资料的时限。逾期不告知的，自收到申请资料之日起即为受理；"
    },
    {
        "instruction":"已知信息：\n'Article 36 The inspection team shall submit the on-site inspection report, on-site inspection question sheet and related dossiers to CFDI within the prescribed time limit as required.'可被翻译为：第三十六条 核查组应当按照要求在规定时限内，将现场核查报告、现场核查问题表及相关材料报送核查中心。\n'Article 26 After receiving the recommendations for on-site inspection, the CFDI shall conduct on-site inspection within 20 days.'可被翻译为：第二十六条 核查中心接到现场检查建议后，应当在20日内进行现场检查。\n'Article 35 Before the end of the on-site inspection, the inspection team shall preside over the close meeting, feedback the on-site inspection situation to the inspected institution and\/or applicant, and report the problems found in the on-site inspection.'可被翻译为：第三十五条 现场核查结束前，核查组应当主持召开末次会议，向被核查单位和(或)申请人反馈现场核查情况，通报现场核查发现的问题。\n'Article 49 CFDI shall, within 40 days from the end of the on-site inspection, and within 20 days from the end of the on-site inspection for those included in the priority evaluation and approval procedures, complete the review of the inspection report, make the review conclusion, and report the registration inspection and inspection results to CDE.'可被翻译为：第四十九条 核查中心在现场核查结束之日起40日内、纳入优先审评审批程序的在现场核查结束之日起20日内，完成核查报告审核，作出审核结论，并将注册核查情况和核查结果反馈药品审评中心。\n\n根据上述已知信息，请将'Article 48 The inspection team shall submit the on-site inspection report and related dossiers to CFDI within 5 days after the completion of the on-site inspection.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十八条 核查组应当在现场核查结束之日起5日内，将现场核查报告及相关资料报送核查中心。"
    },
    {
        "instruction":"已知信息：\n'Action to eliminate the cause of a potential non-conformity or other undesirable potential situation. NOTE: Preventive action is taken to prevent occurrence whereas corrective action is taken to prevent recurrence. (ISO 9000:2005)'可被翻译为：为消除潜在的违规或其他潜在的非期望状况的原因(所采取)的措施。注:采取预防措施是为了防止(事情)发生，而采取纠正措施是为了防止(事情)再次发生。(ISO 9000:2005)\n'Action to eliminate the cause of a detected non-conformity or other undesirable situation. NOTE: Corrective action is taken to prevent recurrence whereas preventive action is taken to prevent occurrence. (ISO 9000:2005)'可被翻译为：为消除已发现的违规或其他非期望状况的原因(所采取)的措施。注:采取纠正措施是为了防止(事情)再次发生，而采取预防措施是为了防止(事情)发生。 (ISO 9000:2005)\n'preventive action'可被翻译为：预防措施\n'corrective action'可被翻译为：纠正措施\n\n根据上述已知信息，请将'Corrective Action and Preventive Action – System that focuses on investigating, understanding, and correcting discrepancies while attempting to prevent their occurrence'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"纠正措施和预防措施用于调查、理解和纠正偏差并预防其再次发生的系统。"
    },
    {
        "instruction":"已知信息：\n'A limit above (>) which an impurity should be qualified.'可被翻译为：为一限度，高于此限度的降解产物需界定其安全性。\n'A limit above (>) which an impurity should be reported. Reporting threshold is the same as reporting level in Q2B.'可被翻译为：为一限度，高于此限度的杂质需报告其含量。即 Q2B 中的“报告水平”（reporting level）\n'An impurity for which a structural characterisation has been achieved.'可被翻译为：已确证了其结构特征的杂质。\n'The legal conditions under which pharmaceutical activities should be organized (see also legislation above)'可被翻译为：组织药品活动的法律条件(另见上文立法)\n\n根据上述已知信息，请将'A limit above (>) which an impurity should be identified.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为一限度，高于此限度的杂质需鉴定其结构。"
    },
    {
        "instruction":"已知信息：\n'Organic compounds containing two or more polyvalent atoms, because the free rotation of single bonds causes other atoms or groups in the molecule to be arranged differently in space, this stereoscopic image of the molecule is called conformation.'可被翻译为：含有两个或两个以上多价原子的有机化合物，由于单键自由旋转导致分子中其他原子或基团在空间排列不同，分子的这种立体形象称为构象。\n'The arrangement of all the atoms in a compound molecule in space.'可被翻译为：化合物分子中所有原子在空间的排布方式。\n'The process by which the number of carbon atoms in the molecule of an organic compound is reduced, the molecular weight is reduced, or the macromolecule of a polymer compound is broken down into smaller molecules.'可被翻译为：有机化合物分子中的碳原子数目减少，分子量降低，或高分子化合物的大分子分解成较小的分子的过程。\n'A compound in which one or more atoms or chemical groups in a molecule are replaced by an easily identifiable atom (tracer atom) or group.'可被翻译为：化合物分子中的一个或多个原子或化学基团，被易辨认的原子（示踪原子）或基团所取代而得到的化合物。\n\n根据上述已知信息，请将'A compound containing asymmetric atoms in a molecule, but which is not optically active because of the symmetry factor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在分子内虽然含有不对称原子，但因具有对称因素而使其不具有旋光性的化合物。"
    },
    {
        "instruction":"已知信息：\n'Remove any residue or debris that would detrimentally impact the effectiveness of the disinfecting agent used.'可被翻译为：去除对使用的消毒剂的有效性产生不利影响的所有残留物或碎片。\n'material of construction of contact surfaces;'可被翻译为：接触面结构材料；\n'A process designed to remove or inactivate pyrogenic material (such as endotoxin) to a specified minimum quantity.'可被翻译为：去除或灭活致热物质(如内毒素)至规定最小量的过程。\n'Depyrogenation - A process designed to remove or inactivate pyrogenic material (e.g. endotoxin) to a specified\nminimum quantity.'可被翻译为：除热原： 旨在将致热物质（例如内毒素）去除或灭活至规定最小量的过程。\n\n根据上述已知信息，请将'1.The ability of a cleaning procedure to effectively remove material, cleaning agent residue and microbial contamination.\n2.The factors that impact the ability to remove a residue from surfaces, including material of construction, the solubility of the material in different agents and the matrix of the material being cleaned.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.清洗程序有效去除物料、清洗剂残留和微生物污染的能力。\n2.影响清除表面残留物能力的因素，包括建筑材料、材料在不同介质中的溶解度和被清洁材料的基质。"
    },
    {
        "instruction":"已知信息：\n'Bioburden samples should be taken from the bulk product and immediately prior to the final sterile filtration. In case where a redundant filtration set-up is used, it should be taken prior to the first filter. Systems for taking samples should be designed so as not to introduce contamination.'可被翻译为：生物负载样品应取自待包装产品，并在最终除菌过滤前即时取样。如果配备了冗余过滤装置，应在第一个过滤器之前进行取样。取样系统的设计不得引入污染。\n'Article 121: Packaging materials should be issued for use only by designated personnel according to operation procedures. Measures should be taken to prevent mixups and errors to ensure the correct use of packaging materials for drug production.'可被翻译为：第一百二十一条 包装材料应当由专人按照操作规程发放，并采取措施避免混淆和差错，确保用于药品生产的包装材料正确无误。\n'1) There should be reference samples for each batch. Where a batch is packaged into several distinct packaging operations, at least one reference sample should be taken from each individual packaging operation.'可被翻译为：1.每批药品均应当有留样；如果一批药品分成数次进行包装，则每次包装至少应当保留一件最小市售包装的成品。\n'For products which have been lyophilized, samples taken from different lyophilization loads.'可被翻译为：对于已冻干的产品，从不同的冻干负载取样。\n\n根据上述已知信息，请将'Samples taken away from the packaging line should not be returned to prevent the products from mixups or contamination.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"样品从包装生产线取走后不应当再返还，以防止产品混淆或污染。"
    },
    {
        "instruction":"已知信息：\n'(II) Any suspected falsified drug shall be in a timely manner reported to the food and drug regulatory department;'可被翻译为：（二）怀疑为假药的，及时报告食品药品监督管理部门；\n'Article 109 Where a drug regulatory department fails to discover systemic risks of drug safety in a timely manner or fails to eliminate drug safety hazards within their supervision and administration region in a timely manner, the people's government at the same level or the drug regulatory department of the people's government at a higher level shall schedule a warning meeting with the person-in-charge of the drug regulatory department.'可被翻译为：第一百零九条 药品监督管理部门未及时发现药品安全系统性风险，未及时消除监督管理区域内药品安全隐患的，本级人民政府或者上级人民政府药品监督管理部门应当对其主要负责人进行约谈。\n'Article 116 Enterprises shall in a timely manner record the information including complaints and results of handling in the file for the purpose of inquiry and tracing.'可被翻译为：第一百一十六条 企业应当及时将投诉及处理结果等信息记入档案，以便查询和跟踪。\n'Article 43 Enterprises shall have business premises and warehouses adapted to their drug distribution scale and scope.'可被翻译为：第四十三条 企业应当具有与其药品经营范围、经营规模相适应的经营场所和库房。\n\n根据上述已知信息，请将'Article 174 Enterprises shall publish the supervisory telephone number of food and drug regulatory department in their business premises, set up customer's book, and in a timely manner handle customer complaints of drug quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百七十四条 企业应当在营业场所公布食品药品监督管理部门的监督电话，设置顾客意见簿，及时处理顾客对药品质量的投诉。"
    },
    {
        "instruction":"已知信息：\n'Heating and cooling and hydraulic systems'可被翻译为：加热、冷却和液压系统\n'Isolators or RABS, which are different technologies, and the associated processes, should be designed to provide protection through separation of the grade A environment from the environment of the surrounding room.\nThe hazards introduced from entry or removal of items during processing should be minimized and supported by high capability transfer technologies or validated systems that robustly prevent contamination and are appropriate\nfor the respective technology.'可被翻译为：隔离器或 RABS（两种不同的技术）及其相关工艺的设计中，应通过将 A 级环境与周围房间环境分隔来提供保护。应尽量减少工艺过程中物品进出所带来的危害，并通过高性能转移技术或经过验证的系统提供支持，其能有效防止污染且适合于各自的技术。\n'The nature and extent of controls applied to utility systems should be commensurate with the risk to product quality associated with the utility. The impact should be determined via a risk assessment and documented as part\nof the CCS.'可被翻译为：公用设施系统所用控制措施的性质和程度应与该公用设施相关的产品质量风险相称。应通过风险评估来确定其影响并进行记录，作为 CCS 的一部分。\n'The  sterilisation  of the  lyophilizer  and  associated  equipment  (e.g.  trays, vial  support rings)  should  be validated and the holding time between the sterilisation cycle and use appropriately challenged during APS (see paragraph 9.33). The lyophilizer should be sterilised regularly, based on system design. Re-sterilisation should be performed  following  maintenance  or  cleaning.   Sterilised   lyophilizers  and  associated  equipment  should  be protected from contamination after sterilisation.'可被翻译为：冻干机和相关设备（例如托盘、西林瓶支撑环）的灭菌应经过验证，应在 APS 期间适当挑战灭菌循环和使 用之间的保持时间（参见第 9.33 节）。冻干机应根据系统设计定期灭菌。在维护或清洁后应进行再灭菌。应保护灭菌后的冻干机和相关设备，防止污染。\n\n根据上述已知信息，请将'Major items of equipment associated with hydraulic, heating and cooling systems should, where possible, be located outside the filling room. There should be appropriate controls to contain any spillage and\/or cross contamination associated with the system fluids.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"液压、加热和冷却系统相关的设备主要部分应尽可能位于灌装室外。应有适当的控制措施来处理与系统液体相关的任何泄漏和\/或交叉污染。"
    },
    {
        "instruction":"已知信息：\n'I. The sponsors shall conduct research in accordance with the ICH guidelines as soon as possible on the basis of the existing technical requirements. The 13 ICH safety guidelines shall be adopted for non-clinical studies starting from May 1, 2020, and the starting dates of non-clinical studies shall be determined in accordance with the relevant provisions of the Good Laboratory Practice.'可被翻译为：一、申请人需在现行技术要求基础上尽早按照ICH指导原则开展研究；自2020年5月1日起开始的非临床研究适用13个ICH非临床指导原则，非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。\n'NMPA Announcement on Adopting ICH Guidelines S5 (R3) and S11'可被翻译为：国家药监局关于适用《S5（R3）》和《S11》国际人用药品注册技术协调会指导原则的公告\n'Article 22 A pre-clinical drug study shall be in conformity with relevant requirements, among which the Good Laboratory Practice for Non-Clinical Laboratory Studies shall be implemented in the study of safety evaluation.'可被翻译为：第二十二条 药物临床前研究应当执行有关管理规定，其中安全性评价研究必须执行《药物非临床研究质量管理规范》。\n'To keep pace with the international technical standards for drug registration, the NMPA has decided to adopt two guidelines of ICH(International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use), including S5 (R3): Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals and S11: Nonclinical Safety Testing in Support of Development of Pediatric Pharmaceuticals (hereinafter referred to as S5 (R3) and S11).'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《S5（R3）:人用药物生殖与发育毒性检测》和《S11:支持儿科药物开发的非临床安全性评价》（以下简称：S5（R3）和S11）国际人用药品注册技术协调会（ICH）指导原则。\n\n根据上述已知信息，请将'Guidelines S5 (R3) and S11 shall be applicable to the non-clinical studies starting upon issuance of this Announcement. The designation of the starting date of nonclinical study shall be in accordance with the relevant provisions specified in the Good Laboratory Practice.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"自本公告发布之日起开始的非临床研究适用S5（R3）和S11指导原则。非临床研究起始日期的认定遵照《药物非临床研究质量管理规范》中相关规定执行。"
    },
    {
        "instruction":"已知信息：\n'(2) Drugs that are urgently needed for public health, whose efficacy has been demonstrated by data in drug clinical trials and whose clinical values can be predicted;'可被翻译为：（二）公共卫生方面急需的药品，药物临床试验已有数据显示疗效并能预测其临床价值的；\n'Article 26 Drugs used for the treatment of severe life-threatening diseases for which there is no effective treatment and drugs urgently needed for public health, where the drug clinical trial data have shown their efficacy and predictable clinical results, may be conditionally approved, and the relevant information should be stated in the drug approval license.'可被翻译为：第二十六条 对治疗严重危及生命且尚无有效治疗手段的疾病以及公共卫生方面急需的药品，药物临床试验已有数据显示疗效并能预测其临床价值的，可以附条件批准，并在药品注册证书中载明相关事项。\n'Article 59 During clinical trials, for innovative drugs or modified new drugs used for the prevention and treatment of serious life-threatening diseases or diseases that seriously affect the quality of life but no effective means of prevention and treatment is available, or significantly clinically superior over current treatments with sufficient evidence is demonstrated, the applicant may apply for the breakthrough therapy drug procedure.'可被翻译为：第五十九条 药物临床试验期间，用于防治严重危及生命或者严重影响生存质量的疾病，且尚无有效防治手段或者与现有治疗手段相比有足够证据表明具有明显临床优势的创新药或者改良型新药等，申请人可以申请适用突破性治疗药物程序。\n'Article 23 For drugs that are undergoing clinical trials which are to be used for the treatment of severe life-threatening diseases for which there is no effective treatment, where it is concluded from medical observation that such drugs are beneficial and comply with ethical principles, the drugs may, after review and obtaining informed consent, be used on other patients with the same condition within the clinical trial institutions that are conducting the trial.'可被翻译为：第二十三条 对正在开展临床试验的用于治疗严重危及生命且尚无有效治疗手段的疾病的药物，经医学观察可能获益，并且符合伦理原则的，经审查、知情同意后可以在开展临床试验的机构内用于其他病情相同的患者。\n\n根据上述已知信息，请将'(1) Drugs used for treating serious life-threatening diseases for which no effective treatment is available, whose efficacy has been verified by data in drug clinical trials and whose clinical values can be predicted;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）治疗严重危及生命且尚无有效治疗手段的疾病的药品，药物临床试验已有数据证实疗效并能预测其临床价值的；"
    },
    {
        "instruction":"已知信息：\n'Article 51 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue a acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug registration application if requirements are not met.'可被翻译为：第五十一条 省、自治区、直辖市药品监督管理部门应当对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。\n'Article 57 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue an acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug registration application if requirements are not met.'可被翻译为：第五十七条 省、自治区、直辖市药品监督管理部门应当对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。\n'Article 123 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall review the application dossiers, and issue a acceptance notice of drug re-registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug re-registration application if requirements are not met.'可被翻译为：第一百二十三条 省、自治区、直辖市药品监督管理部门对申报资料进行审查，符合要求的，出具药品再注册申请受理通知书；不符合要求的，出具药品再注册申请不予受理通知书，并说明理由。\n'Article 111 The applicant shall fill in Supplementary Drug Application Form and submit relevant dossier and explanation to the drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the applicant is located. Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue an acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, with reasons, of drug registration application if requirements are not met.'可被翻译为：第一百一十一条 申请人应当填写《药品补充申请表》，向所在地省、自治区、直辖市药品监督管理部门报送有关资料和说明。省、自治区、直辖市药品监督管理部门对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。\n\n根据上述已知信息，请将'Article 76 Drug regulatory departments of provinces, autonomous regions, or municipalities directly under the Central Government shall conduct the preliminary review of the application dossiers, and issue an acceptance notice of drug registration application if requirements are met, or issue a non-acceptance notice, in which reasons shall be given, of drug registration application if requirements are not met.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十六条 省、自治区、直辖市药品监督管理部门对申报资料进行形式审查，符合要求的，出具药品注册申请受理通知书；不符合要求的，出具药品注册申请不予受理通知书，并说明理由。"
    },
    {
        "instruction":"已知信息：\n'A culture method in which the cells and culture medium of microorganisms or animals and plants are loaded into the reactor at one time for culture, the cells are continuously increased, the product liquid is continuously formed, and after a period of reaction, the whole reaction system is taken out.'可被翻译为：将微生物或动植物的细胞和培养液一次性装入反应器中,进行培养，细胞不断增加，产物液不断形成,经过一段时间反应后,将整个反应体系取出的培养方法。\n'In the culture process, the culture medium is continuously added to the fermenter, while the same flow rate from the fermenter flowing out of the culture liquid fermentation mode.'可被翻译为：在培养过程中，连续地向发酵罐中加入培养基，同时以相同的流量从发酵罐中流出培养液的发酵方式。\n'batch culture'可被翻译为：分批培养\n'The period in which the bacteria are inoculated into the fermentation medium and begin to grow and reproduce under suitable culture conditions.'可被翻译为：产生菌接种至发酵培养基后，在合适的培养条件下，开始生长和繁殖的时期。\n\n根据上述已知信息，请将'Corresponding to batch culture. When the microorganisms were cultured in batch culture to the late exponential stage (logarithmic stage), on the one hand, they continuously flowed into the fresh medium at a certain speed; On the other hand, the culture after mixing is continuously flowed out of the incubator by overflow mode, so that it can continue to grow and produce metabolites for a long time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"与分批培养相对应。当微生物以分批式培养方式培养到指数期（对数期）的后期时，一方面以一定速度连续流进新鲜培养基；另一方面经搅拌均匀后的培养物又经溢流方式不断流出培养器，从而使其能长时期进行连续生长和产生代谢产物的培养技术。"
    },
    {
        "instruction":"已知信息：\n'A continuous or discontinuous density gradient is formed with a certain medium in the centrifugal tube, and the cell suspension or homogenate is placed on the top of the medium, and the cells are stratified and separated by the action of gravity or centrifugal force field. This kind of separation can be divided into two kinds: rate zone centrifugation and equal density centrifugation. The commonly used media are chloride, sucrose and polysucrose.'可被翻译为：用一定的介质在离心管内形成一连续或不连续的密度梯度，将细胞混悬液或匀浆置于介质的顶部，通过重力或离心力场的作用使细胞分层、分离的方法。这类分离又可分为速率区带离心和等密度离心两种。常用的介质为氯化铭、蔗糖和多聚蔗糖。\n'A technical method for instrumental analysis. In the process of analysis, the sample solution is directly injected into the reagent carrier of the pipeline in the form of \"sample plug\", the sample liquid plug is driven forward by the carrier, relying on convection and diffusion to form a sample liquid belt with concentration gradient, and there are reagents in the interceptor reaction, brought into the monitor for continuous detection and processing.'可被翻译为：仪器分析的一种技术方法。在分析过程中，把试样溶液直接以“试样塞”的形式注入到管道的试剂载流中，试样液塞被载流推动前进，依靠对流和扩散形成一个具有浓度梯度的试样液带，并且在截流中有试剂进行反应，带入监测器而进行连续检测处理。\n'A method of targeting resistant mutants by using AGAR medium with gradient distribution of drug concentration from one side of the petri dish to the other.'可被翻译为：利用培养皿的一侧至另一侧铺有药物浓度呈梯度分布的琼脂培养基，以定向筛选相应抗药性突变体的方法。\n'A device for determining the viscosity of a test solution by the falling velocity of a ball of a certain relative density in a vertical tube containing the solution'可被翻译为：以一定相对密度的圆球在含有试验溶液的垂直管内的落下速度测定该溶液黏度的装置\n\n根据上述已知信息，请将'The centrifuged sample is placed in a medium with a gradient distribution for horizontal or vertical centrifugation. Commonly used media are sucrose and chlorination, the former need to be prepared in advance in the centrifuge tube continuous or discontinuous gradient, the latter is prepared into a certain concentration of solution, in the centrifuge process will form a continuous gradient.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"被离心样品置于成梯度分布的介质中进行水平或垂直离心。常用的介质有蔗糖及氯化铭，前者需事先在离心管中配制好连续或不连续梯度，后者配成一定浓度溶液，在离心过程中会形成连续梯度。"
    },
    {
        "instruction":"已知信息：\n'Article 77 The filing certificate for class I medical device shall be arranged in the following form:'可被翻译为：第七十七条 第一类医疗器械备案凭证编号的编排方式为：\n'Article 67 Filing for a class I in-vitro diagnostic reagent shall be conducted prior to production.'可被翻译为：第六十七条 第一类体外诊断试剂生产前，应当办理产品备案。\n'Article 30 For filing of a class I in-vitro diagnostic reagent, clinical trial is not required. For application for registration of a class II or class III in-vitro diagnostic reagent, clinical trial shall be conducted; however,'可被翻译为：第三十条 办理第一类体外诊断试剂备案，不需进行临床试验。申请第二类、第三类体外诊断试剂注册，应当进行临床试验。\n'For the filing of class I in-vitro diagnostic reagent, the filing entity may submit the product self-testing report.'可被翻译为：办理第一类体外诊断试剂备案的，备案人可以提交产品自检报告。\n\n根据上述已知信息，请将'Article 86 The filing certificate for class I in-vitro diagnostic reagent shall be arranged in the following form:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十六条 第一类体外诊断试剂备案凭证编号的编排方式为："
    },
    {
        "instruction":"已知信息：\n'Medications to relieve migraine symptoms. There are mainly HT1 receptor agonists such as Sumatriptan and dihydroergosine, among others.'可被翻译为：缓解偏头痛症状的药物。主要有HT1受体激动剂，如舒马曲坦和二氢麦角碱等。\n'A drug that excites the central nervous system function and improves brain activity function. According to the site of action can be divided into excitatory cerebral cortex drugs, such as xanthine derivatives, such as caffeine, theophylline; Excitatory medullary respiratory center drugs, such as nicoxal rice; Drugs that excite the spinal cord, such as strychnine; And intelligence-boosting drugs that promote brain cell metabolism and improve brain function, such as piracetam.'可被翻译为：具有兴奋中枢神经系统功能，提高脑活动功能的药物。按照作用部位可分为兴奋大脑皮质的药物，如黄嘌吟衍生物，如咖啡因、茶碱等；兴奋延髓呼吸中枢的药物，如尼可刹米等；兴奋脊髓的药物，如士的宁；促进脑细胞代谢、改善脑功能的智能促进药物如吡拉西坦等。\n'The drugs that can make the pupil shrink and the intraocular pressure drop after the application of local eye drops are mostly paracoleceptive agents. Including M receptor agonists and cholinesterase inhibitors, such as pilocarpine, physostigmine, etc., for glaucoma.'可被翻译为：局部滴眼应用后能使瞳孔缩小、眼压下降的药，多为拟副交感受神经药。包括M受体激动药及胆碱酯酶抑制药，如毛果芸香碱、毒扁豆碱等，用于青光眼。\n'Drugs that inhibit the contraction of uterine smooth muscle are used to prolong pregnancy and prevent premature birth. Such as Ritodrine.'可被翻译为：抑制子宫平滑肌收缩用于延长妊娠和防止早产的药物。如利托君。\n\n根据上述已知信息，请将'Drugs that inhibit bronchospasm, improve lung ventilation, and prevent asthma symptoms. There are: beta-2 receptor agonists, such as salbutamol, etc.; Theophylline, such as theophylline, dihydroxypropylline.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"抑制支气管痉挛，改善肺通气，防治哮喘症状发作的药物。有：β2受体激动剂，如沙丁胺醇等；茶碱类，如茶碱，二羟丙茶碱。"
    },
    {
        "instruction":"已知信息：\n'Article 33 The registrant, filing entity or contract manufacturer of medical devices shall establish record management procedures, to ensure the authenticity, accuracy, integrity and traceability of the records.'可被翻译为：第三十三条  医疗器械注册人、备案人、受托生产企业应当建立记录管理制度，确保记录真实、准确、完整和可追溯。\n'Article 28 The registrant, filing entity or contract manufacturer of medical devices shall carry out training in aspects such as laws, regulations, provisions, standards and quality management, etc. of medical devices, establish training system, formulate training plan, strengthen the assessment and keep proper training records.'可被翻译为：第二十八条  医疗器械注册人、备案人、受托生产企业应当开展医疗器械法律、法规、规章、标准以及质量管理等方面的培训，建立培训制度，制定培训计划，加强考核并做好培训记录。\n'Article 29 The registrant, filing entity or contract manufacturer of medical devices shall, based on the characteristics, technical process and requirements for manufacturing environment of the manufactured products, rationally equip and use of the facilities and equipment, strengthen the management of the facilities and equipment, and maintain their effective operation.'可被翻译为：第二十九条  医疗器械注册人、备案人、受托生产企业应当按照所生产产品的特性、工艺流程以及生产环境要求合理配备、使用设施设备，加强对设施设备的管理，并保持其有效运行。\n'Article 31 The registrant, filing entity or contract manufacturer of medical devices shall enhance purchase management, establish suppliers audit system, and evaluate the suppliers, to ensure that the purchased products and services conform to relevant regulations and requirements.'可被翻译为：第三十一条  医疗器械注册人、备案人、受托生产企业应当加强采购管理，建立供应商审核制度，对供应商进行评价，确保采购产品和服务符合相关规定要求。\n\n根据上述已知信息，请将'The registrant, filing entity or contract manufacturer of medical devices are encouraged to establish information management system by advanced technical means, to strengthen management of the manufacturing process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"鼓励医疗器械注册人、备案人、受托生产企业采用先进技术手段，建立信息化管理系统，加强对生产过程的管理。"
    },
    {
        "instruction":"已知信息：\n'A process designed to remove or inactivate pyrogenic material (such as endotoxin) to a specified minimum quantity.'可被翻译为：去除或灭活致热物质(如内毒素)至规定最小量的过程。\n'When a thermal process is used as part of the depyrogenation process for any component or product contact equipment\/material, validation studies should be performed to demonstrate that the process provides a suitable Fh value and results in a minimum 3 log10  reduction in endotoxin concentration. When this is attained, there is no additional requirement to demonstrate sterilisation in these cases.'可被翻译为：当使用热处理作为任何组分或产品接触设备\/物料的除热原工艺的一部分时，应进行验证研究以证明该工艺 能提供合适的 Fh 值，并使内毒素浓度至少降低 3 个对数值。这一要求得到满足，不需要额外证明在这些情况下的灭菌效果。\n'Viral clearance studies in which non-specific “model” viruses are used to assess the robustness of the manufacturing process to remove and\/or inactivate viruses.'可被翻译为：用非特异“模型”病毒评价生产过程清除和\/或灭活病毒可靠性的研究。\n'Viral clearance studies in which “relevant” and\/or specific “model” viruses are used to determine the ability of the manufacturing process to remove and\/or inactivate these viruses.'可被翻译为：用 “相关”和\/或特异“模型” 病毒确定生产工艺清除和\/或灭活病毒效果的研究。\n\n根据上述已知信息，请将'Depyrogenation - A process designed to remove or inactivate pyrogenic material (e.g. endotoxin) to a specified\nminimum quantity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除热原： 旨在将致热物质（例如内毒素）去除或灭活至规定最小量的过程。"
    },
    {
        "instruction":"已知信息：\n'a class of biological macromolecules widely present in living organisms, consisting of a peptide chain formed by a peptide bond between A amino acid encoded by nucleic acid through A amino group and A carboxyl group, and an active macromolecule with a specific three-dimensional structure generated by post-translational processing.'可被翻译为：生物体中广泛存在的一类生物大分子，由核酸编码的a氨基酸之间通过a氨基和a竣基形成的肽键连接而成的肽链，经翻译后加工而生成的具有特定立体结构的、有活性的大分子。\n'A compound consisting of a negatively charged group or electrically neutral polar molecule that forms a coordination bond with a metal ion or atom.'可被翻译为：由一些带负电的基团或电中性的极性分子，同金属离子或原子形成的配位键化合物。\n'agarose gel'可被翻译为：琼脂糖凝胶\n'In the sequence of peptide or protein, the amino group and the carboxyl group between amino acids are dehydrated to form a bond, so the amino acid in the peptide or protein molecule is not a complete amino acid and is called residue.'可被翻译为：在肽或蛋白质的序列中，氨基酸之间的氨基和竣基脱水成键，因此肽或蛋白质分子中的氨基酸已不是完整的氨基酸，被称为残基。\n\n根据上述已知信息，请将'After the charged AGAR is removed from the AGAR, the remaining neutral part of the charged group does not contain sulfonic acid group, carboxylic acid group, etc. The structure is a chain of polygalactose, easily soluble in boiling water, after cooling can rely on the hydrogen bond attraction between sugar groups to form a network structure of gel. The mesh size of the gel and the mechanical strength of the gel depend on the agarose concentration. It can be used as a molecular sieve and is often used for gel chromatography and electrophoresis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"从琼脂中除去带电荷的琼脂胶后，剩下的不含磺酸基团、竣酸基团等带电荷基团的中性部分。结构是链状的聚半乳糖，易溶于沸水，冷却后可依靠糖基间的氢键引力形成网状结构的凝胶。凝胶的网孔大小和凝胶的机械强度取决于琼脂糖浓度。可作为分子筛，常用于凝胶层析和电泳。"
    },
    {
        "instruction":"已知信息：\n'12.2. During the initiation phase of the project, a unit should normally identify the need for the technology transfer. This may be because of lack of capacity, transfer from development to commercial site or transfer from one company to another.'可被翻译为：在项目的启动阶段，通常应由一方识别出技术转移的需求。这可能是因为缺乏从开发转移至商业化场所或从一个公司转移至另一个公司能力。\n'A logical procedure that controls the transfer of any product or process, including product or process knowledge, together with its documentation and professional expertise. Technology transfer may involve development, manufacturing or testing sites.'可被翻译为：控制任何产品或工艺(包括产品或工艺知识)及其文件和专业知识转让的逻辑程序。技术转让可能涉及开发、制造或测试场所。\n'5.6. The technology transfer should be managed by responsible persons from each site (the SU and RU) and any other units with the appropriate technical and quality oversight. A technology transfer team may be appointed with identified and documented responsibilities.'可被翻译为：技术转移应由来自双方（SU和RU）的负责人，和其它技术和质量监管部门的人进行管理。可指定一个技术转移小组，并书面说明其职责。\n'1.3. A technology transfer, particularly one between different companies, has legal and economic implications which may include intellectual property rights, royalties, pricing, conflicts of interest and confidentiality agreements. Such matters should therefore be addressed before and during the planning and execution of the transfer.'可被翻译为：技术转移，尤其是不同公司之间的技术转移有法律和经济内涵，其中可能还包括知识产权、请诚信、价格、利益冲突和保密协议。因此此类问题应在规划和执行转移之前和期间解决。\n\n根据上述已知信息，请将'1.2. The transfer of production and control procedures of pharmaceutical products from one site to another may take place before or after obtaining regulatory marketing authorization Product transfer may therefore occur during development, during clinical trials, or for full-scale commercialization and commercial batch manufacturing. The level of rigor applied in the technology transfer should be commensurate with the respective product life cycle phase.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品生产和检测方法从一个场所转移至另一个场所可能会发生在在获得上市批准之前或之后。因此产品转移可能会在开发过程中、临床试验过程中或全面商业化及商业化批生产过程中发生。技术转移时的严格程序应与产品所处生命周期阶段相称。"
    },
    {
        "instruction":"已知信息：\n'5. Place the EM sample into a sterile Whirl-pak® bag and identify the bag immediately after.'可被翻译为：将 EM 样品放入 Whirl-pak®无菌袋，然后立即对袋子进行标示。\n'e. Glove Sterility Control: If the sampler uses ORS sterile gloves then have an intact unit containing gloves placed into a sterile plastic bag and sent as a control.'可被翻译为：手套无菌性控制：如果取样器使用 ORS 无菌手套，则将带有手套的完整装置放入无菌塑料袋中，并作为对照。\n'bag'可被翻译为：袋\n'a. Aseptic Technique Control: Place one (1) sterile Dacron or cotton swab into sterile water and place back into its sterile transport media solution. Place this negative control into a sterile Whirl- pak® bag.\nNote: This control may not be needed if the sponges and\/or swabs are received premoistened. There is no surface contact for this control.'可被翻译为：无菌技术控制：将一个无菌涤纶或棉签放入无菌水中，并放回其无菌输送培养基溶液中，将此阴性对照放入无菌 Whirl- pak®袋中。\n注：如果海绵和\/或棉签在收到之前就已蘸湿则不需要该控制。该控制没有表面接触。\n\n根据上述已知信息，请将'd. Whirl-pak® bag Sterility Control: Include one unopened Whirl- pak® bag as a closed control.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"Whirl- pak®袋的无菌控制：放入一个未开封的 Whirl- pak®袋作为密封控制。"
    },
    {
        "instruction":"已知信息：\n'If an inspection team is formed together, the inspection team leader and team members should be qualified national GMP inspectors. The inspection team leader shall be determined by the CFDI and the provincial authority through joint discussion.'可被翻译为：如共同组建检查组，检查组长和组员均应为国家药品GMP 检查员。检查组长由核查中心和省级局共同协商确定。\n'Article 48 The inspection team shall submit the on-site inspection report and related dossiers to CFDI within 5 days after the completion of the on-site inspection.'可被翻译为：第四十八条 核查组应当在现场核查结束之日起5日内，将现场核查报告及相关资料报送核查中心。\n'Article 6 In accordance with the requirements and functions of laws and regulations, the CFDI and provincial authorities shall form inspection team in accordance with procedures to complete the drug registration inspection and Pre-market GMP inspection.'可被翻译为：第六条 根据法规要求和职能， 核查中心和省级局按程序组建检查组，完成药品注册现场核查和上市前 GMP 检查工作。\n'Article 3 When the CFDI coordinates the collaborative inspections with provincial authorities, both parties shall, in accordance with the regulatory requirements and their respective functions, follow the concept of risk management and work together to ensure the smooth collaboration between registration inspection and Pre-market GMP inspection.'可被翻译为：第三条 核查中心协调省级局同步实施检查工作时，双方应当根据法规要求和各自职能，遵循风险管理的理念，共同合作，保证注册核查与上市前GMP 检查的有机衔接。\n\n根据上述已知信息，请将'Article 5 After confirming the inspection arrangements with the applicant taking consideration of the characteristics, processes, risks, etc. of the product, the CFDI shall work together with the provincial authorities to agree on the work arrangements to clarify the composition of the inspection team and the inspection time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五条 核查中心根据品种的特性、工艺、风险等情况，在与申请人沟通确认检查安排后，同省级局共同商定工作安排，明确检查组组成方式和检查时间。"
    },
    {
        "instruction":"已知信息：\n'Article 140: Documents and records should be established for qualification and validation as an evidence for the following intended purposes:'可被翻译为：第一百四十条 应当建立确认与验证的文件和记录，并能以文件和记录证明达到以下预定的目标：\n'Article 148: Qualification or validation should be implemented in accordance with a predefined and approved protocol, and be recorded. Upon completion of qualification or validation, a report should be prepared, reviewed and approved. The qualification or validation result and conclusion (including comments and suggestions) should be recorded and archived.'可被翻译为：第一百四十八条 确认或验证应当按照预先确定和批准的方案实施，并有记录。确认或验证工作完成后，应当写出报告，并经审核、批准。确认或验证的结果和结论（包括评价和建议）应当有记录并存档。\n'installation qualification'可被翻译为：安装确认\n'Cleanroom and clean air equipment qualification is the overall process of assessing the level of compliance of a classified cleanroom or clean air equipment with its intended use. As part of the qualification requirements of Annex 15, the qualification of cleanrooms and clean air equipment should include (where relevant to the\ndesign\/operation of the installation):'可被翻译为：洁净室和洁净空气设备的确认是评估分级的洁净室或洁净空气设备与其预期用途的符合程度的整体过程。\n作为附录 15 的确认要求的一部分，洁净室和洁净空气设备的确认应包括（与设施的设计\/运行相关的）：\n\n根据上述已知信息，请将'Article 73: The documents and records for equipment procurement, installation, and qualification should be archived.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十三条 应当建立并保存设备采购、安装、确认的文件和记录。"
    },
    {
        "instruction":"已知信息：\n'2.2 Drugs that contain known active ingredients with new dosage form (including new drug delivery system), new formulation process or new route of administration, and have significant clinical advantages.'可被翻译为：2.2含有已知活性成份的新剂型（包括新的给药系统）、新处方工艺、新给药途径，且具有明显临床优势的药品。\n'2.1 Drugs that contain an optical isomer of known active ingredients obtained by resolution or synthesis, or esterification of known active ingredients, or salification of known active ingredients (including salt containing hydrogen bonds or coordination bonds), or change in acid group, basic group, or metallic element of known active ingredients of salt, or formation of other non-covalent bond derivatives (e.g. ,complex, chelate or clathrate), and have significant clinical advantages.'可被翻译为：2.1含有用拆分或者合成等方法制得的已知活性成份的光学异构体，或者对已知活性成份成酯，或者对已知活性成份成盐（包括含有氢键或配位键的盐），或者改变已知盐类活性成份的酸根、碱基或金属元素，或者形成其他非共价键衍生物（如络合物、螯合物或包合物），且具有明显临床优势的药品。\n'(3) New compound preparations composed of active ingredients of non-prescription drugs authorized by the NMPA;'可被翻译为：（三）使用国家药品监督管理局确定的非处方药的活性成份组成的新的复方制剂；\n'2.4 Drugs for new indications that contain known active ingredients.'可被翻译为：2.4含有已知活性成份的新适应症的药品。\n\n根据上述已知信息，请将'2.3 New compound preparations that contain known active ingredients and havesignificant clinical advantages.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2.3含有已知活性成份的新复方制剂，且具有明显临床优势。"
    },
    {
        "instruction":"已知信息：\n'Article 20 Where the change management category of circumstances of change has been specified in laws, regulations or technical guidelines, MAHs shall generally determine the change management category in accordance with relevant provisions.'可被翻译为：第二十条 变更情形在法律、法规或技术指导原则中已明确变更管理类别的，持有人一般应当根据有关规定确定变更管理类别。\n'Article 22 MAHs may adjust the change management category according to the management and production technology changes, and implement the change as per the adjusted change management category upon approval or filing, or report.'可被翻译为：第二十二条 持有人可以根据管理和生产技术变化对变更管理类别进行调整，并按照调整后的变更管理类别经批准、备案后实施或报告。\n'Where it is specified in laws, regulations and guidelines as a major change or determined by MAHs as a major change, it shall be implemented after being approved in accordance with relevant provisions. For the change to lower the category after communicating with and reaching an agreement with the drug regulatory department, the application for filing or reporting shall be filed according to the agreed category of change management. For the changes of filing and reporting categories specified in laws, regulations and technical guidelines or defined by MAHs, those shall be submitted in accordance with relevant provisions.'可被翻译为：法律、法规、指导原则中明确为重大变更或持有人确定为重大变更的，应当按照有关规定批准后实施。与药品监管部门沟通并达成一致后降低变更管理类别的变更，应当按照达成一致的变更管理类别申报备案或报告。法律、法规、技术指导原则中明确为备案、报告管理的变更或持有人确定为备案、报告管理的变更，应当按照有关规定提出备案或报告。\n'Article 4 MAHs are the main body of responsibility for the management of post-approval changes of drugs. MAHs shall establish a post-approval change control system in accordance with the laws and regulations on drug supervision, the Good Manufacturing Practice for Drugs and other relevant requirements; formulate and implement the principle for internal classification of changes, list of changes, working procedures and risk management requirements of MAH in accordance with the relevant technical guidelines of NMPA and ICH; and determine the change management category after sufficient study, evaluation and necessary verification in combination with product characteristics.'可被翻译为：第四条 持有人是药品上市后变更管理的责任主体，应当按照药品监管法律法规和药品生产质量管理规范等有关要求建立药品上市后变更控制体系；根据国家药品监督管理局有关技术指导原则和国际人用药注册协调组织（ICH）有关技术指导原则制定实施持有人内部变更分类原则、变更事项清单、工作程序和风险管理要求，结合产品特点，经充分研究、评估和必要的验证后确定变更管理类别。\n\n根据上述已知信息，请将'Article 27 The reporting category shall be managed by the MAHs in accordance with the relevant requirements for change management, which shall be indicated in the annual report.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十七条 报告类变更应当由持有人按照变更管理的有关要求进行管理，在年度报告中载明。"
    },
    {
        "instruction":"已知信息：\n'1.All phases in the life of a product from the initial development through marketing until the product’s discontinuation (ICH Q8 (4))\n2.All phases in the life of a medical device, from the initial conception to final decommissioning and disposal.\n3.All phases in the life of a product from the initial development through marketing until the product’s discontinuation (4).'可被翻译为：1.产品生命周期的所有阶段，从最初的开发到营销，直到产品停产(ICH Q8 (4))\n2.医疗器械生命周期的所有阶段，从最初的构思到最终的退役和处置。\n3.产品生命周期的所有阶段，从最初的开发到营销，直到产品停产(4)。\n'All phases in the life of the product from the initial development through marketing until the product’s discontinuation. (ICH Q9)'可被翻译为：从最初的研发到上市直至撤市的产品生命中的所有阶段。（ICH Q9）\n'All stages of the product from its development, launch to market, till discontinuation.'可被翻译为：产品从最初的研发、上市直至退市的所有阶段。\n'Announcement of NMPA on Recommended Application of 4 ICH Guidelines Including Q8 (R2): Pharmaceutical Development'可被翻译为：国家药监局关于推荐适用《Q8（R2）：药品研发》等4个国际人用药品注册技术协调会指导原则的公告\n\n根据上述已知信息，请将'All phases in the life of a product from the initial development through marketing until the product’s discontinuation (ICH Q8).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一个产品从开始研发到上市，直至产品终止上市的整个过程。"
    },
    {
        "instruction":"已知信息：\n'5. Chromatogram integration'可被翻译为：5.色谱积分\n'(2) If reintegration is conducted for standard curve and the quality control chromatogram, verify whether the reintegration impacts the acceptance of the analysis batch.'可被翻译为：(2) 标准曲线和质控色谱如果进行了重积分， 核实重积分是否影响该分析批的接受。\n'Change of the original integration of a chromatographic peak'可被翻译为：重新分析色谱峰。\n'chromatogram'可被翻译为：色谱图\n\n根据上述已知信息，请将'(1) Chromatogram adopts automatic integration; the same integration parameters are used in the same analysis batch. If reintegration and manual integration of chromatogram are adopted, record the reason of modification and retain the original and reintegrated chromatogram and data, which are consist with the application dossier.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"(1) 色谱使用自动积分， 同一个分析批中采用相同的积分参数。如果色谱重积分和手动积分， 记录修改理由并保留原始和重积分的图谱和数据， 与申报资料一致。"
    },
    {
        "instruction":"已知信息：\n'toxic effect'可被翻译为：毒效应\n'delayed toxic effect'可被翻译为：迟发型毒性作用\n'spectrum of toxic effect'可被翻译为：毒效应谱\n'The phenomenon of two chemical agents acting on an organism in which one interferes with the toxic effect of the other, or with each other, so that the overall toxic effect decreases.'可被翻译为：两种化学药剂作用于生物机体时，一种化学药剂干扰另--种药剂的毒效，或彼此互相F扰对方的毒效，使总体毒效下降的现象。\n\n根据上述已知信息，请将'For dark yellow toxic gas. Dissolved in ethylene, tetrahydroyvean, etc., heated to 100 hours explosion; It decomposes rapidly in water and ethanol, and is relatively stable in ethyl-sweet wine. It is highly toxic and has a strong irritating effect on eyes and mucous membranes. It is an important methylation reagent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为深黄色有毒气体。溶于乙触、四氢吠喃等，加热至100工时爆炸；在水和乙醇中迅速分解，在乙醴中比较稳定。有剧毒，对眼睛和黏膜有强烈的刺激作用，为重要的甲基化试剂。"
    },
    {
        "instruction":"已知信息：\n'(1) drugs to be marketed in China for the first time;'可被翻译为：（一）首次在中国境内销售的药品；\n'Clinical Technical Requirements for Drugs Marketed Overseas but Not Marketed in China'可被翻译为：境外已上市境内未上市药品临床技术要求\n'(IV) First commercial varieties: drugs purchased by the enterprise for the first time;'可被翻译为：（四）首营品种：本企业首次采购的药品。\n'Chapter II Application and Approval of First Importation of Crude Drugs'可被翻译为：第二章 首次进口药材申请与审批\n\n根据上述已知信息，请将'(II) drugs to be marketed in China for the first time; and'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）首次在中国境内销售的药品；"
    },
    {
        "instruction":"已知信息：\n'The registrant or filing entity of medical devices may sell by itself, or entrust medical device distributors to sell the medical devices registered or filed.'可被翻译为：医疗器械注册人、备案人可以自行销售，也可以委托医疗器械经营企业销售其注册、备案的医疗器械。\n'Article 37 The registrant, filing entity and distributor of the medical devices shall strengthen training and management of the sales personnel, and assume legal liabilities for purchase or sale of medical devices of the sales personnel in the name of the enterprise.'可被翻译为：第三十七条  医疗器械注册人、备案人和经营企业应当加强对销售人员的培训和管理，对销售人员以本企业名义从事的医疗器械购销行为承担法律责任。\n'Article 59 If the registrant, filing entity and distributor of the medical devices fail to take effective removal measures for the existing quality and safety risks of the medical devices, the drug regulatory departments may hold a liability interview with legal representative or person in charge of enterprise of the registrant, filing entity and distributor of the medical devices.'可被翻译为：第五十九条  医疗器械注册人、备案人、经营企业对存在的医疗器械质量安全风险，未采取有效措施消除的，药品监督管理部门可以对医疗器械注册人、备案人、经营企业的法定代表人或者企业负责人进行责任约谈。\n'Article 41 The medical device distributors shall assist with the registrant and filing entity of the medical devices in carrying out monitoring of adverse events of the distributed medical devices, and then report to technical institution for monitoring adverse events of medical devices in accordance with regulations of the NMPA.'可被翻译为：第四十一条  医疗器械经营企业应当协助医疗器械注册人、备案人，对所经营的医疗器械开展不良事件监测，按照国家药品监督管理局的规定，向医疗器械不良事件监测技术机构报告。\n\n根据上述已知信息，请将'Article 31 The medical device distributors shall purchase medical devices from medical device registrant, filing entity and distributor with legal qualification.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十一条  医疗器械经营企业应当从具有合法资质的医疗器械注册人、备案人、经营企业购进医疗器械。"
    },
    {
        "instruction":"已知信息：\n'An emulsion having oil as the dispersing phase and water as the dispersing medium.'可被翻译为：以油为分散相，以水为分散介质的乳剂。\n'An emulsion in which water is the dispersing phase and oil is the dispersing medium.'可被翻译为：以水为分散相，以油为分散介质的乳剂。\n'The liquid drug or drug solution with the projectile (liquid that is insoluble in water) forms an oil-in-water (O\/W) or oil-in-water (W\/O) emulsion! L Oil-in-water emulsions are ejected in foam form as the inner phase ejector vaporizes during ejection. The oil-in-water emulsion forms a flow as the outer phase ejector vaporizes during ejection.'可被翻译为：液体药物或药物溶液与抛射剂（不溶于水的液体）形成水包油（O\/W）或油包水（W\/O）乳齐!L水包油乳剂在喷射时随着内相抛射剂的气化而以泡沫形式喷出。油包水乳剂在喷射时随着外相抛射剂的气化而形成流液。\n'An emulsion made by further dispersing colostrum of oil in water (o\/w) or water in oil (W\/O) in an oil phase (O\/W\/O) or water phase (W\/O\/W) for emulsification.'可被翻译为：将水包油(o\/w)或油包水(W\/O)的初乳进一步分散在油相(O\/W\/O)或水相(W\/O\/W)中进行乳化所制成的乳剂。\n\n根据上述已知信息，请将'Drugs and natural polymer materials for the water phase, emulsifier oil phase stirring emulsification, the use of polymer solution itself surface tension to form a spherical emulsion, forming a stable oil-in-water emulsion, need to add chemical crosslinking agent, amine aldehyde condensation or aldol condensation reaction, preparation of powdered microspheres method.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物和天然高分子材料为水相，与含乳化剂的油相搅拌乳化，在搅拌下利用高分子溶液本身的表面张力形成球形乳滴，形成稳定的油包水型乳状液，需加入化学交联剂，发生胺醛缩合或醇醛缩合反应，制得粉末状微球的方法。"
    },
    {
        "instruction":"已知信息：\n'It uses the basic methods and techniques of toxicology to study the characteristics and mechanisms of the damaging effects of foreign chemicals on the liver.'可被翻译为：利用毒理学的基本方法和技术，研究外源化学物对肝脏的损害作用特点及其机制的学科。\n'The discipline that studies the characteristics and mechanisms of the damaging effects of foreign chemicals on the kidney by using the basic methods and techniques of toxicology.'可被翻译为：利用毒理学的基本方法和技术，研究外源化学物对肾脏的损害作用特点及其机制的学科。\n'The branch of toxicology that deals with the toxic effects of foreign chemicals, especially at low doses of chronic exposure, on human neurobehavior, that is, human mental functioning.'可被翻译为：毒理学的一个分支，主要研究外源化学物特别是在低剂量慢性接触对人的神经行为，即人的心理功能的毒性效应。\n'The branch of toxicology that deals with the toxic effects of chemicals on the hearing, balance organs, or auditory nerves.'可被翻译为：研究化学物对听觉、平衡器官或听神经产生的毒性作用的毒理学分支学科。\n\n根据上述已知信息，请将'The branch of toxicology that studies the damaging effects of foreign chemicals on the respiratory system, explores methods of detection, and elucidates mechanisms of damage. Its research is helpful for the diagnosis, treatment, prevention and mechanism of poisoning.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究外源化学物对呼吸系统的损害作用，探讨检测方法以及阐述损害机制的毒理学分支学科。其研究有助于对中毒的诊断、治疗、预防以及中毒机制的探讨。"
    },
    {
        "instruction":"已知信息：\n'Article 96 The State encourages the research, development, and manufacture of drugs in shortage, and implements priority review and approval for drugs in shortage in urgent clinical needs or new drugs for prevention and treatment of serious infectious diseases and rare diseases.'可被翻译为：第九十六条 国家鼓励短缺药品的研制和生产，对临床急需的短缺药品、防治重大传染病和罕见病等疾病的新药予以优先审评审批。\n'Article 5 The State encourages research and development of new drugs, and protects the legitimate rights and interests of citizens, legal bodies and other institutions in research and development of new drugs.'可被翻译为：第五条 国家鼓励研究和创制新药，保护公民、法人和其他组织研究、开发新药的合法权益。\n'Article 16 The State supports innovation in drug development which is guided by clinical value and has clear or specific therapeutic effect on human diseases, encourages research and development of new drugs with new therapeutic mechanisms, treats serious life-threatening or rare diseases, makes use of targeted and systemic regulatory interventions for humans, and promotes technological advancement in drug development.'可被翻译为：第十六条 国家支持以临床价值为导向、对人的疾病具有明确或者特殊疗效的药物创新，鼓励具有新的治疗机理、治疗严重危及生命的疾病或者罕见病、对人体具有多靶向系统性调节干预功能等的新药研制，推动药品技术进步。\n'Article 8 The State encourages the research and innovation of medical devices, implements special review for innovative medical devices, accelerates the popularization and application for new technologies of medical devices and promotes the development of medical device industry.'可被翻译为：第八条 国家鼓励医疗器械的研究与创新，对创新医疗器械实行特别审批，促进医疗器械新技术的推广与应用，推动医疗器械产业的发展。\n\n根据上述已知信息，请将'Article 4 The State encourages the research and development of new drugs and adopts the special review and approval with respect to innovative drugs, new drugs for serious and life-threatening diseases and to address unmet medical needs and drugs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四条 国家鼓励研究创制新药，对创制的新药、治疗疑难危重疾病的新药实行特殊审批。"
    },
    {
        "instruction":"已知信息：\n'turbulent flow'可被翻译为：紊流\n'To minimize the risk of biofilm formation, sterilisation, disinfection or regeneration of water systems should be carried out according to a predetermined schedule and as a remedial action following out-of-limit or specification results. Disinfection of a water system with chemicals should be followed by a validated rinsing\/flushing procedure. Water should be tested after disinfection\/regeneration. Chemical testing results should be approved before the water system is returned to use and microbiological\/endotoxin results verified to be within specification and approved before batches manufactured using water from the system are considered for certification\/release.'可被翻译为：为最大程度降低生物膜形成的风险，应按照预定的时间表对水系统进行灭菌、消毒或再生，并作为超限或超标后的整改措施。用化学品对水系统进行消毒后，用经过验证的程序进行淋洗\/冲洗。应在消毒\/再生后进行水质检测。在水系统恢复使用之前，化学检验结果应得到批准，并且在使用该系统的水生产的批次得到认证\/放行之前，微生物\/内毒素结果应经过核实在质量标准范围内并得到批准。\n'turbulent air flow'可被翻译为：湍流\n'Water treatment plant and distribution systems should be designed, constructed, installed, commissioned, qualified, monitored and maintained to prevent microbiological contamination and to ensure a reliable source of\nwater of an appropriate quality. Measures should be taken to minimize the risk of presence of particulates, microbial contamination\/proliferation and endotoxin\/pyrogen (e.g. sloping of piping to provide complete drainage and the avoidance of dead legs). Where filters are included in the system, special attention should be given to their\nmonitoring and maintenance. Water produced should comply with the current monograph of the relevant\nPharmacopeia.'可被翻译为：水处理设施及其分配系统地设计、建造、安装、调试、确认、监测和维护应防止微生物污染，并确保高质量的可靠水源。应釆取措施，最大程度降低微粒、微生物污染\/增殖和内毒素\/热原的风险（例如倾斜管道以完全排水以及避免死角）。当系统中包含过滤器时，应特别注意对其进行监测和维护。产出的水应符合相关药典的现行各论。\n\n根据上述已知信息，请将'Water flow should remain turbulent through the pipes in water distribution systems to minimize the risk of microbial adhesion, and subsequent biofilm formation. The flow rate should be established during qualification and be routinely monitored.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"水流在水分配系统的管道中应保持湍流状态，以最大程度降低微生物粘附及随后生物膜形成的风险。应在确认过程中确定流速并进行日常监测。"
    },
    {
        "instruction":"已知信息：\n'A liquid sol with a solid as a dispersing phase, that is, a dispersing system formed by an insoluble solid dispersed in a liquid. The linear size of solid particles is above 0.1pm.'可被翻译为：以固体为分散相的液溶胶，即由不溶性的固体分散在液体中所形成的分散物系。固体粒子的线性大小在0.1pm以上。\n'A dispersion system formed in a highly dispersed solid carrier (or substrate).'可被翻译为：固体药物高度分散在固体载体（或基质）中形成的分散体系。\n'A dispersion system in which droplets with a particle size of less than 100nm are dispersed in another insoluble liquid.'可被翻译为：粒径小于100nm的乳滴分散在另一种互不相溶的液体中形成的分散体系。\n'Insoluble solid drug A heterogeneous liquid preparation formed in the form of particles dispersed in a liquid medium.'可被翻译为：难溶性固体药物以微粒的形式分散于液体介质中形成的非均相液体制剂。\n\n根据上述已知信息，请将'A suspension formed when the seeds are dispersed by shaking them into a sterile liquid.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"将抱子转入无菌液体中振摇，使抱子分散后形成的悬浮液。"
    },
    {
        "instruction":"已知信息：\n'Full name \"Pharmacokinetics\". It mainly studies the dynamic changes of the body's treatment of drugs, including the absorption, distribution, biotransformation and excretion processes of drugs in the body, especially the discipline of blood drug concentration changes with time.'可被翻译为：全称\"药物代谢动力学”。主要研究机体对药物的处置的动态变化，包括药物在机体内的吸收、分布、生物转化及排泄的过程，尤其是血药浓度随时间变化规律的学科。\n'The absorption and distribution of drugs in the body Biotransformation and excretion.'可被翻译为：药物在体内的吸收分布生物转化和排泄。\n'The study of the absorption, distribution, metabolism, excretion and other processes of drugs and their dosage forms in the body, and the elucidation of the relationship between drug dosage forms, biological factors and efficacy.'可被翻译为：研究药物及其剂型在体内的吸收、分布、代谢、排泄等过程，阐明药物的剂型因素、机体生物因素和药效之间相互关系的一门学科。\n'The process by which a drug is transported through the body at such spatial locations as absorption, distribution, and excretion (including across vascular tissues, cells, etc.).'可被翻译为：药物在体内的吸收、分布、排泄等空间位置上(包括跨血管组织、细胞等)的迁移过程。\n\n根据上述已知信息，请将'The subject of quantitative study of the dynamic laws of the absorption, distribution, biotransformation and excretion of toxicants in the body over time.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"定量研究毒物在体内吸收、分布、生物转化、排泄等过程随时间变化的动态规律的学科。"
    },
    {
        "instruction":"已知信息：\n'1. The consistency of the application dossiers with the study protocol, raw data and final report should be audited;'可被翻译为：1.核查申报资料与试验方案、原始数据、总结报告的一致性；\n'3. The storage conditions of the test\/control articles and their formulations, biological samples, study files and specimens, etc. should be in conformity with those specified in the study protocol, SOPs or other operational instructions; records of corresponding environmental monitoring and handling of unexpected events in the course of the study should be retained completely.'可被翻译为：3.受试物\/对照品及其配制制剂、生物样本、研究档案和 标本等储存保管条件应符合试验方案及机构 SOP或其他试验操作文件要求；应完整保存研究开展期间相应环境控制数据以及异常情况处理等记录。\n'The on-site inspection of CMC development is mainly to inspect the original data, records, including pharmaceutical formulation and process study, trial sample manufacturing, quality control study and stability study etc. development activities, and on-site inspection.'可被翻译为：药学研制现场核查主要是对药学研制情况，包括药学处方与工艺研究、样品试制、质量控制研究及稳定性研究等研制工作的原始数据、记录和现场进行的核查。\n'1. Fabricating or modifying the information of the test system, study data, study records, test\/control articles without reasonable explanation;'可被翻译为：1.编造或者无合理解释地修改实验系统信息以及试验数据、试验记录、受试物和对照品信息；\n\n根据上述已知信息，请将'1. The applicant and the testing facility under inspection should ensure that the original study materials retained are complete and can be provided for inspection in a timely manner, including an original copy of protocol, raw data, specimens, relevant testing reports, reserve samples of test\/control articles, an original copy of the final study report and other documentation related to the study;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.现场核查期间，申请人及被核查研究机构应确保研究 原始资料保存完整并能够及时提供、接受核查，包括试验方案的原件、原始数据、标本、相关检测报告、留样受试物和对照品、总结报告的原件以及研究有关的各种文件；"
    },
    {
        "instruction":"已知信息：\n'Article 69 Where a drug manufacturer does not conduct production of the new drug, for which an observation period is set, within two years from the date of the approval, the State Food and Drug Administration may approve the application of another drug manufacturer to produce the new drug and reset the observation period of the drug.'可被翻译为：第六十九条 药品生产企业对设立监测期的新药从获准生产之日起2年内未组织生产的，国家食品药品监督管理局可以批准其他药品生产企业提出的生产该新药的申请，并重新对该新药进行监测。\n'Article 71 Starting from the date a new drug enters the observation period, other registration applications for the same drug shall no longer be accepted. The other applicants' applications for the same drug already accepted but not yet approved for clinical trials shall be returned; upon the expiration of the observation period of the drug, the registration of a generic or import drug may be applied for.'可被翻译为：第七十一条 新药进入监测期之日起，不再受理其他申请人的同品种注册申请。已经受理但尚未批准进行药物临床试验的其他申请人同品种申请予以退回；新药监测期满后，申请人可以提出仿制药申请或者进口药品申请。\n'Article 70 Starting from the date a new drug enters the observation period, any other application for the clinical trial of the same drug already approved by the State Food and Drug Administration may proceed along drug registration application, review and approval procedures; where regulations are conformed to, the State Food and Drug Administration shall approve the production or importation of the same drug. The observations of the drugs produced by the domestic manufacturers should be conducted together with the drug already in the observation period.'可被翻译为：第七十条 新药进入监测期之日起，国家食品药品监督管理局已经批准其他申请人进行药物临床试验的，可以按照药品注册申报与审批程序继续办理该申请，符合规定的，国家食品药品监督管理局批准该新药的生产或者进口，并对境内药品生产企业生产的该新药一并进行监测。\n'Section 3  New Drug Observation Period'可被翻译为：第三节 新药监测期\n\n根据上述已知信息，请将'Article 66 In order to protect the public health, the State Food and Drug Administration may set an observation period for any new drug approved for production. The observation period of a new drug shall be no longer than five years from the date the drug is approved for production.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十六条 国家食品药品监督管理局根据保护公众健康的要求，可以对批准生产的新药品种设立监测期。监测期自新药批准生产之日起计算，最长不得超过5年。"
    },
    {
        "instruction":"已知信息：\n'7. Product Test Failure - When a firm has a final product or in-process test result that indicates a failure (USP test failure, OOS, etc.) ask– Were the results due to laboratory error or a true process contamination?'可被翻译为：产品检测失败—如果一个公司有一个成品或中控检测结果显示失败（USP 检测失败，OOS 等），询问—结果是因为实验室错误还是真正的工艺污染？\n'Run the method suitability test concurrently with product sterility tests when time is critical, and problems associated with 1. above have been resolved. However, it should be noted that if the Method Suitability Test is run concurrently with the product sterility test and the Method Suitability Test should fail, the results of the product test are invalid and the Method Suitability Test as well as the product test will need to be repeated with proper method modification to neutralize the inhibiting property.'可被翻译为：如果时间紧急，并且上述问题已得到解决，则可在进行产品无菌测试时同步进行方法适用性测试。但是应注意的如果方法适用性试验与产品无菌检测同时进行，方法适用性试验失败，则产品检测结果是无效的，需要适当修改方法，中和抑菌性，再重复进行适用性试验和产品检测。\n'Suitability demonstrates that the products tested do not exhibit inhibitory effects on the growth of microorganisms under the conditions of the tests. Although the intent is to perform the suitability test before performing the analysis of the product, it is acceptable to run the product test and the suitability test concurrently. However, it should be noted that if the suitability test is run concurrently with the product test and the suitability test should fail, the results of the product test are invalid and the suitability test as well as the product test will need to be repeated with proper method modification to neutralize the inhibiting property.'可被翻译为：适用性表明所测试的产品在测试条件下对微生物生长没有抑制作用。尽管期望在进行产品分析 前进行适用性试验，但同时进行产品测试和适用性试验也是可以接受的。但应注意的是，如果 同时进行适用性试验和产品测试，适用性试验失败，则产品检测结果是无效的，应对方法进行 适当修改，中和抑菌性，然后再重复进行适用性试验和产品检测方法。\n'This chapter of the Sterility Analytical Manual is intended to supplement the methodology procedures found in the USP<85> BACTERIAL ENDOTOXINS TEST and USP<161> MEDICAL DEVICES-BACTERIAL ENDOTOXIN AND PYROGEN TESTS. The USP<85> test is based on a reaction between bacterial endotoxin and the LAL reagent. Requirements for the LAL test includes optimal pH, ionic strength, temperature and incubation time. The USP<85> methods include the gel-clot LAL method and photometric technique methods such as the turbidimetric and chromogenic kinetic LAL methods. The USP<161> chapter describes the bacterial endotoxin extraction procedure for medical devices, if required. After the medical device extraction is performed, the USP<85> chapter is followed to detect and quantify any bacterial endotoxin present in the sample.'可被翻译为：无菌分析手册中的该章节意在补充USP<85>“细菌内毒素检测”和USP<161>“医疗器械细 菌内毒素和热源测试”中的方法学程序。USP<85>的方法是基于细菌内毒素与LAL试剂之间的反应。LAL检测要求包括优化pH、离子化强度、温度和培养时间。USP<85>方法包括 凝胶LAL方法和光度技术方法，如浊度和光度动力学LAL方法。USP<161>描述了医疗器 械的细菌内毒素提取程序（如需要）。在提取之后，按USP<85>方法检测和定量医疗器械 样本中的细菌内毒素。\n\n根据上述已知信息，请将'When conflicting results occur within a test run, the analyst should consult USP Chapter<85> , Gel-Clot Limits Test, Interpretation, for guidance on repeat testing. As specified in Chapter<85> , if the test failure occurred at less than the maximum valid dilution (MVD), the test should be repeated using a greater dilution not exceeding the MVD. A record of this failure should be included in the laboratory results. If a test is performed at the MVD and an out-of- specification (OOS) test result occurs that cannot be attributed to testing error, continue product dilution until the actual endotoxin concentration can be calculated. These results should be recorded on your worksheets.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果在同一次检测中得到相互矛盾的结果，化验员应遵守US<85>P“凝胶法限度测 试”结果诠释中的复测指导。正如第<85>章所述，如果低于MVD时检测结果不合 格，应使用不超过MVD的较大稀释倍数重复检测。该检测不合格结果记录要放在 实验室结果中。如果在MVD执行检测并得到不可归因于检测错误的OOS结果，则 要持续稀释产品直到实际内毒素浓度可计算为止。这些结果均应记录在你的工作表 中。"
    },
    {
        "instruction":"已知信息：\n'Microorganisms detected in the grade A and grade B areas should be identified to species level and the potential  impact  of such microorganisms  on product  quality  (for  each batch  implicated)  and  overall  state  of control should be evaluated. Consideration should also be given to the identification of microorganisms detected in grade C and D areas (for example where action limits or alert levels are exceeded) or following the isolation of organisms that may indicate a loss of control, deterioration in cleanliness or that may be difficult to control such as spore-forming microorganisms and moulds and at a sufficient frequency to maintain a current understanding of\nthe typical flora of these areas.'可被翻译为：如果 A 级和 B 级区监测到微生物，应将其鉴定到种，并应评估此类微生物对产品质量（每个相关批次）和 整体受控状态的潜在影响。还应考虑对 C 级和 D 级区检出的微生物进行鉴定（例如，超出行动限或警戒限）， 或在分离出可能表明洁净度失控、恶化的微生物或难以控制的微生物（例如可形成孢子的微生物和霉菌）后进行鉴定，并定期充分更新对这些区域中典型菌群的认知。\n'The equipment should be installed in at least a grade C environment, provided that grade A\/B clothing is used. The microbiological monitoring of operators wearing grade A\/B clothing in a grade C area, should be performed in  accordance  with  risk   management  principles,   and  the   limits  and  monitoring   frequencies  applied  with consideration of the activities performed by these operators.'可被翻译为：如果使用 A\/B 级工作服，设备应至少安装在 C 级环境中。在 C 级区穿着 A\/B 级工作服的操作人员的微生物监测应按照风险管理原则进行，应考虑这些操作人员所从事的活动来确定适用的限值和监测频率。\n'Cleanroom gowning should be performed in change rooms of an appropriate cleanliness grade to ensure\ngown cleanliness is maintained. Outdoor clothing including socks (other than personal underwear) should not be\nbrought into changing rooms leading directly to grade B and C areas. Single or two-piece facility trouser suits,\ncovering the full length of the arms and the legs, and facility socks covering the feet, should be worn before entry\nto change rooms for grades B and C. Facility suits and socks should not present a risk of contamination to the\ngowning area or processes.'可被翻译为：洁净室更衣应在适当洁净级别的更衣室进行，以确保维持工作服的洁净度。不得将包括袜子在内的便服（个\n人内衣除外）带入直接通往 B 级和 C 级区的更衣室。在进入 B 级和 C 级的更衣室之前，应穿着覆盖整个\n手臂和腿部的连体服或分体式工作服，以及覆盖脚部的工作袜。工作服和工作袜不应对更衣区或者工艺带\n来污染风险。\n'The table below provides an example of documentation commonly required for the transfer of technology.'可被翻译为：下表是技术转移通常所需文件举例\n\n根据上述已知信息，请将'A description of typical clothing required for each cleanliness grade is given below:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"各洁净级别通常要求的着装说明如下："
    },
    {
        "instruction":"已知信息：\n'The Medical Device Distribution License applies the uniform format made by NMPA, and shall be printed by the department in charge of drug supervision and administration at the level of a city divided into districts.'可被翻译为：医疗器械经营许可证由国家药品监督管理局统一样式，由设区的市级负责药品监督管理的部门印制。\n'Article 18 If a medical device manufacturer establishes the manufacturing premises across the province, autonomous region or municipality directly under the central government, it shall apply to the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the manufacturing premises is located for Medical Device Manufacturing License.'可被翻译为：第十八条  医疗器械生产企业跨省、自治区、直辖市设立生产场地的，应当向新设生产场地所在地省、自治区、直辖市药品监督管理部门申请医疗器械生产许可。\n'After receiving the report, the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device distributor or using unit is located shall, in a timely manner, inform the food and drug regulatory department of the province, autonomous region, or municipality directly under the Central Government where the medical device manufacturer is located.'可被翻译为：医疗器械经营企业、使用单位所在地省、自治区、直辖市食品药品监督管理部门收到报告后，应当及时通报医疗器械生产企业所在地省、自治区、直辖市食品药品监督管理部门。\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government shall be responsible for supervision and administration of medical device distribution within their administrative areas.'可被翻译为：省、自治区、直辖市药品监督管理部门负责本行政区域的医疗器械经营监督管理工作。\n\n根据上述已知信息，请将'The Medical Device Manufacturing License applies the uniform format made by NMPA, and shall be printed by the drug regulatory department of the province, autonomous region, or municipality directly under the central government.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械生产许可证由国家药品监督管理局统一样式，由省、自治区、直辖市药品监督管理部门印制。"
    },
    {
        "instruction":"已知信息：\n'Article 14 The Medical Device Manufacturing License consists of the original and duplicate, with a valid term of 5 years. Both the original and the duplicate shall be indicated with the license number, enterprise name, unified social credit identifier, legal representative (person in charge of the enterprise), domicile, manufacturing address, manufacturing scope, license issuing department, date of issuance, and valid term. The duplicate shall record changes in items stated in the original copy or major modification of the production line and other conditions. Items such as the enterprise name, unified social credit identifier, legal representative (person in charge of the enterprise) and domicile, etc. shall be consistent with those stated in the Business License.'可被翻译为：第十四条  医疗器械生产许可证分为正本和副本，有效期为5年。正本和副本载明许可证编号、企业名称、统一社会信用代码、法定代表人（企业负责人）、住所、生产地址、生产范围、发证部门、发证日期和有效期限。副本记载许可证正本载明事项变更以及车间或者生产线重大改造等情况。企业名称、统一社会信用代码、法定代表人（企业负责人）、住所等项目应当与营业执照中载明的相关内容一致。\n'Article 14 The Medical Device Distribution License shall be valid for 5 years, and indicated with the license number, enterprise name, unified social credit identifier, legal representative, person in charge of the enterprise, domicile, distribution premises, distribution mode, distribution scope, warehouse address, license issuing department, date of issuance, and valid term, etc.'可被翻译为：第十四条  医疗器械经营许可证有效期为5年，载明许可证编号、企业名称、统一社会信用代码、法定代表人、企业负责人、住所、经营场所、经营方式、经营范围、库房地址、发证部门、发证日期和有效期限等事项。\n'Article 14 The Drug Manufacturing Certificate shall describe the following information including license number, classification code, company name, unified social credit code, residence (business place), name of the legal representative, name of the company principal, name of production responsible person, name of quality responsible person, name of the qualified person, address of manufacturing site and manufacturing scope, the authority which issues the Certificate, the date of issuance, and the valid term etc.'可被翻译为：第十四条 药品生产许可证应当载明许可证编号、分类码、企业名称、统一社会信用代码、住所（经营场所）、法定代表人、企业负责人、生产负责人、质量负责人、质量受权人、生产地址和生产范围、发证机关、发证日期、有效期限等项目。\n'Items such as company name, unified social credit code, residence (business place) and legal representative etc. shall be consistent with that described in the business license issued by the administrations of market regulation.'可被翻译为：企业名称、统一社会信用代码、住所（经营场所）、法定代表人等项目应当与市场监督管理部门核发的营业执照中载明的相关内容一致。\n\n根据上述已知信息，请将'Article 15 The Cosmetics Manufacturing License shall be indicated with the license number, the manufacturer’s name, domicile, manufacturing address, unified social credit identifier, legal representative or responsible person, the manufacturing licensed items, expiry date, issuing authority and date of issuance, etc.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十五条 化妆品生产许可证应当载明许可证编号、生产企业名称、住所、生产地址、统一社会信用代码、法定代表人或者负责人、生产许可项目、有效期、发证机关、发证日期等。"
    },
    {
        "instruction":"已知信息：\n'(3) the distribution scope and mode of medical devices;'可被翻译为：（三）医疗器械经营范围、经营方式；\n'(3) issue a Drug Manufacturing Certificate, Drug Distribution Certificate, or Pharmaceutical Preparation Certificate for Medical Institution to organizations which do not satisfy the criteria.'可被翻译为：（三）对不符合条件的单位颁发药品生产许可证、药品经营许可证或者医疗机构制剂许可证。\n'(3) having storage conditions compatible with the distribution scope and scale;'可被翻译为：（三）与经营范围和经营规模相适应的贮存条件；\n'(4) being ordered to stop selling, being revoked the drug approval documents or being revoked the drug distribution certificate by the drug regulatory department due to illegal acts;'可被翻译为：（四）因违法行为被药品监督管理部门责令停止销售、吊销药品批准证明文件或者吊销药品经营许可证的；\n\n根据上述已知信息，请将'(3) selling drugs beyond the scope of the drug distribution certificate;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）超过药品经营许可范围销售药品的；"
    },
    {
        "instruction":"已知信息：\n'carry-over'可被翻译为：残留效应\n'Phototoxicity due to cellular, biochemical or physiological alterations caused by the drug or excipient, but not related to photochemical reactivity of the drug or excipient (e.g., perturbation of heme homeostasis).'可被翻译为：由药物或辅料引起的细胞、生化或生理变 化导致的光毒性，与药物或辅料的光化学反应性无关（ 如血 红素稳态异常）。\n'Contamination of a material or product with another material or product.'可被翻译为：一种原料或制品污染了另一种原料或制品。\n'A temporary condition in which a process goes through a dynamic change. This change may be due to a disturbance or an intentional alteration in the selected operating conditions (e.g., start-up, shutdown, changes from one operating condition to another).'可被翻译为：工艺中的一个基本步骤。单元操作涉及物理、化学或生物转化，如反应、结晶、过滤、混合、制粒、压片、细胞培养、纯化或病毒灭活。\n\n根据上述已知信息，请将'The blending of carry-over material from one grade of an excipient with another, usually due to a continuous process.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通常由于一个连续的过程，将一种等级的赋形剂的残留物质与另一种等级的赋形剂混合。"
    },
    {
        "instruction":"已知信息：\n'After review and approval, NMPA published the YY 0096-2019 Co-60 Teletherapy Unit and other 26 medical device industry standards, as well as the No. 1 amendment form for YY 0285.3-2017 Intravascular catheters—Sterile and single-use catheters—Part 3: Central venous catheters medical device industry standard on May 31, 2019. See Annex for the standard code, name, scope of application, date of implementation and contents of the amendment (Annex omitted).'可被翻译为：经审查和批准，国家药监局发布了YY 0096-2019《钴-60远距离治疗机》和其他26项医疗器械行业标准，以及YY0285.3-2017《血管内导管 一次性使用无菌导管 第3部分：中心静脉导管》医疗器械行业标准第1号修改单于2019年5月31日。标准编号、名称、适用范围、实施日期和修改单内容见附件（附件略）。\n'NMPA Issued 27 Medical Device Industry Standards (Covering YY 0096-2019 Co-60 Teletherapy Unit) and 1 Amendment Form'可被翻译为：关于发布YY 0096—2019《钴-60远距离治疗机》等27项医疗器械行业标准和1项修改单的公告\n'On November 13, 2019, NMPA issued the Announcement on 21 Medical Device Industry Standards such as YY\/T 0464-2019 Single-Use Hemoperfutor and 1 Modification Order. For the codes, names, scope of application and implementation date of the standards, please see the attachment (omitted).'可被翻译为：2019年11月13日，国家药监局审定通过并发布了YY\/T 0464-2019《一次性使用血液灌流器》等21项医疗器械行业标准和YY\/T 0953-2015《医用羧甲基壳聚糖》医疗器械行业标准第1号修改单。标准编号、名称、适用范围和实施日期详见附件（省略）。\n'Article 23 Where modification is needed because certain technical content affects application of the standard or the original standard needs minor addition or deletion after the medical device standard has been approved and issued, a standards amendment form shall be used. The standards amendment form shall be prepared in accordance with the procedures for standards formulation and revision, and reviewed and issued by the original approval department for the medical device standard.'可被翻译为：第二十三条 医疗器械标准批准发布后，因个别技术内容影响标准使用、需要进行修改，或者对原标准内容进行少量增减时，应当采用标准修改单方式修改。标准修改单应当按照标准制修订程序制定，由医疗器械标准的原批准部门审查发布。\n\n根据上述已知信息，请将'After review and approval, NMPA published the YY0096-2019 Co-60 Teletheraphy Unit and other 26 medical device industry standards, as well as the No.1 amendment form for YY0285.3-2017 Intravascular catheters-Sterile and single-use catheters-Part 3: Central venous catheters medical device industry standard on May 31, 2019. See Annex for the standard code, name, scope of application, date of implementation and contents of the amendment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药检局于2019年5月31日发布了YY 0096-2019《钴-60远距离治疗机》等27项医疗器械行业标准和YY0285.3-2017《血管内导管 一次性使用无菌导管 第3部分：中心静脉导管》医疗器械行业标准第1号修改单已经审定通过。标准编号、名称、适用范围、实施日期和修改单内容见附件。"
    },
    {
        "instruction":"已知信息：\n'The sale of drugs prescribed in item (1) to item (3) of the preceding paragraph, or the use of drugs prescribed in item (1) to item (5) of the preceding paragraph by drug use institutions, shall be punished in accordance with the provisions of the preceding paragraph. In serious circumstances, where the legal representative, the principal responsible person, the persons directly in charge, and other directly responsible persons as well as other responsible personnel that have a medical license, the medical license shall be subject to revocation.'可被翻译为：销售前款第一项至第三项规定的药品，或者药品使用单位使用前款第一项至第五项规定的药品的，依照前款规定处罚；情节严重的，药品使用单位的法定代表人、主要负责人、直接负责的主管人员和其他责任人员有医疗卫生人员执业证书的，还应当吊销执业证书。\n'When finding any drug manufacturer or distributor violates the requirements in the previous paragraph of this article, the drug regulatory department shall seal up or seize the drugs concerned immediately and deal with the matter in accordance with law.'可被翻译为：药品监督管理部门发现药品生产、经营企业违反本条前款规定的，应当立即查封、扣押所涉药品，并依法进行处理。\n'Article 34 The relevant requirements for the combined application of different supplementary applications shall be implemented in accordance with the relevant requirements of the Provisions for Drug Registration.'可被翻译为：第三十四条 不同补充申请合并申报的有关要求按照《药品注册管理办法》相关规定执行。\n'(IV) The quality of drugs shall comply with relevant requirements such as drug standards;'可被翻译为：（四）药品质量符合药品标准等有关要求；\n\n根据上述已知信息，请将'Where a drug manufacturer violates Item (IV) or (V) of the preceding paragraph, re-registration of relevant drugs shall be prohibited in accordance with requirements of the Provisions for Drug Registration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品生产企业有前款规定第（四）项、第（五）项情形之一的，按照《药品注册管理办法》的规定对相应药品不予再注册。"
    },
    {
        "instruction":"已知信息：\n'Article 16 The organization being inspected and their related personnel shall, as required by the inspection team, timely specify person(s) responsible for the inspection site, open the relevant places or areas, cooperate with the inspection of related equipment and facilities, maintain normal production and operation conditions, provide true, valid and complete documents, records, receipts, vouchers, electronic data and other related materials, and truthfully answer the questions raised by the inspection team.'可被翻译为：第十六条 被检查单位及有关人员应当及时按照检查组要求，明确检查现场负责人，开放相关场所或者区域，配合对相关设施设备的检查，保持正常生产经营状态，提供真实、有效、完整的文件、记录、票据、凭证、电子数据等相关材料，如实回答检查组的询问。\n'The inspected institution shall introduce to the inspection team the development and manufacturing of the inspected variety in the institution and clarify the person in charge of the inspection site.'可被翻译为：被核查单位应当向核查组介绍核查品种在本单位开展的研究、生产等情况，明确核查现场负责人。\n'Article 29 At the beginning of the on-site inspection, the inspection team shall preside over the open meeting, present the authorization certificate to the applicant and the inspected institution, notify the inspector composition, inspection purpose and scope, declare inspection precautions and inspection disciplines, etc., and inform the rights and obligations of the inspected institution.'可被翻译为：第二十九条 现场核查开始时，核查组应当主持召开首次会议，向申请人和被核查单位出示授权证明文件，通报核查人员组成、核查目的和范围，声明检查注意事项及检查纪律等，告知被核查单位的权利和义务。\n'The inspected institution shall confirm the feedback from the inspection team, and may put forward different opinions, explanations, and explanations if there is any objection. The inspection team shall make further verification and make necessary adjustments to the relevant content of the on-site inspection report and the on-site inspection question sheet based on the inspection situation.'可被翻译为：被核查单位应当对核查组反馈的情况进行确认，有异议的，可提出不同意见、作出解释和说明。核查组应当就此予以进一步核实，并结合核实情况对现场核查报告、现场核查问题表相关内容进行必要调整。\n\n根据上述已知信息，请将'The inspected institution shall cooperate with the inspection team, open relevant venues, provide documents, records, electronic data, etc. required for the inspection in a timely manner, answer the inspection team's inquiries truthfully, and ensure the authenticity of the information provided.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"被核查单位应当配合核查组工作，开放相关场地，及时提供核查所需的文件、记录、电子数据等，如实回答核查组的询问，保证所提供的资料真实。"
    },
    {
        "instruction":"已知信息：\n'LAL manufacturers recommend the test sample to have a pH range of 6.0 to 8.0 for optimal assay performance. Since the lysate is buffered, sample dilutions in pyrogen-free water may be enough to test the sample with the LAL assay. Determine the pH of the sample with the added lysate and document the results. If pH adjustment is needed, use pyrogen-free acid, base or buffers.'可被翻译为：LAL生产商建议检测样本pH范围为6.0-8.0以优化检测表现。由于鲎试剂被缓冲， 样本在无热源水中的稀释级别可能足以使用LAL方法检测样本。将鲎试剂加入样 本中，检测pH值，记录结果。如果需要调整pH值，使用无热源的酸、碱或缓冲 液。\n'Primary and working cultures should be identified with the microorganism specie name, ATCC \n(American Type Culture Collection) number and preparation and expiration date. \nRecommended storage requirements for primary and working inoculum stock are specified in \nUSP <81>. To reduce assay variability, a primary stock culture of ≤ 14 days should be used to \nprepare a working stock culture; also, a working stock culture of ≤ 7 days should be used to \nprepare a test inoculum. The test microorganism bioactivity is known to decrease over time and \nadjustments to the test inoculum volume may be required to meet testing acceptance criteria (e.g. \nZOI diameters between 14-16 mm as exhibited by the median reference standard ([S3]).'可被翻译为：原代和工作培养物应标有微生物种类名称、ATCC（美国典型培养物保藏中心）编号以\n及制备和失效日期。USP <81> 中规定了原代和工作接种物的推荐储存要求。为减少测定\n变异性，应使用≤14 天的原代贮备培养物来制备工作贮备培养物；此外，应使用≤7 天\n的工作贮备培养物来制备测试接种物。已知测试微生物的生物活性会随着时间的推移而\n降低，因此可能需要调整测试接种量以满足测试可接受标准（例如，中值标准品 (【S3】) \n显示的 ZOI 直径在 14-16 毫米之间）。\n'Prepare a 1% stock solution by placing one (1) gram of sodium lauryl sulfate (SLS) into a depyrogenated glass flask and add 99 ml of pyrogen-free water. Allow the SLS to fully dissolve. This should be followed by filtration through a 10,000 MW depyrogenation membrane filter into a pyrogen-free glass or plastic container.'可被翻译为：向除热源处理的玻璃瓶中加入1g月桂基硫酸钠（SLS），再加入99ml无热源水，制备1%贮备溶液。让SLS完全溶解。用10000MW除热源膜过滤至无热源玻璃或塑料容器中。\n'NOTE: The USP does not require a specific volume of product to be added to each of the five sterile tubes. It is recommended that 20 mL\/tube be used to standardize testing for all ORS laboratories.'可被翻译为：注：USP没有要求将特定量的产品分别加入到五个无菌试管中。建议使用20mL\/管对所有FDA 实验室进行标准化测试。\n\n根据上述已知信息，请将'When using commercially purchased pyrogen-free water for product dilutions, it is recommended to transfer a working volume from the original stock container to an individual pyrogen-free test tube or flask in order to minimize back contamination. Run a negative control for the working volume for each sample run.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果产品稀释使用的是商业化采购的无热源水，建议从原始存贮容器中转移工作用 体积的水至单个无热源试管或烧瓶中，以最大程度减少背景污染。每次检测样品时 均要使用工作体积的水进行阴性对照试验。"
    },
    {
        "instruction":"已知信息：\n'(I) The applicant fails to carry out Manufacturing Site Inspection within the prescribed time limit, or fails to accept on-site inspection within the prescribed time limit, except for the legitimate reasons of force majeure such as natural disaster or government acts;'可被翻译为：(一)除自然灾害、政府行为等不可抗力的正当理由外，申请人未在规定时限内进行生产现场核查确认，或者不能在规定时限内接受现场核查的；\n'The applicant shall be subject to inspection within the specified timeline.'可被翻译为：申请人应当在规定时限内接受核查。\n'Where drug registration inspection and testing are initiated during review based on risks, relevant technical institutions shall complete inspection and testing within specified timelines.'可被翻译为：审评过程中基于风险启动药品注册核查、检验，相关技术机构应当在规定时限内完成核查、检验工作。\n'Article 23 CFDI shall organize the implementation of the registration inspection work within the registration inspection time limit, determine the inspection time, and notify the applicant and the inspected institution to accept the registration inspection. If a dynamic manufacturing on-site inspection is required, Manufacturing Site Inspection time shall be determined based on the applicant's dynamic production arrangement.'可被翻译为：第二十三条 核查中心在注册核查时限内，组织实施注册核查工作，确定核查时间，通知申请人和被核查单位接受注册核查。需要进行动态生产现场核查的，结合申请人动态生产安排确定生产现场核查时间。\n\n根据上述已知信息，请将'(5) The applicant refuses to accept drug registration inspection and testing or, without justifiable reasons, fails to accept drug registration inspection and testing within the specified timeline.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）申请人拒绝接受或者无正当理由未在规定时限内接受药品注册核查、检验的；"
    },
    {
        "instruction":"已知信息：\n'The requalification of cleanrooms and clean air equipment should be carried out periodically following defined procedures. The requalification should include at a minimum the following:'可被翻译为：洁净室和洁净空气设备的再确认应按照规定的程序定期执行。再确认应至少包括以下内容：\n'The manufacture of sterile products should be carried out in appropriate cleanrooms, entry to which should be through change rooms that act as airlocks for personnel and airlocks for equipment and materials. Cleanrooms and change rooms should be maintained to an appropriate cleanliness standard and supplied with air that has passed\nthrough filters of an appropriate efficiency. Controls and monitoring should be scientifically justified and should effectively evaluate the state of environmental conditions of cleanrooms, airlocks and pass-through hatches.'可被翻译为：无菌产品的生产应在适当的洁净室内进行，应通过更衣室（起到人员气锁及设备和物料气锁的作用）进入洁净室。洁净室和更衣室应保持适当的洁净度标准，并通过适当效率的过滤器送风。控制和监测应经过科学论证，并应有效地评估洁净室、气锁和传递窗的环境条件的状态。\n'Critical  process  parameters  for  BFS  should  be  determined  during  equipment  qualification  and  should include, but are not limited to:'可被翻译为：BFS 的关键工艺参数应在设备确认过程中确定，包括但不限于：\n'Critical  process  parameters  for  FFS  should  be  determined  during  equipment  qualification  and  should include, but are not limited to:'可被翻译为：FFS 的关键工艺参数应在设备确认过程中确定，包括但不限于：\n\n根据上述已知信息，请将'Appropriate requalification consisting of at least the above tests should also be carried out following completion of remedial action implemented to rectify an out of compliance equipment or facility condition or after changes to equipment, facility or processes as appropriate. The significance of a change should be determined through the change management process. Examples of changes to be considered include but are not limited to the following:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在纠正设备或设施缺陷而采取的整改措施完成后，或设备、设施或工艺的变更后，还应视情况进行上述检测进行适当的再确认。变更的重要性应通过变更管理程序确定。需要考虑的变更案例包括但不限于："
    },
    {
        "instruction":"已知信息：\n'This section contains supplemental information for the quantitative enumeration of viable microorganisms and the determination of the absence of specified microorganisms in finished pharmaceutical products and raw materials, previously referred to as Microbial Limits Testing (MLT). The detailed procedures for these tests are not addressed in this PMM chapter because they are found in USP<60> MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: TESTS FOR BURKHOLDERIA CEPACIA COMPLEX, USP<61> MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: MICROBIAL ENUMERATION TESTS and MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: TESTS FOR SPECIFIED MICROORGANISMS.'可被翻译为：本部分包括活体微生物定量计数和测定成品及原料药中不得检出的特定微生物的补充信息，以 前被称为微生物限度试验（MLT）。这些测试的详细程序没有列入本PMM中，因为可以在 USP<60>“非无菌药品的微生物检查：洋葱伯克霍尔德菌复合体的检测”、USP<61>“非无菌 产品的微生物检查：微生物计数检测”和“非无菌产品的微生物检查：特定微生物检测” 中找到。\n'f. <62> Microbiological Examination of Nonsterile products: Tests for Specified Microorganisms'可被翻译为：<62>非无菌药品的微生物检查\n'd. <60> Microbiological Examination of Nonsterile Products: Tests for Burkholderia cepacia complex'可被翻译为：<60>非无菌药品的微生物检查：洋葱伯克霍尔德菌复合物检测\n'2. Review the original results for the following: sterility, bacterial endotoxin, microbiological examination of nonsterile products: specified microorganisms and enumeration, \nantimicrobial- effectiveness test, bioburden determination, water quality control testing.'可被翻译为：查看以下原始结果：无菌性、细菌内毒素、非无菌产品的微生物限度：控制菌和计数、抑菌效力测试、生物负载测定、水质控制检测。\n\n根据上述已知信息，请将'e. <61> Microbiological Examination of Nonsterile products: Microbial enumeration tests'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"<61>非无菌药品的微生物检查：微生物计数"
    },
    {
        "instruction":"已知信息：\n'1.Contamination of a starting material, intermediate product or finished product with another starting material or product.\n2.Contamination of a starting material, intermediate product or finished product with another starting material or product during production.\n3.Contamination of a starting material, intermediate product or finished product with another starting material or product during production.\n4.Contamination of a material or product with another material or product.\n5.Contamination of a starting material, intermediate product or finished pharmaceutical product with another starting material or product during production, storage and transportation.\n6.Contamination of a starting material, intermediate product or ﬁnished pharmaceutical product or medical product with another starting material or product, during production, storage and transportation.'可被翻译为：1.一种原料、中间产品或成品被另一种原料或产品污染。\n2.一种原料、中间产品或成品在生产过程中被另一种原料或产品污染。\n3.一种原料、中间产品或成品在生产过程中被另一种原料或产品污染。\n4.污染:一种材料或产品被另一种材料或产品污染\n5.在生产、储存、运输过程中，原料药、中间产品或药品成品被另一原料药或产品污染的。\n6.在生产、储存、运输过程中，原料药、中间产品、药品、医疗产品被其他原料药、产品污染的。\n'The date when a starting or packaging material, after storage for a certain period, should be re-examined to ensure that it is still suitable for its intended use. The retest date is determined by the manufacturer.'可被翻译为：原辅料、包装材料贮存一定时间后，为确保其仍适用于预定用途，由企业确定的需重新检验的日期。\n'Raw, starting and packaging material attributes;'可被翻译为：原料、起始物料和包装材料属性；\n'1.All operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product. Sterile filling would not normally be regarded as part of packaging, the bulk product being the filled, but not the finally packaged, primary container.\n2.All operations, including filling and labelling, that a bulk product has to undergo in order to become a finished product. Filling of a sterile product under aseptic conditions or a product intended to be terminally sterilized, would not normally be regarded as part of packaging.'可被翻译为：1.散装产品为成为成品而必须经历的所有操作，包括灌装和贴标签。无菌灌装通常不被视为包装的一部分，散装产品是被灌装的，但不是最终包装的主要容器。\n2.散装产品为成为成品而必须经历的所有操作，包括灌装和贴标签。在无菌条件下灌装无菌产品或打算最终灭菌的产品，通常不被视为包装的一部分。\n\n根据上述已知信息，请将'A sample of a batch of starting material, packaging material, product contained in its primary packaging, or finished product that is stored for the purpose of being analysed, should the need arise. This may include storage in a suitable bulk container.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一批起始原料、包装材料、包含在其主要包装中的产品或成品的样品，如果需要，为分析目的而储存。这可能包括储存在合适的散装容器中。"
    },
    {
        "instruction":"已知信息：\n'Drugs with severe toxicity, therapeutic doses close to toxic doses, and improper use of which can cause poisoning or death.'可被翻译为：毒性剧烈、治疗剂量与中毒剂量相近，使用不当会致人中毒或死亡的药品。\n'The branch of toxicology that deals with the toxic effects of foreign chemicals, especially at low doses of chronic exposure, on human neurobehavior, that is, human mental functioning.'可被翻译为：毒理学的一个分支，主要研究外源化学物特别是在低剂量慢性接触对人的神经行为，即人的心理功能的毒性效应。\n'After long-term exposure to some chemicals, the prototype of the chemical or its metabolites can not be detected in the body, but chronic toxic effects appear.'可被翻译为：有些化学物经长期接触后，在体内测不出该化学物的原型或其代谢产物，却出现了慢性毒性作用。\n'Toxic effects observed in laboratory animals.'可被翻译为：在实验动物中观察到的毒性效应。\n\n根据上述已知信息，请将'Medications that can pose occupational exposure risks or hazards, including those with genotoxic, carcinogenic, teratogenic effects, or those causing reproductive harm. Additionally, drugs with severe organ toxicity or other significant toxic effects at low doses fall into this category.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"能产生职业暴露危险或者危害的药品，即具有遗传毒性、致癌性、致畸性，或者对生育有损害作\n用以及在低剂量下可产生严重的器官或其他方面毒性的药品。"
    },
    {
        "instruction":"已知信息：\n'Where a drug retailer, in violation of the second paragraph of Article 18 of the Provisions, sells prescription drugs or Class A non-prescription drugs in absence of licensed pharmacists or other qualified pharmaceutical professionals, it shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so, it shall be fined not more than RMB 1,000 yuan.'可被翻译为：违反本办法第十八条第二款规定，药品零售企业在执业药师或者其他依法经过资格认定的药学技术人员不在岗时销售处方药或者甲类非处方药的，责令限期改正，给予警告；逾期不改正的，处以一千元以下的罚款。\n'The online drug retailers shall display prescription drugs and non-prescription drugs separately, and prominently mark prescription drugs and non-prescription drugs on relevant web pages.'可被翻译为：药品网络零售企业应当将处方药与非处方药区分展示，并在相关网页上显著标示处方药、非处方药。\n'The online drug retailers shall not, in violation of regulations, give prescription drugs and Class A non-prescription drugs to individuals in the form of gifts for buying drugs or buying commodities.'可被翻译为：药品网络零售企业不得违反规定以买药品赠药品、买商品赠药品等方式向个人赠送处方药、甲类非处方药。\n'Legally qualified pharmacists or other pharmaceutical professionals shall be responsible for the drug management, prescription examination and dispensing, and guidance of rational use of drugs.'可被翻译为：依法经过资格认定的药师或者其他药学技术人员负责本企业的药品管理、处方审核和调配、合理用药指导等工作。\n\n根据上述已知信息，请将'Any drug retailer selling prescription drugs or Class A non-prescription drugs shall, in the absence of its licensed pharmacists and other qualified pharmaceutical professionals, put up a public notice and stop selling prescription drugs and Class A non-prescription drugs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"经营处方药和甲类非处方药的药品零售企业，执业药师或者其他依法经资格认定的药学技术人员不在岗时，应当挂牌告知，并停止销售处方药和甲类非处方药。"
    },
    {
        "instruction":"已知信息：\n'Article 123 The quality management department or quality management personnel of enterprises shall fulfill the following responsibilities:'可被翻译为：第一百二十三条 企业应当设置质量管理部门或者配备质量管理人员，履行以下职责：\n'Article 28 The legal representative and the principal of a drug MAH shall be fully responsible for drug quality and fulfill the following responsibilities:'可被翻译为：第二十八条 药品上市许可持有人的法定代表人、主要负责人应当对药品质量全面负责，履行以下职责：\n'Article 17: The quality management department should participate in all quality related activities, and review all GMP related documents. The responsibilities of quality management personnel are not permitted to be delegated to personnel of other departments.'可被翻译为：第十七条 质量管理部门应当参与所有与质量有关的活动，负责审核所有与本规范有关的文件。质量管理部门人员不得将职责委托给其他部门的人员。\n'Article 122 The responsible person of an enterprise is the principal person in charge of drug quality, takes responsibilities for daily management of the enterprise and provides necessary conditions to ensure that the quality management department or quality management personnel effectively fulfill the responsibilities and that the enterprise distributes drugs according to the requirements in this GSP.'可被翻译为：第一百二十二条 企业负责人是药品质量的主要责任人，负责企业日常管理，负责提供必要的条件，保证质量管理部门和质量管理人员有效履行职责，确保企业按照本规范要求经营药品。\n\n根据上述已知信息，请将'Article 17 The quality management department shall fulfill the following responsibilities:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十七条 质量管理部门应当履行以下职责："
    },
    {
        "instruction":"已知信息：\n'Among the 5,574 applications requiring technical review, 4,459 were for chemical drugs, accounting for 80% of all those for technical reviews, and 300 and 815 were for TCMs and biologicals, respectively.'可被翻译为：需技术审评的5574件注册申请中，化药为4459件，占全部需技术审评的注册申请受理量的80%，中药和生物制品注册申请分别为300件和815件。\n'In 2019, 6,199 registration applications requiring technical review were accepted, increased by 11.21% as compared with those in 2018. Among them, 4,937 registration applications were for chemical drugs, increased by 10.72% as compared with those in 2018, accounting for 79.64% of the total number of registration applications requiring technical review; 257 registration applications were for TCMs, decreased by 14.33% as compared with those in 2018;1,005 registration applications were for biological products, increased by 23.3% as compared with those in 2018. The details of acceptance of registration applications for chemical drugs, TCMs and biological products requiring technical review in 2016-2019 are shown in Figure 2.'可被翻译为：2019年，受理需技术审评的注册申请6199件，较2018年增加11.21%，其中化学药注册申请为4937件，较2018年增长了10.72%，占全部需技术审评的注册申请受理量的79.64%；中药注册申请257件，较2018年降低了14.33%；生物制品注册申请1005件，较2018年增长了23.3%。2016-2019年需技术审评的化学药、中药和生物制品注册申请受理情况详见图2。\n'Of the applications with completed review, 6,624 were registered for chemical drugs, accounting for about 83%. The completion status of various types of drug registration applications in 2015-2018 is detailed in Figure 12.'可被翻译为：完成审评的申请中，化药注册申请为6624件，约占全部审评完成量的83%。2018年各类药品注册申请审评完成情况与近三年比较详见图12。\n'In 2019, a total of 8,730 registration applications (including 5 drug-device combination products) were subject to review and approval, of which 6817 applications were subject to technical review(including 4,075 applications subject to technical review and administrative approval of CDE), and the rest 1,908 applications were subject to direct administrative approval. The number of registration applications subject to review and approval and those pending for review and approval has dropped from nearly 22,000 at the peak of September 2015 to 4,423 (excluding those applications whose review have been completed and are pending for the Applicants' supplementary materials) by the end of 2019, consolidating the reform accomplishment of liquidating the backlog of registration applications as required by Document No.44.'可被翻译为：2019年完成审评审批的注册申请共8730件（含器械组合产品5件），其中完成需技术审评的注册申请6817件（含4075件需药审中心技术审评和行政审批注册申请），完成直接行政审批的注册申请1908件。2019年底在审评审批和等待审评审批的注册申请已由2015年9月高峰时的近22000件降至4423件（不含完成审评因申报资料缺陷等待申请人回复补充资料的注册申请），巩固了44号文件要求解决注册申请积压的改革成效。\n\n根据上述已知信息，请将'Among the 6,817 registration applications with completed technical review, 300 applications were for TCMs , 1104 applications were for biological products, and 5,413 applications were for chemical drugs (accounting for about 79% of all completed reviews).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"完成技术审评的6817件注册申请中，中药注册申请300件，生物制品注册申请1104件，化学药注册申请为5413件，化学药注册申请约占全部审评完成量的79%。"
    },
    {
        "instruction":"已知信息：\n'The State formulates development planning and industry policies for the vaccine industry to support development and structural optimization of the vaccine industry, and encourages scale and intensive production and constant improvement on the production process and quality of vaccines.'可被翻译为：国家制定疫苗行业发展规划和产业政策，支持疫苗产业发展和结构优化，鼓励疫苗生产规模化、集约化，不断提升疫苗生产工艺和质量水平。\n'Section 2  Production of New Drugs'可被翻译为：第二节 新药生产\n'(VII) Improving production process, design and product technical requirements etc.;'可被翻译为：（七）改进生产工艺、设计、产品技术要求等；\n'Article 3 MAHs shall proactively carry out post-approval study of drugs to realize the lifecycle management of drugs. It is encouraged that MAHs shall continuously improve and optimize the production process by using new production technologies, new methods, new equipment and new scientific and technological achievements, continuously improve drug quality and improve drug safety, efficacy and quality.'可被翻译为：第三条 持有人应当主动开展药品上市后研究，实现药品全生命周期管理。鼓励持有人运用新生产技术、新方法、新设备、新科技成果，不断改进和优化生产工艺，持续提高药品质量，提升药品安全性、有效性和质量可控性。\n\n根据上述已知信息，请将'The branch of pharmacy that studies the industrial production of drugs and provides scientific basis and technical support for the design of new drugs and dosage forms, the improvement of production technology and the improvement of product quality.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"研究药品的工业化生产，为新药和新剂型的设计、生产工艺的改进和产品质量的提高提供科学依据和技术支持的药学分支学科。"
    },
    {
        "instruction":"已知信息：\n'The estimation of the risk associated with the identified hazards. (ICH Q9)'可被翻译为：与已识别的危害相关的风险评估。（ICH Q9）\n'A systematic process for the assessment, control, communication, and review of risks to the quality of the drug product across the product lifecycle. (ICH Q9)'可被翻译为：对产品生命周期中药品质量风险进行评估、控制、沟通和回顾的系统过程。（ICHQ9）\n'All phases in the life of the product from the initial development through marketing until the product’s discontinuation. (ICH Q9)'可被翻译为：从最初的研发到上市直至撤市的产品生命中的所有阶段。（ICH Q9）\n'The systematic application of quality management policies, procedures, and practices to the tasks of assessing, controlling, communicating, and reviewing risk. (ICH Q9)'可被翻译为：系统地应用质量管理策略、程序和规范进行风险的评估、控制、沟通和回顾。（ICH Q9）\n\n根据上述已知信息，请将'A measure of the possible consequences of a hazard. (ICH Q9)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种危害所造成可能结果的量度。（ICH Q9）"
    },
    {
        "instruction":"已知信息：\n'good storage practices (gsp)'可被翻译为：良好存储规范(GSP)\n'BEST PRACTICES'可被翻译为：最优方案\n'g. <1117> Microbiological Best Laboratory Practices'可被翻译为：<1117>微生物最佳实验室规范\n'Good Laboratory Practices'可被翻译为：非临床研究质量管理规范\n\n根据上述已知信息，请将'In addition to following good cell culture practices, analysts should note the availability of a specific guidance that contains principles and best practices in the procurement, banking, testing, and storage of hESCs for research purposes (see the ISCB 2009 reference in the Appendix). This guidance is useful for both iPSC and hESC lines.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"除了遵循良好的细胞培养规范外，分析人员应该还注意到一个具体的指南的可用性，其中包含用于研究目的hESCs的采购、存储机构、测试和存储的原则 (参见附录中的ISCB 2009参考)。本指南对iPSC和hESC都是实用的。"
    },
    {
        "instruction":"已知信息：\n'(1) To alter the dosage form of a non-prescription drug determined by the State Food and Drug Administration without changing the indications or functions, dosage and route of administration; or'可被翻译为：（一）经国家食品药品监督管理局确定的非处方药改变剂型，但不改变适应症或者功能主治、给药剂量以及给药途径的药品；\n'A New Drug Certificate shall not be issued to the approved registration applications for changing dosage forms without changing route of administration or claiming for new indications, with exceptions for special dosage forms such as targeting delivery, sustained release and controlled release preparations, etc.'可被翻译为：改变剂型但不改变给药途径，以及增加新适应症的注册申请获得批准后不发给新药证书；靶向制剂、缓释、控释制剂等特殊剂型除外。\n'Misallocation of drug varieties, specifications, dosages, dose switches, dosage forms and routes of administration.'可被翻译为：错误地调配药品品种、规格、剂量、剂量转换、剂型及用药途径等。\n'(1) Drugs with the same active ingredients, indications, dosage forms and strengths as non-prescription drugs that have been marketed within the territory of the People's Republic of China;'可被翻译为：（一）境内已有相同活性成分、适应症（或者功能主治）、剂型、规格的非处方药上市的药品；\n\n根据上述已知信息，请将'(2) Drugs developed by changing the dosage forms or strength of non-prescription drugs authorized by the NMPA without changing the indications, dosages or administration routes;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）经国家药品监督管理局确定的非处方药改变剂型或者规格，但不改变适应症（或者功能主治）、给药剂量以及给药途径的药品；"
    },
    {
        "instruction":"已知信息：\n'Article 299: A person should be designated as responsible for execution and coordination of recalls and should be supported by sufficient staff. This responsible person should be independent of the sales and marketing organization. If this person is not the Authorized Person, the latter should be made aware of any recall activity.'可被翻译为：第二百九十九条 应当指定专人负责组织协调召回工作，并配备足够数量的人员。产品召回负责人应当独立于销售和市场部门；如产品召回负责人不是质量受权人，则应当向质量受权人通报召回处理情况。\n'Batch records stored electronically should be protected by back-up transfer on magnetic tape, microfilm, paper or other means. It is particularly important that the data are safe, and readily available throughout the period of retention.'可被翻译为：用电子方法保存的批记录，应当采用磁带、缩微胶卷、纸质副本或其他方法进行备份，以确保记录的安全，且数据资料在保存期内便于查阅。\n'Article 298: Operation procedures for recall should be established to ensure the effectiveness of recalls.'可被翻译为：第二百九十八条 应当制定召回操作规程，确保召回工作的有效性。\n'Article 23 The legal representative and principal responsible person of vaccine MAHs shall have good credit records, and personnel in key positions such as the responsible person for manufacturing management, the responsible person for quality management and the quality authorized person shall have relevant professional background and work experience.'可被翻译为：第二十三条 疫苗上市许可持有人的法定代表人、主要负责人应当具有良好的信用记录，生产管理负责人、质量管理负责人、质量受权人等关键岗位人员应当具有相关专业背景和从业经历。\n\n根据上述已知信息，请将'Article 302: The distribution records should be readily available to the person(s) responsible for recalls.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三百零二条 产品召回负责人应当能够迅速查阅到药品发运记录。"
    },
    {
        "instruction":"已知信息：\n'Article 66 The State buildss vaccines into the stockpile of strategic materials, implementing the stockpile at the national and provincial levels.'可被翻译为：第六十六条 国家将疫苗纳入战略物资储备，实行中央和省级两级储备。\n'Article 26 The State implements lot release system for vaccines.'可被翻译为：第二十六条 国家实行疫苗批签发制度。\n'Article 22 The State implements strict access system for vaccine manufacturing.'可被翻译为：第二十二条 国家对疫苗生产实行严格准入制度。\n'Article 68 The State implements a compulsory liability insurance system for vaccines.'可被翻译为：第六十八条 国家实行疫苗责任强制保险制度。\n\n根据上述已知信息，请将'Article 92 The State implements a drug stockpile system by the establishment of national and local drug stockpile.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第九十二条 国家实行药品储备制度，建立中央和地方两级药品储备。"
    },
    {
        "instruction":"已知信息：\n'Article 78  The content of medical device adverse event report, risk analysis and evaluation report and statistical data are the basis for strengthening   supervision and administration on medical devices and guiding proper use, but shall not serve as the basis for medical disputes, medical litigation or handling quality accident of medical devices.'可被翻译为：第七十八条  医疗器械不良事件报告的内容、风险分析评价报告和统计资料等是加强医疗器械监督管理、指导合理用械的依据，不作为医疗纠纷、医疗诉讼和处理医疗器械质量事故的依据。\n'A drug list and prescribing manual reviewed and formulated by the drug treatment Committee of a medical institution. It is the basis and basis for the purchase, management and rational use of drugs.'可被翻译为：由医疗机构药物治疗委员会审核制定的药品目录和处方手册。是采购、管理及合理使用药品的基础和依据。\n'(XIII) Management of pharmaceutical services such as providing consultation on drug use and guiding rational use of drugs;'可被翻译为：（十三）提供用药咨询、指导合理用药等药学服务的管理；\n'Distribution of drug categories involved in ADR\/ADE reports'可被翻译为：药品不良反应\/事件报告涉及药品情况\n\n根据上述已知信息，请将'Article 57 The contents and statistical data of ADR reports are the basis for strengthening drug regulation and providing guidance for rational drug use.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十七条 药品不良反应报告的内容和统计资料是加强药品监督管理、指导合理用药的依据。"
    },
    {
        "instruction":"已知信息：\n'ammonia nitrogen'可被翻译为：氨氮\n'nichrome coil'可被翻译为：镍铬线圈\n'amino nitrogen'可被翻译为：氨基氮\n'nitrogen equilibrium'可被翻译为：氮平衡\n\n根据上述已知信息，请将'Nitrogen in the medium in the form of ammonia and coil ions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"培养基中以氨与卷离子形式存在的氮。"
    },
    {
        "instruction":"已知信息：\n'Article 86 The clinical trial report shall be signed and dated by the investigator, and submitted to the sponsor after being issued with opinions, dated and affixed with the seal of the clinical trial institution by the medical device clinical trial management department of the clinical trial institution.'可被翻译为：第八十六条 临床试验报告应当由研究者签名、注明日期，经临床试验机构医疗器械临床试验管理部门审核出具意见、注明日期并加盖临床试验机构印章后交申办者。\n'Article 83 The investigator shall verify or confirm the safety and effectiveness of the investigational medical device in accordance with the design requirements of the clinical trial protocol and complete the clinical trial report. The clinical trial report of a multicenter clinical trial shall include the summaries of each clinical trial of the sub-site.'可被翻译为：第八十三条 研究者应当按照临床试验方案的设计要求，验证或者确认试验用医疗器械的安全性和有效性，并完成临床试验报告。多中心临床试验的临床试验报告应当包含各分中心的临床试验小结。\n'Article 17 Before the clinical trial, the sponsor shall submit the following materials to the ethics committee through the investigator and the medical device clinical trial management department of the clinical trial institution:'可被翻译为：第十七条 临床试验前，申办者应当通过研究者和临床试验机构的医疗器械临床试验管理部门向伦理委员会提交下列文件：\n'Article 84 For a multicenter clinical trial, the clinical trial summaries of each sub-site shall include at least a summary of the clinical trial, clinical general information, information for the investigational medical device and the compared device, safety and effectiveness data sets, incidence rate of the adverse events, description of deviation from the protocol and the case report form.'可被翻译为：第八十四条 对于多中心临床试验，各分中心临床试验小结应当至少包括临床试验概况、临床一般资料、试验用医疗器械以及对照用医疗器械的信息描述、安全性和有效性数据集、不良事件的发生率以及处理情况、方案偏离情况说明等，并附病例报告表。\n\n根据上述已知信息，请将'In a multicenter clinical trial, the summaries of each clinical trial of sub-site shall be signed and dated by the investigator of the corresponding center, and reviewed, dated and affixed with the seal of the clinical trial institution by the medical device clinical trial management department of the center, and then submitted to the leading unit.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"多中心临床试验中，各分中心临床试验小结应当由该中心的研究者签名并注明日期，经该中心的医疗器械临床试验管理部门审核、注明日期并加盖临床试验机构印章后交牵头单位。"
    },
    {
        "instruction":"已知信息：\n'Article 48 In case of discovering the following serious illegal acts, the operator of cosmetic e-commerce platform shall immediately suspend provision of e-commerce platform services for the marketers of cosmetics in the platform:'可被翻译为：第四十八条 化妆品电子商务平台经营者发现有下列严重违法行为的，应当立即停止向平台内化妆品经营者提供电子商务平台服务：\n'If the operators of cosmetic e-commerce platform know or shall know that the cosmetic marketers in the platform are prohibited from engaging in manufacturing and marketing of cosmetics according to law, they shall not provide e-commerce platform services to such marketers.'可被翻译为：化妆品电子商务平台经营者知道或者应当知道平台内化妆品经营者被依法禁止从事化妆品生产经营活动的，不得向其提供电子商务平台服务。\n'The operators of cosmetic e-commerce platform shall assume the responsibility for managing cosmetic marketers within the platform according to law, make daily inspection of the marketing behavior of the cosmetic marketers within the platform, urge the cosmetic marketers within the platform to perform obligations specified in the Regulations on Supervision and Administration of Cosmetics and these Provisions according to law. In case of discovering illegal marketing of cosmetics, the inspectors shall stop timely by necessary means of deleting, shielding and unlinking, etc. in accordance with the laws or with service agreement and trading provisions of the platform, and report to the drug regulatory department of the province, autonomous region or municipality directly under the central government of the place where it is located.'可被翻译为：化妆品电子商务平台经营者应当依法承担平台内化妆品经营者管理责任，对平台内化妆品经营者的经营行为进行日常检查，督促平台内化妆品经营者依法履行化妆品监督管理条例以及本办法规定的义务。发现违法经营化妆品行为的，应当依法或者依据平台服务协议和交易规则采取删除、屏蔽、断开链接等必要措施及时制止，并报告所在地省、自治区、直辖市药品监督管理部门。\n'Article 45 The operators of cosmetic e-commerce platform shall register the real names of the cosmetic marketers who apply for being stationed in the platform, ask them to submit authentic information on their identity, address and contact information, etc., conduct verification and registration, establish registration files, and carry out verification and updating at least once every 6 months. Operator of an e-commerce platform shall keep identity information of the cosmetic marketers inside the platforms for not less than 3 years from the date of their withdrawal from the platform.'可被翻译为：第四十五条 化妆品电子商务平台经营者应当对申请入驻的平台内化妆品经营者进行实名登记，要求其提交身份、地址、联系方式等真实信息，进行核验、登记，建立登记档案，并至少每6个月核验更新一次。化妆品电子商务平台经营者对平台内化妆品经营者身份信息的保存时间自其退出平台之日起不少于3年。\n\n根据上述已知信息，请将'If the cosmetic marketers within the platform are placed on a file for investigation or are initiated a public prosecution due to being suspected of crime related with quality and safety of cosmetics, and there are evidences proving that this might cause potential harm to human health, then the operators of cosmetic e-commerce platform could suspend provision of e-commerce platform services for the cosmetic marketers within the platform in accordance with the laws or with the service agreement and trading provisions of the platform.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"因涉嫌化妆品质量安全犯罪被立案侦查或者提起公诉，且有证据证明可能危害人体健康的，化妆品电子商务平台经营者可以依法或者依据平台服务协议和交易规则暂停向平台内化妆品经营者提供电子商务平台服务。"
    },
    {
        "instruction":"已知信息：\n'Article 14 The documents for registration application or filing shall be in Chinese, where they are translated from a foreign language, the original documents shall also be provided at the same time. When referring to unpublished literature, the applicant shall provide documents proving of the owner's permission to use the information.'可被翻译为：第十四条 申请注册或者办理备案的资料应当使用中文。根据外文资料翻译的，应当同时提供原文。引用未公开发表的文献资料时，应当提供资料所有者许可使用的证明文件。\n'Article 35 A label shall be attached to the minimum sales unit of cosmetics in Chinese. The label contents shall be consistent with the sample manuscript of the product label in registration or filing documents of the cosmetics.'可被翻译为：第三十五条 化妆品的最小销售单元应当有中文标签。标签内容应当与化妆品注册或者备案资料中产品标签样稿一致。\n'If the product is not managed as medical device in the country (region) where the applicant or filing entity is registered or the manufacture is carried out, the applicant or filing entity shall provide relevant proof documents, including the permission for distribution of sold product in the country (region) where the applicant or filing entity is registered or the manufacture is carried out.'可被翻译为：申请人或者备案人注册地或者生产地址所在国家（地区）未将该产品作为医疗器械管理的，申请人或者备案人需提供相关证明文件，包括注册地或者生产地址所在国家（地区）准许该产品上市销售的证明文件。\n'(3) Where supplementary documents are required from the applicant, the applicant shall be notified once of all the contents to be supplemented; the applicant shall provide supplementary documents at one time as required within 90 working days, and the evaluation time limit shall be recalculated after the technical assessment agency receives the supplementary documents; if the supplementary documents are not submitted within the specified timeline, the technical assessment agency shall make an evaluation conclusion of disapproval.'可被翻译为：（三）需要申请人补充资料的，应当一次告知需要补充的全部内容；申请人应当在90个工作日内按照要求一次提供补充资料，技术审评机构收到补充资料后审评时限重新计算；未在规定时限内补充资料的，技术审评机构应当作出技术审评不通过的审评结论。\n\n根据上述已知信息，请将'Article 12 The documents for registration application or filing shall be in Chinese. Where they are translated from another language, the original documents shall also be provided at the same time. When referring to unpublished literature, the applicant shall provide documents proving the owner’s permission to use the information.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十二条 申请注册或者办理备案的资料应当使用中文。根据外文资料翻译的，应当同时提供原文。引用未公开发表的文献资料时，应当提供资料所有者许可使用的证明文件。"
    },
    {
        "instruction":"已知信息：\n'Proportion of living cells among dead cells, usually determined by staining or colony counting methods after a certain treatment interval.'可被翻译为：存活细胞与死亡细胞的比例。通常经过一段给药时间后，采用染色或集落计数的方法来确定。\n'The process of combining two or more cells to form a single cell under natural conditions or by artificial means (physical, chemical, biological).'可被翻译为：在自然条件下或用人工方法（物理的、化学的、生物的）使两个或两个以上的细胞合并形成一个细胞的过程。\n'The ability of cells to divide and to form daughter cells.'可被翻译为：细胞分化以及形成子细胞的能力。\n'A mixture of leukotrienes, important inflammatory mediators in the body. Usually found in conjugated form in mast cells and neutrophils, it is bioactive in nanograms when stimulated by an allergen.'可被翻译为：白三烯的混合物，体内重要的炎症介质。通常以结合形式存在于肥大细胞及中性粒细胞中，当受过敏原刺激后即游离出来生物活性极强，纳克量即可发生作用。\n\n根据上述已知信息，请将'The efficiency of single cells to form clones. It is usually measured after seeding low numbers of cells in a suitable environment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单个细胞形成克隆的能力。通常将少量细胞接种于适宜的环境培养后测量。"
    },
    {
        "instruction":"已知信息：\n'When atoms form molecules, the atomic orbitals are linearly combined into molecular orbitals, which are called bonding orbitals if the energy of the constituent molecular orbitals is lower than the energy of the atomic orbitals.'可被翻译为：原子组成分子时，原子轨道线性组合成分子轨道，组成的分子轨道的能量若低于原子轨道的能量，则该分子轨道叫做成键轨道。\n'When atoms form molecules, the atomic orbitals are linearly combined into the component F orbitals, and the energy of the component molecular orbitals is equal to the energy of the atomic orbitals, then the molecular orbitals are called non-bonding orbitals.'可被翻译为：原子组成分子时，原子轨道线性组合成分F轨道，组成的分子轨道的能量若等于原子轨道的能量，则该分子轨道叫做非键轨道。\n'In molecular orbitals that are not occupied by electrons, the ones with the lowest energy.'可被翻译为：在电子未占有的分子轨道中，能量最低的分子轨道。\n'A chemical bond between atoms that results from overlapping atomic orbitals of bonding electrons.'可被翻译为：原子间由于成键电子的原子轨道重叠而形成的化学键。\n\n根据上述已知信息，请将'When atoms form a molecule, the atomic orbitals are linearly combined into molecular orbitals, and if the energy of the constituent molecular orbitals is higher than the energy of the atomic orbitals, the molecular orbitals are called antibonding orbitals.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"原子组成分子时，原子轨道线性组合成分子轨道，组成的分子轨道的能量若高于原子轨道的能量，则该分子轨道叫做反键轨道。"
    },
    {
        "instruction":"已知信息：\n'In the case of a derivative, a compound having a basic structure.'可被翻译为：对一类衍生物而言，具有基本结构的化合物。\n'The chemical modification of a biologically active compound to form a new compound, which is released in the body by the action of enzymes.'可被翻译为：具有生物活性的化合物，经化学结构修饰后形成新化合物，后者在体内经酶的作用释出原药发挥作用。\n'A compound having a chemical structure similar to that of existing drug molecules.'可被翻译为：与现有药物分子在化学结构上具有相似性的化合物。\n'A compound having the same molecular formula but with a different arrangement of atoms.'可被翻译为：具有相同分子式而分子中原子排列不同的化合物。\n\n根据上述已知信息，请将'A compound having a structural characteristic necessary for the action of a drug. The compound is not metabolized or transformed in living organisms, avoiding the production of certain toxic metabolites.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"具有发挥药物作用所必需的结构特征的化合物。该化合物在生物体内不发生代谢或转化，可避免产生某些毒性代谢产物。"
    },
    {
        "instruction":"已知信息：\n'Representing the bonding form and spatial arrangement of all constituent atoms in a molecule.'可被翻译为：表示分子中全部构成原子的成键形式与空间排列。\n'The spatial arrangement form of the pharmacodynamic characteristic elements that play an important role in the activity of bioactive molecules.'可被翻译为：在生物活性分子中对活性起重要作用的药效特征元素的空间排列形式。\n'The true arrangement in space of the groups that connect the chiral parts of a molecule (such as the chiral centers).'可被翻译为：连接分子手性部分(如手性中心)的基团在空间的真实排列情况。\n'A compound with the same molecular formula as the drug substance that differs in the spatial arrangement of atoms within the molecule and is a non-superimposable mirror image.'可被翻译为：与药物具有相同的分子式，但其分子中原子的空间排列不同并且为不能重合的镜像的化合物。\n\n根据上述已知信息，请将'The mutual repulsion caused by the spatial arrangement of groups inside the molecule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"分子内部基团在空间排布造成的相互排斥作用。"
    },
    {
        "instruction":"已知信息：\n'To keep pace with the international technical standards for drug registration, NMPA has decided to apply 11 ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines, including the Q2(R1): Validation of Analytical Procedures: Text and Methodology. The relevant matters are hereby announced as follows.'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《Q2（R1）：分析方法论证：正文和方法学》等11个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。\n'To keep pace with the international technicalstandards for drug registration, NMPA has decided after research to apply 15 ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) Guidelines, including the E1: Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-ThreateningConditions (see annex for details). The relevant matters are announced as follows:'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《E1：人群暴露程度：评估非危及生命性疾病长期治疗药物的临床安全性》等15个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。\n'To keep pace with the international technical standards for drug registration, the NMPA has decided to adopt two guidelines of ICH(International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use), including S5 (R3): Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals and S11: Nonclinical Safety Testing in Support of Development of Pediatric Pharmaceuticals (hereinafter referred to as S5 (R3) and S11).'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《S5（R3）:人用药物生殖与发育毒性检测》和《S11:支持儿科药物开发的非临床安全性评价》（以下简称：S5（R3）和S11）国际人用药品注册技术协调会（ICH）指导原则。\n'To keep pace with the international technical standards for drug registration, NMPA has decided to recommend the application of 4 ICH Guidelines, including the Q8 (R2): Pharmaceutical Development. The relevant matters are hereby announced as follows.'可被翻译为：为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定推荐适用《Q8（R2）：药品研发》等4个国际人用药品注册技术协调会（ICH）指导原则（详见附件）。现就有关事项公告如下。\n\n根据上述已知信息，请将'To keep pace with the international technical standards for drug registration, NMPA has decided after research to apply 13 ICH(International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines, including the S1A: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals.The relevant matters are announced as follows:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为推动药品注册技术标准与国际接轨，经研究，国家药品监督管理局决定适用《S1A：药物致癌性试验必要性指导原则》等13个国际人用药品注册技术协调会（ICH）指导原则。现就有关事项公告如下。"
    },
    {
        "instruction":"已知信息：\n'A volumetric utensil for accurately removing a given volume of solution. It is a glass tube with two slender ends and an enlarged part in the middle. The bottom end of the tube is needle-shaped, and there is a ring mark in the upper part. The mark marks the volume of the liquid when the liquid is filled to the scale at the specified temperature and left to flow out naturally. The commonly used pipette has 50ml, 25ml, 20ml, 10ml, 5ml, 2ml, 1ml and other specifications.'可被翻译为：一种准确移取一定体积溶液的容量器皿。是一根两头细长而中间有膨大部分的玻璃管。管的最下端呈尖嘴状，在上部有一环形标线，该标线标示在指定的温度下把液体充满到刻度后，任其自然流出时流出液体的体积。常用的移液管有50ml、25ml、20ml、10ml、5ml、2ml、1ml等多种规格。\n'volumetric solution'可被翻译为：滴定液\n'The electrophoretic mode, in which solutes migrate at different speeds in the background electrolyte solution in the capillary tube to form independent solute bands, is the most basic and widely used separation mode in capillary electrophoresis.'可被翻译为：溶质在毛细管内的背景电解质溶液中，以不同速度迁移而形成独立溶质带的电泳模式，是毛细管电泳中最基本、应用最广泛的一种分离模式。\n'For immersion cells, the volume of receptor solution to be filled in the dissolution vessel should be accurately measured with the appropriate volumetric glassware and transferred to the dissolution vessel.'可被翻译为：对于浸没池，应使用适当体积的玻璃器皿准确测量所用的受体溶液体积，并将其转移到溶出杯中。\n\n根据上述已知信息，请将'A graduated slender glass tube, the most basic instrument for titrating the volume of a solution in volumetric analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"容量分析中滴定溶液的体积最基本的仪器，有刻度的细长玻璃管。"
    },
    {
        "instruction":"已知信息：\n'CFDI shall feedback the problems found in the registration inspection to the drug regulatory authorities of the province, autonomous region, or municipality directly under the Central Government where the applicant and the inspected institution are located.'可被翻译为：核查中心向申请人和被核查单位所在地省、自治区、直辖市药品监督管理部门反馈注册核查发现的问题。\n'Article 12 If the drug regulatory authorities of a province, autonomous region, or municipality directly under the Central Government determine that it is necessary to conduct Pre-market inspection of Good Manufacturing Practice of Medical Products (GMP) during the Manufacturing Site Inspection period, CFDI shall coordinate the drug regulatory authorities of the relevant province, autonomous region, or municipality directly under the Central Government to implement the inspection simultaneously with Manufacturing Site Inspection.'可被翻译为：第十二条 对于省、自治区、直辖市药品监督管理部门确定需要在生产现场核查期间开展上市前药品生产质量管理规范符合性检查的，核查中心协调相关省、自治区、直辖市药品监督管理部门与生产现场核查同步实施。\n'(2) Where drug registration on-site inspection is not needed for the drug to be manufactured, the NMPA Center for Drug Evaluation shall inform the drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the manufacturing site is located and the applicant; and the drug regulatory department of the province, autonomous region or municipality directly under the Central Government shall carry out pre-marketing GMP compliance inspection of its own accord.'可被翻译为：（二）拟生产药品不需要进行药品注册现场核查的，国家药品监督管理局药品审评中心告知生产场地所在地省、自治区、直辖市药品监督管理部门和申请人，相关省、自治区、直辖市药品监督管理部门自行开展上市前的药品生产质量管理规范符合性检查；\n'Article 8 The local drug regulatory department of the province, autonomous region or municipality directly under the Central Government where the manufacturer of the recalled drug is located is responsible for supervising and managing recall of the drug. The drug regulatory departments of other provinces, autonomous regions or municipalities directly under the Central Government shall cooperate and assist in work relating to recall of the drug.'可被翻译为：第八条 召回药品的生产企业所在地省、自治区、直辖市药品监督管理部门负责药品召回的监督管理工作，其他省、自治区、直辖市药品监督管理部门应当配合、协助做好药品召回的有关工作。\n\n根据上述已知信息，请将'Article 25 The drug regulatory authorities of the province, autonomous region, or municipality directly under the Central Government where the inspected institution is located shall select a drug regulatory officer as an observer to assist in the registration inspection work and be responsible for transferring the problems found in the registration inspection to the drug regulatory authorities of the province, autonomous region, or municipality directly under the Central Government.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十五条 被核查单位所在地省、自治区、直辖市药品监督管理部门选派1名药品监督管理人员作为观察员协助注册核查工作，负责将注册核查发现的问题等转送给省、自治区、直辖市药品监督管理部门。"
    },
    {
        "instruction":"已知信息：\n'The involved disciplines at an organization from where a designated product, process or method is expected to be transferred.'可被翻译为：指定的产品、过程或方法预计将从该组织转移，该组织所涉及的学科。\n'receiving unit (RU). The involved disciplines at an organization where a designated product, process or method is expected to be transferred.'可被翻译为：接收方（RU）：准备接收所转移产品、工艺或方法的一方\n'sending unit (SU). The involved disciplines at an organization from where a designated product, process or method is expected to be transferred.'可被翻译为：转出方（SU）：准备转出产品、工艺或方法的一方\n'validation. Action of proving and documenting that any process, procedure or method actually and consistently leads to the expected results.'可被翻译为：验证：证明和记录工艺、程序或方法可以实际并持续得到预期结果的活动\n\n根据上述已知信息，请将'The involved disciplines at an organization where a designated product, process or method is expected to be transferred.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"组织中涉及的学科，其中指定的产品、过程或方法预计将被转移。"
    },
    {
        "instruction":"已知信息：\n'Article 19  For the lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. For other biological products, lot release may be conducted by means of independent dossier review or by combining dossier review with sample testing, and on-site verification may be conducted as required. For the testing items and testing proportion for different varieties, the NIFDC shall organize the demonstration and submit a copy to the NMPA. Each lot release institution shall conduct test in accordance with the determined specifications.'可被翻译为：第十九条    疫苗批签发应当逐批进行资料审核和抽样检验，其他生物制品批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种检验项目和检验比例，由中检院负责组织论证，并抄报国家药品监督管理局。批签发机构按照确定的检验要求进行检验。\n'Article 18 Lot release may be conducted by means of independent dossier review or by combining dossier review with sample test, and on-site inspection may be conducted as required. For the lot release mode as well as the testing items and testing proportion for different products, the NIFDC shall organize the demonstration and each lot release institution shall conduct test in accordance with the determined mode for lot release and specifications.'可被翻译为：第十八条 批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种所采用的批签发方式及检验项目和检验比例，由中检院负责组织论证，各批签发机构按照确定的批签发方式和检验要求进行检验。\n'In the process of the lot release of specific variety, the lot release institution may make a comprehensive evaluation according to the process and quality control maturity of the variety and previous lot release and dynamically adjust the testing items and testing frequency of the variety. Where there is any nonconforming item of the products subject to lot release, the lot release institution shall increase the testing frequency on the corresponding item of the products in subsequent batches.'可被翻译为：批签发机构在对具体品种的批签发过程中，可以根据该品种的工艺及质量控制成熟度和既往批签发等情况进行综合评估，动态调整该品种的检验项目和检验频次。批签发产品出现不合格项目的，批签发机构应当对后续批次产品的相应项目增加检验频次。\n'In the process of the lot release of a specific product, the lot release institution may make a comprehensive evaluation according to the process and quality control maturity of the product variety and previous lot release and dynamically adjust the testing items and testing frequency in the registration specification of the product variety. Where there is any nonconforming item of the products subject to lot release, the lot release institution shall add the testing frequency on the corresponding item of the products of subsequent batches.'可被翻译为：批签发机构在对具体品种的批签发过程中，可以根据该品种的工艺及质量控制成熟度和既往批签发等情况进行综合评估，动态调整该品种注册标准中的检验项目和检验频次。批签发产品出现不合格项目的，批签发机构应当对后续批次产品的相应项目增加检验频次。\n\n根据上述已知信息，请将'Article 29 For lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. The testing items and testing frequency for lot release of vaccines shall be dynamically adjusted according to the vaccine quality risk evaluation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十九条 疫苗批签发应当逐批进行资料审核和抽样检验。疫苗批签发检验项目和检验频次应当根据疫苗质量风险评估情况进行动态调整。"
    },
    {
        "instruction":"已知信息：\n'l. <1223> Validation of alternative microbiological methods'可被翻译为：<1223>替代微生物方法的验证\n'b. Validation of Growth-Based Rapid Microbiological Methods for Sterility Testing of Cellular and Gene Therapy Products (draft guidance, 2\/2008)'可被翻译为：基于生长快速微生物方法用于细胞和基因治疗产品无菌检测的验证（2008 年 2月，草案）\n'2. Relevant physical, chemical, microbiological and biological testing methods, with consideration of the specified stability study testing methods;'可被翻译为：（二）相关的物理、化学、微生物和生物学检验方法，可考虑采用稳定性考察专属的检验方法；\n'perform the appropriate level of validation or verification to support the implementation of the methods; and'可被翻译为：执行适当水平的验证或确认以支持方法的实施，以及\n\n根据上述已知信息，请将'Evaluation, Validation and Implementation of New Microbiological Testing Methods'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"新微生物检测方法的评估、验证和实施"
    },
    {
        "instruction":"已知信息：\n'10.7. Qualification and validation procedures, protocols, data and results should be appropriately recorded. The documents should be retained as defined in procedures.'可被翻译为：应适当记录确认和验证程序、方案、数据和结果。应按程序规定保存文件。\n'6.1. The SU and RU should each have an appropriately designed, clearly defined and documented quality system.'可被翻译为：SU与RU应分别具备经过恰当设计、清楚规定和文件化的质量体系。\n'12.34. Where products are transferred from one unit to another, the applicable analytical procedures should also be transferred.'可被翻译为：如果产品是从一个部门转移至另一个部门，亦应转移相关的分析方法。\n'5.13. The SU and the RU should jointly verify that the following, satisfactorily completed, validation protocols are available:  Installation qualification (IQ) and operational qualification (OQ) data for manufacturing and packaging equipment at the RU site and analytical equipment; and  Qualification of the rooms for both manufacture and packaging at the RU site.'可被翻译为：SU和RU应一起核查以下内容已圆满完成，并有验证方案： RU工厂生产和包装设备及分析设备的安装确认（IQ）和运行确认（OQ）数据；以及  RU工厂生产和包装间的确认。\n\n根据上述已知信息，请将'10.4. Production process and analytical procedures should be appropriately transferred to the RU following documented procedures. Where validation data exist, these should be included in the \ntransfer.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"生产工艺和分析方法应按照文件程序妥善转移至 RU 处。如果有验证数据，应该包括在转移中。"
    },
    {
        "instruction":"已知信息：\n'national regulatory authority (nra)'可被翻译为：国家监管机构(NRA)\n'reliance'可被翻译为：依赖\n'abridged regulatory pathways'可被翻译为：精简的监管途径\n'Implies strong similarity between two regulatory systems, as mutually established and documented through objective evidence. Equivalence can be established using criteria and approaches such as similarity of the regulatory framework and practices, adherence to the same international standards and guidelines, experience gained in use of assessments for regulatory decision making, joint activities and exchanges of staff. It is expected that equivalent regulatory systems will result in similar standards and levels of regulatory oversight or “control”.'可被翻译为：意味着两个监管体系之间的高度相似性，通过客观证据相互建立和记录。等效性可以通过诸如监管框架和实践的相似性、遵守相同的国际标准和指南、在使用监管决策评估方面获得的经验、联合活动和人员交流等标准和方法来建立。预计同等的监管制度将导致类似的标准和监管监督或“控制”水平。\n\n根据上述已知信息，请将'Regulatory procedures facilitated by reliance, whereby a regulatory decision is solely or partially based on application of reliance. This usually involves some work by the national regulatory authority (NRA) that is practising reliance (see section 5.4 Risk-based approach). It is expected that use of reliance in these pathways will save resources and time as compared with standard pathways, while ensuring that the standards of regulatory oversight are maintained.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"信赖促进了监管程序，即监管决定完全或部分基于信赖的应用。这通常涉及实施信赖的国家监管机构(NRA)的一些工作(见第5.4节基于风险的方法)。预计与标准途径相比，在这些途径中使用依赖将节省资源和时间，同时确保维持监管监督的标准。"
    },
    {
        "instruction":"已知信息：\n'Before the processing operation starts , the names, codes, batch numbers and labeling of all materials and intermediate products should also be checked , to guarantee that they are correct and in accordance with the requirements.'可被翻译为：生产操作前，还应当核对物料或中间产品的名称、代码、批号和标识，确保生产所用物料或中间产品正确且符合要求。\n'Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.'可被翻译为：第七十二条 应当建立设备使用、清洁、维护和维修的操作规程，并保存相应的操作记录。\n'Article 228: Operation procedures for release of the materials and products should be respectively established with well defined criteria and responsibilities. Relevant records should be available.'可被翻译为：第二百二十八条 应当分别建立物料和产品批准放行的操作规程，明确批准放行的标准、职责，并有相应的记录。\n'Article 298: Operation procedures for recall should be established to ensure the effectiveness of recalls.'可被翻译为：第二百九十八条 应当制定召回操作规程，确保召回工作的有效性。\n\n根据上述已知信息，请将'Article 182: Premises, equipment, materials, documents and records should have codes (or reference numbers). Operation procedures should be established for the numbering\/coding system to ensure the uniqueness of the codes (or reference numbers).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百八十二条 厂房、设备、物料、文件和记录应当有编号（或代码），并制定编制编号（或代码）的操作规程，确保编号（或代码）的唯一性。"
    },
    {
        "instruction":"已知信息：\n'The MAH shall establish a marketing release procedure to review the testing results and release documents of the product released by the drug manufacturers, and the drug products can be released only after signed off by qualified person.'可被翻译为：药品上市许可持有人应当建立药品上市放行规程，对药品生产企业出厂放行的药品检验结果和放行文件进行审核，经质量受权人签字后方可上市放行。\n'Drug manufacturers shall establish drug release procedures and specify the release standards and criteria. Drug products that meet the standards and criteria shall be released upon signature by the qualified person.'可被翻译为：药品生产企业应当建立药品出厂放行规程，明确出厂放行的标准、条件。符合标准、条件的，经质量受权人签字后方可放行。\n'Article 47 Drug manufacturers shall perform drug quality tests. Drugs that do not meet the national drug standards shall not be released.'可被翻译为：第四十七条 药品生产企业应当对药品进行质量检验。不符合国家药品标准的，不得出厂。\n'Lot release products shall be manufactured in accordance with the approved process and shall conform to the national drug standards and drug registration standards. The entire production process shall comply with the Good Manufacture Practice for Pharmaceutical Products. MAHs shall establish a complete production quality management system and continuously strengthen the management of deviation. MAHs shall be responsible for the authenticity of the materials, records and data generated during the production, testing and relevant processes of the lot release products. Lot release materials shall be reviewed, signed and issued by the qualified person of the MAHs.'可被翻译为：批签发产品应当按照经核准的工艺生产，并应当符合国家药品标准和药品注册标准。生产全过程应当符合药品生产质量管理规范的要求。药品上市许可持有人应当建立完整的生产质量管理体系，持续加强偏差管理。药品上市许可持有人对批签发产品生产、检验等过程中形成的资料、记录和数据的真实性负责。批签发资料应当经药品上市许可持有人的质量受权人审核并签发。\n\n根据上述已知信息，请将'Article 33 MAHs shall establish a marketing release procedure to audit drug products released by drug manufacturers. Drug products shall not be released until signed off by a qualified person and those that do not conform to national drug standards shall not be released.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十三条 药品上市许可持有人应当建立药品上市放行规程，对药品生产企业出厂放行的药品进行审核，经质量受权人签字后方可放行。不符合国家药品标准的，不得放行。"
    },
    {
        "instruction":"已知信息：\n'Alert level excursions should be documented and reviewed, and include an investigation to determine whether the excursion is a single (isolated) event or if results are indicative of an adverse trend or system deterioration. Each action limit excursion should be investigated to determine the probable root causes and any\npotential impact on the quality of products and manufacturing processes as a result of the use of the water'可被翻译为：偏离警戒限的异常情况应进行记录和审核，包括调查确定偏离是否为单个（独立）事件，或结果是否表明不良趋势或系统恶化。应对偏离行动限的每个异常情况进行调查，以确定可能的根本原因以及工艺用水对产品质量和生产工艺的任何潜在影响。\n'All other batches not released to the market should be included in the scope of the investigation. Any decision regarding their release status should consider the investigation outcome.'可被翻译为：所有尚未放行至市场的其它批次都应纳入调查范围内。任何有关其放行状态的决定均应考虑调查结果。\n'6) Deviations related to this batch are clearly explained or illustrated, or thoroughly investigated and appropriately handled; if other batches are involved in the deviation, all batches should be dealt together.'可被翻译为：6.所有与该批产品有关的偏差均已有明确的解释或说明，或者已经过彻底调查和适当处理；如偏差还涉及其他批次产品，应当一并处理。\n'If action limits are exceeded, operating procedures should prescribe a root cause investigation, an assessment of the  potential  impact  to  product  (including  batches  produced  between  the  monitoring  and  reporting)  and requirements  for  corrective  and preventive  actions.  If alert  levels  are  exceeded,  operating procedures  should prescribe assessment  and follow-up, which  should include consideration of an investigation and\/or corrective actions to avoid any further deterioration of the environment.'可被翻译为：如果超出行动限，操作程序应规定根本原因调查，对产品（包括在监测和报告之间生产的批次）潜在影响 性的评估以及纠正和预防措施要求。如果超出警戒限，操作程序程应规定评估和跟踪，其中应包括对调查和\/或纠正措施的考量， 以避免环境的进一步恶化。\n\n根据上述已知信息，请将'All non-conformities, such as sterility test failures, environmental monitoring excursions or deviations from established procedures should be adequately investigated before certification\/release of the batch. The\ninvestigation should determine the potential impact upon process and product quality and whether any other processes or batches are potentially impacted. The reason for including or excluding a product or batch from the\nscope of the investigation should be clearly justified and recorded.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"所有不合格情况应在批次认证\/放行之前充分调查，例如无菌检验不通过、环境监测异常或偏离既定程序的偏差等。调查中，应确定不合格情况对工艺和产品质量的潜在影响，以及是否有可能影响任何其它工艺或批次。某一产品或批次纳入调查范围或排除在外的理由应予以明确说明并记录。"
    },
    {
        "instruction":"已知信息：\n'The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.'可被翻译为：《药品流通监督管理办法》于2006年12月8日经国家食品药品监督管理局局务会审议通过，现予公布，自2007年5月1日起施行。\n'The Provisions for Drug Insert Sheets and Labels, adopted at the executive meeting of the State Food and Drug Administration on March 10, 2006, is hereby promulgated and shall go into effect as of June 1, 2006.'可被翻译为：《药品说明书和标签管理规定》于2006年3月10日经国家食品药品监督管理局局务会审议通过，现予公布，自2006年6月1日起施行。\n'The Provisions for Registration and Filing of Cosmetics adopted at the 14th Executive Meeting of the State Administration for Market Regulation on December 31, 2020 is hereby promulgated and shall go into effect as of May 1, 2021.'可被翻译为：《化妆品注册备案管理办法》已于2020年12月31日经国家市场监督管理总局2020年第14次局务会议审议通过，现予公布，自2021年5月1日起施行。\n'The Amendment to Provisions for In Vitro Diagnostic Reagent Registration adopted at the executive meeting of China Food and Drug Administration on January 5, 2017, is hereby promulgated and shall be effective as of the date of promulgation.'可被翻译为：《体外诊断试剂注册管理办法修正案》已于2017年1月5日经国家食品药品监督管理总局局务会议审议通过，现予公布，自公布之日起施行。\n\n根据上述已知信息，请将'The Provisions for Drug Recall was deliberated and adopted by the executive meeting of the State Food and Drug Administration on December 6, 2007 and now is issued. These Provisions shall go into effect as of the date of promulgation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"《药品召回管理办法》于2007年12月6日经国家食品药品监督管理局局务会审议通过，现予公布，自公布之日起施行。"
    },
    {
        "instruction":"已知信息：\n'I. Applicants should select, as far as practicable, the brand-name drug that has been approved for import registration or clinical trial in China as reference drugs for biosimilar clinical trials.'可被翻译为：一、申请人应尽可能选择已在我国获批进口注册或临床试验的原研药作为生物类似药临床试验用参照药。\n'Article 40 The sponsor shall, according to the characteristics of the investigational medical device, select the trial institutions and investigators among certified medical device clinical trial institutions. The sponsor shall provide the latest investigator's brochure and other relevant documents to the clinical trial institutions and investigators before signing the clinical trial protocol with the clinical trial institution, so that they can decide whether they are able to undertake the clinical trial.'可被翻译为：第四十条 申办者应当根据试验用医疗器械的特性，在经资质认定的医疗器械临床试验机构中选择试验机构及其研究者。申办者在与临床试验机构签署临床试验协议前，应当向临床试验机构和研究者提供最新的研究者手册以及其他相关文件，以供其决定是否可以承担该项临床试验。\n'Article 33 The applicant shall conclude and sign the contract of clinical trial with the clinical trial institution, prepare and improve the clinical trial protocol by referring to the related technical guidelines, provide samples for clinical trial for free, and assume the costs of clinical trials.'可被翻译为：第三十三条 申请人应当与临床试验机构签订临床试验合同，参考相关技术指导原则制定并完善临床试验方案，免费提供临床试验用样品，并承担临床试验费用。\n'Article 166 Where an applicant submits false drug registration dossier and samples when applying for clinical trial, the drug regulatory department shall not accept the application or disapprove the applied clinical trial, give a disciplinary warning to the applicant, and not accept any further application for clinical trial of the drug made by the applicant within one year; where clinical trial of the drug is already approved, the Drug Clinical Trial Approval shall be withdrawn, a fine of no less than 10,000 yuan but no more than 30,000 yuan shall also be imposed, and no further application for clinical trial of the drug made by the applicant shall be accepted within three years.'可被翻译为：第一百六十六条 申请人在申报临床试验时，报送虚假药品注册申报资料和样品的，药品监督管理部门不予受理或者对该申报药品的临床试验不予批准，对申请人给予警告，1年内不受理该申请人提出的该药物临床试验申请；已批准进行临床试验的，撤销批准该药物临床试验的批件，并处1万元以上3万元以下罚款，3年内不受理该申请人提出的该药物临床试验申请。\n\n根据上述已知信息，请将'Article 34 When a drug clinical trial is approved, the applicant shall select institutions for the clinical trial from those certified for conducting drug clinical trials.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十四条 药物临床试验批准后，申请人应当从具有药物临床试验资格的机构中选择承担药物临床试验的机构。"
    },
    {
        "instruction":"已知信息：\n'A substance that lowers the level of cholesterol in the body.'可被翻译为：能降低机体内胆固醇水平的物质。\n'A class of inactive endogenous peptides synthesized in the liver and present in most body fluids. Converted by enzymolysis into active kinin, which is involved in inflammation, blood clotting, and complement reaction.'可被翻译为：在肝中合成并存在于绝大多数体液的一类无活性内源性肽类。经酶解作用转变成活性的激肽，后者与炎症、血液凝固、补体反应等有关。\n'An enzyme that causes plasma coagulation by converting fibrinogen to fibrin in human or rabbit plasma, generally coagulase produced by pathogenic staphylococcus.'可被翻译为：能使人或兔血浆中的纤维蛋白原转变为纤维蛋白而引起血浆凝固的酶，一般指由致病性葡萄球菌产生的凝固酶。\n'kinin'可被翻译为：激肽\n\n根据上述已知信息，请将'A precursor substance of kinin in the body. Produced in the liver, it is -plasma 012-globulin.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"体内激肽的前体物质。产生于肝脏，是-种血浆012-球蛋白。"
    },
    {
        "instruction":"已知信息：\n'(XII) Items irrelevant to storage management shall not be stored in the storage area of drugs.'可被翻译为：（十二）药品储存作业区内不得存放与储存管理无关的物品。\n'Article 45 Operating area for drug storage and auxiliary section shall be separated from office area and living quarters by some distance or there shall be isolation measures.'可被翻译为：第四十五条 药品储存作业区、辅助作业区应当与办公区和生活区分开一定距离或者有隔离措施。\n'1. Personnel of quality management department should have the authority to access to production and storage areas for sampling and investigation.'可被翻译为：（一）质量管理部门的人员有权进入生产区和仓储区进行取样及调查。\n'Article 24 Purchasing personnel shall have a degree of technical school or above in pharmacy or medicine, biology, chemistry and other related disciplines, and sales or storage personnel shall have a degree of senior high school or above.'可被翻译为：第二十四条 从事采购工作的人员应当具有药学或者医学、生物、化学等相关专业中专以上学历，从事销售、储存等工作的人员应当具有高中以上文化程度。\n\n根据上述已知信息，请将'(XI) The unapproved personnel shall not enter the storage area, and the personnel in storage area shall not have any action affecting the quality and safety of drugs;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十一）未经批准的人员不得进入储存作业区，储存作业区内的人员不得有影响药品质量和安全的行为；"
    },
    {
        "instruction":"已知信息：\n'As of January 1, 2022, for the registration application of cosmetics for spot correcting, whitening and preventing hair loss, registration persons shall submit the human efficacy test report conforming to the requirements in accordance with the Rules.'可被翻译为：自2022年1月1日起，申请祛斑美白、防脱发化妆品注册时，注册申请人应当按照规定，提交符合要求的人体功效试验报告。\n'For the cosmetics for spot correcting, whitening and preventing hair loss with the application submitted and registration completed prior to May 1, 2021, registration persons shall submit the human efficacy test report prior to May 1, 2023.'可被翻译为：2021年5月1日前申请并取得注册的祛斑美白、防脱发化妆品，注册人应当在2023年5月1日前补充提交人体功效试验报告。\n'For the cosmetics for spot correcting, whitening and preventing hair loss with the application submitted and registration completed between May 1 and December 31, 2021, registration persons shall submit the human efficacy test report conforming to the requirements prior to May 1, 2022.'可被翻译为：2021年5月1日至12月31日期间申请并取得注册的祛斑美白、防脱发化妆品，注册人应当于2022年5月1日前补充提交符合要求的人体功效试验报告。\n'As of January 1, 2022, in case of registration or notification, registration or notification persons shall provide safety-related information of the ingredients with functions of preservative, sunscreen, colorant, hair dye, spot corrector and whitening in accordance with the Rules.'可被翻译为：自2022年1月1日起，注册人备案人申请注册或者进行备案时，应当按照《规定》的要求，提供具有防腐、防晒、着色、染发、祛斑美白功能原料的安全相关信息。\n\n根据上述已知信息，请将'IV. Efficacy evaluation and test report of cosmetics for spot correcting, whitening and preventing hair loss'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"四、关于祛斑美白和防脱发化妆品功效评价检验报告"
    },
    {
        "instruction":"已知信息：\n'therapeutic effect'可被翻译为：治疗作用\n'A pharmacological effect occurring at a therapeutic dose independent of the therapeutic effect.'可被翻译为：在治疗剂量下出现的，和治疗作用无关的药理效应。\n'The ratio of median lethal dose to median effective dose. A large therapeutic index indicates high curative effect and relatively safe drug use.'可被翻译为：半数致死量与半数有效量的比值。治疗指数大表示疗效高、用药比较安全。\n'The number of doses that produce a therapeutic effect after a single dose. Unit weight in kilograms (kg), grams (g), milligrams (mg), micrograms (seat) four weight measurement units; Capacity is expressed in liters (L) or milliliters (mL).'可被翻译为：一次给药后产生药物治疗作用的数量。单位重量以千克(kg)、克(g)、毫克(mg)、微克(座)四级重量计量单位表示；容量以升(L)或毫升(mL)表示。\n\n根据上述已知信息，请将'The adverse reactions that occur after the therapeutic effect of drugs are the consequences of the therapeutic effect itself under the therapeutic dose.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物治疗作用之后出现的不良反应，是治疗剂量下治疗作用本身带来的后果。"
    },
    {
        "instruction":"已知信息：\n'Article 104 The State establishes a professional and specialized team of drug inspectors who are familiar with drug laws and regulations and have professional knowledge of drugs.'可被翻译为：第一百零四条 国家建立职业化、专业化药品检查员队伍。检查员应当熟悉药品法律法规，具备药品专业知识。\n'Article 10 The persons undertaking registration or filing for medical devices shall have corresponding specialized knowledge and be familiar with the laws, rules, regulations and technical requirements of the administration on registration or filing of medical devices.'可被翻译为：第十条 办理医疗器械注册或者备案事务的人员应当具有相应的专业知识，熟悉医疗器械注册或者备案管理的法律、法规、规章和技术要求。\n'Article 11 The persons undertaking registration or filing for in-vitro diagnostic reagents shall have corresponding specialized knowledge and be familiar with the laws, rules, regulations and technical requirements of the administration on registration or filing of in-vitro diagnostic reagent.'可被翻译为：第十一条 办理体外诊断试剂注册或者备案事务的人员应当具有相应的专业知识，熟悉医疗器械注册或者备案管理的法律、法规、规章和技术要求。\n'The inspectors shall be familiar with laws and regulations of medical devices, and have professional knowledge and inspection skills in terms of medical devices.'可被翻译为：检查员应当熟悉医疗器械法律法规，具备医疗器械专业知识和检查技能。\n\n根据上述已知信息，请将'The persons who handle the application for drug registration shall have professional knowledge and be familiar with the laws and regulations on, and the technical requirements for, drug registration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"办理药品注册申请事务的人员应当具有相应的专业知识，熟悉药品注册的法律、法规及技术要求。"
    },
    {
        "instruction":"已知信息：\n'(3) A medical device used to monitor or influence the essential functions of another medical device, its class shall be identical to the medical device being monitored or influenced.'可被翻译为：（三）监控或者影响医疗器械主要功能的医疗器械，其分类应当与被监控、影响的医疗器械的分类一致。\n'Article 80 MAHs shall monitor for adverse reactions of marketed drugs, take the initiative to collect, track and analyze information on suspected adverse drug reactions, and promptly take risk control measures for drugs for which risks are identified.'可被翻译为：第八十条 药品上市许可持有人应当开展药品上市后不良反应监测，主动收集、跟踪分析疑似药品不良反应信息，对已识别风险的药品及时采取风险控制措施。\n'Section 3 Adverse Drug Event Clusters'可被翻译为：第三节 药品群体不良事件\n'The State establishes the pharmacovigilance system to monitor, detect, assess and control adverse reactions or other harmful reactions related to use of drugs.'可被翻译为：国家建立药物警戒制度，对药品不良反应及其他与用药有关的有害反应进行监测、识别、评估和控制。\n\n根据上述已知信息，请将'(3) They shall have the abilities to monitor and evaluate adverse reactions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）有不良反应监测与评价的能力。"
    },
    {
        "instruction":"已知信息：\n'Article 35 Enterprises shall ensure that all posts have access to necessary documents corresponding to their work contents, and carry out their work in strict accordance with the provisions.'可被翻译为：第三十五条 企业应当保证各岗位获得与其工作内容相对应的必要文件，并严格按照规定开展工作。\n'Article 45 An enterprise to be engaged in distribution activities of medical devices shall not engage in distributing medical devices that have not been registered or filed, without qualification certification documents or that have been expired, invalid or obsolete.'可被翻译为：第四十五条  从事医疗器械经营活动的，不得经营未依法注册或者备案，无合格证明文件以及过期、失效、淘汰的医疗器械。\n'VII. Where the management attributes have been clearly specified in relevant regulations and documents, such provisions shall prevail.'可被翻译为：七、相关法规、文件中已有明确管理属性规定的，按其规定执行。\n'(4) If the application documents are incomplete or do not conform to statutory form, the applicant shall be notified of all contents ought to be supplemented and corrected on site or within 5 working days one-off. If no notification is made within the prescribed time limit, the application shall be deemed to have been accepted upon receipt of the application documents;'可被翻译为：（四）申请资料不齐全或者不符合法定形式的，应当当场或者在5个工作日内一次告知申请人需要补正的全部内容以及提交补正资料的时限。逾期不告知的，自收到申请资料之日起即为受理；\n\n根据上述已知信息，请将'Article 34 Enterprises shall periodically review and revise the documents, and the documents used shall be current valid versions. Documents that have been abolished or invalid shall not appear on the work site unless they are kept for reference.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三十四条 企业应当定期审核、修订文件，使用的文件应当为现行有效的文本，已废止或者失效的文件除留档备查外，不得在工作现场出现。"
    },
    {
        "instruction":"已知信息：\n'Article 1 These Provisions are formulated in accordance with the Regulations on Supervision and Administration of Medical Devices for the purpose of strengthening the supervision and administration of medical device distribution, regulating the distribution activities of medical devices, and ensuring the safety and effectiveness of medical devices.'可被翻译为：第一条  为了加强医疗器械经营监督管理，规范医疗器械经营活动，保证医疗器械安全、有效，根据《医疗器械监督管理条例》，制定本办法。\n'Article 1 These Provisions are formulated in accordance with the Regulations on Supervision and Administration of Medical Devices for the purpose of strengthening supervision and administration of medical device manufacturing, regulating the manufacturing activities of medical devices, and ensuring the safety and effectiveness of medical devices.'可被翻译为：第一条  为了加强医疗器械生产监督管理，规范医疗器械生产活动，保证医疗器械安全、有效，根据《医疗器械监督管理条例》，制定本办法。\n'Article 6 China Food and Drug Administration shall develop the medical device standards plan, establish the working mechanism for medical device standards administration and improve the medical device standards administration system in accordance with laws.'可被翻译为：第六条 国家食品药品监督管理总局依法编制医疗器械标准规划，建立医疗器械标准管理工作制度，健全医疗器械标准管理体系。\n'Article 1 The Provisions is formulated in accordance with the Regulations on Supervision and Administration of Medical Devices, with a view to standardizing the administration of medical device registration and filing and guaranteeing the safety and effectiveness of medical devices.'可被翻译为：第一条 为规范医疗器械的注册与备案管理，保证医疗器械的安全、有效，根据《医疗器械监督管理条例》，制定本办法。\n\n根据上述已知信息，请将'Article 2 Medical device standards stated in these Provisions refer to the unified technical requirements for the research and development, manufacturing, distribution, use, supervision and administration of medical devices which are formulated and revised by China Food and Drug Administration as per its duties and issued in accordance with the legal procedures so as.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二条 本办法所称医疗器械标准，是指由国家食品药品监督管理总局依据职责组织制修订，依法定程序发布，在医疗器械研制、生产、经营、使用、监督管理等活动中遵循的统一的技术要求。"
    },
    {
        "instruction":"已知信息：\n'Article 21 An enterprise to be engaged in Class II medical device distribution shall file the matter with the department in charge of drug supervision and administration at the level of a city divided into districts, and submit the related materials as prescribed in Article 10 of these Provisions (except Item (7)) to complete the distribution filing, and obtain the filing number.'可被翻译为：第二十一条  从事第二类医疗器械经营的，经营企业应当向所在地设区的市级负责药品监督管理的部门备案，并提交符合本办法第十条规定的资料（第七项除外），即完成经营备案，获取经营备案编号。\n'Article 10 An enterprise to be engaged in Class III medical device distribution shall file an application to the department in charge of drug supervision and administration at the level of a city divided into districts, and submit the following materials:'可被翻译为：第十条  从事第三类医疗器械经营的，经营企业应当向所在地设区的市级负责药品监督管理的部门提出申请，并提交下列资料：\n'To engage in manufacturing of Class II and Class III medical devices, an entity shall obtain approval from the drug regulatory department of the local province, autonomous region, or municipality directly under the central government, and acquire Medical Device Manufacturing License according to law; to engage in manufacturing of Class I medical devices, an entity shall handle medical device manufacturing filing formalities at the local department in charge of drug supervision and administration at the level of a city divided into districts.'可被翻译为：从事第二类、第三类医疗器械生产活动，应当经所在地省、自治区、直辖市药品监督管理部门批准，依法取得医疗器械生产许可证；从事第一类医疗器械生产活动，应当向所在地设区的市级负责药品监督管理的部门办理医疗器械生产备案。\n'To apply for filing of class I domestic medical devices, the filing entity shall submit the filing documents to the food and drug regulatory department of the city consisting of districts .'可被翻译为：境内第一类医疗器械备案，备案人向设区的市级食品药品监督管理部门提交备案资料。\n\n根据上述已知信息，请将'Article 22 An enterprise to be engaged in manufacturing Class I medical devices shall file the matter with the department in charge of drug supervision and administration at the level of a city divided into districts, and submit the related materials as prescribed in Article 10 of these Provisions to complete the manufacturing filing, and obtain the filing number. Where the medical device filing entities manufacture Class I medical devices by themselves, they may handle the manufacturing filing together with the product filing.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十二条  从事第一类医疗器械生产的，应当向所在地设区的市级负责药品监督管理的部门备案，在提交本办法第十条规定的相关材料后，即完成生产备案，获取备案编号。医疗器械备案人自行生产第一类医疗器械的，可以在办理产品备案时一并办理生产备案。"
    },
    {
        "instruction":"已知信息：\n'manifold'可被翻译为：廖\n'See Air-handling unit.'可被翻译为：参见空气处理机组。\n'world health assembly'可被翻译为：世界卫生大会\n'The cosmetics used in the operation of beauty and hair salons and the cosmetics provided to consumers by hotels, etc., shall comply with provisions on label of the minimum sales unit.'可被翻译为：美容美发机构经营中使用的化妆品以及宾馆等为消费者提供的化妆品应当符合最小销售单元标签的规定。\n\n根据上述已知信息，请将'An assembly of cylinders that are fastened together, interconnected by a manifold, transported and used as a unit.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种钢瓶的组合，它们被固定在一起，通过歧管相互连接，作为一个整体运输和使用。"
    },
    {
        "instruction":"已知信息：\n'(1) If the subject matter of application falls within the scope of this administrative authority, and the application dossiers are complete and conform to statutory form, then the application shall be accepted;'可被翻译为：（一）申请事项属于本行政机关职权范围，申请资料齐全、符合法定形式的，应当受理申请；\n'(2) Where the application items do not fall within the scope of NMPA's terms of reference in accordance with law, a decision of non-acceptance shall be made, a notice of non-acceptance shall be issued, and the applicant shall be informed to apply to the relevant administrative organization;'可被翻译为：（二）申请事项依法不属于国家药品监督管理局职权范围的，应当作出不予受理的决定，出具不予受理通知书，并告知申请人向有关行政机关申请；\n'(2) If the application items are not within the scope of authority of drug regulatory department in accordance with the law, the relevant department shall make a decision of non-acceptance, issue a notification of non-acceptance, and inform the applicant to resubmit the application to the applicable administrative authority；'可被翻译为：（二）申请事项依法不属于药品监督管理部门职权范围的，应当作出不予受理的决定，出具不予受理通知书，并告知申请人向有关行政机关申请；\n'(IV) Where an application is not within the functions and duties of the department, the applicant shall be notified immediately of unacceptance.'可被翻译为：（四）申请事项不属于本部门职权范围的，应当即时告知申请人不予受理。\n\n根据上述已知信息，请将'(4) If the subject matter of the application does not fall within the scope of this administrative authority, a decision of not accepting the application shall be made immediately, and the applicant shall be notified of applying to relevant administrative authority.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）申请事项不属于本行政机关职权范围的，应当即时作出不予受理的决定，并告知申请人向有关行政部门申请。"
    },
    {
        "instruction":"已知信息：\n'Determine whether equipment malfunctioned or was not operated properly. If a malfunction occurred, determine whether it was likely to cause the contamination. Determine if monitoring records and any checklists or logs indicate that the ISO 5 environment was in good state of control (serious environmental quality or equipment repair issues) at the time of the sterility test. Be aware of the most likely failure modes in the equipment (e.g., laminar flow hood, glovebox, or isolator) used.'可被翻译为：确定是否设备故障，或操作不当。如果发生故障，确定是否可能导致污染。确定在 无菌测试时监测记录和检查清单或日志是否显示ISO5环境处于良好的受控状态 （严重环境质量或设备维修问题）。了解所用设备（例如，层流罩、手套箱或隔离 器）的最可能失效模式。\n'Determine whether there were any anomalies or deviations from the analytical method. Adherence to method should be verified at the time of analysis, and any major breach of sterility test procedure should also be documented at that time. If any method breaches occurred, determine whether it was likely to cause the contamination. Be aware of any possible weaknesses in the test method (e.g., kit, manifold, etc.) used.'可被翻译为：确定是否有异常或分析方法偏差。核查分析时是否遵守检验方法，严重违反无菌检 测程序的情况亦要即时记录。如果发现违背方法的情况，确定是否有可能导致污染。 了解所用检测方法（例如，检测盒，歧管等）中是否有任何可能弱点。\n'negative control'可被翻译为：阴性对照\n'Environmental Control'可被翻译为：环境控制\n\n根据上述已知信息，请将'Determine whether there was adverse environmental data. Note that a negative control failure, on its own, is not necessarily cause for invalidating a result. If a negative control was contaminated, consider whether the microbe identified is similar to, or the same as, the sterility test isolate and also consider whether there are other adverse environmental trends.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"确定是否有不良环境数据。注意阴性控制失败其本身并不一定导致结果无效。如果 阴性对照受到污染，考虑所鉴别的微生物是否类似或相同于无菌测试分离物，同时 考虑是否有其它不良环境趋势。"
    },
    {
        "instruction":"已知信息：\n'2019 China Cancer Immunotherapy Workshop Successfully Held'可被翻译为：2019中国肿瘤免疫治疗会议成功举办\n'The China Cancer Immunotherapy Workshop has been successfully held for five consecutive years with rising social attention and influence. The Workshop has provided an important academic exchange platform for Chinese and foreign drug regulatory authorities, academia and industry, promoting the exchange of professional knowledge and experience in the field of cancer immunotherapy. It has played a positive role in promoting international exchanges and cooperation in the field of drug regulation and enhancing innovation and development in the field of cancer immunotherapy.'可被翻译为：中国肿瘤免疫治疗会议已连续成功举办了5届，社会关注度和影响力不断扩大，会议为中外药品监管机构、学术界、企业界搭建了一个重要学术交流平台，促进了肿瘤免疫治疗领域的专业知识和经验交流，为推动我国药品监管领域的国际交流合作和肿瘤免疫治疗领域创新发展发挥了积极的作用。\n'(I) It is applicable to the on-site inspection of Pharmacological and Toxicological study in the research and development (R&D) on-site inspection of drug registration initiated by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and organized and implemented by the Center for Food and Drug Inspection (CFDI) of NMPA.'可被翻译为：(一)适用于由国家药品监督管理局药品审评中心启动、 由国家药品监督管理局食品药品审核查验中心组织实施的药品注册研制现场核查中的药理毒理学研究现场核查。\n'To fully reflect the monitoring of adverse events in relation to China's medical devices in 2019, the National Center for Adverse Drug Reaction Monitoring has compiled and released the Annual Report for National Medical Device Adverse Event Monitoring (2019).'可被翻译为：为全面反映2019年我国医疗器械不良事件监测情况，国家药品不良反应监测中心编撰了《国家医疗器械不良事件监测年度报告（2019年）》。\n\n根据上述已知信息，请将'2019 China Cancer Immunotherapy Workshop was successfully held on June 29-30, 2019 in Tianjin, China. The Workshop was organized by China Center for Food and Drug International Exchange(CCFDIE),in cooperation with the Center for Drug Evaluation(CDE) of National Medical Products Administration(NMPA), Chinese American Hematologist and Oncologist Network(CAHON) and School of Medicine Tsinghua University.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2019年6月29日至6月30日，由中国食品药品国际交流中心(CCFDIE)主办，药品审评中心(CDE)、美国华裔血液及肿瘤专家学会(CAHON)和清华大学医学院协办的2019中国肿瘤免疫治疗会议在天津成功举办。"
    },
    {
        "instruction":"已知信息：\n'dna strand breaks'可被翻译为：DNA链断裂\n'The process of removing impurities from a sample so that it contains only one type of molecule.'可被翻译为：从一样品中除掉杂质，得到只含一种类型分子的过程。\n'(l) A mutated form of DNA or RNA in which one or more additional nucleotides are inserted into a polynucleoxylic acid chain. (2) A process by which one or more additional nucleotides are added to a strand of DNA or RNA.'可被翻译为：（l）DNA或RNA的一种突变形式，在多核昔酸链内插入了一个或多个额外核昔酸的过程。（2）在DNA或RNA链中增加一个或多个额外核昔酸的过程。\n'A piece of DNA that can be transcribed by an RNA polymerase into a continuous strand of mRNA, including the start and stop signals for transcription. A simple transcription unit carries information for the synthesis of only one protein, while a complex transcription unit carries information for more than one protein molecule.'可被翻译为：一段可被RNA聚合酶转录成一条连续的mRNA链的DNA,包括转录的起始和终止信号。一个简单的转录单位只携带合成一种蛋白质的信息，复合转录单位则可携带不只一种蛋白质分子的信息。\n\n根据上述已知信息，请将'If one of the two strands of plasmid DNA breaks in one or more places, the molecule can spin around, removing tension from the strand and forming a relaxed circular molecule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"如果质粒DNA两条链中有一条链发生-处或多处断裂，分子就能旋转而消除链的张力，形成松弛型的环状分子。"
    },
    {
        "instruction":"已知信息：\n'In order to culture a pure and robust test organism, proper use and preparation of growth media (agar or broth), buffers and diluents is required. Components or final preparations of growth media, reagents or diluents may be prepared on-site and\/or purchased from outside sources. Regardless of origin, any final product made from growth media components and\/or \npreparations must be verified for identification, expiry, sterility and growth promotion, prior to \nuse in test. Refer to USP <81> for preparation, use and storage of all growth media, buffers and \ndiluents.'可被翻译为：为了培养纯净且耐用的测试生物，需要正确使用和制备生长培养基（琼脂或肉汤）、缓冲液和稀释剂。生长培养基、试剂或稀释剂的成分或成品可以现场制备和\/或从外部来源购买。无论来源如何，任何由生长培养基成分和\/或成品制备的最终产品在用于测试之前都必须进行鉴定，并确认其有效期、无菌性和促生长能力。所有生长培养基、缓冲液和稀释剂的制备、使用和储存参见 USP <81>。\n'Growth Promotion of the Media'可被翻译为：培养基促生长\n'Media used for testing needs to be tested for growth promotion by inoculating the medium with appropriate microorganisms. It is preferable that test microorganisms be chosen for growth promotion testing (Section D).'可被翻译为：用于测试的培养基需要通过用适当微生物的培养基接种来测试促菌生长能力。最好选择测试微 生物用于促菌生长能力试验（D部分）。\n'Growth Promotion, Indicative and Inhibitory Properties of the Media'可被翻译为：培养基的促生长、指示 性和抑制特性\n\n根据上述已知信息，请将'Both prepared and purchased media must meet the requirements of the USP growth promotion test of aerobes, anaerobes and fungi.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"无论是制备的还是购买的培养基均应满足USP的需氧菌、厌氧菌和真菌促生长测试 要求。"
    },
    {
        "instruction":"已知信息：\n'Environmental control, cleaning, sterilisation and monitoring of the critical extrusion, transfer and filling areas as relevant.'可被翻译为：关键挤压出区、转移区和灌装区的环境控制、清洁、灭菌和监测（如相关）。\n'An  environmental  monitoring  programme  should  be  established  and  documented.  The  purpose  of  the environmental monitoring programme, is to:'可被翻译为：应制订并记录环境监测计划。环境监测计划的目的是：\n'5. Environmental monitoring;'可被翻译为：（五）环境监测；\n'Environmental & process monitoring'可被翻译为：环境监测和工艺监测\n\n根据上述已知信息，请将'Environmental control and monitoring, both of the machine and the background in which it is placed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"环境控制和监测，包括设备及其环境。"
    },
    {
        "instruction":"已知信息：\n'Article 20 During the safety monitoring period, registrants and filing persons of new cosmetic ingredients may use the new cosmetic ingredient to produce cosmetics.'可被翻译为：第二十条 安全监测的期限内，化妆品新原料注册人、备案人可以使用该化妆品新原料生产化妆品。\n'Registrants and filing persons of new cosmetic ingredients shall, within 30 working days before a year period of safety monitoring of new cosmetic ingredients, prepare an annual report summarizing and analyzing the use and safety conditions of new ingredients, and submit it to the NMPA.'可被翻译为：化妆品新原料注册人、备案人应当在化妆品新原料安全监测每满一年前30个工作日内，汇总、分析化妆品新原料使用和安全情况，形成年度报告报送国家药品监督管理局。\n'Article 23 The registrant and filing person of cosmetics who use new cosmetic ingredients to produce cosmetics shall give prompt feedback on the use and safety of the new cosmetic ingredients to the registrant and filing person of new cosmetic ingredients.'可被翻译为：第二十三条 使用化妆品新原料生产化妆品的化妆品注册人、备案人，应当及时向化妆品新原料注册人、备案人反馈化妆品新原料的使用和安全情况。\n'(2) Assisting the registrants and filing persons in carrying out cosmetic adverse reaction monitoring, safety monitoring and reporting of new cosmetic ingredients;'可被翻译为：（二）协助注册人、备案人开展化妆品不良反应监测、化妆品新原料安全监测与报告工作；\n\n根据上述已知信息，请将'Article 21 Registrants and filing persons of new cosmetic ingredients shall establish a safety risk monitoring and evaluation system after the launch of new cosmetic ingredients, conduct follow-up research on the safety of new cosmetic ingredients, and continue to monitor and evaluate the use and safety of new cosmetic ingredients.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十一条 化妆品新原料注册人、备案人应当建立化妆品新原料上市后的安全风险监测和评价体系，对化妆品新原料的安全性进行追踪研究，对化妆品新原料的使用和安全情况进行持续监测和评价。"
    },
    {
        "instruction":"已知信息：\n'4. Clinical trial data recording and reporting'可被翻译为：4.临床试验数据记录和报告\n'(2) Follow the data recording and reporting procedures;'可被翻译为：（二）遵循数据记录和报告程序；\n'3. The quality status of the contents (e.g. in quarantine, released, rejected, sampled);'可被翻译为：（三）物料质量状态（如待验、合格、不合格、已取样）；\n'5. The quality status of the product (e.g. in quarantine, released, rejected and sampled, if necessary).'可被翻译为：（五）产品质量状态（必要时，如待验、合格、不合格、已取样）。\n\n根据上述已知信息，请将'provide a documentation system capable of recording receipt and testing of samples to the required specification using approved test methods, and of reporting, recording and collating data and designation of status (approved, rejected, quarantine);'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"提供可记录接收样品并采用批准的检测方法按所需标准检测样品，并报告、记录和整合数据，确定其结果（批准、拒收、隔离）的文件系统；"
    },
    {
        "instruction":"已知信息：\n'trauma therapeutic preparation'可被翻译为：创面用制剂\n'A sterilizing preparation made of medicine for injection into the body.'可被翻译为：药物制成的供注入人体内的灭菌制剂。\n'(11) Trauma'可被翻译为：（十一）创伤\n'Sterilizing Filtration of Liquids'可被翻译为：液体除菌过滤\n\n根据上述已知信息，请将'A sterilizing preparation for ulcers, burns, and trauma sites.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用于溃疡、烧伤及外伤部位的灭菌制剂。"
    },
    {
        "instruction":"已知信息：\n'Article 169 Where there is any of the following circumstances, the State Food and Drug Administration shall withdraw the drug approval number, and announce to the public:'可被翻译为：第一百六十九条 具有下列情形之一的，由国家食品药品监督管理局注销药品批准文号，并予以公布：\n'Article 104 The overseas drug manufacturer providing the drug shall be responsible for the quality of the repackaged drug. If there is any quality problem, the State Food and Drug Administration may withdraw the approval number of the repackaged drug, revoke the Import Drug License or the Pharmaceutical Product License when necessary according to the requirements of Article 42 of the Drug Administration Law.'可被翻译为：第一百零四条 提供药品的境外制药厂商应当对分包装后药品的质量负责。分包装后的药品出现质量问题的，国家食品药品监督管理局可以撤销分包装药品的批准文号，必要时可以依照《药品管理法》第四十二条的规定，撤销该药品的《进口药品注册证》或者《医药产品注册证》。\n'Article 69 Where a drug MAH or drug manufacturer has failed to carry out manufacturing activities as per GMP requirements in any of the following circumstances and the circumstance belongs to the serious circumstances as specified in Article 126 under the Drug Administration Law, penalties shall be imposed according to law:'可被翻译为：第六十九条 药品上市许可持有人和药品生产企业未按照药品生产质量管理规范的要求生产，有下列情形之一，属于《药品管理法》第一百二十六条规定的情节严重情形的，依法予以处罚：\n'Article 154 Where there is any of the following circumstances, the State Food and Drug Administration shall not approve the application:'可被翻译为：第一百五十四条 有下列情形之一的，国家食品药品监督管理局不予批准：\n\n根据上述已知信息，请将'Article 159 In any of the circumstances prescribed in Article 69 of the Administrative Permission Law, the State Food and Drug Administration may withdraw the relevant drug approval documents upon the request of any interest party or according to its responsibilities and authorities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百五十九条 有《行政许可法》第六十九条规定情形的，国家食品药品监督管理局根据利害关系人的请求或者依据职权，可以撤销有关的药品批准证明文件。"
    },
    {
        "instruction":"已知信息：\n'Processes associated with the finishing, storage and transport of sterile products should not compromise the sterile product. Aspects that should be considered include: container integrity, risks of contamination and avoidance of degradation by ensuring that products are stored and maintained in accordance with the registered\nstorage conditions.'可被翻译为：与无菌产品的最终处理、贮存和运输相关的过程不应损害无菌产品。应考虑的方面包括：容器完整性，污染风险，以及通过确保产品按照注册贮存条件贮存和维护来避免降解。\n'It  is  critical  to  ensure  the  sterility  of  all  product  contact  surfaces  of closed  systems  used  for  aseptic processing. The design and selection of any closed system used for aseptic processing should ensure maintenance of sterility. Connection of sterile equipment (e.g. tubing\/pipework) to the sterilised product pathway after the final sterilising grade filter should be designed to be connected aseptically (e.g. by intrinsic sterile connection devices).'可被翻译为：确保无菌工艺中密闭系统的所有产品接触表面的无菌性至关重要。无菌工艺中任何密闭系统的设计和选择 都应确保维持无菌性。最终除菌级过滤器之后，无菌设备（例如管道\/管道系统）与已灭菌产品通路的连接应设计成无菌连接（例如通过内在无菌连接装置）。\n'Aseptic connections should be performed in grade A with a grade B background unless subsequently\nsterilised in place or conducted with intrinsic sterile connection devices that minimize any potential contamination\nfrom the immediate environment. Intrinsic sterile connection devices should be designed to mitigate risk of\ncontamination'可被翻译为：无菌连接应在 B 级环境下的 A 级区域内进行，除非随后经在线灭菌或使用内部无菌连接装置，从而最大程度地降低来自周围环境的潜在污染。内部无菌连接装置的设计应降低污染风险。\n'The container closure integrity validation should take into consideration any transportation or shipping\nrequirements that may negatively impact the integrity of the container (e.g. by decompression or extreme temperatures).'可被翻译为：容器密封完整性验证应考虑任何可能对容器完整性产生负面影响的运输或装运要求（例如减压或极端温度）。\n\n根据上述已知信息，请将'SUS  should  be  designed  to  maintain  integrity  throughout  processing  under  the  intended  operational conditions. Attention to the structural integrity of the single use components is necessary where these may be exposed to more extreme conditions (e.g. freezing and thawing processes) either during routine processing or transportation.  This  should  include verification that intrinsic  sterile  connection  devices  (both heat  sealed and mechanically sealed) remain integral under these conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"SUS 的设计应能在预期操作条件和持续时间内保持完整性。在日常加工或运输过程可能出现暴露于极端条 件（例如冻融过程）的情况，有必要注意一次性组件的结构完整性。这应包括确认内部无菌连接装置（热密封和机械密封）在这些条件下保持完整。"
    },
    {
        "instruction":"已知信息：\n'Article 95 This GCP does not apply to in-vitro diagnostic reagents which are regulated as medical devices.'可被翻译为：第九十五条 本规范不适用于按照医疗器械管理的体外诊断试剂。\n'Article 9 The naming of in-vitro diagnostic reagents which are regulated as medical devices shall comply with the Provisions for In-Vitro Diagnostic Reagent Registration (Decree No.5 of China Food and Drug Administration).'可被翻译为：第九条 按照医疗器械管理的体外诊断试剂的命名依照《体外诊断试剂注册管理办法》（国家食品药品监督管理总局令第5号）的有关规定执行。\n'The clinical trial of in-vitro diagnostic reagents (including the comparative study made with the marketed products) refers to the systematic study on the clinical performance of in-vitro diagnostic reagents in the corresponding clinical environment.'可被翻译为：体外诊断试剂临床试验（包括与已上市产品进行的比较研究试验）是指在相应的临床环境中，对体外诊断试剂的临床性能进行的系统性研究。\n'(2) The mandatory standard(s) of in-vitro diagnostic reagents have been revised or national standard products and reference products have been established, and the in-vitro diagnostic reagent fails to meet the requirements of the new standards.'可被翻译为：（二）体外诊断试剂强制性标准已经修订或者有新的国家标准品、参考品，该体外诊断试剂不能达到新要求的；\n\n根据上述已知信息，请将'(3) Biological products, radiopharmaceuticals and in-vitro diagnostic reagents regulated as drugs;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）生物制品、放射性药品和按照药品管理的体外诊断试剂；"
    },
    {
        "instruction":"已知信息：\n'A secondary chemical reference substance is a substance whose characteristics are assigned and\/or calibrated by comparison with a primary chemical reference substance. The extent of characterization and testing of a secondary chemical reference substance may be less than  for a primary chemical reference substance. Although this definition may apply inter alia to some substances termed “working standards”, part B of these guidelines is intended to apply to secondary reference substances supplied as “official”, e.g. regional\/national standards, and not to manufacturers’ or other laboratories’ working standards.'可被翻译为：二级化学标准物质是通过与一级化学标准物质比较而确定和\/或校准其特性的物质。二级化学标准物质的表征和测试范围可能小于一级化学标准物质。虽然该定义可特别适用于一些被称为“工作标准”的物质，但本指南B部分旨在适用于作为“官方”提供的二级标准物质，例如区域\/国家标准，而不适用于制造商或其他实验室的工作标准。\n'A substance whose characteristics are assigned and\/or calibrated by comparison with a primary reference substance. The extent of characterization and testing of a secondary reference substance may be less than for a primary reference substance.Note: Often referred to as an “in-house” working standard.'可被翻译为：通过与主要标准物质比较而确定和\/或校准其特性的物质。二级标准物质的表征和测试范围可能小于一级标准物质。注:通常被称为“内部”工作标准。\n'A substance that is widely acknowledged to possess the appropriate qualities within a specified context, and whose assigned content is accepted without requiring comparison with another chemical substance (8). Note: Pharmacopoeial chemical reference substances are considered to be primary reference substances. In the absence of a pharmacopoeial reference substance, a manufacturer should establish a primary reference substance.'可被翻译为：在特定环境中被广泛认可具有适当质量的物质，其指定含量被接受而无需与另一种化学物质进行比较(8)。注:药典化学标准物质被认为是主要标准物质。在没有药典标准物质的情况下，生产企业应当建立主要标准物质。\n'secondary chemical reference substance'可被翻译为：二级化学参比物质\n\n根据上述已知信息，请将'Secondary chemical reference substances (also called working standards) are substances whose characteristics are assigned and\/or calibrated by comparison with a primary chemical reference substance. The extent of characterization and testing of a secondary chemical reference substance may be less than for a primary chemical reference substance (7).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"二级化学标准物质(也称为工作标准品)是通过与一级化学标准物质比较而确定和\/或校准其特性的物质。二级化学标准物质的表征和测试范围可能小于一级化学标准物质(7)。"
    },
    {
        "instruction":"已知信息：\n'(3) The sponsor fails to submit the DSUR as required;'可被翻译为：（三）申办者未按照要求提交研发期间安全性更新报告的；\n'Article 29 The registrant, the filing entity and the contract manufacturer of cosmetics shall establish and implement the health management system for employees, and establish health files of the employees. The health files shall be kept for at least 3 years.'可被翻译为：第二十九条 化妆品注册人、备案人、受托生产企业应当建立并执行从业人员健康管理制度，建立从业人员健康档案。健康档案至少保存3年。\n'(1) failing to establish vaccine electronic traceability system as required;'可被翻译为：（一）未按照规定建立疫苗电子追溯系统；\n'(1) Establish and organize implementation of quality management system of the enterprise, and implement the responsibility for quality and safety management;'可被翻译为：（一）建立并组织实施本企业质量管理体系，落实质量安全管理责任；\n\n根据上述已知信息，请将'(3) fails to establish and implement a drug tracking system as required;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）未按照规定建立并实施药品追溯制度；"
    },
    {
        "instruction":"已知信息：\n'(II) the Import Drug License (or the Pharmaceutical Product License), or the Import License for narcotic drugs and psychotropic substances has expired at the time of importation record filing;'可被翻译为：（二）办理进口备案时，《进口药品注册证》（或者《医药产品注册证》），或者麻醉药品、精神药品的《进口准许证》已超过有效期的；\n'Article 25 Where the application is only for registration of pharmaceutical preparations, any drug substance used for the study shall have a drug approval number, an Import Drug License or a Pharmaceutical Product License, and be acquired through legitimated means. Where a drug substance used for the study has no drug approval number, Import Drug License or Pharmaceutical Product License, the use of drug substance in study shall be approved by the State Food and Drug Administration.'可被翻译为：第二十五条 单独申请注册药物制剂的，研究用原料药必须具有药品批准文号、《进口药品注册证》或者《医药产品注册证》，且必须通过合法的途径获得。研究用原料药不具有药品批准文号、《进口药品注册证》或者《医药产品注册证》的，必须经国家食品药品监督管理局批准。\n'Article 19 The importation of drugs in urgent clinical needs, drugs for donation purpose, samples or comparator products required for new drug research and drug registration and so on shall apply for approval from the State Food and Drug Administration, and shall go through the formalities of importation record filing in accordance with Article 16 of the Provisions by presenting the Import Drug Approval issued by the State Food and Drug Administration.'可被翻译为：第十九条 进口临床急需药品、捐赠药品、新药研究和药品注册所需样品或者对照药品等，必须经国家食品药品监督管理局批准，并凭国家食品药品监督管理局核发的《进口药品批件》，按照本办法第十六条的规定，办理进口备案手续。\n'In addition, to import narcotic drugs and psychotropic substances, an importer shall obtain the Import License for narcotic drugs and psychotropic substances issued by the State Food and Drug Administration.'可被翻译为：进口麻醉药品、精神药品，还必须取得国家食品药品监督管理局核发的麻醉药品、精神药品《进口准许证》。\n\n根据上述已知信息，请将'Article 5 An importer may go through the formalities of importation record filing and port testing of drugs to be imported only after it has obtained the Import Drug License (or Pharmaceutical Product License) or Import Drug Approval issued by State Food and Drug Administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五条 进口药品必须取得国家食品药品监督管理局核发的《进口药品注册证》（或者《医药产品注册证》），或者《进口药品批件》后，方可办理进口备案和口岸检验手续。"
    },
    {
        "instruction":"已知信息：\n'5. All changes of the process or testing methods;'可被翻译为：（五）生产工艺或检验方法等的所有变更；\n'Article 254: CAPA implementation should be recorded and retained by the quality management department.'可被翻译为：第二百五十四条 实施纠正和预防措施应当有文件记录，并由质量管理部门保存。\n'Article 253: The manufacturer should establish operation procedures for the implementation of CAPA, including at least the following:'可被翻译为：第二百五十三条 企业应当建立实施纠正和预防措施的操作规程，内容至少包括：\n'capa'可被翻译为：纠正措施和预防措施\n\n根据上述已知信息，请将'5. To record all changes during CAPA implementation;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）对实施纠正和预防措施过程中所有发生的变更应当予以记录。"
    },
    {
        "instruction":"已知信息：\n'Settle plates should be exposed for the duration of operations and changed as required after a maximum of 4 hours. Exposure time should be based on recovery studies and should not allow desiccation of the media used.'可被翻译为：沉降碟应在操作期间暴露，并在最多 4 小时后按需要更换。暴露时间应基于回收率研究，并且避免所所用培养基干燥。\n'(a)  Settle plates should be exposed in grade A and B areas for the duration of operations (including equipment set-up)  and  changed  as required after  a maximum  of 4 hours  (exposure time  should be based  on validation including recovery studies and it should not have any negative effect on the suitability of the media used).'可被翻译为：沉降碟应在操作期间（包括设备安装）暴露在 A 级和 B 级区，并在最多 4 小时后按要求更换（暴露时间应基于验证，包括回收研究，不应对所用培养基的适用性产生任何负面影响）。\n'For containers having volumes of less than 25 mL, test a solution pool of 10 or more units to obtain a volume of no less than 25 mL. Single units of small-volume injections may be tested individually if the individual unit volume is 25 mL or greater.'可被翻译为：对于容积小于25ml的容器，检测合并了10个或更多单元的样品溶液得到不少于 25ml的样品体积。如果单剂量体积大于等于25ml，小容量注射剂单个单元亦可 单独检测。\n'It is unconventional for IVRT sampling times to be selected within a study duration of less than 4 hours. This may occur in situations where the fixed product dose was depleted to such a great extent by 4 hours that the release kinetics were no longer linear thereafter (when plotted vs. the square root of time). In such instances, it would be appropriate to explain the efforts that were made to optimize the IVRT method (e.g., using a different diffusion cell equipment that allowed for a larger product dose to be used) so that the sustained steady state release kinetics could potentially be characterized over a conventional IVRT duration of 4 to 6 hours.'可被翻译为：通常情况下，所选的IVPT取样时长不应少于4小时。但是，对于某些特定类型的制剂，如果在大于4小时后，因产品剂量消耗非常大，之后的时间点不能呈线性关系（以释放量对时间的平方根作图）。在这种情况下，应该阐述为优化IVRT方法所做的努力（例如，使用不同的扩散池设备，以便可以采用更大的产品上样量），确保在4～6小时内呈现持续稳态释放动力学。\n\n根据上述已知信息，请将'Individual settle plates may be exposed for less than 4 hours.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"单个沉降碟的暴露时间可以少于 4 小时。"
    },
    {
        "instruction":"已知信息：\n'Article 4 The registrant and the filing entity of cosmetics shall establish a quality management system for cosmetics manufacturing according to law, perform obligations related to product including adverse reaction monitoring, risk control, recall etc, and shall be responsible for their quality, safety and efficacy claims of cosmetics. Manufacturers and marketers of cosmetics shall comply with laws, regulations, provisions, mandatory national standards and technical specifications in engaging in manufacturing and marketing activities and conduct vigorous management, maintain integrity and practice self-discipline, thus to ensure the quality and safety of cosmetics.'可被翻译为：第四条 化妆品注册人、备案人应当依法建立化妆品生产质量管理体系，履行产品不良反应监测、风险控制、产品召回等义务，对化妆品的质量安全和功效宣称负责。化妆品生产经营者应当依照法律、法规、规章、强制性国家标准、技术规范从事生产经营活动，加强管理，诚信自律，保证化妆品质量安全。\n'Article 27 The registrant, the filing entity and the contract manufacturer of cosmetics shall establish responsibility system for quality and safety of cosmetics, and implement subject responsibility for quality and safety of cosmetics.'可被翻译为：第二十七条 化妆品注册人、备案人、受托生产企业应当建立化妆品质量安全责任制，落实化妆品质量安全主体责任。\n'Article 6 Manufacturers and marketers of cosmetics shall establish, in accordance with the law, documentation system for the check and test of purchases, and product sales record, and other systems, to ensure traceability of the products.'可被翻译为：第六条 化妆品生产经营者应当依法建立进货查验记录、产品销售记录等制度，确保产品可追溯。\n'Article 5 Drug manufacturers shall establish and improve the drug recall system according to these Provisions, collect relevant drug safety information, investigate and assess drugs with potential safety hazards and recall drugs with safety hazards.'可被翻译为：第五条 药品生产企业应当按照本办法的规定建立和完善药品召回制度，收集药品安全的相关信息，对可能具有安全隐患的药品进行调查、评估，召回存在安全隐患的药品。\n\n根据上述已知信息，请将'Manufacturers and marketers of cosmetics are encouraged to adopt information technology to collect and store information on manufacturing and marketing, and establish a traceability system for quality and safety of cosmetics.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"鼓励化妆品生产经营者采用信息化手段采集、保存生产经营信息，建立化妆品质量安全追溯体系。"
    },
    {
        "instruction":"已知信息：\n'point extraction'可被翻译为：点提取\n'extraction'可被翻译为：提取\n'Extraction procedure'可被翻译为：萃取程序\n'extraction gravimetry'可被翻译为：提取重量法\n\n根据上述已知信息，请将'1.Air extraction to remove dust with the extraction point located as close as possible to the source of the dust.\n2.Air extraction point located so that it effectively captures dust near its source.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.抽气除尘，抽气点尽量靠近粉尘源。\n2.排风点的位置使它能有效地在其源头附近捕获灰尘。"
    },
    {
        "instruction":"已知信息：\n'This test is performed to validate that a filter can remove bacteria from a gas or liquid. The test is usually performed using a standard organism, such as Brevundimonas diminuta, at a minimum concentration of 107 colony-forming units\/cm2'可被翻译为：进行这种测试是为了验证过滤器可以从气体或液体中去除细菌。该测试通常使用标准生物进行，如微小Brevundimonas，最低浓度为107菌落形成单位\/cm2\n'During filter validation, wherever possible, the product to be filtered should be used for bacterial retention testing of the sterilising grade filter. Where the product to be filtered is not suitable for use in bacterial retention testing, a suitable surrogate product should be justified for use in the test. The challenge organism used in the bacterial retention test should be justified.'可被翻译为：在过滤器验证过程中，应尽可能使用待过滤产品进行除菌级过滤器的细菌截留测试。如果待过滤产品不适 合用于细菌截留测试，应使用合适的替代产品进行测试并说明原因。应论证用于细菌截留试验的挑战微生物的合理性。\n'In a redundant filtration system (where a second redundant sterilising grade filter is present as a backup but the sterilising process is validated as only requiring one filter), post-use integrity test of the primary sterilising grade filter should be performed and if demonstrated to be integral, then a post-use integrity test of the redundant (backup) filter is not necessary. However, in the event of a failure of the post-use integrity test on the primary filter, post-use integrity test  on the  secondary (redundant) filter  should be performed, in conjunction with an investigation and risk assessment to determine the reason for the primary filter test failure.'可被翻译为：对于冗余过滤系统（存在第二个冗余除菌级过滤器作为备用过滤器，但灭菌工艺验证时仅用一个过滤器）， 应进行主除菌级过滤器的使用后完整性测试，如果证明该过滤器是完整的，则不需要对冗余（备用）过滤 器进行使用后完整性测试。但如果主过滤器的使用后完整性测试失败，应对二级（冗余）过滤器进行使用后完整性测试，同时进行调查和风险评估，确定主过滤器测试失败的原因。\n'Testing is performed in triplicate over a period of three independent test runs'可被翻译为：在3个独立的测试运行期间执行一式三份平行样品检测\n\n根据上述已知信息，请将'Bacterial retention testing - This test is performed to validate that a filter can remove bacteria from a gas or liquid. The  test  is  usually  performed  using  a  standard  organism,  such  as  Brevundimonas  diminuta  at  a  minimum concentration of 107 Colony Forming Units\/cm2.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"细菌截留试验：进行该试验是为了验证过滤器可以去除气体或液体中的细菌。该试验通常采用标准微生物进行，例如最低浓度 107 CFU\/cm2 的缺陷短波单孢菌（Brevundimonas diminuta）。"
    },
    {
        "instruction":"已知信息：\n'The on-site inspection question sheet shall be signed by all members of the inspection team, observers, and the person in charge of the inspected, and shall be affixed with the official seal of the inspected institution.'可被翻译为：现场核查问题表应当由核查组全体成员、观察员、被核查单位负责人签名，并加盖被核查单位公章。\n'The inspected institution shall introduce to the inspection team the development and manufacturing of the inspected variety in the institution and clarify the person in charge of the inspection site.'可被翻译为：被核查单位应当向核查组介绍核查品种在本单位开展的研究、生产等情况，明确核查现场负责人。\n'After the on-site inspection is completed, the inspection team shall return the supporting proof dossiers and other dossiers other than evidential dossiers to the inspected institution or delete them. The on-site inspection question sheet shall be sent to the inspected institution and the applicant.'可被翻译为：现场核查结束后，核查组应当将支持性证明材料、证据性材料以外其他材料退还被核查单位或者删除。现场核查问题表送被核查单位和申请人。\n'Article 47 CFDI shall notify the applicant and the inspected institution 5 days before the on-site inspection; the applicant and the inspected institution may not be notified in advance for cause-related inspection.'可被翻译为：第四十七条 核查中心于现场核查前5日通知申请人和被核查单位；有因检查可不提前通知申请人和被核查单位。\n\n根据上述已知信息，请将'If the inspected institution refuses to sign and seal, the inspection team shall indicate it in the on-site inspection report. The inspected institution shall give another written explanation on the refusal of signature and seal, which shall be signed by the person in charge of the inspected institution and stamped with the official seal of the inspected institution and submitted to the inspection team.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"被核查单位拒绝签字盖章的，核查组应当在现场核查报告中予以注明。被核查单位应当就拒绝签字盖章情况另行书面说明，由被核查单位负责人签字，并加盖被核查单位公章交核查组。"
    },
    {
        "instruction":"已知信息：\n'This manual was written to reduce compendia method ambiguity and increase standardization between ORS laboratories. By providing clearer instructions to ORS labs, greater transparency can be provided to both industry and the public.'可被翻译为：本手册旨在减少药典方法的歧义并提高 ORS 实验室之间的标准化。 通过向 ORS 实验室提供 更清晰的说明，可以为行业和公众提供更大的透明度。\n'1.The term transparency means: — defining policies and procedures in writing and publishing the written documentations; and — giving reasons for decisions to the public (see also accountability above).\n2.Defining policies and procedures in writing and publishing the written documentation, and giving reasons for decisions to the public.'可被翻译为：1.“透明度”一词是指:-以书面形式确定政策和程序，并公布书面文件;以及-向公众提供决策的理由(另见上文的问责制)。\n2.以书面形式确定政策和程序并公布书面文件，向公众说明作出决定的理由。\n'transparency'可被翻译为：透明度\n'(3) Biometrics means a method of verifying an individual's identity based on measurement of the individual's physical feature(s) or repeatable action(s) where those features and\/or actions are both unique to that individual and measurable.'可被翻译为：生物识别技术系指一种根据个人身体特征及重复行为（这些特征和\/或行为对个体独特，且可予以测定）的测定来识别个人身份的方法。\n\n根据上述已知信息，请将'The obligation to account for one's conduct and actions, ussually to an individual or group, but ultimately to the public. Both individuals and organizations may be accountable. There is some overlap between accountability and transparency (see transparency).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对自己的行为和行为负责的义务，通常是对个人或团体负责，但最终是对公众负责。个人和组织都有责任。问责制和透明度之间有一些重叠(见透明度)。"
    },
    {
        "instruction":"已知信息：\n'A document containing the information as set out in Appendix 1 of the guidelines that is validated and issued for a specific product by the competent authority of the exporting country and intended for use by the competent authority in the importing country or - in the absence of such an authority - by the drug procurement authority (see also section 3.5 of the guidelines). Transmission of product certificate: see sections 3.8 and 4.9 of the guidelines.Validity of product certificate: see section 3.9 of the guidelines.When to request a product certificate: see section 3.5 of the guidelines.'可被翻译为：包含指南附录1中所列信息的文件，由出口国主管部门对特定产品进行验证和签发，供进口国主管部门使用，或者在没有此类主管部门的情况下，供药品采购主管部门使用(另见指南第3.5节)。产品证书的传递:见指南第3.8节和4.9节。产品证书有效期:见指南第3.9节。何时申请产品证书:见指南第3.5节。\n'A document containing information, as set out in Appendix 3 of the guidelines, will normally be issued for each batch by the manufacturer. Furthermore, a batch certificate may exceptionally be validated or issued by the competent authority of the exporting country, particularly for vaccines, sera and other biological products. The batch certificate accompanies every major consignment (see also section 3.14 of the guidelines).'可被翻译为：如指南附录3所示，制造商通常会为每个批次签发一份包含信息的文件。此外，批号证书可例外地由出口国主管当局验证或签发，特别是对于疫苗、血清和其他生物制品。批证书随每批主要货物一起签发(另见指南第3.14节)。\n'competent authority'可被翻译为：主管机关\n'competent regulatory authority'可被翻译为：主管监管机关\n\n根据上述已知信息，请将'A document containing the information (as set out in Appendix 1 of these Guidelines) that is validated and issued for a specific starting material by the competent authority of the exporting country and intended for use by the competent authority in the importing country or in the absence of such an authority by, for example, the manufacturer of the finished product when exporting.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一份包含信息的文件(如本指南附录1所述)，由出口国主管当局就特定起始材料进行验证和签发，供进口国主管当局使用，或在没有此类当局的情况下，供成品制造商在出口时使用。"
    },
    {
        "instruction":"已知信息：\n'The general name of antitoxin, toxoid and antiviral serum in biological products. Such as tetanus, diphtheria, snake venom antitoxin: anti-rabies serum; Anti-anthrax serum, etc.'可被翻译为：生物制品中抗毒素、类毒素、抗病毒血清的总称。如破伤风、白喉、蛇毒抗毒素:抗狂犬病血清；抗炭疽血清等。\n'A person who routinely donates blood, blood components or plasma in the same blood establishment in accordance with the minimum time intervals.'可被翻译为：在同一血库按最低时间间隔定期捐献血液、血液成分或血浆的人。\n'A donor whose blood or plasma is tested for the first time for infectious disease markers in a blood establishment.'可被翻译为：首次在血液机构进行血液或血浆传染病标志物检测的献血者。\n'The concentration of a particular drug in the urine.'可被翻译为：尿液中所含特定药物的浓度。\n\n根据上述已知信息，请将'A biological material including, but not limited to, blood, serum, plasma and urine.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种生物材料，包括但不限于全血、血清、血浆和尿液。"
    },
    {
        "instruction":"已知信息：\n'rating scale'可被翻译为：刻度法\n'A method used to determine the reliability of an analytical outcome (e.g., cost-effectiveness analysis, decision analysis). The extent to which an important variable (e.g., cost, outcome, probability of an event, etc.) is affected by examining the possible range of variation.'可被翻译为：用来测定某种分析结果（如成本-效果分析、决策分析）可靠性的方法。通过检验重要变量（如成本、结果、事件的概率等）可能的变化范围来判断对分析结果产生影响的程度。\n'A statistical test of whether and to what extent variables are correlated.'可被翻译为：对变量之间是否相关以及相关的程度如何所进行的统计检验。\n'The degree to which the Quality of Life scale measures results reliably or reproducibly.'可被翻译为：生存质量量表测量结果的可靠程度或可重复程度。\n\n根据上述已知信息，请将'The extent to which a variable (e.g. a rating scale) measures what it is supposed to measure.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是指一个指标（如量表）测量它所预期测量的内容的程\n度。"
    },
    {
        "instruction":"已知信息：\n'A subject in a clinical trial who for any reason fails to continue in the trial until the last visit required of him\/her by the study protocol.'可被翻译为：是指临床试验的受试者由于任何原因不能继续按研究\n方案进行到所要求的最后一次随访。\n'The  outcome  of  the  review   should  include  a  risk  assessment   of  potential  sterile  breaches  in  batches\nmanufactured since the last successful APS.'可被翻译为：回顾的结果应包括，对自上次成功 APS 以来生产的批次中潜在无菌偏差的风险评估。\n'During use, when the liquid level drops to the liquid outlet and stops, the last residual solution is then blown out.'可被翻译为：使用过程中液面降至流液口并静止时，随即将最后残留的溶液次吹出的吸管。\n'A method of analyzing trial data on the relationship between time and health outcomes, such as death.'可被翻译为：对时间与健康产出（如死亡）之间的关系进行试验数据分析的一种方法。\n\n根据上述已知信息，请将'The checking and assessment of data during the period of time between trial completion (the last observation on the last subject) and the breaking of the blind, for the purpose of finalising the planned analysis.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"是指在试验完成（最后一位受试者的最后一次观察）到揭盲这段时间内对数据的检查和评价，旨在最终确定分析计划。"
    },
    {
        "instruction":"已知信息：\n'Two types of diffusion cells are commonly used for IVPT studies: the vertical diffusion cell (VDC) (see Figures 1–5) and the flow-through diffusion cell (FDC) (see Figures 8–10). Equipment features (e.g., bubble-free cells or cells with a vent hole) other than the ones depicted below may be suitable once qualified. VDCs are well characterized and can be utilized for both, IVRT and IVPT studies. FDCs are used exclusively for IVPT studies (not IVRT studies) and have the advantage that the sampling is more easily automated, which can make it easier to acquire samples at times when investigators are typically not in the laboratory (e.g., the middle of the night). VDCs and FDCs can both produce excellent results when the IVPT method is appropriately developed, and each type of cell has its advantages.'可被翻译为：两种类型的扩散池通常用于IVPT研究:垂直扩散池(VDC)(见图1-5)和流通扩散池(FDC)(见图8-10)。除了下面描述的设备特征(例如，无气泡池体或带有排气孔的池体)，一旦合格，可能也适用。VDC具有良好的特征，可用于IVRT和IVPT研究。FDC专门用于IVPT研究(而不是IVRT研究)，其优点是采样更容易自动化，这可以使研究人员通常不在实验室(例如，半夜)时更容易获取样本。当IVPT方法得到适当的发展时，VDC和FDC都可以产生优异的结果，每种类型的池体都有其优点。\n'2. Empirically measured volume of the receptor solution compartment\/vessel for each VDC or immersion cell, or the empirically measured outflow tube length for each FDC'可被翻译为：经验性测量每个VDC或浸没池的受体溶液室\/容器的体积，或经验性测量每个FDC的流出管长度\n'The immersion cell system consists of the following components:'可被翻译为：对于浸没池，USP装置2应根据溶解<711>中描述的程序进行鉴定。浸没池系统由以下部分组成:\n'Suitable equipment for the IVRT method are described in USP General Chapter<1724>. These include different models of a vertical diffusion cell and an immersion cell. Other models of vertical diffusion cells and immersion cells that are essentially the same in design and\/or operational principles as those described in USP General Chapter<1724>may also be suitable.'可被翻译为：在USP<1724>中有可用于IVRT方法的相应设备描述，包括不同模型的立式扩散池和一种的浸没池。与USP<1724>中描述的立式扩散池和浸没池具有相同的设计和\/或操作原理的其他设备，也可以使用。\n\n根据上述已知信息，请将'The VDC, immersion cells, and FDC should match the general descriptions provided below and may have design variations of the types shown among specific examples illustrated in Figures 1–5 for VDCs, Figures 6 and 7 for immersion cells, or Figures 8–10 for FDCs. The VDC, immersion cell, and FDC components should be manufactured with inert materials that do not adsorb, absorb, bind, or react with the analyte. The diffusion cell and its components should not alter the amount of diffusing drug that is measured, either by adsorbing, absorbing, binding, or reacting with the drug, or by releasing drug that was adsorbed, absorbed, bound, or reacted with in a previous experiment.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"VDC、浸没池和FDC应符合下面提供的一般描述，并且可以在图1-5所示的VDC、图6和图7所示的浸没池或图8-10所示的FDC的具体示例中具有不同的设计类型。VDC、浸没池和FDC组件应使用惰性材料制造，这些材料不会吸附、吸收、结合或与分析物发生反应。扩散池及其组件不应通过吸附、吸收、结合或与药物反应，或通过释放先前实验中吸附、吸收、结合或与之反应的药物来改变所测量的扩散药物的量。"
    },
    {
        "instruction":"已知信息：\n'Article 73 The investigator shall ensure that the clinical trial data is accurately, completely, clearly and promptly entered in the case report form. The case report form shall be signed by the investigator; any change in the data shall be signed and dated by the investigator and meanwhile clear and identifiable original records shall be kept.'可被翻译为：第七十三条 研究者应当保证将临床试验数据准确、完整、清晰、及时地载入病例报告表。病例报告表由研究者签署姓名，任何数据的更改均应当由研究者签名并标注日期，同时保留原始记录，原始记录应当清晰可辨识。\n'Article 58 In the multicenter clinical trial, the sponsor shall ensure that the case report form is well designed to enable the coordinating investigator to obtain all the data from each clinical trial institution.'可被翻译为：第五十八条 在多中心临床试验中，申办者应当保证病例报告表的设计严谨合理，能够使协调研究者获得各分中心临床试验机构的所有数据。\n'Article 83 The investigator shall verify or confirm the safety and effectiveness of the investigational medical device in accordance with the design requirements of the clinical trial protocol and complete the clinical trial report. The clinical trial report of a multicenter clinical trial shall include the summaries of each clinical trial of the sub-site.'可被翻译为：第八十三条 研究者应当按照临床试验方案的设计要求，验证或者确认试验用医疗器械的安全性和有效性，并完成临床试验报告。多中心临床试验的临床试验报告应当包含各分中心的临床试验小结。\n'Article 74 The clinical trial institution and the investigator shall ensure that the data, documents and records formed in the clinical trial are authentic, accurate, clear and secure.'可被翻译为：第七十四条 临床试验机构和研究者应当确保临床试验所形成数据、文件和记录的真实、准确、清晰、安全。\n\n根据上述已知信息，请将'Article 80 In the clinical trial, the investigator shall ensure that any observation and finding are recorded in the correct and complete manner and that the case report form is carefully filled out. Records shall include at least:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十条 在临床试验中，研究者应当确保将任何观察与发现均正确完整地予以记录，并认真填写病例报告表。记录至少应当包括："
    },
    {
        "instruction":"已知信息：\n'Monitoring agencies designated by the NMPA (hereinafter referred to as national monitoring agencies) shall be responsible for unified management of all the information of medical device adverse events collected and provide feedback of relevant monitoring information of medical device adverse events to relevant monitoring agencies, MAHs, distributing enterprises or user facilities.'可被翻译为：国家药品监督管理局指定的监测机构（以下简称国家监测机构）负责对收集到的医疗器械不良事件信息进行统一管理，并向相关监测机构、持有人、经营企业或者使用单位反馈医疗器械不良事件监测相关信息。\n'Article 20 MAHs shall release the contact information such as telephone, correspondence address, email and fax, designate the contact person, and voluntarily collect the adverse event information from medical device distributing enterprises, user facility and users; In case of identifying or knowing any suspected medical device adverse event, MAHs shall report and evaluate the medical device adverse event directly through the National Medical Device Adverse Events Monitoring Information System and submit investigation report of group adverse events of medical device as well as periodic risk evaluation report.'可被翻译为：第二十条  持有人应当公布电话、通讯地址、邮箱、传真等联系方式，指定联系人，主动收集来自医疗器械经营企业、使用单位、使用者等的不良事件信息；对发现或者获知的可疑医疗器械不良事件，持有人应当直接通过国家医疗器械不良事件监测信息系统进行医疗器械不良事件报告与评价，并上报群体医疗器械不良事件调查报告以及定期风险评价报告等。\n'Article 5 National Medical Products Administration (hereinafter referred to as the NMPA) shall establish the National Medical Device Adverse Event Monitoring Information System and strengthen the construction of medical device adverse event monitoring information network and database.'可被翻译为：第五条  国家药品监督管理局建立国家医疗器械不良事件监测信息系统，加强医疗器械不良事件监测信息网络和数据库建设。\n'Article 63 The drug regulatory departments shall, based on their responsibilities, supervise and inspect the medical device adverse event monitoring and re-evaluation carried out by MAHs and distributing enterprises, and supervise and inspect the medical device adverse event monitoring by user facility of medical device jointly with the health administrative departments at the same level.'可被翻译为：第六十三条  药品监督管理部门应当依据职责对持有人和经营企业开展医疗器械不良事件监测和再评价工作情况进行监督检查，会同同级卫生行政部门对医疗器械使用单位开展医疗器械不良事件监测情况进行监督检查。\n\n根据上述已知信息，请将'Article 3 Medical device marketing authorization holders (hereinafter referred to as MAHs) shall possess the capacities of quality management and corresponding responsibilities to ensure that the medical devices are safe and effective, establish medical device adverse event monitoring system and directly report medical device adverse events to medical device adverse event monitoring agencies (hereinafter referred to as monitoring agencies). Distributing enterprises and user facility of medical device authorized by MAHs shall report medical device adverse events to MAHs and monitoring agencies.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第三条  医疗器械上市许可持有人（以下简称持有人），应当具有保证医疗器械安全有效的质量管理能力和相应责任能力，建立医疗器械不良事件监测体系，向医疗器械不良事件监测技术机构（以下简称监测机构）直接报告医疗器械不良事件。由持有人授权销售的经营企业、医疗器械使用单位应当向持有人和监测机构报告医疗器械不良事件。"
    },
    {
        "instruction":"已知信息：\n'Article 119 Where drug use institutions use counterfeit drugs or inferior drugs, they shall be punished in accordance with the provisions on the sale of counterfeit drugs and inferior drugs. In serious circumstances, and if the legal representative, the principal responsible persons, the persons directly in charge, and other directly responsible persons as well as other responsible personnel have a medical license, the medical license shall be revoked.'可被翻译为：第一百一十九条 药品使用单位使用假药、劣药的，按照销售假药、零售劣药的规定处罚；情节严重的，法定代表人、主要负责人、直接负责的主管人员和其他责任人员有医疗卫生人员执业证书的，还应当吊销执业证书。\n'Where a drug manufacturer violates Item (IV) or (V) of the preceding paragraph, re-registration of relevant drugs shall be prohibited in accordance with requirements of the Provisions for Drug Registration.'可被翻译为：药品生产企业有前款规定第（四）项、第（五）项情形之一的，按照《药品注册管理办法》的规定对相应药品不予再注册。\n'Where a drug MAH, drug manufacturer or drug distributor bribes State officials in the process of drug development, manufacture, and distribution, the legal representative, the principal responsible person, the persons directly in charge, and other directly responsible persons as well as other responsible personnel shall be banned from engaging in drug production and operation for life.'可被翻译为：药品上市许可持有人、药品生产企业、药品经营企业在药品研制、生产、经营中向国家工作人员行贿的，对法定代表人、主要负责人、直接负责的主管人员和其他责任人员终身禁止从事药品生产经营活动。\n'Where any disease prevention and control institution or immunization entity commits illegal acts as prescribed in the preceding paragraph, the competent health department of the people's government at or above the county level may impose sanctions of  warning and up to the dismissal on the main responsible person, the executive in charge and other directly responsible personnel according to law, and order the responsible medical and health personnel to suspend practice activities for more than six months and less than one year; and for serious consequences, give a dismissal to the principal, the executive in charge and other directly responsible personnel according to law, and responsible medical and health personnel shall be revoked of business certificate by original issuing department.'可被翻译为：疾病预防控制机构、接种单位有前款规定违法行为的，县级以上人民政府卫生健康主管部门可以对主要负责人、直接负责的主管人员和其他直接责任人员依法给予警告直至撤职处分，责令负有责任的医疗卫生人员暂停六个月以上一年以下执业活动；造成严重后果的，对主要负责人、直接负责的主管人员和其他直接责任人员依法给予开除处分，由原发证部门吊销负有责任的医疗卫生人员的执业证书。\n\n根据上述已知信息，请将'The sale of drugs prescribed in item (1) to item (3) of the preceding paragraph, or the use of drugs prescribed in item (1) to item (5) of the preceding paragraph by drug use institutions, shall be punished in accordance with the provisions of the preceding paragraph. In serious circumstances, where the legal representative, the principal responsible person, the persons directly in charge, and other directly responsible persons as well as other responsible personnel that have a medical license, the medical license shall be subject to revocation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"销售前款第一项至第三项规定的药品，或者药品使用单位使用前款第一项至第五项规定的药品的，依照前款规定处罚；情节严重的，药品使用单位的法定代表人、主要负责人、直接负责的主管人员和其他责任人员有医疗卫生人员执业证书的，还应当吊销执业证书。"
    },
    {
        "instruction":"已知信息：\n'Method of sterilization in saturated steam, boiling water, or circulating steam.'可被翻译为：在饱和蒸汽、沸水或流通蒸汽中进行灭菌的方法。\n'boiling sterilization'可被翻译为：煮沸灭菌\n'The combined process of heating a liquid substance to boiling to vapor and of cooling the vapor to liquid. It is a common method of purifying liquid substances and separating mixtures.'可被翻译为：将液态物质加热到沸腾变为蒸气，又将蒸气冷却为液体的两个联合操作过程。是提纯液体物质和分离混合物的一种常用的方法。\n'k. <1211> Sterilization and Sterility Assurance of Compendial Articles'可被翻译为：<1211>药典品种的灭菌和无菌保证\n\n根据上述已知信息，请将'The method of sterilization by heating the articles to be sterilized in boiling water.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"把待灭菌物品放入沸水中加热灭菌的方法。"
    },
    {
        "instruction":"已知信息：\n'Adverse reactions not mentioned in the drug product labeling. If the nature, severity, consequences, or frequency of an adverse reaction differs from or is more severe than what is described in the product labeling, it should be handled according to the new adverse reaction information.'可被翻译为：药品说明书中未载明的不良反应。说明书中已有描述，但不良反应发生的性质、程度、后果或者\n频率与说明书描述不一致或者更严重的，按照新的药品不良反应处理。\n'adverse drug reaction (adr)'可被翻译为：药物不良反应\n'An adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g., Investigator's Brochure for an unapproved investigational medicinal product). (See section III.C.)'可被翻译为：指的是不良反应的性质和严重程度同已有的药品资料不符(如对于未获批准的研究药物，指的是研究者手册 )。（见第Ⅲ.C.章）\n'New and Serious ADR\/ADE Reporting'可被翻译为：新的和严重药品不良反应\/事件报告情况\n\n根据上述已知信息，请将'(IV) A new ADR refers to any adverse reaction that is not listed on the package insert. An ADR that is listed but is in consistent with or more severe than that described on the package insert in nature, severity, outcome and frequency shall be handled as a new ADR.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）新的药品不良反应，是指药品说明书中未载明的不良反应。说明书中已有描述，但不良反应发生的性质、程度、后果或者频率与说明书描述不一致或者更严重的，按照新的药品不良反应处理。"
    },
    {
        "instruction":"已知信息：\n'III. The drugs imported under the same contract may be sampled as the same batch only if the drug name, country of manufacture, manufacturer, package, batch number, dosage form, strength, shipping mark and contract number are identical. If drugs are imported under the same contract but shipped in different batches, they shall be sampled in different batches.'可被翻译为：三、同一合同，药品名称、生产国家、厂商、包装、批号、剂型、规格、唛头标记以及合同编号均相同者，方可作为同批药品进行抽样；同一合同进口的药品分次到货者，分次抽样。\n'(IV) For dismantling sales, clean and sanitary package shall be used, on which the name, strength, quantity, usage, dosage, lot number, and expiry date of the drug, and name of the drug store shall be indicated;'可被翻译为：（四）拆零销售应当使用洁净、卫生的包装，包装上注明药品名称、规格、数量、用法、用量、批号、有效期以及药店名称等内容；\n'1) Name of the material or product, dosage form, strength, batch number or shipping batch number, where appropriate, the name of the manufacturer and\/or supplier;'可被翻译为：1.产品或物料的名称、剂型、规格、批号或供货批号，必要时注明供应商和生产商（如不同）的名称或来源；\n'(II) After unsealing the package of drug substances, samples shall be taken at different parts to make the total amount reach the sampling quantity, and then directly pour them into the sample bottle and mix well.'可被翻译为：（二）原料药包装开启后，于不同部位分别取样，使总量达到抽样数量，直接倾入样品瓶内、混匀。\n\n根据上述已知信息，请将'(I) Before unsealing the sample, the outer package, shipping mark number or contract number, and name and quantity of the product shall be checked against the materials submitted for testing. After unsealing, the name of drug, the name of factory and the batch number of the drugs in the sub-package shall be checked, and whether the package is intact and clean without water stain, mildew or other material pollution shall be determined. If the drugs within part of the packages deteriorate, samples shall be taken for testing separately.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）抽样启封前，应当与报验资料核对外包装，唛头号或合同编号，以及品名、数量等。启封后应当核对小包装品名、厂名和批号等，并注意检查包装的完整性和清洁程度以及有无水迹、霉烂或其它物质污染等。如有部分包件变质，应当另行抽样检验。"
    },
    {
        "instruction":"已知信息：\n'In the 2018 ADR\/ADE reports, the ratio of male to female patients was 0.86:1, with men slightly outnumbered by women.Reports of pediatric patients under 14 years of age accounted for 9.8%; reports of elderly patients over the age of 65 accounted for27.7% (Figure 5).'可被翻译为：2018年药品不良反应\/事件报告中，男女患者比为0.86:1，女性略多于男性。14岁以下儿童患者的报告占9.8%；65岁以上老年患者的报告占27.7%（图5）。\n'Patients involved in the ADR\/ADE reports'可被翻译为：药品不良反应\/事件报告涉及患者情况\n'7. Patients involved in the ADR\/ ADE reports'可被翻译为：7.药品不良反应\/事件报告涉及患者情况\n'In 2019, the National ADR Monitoring Network received 156,000 reports of reports serious adverse drug reactions\/incidents, and serious ADR\/ADE reports accounted for 10.3 percent of the total reports for the same period (Figure 2).'可被翻译为：2019年全国药品不良反应监测网络收到严重药品不良反应\/事件报告15.6万份，严重药品不良反应\/事件报告占同期报告总数的10.3%（图2）。\n\n根据上述已知信息，请将'In the 2019 ADR\/ADE reports, the ratio of male to female patients was 0.86:1, with men slightly outnumbered by women. Reports of pediatric patients under 14 years of age accounted for 10.2 percent; and reports of elderly patients over 65 accounted for 29.1 percent.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2019年药品不良反应\/事件报告中，男女患者比为0.86:1，女性略多于男性。14岁以下儿童患者占10.2%；65岁及以上老年患者占29.1%。"
    },
    {
        "instruction":"已知信息：\n'CDE reviewed and approved the marketing of 10 varieties of Class 1 innovative drugs, and 58 varieties of imported brand-name drugs (including new indications).'可被翻译为：审评通过上市1类创新药10个品种，审评通过进口原研药58个品种（含新适应症）。\n'CDE accepted registration applications for 157 varieties of Class 1 innovative chemicals, covering 16 innovative NDAs (up by 100% YOY), 115 varieties of domestically produced innovative chemicals, and 42 imported ones. For such details from 2015 to 2018, see Figure 4.'可被翻译为：药审中心受理1类化药创新药注册申请157个品种，整体较2017年略有增加，其中受理创新药NDA 16个品种，较2017年增长了一倍。2018年受理的157个化药创新药注册申请中，国产化药创新药注册申请为115个品种，进口化药创新药注册申请为42个品种，2015年至2018年创新药注册申请受理情况详见图4。\n'CDE completed reviews for 603 applications for chemicals IND, 554 of which were approved, including 449 IND applications for Class 1 innovative drugs (involving 172 varieties). The numbers of IND approved for Class 1 chemical innovative drugs in 2015-2018 (in terms of variety) are shown in Figure 16.'可被翻译为：药审中心完成审评的化药IND申请603件，审评通过批准IND申请554件，其中批准1类创新药临床试验申请449件（涉及172个品种）。1类化药创新药临床试验批准数量与前三年比较（以品种计）详见图16。\n'CDE accepted 75 applications for registration of Class 5.1 imported chemical brand name drugs (involving 50 varieties), and85 applications for registration of imported innovative drugs (incl. 42 varieties). The indications for innovative drugs are mainly focused on anti-tumor, circulatory and digestive systems.'可被翻译为：药审中心受理5.1类化药进口原研药注册申请75件（涉及50个品种），受理1类进口创新药注册申请85件（涉及42个品种），创新药的适应症主要集中在抗肿瘤、循环系统和消化系统领域。\n\n根据上述已知信息，请将'CDE reviewed and approved the marketing of 9 varieties of Class 1 innovative drugs, and67 varieties of imported brand-name drugs.For details, see Annexes 1 and 2.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"审评通过上市1类创新药9个品种，审评通过进口原研药67个品种，具体品种详见附件1、2。"
    },
    {
        "instruction":"已知信息：\n'For terminally sterilised products, the validation of terminal sterilisation processes should ensure the sterility of all critical product pathways between the component and moulded container, including areas that are not wetted during sterilisation.'可被翻译为：对于最终灭菌产品，最终灭菌工艺的验证应确保组件和成型容器之间的所有关键产品通路的无菌性，包括灭菌过程中未润湿的区域。\n'The holding time for sterilised equipment, components, and containers before use and during filling\/assembly.'可被翻译为：已灭菌设备、组分和容器在使用前和灌装\/装配过程中的保持时间。\n'The  sterilisation  of the  lyophilizer  and  associated  equipment  (e.g.  trays, vial  support rings)  should  be validated and the holding time between the sterilisation cycle and use appropriately challenged during APS (see paragraph 9.33). The lyophilizer should be sterilised regularly, based on system design. Re-sterilisation should be performed  following  maintenance  or  cleaning.   Sterilised   lyophilizers  and  associated  equipment  should  be protected from contamination after sterilisation.'可被翻译为：冻干机和相关设备（例如托盘、西林瓶支撑环）的灭菌应经过验证，应在 APS 期间适当挑战灭菌循环和使 用之间的保持时间（参见第 9.33 节）。冻干机应根据系统设计定期灭菌。在维护或清洁后应进行再灭菌。应保护灭菌后的冻干机和相关设备，防止污染。\n'A hard glass container that is fusible and sealable. For holding injection or water for injection.'可被翻译为：可熔封的硬质玻璃容器。用以盛装注射液或注射用水。\n\n根据上述已知信息，请将'The holding time between equipment, component, and container cleaning, drying and sterilisation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"设备、组件和容器清洁、干燥和灭菌之间的保持时间。"
    },
    {
        "instruction":"已知信息：\n'For drugs marketed overseas but not marketed in China, technical requirements for clinical trials to support its marketing in China should be established in compliance with the basic logic of clinical evaluation and on the basis of full evaluation of clinical demand of Chinese patients, clinical safety and effectiveness of overseas originator drugs, influences of racial factors as well as the need of benefit\/risk evaluation in Chinese patients.'可被翻译为：境外已上市境内未上市药品的临床技术要求，应遵循临床评价基本逻辑，在充分评价中国患者临床需求、境外原研药品临床安全性和有效性、以及种族因素影响的基础上，基于中国患者获益\/风险评估的需要，确定其在境内上市需开展的临床试验技术要求。\n'For the drugs marketed overseas but not marketed in China, full evaluation should be performed for the clinical study data of the originator drugs according to the basic logic of clinical evaluation and in combination with the actual situation of the drugs, and the clinical trial requirements should be determined according to the evaluation results. For drugs with different R & D backgrounds, the clinical trials required to be carried out should be determined case by case.'可被翻译为：对于境外已上市境内未上市的药品，需结合药品具体情况，按照临床评价的基本逻辑对原研药品的临床研究数据进行充分评价，根据评价结果确定临床试验要求。对于不同研发背景的药品，其所需开展的临床试验应具体问题具体分析。\n'For adding new dosage form (with clinical advantage), new administration route, new usage and dosage approved overseas but not in China for approved indications of drugs marketed in China, and each domestically marketed single drug in a new compound drug marketed overseas but not marketed in China, when the following conditions are met simultaneously, reduction or exemption of clinical trials can be considered according to the evaluation of overseas clinical trial data : ①Data of completed clinical trials of marketed originator drugs indicates that benefits of the drug for Chinese patients outweigh the risks, and there is no significant impact of racial factors compared with data in foreign populations; ②The overseas clinical trial data of new dosage form, new administration route, new usage and dosage or new compound of the drug can be used to fully evaluate its safety and effectiveness.'可被翻译为：对于境内已上市药品增加境外已批准境内未批准的新剂型（有临床优势的）、新给药途径、新用法用量，用于境内已上市药品已批准适应症的情形，以及境外已上市境内未上市新复方药品中各单药均已在境内上市的情形，在同时满足以下条件时，可考虑基于境外临床试验数据评价情况，减或免临床试验：①已上市原研药品完成的临床试验数据显示，该药品用于中国患者的获益大于风险，且与境外人群数据相比未见明显种族因素的影响；②递交的该药物新剂型、新给药途径、新用法用量，或新复方的境外临床试验数据可用于充分评价其安全性和有效性。\n'As for the requirements for clinical trials of generic drugs marketed overseas but not marketed in China, they should be determined after comprehensive consideration of two factors including clinical evaluation results and pharmaceutics of originator drugs.'可被翻译为：对于境外已上市境内未上市药品的仿制药的临床试验要求，需结合原研药品临床评价结果及制剂学两个方面的因素综合考虑后确定。\n\n根据上述已知信息，请将'If a new indication that has been approved overseas but not in China is added to drugs marketed domestically, besides complying with the above-mentioned basic logic of clinical evaluation and clinical trial requirements, analysis should be based on cases because multi-dimensional complicated factors of diseases and drugs are involved. It is suggested to communicate with regulatory authorities before application.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于境内已上市药品增加境外已批准境内未批准的新适应症的情形，除应遵循上述临床评价基本逻辑和临床试验要求外，因涉及疾病和药物等多维度复杂因素，应具体问题具体分析，建议申报前与监管机构进行沟通。"
    },
    {
        "instruction":"已知信息：\n'A product that has undergone all stages of production, including packaging in its ﬁnal container and labelling. A finished pharmaceutical product may contain one or more APIs. In some cases, it may be in combination with a medical device.'可被翻译为：经过所有生产阶段的产品，包括最终容器的包装和标签。药品成品可能含有一种或多种原料药。在某些情况下，它可能与医疗器械结合使用。\n'Development of a cryopreservation process for a clinical cell therapy must consider the consequences for the product, the patient, and the overall feasibility of the therapy. For the cell product, the manufacturer must ensure that expected cell losses because of cryopreservation and thaw occur in a manner that is reasonably predictable and must ensure that the final product administered to the patient will meet specifications for cell number, viability, and functional characteristics.'可被翻译为：开发用于临床细胞治疗的冷冻保存过程必须考虑对产品、病人和治疗整体可行性的影响。对于细胞产品,制造商必须确保由于低温贮藏和解冻产生的预期细胞损失是合理的可预见的，并且必须确保患者使用的最终产品符合细胞数量、生存能力和功能特征的规范。\n'7. Product Test Failure - When a firm has a final product or in-process test result that indicates a failure (USP test failure, OOS, etc.) ask– Were the results due to laboratory error or a true process contamination?'可被翻译为：产品检测失败—如果一个公司有一个成品或中控检测结果显示失败（USP 检测失败，OOS 等），询问—结果是因为实验室错误还是真正的工艺污染？\n'finished pharmaceutical product (FPP). A product that has undergone all stages of production, including packaging in its final container and labelling. An FPP may contain one or more active pharmaceutical ingredients (APIs). In some cases, it may be in combination with a medical device.'可被翻译为：制剂成品（FPP） 经过了所有生产步骤包括包装在最终容器中并贴上标签的产品。一种FPP可包括一种或多种API。有时可能会与医疗器械的组合。\n\n根据上述已知信息，请将'Although bedside thawing of cell therapy products before infusion has been a common clinical practice, the use of trained personnel in a controlled laboratory environment is now recognized asthe preferred method for thawing because it allows a more standardized process and a higher degree of control when staff must respond to a container failure,which may require product salvage in a more sterile environment. Product thawing typically is done by immersion in 37° water baths and using over wrap bags to minimize product loss and contamination in case of primary container failure. Bags may be gently kneaded during thaw to reduce temperature gradients across the bag and to accelerate thawing. The product is removed from the water bath when some ice is still present in the product but the majority of the product is thawed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"尽管在输液前在床边对细胞治疗产品进行解冻是一种常见的临床过程，但现在公认受过培训的人员在受控实验室环境中解冻是首选的方案。因为这样可以使工作人员在无菌环境中通过更标准化的操作过程和更高程度的控制细胞解冻过程，并对容器故障作出响应来产品回收。解冻通常是通过浸37°水浴中并使用复温袋来完成的，以便在主容器发生故障的情况下将产品损失和污染降至最低。解冻过程中可以轻轻揉捏袋子，降低袋子上的温度梯度并加速解冻。当产品中仍然存在一些冰而大部分产品已经解冻后，将产品从水浴中取出。"
    },
    {
        "instruction":"已知信息：\n'5) Approved master manufacturing documents and operation procedures;'可被翻译为：5.经批准的工艺规程和操作规程；\n'1. The Master Manufacturing Formula:'可被翻译为：（一）生产处方：\n'Article 149: Master manufacturing documents and operation procedures should be established according to the validation results.'可被翻译为：第一百四十九条 应当根据验证的结果确认工艺规程和操作规程。\n'The documentation in the Provisions includes specifications, master manufacturing documents, operation procedures, records, reports, and etc.'可被翻译为：本规范所指的文件包括质量标准、工艺规程、操作规程、记录、报告等。\n\n根据上述已知信息，请将'1. The review and approval of master manufacturing documents, procedures, etc;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）审核和批准产品的工艺规程、操作规程等文件；"
    },
    {
        "instruction":"已知信息：\n'Article 34 If the registrant, the filing entity and the contract manufacturer of cosmetics have suspended manufacturing for more than 1 year consecutively, it shall make comprehensive internal audit before the manufacturing is resumed, and can resume the manufacturing only after confirming that the requirements are met. The internal audit and rectification conditions shall be reported to the drug regulatory department of the province, autonomous region or municipality directly under the central government where it is located within 10 workings days from date of resumption of manufacturing.'可被翻译为：第三十四条 化妆品注册人、备案人、受托生产企业连续停产1年以上，重新生产前，应当进行全面自查，确认符合要求后，方可恢复生产。自查和整改情况应当在恢复生产之日起10个工作日内向所在地省、自治区、直辖市药品监督管理部门报告。\n'Article 18 If a medical device manufacturer establishes the manufacturing premises across the province, autonomous region or municipality directly under the central government, it shall apply to the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the manufacturing premises is located for Medical Device Manufacturing License.'可被翻译为：第十八条  医疗器械生产企业跨省、自治区、直辖市设立生产场地的，应当向新设生产场地所在地省、自治区、直辖市药品监督管理部门申请医疗器械生产许可。\n'Where a comprehensive on-site inspection is required due to changes in manufacturing licensed items, etc., if the manufacturer conforms to requirements upon on-site inspection by the drug regulatory department of the province, autonomous region or municipality directly under the central government, a new Cosmetics Manufacturing License shall be issued with the license number unchanged, and the validity period thereof will be recalculated from the date of issuance.'可被翻译为：因生产许可项目等的变更需要进行全面现场核查，经省、自治区、直辖市药品监督管理部门现场核查并符合要求的，颁发新的化妆品生产许可证，许可证编号不变，有效期自发证之日起重新计算。\n'The NMPA shall be responsible for making template of the Cosmetics Manufacturing License. The drug regulatory department of the province, autonomous region or municipality directly under the central government shall be responsible for printing, issuing and other management work of the cosmetics manufacturing license.'可被翻译为：国家药品监督管理局负责制定化妆品生产许可证式样。省、自治区、直辖市药品监督管理部门负责化妆品生产许可证的印制、发放等管理工作。\n\n根据上述已知信息，请将'Where changes occur in the manufacturing conditions are discovered upon internal audit, so that the conditions no longer meet the requirements of Good Manufacturing Practice for cosmetics, the registrant, the filing entity and the contract manufacturer of cosmetics shall immediately take measures for rectification; upon discovering that the quality and safety of cosmetics may be affected, they shall immediately stop the manufacturing and report the matter to the drug regulatory department of the province, autonomous region or municipality directly under the central government where it is located. Manufacturing can be resumed only upon removal of the risk factors affecting the quality and safety. The drug regulatory department of the province, autonomous region or municipality directly under the central government may organize on-site inspection based on actual conditions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"经自查发现生产条件发生变化，不再符合化妆品生产质量管理规范要求的，化妆品注册人、备案人、受托生产企业应当立即采取整改措施；发现可能影响化妆品质量安全的，应当立即停止生产，并向所在地省、自治区、直辖市药品监督管理部门报告。影响质量安全的风险因素消除后，方可恢复生产。省、自治区、直辖市药品监督管理部门可以根据实际情况组织现场检查。"
    },
    {
        "instruction":"已知信息：\n'An enveloped single-stranded, RNA virus that is the causative agent of hepatitis C.'可被翻译为：丙型肝炎病毒一种包膜单链RNA病毒，是丙型肝炎的病原体\n'A non-enveloped single-stranded RNA virus that is the causative agent of hepatitis A.'可被翻译为：一种非包膜单链RNA病毒，是甲型肝炎的病原体。\n'An enveloped single-stranded RNA virus that is the causative agent of West Nile fever.'可被翻译为：一种包膜单链RNA病毒，是西尼罗河热的病原体。\n'An enveloped, single-stranded RNA virus that is the causative agent of the acquired immunodeficiency syndrome (AIDS).'可被翻译为：一种包膜单链RNA病毒，是获得性免疫缺陷综合征(艾滋病)的病原体。\n\n根据上述已知信息，请将'An enveloped double-stranded DNA virus that is the causative agent of hepatitis B.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种包膜双链DNA病毒，是乙型肝炎的病原体。"
    },
    {
        "instruction":"已知信息：\n'A distinctive combination of numbers and\/or letters which specifically identifies a batch.'可被翻译为：用于识别一个特定批的具有唯一性的数字和（或）字母的组合。\n'A set of numbers or letters plus numbers used to identify the \"lot\". Used to trace and review the manufacturing history of the drug.'可被翻译为：用于识别''批”的一组数字或字母加数字。用以追溯和审查该药品的生产历史。\n'UDI refers to the code on any medical device itself or its package comprising figures, letters or symbols, which is used for unique identification of medical devices.'可被翻译为：医疗器械唯一标识，是指在医疗器械产品或者包装上附载的，由数字、字母或者符号组成的代码，用于对医疗器械进行唯一性识别。\n'Article 171: A batch processing record should be kept for each batch of product so that the production history and quality related status of that batch can be traced.'可被翻译为：第一百七十一条 每批产品均应当有相应的批生产记录，可追溯该批产品的生产历史以及与质量有关的情况。\n\n根据上述已知信息，请将'A unique combination of numbers, letters, and\/or symbols that identifies a batch (or lot) and from which the production and distribution history can be determined.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"用以标明一个批次的数字、字母和\/或符号的唯一组合，从中可以确定生产和分销的历史。"
    },
    {
        "instruction":"已知信息：\n'Article 40 The registrant, filing entity or contract manufacturers of medical devices shall perform their responsibility for monitoring adverse events in accordance with relevant regulations on monitoring adverse events of medical devices, carry out monitoring of adverse events, and report their investigation, analysis, reevaluation, product risk control results, etc. to the medical devices adverse event monitoring technical institutions.'可被翻译为：第四十条  医疗器械注册人、备案人、受托生产企业应当按照医疗器械不良事件监测相关规定落实不良事件监测责任，开展不良事件监测，向医疗器械不良事件监测技术机构报告调查、分析、评价、产品风险控制等情况。\n'Article 46 The drug regulatory departments at provincial level or above may designate the units with certain qualifications to be monitoring sentinels to voluntarily collect intensive surveillance data. Monitoring sentinels shall provide the use information of medical device varieties under intensive surveillance, voluntarily collect and report adverse event monitoring information, organize or recommend relevant experts to carry out or to cooperate with monitoring agencies to carry out scientific research related to risk evaluation.'可被翻译为：第四十六条  省级以上药品监督管理部门可以指定具备一定条件的单位作为监测哨点，主动收集重点监测数据。监测哨点应当提供医疗器械重点监测品种的使用情况，主动收集、报告不良事件监测信息，组织或者推荐相关专家开展或者配合监测机构开展与风险评价相关的科学研究工作。\n'MAHs of innovative medical devices shall, within the first registration cycle, submit analysis, evaluation and summary report of product adverse event monitoring to national monitoring agency every half a year. In case of identifying any possible serious defects of a medical device, national monitoring agency shall promptly report to National Medical Products Administration.'可被翻译为：创新医疗器械持有人应当在首个注册周期内，每半年向国家监测机构提交产品不良事件监测分析评价汇总报告。国家监测机构发现医疗器械可能存在严重缺陷的信息，应当及时报国家药品监督管理局。\n'Article 45 MAHs of the medical device varieties under intensive surveillance shall, in accordance with requirements in intensive surveillance project of medical devices, carry out relevant works, voluntarily collect the adverse event reports of products and relevant risk information, write risk evaluation report and submit the report to authorities organizing the intensive surveillance project as required.'可被翻译为：第四十五条  医疗器械重点监测品种涉及的持有人应当按照医疗器械重点监测工作方案的要求开展工作，主动收集其产品的不良事件报告等相关风险信息，撰写风险评价报告，并按要求报送至重点监测工作组织部门。\n\n根据上述已知信息，请将'Article 47 MAHs of innovative medical devices shall strengthen voluntary monitoring of innovative medical devices, formulate product monitoring plans, voluntarily collect relevant adverse event reports and product complaint information, and carry out investigation, analysis and evaluation.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十七条  创新医疗器械持有人应当加强对创新医疗器械的主动监测，制定产品监测计划，主动收集相关不良事件报告和产品投诉信息，并开展调查、分析、评价。"
    },
    {
        "instruction":"已知信息：\n'Root cause analysis of procedural, process or equipment failure is performed in such a way that the risk to product is correctly identified and understood so that suitable corrective and preventive actions (CAPA) are implemented.'可被翻译为：对程序、工艺或设备失败进行根本原因分析，正确识别和理解产品风险，从而实施适当的纠正和预防措施（CAPA）\n'Article 252: The manufacturer should establish a corrective actions and preventive actions (CAPA) system, for the investigation of complaints, recalls, deviations, findings of self-inspections or external inspections, process performances and quality monitoring trends, etc, and take corrective actions and preventive actions. The extent and formality of investigations should be commensurate with the level of risk. The CAPA system should result in enhanced product and process understanding, and product and process improvements.'可被翻译为：第二百五十二条 企业应当建立纠正措施和预防措施系统，对投诉、召回、偏差、自检或外部检查结果、工艺性能和质量监测趋势等进行调查并采取纠正和预防措施。调查的深度和形式应当与风险的级别相适应。纠正措施和预防措施系统应当能够增进对产品和工艺的理解，改进产品和工艺。\n'Section 6 Corrective Actions and Preventive Actions'可被翻译为：第六节 纠正措施和预防措施\n'(vii) Any significant deviations are fully recorded, investigated with the objective of determining the root cause and appropriate corrective and preventive action implemented;'可被翻译为：(vii)任何重大偏差都要充分记录，调查以确定根本原因并采取适当的纠正和预防措施；\n\n根据上述已知信息，请将'Prevention mechanisms - trend analysis, detailed investigation, root cause determination, corrective and preventive actions (CAPA) and the need for comprehensive investigational tools.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"预防机制——趋势分析、详细调查、确定根本原因、纠正和预防措施（CAPA）以及对全面调查工具的需求。"
    },
    {
        "instruction":"已知信息：\n'A liposome consisting of lipids whose phase transition temperature is slightly higher than body temperature. Its drug release is temperature-sensitive.'可被翻译为：由相转变温度稍高于体温的脂质组成的脂质体。其药物的释放对温度具有敏感性。\n'The temperature at which the solubility of ionic micelles increases sharply in water.'可被翻译为：离子型胶团在水中溶解度陡增的温度。\n'phase transition temperature'可被翻译为：相变温度\n'The temperature at which a substance melts from a solid phase into a liquid phase, as determined by a prescribed method. Is the physical constant of a substance.'可被翻译为：种物质按照规定的方法测定，由固相融化成液相时的温度。是物质的-项物理常数。\n\n根据上述已知信息，请将'The temperature at which a phase transition occurs in the liposome membrane. When the temperature increases, the acyl side bonds in the bilayer of liposome change from ordered to disordered, from colloidal to liquid crystal, and the cross section of the membrane increases, the thickness decreases, and the fluidity increases.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"脂质体膜发生相态转变的温度。当温度升高时，脂质体双分子层中酰基侧键可从有序排列变为无序排列，由胶晶变为液晶态，膜的横切面增加、厚度减少、流动性增加等。"
    },
    {
        "instruction":"已知信息：\n'III. Review of the application projects already accepted for registration before implementation of the new mandatory standards'可被翻译为：三、关于新的强制性标准实施之日前受理注册申请项目的审查\n'Article 39 Upon implementation of new mandatory standards, the registrant or filing entity of medical devices shall identify the differences between the technical specifications and the mandatory standards of the products. If it is necessary to make registration change or filing change, they shall handle relevant formalities according to stipulations on administration of registration and filing.'可被翻译为：第三十九条  新的强制性标准实施后，医疗器械注册人、备案人应当及时识别产品技术要求和强制性标准的差异，需要进行注册变更或者备案变更的，应当按照注册备案管理的规定办理相关手续。\n'To further unify the understanding of mandatory industry standards, and truly promote the implementation of mandatory industry standards of medical devices,in accordance with the Standardization Law of the People's Republic of China,the Regulations for the Supervision and Administration of Medical Devices,the Provisions for Mandatory National Standards and the Provisions for Medical Device Standards, on July 7, 2020, NMPA issued the notice on matters related to further strengthening management for mandatory industry standards of medical devices, requiring drug regulatory authorities at all levels to effectively maintain the legal status of mandatory industry standards,further improve the mandatory industry standard system, promote the drafting and implementation of mandatory industry standards, reinforce the publicity,implementation and training, standardize the implementation of mandatory industry standards, and reinforce the evaluation on implementation of mandatory industry standards.'可被翻译为：为进一步统一对强制性行业标准的认识，切实推进医疗器械强制性行业标准规范、有效实施，根据《中华人民共和国标准化法》《医疗器械监督管理条例》《强制性国家标准管理办法》和《医疗器械标准管理办法》，现就进一步加强医疗器械强制性行业标准管理有关事项通知：切实维护强制性行业标准的法律地位、进一步完善强制性行业标准体系、完善强制性行业标准起草和实施、加强强制性行业标准的宣贯培训、规范强制性行业标准的执行、强化强制性行业标准的实施评估。\n'1. After the release of the new Provisions, the normative documents and technical guidelines related to the new Provisions (hereinafter collectively referred to as the new Provisions and related documents) will be issued as per procedures. New stipulations and requirements made in the new Provisions shall prevail; and otherwise, the existing relevant stipulations and requirements shall apply.'可被翻译为：一、新《办法》发布后，与新《办法》相关的规范性文件、技术指导原则等（以下简称新《办法》及其相关文件）将按程序陆续发布。新《办法》及其相关文件已作出规定和要求的，从其规定；无新规定和要求的，按照现行的有关规定和要求执行。\n\n根据上述已知信息，请将'Unless otherwise specified in the standard documents issued and implemented by NMPA, a medical device with the application already accepted for registration before implementation of the new standards can be reviewed and approved according to original provisions where the mandatory standards cited in the product technical requirements have changed. As of the date of implementation of the new standards, enterprises shall fully implement the new standards and their products shall meet the requirements of the new standards.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于申请注册的医疗器械，其产品技术要求中引用的强制性标准发生变化的，除国家药监局在发布实施标准文件中另有规定外，在新标准实施之日前受理注册的，可以按照原标准进行审评审批。自新标准实施之日起，企业应当全面实施新标准，产品应当符合新标准要求。"
    },
    {
        "instruction":"已知信息：\n'Article 1    The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People's Republic of China and the Regulations for Implementation of the Drug Administration Law of the People's Republic of China.'可被翻译为：第一条 为规范药品说明书和标签的管理，根据《中华人民共和国药品管理法》和《中华人民共和国药品管理法实施条例》制定本规定。\n'Rules for Labels of Prepared Slices of Chinese Crude Drugs Issued by China NMPA'可被翻译为：国家药监局关于发布《中药饮片标签管理规定》的公告\n'Annex: The Rules for Labels of Prepared Slices of Chinese Crude Drugs'可被翻译为：附件：中药饮片标签管理规定\n'Article 1 In order to strengthen the supervision and administration of crude drugs importation and ensure their quality, these Provisions are formulated in accordance with the Drug Administration Law of the People's Republic of China, the Regulations for Implementation of the Drug Administration Law of the People's Republic of China and other laws and regulations.'可被翻译为：第一条 为加强进口药材监督管理，保证进口药材质量，根据《中华人民共和国药品管理法》《中华人民共和国药品管理法实施条例》等法律、行政法规，制定本办法。\n\n根据上述已知信息，请将'To further standardize the regulation on labels of prepared slices of Chinese crude drugs, in accordance with laws, administrative regulations and provisions including the Drug Administration Law of the People's Republic of China, the Regulations for Implementation of the Drug Administration Law of the People's Republic of China and the Provisions for Drug Insert Sheets and Labels, the NMPA organized to formulate the Rules for Labels of Prepared Slices of Chinese Crude Drugs, which is hereby released and shall be implemented since August 1, 2024. The labeling of expiration date according to the Rules shall be implemented since August 1, 2025.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为进一步规范中药饮片标签的管理，根据《中华人民共和国药品管理法》《中华人民共和国药品管理法实施条例》《药品说明书和标签管理规定》等法律、行政法规和规章，国家药监局组织制定了《中药饮片标签管理规定》，现予发布，自2024年8月1日起施行，其中，保质期的标注自2025年8月1日起施行。"
    },
    {
        "instruction":"已知信息：\n'Article 3 Medical device marketing authorization holders (hereinafter referred to as MAHs) shall possess the capacities of quality management and corresponding responsibilities to ensure that the medical devices are safe and effective, establish medical device adverse event monitoring system and directly report medical device adverse events to medical device adverse event monitoring agencies (hereinafter referred to as monitoring agencies). Distributing enterprises and user facility of medical device authorized by MAHs shall report medical device adverse events to MAHs and monitoring agencies.'可被翻译为：第三条  医疗器械上市许可持有人（以下简称持有人），应当具有保证医疗器械安全有效的质量管理能力和相应责任能力，建立医疗器械不良事件监测体系，向医疗器械不良事件监测技术机构（以下简称监测机构）直接报告医疗器械不良事件。由持有人授权销售的经营企业、医疗器械使用单位应当向持有人和监测机构报告医疗器械不良事件。\n'Article 12 National monitoring agencies shall be responsible for receiving medical device adverse events information reported by MAHs, distributing enterprises and user facility, assume relevant technical works related to medical device adverse event monitoring and re-evaluation nationwide; be responsible for the construction, maintenance and information management of national network and database of monitoring information of medical device adverse event, organize to develop technical specifications and guidelines, organize the investigation, evaluation and feedback of relevant adverse events information of the medical devices approved by the NMPA to be registered, summarize, analyze and guide relevant adverse events information of the medical devices approved by local drug regulatory departments above municipal level to be registered or filed, and investigate and evaluate group adverse events of medical device that have great influence nationwide and cause severe injuries or death and other serious consequences.'可被翻译为：第十二条  国家监测机构负责接收持有人、经营企业及使用单位等报告的医疗器械不良事件信息，承担全国医疗器械不良事件监测和再评价的相关技术工作；负责全国医疗器械不良事件监测信息网络及数据库的建设、维护和信息管理，组织制定技术规范和指导原则，组织开展国家药品监督管理局批准注册的医疗器械不良事件相关信息的调查、评价和反馈，对市级以上地方药品监督管理部门批准注册或者备案的医疗器械不良事件信息进行汇总、分析和指导，开展全国范围内影响较大并造成严重伤害或者死亡以及其他严重后果的群体医疗器械不良事件的调查和评价。\n'(III) Collecting medical device adverse events, promptly reporting to MAHs, and reporting to the monitoring agencies as required;'可被翻译为：（三）收集医疗器械不良事件，及时向持有人报告，并按照要求向监测机构报告；\n'National monitoring agencies shall carry out Meta-analysis on the annual monitoring information of medical device adverse events nationwide, complete annual report and submit it to the NMPA by the end of March each year.'可被翻译为：国家监测机构应当对全国医疗器械不良事件年度监测情况进行汇总分析，形成年度报告，于每年3月底前报国家药品监督管理局。\n\n根据上述已知信息，请将'Monitoring agencies designated by the NMPA (hereinafter referred to as national monitoring agencies) shall be responsible for unified management of all the information of medical device adverse events collected and provide feedback of relevant monitoring information of medical device adverse events to relevant monitoring agencies, MAHs, distributing enterprises or user facilities.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药品监督管理局指定的监测机构（以下简称国家监测机构）负责对收集到的医疗器械不良事件信息进行统一管理，并向相关监测机构、持有人、经营企业或者使用单位反馈医疗器械不良事件监测相关信息。"
    },
    {
        "instruction":"已知信息：\n'Studies designed to increase the rate of chemical degradation and physical change of a drug by using exaggerated storage conditions as part of the formal stability testing programme. The data thus obtained, in addition to those derived from real-time stability studies, may be used to assess longer-term chemical effects under non-accelerated conditions and to evaluate the impact of short-term excursions outside the label storage conditions, as might occur during shipping. The results of accelerated testing studies are not always predictive of physical changes.'可被翻译为：作为正式稳定性试验计划的一部分，通过使用夸张的储存条件来提高药物的化学降解和物理变化速度的研究。由此获得的数据，除了来自实时稳定性研究的数据外，可用于评估非加速条件下的长期化学效应，并评估在标签存储条件之外的短期漂移的影响，如在运输过程中可能发生的影响。加速试验研究的结果并不总是能预测物理变化。\n'Studies designed to increase the rate of chemical degradation or physical change of a drug substance or drug product by using exaggerated storage conditions as part of the formal stability studies. Data from these studies, in addition to long term stability studies, can be used to assess longer term chemical effects at non-accelerated conditions and to evaluate the effect of short term excursions outside the label storage conditions such as might occur during shipping. Results from accelerated testing studies are not always predictive of physical changes.'可被翻译为：加速试验是通过使用超常的贮存条件来加速原料药或制剂的化学降解或物理变化。它是正式的稳定性研究的一部分。除了长期稳定性研究外，从这些研究中得到的数据也可以评估在非加速条件下更长时间内的化学变化以及评价在短期偏离标签上所注明的储存条件，如运输过程中可能遇到的情况时的影响，加速试验研究的结果有时不能预示物理变化。\n'Studies designed to increase the rate of chemical or physical degradation of a drug by using degradation reactions and predicting the shelf-life under normal storage conditions. The design of accelerated studies may include elevated temperature (e.g., 37-49°C and up to 50- 55°C), high humidity and light.Only a provisional shelf-life may be established on the basis of these studies. Therefore, accelerated studies should always be supplemented by real-time studies under expected storage conditions.'可被翻译为：通过降解反应和预测药物在正常储存条件下的保质期来提高药物化学或物理降解速度的研究。加速研究的设计可能包括高温(例如，37-49°C和高达50- 55°C)、高湿度和光照。在这些研究的基础上，只能建立临时的保质期。因此，在预期的储存条件下，加速研究应始终辅以实时研究。\n'Studies undertaken to elucidate the intrinsic stability of API. Such testing is part of the development strategy and is normally carried out under more severe conditions than those used for accelerated testing.'可被翻译为：为阐明API的内在稳定性而进行的研究。此类测试是开发策略的一部分，通常在比用于加速测试的条件更严格的条件下进行。\n\n根据上述已知信息，请将'Studies designed to increase the rate of chemical degradation and physical change of an API or FPP by  using exaggerated storage conditions as part of the stability testing programme. The data thus obtained, in addition to those derived from long-term stability studies, may be used to assess longer term chemical effects under non-accelerated conditions and to evaluate the impact of short-term excursions outside the label storage conditions, as might occur during shipping. The results of accelerated testing studies are not always predictive of physical changes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"通过使用夸张的储存条件作为稳定性测试程序的一部分，旨在增加API或FPP的化学降解和物理变化速率的研究。由此获得的数据，除了来自长期稳定性研究的数据外，可用于评估非加速条件下的长期化学效应，并评估标签存储条件外的短期漂移的影响，如在运输过程中可能发生的影响。加速试验研究的结果并不总是能预测物理变化。"
    },
    {
        "instruction":"已知信息：\n'soft capsule'可被翻译为：软胶囊剂\n'A solid preparation made of drugs and excipients filled in hollow capsules in an appropriate form.'可被翻译为：药物及辅料以适当形式填装于空心胶囊中制成的固体制剂。\n'The use of natural or synthetic polymer material as the membrane shell, solid or liquid drugs as the core of the capsule wrapped into the drug store-like micro capsule.'可被翻译为：利用天然或合成的高分子材料为膜壳，将固体或液体药物作为囊心物包裹而成的药库型微小胶囊。\n'A solid preparation made of drugs and excipients in an appropriate form by pressing (or dropping) sealed in soft sacs.'可被翻译为：药物及辅料以适当形式通过压制法（或滴制法）密封于软质囊材中而制成的固体制剂。\n\n根据上述已知信息，请将'A solid preparation prepared by filling a hollow capsule or sealing in a soft capsule.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药物及辅料填装于空心胶囊或密封于软质囊材中制得的固体制剂。"
    },
    {
        "instruction":"已知信息：\n'The State encourages and guides the operation of retail drug chains. The headquarters of a retail drug chain shall establish a unified quality management system and perform management responsibilities for the business activities of the chain retailers.'可被翻译为：国家鼓励、引导药品零售连锁经营。从事药品零售连锁经营活动的企业总部，应当建立统一的质量管理制度，对所属零售企业的经营活动履行管理责任。\n'Article 124 The personnel engaged in drug distribution and quality management of an enterprise shall comply with the qualification requirements specified in relevant laws and regulations and this GSP, and shall be under no Job Forbidden by relevant laws and regulations.'可被翻译为：第一百二十四条 企业从事药品经营和质量管理工作的人员，应当符合有关法律法规及本规范规定的资格要求，不得有相关法律法规禁止从业的情形。\n'Article 18 The personnel engaged in drug distribution and quality management of an enterprise shall comply with the qualification requirements specified in relevant laws and regulations and this GSP, and shall be under no Job Forbidden by relevant laws and regulations.'可被翻译为：第十八条 企业从事药品经营和质量管理工作的人员，应当符合有关法律法规及本规范规定的资格要求，不得有相关法律法规禁止从业的情形。\n'Article 180 The GSP provides basic requirements for quality management of drug distribution. Specific requirements for enterprise informatization management, automatic monitoring of temperature and humidity for drug storage and transportation, drug acceptance inspection management, drug cold chain logistics management, and retail chain management shall be separately formulated by the National Medical Products Administration (NMPA) in the form of appendixes.'可被翻译为：第一百八十条 本规范为药品经营质量管理的基本要求。对企业信息化管理、药品储运温湿度自动监测、药品验收管理、药品冷链物流管理、零售连锁管理等具体要求，由国家食品药品监督管理总局以附录方式另行制定。\n\n根据上述已知信息，请将'Article 179 The management of the headquarters of drug retail chain enterprise shall comply with the relevant provisions of the GSP for drug wholesale enterprises, and the management of its stores shall comply with the relevant provisions of the GSP for drug retail enterprises.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百七十九条 药品零售连锁企业总部的管理应当符合本规范药品批发企业相关规定，门店的管理应当符合本规范药品零售企业相关规定。"
    },
    {
        "instruction":"已知信息：\n'electrical conductivity'可被翻译为：电导率\n'WFI systems should include continuous monitoring systems such as Total Organic Carbon (TOC) and\nconductivity, as these may give a better indication of overall system performance than discrete sampling. Sensor locations should be based on risk.'可被翻译为：WFI 系统应包括连续监测系统，监测总有机碳（TOC）和电导率等指标，因为这些参数比离散取样更好地指示整体系统性能。传感器位置应基于风险。\n'An atom or group of atoms that has a greater ability to attract electrons and a greater electronegativity than a hydrogen atom.'可被翻译为：吸引电子的能力比氢原子强，电负性比氢原子大的一个原子或原子团。\n'Chromatographic method in which the polarity of mobile phase is greater than that of stationary phase.'可被翻译为：流动相的极性大于固定相极性的色谱方法。\n\n根据上述已知信息，请将'The reciprocal of resistivity. Is a physical indicator of the electrical conductivity of a substance. The greater the conductivity, the stronger the material conductivity, the smaller the resistance, on the contrary, the worse the conductivity, the greater the resistance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"电阻率的倒数。是表示物质导电性能的物理指标。电导率越大则物质导电性能越强，电阻就越小，反之导电性能越差，电阻越大。"
    },
    {
        "instruction":"已知信息：\n'Article 282: The contract giver should supervise the entire process of contract manufacturing or analysis.'可被翻译为：第二百八十二条 委托方应当对受托生产或检验的全过程进行监督。\n'The contract giver should ensure that the contract acceptor is fully aware of any problems associated with the product or the work which might pose a hazard to the environment, premises, equipment, personnel, and other materials or products of the contract acceptor.'可被翻译为：委托方应当使受托方充分了解与产品或操作相关的各种问题，包括产品或操作对受托方的环境、厂房、设备、人员及其他物料或产品可能造成的危害。\n'Article 292: The contract should define that the contract acceptor has the obligation to accept the inspection conducted by drug regulatory department.'可被翻译为：第二百九十二条 委托检验合同应当明确受托方有义务接受药品监督管理部门检查。\n'Article 290: The contract should define that processing, testing and distribution records and samples kept by the contract acceptor, should be available to the contract giver whenever needed. Any records relevant to assessing the quality of a product in the event of complaints, a suspected defect or recalls must be accessible to the contract giver.'可被翻译为：第二百九十条 合同应当规定由受托方保存的生产、检验和发运记录及样品，委托方应当能够随时调阅或检查；出现投诉、怀疑产品有质量缺陷或召回时，委托方应当能够方便地查阅所有与评价产品质量相关的记录。\n\n根据上述已知信息，请将'Article 291: The contract should clearly define that the contract giver can conduct on-site inspection or audit to the contract acceptor.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二百九十一条 合同应当明确规定委托方可以对受托方进行检查或现场质量审计。"
    },
    {
        "instruction":"已知信息：\n'Article 139: The premises, facilities, equipment and testing instruments should be qualified. The validated manufacturing process, operation procedures and testing methods should be used for production, operation and testing, and this validated state should be maintained.'可被翻译为：第一百三十九条 企业的厂房、设施、设备和检验仪器应当经过确认，应当采用经过验证的生产工艺、操作规程和检验方法进行生产、操作和检验，并保持持续的验证状态。\n'12.4. The RU should be able to accommodate the intended activity.'可被翻译为：RU应有能力接收准备转移的活动。\n'There should be mechanisms in place to detect a sterilisation cycle that does not conform to the validated parameters. Any failed sterilisation or sterilisation that deviated from the validated process (e.g. have longer or shorter phases such as heating cycles) should be investigated.'可被翻译为：应建立适当机制，发现不符合验证参数的灭菌循环。应对任何失败的灭菌或不符合经验证工艺过程的灭菌（例如加热循环等阶段较长或较短）进行调查。\n'The bio-decontamination process of the interior should be automated, validated and controlled within defined cycle parameters and should include a sporicidal agent in a suitable form (e.g. gaseous or vaporized form). Gloves should be appropriately extended with fingers separated to ensure contact with the agent. Methods used (cleaning and sporicidal bio-decontamination) should render the interior surfaces and critical zone of the isolator free from viable microorganisms.'可被翻译为：内部的净化消毒过程应是自动化的、经过验证的，应控制在规定的周期参数范围内，并应包括适当形式的杀孢子剂（例如气态或汽化形式）。手套应展开，五指分开，与杀孢子剂充分接触。所用方法（清洁和杀孢子生物消毒）应确保隔离器的内部表面和关键区域不存在活的微生物。\n\n根据上述已知信息，请将'The cleaning process should be validated to be able to:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"清洁程序应进行验证，确保其能够："
    },
    {
        "instruction":"已知信息：\n'Article 152 The State Food and Drug Administration shall make the review and approval decision within 20 days; where a decision cannot be made within 20 days, another ten days may be extended with the approval of the State Food and Drug Administration head in charge, and the applicant shall be informed of the reason of the time extended.'可被翻译为：第一百五十二条 国家食品药品监督管理局应当在20日内作出审批决定；20日内不能作出决定的，经主管局领导批准，可以延长10日，并应当将延长时限的理由告知申请人。\n'(5) a decision is made to give an administrative sanction of revoking the drug approval document by law; and'可被翻译为：（五）依法作出撤销药品批准证明文件的行政处罚决定的；\n'Article 17 Where the provincial drug regulatory department decides to grant approval, it shall, within 10 days after the decision of approval is made, serve the approval document for crude drugs importation or for supplementary application for crude drugs importation to the applicant; where the drug regulatory department decides to grant disapproval, it shall, within 10 days after the decision of disapproval is made, serve a Notice of Review Opinions to the applicant with the reasons explained, and inform the applicant of the right to apply for administrative reconsideration or bring an administrative suit according to law.'可被翻译为：第十七条 省级药品监督管理部门决定予以批准的，应当在作出批准决定后10日内，向申请人送达进口药材批件或者进口药材补充申请批件；决定不予批准的，应当在作出不予批准决定后10日内，向申请人送达审查意见通知书，并说明理由，告知申请人享有依法申请行政复议或者提起行政诉讼的权利。\n'Article 26 After receiving the recommendations for on-site inspection, the CFDI shall conduct on-site inspection within 20 days.'可被翻译为：第二十六条 核查中心接到现场检查建议后，应当在20日内进行现场检查。\n\n根据上述已知信息，请将'Article 100 A decision on administrative approval shall be made within 20 days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百条 行政审批决定应当在二十日内作出。"
    },
    {
        "instruction":"已知信息：\n'The ability of an IVD medical device to yield results that are correlated with a particular clinical condition\/physiological state in accordance with target population and intended user (4).'可被翻译为：IVD医疗设备根据目标人群和预期用户产生与特定临床状况\/生理状态相关的结果的能力(4)。\n'(II) The monitoring and evaluation results of medical device adverse event indicate that the medical device may have defects;'可被翻译为：（二）医疗器械不良事件监测、评估结果表明医疗器械可能存在缺陷的；\n'1.See drug.\n2.Any substance or pharmaceutical product for human or veterinary use that is intended to modify or explore physiological systems or pathological states for the benefit of the recipient. In this document, the terms medicine and pharmaceutical product (see below) are used interchangeably.\n3.Any substance or combination of substances marketed or manufactured to be marketed for treating or preventing disease in human beings, or with a view to making a medical diagnosis in human beings, or to restoring, correcting or modifying physiological functions in human beings.'可被翻译为：1.看到药物。\n2.任何用于人用或兽用的物质或药品，旨在改变或探索生理系统或病理状态，以使接受者受益。在本文件中，术语“药物”和“药品”(见下文)可互换使用。\n3.为治疗或预防人类疾病，或为了对人类进行医学诊断，或为了恢复、纠正或改变人类的生理功能而销售或制造用于销售的任何物质或物质的组合。\n'(7) In any of the following cases, medical dressings shall be regarded as a class III medical device: the medical dressing is intended to have a function to prevent tissue\/organ adhesion; is used as artificial skin; is to contact with the deep dermis or the injured trauma of tissue below dermis; is used to heal chronic wound, or may be wholly\/partially absorbed by human body.'可被翻译为：（七）医用敷料如果有以下情形，按照第三类医疗器械管理，包括：预期具有防组织或器官粘连功能，作为人工皮肤，接触真皮深层或其以下组织受损的创面，用于慢性创面，或者可被人体全部或部分吸收的。\n\n根据上述已知信息，请将'A medical device intended to measure the physiological, pathological and anatomic parameters or make quantitative determination on the energies\/substances entering or leaving the human body. The measuring results shall be accurately quantified, and the accuracy of such results may have obvious effects on patient's health and safety.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种用于测定生理、病理、解剖参数，或者定量测定进出人体的能量或物质的医疗器械，其测量结果需要精确定量，并且该结果的准确性会对患者的健康和安全产生明显影响。"
    },
    {
        "instruction":"已知信息：\n'NMPA Announcement on Issuing 2 Guidance including the Guidance for Nomenclature of the Generic Names of Neurosurgical and Cardiovascular Surgical Devices'可被翻译为：国家药监局关于发布神经和心血管手术器械通用名称命名指导原则等2项指导原则的通告\n'To strengthen the supervision and guidance of medical device registration, and further improve the quality of registration review, the NMPA organized to formulation of the Guidelines for Technical Review of Vision Screener Registration and the Guidelines for Technical Review of Mammography System Registration, which were published on June 24.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《视力筛查仪注册技术审查指导原则》和《乳腺X射线系统注册技术审查指导原则》，并于6月24日发布。\n'NMPA Issues the Announcement on 6 Technical Review Guidances for Registration Including the Technical Review Guidance for the Registration of Disposable Breast localization Wire'可被翻译为：国家药监局关于发布一次性使用乳腺定位丝注册技术审查等6项注册技术审查指导原则的通告\n'NMPA Announcement on Issuing 6 Guidance including the Guidance for Nomenclature of the Generic Names of Medical Rehabilitation Devices'可被翻译为：国家药监局关于发布医用康复器械通用名称命名指导原则等6项指导原则的通告\n\n根据上述已知信息，请将'NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药监局关于发布视力筛查仪和乳腺X射线系统2项注册技术审查指导原则的通告"
    },
    {
        "instruction":"已知信息：\n'Article 80: Preventive maintenance plans and procedures should be established, and the maintenance and repair activities should be recorded.'可被翻译为：第八十条 应当制定设备的预防性维护计划和操作规程，设备的维护和维修应当有相应的记录。\n'7) Operation procedures and records of the calibration of instruments, and use, cleaning and maintenance of equipment.'可被翻译为：7.仪器校准和设备使用、清洁、维护的操作规程及记录。\n'2. Records of use, cleaning, maintenance, testing, calibration, verification or validation, repair, handling of unexpected events and decommission of instruments and equipment used in the study during the study period should be retained completely; the testing time and items in the use records of instruments and equipment should be in line with that as required by the study;'可被翻译为：2.应完整保留研究期间所使用仪器设备的使用、清洁、 保养、测试、校准、确认或验证、维修、异常情况处理、报废等记录；仪器设备使用记录的时间及内容应与研究对应一致；\n'Article 86: Log books should be established for equipment and instruments used for drug production and testing, to record the use, cleaning, maintenance and repair activities, along with the date, time, and the name, strength ,batch number, etc., of the drug produced and tested.'可被翻译为：第八十六条 用于药品生产或检验的设备和仪器，应当有使用日志，记录内容包括使用、清洁、维护和维修情况以及日期、时间、所生产及检验的药品名称、规格和批号等。\n\n根据上述已知信息，请将'Article 72: Procedures for the use, cleaning, maintenance and repair of the equipment should be established, and their operation records should be retained.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第七十二条 应当建立设备使用、清洁、维护和维修的操作规程，并保存相应的操作记录。"
    },
    {
        "instruction":"已知信息：\n'Manufacturers of Prepared Slices shall fulfill relevant obligations of drug MAHs and ensure the manufacturing of Prepared Slices continuously complies with regulatory requirements.'可被翻译为：中药饮片生产企业应当履行药品上市许可持有人的相关义务，确保中药饮片生产过程持续符合法定要求。\n'The manufacturer of prepared slices of Chinese crude drugs shall perform relevant obligations as the MAH of the drug when selling the prepared slices of Chinese crude drugs.'可被翻译为：中药饮片生产企业销售其生产的中药饮片，应当履行药品上市许可持有人相关义务。\n'(IX) The drawer position of Prepared Slices shall be written with correct name and in regular script; before the loading of Prepared Slices, double check shall be conducted to prevent wrong or confused loading; the drawers shall be cleaned regularly to prevent Prepared Slices from insects, mildew and deterioration; and the drawers shall be cleared before the Prepared Slices of different lots are loaded, which shall be documented;'可被翻译为：（九）中药饮片柜斗谱的书写应当正名正字；装斗前应当复核，防止错斗、串斗；应当定期清斗，防止饮片生虫、发霉、变质；不同批号的饮片装斗前应当清斗并记录。\n'(VI) The Chinese crude drugs and Prepared Slices shall be maintained with effective methods according to their characteristics, which shall be documented. The maintenance methods adopted shall cause no contamination to the drugs;'可被翻译为：（六）对中药材和中药饮片应当按其特性采取有效方法进行养护并记录，所采取的养护方法不得对药品造成污染。\n\n根据上述已知信息，请将'(IV) For the sales of Prepared Slices, they shall be accurately weighed, and the customers shall be informed of the decocting and administration methods and corresponding precautions. The provision of decoction services for Prepared Slices shall conform to the relevant national provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）销售中药饮片做到计量准确，并告知煎服方法及注意事项；提供中药饮片代煎服务，应当符合国家有关规定。"
    },
    {
        "instruction":"已知信息：\n'Article 72 The investigator shall record all the adverse events occurred and the device defects found during the clinical trial and analyze the cause of the event together with the sponsor, form a written analysis report, give the opinion of continuing, suspending or terminating the trial, and report to the ethics committee for review through the medical device clinical trial management department of the clinical trial institution.'可被翻译为：第七十二条 研究者应当记录临床试验过程中发生的所有不良事件和发现的器械缺陷，并与申办者共同分析事件原因，形成书面分析报告，提出继续、暂停或者终止试验的意见，经临床试验机构医疗器械临床试验管理部门报伦理委员会审查。\n'Article 54 The sponsor shall, within five working days after being informed, report serious adverse events and device defects that may lead to serious adverse events to the food and drug administration department where the sponsor makes the registration and the competent health and family planning department of the same level, at the same time inform other clinical trial institutions and investigators involved in the trial, and in a timely manner notify the ethics committee of the clinical trial institution through the medical device clinical trial management department.'可被翻译为：第五十四条 对于严重不良事件和可能导致严重不良事件的器械缺陷，申办者应当在获知后5个工作日内向所备案的食品药品监督管理部门和同级卫生计生主管部门报告，同时应当向参与试验的其他临床试验机构和研究者通报，并经其医疗器械临床试验管理部门及时通知该临床试验机构的伦理委员会。\n'Article 84 For a multicenter clinical trial, the clinical trial summaries of each sub-site shall include at least a summary of the clinical trial, clinical general information, information for the investigational medical device and the compared device, safety and effectiveness data sets, incidence rate of the adverse events, description of deviation from the protocol and the case report form.'可被翻译为：第八十四条 对于多中心临床试验，各分中心临床试验小结应当至少包括临床试验概况、临床一般资料、试验用医疗器械以及对照用医疗器械的信息描述、安全性和有效性数据集、不良事件的发生率以及处理情况、方案偏离情况说明等，并附病例报告表。\n'2. The conditions of collection, handling, storage and transportation of biological samples comply with the requirements of the clinical trial protocol.'可被翻译为：2. 生物样品的采集、处理、储存和转运的条件符合临床试验方案的要求。\n\n根据上述已知信息，请将'(14) Adverse events found in the clinical trial and the handling;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（十四）临床试验中发现的不良事件以及其处理情况；"
    },
    {
        "instruction":"已知信息：\n'Provisions for Drug Recall (SFDA Decree No. 29) (Abolished)'可被翻译为：《药品召回管理办法》【废止】\n'Article 47    The Provisions shall come into force as of May 1, 2007. As of the date when the Provisions goes into effect, the Provisions for Supervision of Drug Distribution (Interim) (SFDA Decree No.7) implemented on August 1, 1999 shall be annulled therefrom.'可被翻译为：第四十七条 本办法自2007年5月1日起施行。自本办法施行之日起，1999年8月1日实施的国家药品监督管理局《药品流通监督管理办法（暂行）》（国家药品监督管理局第7号令）同时废止。\n'Provisions for Supervision of Drug Distribution'可被翻译为：药品流通监督管理办法\n'Article 73 These Provisions shall come into force as of May 1, 2022. Upon effectiveness of these Provisions, the Provisions for Supervision and Administration of Medical Device Distribution issued by Decree No. 8 of the former China Food and Drug Administration on July 30, 2014 shall be abolished.'可被翻译为：第七十三条  本办法自2022年5月1日起施行。2014年7月30日原国家食品药品监督管理总局令第8号公布的《医疗器械经营监督管理办法》同时废止。\n\n根据上述已知信息，请将'Provisions for Supervision of Drug Distribution(SFDA Decree No.26)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"《药品流通监督管理办法》（局令第26号）"
    },
    {
        "instruction":"已知信息：\n'An organization currently engaged in establishing, populating on an initial basis or maintaining controlled vocabularies (ISO). For example, EDQM, ICH, \nIHTSDO.'可被翻译为：目前参与建立、在初步基础上填入或维护受控词汇（ISO）的组织。 例如，EDQM、ICH、IHTSDO。\n'A method of indexing a piece of information multiple times in a document. Pharmacology centered on the study of the effects of drugs on mental activity.'可被翻译为：一个文件中对某个信息多次提及时采用的一种索引方式。以研究药物对精神活动作用为中心内容的药理学。\n'controlled vocabulary (cv)'可被翻译为：受控词汇\n'In a hierarchical medical dictionary, for example MedDRA, the included term is the lowest level of dictionary term to which the investigator description is coded. The preferred term is the level of grouping of included terms typically used in reporting frequency of occurrence. For example, the investigator text “Pain in the left arm” might be coded to the included term “Joint pain”, which is reported at the preferred term level as “Arthralgia”.'可被翻译为：在分层级医学词典中，例如 MedDRA，收录术语是词典\n术语的最低层级，以研究者的描述进行编码。首选术语是收录术语的分组层级，通常用于报告发生率。例如，研究者写的是“左臂疼痛”，收录术语编码为：“关节疼痛”，在首选术语层级上报告为“关节痛”。\n\n根据上述已知信息，请将'A controlled vocabulary is an established list of standardized terminology for use in indexing and retrieval of information. CVs are established lists of \npreferred terms for cataloguing or indexing information (for example as descriptors in databases). CVs can address issues of synonyms or \nstandardised headings. Sample CVs: MedDRA, ISO country codes, EDQM Routes of Administration, etc.)'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"受控词汇表（CV）是一张已确定的标准术语表，用于信息的索引和检索。CV 是已确定的首选术语表，用于分类和索引信息（类似于数据库中的描述符）。CV可以解决同义词或标准化标题的问题。（CV 样例：MedDRA、ISO 国家代码、EDQM 给药途径等。）"
    },
    {
        "instruction":"已知信息：\n'Describes a process step, process condition, test requirement, or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.'可被翻译为：用以描述某个为保证药品符合要求而确立的应当被控制在预先确定的标准范围内的工艺步骤、工艺条件、试验要求或其他有关的参数或项目。\n'critical. Having the potential to impact on product quality or performance in a significant way.'可被翻译为：关键的：可能对产品质量或性能有重大影响者\n'A process parameter whose variability has an impact on a critical quality attribute and therefore should be monitored or controlled to ensure the process produces the desired quality.'可被翻译为：指其波动会影响到产品关键质量属性而应该被监测或控制的工艺参数，以确保能生产出预期质量的产品。\n'Critical Process Parameter – process parameter whose variability has an impact on a critical quality attribute and therefore should be monitored or controlled to assure the process produces the desired product quality. (Q8(R2))'可被翻译为：关键工艺参数——工艺参数，其变动对关键质量属性产生影响，因此应对其进行监测或控制，以确保该工艺生产出符合预期的产品质量。（Q8 R2）\n\n根据上述已知信息，请将'1.Describes a process step, process condition, test requirement or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification.\n2.Having the potential to impact on product quality or performance in a  significant way.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.描述必须控制在预定标准内的工艺步骤、工艺条件、测试要求或其他相关参数或项目，以确保原料药符合其规格。\n2.有可能对产品质量或性能产生重大影响的。"
    },
    {
        "instruction":"已知信息：\n'Article 39 The technical assessment agency shall, within 90 working days from the date of receiving the application dossiers, organize the technical evaluation in accordance with the requirements of technical evaluation, and deal with it respectively according to the following circumstances:'可被翻译为：第三十九条 技术审评机构应当自收到申请资料之日起90个工作日内，按照技术审评的要求组织开展技术审评，并根据下列情况分别作出处理：\n'The service agency shall transfer the application dossiers to the technical assessment agency within 3 working days from the date of accepting the registration application of new cosmetic ingredients.'可被翻译为：受理机构应当自受理注册申请后3个工作日内，将申请资料转交技术审评机构。\n'The technical assessment agency shall make a re-evaluation conclusion within 30 working days from the date of receiving the re-evaluation application.'可被翻译为：技术审评机构应当自收到复核申请之日起30个工作日内作出复核结论。\n'Article 13 To apply for registration of new cosmetic ingredients with functions such as preservative, sunscreen, colorant, hair dye, spot corrector and whitening, the application dossiers shall be submitted in accordance with the requirements of the NMPA. The service agency shall complete the format review of the application dossiers within 5 working days from the date of receipt, and deal with it separately according to the following circumstances:'可被翻译为：第十三条 申请注册具有防腐、防晒、着色、染发、祛斑美白功能的化妆品新原料，应当按照国家药品监督管理局要求提交申请资料。受理机构应当自收到申请之日起5个工作日内完成对申请资料的形式审查，并根据下列情况分别作出处理：\n\n根据上述已知信息，请将'Article 14 The technical assessment agency shall, within 90 working days from the date of receiving the application dossiers, organize the technical evaluation in accordance with the requirements of the technical evaluation, and deal with it separately according to the following circumstances:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十四条 技术审评机构应当自收到申请资料之日起90个工作日内，按照技术审评的要求组织开展技术审评，并根据下列情况分别作出处理："
    },
    {
        "instruction":"已知信息：\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 5, 2020 the Guidelines for Technical Review of the Registration of Colloidal Gold Immunochromatographic Analyzers, Guidelines for Technical Review of the Registration of Follicle stimulating Hormone Detection Reagents, Guidelines for Technical Review of the Registration of Creatinine Detection Reagents, Guidelines for Technical Review of the Registration of Antinuclear Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Antithyroid Peroxidase Antibody Assay Reagents, Guidelines for Technical Review of the Registration of Glycated Albumin Assay Reagents, and the Guidelines for Technical Review of the Registration of Total Bile Acid Assay Reagents.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定并于2020年3月5日发布了《胶体金免疫层析分析仪注册技术审查指导原则》《促卵泡生成素检测试剂注册技术审查指导原则》《肌酐检测试剂注册技术审查指导原则》《抗核抗体检测试剂注册技术审查指导原则》《抗甲状腺过氧化物酶抗体测定试剂注册技术审查指导原则》《糖化白蛋白测定试剂注册技术审查指导原则》和《总胆汁酸测定试剂注册技术审查指导原则》。\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on March 10, 2020 the Guidelines for Technical Review of the Registration of EB Virus Nucleic Acid Detection Reagents, Guidelines for Technical Review of the Registration of HBV e Antigen, e Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Thalassemia-Related Gene Detection Reagents, and Guidelines for Technical Review of the Registration of HBV-Resistant Gene Mutation Detection Reagents.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2020年3月10日组织制定并发布了《EB病毒核酸检测试剂注册技术审查指导原则》《乙型肝炎病毒e抗原、e抗体检测试剂注册技术审查指导原则》《地中海贫血相关基因检测试剂注册技术审查指导原则》《乙型肝炎病毒耐药相关的基因突变检测试剂注册技术审查指导原则》。\n'NMPA Issued Four Guidelines for Technical Review of the Registration of Assay Reagents for Aspartate Aminotransferase and Others'可被翻译为：国家药监局关于发布天门冬氨酸氨基转移酶测定试剂等4项注册技术审查指导原则的通告\n'To strengthen the supervision and guidance over the registration of medical device products and further improve the quality of registration review, NMPA has organized the formulation of and released on January 18, 2021 the Guidelines for Technical Review of the Registration of Mycoplasma Pneumoniae IgM\/IgG Antibody Detection Reagents, Guidelines for Technical Review of the Registration of Cryptococcus Capsular Polysaccharide Antigen Detection Reagents, and Guidelines for Technical Review of the Registration of Hereditary Hearing Loss Gene Mutation Detection Reagents.'可被翻译为：为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局组织制定了《肺炎支原体IgM\/IgG抗体检测试剂注册技术审查指导原则》《隐球菌荚膜多糖抗原检测试剂注册技术审查指导原则》和《遗传性耳聋相关基因突变检测试剂注册技术审查指导原则》，于2021年1月18日予以发布。\n\n根据上述已知信息，请将'To strengthen the supervision and guidance over medical device product registration and further improve the quality of registration review, NMPA has organized the formulation of and released on October 29, 2019 the Guidelines for Technical Review of the Registration of Assay Reagents for Aspartate Aminotransferase, Guidelines for Technical Review of the Registration of Total Cholesterol Assay Reagents, Guidelines for the Technical Review of Registration of Uric Acid Determination Reagents, and Guidelines for Technical Review of the Registration of Urea Determination Reagents.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为加强医疗器械产品注册工作的监督和指导，进一步提高注册审查质量，国家药品监督管理局于2019年10月29日组织制定并发布了《天门冬氨酸氨基转移酶测定试剂注册技术审查指导原则》《总胆固醇测定试剂注册技术审查指导原则》《尿酸测定试剂注册技术审查指导原则》和《尿素测定试剂注册技术审查指导原则》。"
    },
    {
        "instruction":"已知信息：\n'(1) conceal, withhold, or omit information or make false reports of drug safety incidents;'可被翻译为：（一）瞒报、谎报、缓报、漏报药品安全事件；\n'Any entity or individual shall not conceal, give false information about, delay or omit reporting vaccine safety events and not conceal, forge or destroy relevant evidence.'可被翻译为：有关单位和个人不得瞒报、谎报、缓报、漏报疫苗安全事件，不得隐匿、伪造、毁灭有关证据。\n'Vaccine MAHs, disease prevention and control institutions, and immunization entities shall not conceal information, give false information, omit to report, delay the reporting, or conceal, fabricate or destroy relevant evidence when discovering vaccines with quality problems or vaccines suspected of having quality problems.'可被翻译为：疫苗上市许可持有人、疾病预防控制机构、接种单位发现存在或者疑似存在质量问题的疫苗，不得瞒报、谎报、缓报、漏报，不得隐匿、伪造、毁灭有关证据。\n'(2) concealing information, giving false information, delaying reporting, giving incomplete report of vaccine safety incidents;'可被翻译为：（二）瞒报、谎报、缓报、漏报疫苗安全事件；\n\n根据上述已知信息，请将'(2) providing false information or conceal authentic condition on purpose;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）故意提供虚假信息或者隐瞒真实情况；"
    },
    {
        "instruction":"已知信息：\n'Precision in the laboratory. That is, the influence of varying factors such as different time, different analysts, different instruments and equipment on the measurement results.'可被翻译为：实验室内的精密度。即不同时间、不同分析人员、不同仪器设备等变动因素对测定结果的影响。\n'The intra-run and inter-run precision and reproducibility may be compared for the release rate (slopes) calculated for each diffusion cell. The mean, standard deviation, and percent coefficient of variation (%CV) among slopes may be calculated within and across all runs, and a minimum intra-run and inter-run %CV≤15% is recommended. Runs may be organized to facilitate a simultaneous evaluation of intra\/inter-instrumentation and\/or intra\/inter-operator precision and reproducibility. A minimum of three independent precision and reproducibility runs is recommended.'可被翻译为：可根据每个扩散池的释放速率（斜率）计算批内精密度和批间重现性。应计算并报告所有批内和批间斜率的均值、标准偏差和变异系数（%CV），批内和批间的变异系数（%CV）均应小于等于15%。批的运行应便于仪器内\/间 和\/或 操作者内\/间的精密度和重现性的同时评估。建议至少进行三次精密度和重现性试验。\n'Reproducibility expresses precision between laboratories.'可被翻译为：再现性表示实验室之间的精确性。\n'Precision and Reproducibility'可被翻译为：精密度和重现性\n\n根据上述已知信息，请将'1.The degree of agreement among individual results when the procedure is applied repeatedly to multiple samplings of a homogeneous sample. Precision, usually expressed as relative standard deviation, may be considered at three levels: repeatability (precision under the same operating conditions over a short period of time), intermediate precision (within laboratory variations — different days, different analysts or different equipment) and reproducibility (precision between laboratories).\n2.The degree of agreement among individual results.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"1.当程序重复应用于均匀样本的多个采样时，单个结果之间的一致程度。精密度通常表示为相对标准偏差，可以在三个层面上考虑:重复性(在短时间内相同操作条件下的精密度)、中间精密度(在实验室变化范围内——不同的日期、不同的分析人员或不同的设备)和再现性(实验室之间的精密度)。\n2.一致性:个别结果之间的一致程度"
    },
    {
        "instruction":"已知信息：\n'The process by which drugs or their metabolites are excreted from the body and the process by which drugs are biotransformed.'可被翻译为：体内药物或其代谢产物排出体外的过程以及药物生物转化的过程。\n'Also known as an indirect actingcarcinogen. Substances that are not directly carcinogenic in themselves, but must undergo metabolic transformation in the body before their metabolites have a carcinogenic effect.'可被翻译为：又称\"间接致癌物(indirect-actingcarcinogen)\"。本身不直接致癌，必须在体内经代谢转化，其所形成的代谢产物才具有致癌作用的物质。\n'branched metabolic pathway'可被翻译为：分支代谢途径\n'Excessive metabolic end products in turn directly inhibit the activity of key enzymes in the metabolic pathway, prompting the whole reaction to slow down or stop, avoiding excessive accumulation of end products.'可被翻译为：代谢终产物过量时反过来直接抑制代谢途径中关键酶的活性，促使整个反应减慢或停止，避免末端产物的过多累积。\n\n根据上述已知信息，请将'Prone to metabolizing inactivated drugs. A class of drugs that are rapidly excreted from the body after a step transformation into inactive metabolites in a controlled metabolic pathway and metabolic rate after the completion of the therapeutic effect in order to achieve separation of activity and toxicity.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"容易代谢失活的药物。在完成治疗作用后以可控的代谢途径和代谢速率，经一步转化为无活性的代谢产物迅速排出体外，以便实现活性和毒性分离的一类药物。"
    },
    {
        "instruction":"已知信息：\n'Anticipated ambient temperature variation and duration to which a TTSPP may be exposed during transport.'可被翻译为：TTSPP在运输过程中可能暴露的预期环境温度变化和持续时间。\n'The range and pattern of temperatures and\/or humidity within a temperature controlled storage unit during normal operation.'可被翻译为：温度控制存储单元在正常运行时的温度和\/或湿度的范围和模式。\n'· Suitable storage and transport.'可被翻译为：适当的储存和运输。\n'6) Suitable storage and transport.'可被翻译为：6.适当的贮运条件。\n\n根据上述已知信息，请将'An excursion event in which a TTSPP is exposed to temperatures outside the range(s) prescribed for storage and\/or transport. Temperature ranges for storage and transport may be the same or different; they are determined by the product manufacturer, based on stability data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"TTSPP暴露在超出规定的储存和\/或运输范围的温度下的偏移事件。储存和运输的温度范围可能相同，也可能不同;由产品生产厂家根据稳定性数据确定。"
    },
    {
        "instruction":"已知信息：\n'patient education'可被翻译为：患者用药教育\n'patient education by artificial intelligence'可被翻译为：智能用药指导\n'An observation requiring investigation, and includes problems that might or might not involve individual or groups of investigative subjects.[HL7 Patient Safety]'可被翻译为：需要调查的观察结果，包括可能或可能不涉及个人或研究受试者人群的问题。[HL7 患者安全]\n'An evidence-based recommendation of appropriate treatment or care for a patient with a particular disease or condition.'可被翻译为：以证据为基础的，对特定疾病或状况下的病人适宜治疗或护理方案的推荐。\n\n根据上述已知信息，请将'A record established by a pharmacist of a patient's treatment or prevention of a disease in order to ensure the safety and effectiveness of a drug. It includes professional activities that affect the outcome of the patient's prognosis (protocol development, implementation, efficacy, adverse reaction observation, evaluation, adjustment, patient education). Available in both paper and electronic form.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为保证用药安全有效，由药师建立的患者治疗或预防疾病进行药物治疗过程的记录。包括为影响患者预后结果的专业活动（方案制定，实施，疗效、不良反应观察，评价、调整，患者教育）等内容。有纸质和电子两种形式。"
    },
    {
        "instruction":"已知信息：\n'Where further studies are required when approval is given to a vaccine registration application, the vaccine MAH shall complete the studies within the specified period.'可被翻译为：对批准疫苗注册申请时提出进一步研究要求的，疫苗持有人应当在规定期限内完成研究。\n'Article 67 For a conditionally approved drug, where the MAH fails to complete the studies as required within the specified timeline or fails to prove that the benefits outweigh risks, the NMPA shall handle the matter in accordance with the law until the Drug Approval License is revoked.'可被翻译为：第六十七条 对附条件批准的药品，持有人逾期未按照要求完成研究或者不能证明其获益大于风险的，国家药品监督管理局应当依法处理，直至注销药品注册证书。\n'Article 66 For a conditionally approved drug, the MAH shall take appropriate risk management measures after the drug is marketed and complete relevant studies including drug clinical trials as requested and submit supplementary applications within the specified timeline.'可被翻译为：第六十六条 对附条件批准的药品，持有人应当在药品上市后采取相应的风险管理措施，并在规定期限内按照要求完成药物临床试验等相关研究，以补充申请方式申报。\n'After a drug is marketed after approval, the MAH shall continue to carry out studies on drug safety and efficacy, promptly file for record or submit supplementary applications for revision of the package inserts based on the relevant data, and keep updating and improving the package inserts and labels. Drug regulatory departments may, as per their duties, require the MAH to revise the package inserts and labels based on the results of adverse drug reaction monitoring and post-marketing evaluation.'可被翻译为：药品批准上市后，持有人应当持续开展药品安全性和有效性研究，根据有关数据及时备案或者提出修订说明书的补充申请，不断更新完善说明书和标签。药品监督管理部门依职责可以根据药品不良反应监测和药品上市后评价结果等，要求持有人对说明书和标签进行修订。\n\n根据上述已知信息，请将'Where the Drug Approval License and its attachments require the MAH to carry out relevant post-marketing studies, the MAH shall complete the studies within the specified timeline and submit a supplementary application, filing or report as required.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品注册证书及附件要求持有人在药品上市后开展相关研究工作的，持有人应当在规定时限内完成并按照要求提出补充申请、备案或者报告。"
    },
    {
        "instruction":"已知信息：\n'The lot release institutions designated by the CFDA shall be responsible for the acceptance, dossier review, on-site inspection and sample testing and making the decision on lot release in accordance with the law.'可被翻译为：食品药品监管总局指定的批签发机构负责批签发的受理、资料审核、现场核实、样品检验等工作，并依法作出批签发决定。\n'Article 19  For the lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. For other biological products, lot release may be conducted by means of independent dossier review or by combining dossier review with sample testing, and on-site verification may be conducted as required. For the testing items and testing proportion for different varieties, the NIFDC shall organize the demonstration and submit a copy to the NMPA. Each lot release institution shall conduct test in accordance with the determined specifications.'可被翻译为：第十九条    疫苗批签发应当逐批进行资料审核和抽样检验，其他生物制品批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种检验项目和检验比例，由中检院负责组织论证，并抄报国家药品监督管理局。批签发机构按照确定的检验要求进行检验。\n'Article 18 Lot release may be conducted by means of independent dossier review or by combining dossier review with sample test, and on-site inspection may be conducted as required. For the lot release mode as well as the testing items and testing proportion for different products, the NIFDC shall organize the demonstration and each lot release institution shall conduct test in accordance with the determined mode for lot release and specifications.'可被翻译为：第十八条 批签发可以采取资料审核的方式，也可以采取资料审核和样品检验相结合的方式进行，并可根据需要进行现场核实。对不同品种所采用的批签发方式及检验项目和检验比例，由中检院负责组织论证，各批签发机构按照确定的批签发方式和检验要求进行检验。\n'Article 29 For lot release of vaccines, dossier review and sample testing shall be conducted lot by lot. The testing items and testing frequency for lot release of vaccines shall be dynamically adjusted according to the vaccine quality risk evaluation.'可被翻译为：第二十九条 疫苗批签发应当逐批进行资料审核和抽样检验。疫苗批签发检验项目和检验频次应当根据疫苗质量风险评估情况进行动态调整。\n\n根据上述已知信息，请将'The lot release institutions designated by the NMPA shall be responsible for the acceptance, dossier review, and sample testing and the decision-making on lot release in accordance with the law.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"国家药品监督管理局指定的批签发机构负责批签发的受理、资料审核、样品检验等工作，并依法作出批签发决定。"
    },
    {
        "instruction":"已知信息：\n'A solid preparation made of drugs and excipients in an appropriate form by pressing (or dropping) sealed in soft sacs.'可被翻译为：药物及辅料以适当形式通过压制法（或滴制法）密封于软质囊材中而制成的固体制剂。\n'Containers sealed under vacuum should be tested for maintenance of vacuum after an appropriate\npre-determined period prior to certification\/release and during shelf life.'可被翻译为：在真空下密封的容器应在认证\/放行前适当的预定时间后以及货架期内进行真空维持测试。\n'1.The foil sachet in which the condom is sealed after manufacture.\n2.The film–film or film–Tyvek peel pouch in which the IUD is sealed after manufacture and sterilization.'可被翻译为：1.制造后用来密封避孕套的铝箔小袋。\n2.宫内节育器在制造和消毒后密封的薄膜-薄膜或薄膜-特卫强剥离袋。\n'Ceilings should be designed and sealed to prevent contamination from the space above them.'可被翻译为：吊顶应经过设计和密封以防止来自其上方空间的污染。\n\n根据上述已知信息，请将'Containers that provide a permanent barrier to the passage of gases or solvents, e.g. sealed aluminium tubes for semisolids, sealed glass ampoules for solutions and luminium\/aluminium blisters for solid dosage forms.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为气体或溶剂的通过提供永久屏障的容器，例如，用于半固体的密封铝管，用于溶液的密封玻璃安瓿和用于固体剂型的铝\/铝泡罩。"
    },
    {
        "instruction":"已知信息：\n'Article 56 If the medical device registrant and the contract manufacturer are not in the same province, autonomous region or municipality directly under the central government, the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant of medical devices is located shall be responsible for carrying out supervision and inspection of the registrant’s performance of its legal duties such as operation of quality management system, adverse events monitoring and product recall, etc., and if relevant conditions of the contract manufacturer, the drug regulatory department of the place where the contract manufacturer is located shall make cooperation.'可被翻译为：第五十六条  医疗器械注册人和受托生产企业不在同一省、自治区、直辖市的，医疗器械注册人所在地省、自治区、直辖市药品监督管理部门负责对注册人质量管理体系运行、不良事件监测以及产品召回等法定义务履行情况开展监督检查，涉及受托生产企业相关情况的，受托生产企业所在地药品监督管理部门应当配合。\n'Article 57 If the registrant and the contract manufacturer of medical devices are not in the same province, autonomous region or municipality directly under the central government, and the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or the contract manufacturer is located needs to carry out cross-region inspection, it could also make inspection by means of joint inspection and entrusted inspection, etc.'可被翻译为：第五十七条  医疗器械注册人和受托生产企业不在同一省、自治区、直辖市，医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门需要跨区域开展检查的，可以采取联合检查、委托检查等方式进行。\n'The drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the contract manufacturer is located shall be responsible for carrying out supervision and inspection of the contract manufacturer’s manufacturing activities, and if involving relevant conditions of the registrant, the drug regulatory department of the place where the registrant is located shall carry out supervision and inspection on the registrant.'可被翻译为：受托生产企业所在地省、自治区、直辖市药品监督管理部门负责对受托生产企业生产活动开展监督检查，涉及注册人相关情况的，应当由注册人所在地药品监督管理部门对注册人开展监督检查。\n'Article 59 If suspicious illegal acts is found in cross-region inspection, the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or the contract manufacturer of medical devices is located shall make investigation and handling according to their own duties. The handling condition of the illegal acts shall be promptly informed to the related drug regulatory department.'可被翻译为：第五十九条  在跨区域检查中发现可能存在违法行为的，医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门应当依据各自职责进行调查处理。违法行为处理情况应当及时通报相关药品监督管理部门。\n\n根据上述已知信息，请将'Article 58 If it is found in cross-region inspection that there is defect with the enterprise quality management system, the drug regulatory department of the province, autonomous region, or municipality directly under the central government of the place where the registrant or the contract manufacturer of medical devices is located shall, in accordance with their respective duties, urge relevant enterprises to make prompt rectification in place as required, and inform the inspection and rectification conditions to related drug regulatory department in a timely manner.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十八条  跨区域检查中发现企业质量管理体系存在缺陷的，医疗器械注册人、受托生产企业所在地省、自治区、直辖市药品监督管理部门应当依据各自职责，督促相关企业严格按照要求及时整改到位，并将检查以及整改情况及时通报相关药品监督管理部门。"
    },
    {
        "instruction":"已知信息：\n'For each cell, the individual amount of drug released is plotted versus the square root of time. The slope of the resulting line is the rate of drug release.'可被翻译为：对于每个池，单独的药物释放量与时间的平方根成曲线。所得直线的斜率为药物释放速率。\n'For each cell, the amount of drug released (typically in µg\/cm2) at each sampling time (t1, t2, etc.) is determined, and the cumulative amount released is plotted versus √t. The slope of the resulting line is a measure of the rate of drug release.'可被翻译为：对于每个池，测定每个采样时间(t1、t2等)的药物释放量(通常以µg\/cm2为单位)，并绘制累积释放量与√t的关系。所得直线的斜率是药物释放速率的量度。\n'It is unconventional for IVRT sampling times to be selected within a study duration of less than 4 hours. This may occur in situations where the fixed product dose was depleted to such a great extent by 4 hours that the release kinetics were no longer linear thereafter (when plotted vs. the square root of time). In such instances, it would be appropriate to explain the efforts that were made to optimize the IVRT method (e.g., using a different diffusion cell equipment that allowed for a larger product dose to be used) so that the sustained steady state release kinetics could potentially be characterized over a conventional IVRT duration of 4 to 6 hours.'可被翻译为：通常情况下，所选的IVPT取样时长不应少于4小时。但是，对于某些特定类型的制剂，如果在大于4小时后，因产品剂量消耗非常大，之后的时间点不能呈线性关系（以释放量对时间的平方根作图）。在这种情况下，应该阐述为优化IVRT方法所做的努力（例如，使用不同的扩散池设备，以便可以采用更大的产品上样量），确保在4～6小时内呈现持续稳态释放动力学。\n'Theoretical or empirical information should be provided to explain the selection of IVRT method parameters such as the equipment, product dose amount, sampling times, stirring\/agitation rate, etc. When the equipment selected is among the models of equipment in the USP<1724>, Semisolid Drug Products – Performance Tests, and when the product dose amount or stirring rate is a parameter that is fixed (not adjustable) with the selected equipment, it may be sufficient to explain these facts.'可被翻译为：应提供理论或经验信息来解释IVRT方法参数的选择，如设备、上样量、取样时间、搅拌速率等。当选择的设备是USP<1724>半固体药物制剂—性能测试 中所述设备时，且上样量或搅拌速率与所选的设备匹配（未调节），可充分解释选择的合理性。\n\n根据上述已知信息，请将'When utilizing an appropriately selected receptor solution, membrane, equipment, dose, and sampling duration (as well as other potential method parameters) the release rate of the drug should be linear (when plotted as the amount of drug released versus the square root of time) and reproducible. The amount of drug product in the donor compartment should ensure that dose depletion does not occur to an extent that alters the linear (steady state) release kinetics during the duration of the test (i.e., a pseudo-infinite dose amount should be utilized). Excessive dose depletion is characterized by a nonlinear region in the plotted cumulative amount of drug released curve (when plotted as the amount of drug released versus the square root of time).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"当使用适当选择的受体溶液、膜、设备、剂量和取样时间(以及其他潜在的方法参数)时，药物的释放速度应该是线性的(当绘制为药物释放量与时间的平方根时)并且可重复。给药室中的药物用量应确保在试验过程中，剂量消耗不会达到改变线性(稳态)释放动力学的程度(即，应使用伪无限剂量)。过量剂量消耗的特征是在绘制的药物累积释放量曲线中出现一个非线性区域(当绘制为药物释放量与时间的平方根时)。"
    },
    {
        "instruction":"已知信息：\n'The ratio of the volume of seed liquid fed into the fermenter to the volume of the fermentation medium in the tank.'可被翻译为：接入到发酵罐内的种子液的体积与罐内发酵培养基的体积之比。\n'A culture method in which the cells and culture medium of microorganisms or animals and plants are loaded into the reactor at one time for culture, the cells are continuously increased, the product liquid is continuously formed, and after a period of reaction, the whole reaction system is taken out.'可被翻译为：将微生物或动植物的细胞和培养液一次性装入反应器中,进行培养，细胞不断增加，产物液不断形成,经过一段时间反应后,将整个反应体系取出的培养方法。\n'A fermentation culture in which the living cells of a bacterium are fixed on a solid supporting medium. It is a method that combines the characteristics of solid culture and liquid deep culture.'可被翻译为：把菌体活细胞固定在固体支持介质上的一种发酵培养。是把固体培养和液体深层培养特点相结合的种方法。\n'During the culture process, there is no other fermentation method of exchange with the outside world except for continuous ventilation, adjustment of the pH value of the culture solution, and exhaust gas from the system.'可被翻译为：在培养过程中，除了不断进行通气，调节培养液的pH值、系统排出废气外，与外界没有其他交换的发酵方式。\n\n根据上述已知信息，请将'In the culture process, the culture medium is continuously added to the fermenter, while the same flow rate from the fermenter flowing out of the culture liquid fermentation mode.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在培养过程中，连续地向发酵罐中加入培养基，同时以相同的流量从发酵罐中流出培养液的发酵方式。"
    },
    {
        "instruction":"已知信息：\n'(2) failing to obtain and keep relevant certification documents and temperature monitoring records when receiving or purchasing vaccines;'可被翻译为：（二）接收或者购进疫苗时未按照规定索取并保存相关证明文件、温度监测记录；\n'(I) Failing to establish working system for medical device adverse event monitoring as required;'可被翻译为：（一）未按照要求建立医疗器械不良事件监测工作制度的；\n'(2) The investigator shall keep intact records of AE (Adverse Event), SAE and judgement criteria of drug correlation, meeting the provisions of trial protocol and medical routines.'可被翻译为：(2) 研究者应完整记录 AE(不良事件)、SAE， 与药物相关性判断标准符合试验方案规定和医疗常规。\n'(III) Medical device adverse event monitoring information requiring regularly release;'可被翻译为：（三）需要定期发布的医疗器械不良事件监测信息；\n\n根据上述已知信息，请将'(III) Failing to keep the records of adverse event monitoring or preserve the records for insufficient duration;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）未保存不良事件监测记录或者保存年限不足的；"
    },
    {
        "instruction":"已知信息：\n'Tabular output of all data from individual samples, QCs and calibration standards within the analytical run (e.g., for chromatography retention times, analyte and IS responses, concentrations, and dilution factors if any; for ligand binding assays analyte responses concentrations, dilution factors).'可被翻译为：分析批中单个样品、QC和校正标样的所有数据的表格输出（例如，对于色谱法有保留时间、待测物和IS响应、浓度、稀释因子（如有）、采集时间；对于配体结合分析，有待测物响应、浓度、稀释因子）。\n'minimum required dilution (mrd)'可被翻译为：最低需求稀释度\n'Antibiotic potency samples will vary in physical form, dose and administration; examples of differing sample types include tablets, powders, solutions or semi- solids. Regardless of these physical and chemical attributes, the test sample and reference standard must be diluted prior to testing. Each dilution for the test sample and reference standard must be considered. The dilution factor (for each dilution) and the total dilution (for multiple dilutions) are data required to calculate potency.'可被翻译为：抗生素效价检测样品在物理形式、剂量和给药方式上会有所不同；不同样品类型的例子包括片剂、粉末、溶液或半固体。无论这些物理和化学属性如何，在测试前必须稀释测试样品和标准品。必须考虑测试样品和标准品的每次稀释。稀释因子（对于每次稀释）和总稀释倍数（对于多次稀释）是计算效价所需的数据。\n'dilution factor'可被翻译为：稀释因子\n\n根据上述已知信息，请将'The initial dilution factor by which biological samples are diluted with buffer solution for the analysis by LBAs. The MRD may not necessarily be the ultimate dilution but should be identical for all samples including calibration standards and QCs. However, samples may require further dilution.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于 LBA 分析，生物样品以缓冲液稀释的最初稀释因子。MRD可能不是最终稀释，但应对所有样品保持一致，包括校正标样和QC样品。然而样品可能需要进一步稀释。"
    },
    {
        "instruction":"已知信息：\n'A reaction in which the rate of reaction is dependent on the concentration of the reactant to the power of one.'可被翻译为：反应速率与反应物浓度的一次方相关的反应。\n'A reaction in which the rate of reaction is related to the quadratic concentration of the reactant.'可被翻译为：反应速率与反应物浓度的二次方相关的反应。\n'An amount independent of concentration that is numerically equivalent to the reaction rate at which all the substances involved in the reaction are at unit concentration.'可被翻译为：与浓度无关的量，在数值上相当于参加反应的物质都处于单位浓度时的反应速率。\n'Under certain conditions, most chemical reactions are reversible, when the reversible reaction rate is equal, the concentration of reactants and products no longer change with time.'可被翻译为：在一定条件下，多数化学反应是可逆的，当可逆反应中正逆反应速率相等，反应物和生成物的浓度不再随时间而改变的状态。\n\n根据上述已知信息，请将'Also known as \"reaction rate constant\". The speed at which a chemical reaction proceeds is expressed as a decrease in the concentration of the reactant or an increase in the concentration of the product per unit time. In general, when the temperature is fixed, the specific rate of the reaction is constant.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"反应速率常数”。化学反应进行的快慢，用单位时间内反应物浓度的减少或生成物浓度的增加量来表示。一般来说，当温度一定时，特异反应比速为常数。"
    },
    {
        "instruction":"已知信息：\n'(II) verifying the original Certificate of Analysis for release and Certificate of Origin;'可被翻译为：（二）核查出厂检验报告书和原产地证明原件；\n'(VI)  photocopies of the Certificate of Analysis for release;'可被翻译为：（六）出厂检验报告书复印件；\n'The importer shall, before sampling, provide the original Certificate of Analysis for release and Certificate of Origin.'可被翻译为：进口单位应当在抽样前，提供出厂检验报告书和原产地证明原件。\n'Article 27 To apply for vaccine lot release, materials such as summary protocol of manufacturing and control and samples shall be provided to the lot release institutions as required. For imported vaccines, the certificate of country of origin and certificate of lot release shall also be provided; and if the imported vaccines are exempted from lot release in the country of origin, the exemption certificate of lot release shall be provided.'可被翻译为：第二十七条 申请疫苗批签发应当按照规定向批签发机构提供批生产及检验记录摘要等资料和同批号产品等样品。进口疫苗还应当提供原产地证明、批签发证明；在原产地免予批签发的，应当提供免予批签发证明。\n\n根据上述已知信息，请将'(I) the original Certificate of Analysis for release and Certificate of Origin is not provided, or the original copy provided is inconsistent with the photocopies submitted at the time of importation record filing;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（一）未提供出厂检验报告书和原产地证明原件，或者所提供的原件与申报进口备案时的复印件不符的；"
    },
    {
        "instruction":"已知信息：\n'ADR\/ADE county reporting ratio marks an important indicator for measuring the balanced development and coverage of ADR monitoring in China. The proportion of county-level reports of ADRs\/ADEs in China in 2018 was 97.9%.'可被翻译为：药品不良反应\/事件县级报告比例是衡量我国药品不良反应监测工作均衡发展及覆盖程度的重要指标之一。2018年全国药品不良反应\/事件县级报告比例为97.9%。\n'As one of the important indicators to measure the level of national ADR monitoring, the average number of reports per million people in China marked 1,119 in 2018.'可被翻译为：每百万人口平均报告数量是衡量一个国家药品不良反应监测工作水平的重要指标之一。2018年我国每百万人口平均报告数为1119份。\n'In 2019, the National ADR Monitoring Network received 477,000 new and serious ADR\/ADE reports, accounting for 31.5 percent of the total number reported in the same period.'可被翻译为：2019年全国药品不良反应监测网络收到新的和严重药品不良反应\/事件报告47.7万份；新的和严重药品不良反应\/事件报告占同期报告总数的31.5%。\n'The average number of reports per million population constitutes one of the major indicators to measure the level of a country's ADR monitoring work. The average number of reports per million population in China marked 1,130 in 2019.'可被翻译为：每百万人口平均报告数量是衡量一个国家药品不良反应监测工作水平的重要指标之一。2019年我国每百万人口平均报告数为1，130份。\n\n根据上述已知信息，请将'The ratio of ADR\/ADE reports at county level constitutes one of the important indicators to measure the balanced development and coverage of ADR monitoring in China. In 2019, 97.4 percent of county-level regions across China reported ADRs\/ADEs.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药品不良反应\/事件县级报告比例是衡量我国药品不良反应监测工作均衡发展及覆盖程度的重要指标之一。2019年全国97.4%的县级地区报告了药品不良反应\/事件。"
    },
    {
        "instruction":"已知信息：\n'pilot scale batch'可被翻译为：中试规模批次\n'critical quality attributes (CQAs), critical process parameters (CPPs) and in-process controls;'可被翻译为：关键质量属性（CQA）、关键工艺参数（CPP）和中控；\n'Packaging: Packaging material specification; Master of executed packaging record; Validation; Sampling plan; Acceptance Quality Level (AQL) for products and defects; Packaging validation'可被翻译为：批包装： 包装材料规格、已执行的批包装文件、验证、取样方案、产品和缺陷可接受质量水平（AQL）、包装验证\n'Article 5 Manufacturing Site Inspection is the process of verifying the commercial scale production process validation and pilot production process applied for drug registration, and confirming whether it compliance to the proposed or approved source of raw materials, excipients and packaging materials, formulation, production process, test method and quality specification, stability study, etc. , and the data integrity of relevant commercial scale production process, and whether it is qualified for commercial production.'可被翻译为：第五条 生产现场核查是对药品注册申请的商业规模生产工艺验证、样品生产过程等进行核实，对其是否与申报的或者核定的原辅料及包装材料来源、处方、生产工艺、检验方法和质量标准、稳定性研究等相符合，相关商业规模生产过程的数据可靠性以及是否具备商业化生产条件进行确认的过程。\n\n根据上述已知信息，请将'Batch manufacturing: Master of executed batch record; Scale up information; Risk assessment; Critical process parameters; In-process control specification; Scale up protocol and report; Process validation'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"批生产： 已执行的批记录、放大信息、风险评估、关键工艺参数、中控标准、放大方案和报告、工艺验证"
    },
    {
        "instruction":"已知信息：\n'Article 33 The serial number for medical device national standards shall be made in accordance with regulations of the competent standardization administrative department under the State Council. The code for medical device industry standards is composed of capitalized Chinese phonetic alphabets. The code for mandatory industry standards is \"YY\" , and that for recommended industry standards is \"YY\/T\".'可被翻译为：第三十三条 医疗器械国家标准的编号按照国务院标准化行政主管部门的规定编制。医疗器械行业标准的代号由大写汉语拼音字母等构成。强制性行业标准的代号为“YY”，推荐性行业标准的代号为“YY／Ｔ”。\n'The medical device standards plan projects that are approved by China Food and Drug Administration shall be released to the public. The national standards plan project shall be submitted to the competent standardization administrative department under the State Council for approval and assignment; the industry standards plan project shall be approved and assigned by China Food and Drug Administration.'可被翻译为：国家食品药品监督管理总局审核通过的医疗器械标准计划项目，应当向社会公示。国家标准计划项目送国务院标准化行政主管部门批准下达；行业标准计划项目由国家食品药品监督管理总局批准下达。\n'Article 22 The Center for Medical Device Standardization Administration shall submit the reviewed medical device standards draft for approval and review conclusions to China Food and Drug Administration for examination. Medical device national standards passing the examination shall be submitted to the competent standardization administrative department under the State Council for approval and issuance; for medical device industry standards passing the examination, China Food and Drug Administration shall determine and announce the date and requirements for their implementation.'可被翻译为：第二十二条 医疗器械标准管理中心将审核通过后的医疗器械标准报批稿及审核结论等报送国家食品药品监督管理总局审查。审查通过的医疗器械国家标准送国务院标准化行政主管部门批准、发布；审查通过的医疗器械行业标准由国家食品药品监督管理总局确定实施日期和实施要求，以公告形式发布。\n'The reexamination conclusion for medical device standards shall be submitted to China Food and Drug Administration for approval after passing the review of the Center for Medical Device Standardization Administration. The reexamination conclusion for medical device national standards shall be submitted to the competent standardization administrative department under the State Council for approval; the reexamination conclusion for medical device industry standards shall be submitted to China Food and Drug Administration for review and approval, and standards for which the reexamination conclusion is \"Abolished\" shall be announced by China Food and Drug Administration.'可被翻译为：医疗器械标准复审结论由医疗器械标准管理中心审核通过后，报送国家食品药品监督管理总局审查。医疗器械国家标准复审结论，送国务院标准化行政主管部门批准；医疗器械行业标准复审结论由国家食品药品监督管理总局审查批准，并对复审结论为废止的标准以公告形式发布。\n\n根据上述已知信息，请将'Medical device national standards and industry standards shall be disclosed in accordance with the relevant regulations of the competent standardization administrative department under the State Council for public reference.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"医疗器械国家标准、行业标准按照国务院标准化行政主管部门的相关规定进行公开，供公众查阅。"
    },
    {
        "instruction":"已知信息：\n'Article 63 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter VI of the Provisions shall prevail.'可被翻译为：第六十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。\n'Article 56 Where provisions concerning acceptance and approval procedures of application for registration renewal of medical device are not available in this chapter, Chapter V of the Provisions shall prevail.'可被翻译为：第五十六条 医疗器械延续注册申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。\n'Article 66 Where provisions concerning acceptance and approval procedures of application for registration renewal of medical device are not available in this chapter, Chapter VI of the Provisions shall prevail.'可被翻译为：第六十六条 体外诊断试剂延续注册申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。\n'The food and drug regulatory department accepting the application for change of permission items shall organize technical evaluation within the period specified in Chapter V of the Provisions.'可被翻译为：受理许可事项变更申请的食品药品监督管理部门应当按照本办法第五章规定的时限组织技术审评。\n\n根据上述已知信息，请将'Article 53 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter V of the Provisions shall prevail.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第五十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。"
    },
    {
        "instruction":"已知信息：\n'3. County-level coverage In 2018, the county-level coverage of suspected medical device adverse events in China was 95.9% (Figure 3) .(II) Number of registered grassroots users nationwide As of December 31, 2018, there were a total of 275,715 grassroots user units (including manufacturing enterprises, operating companies and users) registered in the National Medical Device Adverse Event'可被翻译为：3.县级覆盖率\n'3. County-level coverage. In 2019, the county-level coverage rate for reporting of suspected medical device adverse events in China was 96.70 percent, up by 0.80 percentage points YOY (Figure 3).'可被翻译为：3.县级覆盖率。2019年，我国可疑医疗器械不良事件报告的县级覆盖率为96.70%，比上年增加0.80个百分点（图3）。\n'In 2018, the National Medical Device Adverse Event Monitoring Information System received a total of 406,974 reports of suspected medical device adverse events,an increase of 8.19% over 2017, reflecting the increasing awareness of China's medical device adverse event reporting and the effective enhancement of report collection capabilities (Figure 1) .'可被翻译为：2018年，全国医疗器械不良事件监测信息系统共收到可疑医疗器械不良事件报告406974份，较2017年增长8.19%，反映出我国医疗器械不良事件报告意识不断增强、报告收集能力有效提升（图1)。\n'Figure 2 Comparison of the number of suspected medical device adverse events reported per million people across China from2014 to 2018'可被翻译为：2018年，我国每百万人口平均可疑医疗器械不良事件报告数为305份，与2017年相比增长23份(图2)。\n\n根据上述已知信息，请将'Figure 3 County-level coverage of suspected medical device adverse event reports from 2015to 2018 in China'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"2018年，我国可疑医疗器械不良事件报告的县级覆盖率为95.9%(图3 )。"
    },
    {
        "instruction":"已知信息：\n'(III) Auditing the legal qualification of supplier and purchaser, the legality of drugs purchased and the legal qualification of sales personnel of supplier and purchasing personnel of purchaser, and conducting dynamic management according to the changes of audit contents;'可被翻译为：（三）负责对供货单位和购货单位的合法性、购进药品的合法性以及供货单位销售人员、购货单位采购人员的合法资格进行审核，并根据审核内容的变化进行动态管理；\n'(V) Provisions on qualification of supplier, purchaser, sales personnel of supplier and purchasing personnel of purchaser;'可被翻译为：（五）供货单位、购货单位、供货单位销售人员及购货单位采购人员等资格审核的规定；\n'Article 64 Enterprises shall validate and retain the following information about the sales personnel of supplier:'可被翻译为：第六十四条 企业应当核实、留存供货单位销售人员以下资料：\n'(III) Being responsible for the audit of the qualification certificates of suppliers and their sales personnel;'可被翻译为：（三）负责对供货单位及其销售人员资格证明的审核；\n\n根据上述已知信息，请将'(III) Validate the legal qualification of sales personnel of supplier;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（三）核实供货单位销售人员的合法资格；"
    },
    {
        "instruction":"已知信息：\n'Medications to treat and prevent filarial infections. Treatment medications are ethylamizine and albendazole, among others.'可被翻译为：治疗和预防丝虫感染的药物。治疗药物有乙胺嗪和阿苯达唑等。\n'Antimicrobial drugs used to treat infections caused by pathogenic microorganisms such as bacteria, rickettsia, chlamydia, mycoplasma, spirochetes, fungi, etc. Excluded are drugs for treating tuberculosis, parasitic diseases, and various viral infections, as well as traditional Chinese medicine formulations with antibacterial properties.'可被翻译为：治疗细菌、支原体、衣原体、立克次体、螺旋体、真菌等病原微生物所致感染性疾病病原的药物，\n不包括治疗结核病、寄生虫病和各种病毒所致感染性疾病的药物以及具有抗菌作用的中药制剂。\n'A drug that kills or inhibits bacteria and is used to treat or prevent infections caused by bacteria. According to the different sources, it is divided into: ① antibiotics, such as cephalosporin; ② synthetic antimicrobials, such as quinolcopper; ③ antibacterial Chinese herbs, such as coptis, tanshinone, etc.; ④ Antifungal drugs, such as fluconazole, etc.'可被翻译为：对细菌有杀灭或抑制作用，用以治疗或预防细菌引起的感染的药物。根据来源的不同分为：①抗生素，如头孢氨卡等；②合成抗菌药，如喹诺铜类；③抗菌中草药，如黄连、丹参酮等；④抗真菌药，如氟康挫等。\n'c. When targeting fungal populations only, it is necessary to use an appropriate fungal media such as Sabouraud Dextrose or Malt Extract media. It is beneficial to use an antibiotic (i.e. Chlortetracycline) which will help to selectively inhibit bacterial growth and restrict the size and height of colonies of more rapidly growing molds.'可被翻译为：如果仅针对真菌种群，需要使用适当的真菌培养基，如沙氏葡萄糖琼脂培养基或麦芽提取物培养基。使用抗生素（如金霉素）是有益有，这将有助于选择性找抽细菌生长并限制更快速生长的霉菌菌落的大小和高度。\n\n根据上述已知信息，请将'Medications to treat or prevent fungal infections. For superficial fungal infections, there are Terbuchofen and some topical antifungals; Amphotericin and fluorocytosine are suitable for deep fungal infections; Azole antifungals have antibacterial effects on both superficial and deep fungi.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"治疗或预防真菌感染的药物。适用于浅表真菌感染的有特比蔡芬及一些外用抗真菌药；适用于深部真菌感染的有两性霉素和氟胞嘧啶；唑类抗真菌药对浅表和深部真菌都有抗菌作用。"
    },
    {
        "instruction":"已知信息：\n'The early term for capillary gas chromatography refers to gas chromatography using open tube columns (including wall coated open column and carrier coated open column). The types of open column include wall coated open column, carrier coated open column, porous layer open column and immobilized phase open column. Injection methods include shunt injection, no shunt injection and column head injection.'可被翻译为：早期对于毛细管气相色谱的称谓，指使用开管柱(包括涂壁开管柱和涂载体开管柱)的气相色谱法。开管柱的类型有涂壁开管柱、涂载体开管柱、多孔层开管柱和固定化相开管柱等。进样方式有分流进样、无分流进样 和柱头进样等。\n'Combining the high column efficiency of capillary electrophoresis with the high selectivity of high performance liquid chromatography, microcolumn chromatography is a mobile phase driven by electroseepage (or electroseepage combined with a high pressure infusion pump). It includes packed column electrochromatography and open column electrochromatography.'可被翻译为：结合了毛细管电泳的高柱效和高效液相色谱法的高选择性，是以电渗流(或电渗流结合高压输液泵)为流动相驱动力的微柱色谱法。包括填充柱电色谱法和开管柱电色谱法。\n'A reagent used in column chromatography to desorption or eluate the substance to be separated from the column.'可被翻译为：柱色谱分离法中用于将待分离物质从色谱柱中解吸或洗脱出来的试剂。\n'An injection device for high resolution gas chromatography (HRGC) column samples.'可被翻译为：高分辨气相色谱(HRGC)柱上进样所用的进样装置。\n\n根据上述已知信息，请将'In capillary chromatography, a stream of air introduced at the exit of a capillary column. Its role is to reduce the dead volume behind the column, improve the column efficiency, meet the best gas flow rate of the detector, in order to improve the sensitivity of the detector.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"毛细管色谱分析中，在毛细管柱的出口端引入的一路气流。其作用是减少柱后的死体积，改善柱效，满足检测器的最佳气体流速，以提高检测器的灵敏度。"
    },
    {
        "instruction":"已知信息：\n'Article 13 The monitoring agencies designated by the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government (hereinafter referred to as provincial monitoring agencies) shall organize the technical works related to medical device adverse event monitoring and re-evaluation within their respective administrative regions; assume the investigation, evaluation and feedback of adverse events of the medical devices registered or filed within their respective administrative regions, and investigate and evaluate group adverse events of medical device that occurs within their respective administrative regions.'可被翻译为：第十三条  省、自治区、直辖市药品监督管理部门指定的监测机构（以下简称省级监测机构）组织开展本行政区域内医疗器械不良事件监测和再评价相关技术工作；承担本行政区域内注册或者备案的医疗器械不良事件的调查、评价和反馈，对本行政区域内发生的群体医疗器械不良事件进行调查和评价。\n'Article 6 The drug regulatory departments of the provinces, autonomous regions, and municipalities directly under the Central Government are responsible for the following administrative tasks pertaining to drug registration within their respective administrative regions:'可被翻译为：第六条 省、自治区、直辖市药品监督管理部门负责本行政区域内以下药品注册相关管理工作：\n'Article 9 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall be responsible for the supervision and administration of medical device adverse event monitoring and re-evaluation within their respective administrative regions, organize the investigation and handling of group adverse events of medical device that occurs within their respective administrative regions jointly with the health administrative departments at the same level and relevant authorities, and take emergency control measures according to law.'可被翻译为：第九条  省、自治区、直辖市药品监督管理部门负责本行政区域内医疗器械不良事件监测和再评价的监督管理工作，会同同级卫生行政部门和相关部门组织开展本行政区域内发生的群体医疗器械不良事件的调查和处理，依法采取紧急控制措施。\n'Article 8 The food and drug regulatory department of the province, autonomous region and municipality directly under the Central Government where the manufacturer of the recalled medical device is located shall be responsible for the supervision and administration of the recall, and the food and drug regulatory departments of other provinces, autonomous regions and municipalities directly under the Central Government shall cooperate in the recall of medical devices within their respective administrative areas.'可被翻译为：第八条 召回医疗器械的生产企业所在地省、自治区、直辖市食品药品监督管理部门负责医疗器械召回的监督管理，其他省、自治区、直辖市食品药品监督管理部门应当配合做好本行政区域内医疗器械召回的有关工作。\n\n根据上述已知信息，请将'Article 44 The drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government may, in accordance with the requirements for supervision and administration of medical device within their respective administrative regions, carry out provincial intensive surveillance project on Class II medical devices registered and Class I medical devices filed within their respective administrative regions by referring to Article 43 of the Provisions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十四条  省、自治区、直辖市药品监督管理部门可以根据本行政区域内医疗器械监管工作需要，参照本办法第四十三条规定，对本行政区内注册的第二类和备案的第一类医疗器械开展省级医疗器械重点监测工作。"
    },
    {
        "instruction":"已知信息：\n'(3) disturbing or obstructing vaccines-related investigation on illegal or criminal acts or safety incidents;'可被翻译为：（三）干扰、阻碍对疫苗违法行为或者疫苗安全事件的调查；\n'VI. Investigation and Punishment of Illegal Acts of Medical Devices'可被翻译为：六、关于医疗器械违法行为的查处\n'(4) committing illegal acts of the same nature within 1 year after receiving administrative punishment due to illegal acts related with cosmetics, or committing illegal acts concerning quality and safety of cosmetics after receiving criminal punishment due to violation of laws and regulations on quality and safety of cosmetics;'可被翻译为：（四）因化妆品违法行为受到行政处罚后1年内又实施同一性质的违法行为，或者因违反化妆品质量安全法律、法规受到刑事处罚后又实施化妆品质量安全违法行为；\n'(4) occurrence of significant vaccine safety incidents or continuous major vaccine safety incidents within the administrative region.'可被翻译为：（四）本行政区域发生特别重大疫苗安全事故，或者连续发生重大疫苗安全事故。\n\n根据上述已知信息，请将'(4) disturbing or obstructing vaccine-related investigation on illegal acts or safety incidents;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（四）干扰、阻碍对疫苗违法行为或者疫苗安全事件的调查；"
    },
    {
        "instruction":"已知信息：\n'(II) The warehouse has smooth interior walls and ceiling as well as flat floor with tight structure of door and window;'可被翻译为：（二）库房内墙、顶光洁，地面平整，门窗结构严密；\n'Article 164 Where an enterprise establishes a warehouse, the drug storage and maintenance management in the warehouse shall comply with Section 10 of Chapter II herein.'可被翻译为：第一百六十四条 企业设置库房的，库房的药品储存与养护管理应当符合本规范第二章第十节的相关规定。\n'Article 148 A warehouse shall have the following facilities and equipment:'可被翻译为：第一百四十八条 仓库应当有以下设施设备：\n'(I) The internal and external environment of the warehouse is clean without pollutant source; and the ground of warehouse area is hardened or covered by vegetation;'可被翻译为：（一）库房内外环境整洁，无污染源，库区地面硬化或者绿化；\n\n根据上述已知信息，请将'Article 147 Where an enterprise establishes a warehouse, it shall ensure that the inner walls and ceiling of the warehouse are smooth and clean, the floor is flat and the doors and windows have a tight structure; and there are reliable safety protection, anti-theft and other measures.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百四十七条 企业设置库房的，应当做到库房内墙、顶光洁，地面平整，门窗结构严密；有可靠的安全防护、防盗等措施。"
    },
    {
        "instruction":"已知信息：\n'By using the size of the pore size of the microporous membrane, the particles larger than the pore size of the solution are retained to reach the process of solution clarification or separation.'可被翻译为：利用微孔膜孔径的大小，使溶液中大于膜孔径的微粒截留达到溶液澄清或分离的过程。\n'Also known as \"electrodialysis\". A method of using the selective permeability of a semi-permeable membrane to separate different solute particles, such as ions. When dialysis is performed under an electric field, charged solute particles (such as ions) in a solution migrate through the membrane to the other side.'可被翻译为：又称“电透析”。利用半透膜的选择透过性来分离不同的溶质粒子（如离子）的方法。在电场作用下进行渗析时，溶液中的带电的溶质粒子（如离子）通过膜而迁移到膜的另一边。\n'The diffusion of a solvent (or a solvent in a dilute solution) through a semi-permeable membrane into a solution (or a concentrated solution) when the solution is separated from the pure solvent (or two solutions of different concentrations) by a semi-permeable membrane.'可被翻译为：当溶液与纯溶剂（或两种浓度不同的溶液）在半透膜隔开的情况下，溶剂（或较稀溶液中的溶剂）通过半透膜向溶液（或较浓溶液）扩散的现象。\n'When pure water and saline solutions are separated by a semi-permeable membrane, pure water will spontaneously flow to the solution side, and when the pressure applied to the solution side is just enough to stop pure water flowing to the solution side, this pressure is the osmotic pressure of the solution at that concentration.'可被翻译为：当纯水和盐水溶液被半透膜隔开时，纯水会自发流向溶液侧，当施加在溶液侧的压力正好使纯水停止向溶液侧流动时，这压力就是该溶液在该浓度下的渗透压。\n\n根据上述已知信息，请将'The process of separating a solid membrane from a solution containing particles by using pressure as a driving force. When the solution passes through the microporous membrane, suspended matter (colloids, bacteria) and larger microspheres are trapped and removed.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"以压力为推动力，过滤含有微粒的溶液的固体膜分离过程。当溶液通过微孔膜后，悬浮物（胶体、细菌）和粒径较大的微球被截留而被除去。"
    },
    {
        "instruction":"已知信息：\n'The drug regulatory departments at the level of the municipality consisting of districts or county level shall be responsible for medical device-related adverse event monitoring within their respective administrative regions.'可被翻译为：设区的市级和县级药品监督管理部门负责本行政区域内医疗器械不良事件监测相关工作。\n'Article 13 The monitoring agencies designated by the drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government (hereinafter referred to as provincial monitoring agencies) shall organize the technical works related to medical device adverse event monitoring and re-evaluation within their respective administrative regions; assume the investigation, evaluation and feedback of adverse events of the medical devices registered or filed within their respective administrative regions, and investigate and evaluate group adverse events of medical device that occurs within their respective administrative regions.'可被翻译为：第十三条  省、自治区、直辖市药品监督管理部门指定的监测机构（以下简称省级监测机构）组织开展本行政区域内医疗器械不良事件监测和再评价相关技术工作；承担本行政区域内注册或者备案的医疗器械不良事件的调查、评价和反馈，对本行政区域内发生的群体医疗器械不良事件进行调查和评价。\n'Article 28 The monitoring agencies at the level of the municipality consisting of districts shall review the truthfulness, completeness and accuracy of the received medical device adverse event reports within 10 days upon the receipt date, and feed back to relevant MAHs promptly.'可被翻译为：第二十八条  设区的市级监测机构应当自收到医疗器械不良事件报告之日起10日内，对报告的真实性、完整性和准确性进行审核，并实时反馈相关持有人。\n'Drug regulatory departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for the vaccine administration within their respective administrative regions. Departments undertaking responsibilities for drug administration (hereinafter referred to as drug regulatory departments) of the people's governments of municipalities divided into districts and at county level shall undertake the administrative duties on vaccines within their respective administrative regions. The competent health departments of people's governments at or above the county level shall undertake the administration of immunization within their respective administrative regions. Other relevant departments of the people's governments at or above the county level shall undertake the administrative duties on vaccines within the scope of their respective responsibilities.'可被翻译为：省、自治区、直辖市人民政府药品监督管理部门负责本行政区域疫苗监督管理工作。设区的市级、县级人民政府承担药品监督管理职责的部门（以下称药品监督管理部门）负责本行政区域疫苗监督管理工作。县级以上地方人民政府卫生健康主管部门负责本行政区域预防接种监督管理工作。县级以上地方人民政府其他有关部门在各自职责范围内负责与疫苗有关的监督管理工作。\n\n根据上述已知信息，请将'The monitoring agencies at the level of the municipality consisting of districts or county level shall assist in carrying out technical works related to medical device adverse event monitoring within their respective administrative regions.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"设区的市级和县级监测机构协助开展本行政区域内医疗器械不良事件监测相关技术工作。"
    },
    {
        "instruction":"已知信息：\n'Article 13 After completion of manufacturing and testing of biological products subject to lot release administration, the lot release applicant shall fill out the Application Form for Lot Release of Biological Products in the IMS, and apply to the lot release institution under jurisdiction for lot release in the place where the MAH applying for lot release is located or the import port is set.'可被翻译为：第十三条    按照批签发管理的生物制品，批签发申请人在生产、检验完成后，应当在生物制品批签发管理系统内填写生物制品批签发申请表，并根据申请批签发产品的药品上市许可持有人所在地或者拟进口口岸所在地批签发机构设置情况，向相应属地的批签发机构申请批签发。\n'Article 47 Formats of the Application Form for Lot Release of Biological Products, the Registration Form for Lot Release of Biological Products, the Certificate for Lot Release of Biological Products, the Notice of Disapproval of Lot Release of Biological Products, the Notice of Re-review of Lot Release of Biological Products and the Notice of Re-review Result of Lot Release of Biological Products shall be developed in a unified manner and publicized by the NIFDC.'可被翻译为：第四十七条 生物制品批签发申请表、生物制品批签发登记表、生物制品批签发证明、生物制品不予批签发通知书、生物制品批签发复审申请表、生物制品批签发复审结果通知书的格式由中检院统一制定并公布。\n'Formats of the application form for lot release of biological products, the registration form for lot release of biological products, the Certificate for Lot Release of Biological Products, the Notice of Disapproval of Lot Release of Biological Products, the Notice of Re-review Result of Lot Release of Biological Products and the notice of re-review result of lot release of biological products shall be developed in a unified manner and publicized by the NIFDC.'可被翻译为：生物制品批签发申请表、生物制品批签发登记表、生物制品批签发证明、生物制品不予批签发通知书、生物制品批签发复审申请表、生物制品批签发复审结果通知书的格式由中检院统一制定并公布。\n'Article 30 For those in any of the following circumstances, the lot release shall be disapproved, and a Notice of Disapproval of Lot Release of Biological Products shall be issued to the lot release applicant and copied to the drug regulatory departments of provinces, autonomous regions or municipalities directly under the Central Government in the place where the lot release applicant or the import port is located:'可被翻译为：第三十条    有下列情形之一的，不予批签发，向批签发申请人出具生物制品不予批签发通知书，并抄送批签发申请人所在地或者进口口岸所在地省、自治区、直辖市药品监督管理部门：\n\n根据上述已知信息，请将'Article 13 After completion of manufacturing and testing of biological products subject to lot release administration, the lot release applicant shall fill out the Application Form for Lot Release of Biological Products in the Information Management System for Lot Release, and apply to the lot release institution under jurisdiction for lot release in the place where the drug manufacturer applying for lot release is located or the place where the port at which the drug is to be imported is located.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十三条 按照批签发管理的生物制品在生产、检验完成后，批签发申请人应当在批签发信息管理系统内填写生物制品批签发申请表，并根据申请批签发产品的药品生产企业所在地或者拟进口口岸所在地，向相应属地的批签发机构申请批签发。"
    },
    {
        "instruction":"已知信息：\n'A titration method in which 0.05mol\/L chloramine T is used as titration agent, and the end point is indicated by potentiometric method (clamp, calomel electrode) in 2mol sulfuric acid solution and at higher temperature. It is generally used for the determination of drugs containing moonwell.'可被翻译为：以0.05mol\/L的氯胺T作为滴定剂，在2mol的硫酸溶液中及较高的温度下，以电位法（钳，甘汞电极）指示终点的一种滴定方法。一般用于含月井基药物的测定。\n'A glass instrument for determining the content of essential oils containing volatile components in medicinal and plant tissues.'可被翻译为：对药物、植物组织中含有挥发性成分的精油含量进行测定的玻璃仪器。\n'The invention relates to a REDOX titration method, which is a method of directly titrating a reducing substance in an acidic medium with the apatite as the standard solution.'可被翻译为：一种氧化还原滴定法，是以溟酸盐为标准溶液，在酸性介质中直接滴定还原性物质的方法。\n'The titration operation is combined with the absorbance, and the spectrophotometer is used to measure the ever-changing absorbance of the test liquid in the titration process in order to obtain the titration end point, and the method of calculating the content of the substance to be measured.'可被翻译为：将滴定操作与吸光度相结合，利用分光光度计按次序测量试液在滴定过程中不断变化的吸光度，以获得滴定终点，并由此计算出待测物含量的方法。\n\n根据上述已知信息，请将'In acid-base titration analysis, a measuring glass dropper containing a standard alkali titration solution. The lower end is a latex tube containing glass beads.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"酸碱滴定分析中，盛放标准碱滴定液的定量玻璃滴管。下端为含有玻璃珠的乳胶管。"
    },
    {
        "instruction":"已知信息：\n'Article 47 If the drug MAH is an oversea enterprise, it shall authorize a legal person within the territory of China to perform the obligations set forth in the Drug Administration Law and these Regulations, and to provide cooperation for overseas inspections.'可被翻译为：第四十七条 药品上市许可持有人为境外企业的，应当指定一家在中国境内的企业法人，履行《药品管理法》与本办法规定的药品上市许可持有人的义务，并负责协调配合境外检查工作。\n'Article 15 Where the overseas MAH changes the drug manufacturing site and the new manufacturing site is still overseas, it shall conduct study, evaluation and necessary verification in accordance with relevant technical guidelines and submit supplementary application or filing to CDE.'可被翻译为：第十五条 境外持有人变更药品生产场地且变更后生产场地仍在境外的，应按照相关技术指导原则进行研究、评估和必要的验证，向药审中心提出补充申请或备案。\n'Article 42 Where a drug MAH entrusts the drug manufacturing, it shall comply with relevant regulations on drug administration.'可被翻译为：第四十二条 药品上市许可持有人委托生产药品的，应当符合药品管理的有关规定。\n'Article 1 In order to strengthen the supervision and administration of drug manufacturing and standardize drug manufacturing activities, these Provisions has been formulated according to laws and administrative regulations, such as the Drug Administration Law of the People's Republic of China (hereinafter referred to as the \"Drug Administration Law\"), Traditional Chinese Medicine Law of the People's Republic of China, Vaccine Administration Law of the People's Republic of China (hereinafter referred to as the \"Vaccine Administration Law\"), Administrative Licensing Law of the People's Republic of China and Regulations for Implementation of Drug Administration Law of the People's Republic of China.'可被翻译为：第一条 为加强药品生产监督管理，规范药品生产活动，根据《中华人民共和国药品管理法》（以下简称《药品管理法》）、《中华人民共和国中医药法》、《中华人民共和国疫苗管理法》（以下简称《疫苗管理法》）、《中华人民共和国行政许可法》、《中华人民共和国药品管理法实施条例》等法律、行政法规，制定本办法。\n\n根据上述已知信息，请将'Article 48 Where the manufacturing site of a drug MAH is outside the territory of China, it shall organize manufacturing according to the Drug Administration Law and these Regulations and provide cooperation for overseas inspections.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第四十八条 药品上市许可持有人的生产场地在境外的，应当按照《药品管理法》与本办法规定组织生产，配合境外检查工作。"
    },
    {
        "instruction":"已知信息：\n'Article 97: Water treatment plants and distribution systems should be designed, constructed, operated and maintained so as to ensure that water for pharmaceutical use meets the defined specifications. They should not be operated beyond their designed capacity.'可被翻译为：第九十七条 水处理设备及其输送系统的设计、安装、运行和维护应当确保制药用水达到设定的质量标准。水处理设备的运行不得超出其设计能力。\n'Processes and monitoring systems for sterile product manufacture should be designed, commissioned, qualified, monitored and regularly reviewed by personnel with appropriate process, engineering and microbiological knowledge.'可被翻译为：无菌产品生产工艺和监测系统应由具备适当工艺、工程和微生物知识的人员设计、调试、确认、检测和定期回顾。\n'Utilities should be designed, installed, qualified, operated, maintained and monitored in a manner to ensure that the utility system functions as expected.'可被翻译为：公用设施的设计、安装、确认、操作、维护和监测方式应确保该公用设施系统按预期运行。\n'Contamination control and steps taken to minimize the risk of contamination from microbial,\nendotoxin\/pyrogen and particle sources includes a series of interrelated events and measures. These are typically assessed, controlled and monitored individually but their collective effectiveness should be considered together.'可被翻译为：为尽可能降低微生物、内毒素\/热原和微粒的污染风险所釆取的污染控制和步骤包括一系列相互关联的事件和措施。它们通常分开评估、控制和监测的，但应综合考虑它们的共同有效性。\n\n根据上述已知信息，请将'Water treatment plant and distribution systems should be designed, constructed, installed, commissioned, qualified, monitored and maintained to prevent microbiological contamination and to ensure a reliable source of\nwater of an appropriate quality. Measures should be taken to minimize the risk of presence of particulates, microbial contamination\/proliferation and endotoxin\/pyrogen (e.g. sloping of piping to provide complete drainage and the avoidance of dead legs). Where filters are included in the system, special attention should be given to their\nmonitoring and maintenance. Water produced should comply with the current monograph of the relevant\nPharmacopeia.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"水处理设施及其分配系统地设计、建造、安装、调试、确认、监测和维护应防止微生物污染，并确保高质量的可靠水源。应釆取措施，最大程度降低微粒、微生物污染\/增殖和内毒素\/热原的风险（例如倾斜管道以完全排水以及避免死角）。当系统中包含过滤器时，应特别注意对其进行监测和维护。产出的水应符合相关药典的现行各论。"
    },
    {
        "instruction":"已知信息：\n'RABS:\nThe background environment for RABS used for aseptic processing should correspond to a minimum of grade B and airflow pattern studies should be performed to demonstrate the absence of air ingress during interventions, including door openings if applicable.'可被翻译为：用于无菌工艺的RABS的环境应至少为 B级，并且应进行气流流型研究以证明在干预过程中没有空气进入，包括开门（如适用）。\n'The design of open isolators should ensure grade A conditions with first air protection in the critical zone and unidirectional airflow that sweeps over and away from exposed products during processing.'可被翻译为：开放式隔离器的设计通过关键区域的初始气流保护和工艺过程中暴露产品上方和周围的单向流吹扫保证 A级条件。\n'The speed of air supplied by unidirectional airflow systems should be clearly justified in the qualification protocol including the location for air speed measurement. Air speed should be designed, measured and maintained to ensure that appropriate unidirectional air movement provides protection of the product and open\ncomponents at the working position (e.g. where high-risk operations occur and where product and\/or components are exposed). Unidirectional airflow systems should provide a homogeneous air speed in a range of 0.36 - 0.54 m\/s (guidance value) at the working position, unless otherwise scientifically justified in the CCS. Airflow\nvisualization studies should correlate with the air speed measurement.'可被翻译为：单向流系统送风速度的合理性应在确认方案中明确论证，包括风速的测定位置。风速的设计、测定和维持应确保在工作区域（例如，在进行高风险操作的区域以及产品和\/或组分暴露的区域）有合适的单向气流为产品和开放组件提供保护。除非在 CCS 中另有科学论证，否则单向流系统应在工作区域提供 0.36-0.54m\/s（指导值）的均匀风速。气流可视化研究应与风速测定相关联。\n'The design of closed isolators should ensure grade A conditions with adequate protection for exposed products during processing. Airflow may not be fully unidirectional in closed isolators where simple operations are conducted. However, any turbulent airflow should not increase risk of contamination of the exposed product.\nWhere processing lines are included in closed isolators, grade A conditions should be ensured with first air protection in the critical zone and unidirectional airflow that sweeps over and away from exposed products during processing.'可被翻译为：封闭式隔离器的设计通过工艺过程中充分保护暴露产品保证 A 级条件。在进行简单操作的封闭式隔离器中，气流可能不是完全单向的。然而，任何湍流不应增加暴露产品的污染风险。当生产线包含在封闭式隔离器中时，应通过关键区域的初始气流保护和工艺过程中暴露产品上方和周围的单向流吹扫保证 A 级条件。\n\n根据上述已知信息，请将'Airflow pattern studies should be performed at the interfaces of open isolators to demonstrate the absence of air ingress.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应在开放式隔离器的接口处进行气流流型研究，以证明没有空气进入。"
    },
    {
        "instruction":"已知信息：\n'In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of[Adverse reactions], [Contraindications]and [Precautions] in the package inserts of Metoclopramide. Relevant issues are hereby announced as follows:'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对甲氧氯普胺说明书【不良反应】、【禁忌】、【注意事项】等项目进行统一修订。现将有关事项公告如下：\n'In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of[Adverse reactions], [Contraindications]and [Precautions] in the package inserts of oxiracetam preparations. Relevant issues are hereby announced as follows:'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对奥拉西坦制剂说明书【不良反应】、【禁忌】、【注意事项】等项目进行统一修订。现将有关事项公告如下：\n'In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of [Adverse reactions],[Precautions] and [Drug Interactions] in the package inserts of somatostatin for injection. Relevant issues are hereby announced as follows:'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对注射用生长抑素说明书【不良反应】、【注意事项】、【药物相互作用】等项目进行统一修订。现将有关事项公告如下：\n'In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, NMPA decided to modify the items of [Adverse reactions] and[Contraindications] in the package inserts of Vitamin B6 injection. Relevant issues are hereby announced as follows.'可被翻译为：根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对维生素B6注射剂说明书【不良反应】、【禁忌】等项目进行统一修订。现将有关事项公告如下：\n\n根据上述已知信息，请将'In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of [Precautions]in the package inserts of propranolol tablets. Relevant issues are hereby announced as follows:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据药品不良反应评估结果，为进一步保障公众用药安全，国家药品监督管理局决定对普萘洛尔片剂说明书【注意事项】等项目进行统一修订。现将有关事项公告如下："
    },
    {
        "instruction":"已知信息：\n'Drug regulatory departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government shall be responsible for the vaccine administration within their respective administrative regions. Departments undertaking responsibilities for drug administration (hereinafter referred to as drug regulatory departments) of the people's governments of municipalities divided into districts and at county level shall undertake the administrative duties on vaccines within their respective administrative regions. The competent health departments of people's governments at or above the county level shall undertake the administration of immunization within their respective administrative regions. Other relevant departments of the people's governments at or above the county level shall undertake the administrative duties on vaccines within the scope of their respective responsibilities.'可被翻译为：省、自治区、直辖市人民政府药品监督管理部门负责本行政区域疫苗监督管理工作。设区的市级、县级人民政府承担药品监督管理职责的部门（以下称药品监督管理部门）负责本行政区域疫苗监督管理工作。县级以上地方人民政府卫生健康主管部门负责本行政区域预防接种监督管理工作。县级以上地方人民政府其他有关部门在各自职责范围内负责与疫苗有关的监督管理工作。\n'The department in charge of drug supervision and administration of local people's governments at or above the county level shall be responsible for supervision and administration of cosmetics within their administrative areas.'可被翻译为：县级以上地方人民政府负责药品监督管理的部门负责本行政区域的化妆品监督管理工作。\n'The drug regulatory departments of the people's governments of provinces, autonomous regions, or municipalities directly under the central government shall be responsible for drug administration in their administrative areas. The departments in charge of drug administration (hereinafter referred to as the drug regulatory departments) of the people's governments of municipalities divided into districts or of counties shall be responsible for drug administration in their administrative areas. The relevant departments of the people's governments at or above the county level shall be responsible for the related administrative work within the scope of their duties.'可被翻译为：省、自治区、直辖市人民政府药品监督管理部门负责本行政区域内的药品监督管理工作。设区的市级、县级人民政府承担药品监督管理职责的部门（以下称药品监督管理部门）负责本行政区域内的药品监督管理工作。县级以上地方人民政府有关部门在各自职责范围内负责与药品有关的监督管理工作。\n'Article 90 If any disease prevention and control institutions or immunization entities violates this Law to charge fee, the competent health departments of the people's governments at or above the county level shall monitor the return of the illegally charged fee to the original paying entities or individuals, and market regulation department at or above the county level shall give corresponding sanctions thereto according to law.'可被翻译为：第九十条 疾病预防控制机构、接种单位违反本法规定收取费用的，由县级以上人民政府卫生健康主管部门监督其将违法收取的费用退还给原缴费的单位或者个人，并由县级以上人民政府市场监督管理部门依法给予处罚。\n\n根据上述已知信息，请将'Article 15 Entities and individuals that have made significant contributions to drug development, manufacturing, distribution, use and supervision and administration shall be commended and rewarded by the people's government and its relevant departments at or above the county level in accordance with the relevant provisions of the State.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第十五条 县级以上人民政府及其有关部门对在药品研制、生产、经营、使用和监督管理工作中做出突出贡献的单位和个人，按照国家有关规定给予表彰、奖励。"
    },
    {
        "instruction":"已知信息：\n'The different forms of administration of a drug used in the prevention and treatment of a disease are new forms of a drug that have a certain function.'可被翻译为：在防治疾病的过程中所采用的药物的不同给药形式，是具有某种功能的药物新剂型。\n'Different forms of administration prepared to suit therapeutic or preventive needs.'可被翻译为：为适应治疗或预防的需要而制备的不同给药形式。\n'Misallocation of drug varieties, specifications, dosages, dose switches, dosage forms and routes of administration.'可被翻译为：错误地调配药品品种、规格、剂量、剂量转换、剂型及用药途径等。\n'Drugs shall meet the national drug standards and the drug standards approved by the NMPA. The drug standards approved by NMPA are adopted for drug registration. The drug registration standards shall meet the general technical requirements of the Pharmacopoeia of the People's Republic of China and shall not be lower than those prescribed in the Pharmacopoeia of the People's Republic of China. Where the Pharmacopoeia of the People's Republic of China is not applicable to a product applying for registration with regard to the testing items or criteria, the applicant shall provide sufficient supporting data.'可被翻译为：药品应当符合国家药品标准和经国家药品监督管理局核准的药品质量标准。经国家药品监督管理局核准的药品质量标准，为药品注册标准。药品注册标准应当符合《中华人民共和国药典》通用技术要求，不得低于《中华人民共和国药典》的规定。申报注册品种的检测项目或者指标不适用《中华人民共和国药典》的，申请人应当提供充分的支持性数据。\n\n根据上述已知信息，请将'Specific varieties of different forms of administration prepared to meet the needs of treatment or prevention in accordance with the standards approved by the pharmacopoeia or the pharmaceutical administration.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"根据药典或药政管理部门批准的标准，为适应治疗或预防的需要而制备的不同给药形式的具体品种。"
    },
    {
        "instruction":"已知信息：\n'Article 91 Invoices shall be truthfully issued for drugs sold by enterprises, ensuring the consistency among invoice, accounts, goods and amount.'可被翻译为：第九十一条 企业销售药品，应当如实开具发票，做到票、账、货、款一致。\n'Article 73 Upon arrival of drugs, the receiving personnel shall validate whether the mode of transportation meets the requirements, and check the drugs against the accompanying sheet (bill) and the purchase records to ensure consistency among bills, account and goods.'可被翻译为：第七十三条 药品到货时，收货人员应当核实运输方式是否符合要求，并对照随货同行单（票）和采购记录核对药品，做到票、账、货相符。\n'Article 151 Enterprises shall periodically carry out calibration or validation on measuring instruments and temperature and humidity monitoring equipment in accordance with relevant national provisions.'可被翻译为：第一百五十一条 企业应当按照国家有关规定，对计量器具、温湿度监测设备等定期进行校准或者检定。\n'Article 53 Enterprises shall periodically carry out calibration or validation on measuring instruments and temperature and humidity monitoring equipment in accordance with relevant national provisions.'可被翻译为：第五十三条 企业应当按照国家有关规定，对计量器具、温湿度监测设备等定期进行校准或者检定。\n\n根据上述已知信息，请将'Article 88 Enterprises shall periodically carry out inventory check of drugs and ensure consistency between the accounts and goods.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第八十八条 企业应当对库存药品定期盘点，做到账、货相符。"
    },
    {
        "instruction":"已知信息：\n'In metrology absorptiometry, a data processing method used for multi-component analysis.'可被翻译为：在计量学吸光光度法中，对多组分分析时采用的一种数据处理方法。\n'A new method of multivariate statistical data analysis, first proposed by the Swedish econometrician H. Wolde in 1966, is the regression modeling method of multivariate variables to multi-independent variables. In metrology absorptiometry, it is a data processing method for multi-component analysis.'可被翻译为：由瑞典经济计量学家沃尔德（H.Wold）于1966年首次提出的一种新型多元统计数据分析方法，是多因变量对多自变量的回归建模方法。在计量学吸光光度法中，是一种用于多组分分析的数据处理方法。\n'A discipline developed in the middle of the 20th century, all equations and functions in the linear programming model are linear, and it is a method to solve the multi-variable optimal decision. It is a problem to solve or plan the linear objective function optimization of an object under various interrelated multi-variable constraints. In the metrology absorptiometry, it is a data processing method used for multi-component analysis.'可被翻译为：20世纪中期发展起来的学科,线性规划模式中的所有方程式及函数都是线性的，是解决多变量最优决策的方法，是在各种相互关联的多变量约束条件下，解决或规划一个对象的线性目标函数最优的问题。在计量学吸光光度法中，是用于多组分分析的一种数据处理方法。\n'A representation of the purity of a drug after detection by chromatographic analysis in a drug quality standard. It is often used for the analysis of unknown impurities.'可被翻译为：药品质量标准中采用色谱分析方法检测后对药物纯度的一种表述方法。常用于未知杂质的分析。\n\n根据上述已知信息，请将'A stoichiometric data processing method used in the analysis and detection of multi-component systems by metrological absorbance spectrophotometry.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"在计量学吸光光度法分析检测多组分体系时，采用的一种化学计量学数据处理方法。"
    },
    {
        "instruction":"已知信息：\n'When the availability of a given dosage form of a drug is calculated at 100%, the percentage of other dosage forms of that drug that are absorbed at the same dose.'可被翻译为：某药物指定剂型的利用度按100%计算时，该药物其他剂型在相同剂量下吸收的百分率。\n'Misallocation of drug varieties, specifications, dosages, dose switches, dosage forms and routes of administration.'可被翻译为：错误地调配药品品种、规格、剂量、剂量转换、剂型及用药途径等。\n'Different patients show different reactions to the same drug at the same dose. Different reactions to the same dose of the same drug can occur even in patients of exactly the same age, sex, and living environment. There are three forms of response: hypersensitivity, tolerance, and idiosyncrasy.'可被翻译为：不同患者对相同剂量的同一种药物所表现出的不同反应。即使患者的年龄、性别和生活环境完全相同，对于同一剂量的同一种药物也可有不同反应。表现形式有三种：高敏性、耐受性和特异质。\n'The study of the absorption, distribution, metabolism, excretion and other processes of drugs and their dosage forms in the body, and the elucidation of the relationship between drug dosage forms, biological factors and efficacy.'可被翻译为：研究药物及其剂型在体内的吸收、分布、代谢、排泄等过程，阐明药物的剂型因素、机体生物因素和药效之间相互关系的一门学科。\n\n根据上述已知信息，请将'The percentage of other dosage forms of a drug that can be absorbed at the same dose when the intravenous availability of a drug is calculated at 100%.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"某药物静脉注射的利用度按100%计算时，该药物其他剂型在相同剂量下吸收的百分率。"
    },
    {
        "instruction":"已知信息：\n'3. The preparation, storage and use of the laboratory reagents, solutions and culture media should follow the relevant requirements or instructions. In special cases, the laboratory reagents should be identified or tested upon reception or before use.'可被翻译为：（三）应当按照相关规定或使用说明配制、贮存和使用试剂、试液和培养基。特殊情况下，在接收或使用前，还应当对试剂进行鉴别或其他检验。\n'2. There should be records for the receipt of laboratory reagents, solutions and culture media, the date of receipt should be indicated on the container where necessary.'可被翻译为：（二）应当有接收试剂、试液、培养基的记录，必要时，应当在试剂、试液、培养基的容器上标注接收日期。\n'Article 226: The management of laboratory reagents, solutions, culture media and test microorganisms should meet at least the following requirements:'可被翻译为：第二百二十六条 试剂、试液、培养基和检定菌的管理应当至少符合以下要求：\n'4. The batch number, preparation date, and name of the operator should be indicated on the labels of solutions and prepared culture media, and a preparation record (including sterilization) should be available. The shelf life and special storage conditions of unstable laboratory reagents, solutions and culture media should be indicated on the label. For reference solutions and titration solutions, the latest standardization date and calibration factor should be labeled, and the standardization records should be available.'可被翻译为：（四）试液和已配制的培养基应当标注配制批号、配制日期和配制人员姓名，并有配制（包括灭菌）记录。不稳定的试剂、试液和培养基应当标注有效期及特殊贮存条件。标准液、滴定液还应当标注最后一次标化的日期和校正因子，并有标化记录。\n\n根据上述已知信息，请将'8. Laboratory volumetric glassware, reagents, solutions, reference standards and culture media should be tested;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（八）应当对实验室容量分析用玻璃仪器、试剂、试液、对照品以及培养基进行质量检查。"
    },
    {
        "instruction":"已知信息：\n'Article 25 The registrant, the filing entity and the contract manufacturer of cosmetics shall establish and implement the management systems to ensure the quality and safety of cosmetics, such as material supplier selection, check and test for raw materials acceptance, manufacturing process and quality control, equipment maintenance and product test and sample retention, etc.'可被翻译为：第二十五条 化妆品注册人、备案人、受托生产企业应当建立并执行供应商遴选、原料验收、生产过程及质量控制、设备管理、产品检验及留样等保证化妆品质量安全的管理制度。\n'Article 265: The manufacturer should establish a quality archive for each material supplier, which includes the supplier's qualification certificates, quality agreements, specifications, sample testing data and reports, supplier’s certificates of analysis, on-site quality audit reports, product stability study report, periodic quality review reports, etc.'可被翻译为：第二百六十五条 企业应当对每家物料供应商建立质量档案，档案内容应当包括供应商的资质证明文件、质量协议、质量标准、样品检验数据和报告、供应商的检验报告、现场质量审计报告、产品稳定性考察报告、定期的质量回顾分析报告等。\n'Article 24 The NMPA shall formulate the Good Manufacturing Practice for Cosmetics, and specify the requirements for the quality management structure and personnel, quality assurance and control, plant facilities and equipment management, materials and products management, manufacturing process management, and product sales management, etc.'可被翻译为：第二十四条 国家药品监督管理局制定化妆品生产质量管理规范，明确质量管理机构与人员、质量保证与控制、厂房设施与设备管理、物料与产品管理、生产过程管理、产品销售管理等要求。\n'(3) If the product name, formula, etc. changes, which constitutes a new product in essence, the registrant shall re-apply for registration.'可被翻译为：（三）产品名称、配方等发生变化，实质上构成新的产品的，注册人应当重新申请注册。\n\n根据上述已知信息，请将'(2) Management for review of the product formula, manufacturing process and material supplier, etc.;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）产品配方、生产工艺、物料供应商等的审核管理；"
    },
    {
        "instruction":"已知信息：\n'The temperature at which a substance melts from a solid phase into a liquid phase, as determined by a prescribed method. Is the physical constant of a substance.'可被翻译为：种物质按照规定的方法测定，由固相融化成液相时的温度。是物质的-项物理常数。\n'A chemical reaction that takes place in a single solid, gas, or liquid phase. A reaction in which no substance is exchanged with another phase during the reaction.'可被翻译为：在单一固相、气相、液相中进行的化学反应。即在反应过程中与其他物相没有物质交换的反应。\n'Generally refers to solution type aerosol. It is composed of two phases of gas and liquid. The gas phase is the vapor produced by the ejector; The liquid phase is the homogeneous solution formed by the drug and the ejector.'可被翻译为：一般指溶液型气雾剂。由气液两相组成。气相是抛射剂所产生的蒸气；液相为药物与抛射剂所形成的均相溶液。\n'A system in which particles of one substance (dispersed phase) are evenly dispersed into another substance (dispersing medium).'可被翻译为：一种物质（分散相）的粒子均匀分散到另一种物质（分散介质）中所形成的体系。\n\n根据上述已知信息，请将'A substance adsorbed from a solution or gas phase to the surface of another substance.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"从溶液或气相中被吸附至另一物质表面的物质。"
    },
    {
        "instruction":"已知信息：\n'cell free system'可被翻译为：无细胞系统\n'An enzyme secreted outside the cell to function. This enzyme exists in a free state in the cytoplasm and can be extracted from cells by the method of protein fractionation.'可被翻译为：分泌到细胞外发挥作用的酶。这种酶在细胞质中以游离状态存在，能用蛋白质分级分离的方法从细胞中提取出来。\n'When two cells or two mycelia with different traits are connected and anastomosed, two or more nuclei of different genetic types coexist in one cell or one mycelia.'可被翻译为：具有不同性状的两个细胞或两条菌丝相互联结吻合时，导致在一个细胞或一条菌丝中并存两种或两种以上不同遗传型的核。\n'A new cell or individual produced by deoxyribonucleic acid (DNA) recombination technology (genetic engineering).'可被翻译为：经脱氧核糖核酸(DNA)重组技术(基因工程技术)产生的新细胞或新个体。\n\n根据上述已知信息，请将'Also known as \"free genes\". A genetic structure that exists in a cell either in a free state or in conjunction with a chromosome. Their presence confers certain genetic traits on the cell, but their absence does not cause the cell to die.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"又称\"游离基因\"。在细胞中或以游离态、或以与染色体相结合的状态存在着的遗传结构。其存在给细胞带来一定的遗传性状，但它们的缺失并不会造成细胞的死亡。"
    },
    {
        "instruction":"已知信息：\n'Antihypertensive drugs that can bind to angiotensin converting enzyme and inhibit its activity. Such as captopril, enalapril, Lisinopril, Fosinopril, Ramipril, Benazepril, etc.'可被翻译为：可与血管紧张素转化酶结合，抑制其活性的抗高血压药物。如卡托普利、依那普利、赖诺普利、福辛普利、雷米普利、苯那普利等。\n'The substrate of the enzyme usually has some structural similarity, and can compete with the substrate for the binding site of the enzyme, resulting in reversible inhibitors of enzyme activity.'可被翻译为：与酶的底物通常有某种结构上的相似性，能与底物竞相争夺酶的结合位点，从而产生酶活性的可逆性抑制剂。\n'A substance that changes an enzyme from inactive to active or increases its activity.'可被翻译为：使酶从无活性变为有活性或使酶活性增加的物质。\n'A class of non-peptide, peptide-like, or peptide-like compounds capable of mimicking the interaction of a peptide molecule with a receptor or enzyme that can activate or block a biological activity.'可被翻译为：一类能够模拟肽分子与受体或酶的相互作用，可激活或阻止某种生物活性的非肽、类肽或拟肽化合物。\n\n根据上述已知信息，请将'A non-protein component of an enzyme required for its activity. It can promote the activation of enzymes and reactants, and can be divided into coenzymes and coenzymes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"一种酶的活性所需要的一种非蛋白质成分。能促进酶及反应物进入活化状态，分辅基和辅酶。"
    },
    {
        "instruction":"已知信息：\n'Article 53 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter V of the Provisions shall prevail.'可被翻译为：第五十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。\n'Article 66 Where provisions concerning acceptance and approval procedures of application for registration renewal of medical device are not available in this chapter, Chapter VI of the Provisions shall prevail.'可被翻译为：第六十六条 体外诊断试剂延续注册申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。\n'Article 56 Where provisions concerning acceptance and approval procedures of application for registration renewal of medical device are not available in this chapter, Chapter V of the Provisions shall prevail.'可被翻译为：第五十六条 医疗器械延续注册申请的受理与审批程序，本章未作规定的，适用本办法第五章的相关规定。\n'The food and drug regulatory department accepting the application for change of permission items shall organize technical evaluation within the period specified in Chapter VI of the Provisions.'可被翻译为：受理许可事项变更申请的食品药品监督管理部门应当按照本办法第六章规定的时限组织技术审评。\n\n根据上述已知信息，请将'Article 63 Where provisions concerning acceptance and approval procedures of the application for change of permission items are not available in this chapter, Chapter VI of the Provisions shall prevail.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第六十三条 许可事项变更申请的受理与审批程序，本章未作规定的，适用本办法第六章的相关规定。"
    },
    {
        "instruction":"已知信息：\n'(II) Failing to be equipped with the organization and personnel corresponding to the scale of business or use to carry out relevant works of medical device adverse event monitoring as required;'可被翻译为：（二）未按照要求配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作的；\n'(II) Failing to be equipped with the organization and personnel corresponding to the products to carry out the relevant medical device adverse event monitoring work as required;'可被翻译为：（二）未按照要求配备与其产品相适应的机构和人员从事医疗器械不良事件监测相关工作的；\n'(II) Be equipped with the organization or personnel adapted to the scale of the business or use to carry out relevant works of medical device adverse event monitoring;'可被翻译为：（二）配备与其经营或者使用规模相适应的机构或者人员从事医疗器械不良事件监测相关工作；\n'Article 6 Drug regulatory departments of the provinces, autonomous regions and municipalities directly under the central government shall establish and improve medical device adverse event monitoring system, be equipped with corresponding monitoring agencies and personnel and carry out medical device adverse event monitoring.'可被翻译为：第六条  省、自治区、直辖市药品监督管理部门应当建立医疗器械不良事件监测体系，完善相关制度，配备相应监测机构和人员，开展医疗器械不良事件监测工作。\n\n根据上述已知信息，请将'(II) Equipped with the organization and personnel corresponding to the products to carry out relevant works of medical device adverse event monitoring;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（二）配备与其产品相适应的机构和人员从事医疗器械不良事件监测相关工作；"
    },
    {
        "instruction":"已知信息：\n'The display of drug information on third-party platforms shall meet the requirements in Article 13 of these Provisions.'可被翻译为：第三方平台展示药品信息应当遵守本办法第十三条的规定。\n'Article 167 The sales of drugs shall meet the following requirements:'可被翻译为：第一百六十七条 销售药品应当符合以下要求：\n'Article 169 Dispensing sales of drugs shall meet the following requirements:'可被翻译为：第一百六十九条 药品拆零销售应当符合以下要求：\n'Article 42 The undertaking of drug manufacturing shall meet the following requirements:'可被翻译为：第四十二条 从事药品生产活动，应当具备以下条件：\n\n根据上述已知信息，请将'Article 161 The display of products shall meet the following requirements:'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百六十一条 药品的陈列应当符合以下要求："
    },
    {
        "instruction":"已知信息：\n'Article 35 Drug manufacturers shall have control measures to prevent any contamination, cross-contamination, mix-up and error, and regularly review and evaluate the suitability and effectiveness of these control measures to ensure that the drugs are qualified for the defined national drug standards and drug registration specifications and in compliance with the GMP.'可被翻译为：第三十五条 药品生产企业应当采取防止污染、交叉污染、混淆和差错的控制措施，定期检查评估控制措施的适用性和有效性，以确保药品达到规定的国家药品标准和药品注册标准，并符合药品生产质量管理规范要求。\n'Article 197: Measures should be taken to avoid, as far as possible, contamination and cross-contamination during production, for example:'可被翻译为：第一百九十七条 生产过程中应当尽可能采取措施，防止污染和交叉污染，如：\n'Article 202: Packaging operation procedures should specify the measures to minimize the risk of contamination, cross-contamination, mixups or errors.'可被翻译为：第二百零二条 包装操作规程应当规定降低污染和交叉污染、混淆或差错风险的措施。\n'Article 206: Appropriate segregation or other precautions to effectively prevent contamination, cross-contamination or mixups should be adopted if several packaging lines are working simultaneously.'可被翻译为：第二百零六条 有数条包装线同时进行包装时，应当采取隔离或其他有效防止污染、交叉污染或混淆的措施。\n\n根据上述已知信息，请将'Article 198: Measures to prevent contamination and cross-contamination should be checked regularly and evaluated for their suitability and effectiveness.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第一百九十八条 应当定期检查防止污染和交叉污染的措施并评估其适用性和有效性。"
    },
    {
        "instruction":"已知信息：\n'In case of identifying or knowing any suspected medical device adverse event, medical device distributing enterprises, user facility shall promptly notify MAHs. Any event causing death shall be reported within 7 days and any event causing severe injuries or possibly causing severe injuries or death shall be reported within 20 days through the National Medical Device Adverse Events Monitoring Information System.'可被翻译为：医疗器械经营企业、使用单位发现或者获知可疑医疗器械不良事件的，应当及时告知持有人。其中，导致死亡的还应当在7日内，导致严重伤害、可能导致严重伤害或者死亡的在20日内，通过国家医疗器械不良事件监测信息系统报告。\n'Article 29 After reporting medical device adverse events or knowing relevant medical device adverse events through the National Medical Device Adverse Events Monitoring Information System, MAHs shall carry out subsequent investigation, analysis and evaluation as required. The evaluation results of the events causing death shall be reported to local provincial monitoring agencies where MAHs locate within 30 days and the evaluation results of the events causing severe injuries or possibly causing severe injuries or death shall be reported to local provincial monitoring agencies where MAHs locate within 45 days. If the MAH has any new identification or notification of event information and evaluation results, it shall submit a supplementary report as required.'可被翻译为：第二十九条  持有人在报告医疗器械不良事件后或者通过国家医疗器械不良事件监测信息系统获知相关医疗器械不良事件后，应当按要求开展后续调查、分析和评价，导致死亡的事件应当在30日内，导致严重伤害、可能导致严重伤害或者死亡的事件应当在45日内向持有人所在地省级监测机构报告评价结果。对于事件情况和评价结果有新的发现或者认知的，应当补充报告。\n'Article 26 In case of identifying any medical device adverse event causing or possibly causing severe injuries or death, other units and individuals other than MAHs, distributing enterprises and user facility shall  report to either monitoring agencies or MAHs, distributing enterprises or the medical institutions providing treatment, and provide relevant medical records if necessary.'可被翻译为：第二十六条  除持有人、经营企业、使用单位以外的其他单位和个人发现导致或者可能导致严重伤害或者死亡的医疗器械不良事件的，可以向监测机构报告，也可以向持有人、经营企业或者经治的医疗机构报告，必要时提供相关的病历资料。\n'Article 18 Any suspected medical device adverse events that have caused or possibly caused severe injuries or death shall be reported; for an innovative medical device, all the medical device adverse events shall be reported within initial registration period.'可被翻译为：第十八条  导致或者可能导致严重伤害或者死亡的可疑医疗器械不良事件应当报告；创新医疗器械在首个注册周期内，应当报告该产品的所有医疗器械不良事件。\n\n根据上述已知信息，请将'Article 25 In case of identifying or knowing any suspected medical device adverse event, MAHs shall immediately investigate the cause. Any event causing death shall be reported within 7 days; and any event causing severe injuries or possibly causing severe injuries or death shall be reported within 20 days.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"第二十五条  持有人发现或者获知可疑医疗器械不良事件的，应当立即调查原因，导致死亡的应当在7日内报告；导致严重伤害、可能导致严重伤害或者死亡的应当在20日内报告。"
    },
    {
        "instruction":"已知信息：\n'Active Ingredient(s) and Strength[Not disclosed to the public]'可被翻译为：活性成分与规格[不对外公开]\n'Importing Country \/Region (Requesting Country \/Region)[Not disclosed to the public]'可被翻译为：进口国\/地区(提出要求的国家\/地区)[不对外公开]\n'Package inserts of approved drugs shall be disclosed to the public and promptly updated. For vaccines, the content of labels shall also be disclosed and promptly updated.'可被翻译为：批准上市药品的说明书应当向社会公开并及时更新。其中，疫苗还应当公开标签内容并及时更新。\n'(8) Potential adverse events in the use of product, or ingredients or excipients in product composition that may introduce side effects.'可被翻译为：（八）产品使用中可能带来的不良事件或者产品成分中含有的可能引起副作用的成分或者辅料；\n\n根据上述已知信息，请将'For complete composition including excipients, see attached[Not disclosed to the public]'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"包括辅料在内的完整处方组成（可附表）[不对外公开]"
    },
    {
        "instruction":"已知信息：\n'All product and component contact equipment should be sterilised prior to use.'可被翻译为：所有与产品和组件接触的设备应在使用前进行灭菌。\n'The unwrapping, assembly and preparation of sterilised equipment, components and ancillary items with\ndirect or indirect product contact should be treated as an aseptic process and performed in grade A with a grade B background. The filling line set-up and filling of the sterile product should be treated as an aseptic process and\nperformed in grade A with a grade B background. Where an isolator is used, the background should be in\naccordance with paragraph 4.20'可被翻译为：与产品直接或间接接触的已灭菌设备、组件和辅助用品的拆包、装配和准备应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。无菌产品的灌装线组装和灌装应作为无菌工艺过程，在 B 级环境下的 A 级区域内执行。当使用隔离器时，背景应符合 4.20 节的规定\n'Connections made under aseptic conditions (where sterilised product contact surfaces are exposed) that are post the final sterilising grade filter. These connections should be sterilised by steam-in-place whenever possible.'可被翻译为：最终除菌过滤器后在无菌条件下（已灭菌产品的接触表面暴露处）进行的连接。\n这些连接应在可能的情况下经过在线蒸汽灭菌。\n'For materials, equipment, components and ancillary items that are not a direct or indirect product contact part\nand are necessary for aseptic processing but cannot be sterilised, an effective and validated disinfection and\ntransfer process should be in place. These items, once disinfected, should be protected to prevent recontamination.\nThese items, and others representing potential routes of contamination, should be included in the environmental\nmonitoring programme.'可被翻译为：对于不直接或间接接触产品，并且是无菌工艺所必需但不能灭菌的物料、设备、组件和辅助用品，应建立有效且经验证的消毒和转移程序。消毒后应采取保护措施，防止物品再污染。这些物品以及代表潜在污染途径的其它因素应包含在环境监测计划中。\n\n根据上述已知信息，请将'For aseptic processes, direct and indirect product contact parts should be sterilised. Direct product contact parts are those that the product passes through, such as filling needles or pumps. Indirect product contact parts are equipment parts that do not contact the product, but may come into contact with other sterilised surfaces, the\nsterility of which is critical to the overall product sterility (e.g. sterilised items such as stopper bowls and guides, and sterilised components).'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"对于无菌工艺，直接和间接接触产品的部件应进行灭菌。直接接触产品的部件是指产品通过的部件，例如灌装针或泵。间接接触产品的部件是不接触产品的设备部件，但可能与其它灭菌表面接触，其无菌性对整个产品的无菌性至关重要（例如胶塞桶和导槽等已灭菌物品，以及已灭菌组件）。"
    },
    {
        "instruction":"已知信息：\n'In order to implement the E2B (R3) Regional Implementation Guide for Individual Case Safety Reports (hereinafter referred to as the Regional Implementation Guide), the Center for Drug Evaluation has completed the upgrade of the pharmacovigilance system during clinical trials, which was put into trial operation on January 1, 2022. Applicants shall complete the system configuration in a timely manner, and implement E2B(R3) in accordance with the Regional Implementation Guide no later than July 1,2022.'可被翻译为：为实施《个例安全性报告E2B(R3)区域实施指南》（以下简称区域实施指南），药审中心已完成对临床试验期间药物警戒系统升级改造，已于2022年1月1日上线试运行。申请人应及时完成系统配置,并按照区域实施指南要求实施E2B(R3),时间不得晚于2022年7月1日。\n'Thirdly, the construction of standards is strengthened, and the transformation and implementation of ICH related guidance is promoted. The Guidance for Clinical Safety Literature Evaluation of Marketed Drugs(Interim) and Guidance for Compiling the Annual Pharmacovigilance Report by Marketing Authorization Holders (Interim) were issued to guide MAHs in monitoring, reporting, analysis and evaluation. We steadily promoted the transformation and implementation of E2B (R3: Clinical Safety Data Management - Data Elements for Transmission of Individual Case Safety Reports) of ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use), and released the Regional Implementation Guidance for Individual Case Safety Reports E2B(R3). We promoted the application of the Medical Dictionary for Regulatory Activities(MedDRA), carried out disease term mapping research, strengthened the training for MAHs and monitoring institutions, and provide technical guarantee for full swing of ICH related Guidance.'可被翻译为：三是强化规范建设，推进ICH 相关指导原则转化实施。发布《上市药品临床安全性文献评价指导原则（试行）》《药品上市许可持有人药物警戒年度报告撰写指南（试行）》，指导持有人开展监测、报告、分析和评价工作。稳步推进国际人用药品注册技术协调会（ICH）E2B（R3）转化实施，发布《个例安全性报告E2B（R3）区域实施指南》；促进监管活动医学词典（MedDRA）应用，开展疾病术语映射研究，加强对持有人和监测机构的培训，为全面实施ICH相关指导原则提供技术保障。\n'The relevant technical guidance may be accessed on the website of the Center for Drug Evaluation of NMPA. The Center for Drug Evaluation of NMPA shall be responsible for relevant technical guidance during the implementation of this Announcement.'可被翻译为：相关技术指导原则可在国家局药品监督管理局药品审评中心网站查询。国家药品监督管理局药品审评中心做好本公告实施过程中的相关技术指导工作。\n'II. The relevant technical guidelines maybe accessed on the website of the Center for Drug Evaluation of NMPA. The Center for Drug Evaluation of NMPA shall be responsible for relevant technical guidance during the implementation of this Announcement.'可被翻译为：2. 相关技术指导原则可在国家药品监督管理局药品审评中心网站查询。国家药品监督管理局药品审评中心负责做好本公告实施过程中的相关技术指导工作。\n\n根据上述已知信息，请将'Notice of the Center for Drug Evaluation of NMPA on the Applicability of E2B (R3) Regional Implementation Guide to Individual Case Safety Reports during Drug Clinical Trials'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"药审中心药物临床试验期间个例安全性报告适用E2B(R3)区域实施指南的通知"
    },
    {
        "instruction":"已知信息：\n'(6) the list of main manufacturing equipment and testing equipment;'可被翻译为：（六）主要生产设备和检验设备目录；\n'Section 5 Facilities and Equipment'可被翻译为：第五节 设施与设备\n'The list of essential pharmaceutical products (see above) that has been defined, adopted and published at country level. It is normally used by all health facilities, including the main hospitals.'可被翻译为：已在国家一级确定、通过和公布的基本药物产品清单(见上文)。它通常由包括主要医院在内的所有卫生设施使用。\n'2. Facilities and Equipment System'可被翻译为：设施和设备系统\n\n根据上述已知信息，请将'(5) the list of main facilities and equipment for distribution;'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"（五）主要经营设施、设备目录；"
    },
    {
        "instruction":"已知信息：\n'good review practices (grevp)'可被翻译为：良好审查做法(GRevP)\n'6. Other medically important events that without treatment could lead to the aforementioned outcomes.'可被翻译为：6.导致其他重要医学事件，如不进行治疗可能出现上述所列情况的。\n'The spatial arrangement form of the pharmacodynamic characteristic elements that play an important role in the activity of bioactive molecules.'可被翻译为：在生物活性分子中对活性起重要作用的药效特征元素的空间排列形式。\n'A prompt review of all appropriate records relating to aseptic production since the last successful APS.'可被翻译为：及时回顾自上次成功 APS 以来所有与无菌生产有关的适用记录。\n\n根据上述已知信息，请将'The important GRevP elements for Ras to implement in order to achieve successful review outcomes.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"为了获得成功的评审结果，Ras需要实施的重要GRevP元素。"
    },
    {
        "instruction":"已知信息：\n'12.48. A technology transfer report should be prepared, based on the data and information obtained during the project. The supportive data should be kept and be accessible.'可被翻译为：应根据项目期间获得的数据和资料编写一份技术转让报告。支持性数据应保存并便于查阅。\n'5.16. The execution of the technology transfer project should be documented in a report which is supported by the relevant data.'可被翻译为：技术转移项目的执行应记录在一份报告中，并有相关数据支持。\n'1.7. A technology transfer should include relevant documentation, data, information and knowledge from the SU in order to enable the RU to effectively perform the specified process or procedure in, for example, production and QC. A successful transfer of technology should result in proof that the RU can routinely reproduce the transferred product, process or procedure against a predefined set of specifications as agreed between the SU and RU.'可被翻译为：技术转移应包括来自SU的相关文件、数据、信息和知识，使得RU能够有效实施指定的工艺或方法，例如生产和QC。成功的技术转移应证明RU可以常规化地按SU与RU之间预定的标准生产出所转移的产品、工艺或方法。\n'7.2. Standard operating procedures (SOPs) should be followed, describing actions to be taken during the technology transfer process.'可被翻译为：应遵守描述技术转移过程中所要采取的措施的标准操作程序（SOP）。\n\n根据上述已知信息，请将'Records should be maintained for the activities performed during the technology transfer process (e.g. a technology transfer report). The report content should reflect the protocol and SOPs that were followed. The report should summarize the scope of the transfer, the critical parameters as obtained in the SU and RU, and the final conclusions of the transfer. Changes, deviations, investigations and relevant appropriate actions taken should be recorded. The SU should provide all the relevant supportive documents with data, results and other relevant information to facilitate a successful transfer of technology and also comparison of data.'翻译为中文，只能输出翻译后的句子，不允许添加编造成分。",
        "output":"应保存技术转移过程中所执行活动的记录（例如，技术转移报告）。报告内容应反映出所遵守的方案和SOP。报告应总结转移的范围、SU和RU所得的关键参数，以及转移的最终结论。变更、偏差、调查和所采取的相关恰当措施均应有记录。SU应提供所有相关支持性文件及数据、结果和其它相关信息，以使得技术转移获得成功，同时还要对数据进行比较。"
    }
]